data_1ryj_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1ryj _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.426 HD13 ' H ' ' A' ' 6' ' ' ILE . 0.1 OUTLIER . . . . . 0 C--O 1.234 0.256 0 CA-C-O 121.068 0.461 . . . . 0.0 110.864 . . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.29 105.96 0.21 Allowed Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -177.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.559 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.1 ptt? -110.48 130.54 55.53 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.858 0.361 . . . . 0.0 111.044 -174.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.434 ' HB2' ' HB3' ' A' ' 22' ' ' GLU . 3.5 ttpm? -115.03 126.6 54.92 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 174.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 28.8 p90 -138.79 167.89 21.0 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.313 -175.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.46 ' HB ' HD11 ' A' ' 20' ' ' ILE . 13.1 t -125.38 132.02 52.86 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.201 0.524 . . . . 0.0 110.911 178.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.527 HG22 ' HB ' ' A' ' 64' ' ' ILE . 63.0 t -109.28 119.3 58.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 115.458 -0.792 . . . . 0.0 108.946 174.111 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.478 HG23 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -100.34 128.98 51.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.269 0.557 . . . . 0.0 109.949 -177.948 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.406 HG21 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -141.34 -162.81 1.44 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.508 -0.769 . . . . 0.0 108.949 178.507 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.406 ' H ' HG21 ' A' ' 14' ' ' THR . 3.7 m-20 -60.97 -27.44 68.27 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.329 0.585 . . . . 0.0 110.537 176.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -74.46 -9.42 58.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.507 178.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.31 -163.75 19.05 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 111.416 -0.674 . . . . 0.0 111.416 -177.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -76.8 118.76 19.74 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.053 0.454 . . . . 0.0 110.361 175.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 19.8 mtpp -102.48 121.83 43.12 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.18 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.46 HD11 ' HB ' ' A' ' 11' ' ' THR . 21.7 mm -100.32 120.84 50.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.027 0.442 . . . . 0.0 110.913 -177.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.449 ' N ' HD22 ' A' ' 21' ' ' LEU . 2.1 pt? -144.32 141.32 29.68 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.047 176.771 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.434 ' HB3' ' HB2' ' A' ' 9' ' ' LYS . 6.7 pt-20 -121.54 139.01 54.06 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.274 0.559 . . . . 0.0 110.763 178.652 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.9 t -119.9 130.88 55.04 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.518 -0.764 . . . . 0.0 109.446 -176.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -63.43 -31.99 82.63 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 121.23 -0.51 . . . . 0.0 112.868 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.423 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -106.82 123.81 37.41 Favored Pre-proline 0 C--N 1.322 -0.596 0 O-C-N 122.822 -0.222 . . . . 0.0 110.621 178.713 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.559 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 26.1 Cg_exo -63.71 110.89 1.37 Allowed 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.868 2.379 . . . . 0.0 111.544 175.815 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.423 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 14.4 mmm180 -118.57 177.11 4.95 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.232 0.539 . . . . 0.0 111.808 -171.295 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.645 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 15.6 ttp180 -89.88 157.61 17.81 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.946 -179.389 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.517 HD11 HG12 ' A' ' 58' ' ' ILE . 27.1 mm -50.22 -47.41 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 CA-C-O 120.833 0.349 . . . . 0.0 110.308 177.684 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.496 ' HB2' ' O ' ' A' ' 54' ' ' ASP . 46.3 tttp -59.63 -29.56 68.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.275 -176.537 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -64.89 -61.84 1.92 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.057 0.456 . . . . 0.0 110.372 -178.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.1 t -64.84 -38.96 84.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.556 -179.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.447 ' CD1' ' HB ' ' A' ' 38' ' ' ILE . 20.7 tp -63.21 -41.16 99.11 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.363 178.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.23 -35.19 63.97 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 116.009 -0.541 . . . . 0.0 113.376 179.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.437 ' HA ' ' OE1' ' A' ' 35' ' ' GLU . 5.5 mm-40 -65.13 -42.12 94.18 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 117.058 0.429 . . . . 0.0 111.295 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.6 mt -86.11 -8.4 57.9 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 175.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 40.27 70.12 0.27 Allowed 'General case' 0 C--O 1.234 0.269 0 CA-C-N 114.54 -1.209 . . . . 0.0 111.662 -173.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.447 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 63.8 mt -92.6 112.58 56.23 Favored Pre-proline 0 C--N 1.321 -0.667 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 174.701 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.517 ' HB2' HG22 ' A' ' 42' ' ' THR . 34.1 Cg_exo -60.29 103.43 0.21 Allowed 'Trans proline' 0 N--CA 1.46 -0.485 0 C-N-CA 122.693 2.262 . . . . 0.0 112.789 -173.664 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 8.1 tt -65.28 -11.34 11.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 CA-C-O 121.903 0.858 . . . . 0.0 109.493 175.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -66.36 -26.69 67.39 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 114.543 -1.208 . . . . 0.0 111.468 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.517 HG22 ' HB2' ' A' ' 39' ' ' PRO . 5.1 t -125.69 -7.84 6.78 Favored 'General case' 0 C--O 1.234 0.259 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -175.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.545 HG12 ' HB3' ' A' ' 68' ' ' ARG . 2.4 m -121.25 149.55 24.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.668 -177.124 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.4 t -98.85 130.83 47.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.55 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.9 t -103.03 126.73 57.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.137 0.494 . . . . 0.0 110.793 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.567 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 25.5 mttm -125.91 140.56 52.54 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.969 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.533 ' HD2' HG13 ' A' ' 52' ' ' VAL . 31.8 mttm -106.54 102.12 11.53 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.544 171.251 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 60.3 14.85 4.93 Favored 'General case' 0 CA--C 1.536 0.43 0 O-C-N 123.665 0.603 . . . . 0.0 111.164 178.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 126.9 -30.25 4.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.788 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 81.9 mm-40 -86.55 134.21 33.67 Favored 'General case' 0 C--N 1.327 -0.389 0 O-C-N 122.416 -0.461 . . . . 0.0 110.631 -176.024 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.439 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.7 mp -75.21 118.99 22.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -177.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.533 HG13 ' HD2' ' A' ' 47' ' ' LYS . 28.0 m -122.27 166.79 16.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 121.074 0.464 . . . . 0.0 110.745 -177.594 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 22.6 pt -97.81 175.41 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.859 174.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.496 ' O ' ' HB2' ' A' ' 30' ' ' LYS . 13.9 p-10 -81.89 12.84 3.68 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.289 -175.08 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -93.41 -15.84 25.23 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.707 -178.078 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.4 ' O ' ' HG3' ' A' ' 28' ' ' ARG . 60.6 mm-40 -77.33 160.74 28.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.196 -177.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.645 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.1 mp0 -94.17 163.17 13.57 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.989 0.423 . . . . 0.0 111.234 -178.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.517 HG12 HD11 ' A' ' 29' ' ' ILE . 45.8 mt -102.18 144.39 13.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 176.471 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -129.44 155.62 45.4 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.977 0.418 . . . . 0.0 110.693 -176.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.532 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 25.5 t70 -66.55 111.14 3.46 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.356 176.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.58 9.99 42.25 Favored Glycine 0 N--CA 1.445 -0.767 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.242 -177.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 26.2 t70 -88.44 146.3 25.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.859 0.362 . . . . 0.0 110.458 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.418 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.0 mp -113.99 115.91 51.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.278 -178.147 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.527 ' HB ' HG22 ' A' ' 12' ' ' VAL . 4.1 mp -102.04 110.3 28.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.606 179.297 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.567 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 44.1 mt-10 -96.98 98.12 9.81 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.418 HG22 HG23 ' A' ' 64' ' ' ILE . 87.3 t -92.22 101.54 12.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.418 0.628 . . . . 0.0 109.842 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 63.4 mt -109.26 99.97 9.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.501 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.545 ' HB3' HG12 ' A' ' 43' ' ' VAL . 24.3 ptt180 . . . . . 0 C--N 1.321 -0.654 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 173.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.2 pt . . . . . 0 N--CA 1.451 -0.406 0 CA-C-O 121.05 0.452 . . . . 0.0 110.15 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.87 178.6 16.39 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.59 -178.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.522 ' HE1' ' HB ' ' A' ' 58' ' ' ILE . 1.2 mpp? -140.02 140.53 36.23 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.758 0.313 . . . . 0.0 110.67 -176.721 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -111.61 111.43 22.42 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 168.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -134.12 167.75 20.09 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 120.906 0.384 . . . . 0.0 110.679 -172.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.526 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 25.8 m -126.38 123.35 37.75 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 177.045 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.514 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.6 p -105.33 123.87 59.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.294 0.568 . . . . 0.0 110.227 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.433 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -107.26 130.54 59.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 121.157 0.503 . . . . 0.0 109.888 179.28 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.455 HG23 ' HB ' ' A' ' 66' ' ' VAL . 0.2 OUTLIER -146.2 -160.42 1.15 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 177.6 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.401 ' H ' HG21 ' A' ' 14' ' ' THR . 1.3 m-20 -58.81 -25.94 63.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.906 0.384 . . . . 0.0 111.413 179.087 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -89.1 10.2 22.64 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.522 -177.231 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.55 -156.65 18.9 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.459 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 54.4 mttm -105.59 103.51 13.04 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -178.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.8 tptm -106.75 115.06 29.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.87 0.367 . . . . 0.0 111.098 -175.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.526 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -78.59 128.61 38.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 176.798 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 96.7 mt -131.51 139.0 49.18 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.778 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -128.61 146.0 50.98 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.023 0.439 . . . . 0.0 110.602 179.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.5 m -135.24 136.23 41.56 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.886 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -86.8 17.97 37.61 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.509 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.426 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.51 131.51 16.18 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 178.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 25' ' ' ALA . 27.9 Cg_exo -62.45 112.68 1.66 Allowed 'Trans proline' 0 C--O 1.234 0.321 0 C-N-CA 122.693 2.262 . . . . 0.0 111.482 177.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -133.0 153.13 51.78 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.075 0.464 . . . . 0.0 111.01 -176.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.552 ' HG3' ' O ' ' A' ' 56' ' ' GLU . 23.6 ttm180 -83.49 164.73 19.68 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.387 -178.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.472 HD13 HG12 ' A' ' 58' ' ' ILE . 31.9 mm -51.56 -49.54 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 CA-C-O 120.714 0.292 . . . . 0.0 110.324 176.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 33.4 tttp -60.36 -29.58 69.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.843 -178.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.464 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 1.1 t70 -67.68 -50.4 57.92 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -177.649 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 60.9 t -73.26 -39.74 56.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.461 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.528 HD23 ' HB ' ' A' ' 40' ' ' ILE . 36.2 tp -62.65 -39.45 93.93 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.376 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.04 -37.91 95.26 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.783 -0.644 . . . . 0.0 112.156 177.062 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.464 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 6.9 mm-40 -64.23 -41.54 96.95 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.151 0.501 . . . . 0.0 110.323 176.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 95.0 mt -76.76 -16.23 59.53 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.935 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 62.93 26.56 15.59 Favored 'General case' 0 CA--C 1.537 0.448 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.055 174.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.403 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 75.1 mt -86.74 122.61 71.5 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.561 -178.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 18.5 Cg_exo -66.42 110.13 1.75 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.713 2.275 . . . . 0.0 112.268 178.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.528 ' HB ' HD23 ' A' ' 33' ' ' LEU . 13.3 tt -68.02 -17.54 22.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.574 178.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -56.98 -40.16 76.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.932 -178.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.8 t -98.01 2.12 48.55 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.817 0.341 . . . . 0.0 111.783 -172.32 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.517 HG13 ' HB3' ' A' ' 68' ' ' ARG . 12.0 m -129.07 171.5 16.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 O-C-N 122.032 -0.417 . . . . 0.0 111.389 -176.294 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.493 ' HB ' ' O ' ' A' ' 67' ' ' ILE . 61.0 t -126.55 136.44 60.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 173.369 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.5 t -106.27 127.81 61.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.964 0.412 . . . . 0.0 111.341 -175.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.484 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 85.7 mttt -118.01 120.78 38.84 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.561 174.718 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.453 ' HE3' ' O ' ' A' ' 57' ' ' GLU . 10.0 mtpm? -97.32 104.29 16.29 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 174.159 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 12.0 m120 62.43 18.17 10.12 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.719 -176.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 109.66 -13.92 32.46 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.685 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -87.63 123.92 32.98 Favored 'General case' 0 C--N 1.326 -0.418 0 O-C-N 122.759 -0.259 . . . . 0.0 110.682 -178.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 65.6 mt -75.06 121.65 27.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.809 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 28.2 m -135.72 177.42 6.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.28 -175.572 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 42.7 pt -102.74 -175.09 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.353 174.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -80.08 -7.68 59.0 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.73 -175.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -89.95 10.99 21.8 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-O 121.232 0.539 . . . . 0.0 110.793 -178.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.809 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 59.3 mm-40 -89.24 148.77 23.42 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.016 0.436 . . . . 0.0 111.536 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.453 ' O ' ' HE3' ' A' ' 47' ' ' LYS . 1.4 tp10 -85.51 142.74 28.96 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.129 -177.71 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.522 ' HB ' ' HE1' ' A' ' 8' ' ' MET . 45.4 mt -88.98 130.77 37.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 177.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -102.56 156.44 17.61 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.274 179.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -73.49 115.63 13.1 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.947 0.403 . . . . 0.0 110.134 177.138 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 103.34 2.25 47.65 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 121.012 -0.613 . . . . 0.0 111.675 -177.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -75.33 146.77 40.66 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -113.97 113.7 44.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.514 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 41.3 mm -89.5 104.68 15.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.821 -176.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.484 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 36.4 mt-10 -102.25 107.73 18.87 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.835 -179.097 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.455 ' HB ' HG23 ' A' ' 14' ' ' THR . 76.3 t -91.92 99.93 10.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 121.335 0.588 . . . . 0.0 109.888 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.493 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 55.8 mt -105.01 103.75 15.82 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 177.524 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.517 ' HB3' HG13 ' A' ' 43' ' ' VAL . 16.4 ptt180 . . . . . 0 C--N 1.312 -1.034 0 C-N-CA 120.294 -0.563 . . . . 0.0 111.072 -173.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 46.0 mm . . . . . 0 N--CA 1.452 -0.331 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 107.24 76.72 1.01 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.626 -0.797 . . . . 0.0 111.379 -177.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.564 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.0 ptt? -85.74 130.47 34.55 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.12 0.486 . . . . 0.0 110.763 -174.037 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.468 ' HD3' HD12 ' A' ' 20' ' ' ILE . 0.6 OUTLIER -109.77 120.01 41.16 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.464 179.192 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.455 ' CE1' ' HE1' ' A' ' 8' ' ' MET . 45.0 p90 -144.06 167.99 21.07 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.838 0.351 . . . . 0.0 110.761 -175.126 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.504 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 4.7 m -120.93 128.77 53.07 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.684 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 p -108.72 122.44 63.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 121.259 0.552 . . . . 0.0 109.921 175.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.551 ' HB ' ' HG3' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -106.59 118.72 54.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.366 0.603 . . . . 0.0 109.932 179.989 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.4 m -116.47 169.78 9.06 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 177.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -53.97 -38.03 64.58 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.831 0.348 . . . . 0.0 111.58 178.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -77.96 -10.5 59.62 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.821 -175.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 152.74 170.9 19.63 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.321 -0.942 . . . . 0.0 112.578 178.211 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.551 ' HG3' ' HB ' ' A' ' 13' ' ' ILE . 36.4 ttpt -107.14 125.89 51.67 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.265 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -125.69 115.59 20.33 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.139 0.495 . . . . 0.0 111.242 -176.031 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.504 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -88.76 129.89 39.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 174.215 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.1 pp -144.7 165.9 26.73 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.955 0.407 . . . . 0.0 110.566 178.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -123.21 133.15 54.24 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.447 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.1 t -101.96 131.97 48.06 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 177.45 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -55.89 -29.31 54.86 Favored Glycine 0 CA--C 1.518 0.23 0 CA-C-N 116.169 -0.468 . . . . 0.0 113.06 -177.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.476 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -135.22 151.4 75.01 Favored Pre-proline 0 C--N 1.322 -0.591 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 178.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.564 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 28.1 Cg_endo -63.86 127.63 20.01 Favored 'Trans proline' 0 N--CA 1.464 -0.228 0 C-N-CA 122.358 2.039 . . . . 0.0 111.072 174.284 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.476 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 18.3 mmm180 -128.05 170.13 13.27 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.058 0.456 . . . . 0.0 110.894 -173.089 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.6 ttt85 -95.79 159.9 14.75 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 178.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.453 ' CG2' ' HA ' ' A' ' 54' ' ' ASP . 41.6 mm -55.74 -46.77 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 N-CA-C 110.301 -0.259 . . . . 0.0 110.301 178.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.534 ' HZ3' ' HB2' ' A' ' 30' ' ' LYS . 1.8 ttmp? -53.88 -38.56 64.87 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.856 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.418 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 32.9 t70 -62.09 -58.58 7.28 Favored 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.312 -179.514 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.5 t -60.59 -39.62 81.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.729 -179.642 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.521 HD12 ' HB ' ' A' ' 38' ' ' ILE . 15.6 tp -62.81 -47.19 84.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.654 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.42 -45.15 56.07 Favored Glycine 0 N--CA 1.448 -0.541 0 CA-C-N 115.755 -0.657 . . . . 0.0 113.13 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.418 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 34.9 mm-40 -63.47 -41.13 98.61 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.727 0.298 . . . . 0.0 111.658 -177.059 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 82.3 mt -89.22 -0.11 57.2 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.716 -0.22 . . . . 0.0 111.367 -178.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 54.58 73.01 0.42 Allowed 'General case' 0 C--O 1.232 0.181 0 CA-C-O 121.562 0.696 . . . . 0.0 110.772 179.151 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.521 ' HB ' HD12 ' A' ' 33' ' ' LEU . 68.3 mt -118.98 119.68 31.97 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.969 178.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.519 ' HB2' HG23 ' A' ' 42' ' ' THR . 7.0 Cg_exo -73.33 94.5 0.83 Allowed 'Trans proline' 0 N--CA 1.461 -0.425 0 C-N-CA 122.788 2.325 . . . . 0.0 112.34 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 13.4 tt -72.09 -23.07 21.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.362 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -60.81 -34.97 75.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.418 -178.311 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.519 HG23 ' HB2' ' A' ' 39' ' ' PRO . 12.9 t -102.62 -1.52 30.08 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -171.478 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.486 HG13 HG22 ' A' ' 42' ' ' THR . 18.2 m -136.89 -179.77 3.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 O-C-N 122.029 -0.42 . . . . 0.0 110.785 178.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.0 t -115.83 125.76 73.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.05 0.452 . . . . 0.0 111.118 -176.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.6 t -105.31 131.43 54.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.821 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.523 ' HG2' HD13 ' A' ' 51' ' ' ILE . 95.5 mttt -118.85 149.28 41.8 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.135 178.415 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.0 tttm -107.5 104.31 13.84 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 169.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 68.02 -73.89 0.08 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 123.81 0.844 . . . . 0.0 110.662 -174.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -148.4 11.85 1.17 Allowed Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 121.056 -0.592 . . . . 0.0 111.988 178.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -110.86 147.55 34.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.606 0.241 . . . . 0.0 110.805 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.523 HD13 ' HG2' ' A' ' 46' ' ' LYS . 29.6 mm -83.07 116.7 27.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.4 m -126.46 165.32 24.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.075 -175.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 37.8 pt -99.83 -177.21 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.653 172.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.453 ' HA ' ' CG2' ' A' ' 29' ' ' ILE . 6.6 p-10 -83.18 6.54 18.98 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.087 0.47 . . . . 0.0 111.41 -173.31 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -95.27 0.51 53.91 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.152 -175.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -81.15 163.16 23.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.534 176.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.22 154.85 21.17 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.504 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 21.9 mt -103.49 143.15 15.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.065 -179.159 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -123.16 171.18 9.52 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.235 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -70.75 133.76 46.85 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.845 178.486 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.47 30.63 58.1 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.942 -0.647 . . . . 0.0 111.837 -178.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -98.46 162.64 13.05 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.861 0.363 . . . . 0.0 110.769 179.478 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.3 mm -127.64 125.89 66.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.92 179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 2.9 mp -115.82 124.84 72.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 177.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.519 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 35.5 tt0 -110.16 113.87 26.91 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.725 0.298 . . . . 0.0 110.224 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 89.4 t -109.07 104.93 17.86 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.323 0.582 . . . . 0.0 110.352 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.486 HD13 ' HE3' ' A' ' 46' ' ' LYS . 6.3 pt -107.01 129.88 59.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.544 178.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 13.7 ptt180 . . . . . 0 C--N 1.32 -0.689 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.104 -179.132 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.1 tp . . . . . 0 N--CA 1.45 -0.452 0 CA-C-O 121.224 0.535 . . . . 0.0 110.05 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.55 -178.7 17.1 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 -173.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.522 ' HA ' ' HB2' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -160.44 149.17 16.87 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 117.587 0.694 . . . . 0.0 112.284 179.694 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 mtpp -118.2 131.0 56.41 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.119 173.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 24.8 p90 -147.23 157.93 43.77 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.834 0.35 . . . . 0.0 110.805 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.796 HG23 HD11 ' A' ' 63' ' ' ILE . 1.3 t -116.31 140.3 49.48 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 175.637 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.461 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 6.4 p -129.13 129.12 67.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.068 0.461 . . . . 0.0 110.754 -178.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.674 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -92.25 119.96 40.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 172.538 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.07 -157.73 0.84 Allowed 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.722 -174.059 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.902 ' HA ' ' HD2' ' A' ' 68' ' ' ARG . 15.5 t70 -58.29 -44.59 88.55 Favored 'General case' 0 N--CA 1.464 0.259 0 C-N-CA 122.894 0.478 . . . . 0.0 111.897 -171.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -91.25 -10.7 40.55 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -174.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 140.46 -162.9 26.52 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.022 -1.085 . . . . 0.0 112.269 -176.542 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.556 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 36.1 tttt -104.16 120.8 41.9 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.997 0.427 . . . . 0.0 110.836 -174.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -121.67 162.79 20.09 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.424 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -118.52 130.44 73.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.243 0.544 . . . . 0.0 109.725 -179.01 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 98.9 mt -123.44 151.75 42.35 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.72 -176.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -137.27 129.25 29.13 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.758 -0.656 . . . . 0.0 109.528 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.3 m -130.25 154.4 47.63 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.682 0.277 . . . . 0.0 110.659 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.06 -10.91 70.84 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.735 -176.343 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.408 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -124.21 140.12 34.25 Favored Pre-proline 0 C--N 1.323 -0.58 0 O-C-N 122.718 -0.283 . . . . 0.0 110.432 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 25' ' ' ALA . 14.2 Cg_exo -69.27 107.32 1.74 Allowed 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.668 2.246 . . . . 0.0 111.101 176.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 29.7 mmm180 -110.13 169.62 8.61 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.93 0.395 . . . . 0.0 110.605 -176.209 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.531 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 15.1 ttm180 -103.83 160.89 14.41 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.301 178.054 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.535 HG12 ' O ' ' A' ' 56' ' ' GLU . 40.6 mm -53.81 -48.95 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.707 0.289 . . . . 0.0 110.525 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 32.9 tttp -60.41 -24.71 65.37 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.697 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -70.67 -52.36 21.69 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.955 0.407 . . . . 0.0 110.24 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 50.3 t -71.69 -41.07 70.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.374 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.508 HD23 ' HB ' ' A' ' 40' ' ' ILE . 22.0 tp -63.52 -41.49 98.49 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.215 179.253 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.39 -32.13 68.33 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.058 178.375 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.76 -42.4 98.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.068 0.461 . . . . 0.0 110.091 -179.503 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 85.3 mt -91.0 -12.38 36.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.783 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 59.95 77.63 0.31 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.131 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.432 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 68.6 mt -123.76 128.87 25.01 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.999 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.88 115.0 3.36 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.536 2.157 . . . . 0.0 112.92 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.508 ' HB ' HD23 ' A' ' 33' ' ' LEU . 11.3 tp -79.9 -6.05 9.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.803 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -67.26 -43.38 82.01 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.693 -171.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.542 HG22 HG13 ' A' ' 43' ' ' VAL . 8.8 t -92.37 -20.55 20.95 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 113.881 1.067 . . . . 0.0 113.881 -165.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.542 HG13 HG22 ' A' ' 42' ' ' THR . 34.3 m -117.95 163.46 15.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.165 -0.614 . . . . 0.0 111.398 -177.804 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -103.29 139.45 24.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.85 -173.128 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.536 HG23 HG22 ' A' ' 66' ' ' VAL . 89.4 t -120.39 136.53 57.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.939 0.4 . . . . 0.0 110.584 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.575 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 98.1 mttt -128.4 149.62 50.47 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.538 178.483 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.768 ' HE2' ' HB3' ' A' ' 56' ' ' GLU . 52.4 mttm -95.27 100.46 12.24 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.822 -0.806 . . . . 0.0 108.822 167.565 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 66.88 -32.54 0.19 Allowed 'General case' 0 N--CA 1.471 0.609 0 O-C-N 123.953 0.783 . . . . 0.0 111.895 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.558 ' H ' ' C ' ' A' ' 47' ' ' LYS . . . 178.74 -21.5 0.04 OUTLIER Glycine 0 CA--C 1.522 0.511 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.091 -178.34 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -85.85 127.37 34.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.936 0.368 . . . . 0.0 110.419 -178.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.418 HD11 ' H ' ' A' ' 51' ' ' ILE . 3.7 mp -64.82 123.72 18.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 120.64 0.257 . . . . 0.0 110.548 -178.149 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.799 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 27.6 m -130.57 178.76 4.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.091 -177.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 29.6 pt -118.04 -174.5 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.323 177.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.451 ' O ' ' HB ' ' A' ' 29' ' ' ILE . 9.4 p-10 -75.08 -14.58 60.6 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -176.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -84.9 9.33 14.65 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -178.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.799 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 35.0 mm-40 -85.15 137.15 33.2 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.87 0.367 . . . . 0.0 110.731 176.433 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.531 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.1 mp0 -76.96 156.28 32.07 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.406 -179.11 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 58.0 mt -98.26 124.59 51.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -113.46 154.06 27.63 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.581 -178.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.522 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 19.1 t70 -69.11 124.58 24.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.825 178.363 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.46 4.59 70.5 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.845 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -94.01 156.88 16.37 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.796 HD11 HG23 ' A' ' 11' ' ' THR . 47.6 mm -121.73 123.33 69.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 120.776 0.322 . . . . 0.0 110.421 -173.329 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.461 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.2 mm -99.98 107.97 21.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.16 0.505 . . . . 0.0 110.377 -178.304 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.674 ' HA ' HG22 ' A' ' 13' ' ' ILE . 6.3 mm-40 -100.11 97.21 8.06 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.006 -177.446 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.536 HG22 HG23 ' A' ' 45' ' ' VAL . 85.7 t -95.68 106.1 17.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.447 0.641 . . . . 0.0 110.031 177.147 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.2 mt -92.29 99.77 10.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.748 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.902 ' HD2' ' HA ' ' A' ' 15' ' ' ASP . 9.2 ptm180 . . . . . 0 C--N 1.323 -0.58 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 176.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 9.6 tp . . . . . 0 N--CA 1.449 -0.489 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 79.8 -178.12 53.94 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.314 -175.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.405 ' HE2' ' CE1' ' A' ' 10' ' ' PHE . 25.4 ptt? -160.67 137.85 9.16 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 120.961 0.41 . . . . 0.0 111.094 -178.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.664 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 53.6 mtmt -112.15 110.01 20.03 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 169.13 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.405 ' CE1' ' HE2' ' A' ' 8' ' ' MET . 29.2 p90 -122.7 157.12 32.98 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.409 -175.439 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 7.8 m -113.96 117.82 32.42 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.426 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.1 p -102.51 123.45 55.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-O 121.282 0.563 . . . . 0.0 109.906 178.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.448 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -95.68 122.6 47.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -179.655 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.41 HG23 ' H ' ' A' ' 15' ' ' ASP . 0.7 OUTLIER -127.5 175.58 8.13 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.342 -0.845 . . . . 0.0 109.266 -178.609 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.41 ' H ' HG23 ' A' ' 14' ' ' THR . 13.0 p-10 -67.94 -17.7 64.53 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 111.654 0.242 . . . . 0.0 111.654 -176.7 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -91.3 -7.92 49.69 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.891 0.376 . . . . 0.0 110.891 179.115 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 141.05 -179.09 19.67 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.147 179.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.448 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 36.7 ttmt -100.73 110.41 22.51 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.172 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 8.6 mtpp -107.36 114.6 28.73 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.386 -170.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.516 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -82.9 120.58 34.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 173.324 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 95.3 mt -118.63 146.21 44.84 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.374 -177.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.664 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.2 OUTLIER -121.6 141.01 51.51 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.148 0.499 . . . . 0.0 110.842 177.667 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.1 t -135.94 147.04 47.91 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.496 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -76.14 -9.79 85.44 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.679 -179.34 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -136.81 146.06 53.55 Favored Pre-proline 0 C--N 1.326 -0.422 0 O-C-N 122.831 -0.217 . . . . 0.0 110.618 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -63.49 131.37 31.5 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.349 2.033 . . . . 0.0 111.307 176.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.506 ' HD2' ' HB3' ' A' ' 31' ' ' ASP . 15.9 tpp180 -123.39 155.51 37.24 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.004 -175.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.554 ' HG2' ' HA ' ' A' ' 57' ' ' GLU . 96.8 mtt180 -104.18 165.01 11.33 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.765 -0.198 . . . . 0.0 110.715 178.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 45.6 mm -54.8 -55.78 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.974 -175.03 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.888 ' HB3' ' HZ3' ' A' ' 30' ' ' LYS . 2.8 ttpm? -53.15 -39.95 63.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.138 0.494 . . . . 0.0 110.959 179.373 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.506 ' HB3' ' HD2' ' A' ' 27' ' ' ARG . 3.1 m-20 -64.61 -52.44 57.49 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.951 -176.334 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.0 t -62.98 -47.46 92.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.099 0.476 . . . . 0.0 110.713 178.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 14.5 tp -64.7 -38.46 91.06 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.603 -177.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.12 -42.61 66.94 Favored Glycine 0 N--CA 1.447 -0.572 0 CA-C-N 115.492 -0.776 . . . . 0.0 113.108 -179.095 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -68.04 -31.56 71.3 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.903 0.351 . . . . 0.0 111.263 -178.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 97.1 mt -83.0 -4.05 57.89 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.921 0.391 . . . . 0.0 110.292 176.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 55.14 61.81 2.76 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.931 -178.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 62.0 mt -116.98 114.44 39.15 Favored Pre-proline 0 C--N 1.323 -0.577 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.488 175.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.414 ' O ' HG22 ' A' ' 42' ' ' THR . 32.4 Cg_exo -59.57 113.15 1.49 Allowed 'Trans proline' 0 N--CA 1.464 -0.21 0 C-N-CA 122.76 2.306 . . . . 0.0 112.558 -178.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 14.6 tt -63.01 -20.23 25.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 121.383 0.611 . . . . 0.0 110.589 178.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -63.62 -29.96 71.14 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.152 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.414 HG22 ' O ' ' A' ' 39' ' ' PRO . 3.6 t -108.4 4.98 24.97 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-O 120.914 0.388 . . . . 0.0 111.665 -170.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.3 m -136.54 164.57 30.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.14 0.495 . . . . 0.0 111.466 -179.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 56.7 t -123.26 129.28 74.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.499 176.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.0 t -107.3 130.87 58.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 121.283 0.563 . . . . 0.0 111.536 -175.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.812 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 96.3 mttt -117.8 131.88 56.52 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.311 176.274 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.473 ' HB2' HG22 ' A' ' 52' ' ' VAL . 65.0 tttp -93.07 106.29 18.27 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 174.46 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.528 ' HA ' ' HB ' ' A' ' 63' ' ' ILE . 12.5 t-20 68.94 -66.06 0.26 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.064 -177.122 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -159.2 17.23 0.25 Allowed Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.809 -0.516 . . . . 0.0 111.809 179.034 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -131.19 131.27 43.88 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 -177.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.5 mt -64.02 128.86 27.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 176.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.737 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 19.6 m -132.94 178.75 5.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.933 0.397 . . . . 0.0 111.864 -173.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 32.8 pt -88.89 172.73 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.882 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.518 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 6.6 p-10 -76.4 -20.72 56.84 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.326 -176.256 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 68.5 tt0 -85.43 4.99 32.99 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.04 0.448 . . . . 0.0 110.719 -178.056 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.737 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 7.5 mm-40 -72.44 129.89 39.41 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.122 0.487 . . . . 0.0 111.226 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.554 ' HA ' ' HG2' ' A' ' 28' ' ' ARG . 4.7 pt-20 -86.87 140.69 29.4 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.423 179.3 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.459 HG21 HD12 ' A' ' 64' ' ' ILE . 12.0 mt -92.11 150.82 3.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.218 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -124.6 164.65 19.39 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.035 0.445 . . . . 0.0 110.702 -177.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -67.6 128.06 35.07 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.373 176.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.49 12.02 79.05 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.114 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -96.99 161.79 13.68 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 178.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.528 ' HB ' ' HA ' ' A' ' 48' ' ' ASN . 46.4 mm -115.38 138.96 44.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.037 -176.089 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.46 HG22 HG23 ' A' ' 66' ' ' VAL . 49.8 mm -118.29 118.6 58.62 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 176.428 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.812 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 42.7 tt0 -107.5 107.54 18.44 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.46 HG23 HG22 ' A' ' 64' ' ' ILE . 86.0 t -111.99 109.56 28.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.204 0.526 . . . . 0.0 110.51 -179.355 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -114.02 139.0 42.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.426 HH11 ' HD3' ' A' ' 68' ' ' ARG . 35.0 mtm-85 . . . . . 0 C--N 1.323 -0.563 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 174.377 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 65.4 mt . . . . . 0 N--CA 1.454 -0.247 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 97.63 67.04 0.91 Allowed Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.452 -0.88 . . . . 0.0 111.404 -177.215 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.525 ' HE3' ' HB ' ' A' ' 58' ' ' ILE . 26.1 ptt? -87.4 149.95 24.13 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.643 -0.278 . . . . 0.0 111.089 -174.415 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.542 ' HD3' ' OD1' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -129.68 128.96 43.62 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 168.808 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -125.44 153.17 43.88 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -177.593 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.539 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.8 m -109.81 117.67 34.48 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.176 -179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.547 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 3.1 p -112.23 123.41 67.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.458 -178.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.571 HG23 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -88.06 121.02 37.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 177.769 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.92 -162.05 1.14 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.747 -174.264 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -61.96 -45.92 91.54 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 112.202 0.445 . . . . 0.0 112.202 -171.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -87.74 -0.82 57.44 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 111.999 0.37 . . . . 0.0 111.999 -175.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 137.12 -164.73 25.27 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.128 -1.034 . . . . 0.0 112.653 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.558 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.0 ttpt -92.23 116.76 29.24 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.035 0.445 . . . . 0.0 110.212 -177.524 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 41.4 tptt -115.2 113.3 23.74 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.996 -172.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.539 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -84.32 120.54 35.27 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 CA-C-O 121.69 0.757 . . . . 0.0 109.795 174.175 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 97.4 mt -116.02 136.59 52.89 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.24 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.526 ' HG3' ' HB3' ' A' ' 9' ' ' LYS . 39.3 tt0 -113.5 139.49 48.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.275 -0.42 . . . . 0.0 109.974 179.679 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.2 t -132.92 132.91 42.56 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 178.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -66.46 -15.1 63.27 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 121.157 -0.544 . . . . 0.0 113.401 -175.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -133.9 142.32 43.06 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.896 0.348 . . . . 0.0 110.805 -178.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -54.43 133.95 58.96 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.465 2.11 . . . . 0.0 110.845 173.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.444 ' HG3' ' CB ' ' A' ' 31' ' ' ASP . 0.1 OUTLIER -132.56 156.21 47.26 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.487 -168.071 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.428 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 10.2 ttt85 -92.69 158.66 15.82 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 174.192 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 40.8 mm -59.96 -36.94 70.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.126 0.489 . . . . 0.0 109.814 176.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -67.21 -19.83 65.61 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.756 -177.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.444 ' CB ' ' HG3' ' A' ' 27' ' ' ARG . 3.2 m-20 -65.64 -61.8 1.88 Allowed 'General case' 0 CA--C 1.517 -0.312 0 CA-C-O 121.186 0.517 . . . . 0.0 109.766 173.73 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.5 t -59.7 -42.19 87.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.326 179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.541 HD23 ' HB ' ' A' ' 38' ' ' ILE . 1.2 tm? -63.94 -47.6 79.82 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.759 -178.445 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.21 -47.43 36.87 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 116.049 -0.523 . . . . 0.0 113.608 -174.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.4 mm-40 -73.26 -37.16 66.4 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -173.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 79.9 mt -87.64 -13.73 41.9 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.979 -0.288 . . . . 0.0 111.029 -179.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 58.97 77.77 0.29 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.598 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.541 ' HB ' HD23 ' A' ' 33' ' ' LEU . 65.1 mt -118.75 133.21 23.63 Favored Pre-proline 0 C--N 1.319 -0.731 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.51 -179.572 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_exo -62.83 100.49 0.24 Allowed 'Trans proline' 0 CA--C 1.529 0.252 0 C-N-CA 122.562 2.174 . . . . 0.0 112.401 178.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.541 ' HB ' HD21 ' A' ' 33' ' ' LEU . 8.2 tp -85.74 -25.13 6.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.549 -177.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 18.3 tp10 -76.06 -20.55 57.64 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.964 -173.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.49 HG21 HG13 ' A' ' 43' ' ' VAL . 12.9 t -109.1 -10.82 14.99 Favored 'General case' 0 CA--C 1.534 0.365 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 -170.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.49 HG13 HG21 ' A' ' 42' ' ' THR . 25.9 m -122.35 158.54 26.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.049 -179.424 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.0 t -94.98 113.12 28.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.037 -175.65 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 90.4 t -102.83 131.17 51.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.057 0.455 . . . . 0.0 110.439 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.724 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 97.9 mttt -117.28 126.39 52.65 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.948 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.483 ' HB3' HG12 ' A' ' 52' ' ' VAL . 71.1 tttt -96.82 106.06 18.3 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.362 175.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 71.08 -53.24 0.68 Allowed 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 123.947 0.899 . . . . 0.0 110.861 -177.331 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.49 21.49 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.077 178.292 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . 0.593 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 18.6 mm-40 -125.18 143.62 50.85 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.409 HD11 ' N ' ' A' ' 51' ' ' ILE . 3.2 mp -74.61 113.76 13.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 176.388 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.717 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 35.6 m -124.9 178.47 3.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-O 121.14 0.495 . . . . 0.0 111.834 -173.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 23.8 pt -123.22 -171.31 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.597 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -70.08 -12.74 61.82 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.087 -0.506 . . . . 0.0 112.056 -176.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -81.91 -8.51 59.68 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.522 -174.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.717 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 22.0 mm-40 -81.49 163.2 22.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.002 0.43 . . . . 0.0 111.97 -176.445 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.428 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 0.0 OUTLIER -103.15 159.24 15.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.169 177.468 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.525 ' HB ' ' HE3' ' A' ' 8' ' ' MET . 17.9 mt -103.85 154.48 5.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.025 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -128.49 168.41 15.7 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.924 0.392 . . . . 0.0 110.857 -177.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.542 ' OD1' ' HD3' ' A' ' 9' ' ' LYS . 30.8 t70 -81.12 129.42 34.56 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.854 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.04 26.58 72.12 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 121.076 -0.583 . . . . 0.0 111.935 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -97.33 160.97 14.02 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.962 0.411 . . . . 0.0 110.823 -178.055 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 31.3 mm -111.01 113.4 44.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.418 -175.304 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.547 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.1 mm -102.3 109.4 26.25 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.724 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 38.8 tt0 -99.65 99.99 10.92 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.223 -178.735 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 92.3 t -100.37 103.1 14.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.46 0.647 . . . . 0.0 110.522 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 24.2 mt -91.89 99.24 9.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.481 179.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.457 ' HD2' ' O ' ' A' ' 68' ' ' ARG . 0.1 OUTLIER . . . . . 0 C--N 1.323 -0.567 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.624 175.582 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 pt . . . . . 0 N--CA 1.452 -0.359 0 CA-C-O 121.194 0.521 . . . . 0.0 109.747 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 113.16 93.94 2.09 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -170.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.406 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.5 ptt? -106.1 144.72 32.41 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.38 0.609 . . . . 0.0 112.293 -165.76 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.507 ' HG2' ' OD1' ' A' ' 60' ' ' ASP . 23.8 pttm -107.06 141.45 38.28 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.289 -0.869 . . . . 0.0 108.911 168.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 31.1 p90 -156.72 147.96 22.2 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.853 0.359 . . . . 0.0 110.163 178.285 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 9.5 t -112.41 138.01 49.76 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.15 0.5 . . . . 0.0 110.225 178.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.751 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.7 p -126.9 134.54 65.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.966 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.607 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 8.1 tt -88.19 124.85 41.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.944 174.454 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -116.68 174.18 6.22 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.138 -0.937 . . . . 0.0 108.542 177.176 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -58.4 -34.17 70.44 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.25 0.548 . . . . 0.0 110.719 178.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -77.07 -10.79 59.61 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.698 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 136.39 176.76 14.54 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.414 -0.898 . . . . 0.0 112.783 178.579 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.607 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 45.4 tttt -96.43 116.64 29.38 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 6.6 mtpm? -129.65 147.87 51.49 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.845 -175.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.591 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -111.15 131.23 62.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -177.388 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.444 ' N ' HD11 ' A' ' 20' ' ' ILE . 2.0 pt? -134.8 165.1 26.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.751 0.31 . . . . 0.0 111.084 -175.742 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -112.44 150.6 30.94 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.337 -179.299 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.4 t -136.03 134.62 38.69 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 175.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.06 -44.94 95.1 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 121.26 -0.495 . . . . 0.0 113.153 -176.141 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -110.88 146.56 34.68 Favored Pre-proline 0 C--N 1.321 -0.637 0 O-C-N 122.625 -0.338 . . . . 0.0 110.741 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.406 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 25.0 Cg_exo -63.72 119.82 7.01 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.682 2.255 . . . . 0.0 111.2 175.282 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 17.2 mmm180 -115.0 177.18 4.74 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.729 -174.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 54.8 ttm-85 -108.38 159.97 16.24 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.466 HD13 ' HE2' ' A' ' 47' ' ' LYS . 38.0 mm -56.87 -48.76 80.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.913 0.387 . . . . 0.0 110.392 176.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.5 tptm -59.6 -28.04 66.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.186 178.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -65.15 -62.09 1.75 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.849 0.356 . . . . 0.0 110.475 178.637 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.3 t -59.89 -42.94 90.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.704 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.512 HD21 ' HB ' ' A' ' 40' ' ' ILE . 24.0 tp -64.65 -43.45 93.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.811 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.22 -40.21 71.06 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.917 -0.583 . . . . 0.0 112.753 -177.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.5 mm-40 -62.5 -38.71 90.97 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.914 0.388 . . . . 0.0 110.964 178.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.1 mt -83.87 -10.96 57.63 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.505 179.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 54.08 61.54 3.01 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.669 -177.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.434 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 69.2 mt -106.6 115.33 60.81 Favored Pre-proline 0 C--N 1.32 -0.704 0 CA-C-N 115.868 -0.605 . . . . 0.0 109.68 176.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -56.81 113.3 1.41 Allowed 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.695 2.263 . . . . 0.0 112.406 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.512 ' HB ' HD21 ' A' ' 33' ' ' LEU . 15.0 tt -72.7 -6.54 8.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.485 0.659 . . . . 0.0 110.819 -178.514 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -67.83 -29.28 68.4 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.998 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.5 HG21 HG11 ' A' ' 43' ' ' VAL . 9.3 t -106.44 0.05 24.49 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.734 -173.754 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.542 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 34.3 m -132.29 156.26 42.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.021 0.439 . . . . 0.0 111.46 -177.322 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 59.0 t -113.8 139.67 38.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.383 176.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.432 HG13 HG22 ' A' ' 29' ' ' ILE . 37.1 t -102.98 127.42 56.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.032 0.444 . . . . 0.0 110.218 -179.258 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.587 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 41.1 mttm -124.75 145.02 49.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.401 -178.081 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.587 ' HG2' HG21 ' A' ' 52' ' ' VAL . 28.8 mmtp -112.15 102.41 10.6 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 169.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.9 m120 56.05 24.55 7.93 Favored 'General case' 0 N--CA 1.465 0.323 0 O-C-N 123.451 0.469 . . . . 0.0 111.598 -178.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 115.95 -21.04 12.59 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.921 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . 0.467 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 17.0 mm-40 -85.3 132.28 34.28 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.772 0.32 . . . . 0.0 110.833 -176.187 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.407 HD13 ' N ' ' A' ' 51' ' ' ILE . 3.3 mp -73.99 116.76 16.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.957 0.408 . . . . 0.0 110.294 -179.39 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.883 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 29.3 m -123.63 173.94 8.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.673 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 28.1 pt -101.52 175.3 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.572 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.507 ' HB3' HD13 ' A' ' 40' ' ' ILE . 9.5 p-10 -74.53 -15.52 60.86 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.552 -177.437 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.1 tt0 -81.62 -5.08 57.71 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.823 0.344 . . . . 0.0 110.9 -178.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.883 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 17.2 mm-40 -69.16 142.3 54.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.824 0.345 . . . . 0.0 110.944 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 51.1 mp0 -79.9 166.52 21.57 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.562 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.513 HG23 HD13 ' A' ' 64' ' ' ILE . 55.2 mt -112.45 139.25 38.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 175.355 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 80.3 m-85 -124.18 162.24 24.04 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.778 0.323 . . . . 0.0 110.695 -176.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.507 ' OD1' ' HG2' ' A' ' 9' ' ' LYS . 21.6 t70 -71.77 117.33 13.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.329 177.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.53 -9.56 60.71 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 -179.106 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -78.09 143.83 37.04 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.493 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.504 HG23 HG21 ' A' ' 11' ' ' THR . 45.1 mt -115.35 118.5 58.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-O 121.23 0.538 . . . . 0.0 111.126 -173.42 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.751 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 4.0 mp -101.7 130.91 50.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.623 -178.47 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.587 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 53.0 mt-10 -120.64 118.53 30.38 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 178.647 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 62.0 t -114.06 102.79 14.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.129 0.49 . . . . 0.0 110.235 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.08 137.95 51.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 -179.01 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.542 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 76.0 mtp180 . . . . . 0 C--N 1.326 -0.446 0 CA-C-O 120.976 0.417 . . . . 0.0 110.717 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 60.0 mt . . . . . 0 N--CA 1.454 -0.248 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.99 -179.54 16.53 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.446 -178.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.481 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 25.5 ptt? -156.07 137.91 14.36 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.032 0.444 . . . . 0.0 110.887 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -123.72 114.58 20.12 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 174.462 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -127.98 167.99 15.9 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.283 -173.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.455 ' HB ' HD12 ' A' ' 20' ' ' ILE . 12.9 t -115.42 138.51 50.93 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.922 0.391 . . . . 0.0 110.318 178.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.469 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.4 p -128.41 136.79 59.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.099 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.569 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -107.98 124.85 64.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.3 0.571 . . . . 0.0 109.815 177.785 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.7 p -129.15 -163.03 1.25 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.238 -179.038 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -67.57 -24.36 65.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.024 0.44 . . . . 0.0 110.664 178.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -82.69 -11.5 58.29 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.393 0.616 . . . . 0.0 110.48 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 115.93 -167.65 12.49 Favored Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.419 -176.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.569 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 33.1 ttpt -98.99 127.87 45.0 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -177.599 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.456 ' HE3' ' HB2' ' A' ' 19' ' ' LYS . 29.9 ttmt -137.57 164.26 29.19 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.482 -174.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.455 HD12 ' HB ' ' A' ' 11' ' ' THR . 34.3 mm -98.38 126.44 51.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.7 0.286 . . . . 0.0 111.015 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.45 HD13 HG11 ' A' ' 12' ' ' VAL . 6.9 mp -111.51 144.44 40.73 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.192 176.443 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -127.25 134.88 50.02 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.146 -177.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.0 t -134.19 143.79 48.08 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 177.017 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.6 -18.38 75.58 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 121.234 -0.508 . . . . 0.0 113.246 -176.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -139.07 151.14 67.26 Favored Pre-proline 0 C--N 1.324 -0.539 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.481 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 25.0 Cg_exo -63.96 119.53 6.61 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.394 2.063 . . . . 0.0 111.234 174.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.41 ' HB3' ' CB ' ' A' ' 31' ' ' ASP . 50.9 mmm-85 -116.6 157.66 24.96 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.191 -175.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.596 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 23.4 mtt180 -82.08 167.35 18.88 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 172.044 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.533 ' HB ' ' HA ' ' A' ' 54' ' ' ASP . 48.9 mm -61.14 -35.16 63.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 168.363 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 40.7 tptt -61.37 -33.92 74.45 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 114.662 -1.154 . . . . 0.0 110.822 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.41 ' CB ' ' HB3' ' A' ' 27' ' ' ARG . 4.5 m-20 -65.87 -58.48 5.49 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.317 177.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 58.6 t -59.43 -53.04 53.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.329 -176.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.551 ' HG ' ' HB ' ' A' ' 38' ' ' ILE . 10.7 mp -71.82 -35.88 70.06 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.367 -176.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.83 -43.6 58.36 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.662 179.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -73.09 -33.04 65.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.023 0.439 . . . . 0.0 111.154 -175.101 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.0 mt -97.35 -5.99 35.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.449 -0.342 . . . . 0.0 111.511 -178.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 62.23 75.18 0.41 Allowed 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.684 0.754 . . . . 0.0 110.717 -176.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.551 ' HB ' ' HG ' ' A' ' 33' ' ' LEU . 67.4 mt -123.66 116.27 27.93 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.756 178.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 17.1 Cg_exo -67.04 109.64 1.77 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.658 2.238 . . . . 0.0 112.906 -178.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.446 ' HB ' HD21 ' A' ' 33' ' ' LEU . 9.9 tt -81.59 -5.74 9.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 122.009 0.909 . . . . 0.0 109.203 176.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -69.84 -31.64 69.6 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.855 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.53 HG21 HG11 ' A' ' 43' ' ' VAL . 4.6 t -96.14 -36.95 10.79 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.71 0.633 . . . . 0.0 112.71 -172.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.53 HG11 HG21 ' A' ' 42' ' ' THR . 21.3 m -116.56 162.61 14.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 C-N-CA 120.888 -0.325 . . . . 0.0 111.069 -175.745 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.9 t -102.93 131.93 50.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 120.855 0.36 . . . . 0.0 111.671 -173.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.0 t -103.65 130.5 54.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.938 176.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.607 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 92.5 mttt -118.81 143.61 46.83 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.842 0.353 . . . . 0.0 111.442 179.451 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.754 ' HG2' HG23 ' A' ' 52' ' ' VAL . 10.0 mmtp -100.57 102.2 13.3 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 170.273 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 65.49 -1.01 1.06 Allowed 'General case' 0 CA--C 1.541 0.619 0 O-C-N 123.426 0.454 . . . . 0.0 111.512 178.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 132.2 -10.64 5.34 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 121.107 -0.568 . . . . 0.0 111.907 -176.513 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . 0.44 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 14.6 mm100 -87.07 128.1 35.11 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 122.045 0.138 . . . . 0.0 110.664 178.735 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.401 HD11 ' N ' ' A' ' 51' ' ' ILE . 3.8 mp -71.32 114.85 10.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.037 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.754 HG23 ' HG2' ' A' ' 47' ' ' LYS . 28.1 m -125.77 178.79 3.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.117 0.484 . . . . 0.0 111.52 -174.591 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 24.7 pt -115.09 -170.92 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.348 177.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.533 ' HA ' ' HB ' ' A' ' 29' ' ' ILE . 35.1 p-10 -77.49 -7.19 55.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.656 -175.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -72.79 -22.16 60.88 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.918 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.535 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 8.0 mm-40 -69.11 135.71 51.14 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.497 0.554 . . . . 0.0 112.497 -174.379 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.596 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 58.1 mp0 -82.38 144.2 30.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.914 173.315 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 30.9 mt -91.21 142.34 13.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 176.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -119.4 162.2 19.22 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.856 0.36 . . . . 0.0 110.75 -177.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -69.06 131.14 44.55 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.599 173.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.59 23.51 75.07 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.924 -177.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 31.2 t0 -97.4 154.04 17.72 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 178.046 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.443 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.0 mp -110.21 116.78 53.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-O 121.03 0.443 . . . . 0.0 110.525 -177.618 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.469 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 41.5 mm -103.55 108.84 25.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.899 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.607 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 44.5 mt-10 -102.22 107.16 18.13 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 178.205 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 93.4 t -97.05 102.45 13.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.38 0.609 . . . . 0.0 109.681 178.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 64.0 mt -96.36 105.88 17.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.406 -177.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.472 ' HA ' HG12 ' A' ' 43' ' ' VAL . 0.6 OUTLIER . . . . . 0 C--N 1.32 -0.711 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.521 174.641 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.402 HD13 ' N ' ' A' ' 6' ' ' ILE . 3.2 mp . . . . . 0 N--CA 1.455 -0.224 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.33 179.96 45.16 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.14 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.532 ' HA ' ' OD1' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -159.91 158.07 30.15 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.762 0.315 . . . . 0.0 110.221 178.701 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.547 ' HB2' HD12 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -133.79 145.78 50.08 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 173.32 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.49 ' CD2' HD13 ' A' ' 64' ' ' ILE . 38.4 p90 -144.41 141.06 29.39 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.388 -178.507 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.618 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 18.0 m -95.39 118.35 31.98 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.079 0.466 . . . . 0.0 110.06 177.114 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.2 p -107.33 134.17 49.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.955 -179.666 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.49 HG23 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -103.76 127.48 57.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 121.528 0.68 . . . . 0.0 109.6 177.647 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 16.7 m -141.81 166.86 23.58 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.5 m-20 -63.73 -17.77 63.35 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.868 0.366 . . . . 0.0 111.076 177.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -77.73 -10.98 59.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.335 0.588 . . . . 0.0 110.132 175.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 129.44 157.87 9.32 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 112.124 179.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.9 ttmt -86.1 109.96 19.21 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 173.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -129.14 131.86 47.26 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.271 -173.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.618 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -81.84 124.3 38.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.397 0.618 . . . . 0.0 110.042 176.042 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.487 HD11 ' N ' ' A' ' 22' ' ' GLU . 1.1 tm? -106.81 135.28 48.62 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -178.367 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.487 ' N ' HD11 ' A' ' 21' ' ' LEU . 4.9 tm-20 -115.36 131.53 56.9 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -177.018 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.2 m -135.4 126.64 28.24 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.83 0.348 . . . . 0.0 110.787 -179.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -72.0 -17.57 77.16 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.079 178.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -118.77 121.72 30.43 Favored Pre-proline 0 C--N 1.321 -0.665 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 176.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_exo -48.61 139.13 24.21 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.138 2.559 . . . . 0.0 111.729 177.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.536 ' HG3' ' HB2' ' A' ' 31' ' ' ASP . 1.9 tpp85 -133.51 147.48 51.62 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.761 0.315 . . . . 0.0 111.122 -170.576 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.504 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 40.0 ttm105 -91.57 161.1 15.08 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 176.108 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 33.8 mm -58.95 -51.12 76.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 110.376 -0.231 . . . . 0.0 110.376 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.4 tttp -54.83 -36.03 64.59 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.891 176.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.536 ' HB2' ' HG3' ' A' ' 27' ' ' ARG . 22.7 m-20 -61.38 -58.45 8.18 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.145 179.177 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.7 t -60.56 -43.17 93.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.086 0.469 . . . . 0.0 110.672 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.548 HD22 ' HB ' ' A' ' 40' ' ' ILE . 9.3 tp -61.55 -48.18 82.16 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.731 -179.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.88 -38.77 60.24 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.531 -0.759 . . . . 0.0 113.036 -178.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -68.15 -41.74 81.13 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 122.526 0.33 . . . . 0.0 111.48 -176.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.1 mt -89.82 0.34 57.09 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.707 0.289 . . . . 0.0 110.9 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 53.75 65.79 1.41 Allowed 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.753 -178.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.533 ' HB ' HD11 ' A' ' 33' ' ' LEU . 63.2 mt -102.63 121.81 48.34 Favored Pre-proline 0 C--N 1.318 -0.798 0 CA-C-N 115.256 -0.883 . . . . 0.0 109.32 177.671 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 13.8 Cg_exo -68.74 102.53 0.88 Allowed 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.612 2.208 . . . . 0.0 112.492 -178.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.548 ' HB ' HD22 ' A' ' 33' ' ' LEU . 13.2 tt -71.24 -6.51 7.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.736 0.779 . . . . 0.0 109.835 177.034 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 -59.74 -31.77 69.95 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.248 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 12.0 t -130.35 12.01 5.45 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.001 0.429 . . . . 0.0 111.805 -171.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.522 HG11 ' HG2' ' A' ' 68' ' ' ARG . 29.9 m -128.51 144.35 38.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 O-C-N 121.707 -0.621 . . . . 0.0 111.524 -179.298 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.0 t -109.57 131.14 61.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.09 177.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.1 t -103.1 128.49 56.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.032 0.444 . . . . 0.0 110.501 -177.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.551 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 53.3 mttp -123.18 133.39 54.24 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.257 179.372 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.637 ' HG2' HG23 ' A' ' 52' ' ' VAL . 21.5 mmtp -95.02 105.97 17.93 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 171.365 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 18.0 m120 59.52 21.09 9.57 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.361 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 110.51 -17.67 28.16 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.731 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -87.6 131.61 34.36 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 122.636 -0.332 . . . . 0.0 110.827 -177.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.476 HD11 ' H ' ' A' ' 51' ' ' ILE . 4.2 mp -67.25 122.08 17.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.994 179.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 1.136 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 20.5 m -123.65 178.99 2.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.952 -173.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 41.4 pt -113.52 174.66 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.377 0.608 . . . . 0.0 112.626 -171.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -53.33 -39.5 64.14 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.31 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -82.68 0.31 43.85 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -172.332 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 1.136 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 15.6 mm-40 -61.33 133.18 55.57 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.825 0.345 . . . . 0.0 111.023 178.426 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.504 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 31.2 mt-10 -101.92 150.15 23.49 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.374 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 48.7 mt -100.59 126.89 54.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.259 -177.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -108.58 171.52 7.37 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.439 -178.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.532 ' OD1' ' HA ' ' A' ' 8' ' ' MET . 25.8 t70 -69.66 112.81 6.39 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.888 0.375 . . . . 0.0 110.366 -178.436 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.83 36.8 5.94 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.785 -0.722 . . . . 0.0 111.477 -177.268 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.404 ' OD1' ' HD2' ' A' ' 47' ' ' LYS . 2.7 t0 -96.04 161.31 14.03 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 42.2 mm -128.65 112.65 26.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.847 0.356 . . . . 0.0 110.223 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.49 HD13 ' CD2' ' A' ' 10' ' ' PHE . 2.9 mp -110.62 118.62 57.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.148 0.499 . . . . 0.0 110.527 -177.528 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.551 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 41.6 mt-10 -105.42 114.08 28.04 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.227 176.589 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 86.9 t -100.65 108.55 23.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.155 0.502 . . . . 0.0 109.849 177.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 47.7 mt -112.04 117.25 54.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.74 -0.663 . . . . 0.0 110.127 -176.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.522 ' HG2' HG11 ' A' ' 43' ' ' VAL . 49.4 mtm180 . . . . . 0 C--N 1.322 -0.614 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.587 -179.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 69.4 mt . . . . . 0 N--CA 1.451 -0.416 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 105.5 -176.99 22.71 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 -175.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.42 158.57 29.7 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 117.077 0.439 . . . . 0.0 111.525 -179.008 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 25.8 mtpp -120.28 137.91 53.98 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.22 176.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.551 ' CD2' HD12 ' A' ' 64' ' ' ILE . 44.4 p90 -150.13 162.89 39.56 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.002 0.43 . . . . 0.0 110.837 178.216 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 t -109.28 138.85 45.01 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.794 177.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.553 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 5.3 p -129.25 122.13 55.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.25 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.561 HG21 ' HA ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -88.0 125.0 41.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.814 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.456 ' N ' HD12 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -132.62 -171.19 2.6 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.449 -175.732 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -56.81 -46.01 81.87 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -175.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -90.42 7.68 37.52 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 111.722 0.267 . . . . 0.0 111.722 -173.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 131.02 -169.77 21.53 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.328 178.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.55 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.7 ttmt -100.8 123.01 44.38 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.883 0.373 . . . . 0.0 110.085 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 51.0 mttm -103.15 146.36 28.53 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.005 -176.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -120.65 121.15 64.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 170.552 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.3 pp -138.49 171.76 13.9 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.885 0.374 . . . . 0.0 111.4 -173.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -131.61 142.53 49.9 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.249 -174.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -121.56 143.44 49.29 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 176.26 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -73.79 -13.81 80.35 Favored Glycine 0 C--N 1.33 0.226 0 C-N-CA 121.165 -0.54 . . . . 0.0 112.759 -174.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.416 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -138.85 144.32 41.05 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 177.795 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -57.5 120.59 8.61 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 122.321 2.014 . . . . 0.0 111.096 176.387 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.416 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 17.8 mmt180 -113.22 155.97 24.1 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.269 0.557 . . . . 0.0 111.221 -174.096 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.568 ' HD3' ' HA ' ' A' ' 55' ' ' GLU . 28.0 ttm180 -95.48 162.44 13.65 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 173.351 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.519 HD12 HD13 ' A' ' 58' ' ' ILE . 29.2 mm -54.56 -39.53 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.927 0.394 . . . . 0.0 110.733 179.248 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.493 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 17.1 tptm -64.25 -25.93 68.28 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.103 179.331 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.4 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 67.3 m-20 -73.54 -46.59 46.68 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-O 120.689 0.281 . . . . 0.0 110.638 178.707 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.1 t -61.47 -50.16 81.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.642 -178.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -68.36 -29.12 67.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.368 177.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.33 -42.68 64.92 Favored Glycine 0 CA--C 1.522 0.497 0 CA-C-N 115.985 -0.552 . . . . 0.0 112.736 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.4 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 7.2 mm-40 -68.95 -35.72 77.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.849 0.357 . . . . 0.0 111.115 -179.303 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.0 mt -85.64 -14.52 45.33 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.434 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 63.43 20.35 12.2 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.772 179.032 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.436 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 69.6 mt -79.86 131.54 63.41 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.983 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 22.2 Cg_exo -63.54 105.15 0.49 Allowed 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.491 2.127 . . . . 0.0 112.162 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 13.0 tt -67.8 -17.32 22.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.516 0.674 . . . . 0.0 110.377 178.312 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.3 tp10 -64.65 -37.93 89.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.503 -0.772 . . . . 0.0 111.885 -176.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.543 HG22 HG12 ' A' ' 43' ' ' VAL . 10.5 t -85.82 -9.88 56.33 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -170.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.543 HG12 HG22 ' A' ' 42' ' ' THR . 30.8 m -131.06 169.29 21.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 O-C-N 121.974 -0.454 . . . . 0.0 111.118 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.581 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 46.9 t -107.26 134.63 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.778 0.323 . . . . 0.0 111.079 -176.621 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.1 t -108.67 133.21 54.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.975 0.417 . . . . 0.0 110.72 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.61 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 73.6 mttt -118.53 146.54 44.47 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.144 177.732 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.811 ' HG2' HG23 ' A' ' 52' ' ' VAL . 4.0 mmtp -117.69 103.04 9.63 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.125 172.565 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.8 t-20 67.99 7.78 6.04 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.954 176.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 127.95 -25.04 5.02 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.86 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 71.9 mt-30 -87.74 142.42 27.84 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.71 0.255 . . . . 0.0 111.148 -178.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.409 HD11 ' N ' ' A' ' 51' ' ' ILE . 3.5 mp -77.99 119.58 27.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 177.017 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.811 HG23 ' HG2' ' A' ' 47' ' ' LYS . 27.5 m -124.97 178.67 3.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.062 0.458 . . . . 0.0 112.081 -170.723 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 32.2 pt -106.59 -174.01 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.618 178.233 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.493 ' HB2' ' HD3' ' A' ' 30' ' ' LYS . 15.6 p-10 -77.6 -15.2 59.37 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.446 -176.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.568 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 65.3 mm-40 -84.53 5.28 28.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.757 0.313 . . . . 0.0 111.653 -178.56 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.698 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 26.3 mm-40 -80.93 127.77 32.94 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.905 0.384 . . . . 0.0 110.63 176.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.562 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 33.8 mt-10 -88.9 148.01 24.05 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.494 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.519 HD13 HD12 ' A' ' 29' ' ' ILE . 25.3 mt -101.54 120.1 50.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.269 -177.457 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 0.463 ' O ' ' HB2' ' A' ' 62' ' ' ASP . 90.9 m-85 -99.31 170.58 8.55 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.585 -178.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -70.26 114.76 8.71 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.84 0.353 . . . . 0.0 110.605 178.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.26 11.71 38.31 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.705 -177.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.463 ' HB2' ' O ' ' A' ' 59' ' ' PHE . 2.7 t0 -74.49 161.03 30.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 110.277 -177.835 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.8 mm -128.21 111.8 25.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.553 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 2.7 mp -108.95 119.17 58.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.189 0.518 . . . . 0.0 110.649 -178.264 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.61 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 39.7 mt-10 -105.91 112.59 25.71 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.477 176.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 73.1 t -97.33 106.88 19.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.485 0.66 . . . . 0.0 110.424 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.581 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 58.8 mt -93.54 93.22 3.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.11 -179.534 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.404 ' HA ' HG13 ' A' ' 43' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.319 -0.727 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 173.256 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 50.0 mm . . . . . 0 N--CA 1.454 -0.229 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.05 -156.99 19.18 Favored Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 -176.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.566 ' HE2' ' HB ' ' A' ' 58' ' ' ILE . 0.0 OUTLIER -160.69 151.82 18.97 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.919 0.39 . . . . 0.0 111.49 -179.465 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 37.2 ttpt -117.19 119.79 36.3 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 173.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -139.03 167.92 20.98 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.903 0.382 . . . . 0.0 110.835 -173.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.555 ' HB ' HD13 ' A' ' 20' ' ' ILE . 11.4 t -115.04 138.97 50.26 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-O 121.195 0.522 . . . . 0.0 110.738 178.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.478 HG22 ' HB ' ' A' ' 64' ' ' ILE . 10.0 p -127.09 138.28 55.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.253 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.484 HG23 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -116.93 121.24 67.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.345 0.593 . . . . 0.0 109.964 179.955 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 72.8 p -130.88 -163.73 1.35 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.083 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.825 ' HB3' ' HD3' ' A' ' 68' ' ' ARG . 8.7 p-10 -69.97 -21.92 63.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.88 0.371 . . . . 0.0 110.832 178.44 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -82.15 -10.81 59.04 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.478 0.656 . . . . 0.0 110.059 178.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 121.56 -167.91 14.38 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.046 178.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.8 ttmt -104.09 115.23 30.05 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -112.48 154.96 25.07 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.981 0.419 . . . . 0.0 112.009 -174.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.555 HD13 ' HB ' ' A' ' 11' ' ' THR . 24.3 mm -109.06 121.6 62.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 170.459 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -128.53 161.29 29.91 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.064 0.459 . . . . 0.0 110.99 -178.617 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -126.4 141.17 51.99 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.137 -173.441 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.2 t -130.15 140.57 50.76 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 175.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -80.87 -16.12 75.86 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.344 -177.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -138.42 148.61 59.9 Favored Pre-proline 0 C--N 1.321 -0.651 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.159 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -57.74 142.49 96.03 Favored 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.604 2.203 . . . . 0.0 111.782 177.182 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.524 ' HG3' ' HB2' ' A' ' 31' ' ' ASP . 10.4 tpt180 -137.92 158.37 44.48 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.489 -0.559 . . . . 0.0 109.489 -172.253 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.572 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 76.3 mtm180 -102.34 173.62 6.28 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.834 0.349 . . . . 0.0 110.804 173.534 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.577 ' HB ' ' HA ' ' A' ' 54' ' ' ASP . 18.3 mt -68.14 -42.79 85.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.794 175.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.425 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 82.9 tttt -60.69 -32.3 71.53 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.193 176.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.524 ' HB2' ' HG3' ' A' ' 27' ' ' ARG . 81.0 m-20 -67.91 -41.54 82.51 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.701 178.762 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 68.0 t -75.61 -52.75 17.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.862 0.363 . . . . 0.0 110.921 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 10.9 mp -61.78 -35.35 77.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.938 178.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.39 -33.68 68.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.151 177.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -60.52 -45.46 93.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.883 0.373 . . . . 0.0 110.73 -178.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.4 mt -102.0 6.73 41.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.814 -176.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 53.59 69.56 0.69 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.552 0.692 . . . . 0.0 111.064 -176.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 62.8 mt -111.5 117.37 49.23 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.065 179.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.519 ' HB2' HG22 ' A' ' 42' ' ' THR . 17.0 Cg_exo -67.05 113.64 2.9 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.889 2.393 . . . . 0.0 112.016 178.383 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 10.8 tt -79.6 -13.04 13.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.501 0.667 . . . . 0.0 110.59 -178.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -75.63 -17.24 60.06 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.58 -177.027 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.548 HG21 HG13 ' A' ' 43' ' ' VAL . 9.8 t -108.71 -8.33 15.42 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -174.13 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.548 HG13 HG21 ' A' ' 42' ' ' THR . 17.8 m -133.24 167.09 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 O-C-N 122.099 -0.376 . . . . 0.0 110.872 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.44 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 51.9 t -105.26 121.95 57.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.91 -178.222 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.8 t -103.71 127.07 58.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.031 177.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.615 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 98.8 mttt -122.82 144.61 49.07 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.991 0.424 . . . . 0.0 111.82 -178.812 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.556 ' HG2' HG23 ' A' ' 52' ' ' VAL . 17.9 mmtp -100.92 101.9 12.81 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.229 167.753 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.8 t-20 63.28 2.33 1.11 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.996 0.518 . . . . 0.0 111.805 178.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 136.14 -17.27 3.85 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 121.083 -0.579 . . . . 0.0 112.353 -178.533 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . 0.49 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 17.6 mm-40 -87.16 129.53 34.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.407 0.146 . . . . 0.0 110.939 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.6 mp -69.36 120.78 17.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 176.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.556 HG23 ' HG2' ' A' ' 47' ' ' LYS . 17.4 m -124.95 177.48 4.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.149 -176.785 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.459 ' O ' HD13 ' A' ' 29' ' ' ILE . 26.9 pt -113.0 179.63 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.282 174.578 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.577 ' HA ' ' HB ' ' A' ' 29' ' ' ILE . 8.4 p-10 -73.22 -6.09 43.62 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.851 -175.338 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -81.43 -2.12 48.3 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.389 -176.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 58.9 mm-40 -89.69 150.39 22.36 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 122.171 -0.33 . . . . 0.0 111.518 -177.34 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.572 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 21.0 mp0 -88.05 157.07 18.99 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.112 177.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.566 ' HB ' ' HE2' ' A' ' 8' ' ' MET . 2.6 mm -96.47 134.48 33.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 173.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -116.63 167.48 11.03 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.027 0.442 . . . . 0.0 111.275 -175.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -73.97 129.51 38.02 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.111 175.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.75 18.72 79.52 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.433 -176.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -91.51 157.06 17.24 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 179.631 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.448 HG12 HG22 ' A' ' 11' ' ' THR . 10.5 mt -128.3 114.27 33.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.228 0.537 . . . . 0.0 110.897 -175.331 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.478 ' HB ' HG22 ' A' ' 12' ' ' VAL . 22.0 mm -96.67 106.89 19.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.278 -178.373 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.615 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 35.4 tt0 -97.19 101.99 13.66 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 176.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.431 HG23 HG23 ' A' ' 64' ' ' ILE . 80.3 t -100.24 105.94 18.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.209 0.528 . . . . 0.0 110.116 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.44 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 26.2 mt -91.96 95.88 5.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.086 178.415 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.825 ' HD3' ' HB3' ' A' ' 15' ' ' ASP . 1.2 ptm180 . . . . . 0 C--N 1.32 -0.679 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.639 178.094 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 62.4 mt . . . . . 0 N--CA 1.453 -0.323 0 CA-C-O 120.965 0.412 . . . . 0.0 110.385 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 112.27 120.3 3.81 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.979 -0.629 . . . . 0.0 111.73 -177.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.47 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.1 ptt? -113.77 134.38 54.81 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.331 0.586 . . . . 0.0 111.379 -175.354 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.821 ' HD3' ' HB3' ' A' ' 22' ' ' GLU . 6.1 tppt? -106.79 126.64 52.55 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.025 176.37 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.428 ' CE1' ' HE2' ' A' ' 8' ' ' MET . 49.7 p90 -152.81 147.63 26.26 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.141 0.496 . . . . 0.0 111.342 179.135 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.542 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.1 t -98.56 142.59 29.96 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.015 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.6 p -118.73 119.49 61.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.505 0.669 . . . . 0.0 110.002 176.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.507 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -106.75 117.03 51.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-O 121.864 0.84 . . . . 0.0 108.928 176.998 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.406 HG23 ' H ' ' A' ' 15' ' ' ASP . 1.4 m -114.75 175.33 5.54 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.221 -177.472 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.406 ' H ' HG23 ' A' ' 14' ' ' THR . 28.1 t70 -56.34 -23.29 36.35 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-O 120.95 0.405 . . . . 0.0 111.475 178.501 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -87.09 -12.27 47.67 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.559 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 133.43 -174.81 20.52 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.382 -0.913 . . . . 0.0 112.184 -177.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.507 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.7 ttmt -109.94 139.49 44.99 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.66 0.267 . . . . 0.0 110.997 -175.303 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -150.23 136.48 18.77 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 173.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.542 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -98.74 136.18 30.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.748 0.309 . . . . 0.0 110.341 -177.642 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.3 pp -138.58 170.54 15.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.087 177.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.821 ' HB3' ' HD3' ' A' ' 9' ' ' LYS . 13.3 pt-20 -138.84 150.33 45.9 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.925 0.393 . . . . 0.0 111.396 -178.325 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 40.8 m -135.61 133.69 38.52 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.115 177.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -74.31 4.08 35.77 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 121.326 -0.464 . . . . 0.0 113.252 -177.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.442 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -135.35 127.97 18.08 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.648 0.224 . . . . 0.0 110.504 178.527 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.47 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 21.9 Cg_exo -65.15 128.77 21.28 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.781 2.321 . . . . 0.0 110.982 176.159 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.567 ' HA ' ' NE ' ' A' ' 27' ' ' ARG . 0.0 OUTLIER -134.21 171.43 14.25 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.406 -170.838 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.4 ttp-105 -104.03 160.72 14.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.704 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 38.2 mm -56.49 -47.49 81.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.34 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.499 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 29.7 tptp -55.57 -37.99 68.77 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.335 -179.631 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -69.52 -57.43 5.22 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.006 -178.682 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 69.1 t -61.3 -47.93 91.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.855 -177.072 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 19.6 tp -68.02 -35.72 78.75 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.22 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.11 -44.28 61.22 Favored Glycine 0 N--CA 1.447 -0.633 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.62 -179.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -68.97 -21.86 64.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.735 0.302 . . . . 0.0 111.427 179.679 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.5 mt -89.25 -2.87 58.65 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.004 0.43 . . . . 0.0 110.224 174.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 57.48 45.69 19.21 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.125 176.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.425 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 69.0 mt -106.68 117.29 57.23 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.573 176.125 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 16.5 Cg_exo -67.54 112.41 2.61 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.773 2.315 . . . . 0.0 112.766 -176.493 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.537 ' HA ' HG22 ' A' ' 43' ' ' VAL . 11.2 tt -69.23 -14.68 18.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.587 0.708 . . . . 0.0 109.885 177.466 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -60.48 -28.96 68.75 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.61 -179.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 12.9 t -122.53 7.86 9.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.031 0.443 . . . . 0.0 111.589 -172.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 3.6 m -131.65 149.32 32.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 C-N-CA 120.386 -0.525 . . . . 0.0 110.768 -179.162 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.6 t -99.57 129.75 49.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.132 0.491 . . . . 0.0 110.288 179.134 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.8 t -103.3 127.48 57.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.555 -178.651 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.59 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 65.8 mttt -119.29 139.87 51.21 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.696 178.576 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.912 ' HB3' ' HZ3' ' A' ' 47' ' ' LYS . 9.1 mtpm? -127.07 115.88 19.84 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.928 175.152 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 62.36 22.56 13.3 Favored 'General case' 0 C--N 1.326 -0.419 0 O-C-N 123.597 0.56 . . . . 0.0 110.377 178.075 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.85 -14.41 57.43 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.548 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . 0.457 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 68.3 mt-30 -88.07 140.56 29.37 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 122.102 0.161 . . . . 0.0 111.046 -175.625 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.416 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.4 mp -80.07 113.16 19.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 174.124 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.866 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 35.8 m -125.55 178.92 3.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.071 0.462 . . . . 0.0 111.863 -169.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 31.2 pt -112.62 -170.86 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.645 178.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.499 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 7.9 p-10 -81.15 -7.87 59.65 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.794 -174.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -91.08 12.36 20.14 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-O 121.544 0.688 . . . . 0.0 110.216 -177.772 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.866 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 8.3 mm-40 -88.3 128.24 35.48 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.147 179.069 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.559 ' O ' ' HE3' ' A' ' 47' ' ' LYS . 10.7 mm-40 -76.6 142.61 40.65 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.797 177.06 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 39.4 mt -92.23 137.59 21.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 177.119 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -117.06 149.0 41.01 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.055 0.455 . . . . 0.0 111.228 -174.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -66.71 117.2 8.51 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.788 176.168 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.21 11.8 53.46 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 121.152 -0.547 . . . . 0.0 112.223 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 36.6 t0 -97.68 161.94 13.52 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 179.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.436 HD12 HG22 ' A' ' 11' ' ' THR . 50.5 mm -112.24 126.18 69.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.822 0.344 . . . . 0.0 110.531 -177.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 47.3 mm -107.08 130.2 59.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.435 -179.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.59 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 33.7 mt-10 -122.11 129.2 52.15 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 177.651 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 54.3 t -122.33 110.29 26.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.311 0.577 . . . . 0.0 110.634 177.173 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.5 mt -118.28 101.7 12.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.407 -178.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.561 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 14.3 ptt180 . . . . . 0 C--N 1.319 -0.722 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.085 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.1 tp . . . . . 0 N--CA 1.452 -0.353 0 CA-C-O 121.098 0.475 . . . . 0.0 109.743 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.91 151.75 28.2 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.612 -175.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.469 ' HE2' ' HB2' ' A' ' 27' ' ' ARG . 17.1 mtm -128.98 139.91 51.89 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.876 0.369 . . . . 0.0 110.622 -176.051 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -103.89 111.11 23.51 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 173.385 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 23.5 p90 -138.96 161.48 37.25 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.106 0.479 . . . . 0.0 110.923 -178.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.407 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.5 t -118.7 144.3 46.31 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.2 p -117.16 126.3 74.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.122 0.486 . . . . 0.0 109.721 176.278 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.523 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -112.86 127.73 69.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.247 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.408 HG23 ' O ' ' A' ' 66' ' ' VAL . 6.8 m -144.2 -177.04 5.26 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 -177.092 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.405 ' H ' HG21 ' A' ' 14' ' ' THR . 0.8 OUTLIER -49.46 -32.94 13.02 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.184 0.516 . . . . 0.0 110.892 173.714 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -80.5 4.25 18.91 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.153 -177.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 107.49 -177.37 21.35 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.067 177.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.523 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 40.0 ttmt -104.71 117.29 33.72 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 176.464 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -130.62 139.49 50.39 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.077 0.465 . . . . 0.0 110.61 -176.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.449 HD11 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -91.72 137.79 21.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.155 -176.236 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.449 ' N ' HD11 ' A' ' 20' ' ' ILE . 2.2 pt? -137.65 147.69 45.14 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 178.036 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -123.82 126.73 46.96 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.866 0.365 . . . . 0.0 110.412 -177.041 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.0 m -118.91 124.8 47.98 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.896 178.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -77.55 21.22 3.1 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 121.127 -0.559 . . . . 0.0 113.175 -178.538 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.407 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -139.23 138.95 21.58 Favored Pre-proline 0 C--N 1.322 -0.59 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 178.004 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -62.79 127.65 21.12 Favored 'Trans proline' 0 CA--C 1.531 0.337 0 C-N-CA 122.72 2.28 . . . . 0.0 111.484 175.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.469 ' HB2' ' HE2' ' A' ' 8' ' ' MET . 13.9 mmt180 -126.01 160.59 29.63 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.145 0.497 . . . . 0.0 111.298 -172.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.577 ' HG2' ' HA ' ' A' ' 57' ' ' GLU . 65.3 mtm-85 -113.65 168.56 9.67 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 164.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.733 HD12 HG12 ' A' ' 45' ' ' VAL . 24.9 mt -60.76 -45.41 97.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 120.646 0.26 . . . . 0.0 110.566 -178.265 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -61.28 -32.45 72.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.026 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.448 ' OD2' ' HD2' ' A' ' 27' ' ' ARG . 25.6 t70 -73.57 -42.36 61.72 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.484 -179.427 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.4 t -71.3 -51.79 31.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.006 0.431 . . . . 0.0 110.548 177.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 26.2 tp -61.4 -37.85 84.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.427 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.46 -33.31 72.3 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.476 177.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -71.84 -34.11 69.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.167 0.508 . . . . 0.0 109.995 177.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.2 mt -76.92 -10.56 59.45 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.258 174.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 63.3 45.89 4.75 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.689 176.178 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 62.2 mt -115.8 123.08 31.65 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.141 178.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_exo -62.69 132.27 36.94 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.754 2.303 . . . . 0.0 112.339 179.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 10.0 tp -70.38 -15.36 19.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.291 0.567 . . . . 0.0 110.61 -179.038 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -63.87 -32.91 74.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.752 178.568 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.484 HG22 HG11 ' A' ' 43' ' ' VAL . 12.0 t -104.02 -1.66 27.14 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 112.095 0.405 . . . . 0.0 112.095 -172.18 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.559 HG12 ' HG3' ' A' ' 68' ' ' ARG . 33.5 m -128.99 146.46 34.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 120.923 0.392 . . . . 0.0 111.202 -178.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.508 HG11 ' HB ' ' A' ' 67' ' ' ILE . 0.6 OUTLIER -110.02 136.94 44.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 175.555 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.733 HG12 HD12 ' A' ' 29' ' ' ILE . 32.6 t -116.21 133.59 62.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.094 0.473 . . . . 0.0 110.932 -177.777 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.743 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 98.6 mttt -117.84 130.92 56.56 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.255 177.126 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 22.5 ttmm -93.42 105.46 17.53 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 172.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 71.65 -61.3 0.49 Allowed 'General case' 0 C--N 1.33 -0.274 0 O-C-N 124.136 0.897 . . . . 0.0 110.557 -177.099 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -166.6 22.01 0.11 Allowed Glycine 0 N--CA 1.447 -0.585 0 N-CA-C 111.326 -0.709 . . . . 0.0 111.326 177.292 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 35.9 mt-30 -126.5 131.92 51.51 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.194 -0.299 . . . . 0.0 110.194 -176.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.501 HD13 ' HG2' ' A' ' 46' ' ' LYS . 38.9 mm -63.33 122.51 14.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.869 0.366 . . . . 0.0 110.628 177.615 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.683 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 17.3 m -125.74 178.4 4.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.751 -178.688 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.416 ' O ' HD13 ' A' ' 29' ' ' ILE . 26.9 pt -100.17 -177.96 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.659 176.577 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 20.7 p-10 -77.16 -30.12 54.85 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.431 -176.532 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -80.67 14.67 2.01 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 122.094 -0.379 . . . . 0.0 111.897 -173.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.683 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 76.5 mm-40 -86.05 152.07 23.19 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.82 0.343 . . . . 0.0 111.07 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.577 ' HA ' ' HG2' ' A' ' 28' ' ' ARG . 42.2 mp0 -85.52 162.15 19.04 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.925 -177.796 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 39.9 mm -103.81 144.78 13.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 174.199 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 0.735 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 81.0 m-85 -114.15 161.01 18.33 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.735 0.302 . . . . 0.0 110.189 179.179 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -77.63 120.87 23.18 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 175.015 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.51 9.93 68.53 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.904 -0.665 . . . . 0.0 111.789 -176.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.735 ' HB2' ' HB2' ' A' ' 59' ' ' PHE . 22.0 t0 -87.95 147.0 25.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.96 0.409 . . . . 0.0 110.181 -178.357 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 45.5 mm -105.6 122.95 59.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.23 -176.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.405 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 50.0 mm -109.78 115.19 49.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 120.886 0.374 . . . . 0.0 110.718 -177.579 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.743 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 28.3 tt0 -104.3 114.6 28.94 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.878 177.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.408 ' O ' HG23 ' A' ' 14' ' ' THR . 60.1 t -113.08 113.38 43.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.14 -179.049 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.508 ' HB ' HG11 ' A' ' 44' ' ' VAL . 3.8 mt -116.2 118.75 59.81 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.147 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.559 ' HG3' HG12 ' A' ' 43' ' ' VAL . 0.8 OUTLIER . . . . . 0 C--N 1.323 -0.557 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 176.093 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . 0.418 HG23 ' O ' ' A' ' 24' ' ' GLY . 51.4 mm . . . . . 0 N--CA 1.447 -0.583 0 N-CA-C 109.219 -0.659 . . . . 0.0 109.219 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 133.65 163.64 10.47 Favored Glycine 0 N--CA 1.446 -0.667 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 -174.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.576 ' SD ' ' HB ' ' A' ' 58' ' ' ILE . 25.0 ptt? -160.0 137.15 9.43 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 117.173 0.487 . . . . 0.0 111.282 -176.424 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.861 ' HD3' ' HB3' ' A' ' 22' ' ' GLU . 3.8 tppt? -108.19 120.26 41.83 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 175.41 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -140.56 167.96 20.93 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.744 0.306 . . . . 0.0 110.919 -176.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.501 HG21 HD12 ' A' ' 63' ' ' ILE . 1.2 t -133.72 146.71 51.04 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 177.396 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -117.33 119.11 60.83 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.595 177.147 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -103.28 124.56 57.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.523 0.677 . . . . 0.0 109.511 178.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 4.1 m -146.02 173.17 12.41 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -178.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -64.46 -22.39 66.95 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.317 0.58 . . . . 0.0 109.954 174.338 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -72.23 -11.8 60.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.631 175.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 127.19 176.89 14.63 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.904 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -108.17 104.04 13.37 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 177.311 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -104.28 134.12 48.04 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.617 -176.163 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.436 HD12 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -103.33 129.58 54.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 177.269 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.436 ' N ' HD12 ' A' ' 20' ' ' ILE . 94.8 mt -136.26 137.21 40.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.621 -177.379 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.861 ' HB3' ' HD3' ' A' ' 9' ' ' LYS . 17.0 pt-20 -117.62 129.18 55.59 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.364 0.602 . . . . 0.0 110.012 173.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.7 m -109.7 145.46 36.51 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.268 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.418 ' O ' HG23 ' A' ' 6' ' ' ILE . . . -78.29 -10.75 85.97 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.407 -178.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.454 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.54 141.4 31.03 Favored Pre-proline 0 C--N 1.325 -0.496 0 N-CA-C 110.57 -0.159 . . . . 0.0 110.57 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.48 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 11.5 Cg_exo -71.32 123.8 9.87 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.835 2.357 . . . . 0.0 111.742 177.047 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.461 ' HB3' ' CB ' ' A' ' 31' ' ' ASP . 16.2 mmm180 -126.66 175.68 7.78 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -178.205 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.634 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 83.4 mtm180 -94.31 175.2 6.78 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.694 0.283 . . . . 0.0 110.579 175.174 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.728 HD13 HG11 ' A' ' 45' ' ' VAL . 18.2 mt -68.26 -39.73 81.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 177.45 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.529 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 28.2 tptp -59.46 -36.06 75.25 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.695 174.228 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.461 ' CB ' ' HB3' ' A' ' 27' ' ' ARG . 5.9 m-20 -66.07 -62.14 1.65 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.953 177.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.43 HG22 HG13 ' A' ' 58' ' ' ILE . 97.4 t -59.64 -60.6 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.664 -175.686 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 11.1 mp -63.24 -34.36 77.5 Favored 'General case' 0 C--N 1.333 -0.145 0 C-N-CA 120.932 -0.307 . . . . 0.0 111.135 -176.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.3 -47.24 82.07 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.871 -0.681 . . . . 0.0 112.572 -179.309 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -71.08 -22.38 62.11 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.847 0.356 . . . . 0.0 111.09 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 86.6 mt -86.77 1.69 51.37 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.683 176.425 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.9 tt0 65.17 17.17 10.93 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.23 176.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 71.8 mt -83.33 118.24 70.98 Favored Pre-proline 0 C--N 1.324 -0.54 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.129 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -59.93 92.03 0.08 OUTLIER 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 123.128 2.552 . . . . 0.0 112.567 -177.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.533 ' HA ' HG23 ' A' ' 43' ' ' VAL . 14.4 tt -76.24 -17.44 15.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.366 -177.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -67.82 -20.81 65.21 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.685 -177.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.5 t -120.23 10.8 11.42 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -175.106 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.533 HG23 ' HA ' ' A' ' 40' ' ' ILE . 31.5 m -123.0 147.39 27.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 O-C-N 121.769 -0.582 . . . . 0.0 111.372 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 58.8 t -92.48 120.68 42.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.641 178.427 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.728 HG11 HD13 ' A' ' 29' ' ' ILE . 38.5 t -103.4 130.8 53.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.04 0.448 . . . . 0.0 110.854 -176.513 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.726 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 96.9 mttt -118.61 145.78 45.14 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.3 177.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.643 ' HD2' HG12 ' A' ' 52' ' ' VAL . 60.4 mttm -109.34 102.04 10.98 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.179 168.731 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.0 m120 58.54 19.7 6.87 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.628 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 117.97 -18.21 11.54 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.741 178.601 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 70.6 mm-40 -87.57 130.04 34.88 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.881 0.341 . . . . 0.0 110.535 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.433 HD13 ' N ' ' A' ' 51' ' ' ILE . 3.7 mp -73.86 121.28 24.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.055 -179.511 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.801 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 21.2 m -123.99 178.34 3.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.191 -176.033 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.403 ' O ' HD11 ' A' ' 29' ' ' ILE . 32.0 pt -115.1 173.71 3.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 179.764 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.529 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 3.9 p30 -63.03 -23.82 67.63 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -176.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -71.56 -18.09 62.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.12 -176.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.801 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 20.0 mm-40 -67.16 141.46 57.36 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.106 0.479 . . . . 0.0 111.318 -177.701 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.634 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 21.1 mt-10 -89.21 152.02 21.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.578 -179.599 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.576 ' HB ' ' SD ' ' A' ' 8' ' ' MET . 8.1 mm -88.55 146.23 6.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 176.69 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -132.75 163.99 27.79 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.942 0.401 . . . . 0.0 110.569 -178.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -67.64 121.56 16.16 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.987 -0.552 . . . . 0.0 109.615 172.145 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.97 20.2 47.6 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.767 -177.216 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -96.15 131.49 42.54 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.412 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.501 HD12 HG21 ' A' ' 11' ' ' THR . 50.5 mm -111.57 109.99 30.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.696 0.284 . . . . 0.0 110.48 -177.234 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.463 ' HA ' ' O ' ' A' ' 46' ' ' LYS . 40.0 mm -94.97 119.25 42.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.27 -177.024 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.726 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 38.2 tt0 -103.37 120.93 41.74 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 171.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 70.8 t -107.36 108.49 25.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.155 0.502 . . . . 0.0 110.509 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 22.9 mt -103.86 109.15 26.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.756 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 19.1 mtt180 . . . . . 0 C--N 1.325 -0.498 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 176.903 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.3 pt . . . . . 0 N--CA 1.45 -0.437 0 CA-C-O 121.078 0.466 . . . . 0.0 109.781 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.12 -178.09 20.56 Favored Glycine 0 N--CA 1.443 -0.898 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.148 -176.699 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.52 153.94 22.08 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.75 0.31 . . . . 0.0 111.193 -177.685 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.462 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 50.2 mtmt -105.85 128.82 53.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.002 -0.544 . . . . 0.0 109.689 174.171 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 19.3 p90 -139.28 150.26 45.24 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 120.778 0.323 . . . . 0.0 110.76 -178.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.51 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 25.3 m -111.23 120.9 43.82 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.81 0.338 . . . . 0.0 110.435 179.735 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.61 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 21.5 t -112.46 130.32 66.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.898 179.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.605 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 4.0 tt -87.53 129.56 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.807 173.869 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 30.6 p -123.52 -175.22 3.15 Favored 'General case' 0 N--CA 1.442 -0.872 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.822 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -67.63 -28.43 67.72 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.804 -175.274 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.464 ' OD1' ' HE3' ' A' ' 19' ' ' LYS . 3.1 p30 -95.79 -5.94 40.75 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 121.125 -0.23 . . . . 0.0 111.523 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 147.11 -177.36 25.45 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.554 179.08 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.605 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 62.5 tttt -99.25 108.87 21.53 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.083 0.468 . . . . 0.0 109.796 -177.763 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.464 ' HE3' ' OD1' ' A' ' 16' ' ' ASP . 78.3 mttt -103.51 124.72 49.3 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.717 -171.636 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.51 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -90.37 125.14 43.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 170.115 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.412 ' N ' HD22 ' A' ' 21' ' ' LEU . 1.9 pt? -140.52 164.89 28.95 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.462 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.3 OUTLIER -139.58 163.59 32.16 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.9 0.381 . . . . 0.0 111.54 -176.66 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.3 t -134.83 158.24 44.72 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.416 176.591 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -84.76 -4.91 86.99 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.334 -178.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -138.49 141.33 30.9 Favored Pre-proline 0 C--N 1.324 -0.504 0 N-CA-C 110.624 -0.139 . . . . 0.0 110.624 178.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -61.84 131.97 37.68 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.739 2.293 . . . . 0.0 111.498 175.301 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 37.9 mmt180 -132.96 169.49 16.72 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.032 0.444 . . . . 0.0 111.216 -174.044 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -103.14 166.18 10.59 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.467 -0.788 . . . . 0.0 108.887 167.401 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 48.9 mm -55.87 -41.37 66.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.967 0.413 . . . . 0.0 110.394 178.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 46.2 tptt -51.24 -43.29 61.45 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.166 -0.924 . . . . 0.0 111.919 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -66.19 -50.88 62.37 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.842 -174.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.15 -49.29 56.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.018 -178.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.522 HD21 ' HB ' ' A' ' 40' ' ' ILE . 28.1 tp -62.07 -40.6 96.37 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.728 -177.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.73 -44.48 94.78 Favored Glycine 0 N--CA 1.448 -0.523 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.467 -177.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 68.3 mt-10 -72.2 -29.93 64.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.638 0.256 . . . . 0.0 111.615 -179.214 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 72.6 mt -78.18 -8.34 58.19 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 121.068 -0.253 . . . . 0.0 111.006 178.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.9 tt0 64.25 26.13 13.68 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.05 175.209 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.419 ' HB ' HD11 ' A' ' 33' ' ' LEU . 64.7 mt -82.95 124.87 76.31 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.141 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -71.82 108.86 2.52 Favored 'Trans proline' 0 CA--C 1.533 0.44 0 C-N-CA 122.587 2.191 . . . . 0.0 113.02 -179.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.522 ' HB ' HD21 ' A' ' 33' ' ' LEU . 10.0 tt -73.16 -9.75 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-O 121.732 0.777 . . . . 0.0 110.286 178.392 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -69.2 -42.89 75.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.742 -176.108 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.523 HG22 HG11 ' A' ' 43' ' ' VAL . 3.3 t -86.53 -47.68 9.03 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -170.15 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.525 ' CG1' ' HA ' ' A' ' 68' ' ' ARG . 21.7 m -102.01 179.06 0.67 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.213 0 CA-C-O 120.85 0.357 . . . . 0.0 111.8 -173.161 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 30.0 t -103.98 139.55 24.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.565 -172.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 59.6 t -116.17 126.04 73.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 CA-C-O 121.029 0.442 . . . . 0.0 110.249 176.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.506 ' HG2' HD11 ' A' ' 51' ' ' ILE . 95.2 mttt -129.63 151.95 49.68 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.624 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.805 ' HG2' HG21 ' A' ' 52' ' ' VAL . 18.3 mmtp -106.04 100.8 10.33 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 169.46 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 47.6 t30 54.98 24.73 6.17 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.153 177.545 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 124.25 -27.42 5.57 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 120.957 -0.639 . . . . 0.0 113.367 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -89.46 133.96 34.32 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.903 0.351 . . . . 0.0 111.644 -174.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.506 HD11 ' HG2' ' A' ' 46' ' ' LYS . 39.2 mm -65.55 124.19 20.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.674 -0.239 . . . . 0.0 110.389 176.184 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.805 HG21 ' HG2' ' A' ' 47' ' ' LYS . 20.7 m -133.29 178.0 6.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.987 0.422 . . . . 0.0 111.223 -177.563 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.0 pt -109.48 -173.02 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.32 177.265 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 30.1 p-10 -82.19 -19.53 39.64 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 120.905 0.383 . . . . 0.0 110.961 -179.283 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -82.14 26.87 0.51 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.919 0.39 . . . . 0.0 111.856 177.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -96.54 149.95 21.18 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.052 179.132 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -78.33 170.6 16.37 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.999 -177.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 52.2 mt -128.8 120.71 52.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 172.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -112.27 162.2 15.77 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.724 -178.244 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -71.24 126.03 28.53 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.462 177.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.18 6.49 71.35 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.956 -0.64 . . . . 0.0 111.784 -179.255 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 25.8 t0 -88.58 155.79 19.43 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -179.501 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.7 mm -120.79 117.16 52.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 120.932 0.396 . . . . 0.0 110.523 -175.015 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.61 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 3.7 mp -101.71 128.22 54.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 177.873 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.549 ' HA ' HG21 ' A' ' 13' ' ' ILE . 38.2 mt-10 -115.22 107.27 15.07 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 120.771 -0.372 . . . . 0.0 110.996 -178.631 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 78.2 t -99.93 100.53 10.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 121.653 0.74 . . . . 0.0 109.05 174.326 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 51.1 mt -93.07 109.65 22.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.986 -176.131 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.525 ' HA ' ' CG1' ' A' ' 43' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.447 -0.624 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 174.203 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.1 pt . . . . . 0 N--CA 1.452 -0.326 0 CA-C-O 121.291 0.567 . . . . 0.0 110.578 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.31 -178.71 17.17 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -176.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.471 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 23.5 ptt? -161.0 130.88 4.95 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.99 0.424 . . . . 0.0 110.712 179.005 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.65 ' HB3' ' HG3' ' A' ' 22' ' ' GLU . 16.4 ptmt -118.6 119.63 35.07 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 121.294 0.569 . . . . 0.0 109.574 171.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -123.79 151.61 43.12 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.089 -174.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.539 ' CG2' HG13 ' A' ' 63' ' ' ILE . 8.8 t -109.51 134.98 51.24 Favored 'General case' 0 C--N 1.316 -0.857 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.231 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.4 p -110.91 135.96 48.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.039 -179.22 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -114.46 126.54 72.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.385 0.612 . . . . 0.0 110.19 179.695 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.408 HG21 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -146.66 -163.48 1.76 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.369 178.248 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.408 ' H ' HG21 ' A' ' 14' ' ' THR . 14.2 m-20 -65.14 -21.96 66.86 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 121.108 0.48 . . . . 0.0 110.996 178.062 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -86.11 8.25 21.59 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.682 0.753 . . . . 0.0 110.274 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.79 -162.12 18.57 Favored Glycine 0 N--CA 1.448 -0.517 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.712 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -118.15 108.69 15.48 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 177.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -116.0 150.99 36.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.465 -176.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.505 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.2 OUTLIER -106.94 131.09 57.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.091 0.472 . . . . 0.0 109.886 -176.173 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.488 ' N ' HD13 ' A' ' 20' ' ' ILE . 92.2 mt -116.81 135.49 53.7 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.963 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.65 ' HG3' ' HB3' ' A' ' 9' ' ' LYS . 32.4 tt0 -108.96 126.55 53.21 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.948 0.404 . . . . 0.0 110.392 -177.456 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.5 m -118.06 145.39 44.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.958 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -83.17 -9.12 84.5 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 121.047 -0.597 . . . . 0.0 112.605 -176.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.421 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.42 141.89 32.98 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 122.849 -0.207 . . . . 0.0 111.003 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.471 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 7.3 Cg_exo -73.59 121.25 6.94 Favored 'Trans proline' 0 C--O 1.233 0.254 0 C-N-CA 122.817 2.345 . . . . 0.0 110.773 174.045 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 19.2 mmm180 -132.25 177.28 7.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.102 0.477 . . . . 0.0 110.899 -174.087 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.548 ' HG2' ' H ' ' A' ' 30' ' ' LYS . 44.7 ttm180 -94.82 160.85 14.41 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.053 -176.84 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.443 HD11 HG12 ' A' ' 58' ' ' ILE . 37.4 mm -50.97 -41.01 21.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-O 120.815 0.34 . . . . 0.0 110.155 176.315 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.548 ' H ' ' HG2' ' A' ' 28' ' ' ARG . 35.8 tptt -51.03 -37.18 43.7 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.786 -179.329 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -64.93 -62.65 1.43 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.764 0.316 . . . . 0.0 110.845 -177.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.5 t -63.39 -44.21 98.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.762 -177.616 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.774 HD13 ' HB ' ' A' ' 40' ' ' ILE . 3.0 tm? -61.72 -46.43 89.68 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.163 -179.267 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.97 -47.41 46.74 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.141 -175.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -66.53 -34.57 78.22 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 111.954 0.354 . . . . 0.0 111.954 -175.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 82.1 mt -82.6 -4.64 57.98 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.684 0.278 . . . . 0.0 110.9 179.079 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.5 tt0 57.3 34.9 25.41 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.958 177.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.555 ' HB ' HD23 ' A' ' 33' ' ' LEU . 66.0 mt -79.49 125.64 82.46 Favored Pre-proline 0 C--N 1.323 -0.587 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 177.64 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.499 ' HB2' ' HB ' ' A' ' 42' ' ' THR . 34.7 Cg_exo -60.72 101.29 0.17 Allowed 'Trans proline' 0 C--O 1.233 0.226 0 C-N-CA 122.642 2.228 . . . . 0.0 112.874 -176.851 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.774 ' HB ' HD13 ' A' ' 33' ' ' LEU . 9.9 tp -71.29 -19.11 20.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.68 0.752 . . . . 0.0 109.831 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -77.01 -32.11 56.93 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.355 176.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' A' ' 39' ' ' PRO . 22.2 m -92.39 -39.41 11.46 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.193 -171.525 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 10.9 m -112.8 163.17 10.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.458 -175.645 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.401 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 47.3 t -109.89 140.27 29.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.846 -177.827 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.8 t -113.0 130.63 66.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 121.137 0.494 . . . . 0.0 111.467 -178.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.508 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 97.3 mttt -123.08 150.88 42.6 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.743 172.505 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.929 ' HE2' HG11 ' A' ' 52' ' ' VAL . 60.1 pttt -126.76 108.08 10.73 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.638 0.732 . . . . 0.0 110.676 171.619 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.489 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 3.2 t-20 64.26 23.78 13.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.483 -1.235 . . . . 0.0 111.771 174.399 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 112.79 -6.33 25.89 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.8 177.561 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 8.3 mm-40 -111.35 114.54 27.78 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.707 0.289 . . . . 0.0 111.501 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.477 HD11 ' N ' ' A' ' 52' ' ' VAL . 0.1 OUTLIER -62.98 127.15 22.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 175.574 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.929 HG11 ' HE2' ' A' ' 47' ' ' LYS . 23.4 m -138.63 155.89 28.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.084 0.469 . . . . 0.0 111.574 -174.356 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 30.4 pt -96.93 -175.55 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.908 177.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -69.57 -8.91 51.37 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.837 -0.62 . . . . 0.0 112.082 -175.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 29.4 tp10 -81.94 -11.13 59.03 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.03 0.443 . . . . 0.0 111.098 -177.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.724 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 70.1 mm-40 -86.11 146.08 26.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -174.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.5 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.6 mp0 -80.83 160.89 24.68 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.59 173.841 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.443 HG12 HD11 ' A' ' 29' ' ' ILE . 39.9 mt -105.69 147.38 11.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 175.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 0.489 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 98.9 m-85 -111.38 151.84 28.01 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.274 0.559 . . . . 0.0 111.341 -178.138 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.465 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 29.7 t70 -69.61 120.85 16.01 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.958 172.736 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.13 19.31 55.89 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.797 -0.716 . . . . 0.0 111.992 -177.197 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.489 ' OD1' ' HB2' ' A' ' 48' ' ' ASN . 24.0 t0 -94.88 159.9 14.83 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 120.928 0.394 . . . . 0.0 110.448 -179.477 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.539 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.3 mp -117.05 108.55 25.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.03 0.443 . . . . 0.0 110.211 -175.785 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.467 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 1.9 mp -92.77 119.13 39.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-O 121.173 0.511 . . . . 0.0 110.175 -178.59 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.508 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 44.8 tt0 -105.22 115.8 30.87 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.646 178.512 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 79.3 t -100.81 102.62 13.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.352 0.596 . . . . 0.0 110.115 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.401 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 49.1 mt -93.27 93.13 3.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.165 -179.009 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.616 ' HD2' ' O ' ' A' ' 68' ' ' ARG . 0.2 OUTLIER . . . . . 0 C--N 1.317 -0.823 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 170.67 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 47.4 mm . . . . . 0 N--CA 1.453 -0.287 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.452 ' HA2' ' O ' ' A' ' 23' ' ' SER . . . 85.24 100.64 0.68 Allowed Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.351 -176.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.459 ' HE2' ' HB3' ' A' ' 23' ' ' SER . 0.0 OUTLIER -126.1 149.67 48.76 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 -176.704 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.628 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 96.0 mttt -109.75 140.61 43.44 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.297 176.793 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -145.83 152.82 40.12 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.966 0.412 . . . . 0.0 110.268 174.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.505 HG21 ' HG2' ' A' ' 18' ' ' LYS . 4.7 m -110.61 118.06 35.18 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.774 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.639 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.7 p -111.49 132.05 61.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.795 -177.381 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.543 HG23 ' HA ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -87.63 124.56 40.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.293 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.5 p -134.49 -171.06 2.67 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.298 -177.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -74.85 -27.4 60.25 Favored 'General case' 0 N--CA 1.464 0.246 0 O-C-N 122.393 -0.192 . . . . 0.0 111.499 -173.394 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -83.73 -6.23 59.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.112 0.482 . . . . 0.0 110.331 178.306 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 131.4 -173.52 20.4 Favored Glycine 0 N--CA 1.443 -0.839 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 -179.007 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.542 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 66.5 tttt -90.47 106.52 18.55 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.153 0.502 . . . . 0.0 109.788 178.007 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.7 tptm -103.61 121.34 42.72 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.199 -170.056 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.505 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -92.1 126.2 44.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 173.061 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.404 ' N ' HD11 ' A' ' 20' ' ' ILE . 4.0 pp -144.52 162.8 35.65 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.047 177.648 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.628 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -111.91 162.87 14.85 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.138 0.494 . . . . 0.0 110.961 -179.893 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.459 ' HB3' ' HE2' ' A' ' 8' ' ' MET . 40.6 t -130.41 140.59 50.57 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.657 -0.702 . . . . 0.0 109.224 176.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -53.81 -38.62 59.94 Favored Glycine 0 C--N 1.331 0.265 0 O-C-N 123.558 0.537 . . . . 0.0 112.523 -179.168 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.44 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -137.99 152.07 71.35 Favored Pre-proline 0 C--N 1.321 -0.638 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 176.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -59.08 128.38 27.54 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.375 2.05 . . . . 0.0 111.2 174.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.44 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 20.4 mmm180 -129.38 170.7 13.33 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.921 0.391 . . . . 0.0 110.455 -175.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.618 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 45.4 ttm180 -77.34 155.75 31.74 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.099 177.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.56 HG21 HG13 ' A' ' 45' ' ' VAL . 38.1 mm -53.17 -46.59 55.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 CA-C-O 121.712 0.768 . . . . 0.0 109.732 175.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.489 ' HB3' ' HE2' ' A' ' 30' ' ' LYS . 28.7 ttpt -72.39 -20.65 61.41 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.785 -1.098 . . . . 0.0 111.428 -178.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -66.57 -53.48 34.08 Favored 'General case' 0 CA--C 1.514 -0.43 0 CA-C-O 121.094 0.473 . . . . 0.0 109.779 176.389 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.8 t -68.21 -50.02 61.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.928 -177.665 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.507 HD23 ' HB ' ' A' ' 40' ' ' ILE . 15.0 tp -70.48 -28.68 65.17 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.488 -177.117 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.5 -39.47 95.64 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.165 174.7 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -62.59 -39.0 92.33 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.925 0.393 . . . . 0.0 110.658 177.04 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 91.7 mt -75.75 -15.08 60.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.028 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 59.21 75.66 0.39 Allowed 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.523 0.678 . . . . 0.0 110.929 -177.484 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 80.8 mt -134.15 130.45 20.31 Favored Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.195 176.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.463 ' HB2' HG21 ' A' ' 42' ' ' THR . 19.5 Cg_endo -58.61 90.46 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.779 2.32 . . . . 0.0 112.916 -179.608 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.507 ' HB ' HD23 ' A' ' 33' ' ' LEU . 18.9 tt -75.87 -9.81 12.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.672 -178.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -75.5 -43.15 50.68 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.761 -177.08 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.463 HG21 ' HB2' ' A' ' 39' ' ' PRO . 10.0 t -95.27 -5.27 44.04 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -170.182 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.583 ' HB ' ' HA ' ' A' ' 68' ' ' ARG . 17.9 m -115.42 167.94 7.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.906 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.1 t -97.32 123.44 49.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.023 0.44 . . . . 0.0 111.457 -173.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . 0.56 HG13 HG21 ' A' ' 29' ' ' ILE . 61.4 t -103.67 126.57 58.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.94 176.409 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.675 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 25.2 mttm -119.41 114.32 22.15 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.568 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.403 ' HB3' HG13 ' A' ' 52' ' ' VAL . 86.6 tttt -93.64 110.14 21.76 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.828 177.88 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 64.76 16.98 10.75 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.606 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 114.14 -29.16 7.86 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.104 -0.57 . . . . 0.0 112.554 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 15.2 mm100 -88.39 140.88 29.02 Favored 'General case' 0 C--N 1.327 -0.413 0 O-C-N 122.846 -0.208 . . . . 0.0 110.779 -176.62 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 3.4 mp -69.89 118.77 14.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 177.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.403 HG13 ' HB3' ' A' ' 47' ' ' LYS . 34.5 m -122.43 169.93 13.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.087 0.47 . . . . 0.0 110.998 -178.257 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.7 pp -87.76 165.97 2.0 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.906 175.652 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -70.81 -10.59 59.85 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.901 -0.591 . . . . 0.0 112.087 -175.029 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.589 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 2.1 tp10 -83.61 -9.59 58.8 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.449 -175.716 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.417 ' O ' HG12 ' A' ' 29' ' ' ILE . 14.8 mm-40 -66.8 149.67 50.22 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.989 0.423 . . . . 0.0 112.068 -178.311 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.618 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 43.7 mt-10 -103.83 152.64 21.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.576 -179.547 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.491 HG12 HD13 ' A' ' 29' ' ' ILE . 23.6 mt -97.38 143.09 13.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.532 -178.578 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -125.97 171.77 10.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.261 -179.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.42 ' HA ' ' HB2' ' A' ' 8' ' ' MET . 27.0 t70 -71.02 122.58 20.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.813 0.34 . . . . 0.0 111.555 -175.441 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.78 14.13 57.04 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.444 176.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -91.51 161.49 14.94 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.937 0.399 . . . . 0.0 110.368 -178.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.1 mm -120.03 127.36 75.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.927 -176.527 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.639 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.4 mm -116.66 116.39 52.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 120.975 0.417 . . . . 0.0 110.918 -176.707 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.675 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 38.8 mm-40 -104.19 113.79 27.58 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.216 178.813 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 55.9 t -105.18 110.26 30.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.429 0.633 . . . . 0.0 110.289 174.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 62.5 mt -113.16 109.52 28.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.808 -179.12 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.583 ' HA ' ' HB ' ' A' ' 43' ' ' VAL . 13.3 ptt180 . . . . . 0 C--N 1.325 -0.496 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.996 177.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.4 tp . . . . . 0 N--CA 1.452 -0.348 0 CA-C-O 121.332 0.587 . . . . 0.0 110.135 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 106.49 -172.4 18.47 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 -177.147 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.558 ' HA ' ' HB2' ' A' ' 60' ' ' ASP . 26.2 ptt? -160.67 129.09 4.61 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.106 0.479 . . . . 0.0 111.069 179.301 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -111.38 112.39 24.11 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 174.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.459 ' CE1' ' HE3' ' A' ' 8' ' ' MET . 49.2 p90 -136.72 168.13 20.11 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.556 -173.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.483 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.5 t -119.04 146.5 45.0 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.321 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 p -126.02 122.83 62.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.917 176.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.492 HG23 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -101.94 124.86 56.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.565 0.698 . . . . 0.0 110.083 -179.398 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.4 HG23 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -146.08 -160.43 1.15 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.163 177.904 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.4 ' H ' HG23 ' A' ' 14' ' ' THR . 4.7 m-20 -60.71 -29.66 69.49 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.185 0.517 . . . . 0.0 110.594 176.538 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -72.29 -3.19 22.32 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.556 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.04 -167.21 20.47 Favored Glycine 0 N--CA 1.444 -0.823 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -176.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.0 ttmt -93.14 102.97 15.29 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 175.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 84.1 tttt -106.83 120.44 42.02 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.771 -172.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.502 HD12 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -98.62 136.5 29.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.094 -178.871 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.502 ' N ' HD12 ' A' ' 20' ' ' ILE . 4.3 pp -140.33 162.65 34.8 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.684 0.278 . . . . 0.0 110.731 179.221 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -114.97 144.24 43.91 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -178.13 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 47.0 t -131.33 131.55 43.83 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.654 0.264 . . . . 0.0 110.453 -177.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.88 -16.84 74.85 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.221 -0.514 . . . . 0.0 112.778 -179.124 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.457 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.21 144.24 42.41 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 122.785 -0.244 . . . . 0.0 110.967 179.492 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 25' ' ' ALA . 3.0 Cg_exo -75.15 130.14 12.86 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.741 2.294 . . . . 0.0 110.99 174.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 9.5 mtp180 -136.85 164.95 27.09 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.897 0.38 . . . . 0.0 110.71 -175.34 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.599 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 16.3 ttp85 -92.47 164.47 13.45 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.99 -176.823 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.479 HG12 ' O ' ' A' ' 56' ' ' GLU . 45.5 mm -51.84 -46.52 40.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 122.183 0.193 . . . . 0.0 111.288 -179.406 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.468 ' HB2' ' OD2' ' A' ' 54' ' ' ASP . 6.1 tptm -65.19 -26.97 68.38 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.836 0.31 . . . . 0.0 111.836 -177.151 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.403 ' O ' ' HG3' ' A' ' 35' ' ' GLU . 19.8 m-20 -62.72 -57.98 9.08 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 176.367 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 46.1 t -64.51 -41.28 91.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.626 -179.345 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.463 HD22 ' HB ' ' A' ' 38' ' ' ILE . 3.1 tm? -61.57 -46.56 89.39 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.117 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.62 -38.42 93.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 121.133 -0.556 . . . . 0.0 112.583 -178.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.403 ' HG3' ' O ' ' A' ' 31' ' ' ASP . 48.7 mt-10 -65.8 -46.96 76.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.597 0.237 . . . . 0.0 111.518 179.27 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 91.7 mt -76.33 -16.25 59.8 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.755 0.312 . . . . 0.0 110.764 -178.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 60.65 37.24 19.33 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.511 177.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.463 ' HB ' HD22 ' A' ' 33' ' ' LEU . 66.7 mt -79.47 132.48 62.01 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.54 177.752 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -60.59 98.57 0.13 Allowed 'Trans proline' 0 CA--C 1.529 0.255 0 C-N-CA 122.546 2.164 . . . . 0.0 112.437 179.636 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.5 ' HA ' HG21 ' A' ' 43' ' ' VAL . 10.7 tp -69.87 -13.6 17.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.445 0.64 . . . . 0.0 110.149 -179.501 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -64.58 -21.74 66.78 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.245 -0.889 . . . . 0.0 111.076 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.8 t -127.3 10.39 6.8 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 112.282 0.475 . . . . 0.0 112.282 -173.347 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.513 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 35.3 m -131.9 142.26 43.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.121 0.486 . . . . 0.0 111.166 -179.262 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -118.12 138.92 47.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.79 178.378 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.6 t -103.73 136.09 38.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 121.248 0.547 . . . . 0.0 111.071 -176.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.609 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 56.5 mttm -118.1 147.77 42.96 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.008 175.688 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.501 ' HG2' HG23 ' A' ' 52' ' ' VAL . 19.1 mmtp -108.63 101.61 10.74 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.516 172.444 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.463 HD21 ' HA ' ' A' ' 48' ' ' ASN . 0.8 OUTLIER 57.5 27.33 13.86 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.738 177.296 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 116.5 -28.82 7.28 Favored Glycine 0 CA--C 1.522 0.478 0 C-N-CA 121.227 -0.511 . . . . 0.0 113.266 -179.245 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 70.4 mm-40 -88.14 139.81 30.12 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 117.054 0.427 . . . . 0.0 111.38 -172.477 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 26.2 mm -74.63 126.31 35.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.85 0.357 . . . . 0.0 111.052 179.117 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.501 HG23 ' HG2' ' A' ' 47' ' ' LYS . 25.2 m -128.76 178.48 4.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.206 178.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 47.0 pt -118.99 -173.46 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.394 0.616 . . . . 0.0 111.785 -178.401 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.468 ' OD2' ' HB2' ' A' ' 30' ' ' LYS . 16.6 t70 -64.78 -19.98 66.12 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.131 -175.74 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.403 ' HA ' ' HD2' ' A' ' 28' ' ' ARG . 6.0 mm-40 -90.41 3.96 52.3 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.129 -0.487 . . . . 0.0 112.274 -173.468 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.479 ' O ' HG12 ' A' ' 29' ' ' ILE . 0.5 OUTLIER -85.5 135.71 33.72 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.074 0.464 . . . . 0.0 111.366 -179.843 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.599 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 7.1 mp0 -82.11 153.49 26.04 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.257 175.5 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.487 HG21 HD11 ' A' ' 64' ' ' ILE . 22.4 mt -95.84 143.37 12.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 175.309 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 0.566 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 80.3 m-85 -119.51 153.41 35.39 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.212 0.53 . . . . 0.0 111.369 -174.5 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.558 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 29.1 t70 -62.58 121.14 12.6 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.231 172.555 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.13 8.71 74.8 Favored Glycine 0 C--O 1.229 -0.218 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.138 -179.331 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.566 ' HB2' ' HB2' ' A' ' 59' ' ' PHE . 31.4 t70 -93.8 146.96 23.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 -179.653 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 37.9 mm -107.79 128.15 63.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.764 0.316 . . . . 0.0 110.905 -174.219 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.487 HD11 HG21 ' A' ' 58' ' ' ILE . 39.2 mm -108.5 118.48 56.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.946 -177.156 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.609 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 19.0 mp0 -106.09 121.47 44.21 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 172.378 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 97.2 t -105.53 104.04 16.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.198 0.523 . . . . 0.0 110.386 178.02 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.49 HD11 ' HD2' ' A' ' 46' ' ' LYS . 3.1 mp -106.02 114.06 44.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.625 -179.566 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.846 HH11 ' HB2' ' A' ' 68' ' ' ARG . 1.7 mtm105 . . . . . 0 C--N 1.322 -0.62 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 175.708 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 54.2 mt . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.61 166.41 13.31 Favored Glycine 0 N--CA 1.441 -0.97 0 C-N-CA 120.542 -0.837 . . . . 0.0 111.903 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.63 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 0.7 OUTLIER -136.88 139.34 41.57 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 -176.83 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.607 ' HA ' ' HB3' ' A' ' 22' ' ' GLU . 18.0 ttmm -101.03 116.56 33.13 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 172.053 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -136.75 165.48 25.82 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 120.925 0.393 . . . . 0.0 110.442 -179.137 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.872 ' HB ' HD13 ' A' ' 20' ' ' ILE . 12.1 t -121.13 137.2 54.77 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-O 121.288 0.566 . . . . 0.0 110.591 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.1 p -115.15 135.13 56.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.362 176.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.536 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -109.64 122.4 64.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.447 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.82 -165.01 1.54 Allowed 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.067 178.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -71.13 -13.49 61.97 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.09 0.472 . . . . 0.0 110.244 177.485 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -84.49 -9.79 58.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.503 0.668 . . . . 0.0 109.967 175.426 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 112.2 -178.67 19.2 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.986 -179.022 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.536 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.4 ttmt -92.8 114.76 27.4 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 176.011 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.411 ' HB2' ' HE3' ' A' ' 19' ' ' LYS . 30.9 ttmt -127.07 149.1 50.08 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.931 -171.186 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.872 HD13 ' HB ' ' A' ' 11' ' ' THR . 37.5 mm -94.77 126.3 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.829 -178.521 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 3.9 pp -144.64 144.95 31.52 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 172.676 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.607 ' HB3' ' HA ' ' A' ' 9' ' ' LYS . 12.6 pt-20 -139.42 163.4 32.62 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.804 0.335 . . . . 0.0 111.129 -176.144 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.7 t -129.03 165.53 20.99 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.102 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -101.67 14.05 57.78 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 177.314 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -139.3 142.85 33.94 Favored Pre-proline 0 C--N 1.324 -0.509 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 175.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.63 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 34.6 Cg_exo -61.19 136.39 64.37 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.611 2.207 . . . . 0.0 111.15 175.778 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.873 ' HG3' ' HB3' ' A' ' 31' ' ' ASP . 0.0 OUTLIER -140.37 157.87 44.89 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.346 0.593 . . . . 0.0 112.105 -173.06 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.542 ' HD3' ' HA ' ' A' ' 55' ' ' GLU . 43.5 ttm180 -107.06 163.41 13.01 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.08 -0.963 . . . . 0.0 109.134 176.414 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.568 HG13 ' O ' ' A' ' 56' ' ' GLU . 10.1 mt -60.08 -48.32 88.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.375 0 CA-C-O 121.359 0.6 . . . . 0.0 109.615 176.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.9 tptp -51.4 -35.95 41.39 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.678 173.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.873 ' HB3' ' HG3' ' A' ' 27' ' ' ARG . 0.2 OUTLIER -72.45 -55.58 6.78 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.676 179.079 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.408 HG21 ' O ' ' A' ' 28' ' ' ARG . 58.7 t -59.67 -61.07 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.287 -177.687 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.789 ' HG ' HD13 ' A' ' 40' ' ' ILE . 4.1 mm? -69.16 -28.37 66.36 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 121.118 -0.233 . . . . 0.0 111.224 -177.222 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.29 -43.33 63.28 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.454 179.158 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -71.98 -34.52 69.0 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.764 0.316 . . . . 0.0 110.64 178.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.404 ' HG ' ' O ' ' A' ' 32' ' ' VAL . 94.8 mt -73.22 -17.9 61.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.793 0.33 . . . . 0.0 110.147 175.382 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 61.86 36.77 15.79 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.892 174.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.403 HG22 ' HD2' ' A' ' 39' ' ' PRO . 72.4 mt -92.07 139.0 24.29 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.038 179.599 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.403 ' HD2' HG22 ' A' ' 38' ' ' ILE . 35.9 Cg_endo -65.87 65.39 0.42 Allowed 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 122.975 2.45 . . . . 0.0 113.133 177.495 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.789 HD13 ' HG ' ' A' ' 33' ' ' LEU . 7.6 tt -65.62 -22.35 30.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.843 177.593 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -66.29 -19.92 65.96 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.219 -0.9 . . . . 0.0 112.548 -173.111 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.6 t -109.16 11.86 25.33 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.36 -0.536 . . . . 0.0 111.913 -173.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 32.7 m -133.63 173.58 14.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.505 0.193 . . . . 0.0 110.784 178.23 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.834 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 46.5 t -88.26 129.86 38.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.729 0.3 . . . . 0.0 111.242 -175.39 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 19.2 t -108.33 126.04 65.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.826 -179.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.593 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 82.3 mttt -123.25 118.44 27.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.872 175.689 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -97.25 108.42 21.15 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 172.576 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 64.93 14.58 9.38 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.636 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 108.67 -13.08 35.54 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 121.14 -0.552 . . . . 0.0 112.096 -178.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 31.9 mm-40 -89.93 129.39 36.29 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 60.4 mt -72.49 105.78 2.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.263 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.6 m -116.83 171.31 5.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.484 -171.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 35.0 pt -89.45 166.92 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 166.799 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.413 ' O ' ' HB ' ' A' ' 29' ' ' ILE . 14.0 p-10 -77.71 -1.33 30.61 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 120.758 0.313 . . . . 0.0 111.74 -174.485 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.542 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 3.9 tp10 -82.88 12.34 4.98 Favored 'General case' 0 CA--C 1.539 0.547 0 CA-C-O 121.08 0.467 . . . . 0.0 111.066 -177.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.568 ' O ' HG13 ' A' ' 29' ' ' ILE . 26.6 mm-40 -91.23 143.33 26.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.528 178.786 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.529 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 12.3 mp0 -76.0 161.96 28.47 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.849 0.357 . . . . 0.0 110.305 173.4 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.528 ' HB ' ' HE3' ' A' ' 8' ' ' MET . 8.6 mm -104.31 141.34 20.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 174.019 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -118.13 169.8 9.39 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.73 176.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -78.02 122.07 25.07 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.735 -174.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.72 11.53 56.71 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.252 -177.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -83.55 160.81 21.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.979 0.419 . . . . 0.0 110.717 -178.427 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.533 HG12 HG21 ' A' ' 11' ' ' THR . 20.2 mt -129.0 111.28 22.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.452 -179.835 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.405 HD11 ' N ' ' A' ' 64' ' ' ILE . 3.2 mp -95.11 115.67 34.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.277 0.561 . . . . 0.0 109.925 -179.736 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.593 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 37.5 mt-10 -102.29 104.96 15.52 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.086 179.352 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 55.4 t -97.46 107.41 20.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.552 0.691 . . . . 0.0 109.8 178.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.834 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 54.6 mt -92.61 95.07 5.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.251 -176.642 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.323 -0.558 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 173.506 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 7.5 tp . . . . . 0 N--CA 1.448 -0.561 0 CA-C-O 121.055 0.455 . . . . 0.0 109.811 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 121.9 -177.47 16.44 Favored Glycine 0 N--CA 1.443 -0.876 0 C-N-CA 120.728 -0.749 . . . . 0.0 111.689 -178.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' MET . . . . . 0.591 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 25.1 ptt? -156.78 130.99 8.51 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.161 0.505 . . . . 0.0 111.158 -179.328 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.4 ' HE2' ' HB2' ' A' ' 9' ' ' LYS . 7.4 tppt? -101.05 120.03 39.61 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.063 174.136 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 10.0 p90 -141.33 151.75 43.83 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.247 0.546 . . . . 0.0 110.777 -179.727 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' THR . . . . . 0.457 HG21 ' HG2' ' A' ' 18' ' ' LYS . 5.8 m -118.13 128.73 55.01 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.881 178.699 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.766 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.6 p -104.66 122.93 58.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.242 0.544 . . . . 0.0 110.443 178.076 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.436 HG23 ' HG2' ' A' ' 65' ' ' GLU . 7.3 tp -87.53 123.73 40.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 121.213 0.53 . . . . 0.0 109.666 176.026 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.437 ' HB ' ' OD1' ' A' ' 16' ' ' ASP . 0.2 OUTLIER -135.67 -177.19 4.56 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.416 -0.811 . . . . 0.0 108.905 -179.788 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.435 ' H ' HG22 ' A' ' 14' ' ' THR . 4.2 p-10 -71.46 -17.95 62.34 Favored 'General case' 0 C--N 1.327 -0.396 0 O-C-N 122.254 -0.279 . . . . 0.0 111.286 -177.159 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.437 ' OD1' ' HB ' ' A' ' 14' ' ' THR . 9.2 p-10 -90.29 4.23 51.31 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.866 0.365 . . . . 0.0 110.757 179.751 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 122.1 -166.32 14.78 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.778 175.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.457 ' HG2' HG21 ' A' ' 11' ' ' THR . 37.4 tttm -90.34 106.64 18.63 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.402 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.473 ' HB3' HG13 ' A' ' 12' ' ' VAL . 22.7 tttp -103.32 99.02 8.85 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.83 -167.844 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.553 HD12 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -86.12 133.41 29.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.779 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . 0.553 ' N ' HD12 ' A' ' 20' ' ' ILE . 2.1 pt? -144.13 168.23 20.51 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 177.351 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -134.7 148.67 50.36 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.829 0.347 . . . . 0.0 110.445 -177.208 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 22.1 m -129.2 131.97 47.19 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.781 174.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.21 -16.14 59.71 Favored Glycine 0 C--N 1.33 0.246 0 CA-C-N 116.059 -0.519 . . . . 0.0 113.314 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -139.39 144.79 41.43 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 176.075 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.591 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 23.3 Cg_exo -65.69 146.34 83.8 Favored 'Trans proline' 0 C--O 1.234 0.324 0 C-N-CA 122.896 2.397 . . . . 0.0 111.595 176.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.549 ' HD3' ' OD2' ' A' ' 31' ' ' ASP . 96.4 mtt180 -140.16 168.22 20.31 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.309 0.576 . . . . 0.0 111.487 -175.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.592 ' HD3' ' HA ' ' A' ' 55' ' ' GLU . 37.0 ttm105 -94.17 152.52 18.67 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.077 -0.965 . . . . 0.0 108.555 171.022 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.523 HG12 ' O ' ' A' ' 56' ' ' GLU . 46.8 mm -51.13 -44.05 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 122.349 0.26 . . . . 0.0 111.601 -177.532 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.1 tptm -58.43 -27.2 64.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.138 -176.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.549 ' OD2' ' HD3' ' A' ' 27' ' ' ARG . 20.2 t70 -72.47 -53.3 12.49 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.684 -178.101 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 47.5 t -64.97 -44.13 96.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 CA-C-O 121.223 0.535 . . . . 0.0 110.202 178.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.487 HD21 ' HB ' ' A' ' 40' ' ' ILE . 20.7 tp -62.6 -35.66 80.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.977 178.27 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.75 -33.54 66.56 Favored Glycine 0 N--CA 1.449 -0.457 0 CA-C-N 115.446 -0.797 . . . . 0.0 113.099 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -66.37 -46.89 75.14 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 120.851 0.357 . . . . 0.0 111.211 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 92.9 mt -83.58 -16.15 46.42 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.732 -177.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.9 tp10 54.85 80.98 0.11 Allowed 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.824 0.821 . . . . 0.0 110.615 -176.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.452 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 67.8 mt -120.83 127.81 26.07 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.412 178.792 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.47 ' HB2' HG22 ' A' ' 42' ' ' THR . 16.0 Cg_exo -67.16 104.02 0.82 Allowed 'Trans proline' 0 N--CA 1.46 -0.446 0 C-N-CA 122.584 2.189 . . . . 0.0 112.486 -179.248 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.487 ' HB ' HD21 ' A' ' 33' ' ' LEU . 10.7 tt -66.79 -6.07 4.11 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 121.834 0.826 . . . . 0.0 110.237 177.117 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 21.4 tp10 -72.89 -36.2 67.29 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.095 -0.957 . . . . 0.0 110.853 177.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.513 HG21 HG12 ' A' ' 43' ' ' VAL . 15.3 t -101.21 -24.68 14.21 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 120.911 -0.316 . . . . 0.0 111.531 -175.392 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.55 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 34.2 m -116.93 141.56 34.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 110.062 -0.348 . . . . 0.0 110.062 177.074 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.443 HG12 HD11 ' A' ' 51' ' ' ILE . 38.4 t -105.0 140.36 23.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 120.922 0.392 . . . . 0.0 110.653 -177.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 6.9 p -103.39 131.16 52.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.805 -178.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.627 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 87.6 mttt -118.75 146.32 44.86 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.253 177.647 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.731 ' HG2' HG23 ' A' ' 52' ' ' VAL . 13.8 mmtp -109.37 101.25 10.25 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 167.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.5 t-20 50.17 61.11 3.36 Favored 'General case' 0 CA--C 1.537 0.479 0 O-C-N 123.697 0.623 . . . . 0.0 111.122 -179.45 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 87.54 -23.38 12.8 Favored Glycine 0 CA--C 1.52 0.35 0 CA-C-N 116.031 -0.531 . . . . 0.0 113.585 176.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 14.5 mm100 -96.56 127.56 42.67 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 117.06 0.43 . . . . 0.0 111.942 -172.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.532 HD13 ' HG2' ' A' ' 46' ' ' LYS . 33.7 mm -65.2 127.88 26.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.248 177.097 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.731 HG23 ' HG2' ' A' ' 47' ' ' LYS . 29.5 m -131.65 178.8 5.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.075 0.464 . . . . 0.0 111.368 -177.293 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.4 pt -107.81 177.24 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.558 178.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -74.35 -12.9 60.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.033 0.444 . . . . 0.0 110.84 -177.126 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.592 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 14.2 mm-40 -79.99 -5.3 55.47 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.866 179.574 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.523 ' O ' HG12 ' A' ' 29' ' ' ILE . 3.7 mm-40 -68.98 140.04 55.03 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.742 0.306 . . . . 0.0 110.93 178.019 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLU . . . . . 0.558 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 39.3 mt-10 -96.16 147.57 23.61 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 175.197 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.477 ' HB ' ' SD ' ' A' ' 8' ' ' MET . 19.2 mt -89.19 135.22 26.46 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -118.53 146.4 44.59 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.557 -0.292 . . . . 0.0 110.874 -177.089 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.561 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 18.7 t70 -58.66 116.87 3.99 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.598 173.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.14 -17.72 47.44 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 121.039 -0.601 . . . . 0.0 112.145 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 33.2 t0 -77.87 150.77 34.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.888 0.375 . . . . 0.0 110.05 -179.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.1 mm -105.94 115.45 47.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.162 0.506 . . . . 0.0 110.411 -175.203 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.766 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 9.0 tp -95.71 133.26 37.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.38 -179.057 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.627 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 28.6 mt-10 -131.7 130.38 41.93 Favored 'General case' 0 C--N 1.317 -0.814 0 O-C-N 122.166 -0.334 . . . . 0.0 110.795 -175.024 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 86.9 t -115.56 103.97 16.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.173 0.511 . . . . 0.0 109.87 178.149 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 25.6 mt -123.58 109.67 23.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.588 -176.662 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.55 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.533 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 173.114 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.703 ' SD ' HG21 ' A' ' 5' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.482 1.134 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.703 HG21 ' SD ' ' A' ' 4' ' ' MET . 83.1 t -109.26 121.31 62.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 171.495 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.426 HD13 ' H ' ' A' ' 6' ' ' ILE . 0.1 OUTLIER -87.81 132.7 32.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 121.068 0.461 . . . . 0.0 110.864 -179.222 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.29 105.96 0.21 Allowed Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -177.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.559 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.1 ptt? -110.48 130.54 55.53 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.858 0.361 . . . . 0.0 111.044 -174.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.434 ' HB2' ' HB3' ' A' ' 22' ' ' GLU . 3.5 ttpm? -115.03 126.6 54.92 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 174.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 28.8 p90 -138.79 167.89 21.0 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.313 -175.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.46 ' HB ' HD11 ' A' ' 20' ' ' ILE . 13.1 t -125.38 132.02 52.86 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.201 0.524 . . . . 0.0 110.911 178.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.527 HG22 ' HB ' ' A' ' 64' ' ' ILE . 63.0 t -109.28 119.3 58.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 115.458 -0.792 . . . . 0.0 108.946 174.111 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.478 HG23 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -100.34 128.98 51.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.269 0.557 . . . . 0.0 109.949 -177.948 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.406 HG21 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -141.34 -162.81 1.44 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.508 -0.769 . . . . 0.0 108.949 178.507 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.406 ' H ' HG21 ' A' ' 14' ' ' THR . 3.7 m-20 -60.97 -27.44 68.27 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.329 0.585 . . . . 0.0 110.537 176.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -74.46 -9.42 58.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.507 178.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.31 -163.75 19.05 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 111.416 -0.674 . . . . 0.0 111.416 -177.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -76.8 118.76 19.74 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.053 0.454 . . . . 0.0 110.361 175.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 19.8 mtpp -102.48 121.83 43.12 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.18 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.46 HD11 ' HB ' ' A' ' 11' ' ' THR . 21.7 mm -100.32 120.84 50.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.027 0.442 . . . . 0.0 110.913 -177.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.449 ' N ' HD22 ' A' ' 21' ' ' LEU . 2.1 pt? -144.32 141.32 29.68 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.047 176.771 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.434 ' HB3' ' HB2' ' A' ' 9' ' ' LYS . 6.7 pt-20 -121.54 139.01 54.06 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.274 0.559 . . . . 0.0 110.763 178.652 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.9 t -119.9 130.88 55.04 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.518 -0.764 . . . . 0.0 109.446 -176.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -63.43 -31.99 82.63 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 121.23 -0.51 . . . . 0.0 112.868 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.423 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -106.82 123.81 37.41 Favored Pre-proline 0 C--N 1.322 -0.596 0 O-C-N 122.822 -0.222 . . . . 0.0 110.621 178.713 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.559 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 26.1 Cg_exo -63.71 110.89 1.37 Allowed 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.868 2.379 . . . . 0.0 111.544 175.815 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.423 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 14.4 mmm180 -118.57 177.11 4.95 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.232 0.539 . . . . 0.0 111.808 -171.295 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.645 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 15.6 ttp180 -89.88 157.61 17.81 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.946 -179.389 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.517 HD11 HG12 ' A' ' 58' ' ' ILE . 27.1 mm -50.22 -47.41 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 CA-C-O 120.833 0.349 . . . . 0.0 110.308 177.684 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.496 ' HB2' ' O ' ' A' ' 54' ' ' ASP . 46.3 tttp -59.63 -29.56 68.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.275 -176.537 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -64.89 -61.84 1.92 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.057 0.456 . . . . 0.0 110.372 -178.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.1 t -64.84 -38.96 84.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.556 -179.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.447 ' CD1' ' HB ' ' A' ' 38' ' ' ILE . 20.7 tp -63.21 -41.16 99.11 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.363 178.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.23 -35.19 63.97 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 116.009 -0.541 . . . . 0.0 113.376 179.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.437 ' HA ' ' OE1' ' A' ' 35' ' ' GLU . 5.5 mm-40 -65.13 -42.12 94.18 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 117.058 0.429 . . . . 0.0 111.295 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.6 mt -86.11 -8.4 57.9 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 175.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 40.27 70.12 0.27 Allowed 'General case' 0 C--O 1.234 0.269 0 CA-C-N 114.54 -1.209 . . . . 0.0 111.662 -173.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.447 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 63.8 mt -92.6 112.58 56.23 Favored Pre-proline 0 C--N 1.321 -0.667 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 174.701 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.517 ' HB2' HG22 ' A' ' 42' ' ' THR . 34.1 Cg_exo -60.29 103.43 0.21 Allowed 'Trans proline' 0 N--CA 1.46 -0.485 0 C-N-CA 122.693 2.262 . . . . 0.0 112.789 -173.664 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 8.1 tt -65.28 -11.34 11.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 CA-C-O 121.903 0.858 . . . . 0.0 109.493 175.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -66.36 -26.69 67.39 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 114.543 -1.208 . . . . 0.0 111.468 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.517 HG22 ' HB2' ' A' ' 39' ' ' PRO . 5.1 t -125.69 -7.84 6.78 Favored 'General case' 0 C--O 1.234 0.259 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -175.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.545 HG12 ' HB3' ' A' ' 68' ' ' ARG . 2.4 m -121.25 149.55 24.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.668 -177.124 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.4 t -98.85 130.83 47.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.55 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.9 t -103.03 126.73 57.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.137 0.494 . . . . 0.0 110.793 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.567 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 25.5 mttm -125.91 140.56 52.54 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.969 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.533 ' HD2' HG13 ' A' ' 52' ' ' VAL . 31.8 mttm -106.54 102.12 11.53 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.544 171.251 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 60.3 14.85 4.93 Favored 'General case' 0 CA--C 1.536 0.43 0 O-C-N 123.665 0.603 . . . . 0.0 111.164 178.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 126.9 -30.25 4.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.788 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 81.9 mm-40 -86.55 134.21 33.67 Favored 'General case' 0 C--N 1.327 -0.389 0 O-C-N 122.416 -0.461 . . . . 0.0 110.631 -176.024 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.439 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.7 mp -75.21 118.99 22.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -177.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.533 HG13 ' HD2' ' A' ' 47' ' ' LYS . 28.0 m -122.27 166.79 16.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 121.074 0.464 . . . . 0.0 110.745 -177.594 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 22.6 pt -97.81 175.41 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.859 174.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.496 ' O ' ' HB2' ' A' ' 30' ' ' LYS . 13.9 p-10 -81.89 12.84 3.68 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.289 -175.08 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -93.41 -15.84 25.23 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.707 -178.078 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.4 ' O ' ' HG3' ' A' ' 28' ' ' ARG . 60.6 mm-40 -77.33 160.74 28.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.196 -177.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.645 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.1 mp0 -94.17 163.17 13.57 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.989 0.423 . . . . 0.0 111.234 -178.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.517 HG12 HD11 ' A' ' 29' ' ' ILE . 45.8 mt -102.18 144.39 13.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 176.471 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -129.44 155.62 45.4 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.977 0.418 . . . . 0.0 110.693 -176.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.532 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 25.5 t70 -66.55 111.14 3.46 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.356 176.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.58 9.99 42.25 Favored Glycine 0 N--CA 1.445 -0.767 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.242 -177.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 26.2 t70 -88.44 146.3 25.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.859 0.362 . . . . 0.0 110.458 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.418 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.0 mp -113.99 115.91 51.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.278 -178.147 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.527 ' HB ' HG22 ' A' ' 12' ' ' VAL . 4.1 mp -102.04 110.3 28.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.606 179.297 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.567 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 44.1 mt-10 -96.98 98.12 9.81 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.418 HG22 HG23 ' A' ' 64' ' ' ILE . 87.3 t -92.22 101.54 12.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.418 0.628 . . . . 0.0 109.842 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 63.4 mt -109.26 99.97 9.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.501 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.545 ' HB3' HG12 ' A' ' 43' ' ' VAL . 24.3 ptt180 -77.09 135.34 38.59 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 173.575 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.623 HG11 ' HA3' ' A' ' 72' ' ' GLY . 7.7 p -83.09 140.48 16.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.174 0.512 . . . . 0.0 111.615 -169.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 9.9 tt -77.31 138.08 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.577 178.098 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 35.7 t80 63.79 29.71 14.71 Favored 'General case' 0 CA--C 1.534 0.341 0 CA-C-O 121.821 0.819 . . . . 0.0 109.543 -175.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.623 ' HA3' HG11 ' A' ' 69' ' ' VAL . . . -97.72 72.9 0.65 Allowed Glycine 0 N--CA 1.446 -0.662 0 CA-C-N 115.496 -0.774 . . . . 0.0 111.77 179.31 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.865 0 CA-C-O 118.872 -0.96 . . . . 0.0 111.59 -179.499 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 27.6 ttt . . . . . 0 N--CA 1.478 0.966 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 47.6 t -83.54 118.02 30.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.763 -176.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.2 pt -113.32 127.57 70.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.15 176.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.87 178.6 16.39 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.59 -178.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.522 ' HE1' ' HB ' ' A' ' 58' ' ' ILE . 1.2 mpp? -140.02 140.53 36.23 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.758 0.313 . . . . 0.0 110.67 -176.721 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -111.61 111.43 22.42 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 168.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -134.12 167.75 20.09 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 120.906 0.384 . . . . 0.0 110.679 -172.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.526 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 25.8 m -126.38 123.35 37.75 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 177.045 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.514 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.6 p -105.33 123.87 59.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.294 0.568 . . . . 0.0 110.227 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.433 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -107.26 130.54 59.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 121.157 0.503 . . . . 0.0 109.888 179.28 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.455 HG23 ' HB ' ' A' ' 66' ' ' VAL . 0.2 OUTLIER -146.2 -160.42 1.15 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 177.6 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.401 ' H ' HG21 ' A' ' 14' ' ' THR . 1.3 m-20 -58.81 -25.94 63.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.906 0.384 . . . . 0.0 111.413 179.087 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -89.1 10.2 22.64 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.522 -177.231 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.55 -156.65 18.9 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.459 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 54.4 mttm -105.59 103.51 13.04 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -178.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.8 tptm -106.75 115.06 29.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.87 0.367 . . . . 0.0 111.098 -175.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.526 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -78.59 128.61 38.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 176.798 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 96.7 mt -131.51 139.0 49.18 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.778 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -128.61 146.0 50.98 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.023 0.439 . . . . 0.0 110.602 179.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.5 m -135.24 136.23 41.56 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.886 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -86.8 17.97 37.61 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.509 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.426 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.51 131.51 16.18 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 178.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 25' ' ' ALA . 27.9 Cg_exo -62.45 112.68 1.66 Allowed 'Trans proline' 0 C--O 1.234 0.321 0 C-N-CA 122.693 2.262 . . . . 0.0 111.482 177.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -133.0 153.13 51.78 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.075 0.464 . . . . 0.0 111.01 -176.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.552 ' HG3' ' O ' ' A' ' 56' ' ' GLU . 23.6 ttm180 -83.49 164.73 19.68 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.387 -178.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.472 HD13 HG12 ' A' ' 58' ' ' ILE . 31.9 mm -51.56 -49.54 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 CA-C-O 120.714 0.292 . . . . 0.0 110.324 176.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 33.4 tttp -60.36 -29.58 69.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.843 -178.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.464 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 1.1 t70 -67.68 -50.4 57.92 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -177.649 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 60.9 t -73.26 -39.74 56.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.461 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.528 HD23 ' HB ' ' A' ' 40' ' ' ILE . 36.2 tp -62.65 -39.45 93.93 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.376 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.04 -37.91 95.26 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.783 -0.644 . . . . 0.0 112.156 177.062 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.464 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 6.9 mm-40 -64.23 -41.54 96.95 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.151 0.501 . . . . 0.0 110.323 176.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 95.0 mt -76.76 -16.23 59.53 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.935 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 62.93 26.56 15.59 Favored 'General case' 0 CA--C 1.537 0.448 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.055 174.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.403 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 75.1 mt -86.74 122.61 71.5 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.561 -178.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 18.5 Cg_exo -66.42 110.13 1.75 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.713 2.275 . . . . 0.0 112.268 178.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.528 ' HB ' HD23 ' A' ' 33' ' ' LEU . 13.3 tt -68.02 -17.54 22.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.574 178.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -56.98 -40.16 76.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.932 -178.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.8 t -98.01 2.12 48.55 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.817 0.341 . . . . 0.0 111.783 -172.32 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.517 HG13 ' HB3' ' A' ' 68' ' ' ARG . 12.0 m -129.07 171.5 16.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 O-C-N 122.032 -0.417 . . . . 0.0 111.389 -176.294 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.493 ' HB ' ' O ' ' A' ' 67' ' ' ILE . 61.0 t -126.55 136.44 60.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 173.369 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.5 t -106.27 127.81 61.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.964 0.412 . . . . 0.0 111.341 -175.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.484 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 85.7 mttt -118.01 120.78 38.84 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.561 174.718 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.453 ' HE3' ' O ' ' A' ' 57' ' ' GLU . 10.0 mtpm? -97.32 104.29 16.29 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 174.159 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 12.0 m120 62.43 18.17 10.12 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.719 -176.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 109.66 -13.92 32.46 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.685 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -87.63 123.92 32.98 Favored 'General case' 0 C--N 1.326 -0.418 0 O-C-N 122.759 -0.259 . . . . 0.0 110.682 -178.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 65.6 mt -75.06 121.65 27.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.809 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 28.2 m -135.72 177.42 6.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.28 -175.572 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 42.7 pt -102.74 -175.09 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.353 174.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -80.08 -7.68 59.0 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.73 -175.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -89.95 10.99 21.8 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-O 121.232 0.539 . . . . 0.0 110.793 -178.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.809 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 59.3 mm-40 -89.24 148.77 23.42 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.016 0.436 . . . . 0.0 111.536 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.453 ' O ' ' HE3' ' A' ' 47' ' ' LYS . 1.4 tp10 -85.51 142.74 28.96 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.129 -177.71 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.522 ' HB ' ' HE1' ' A' ' 8' ' ' MET . 45.4 mt -88.98 130.77 37.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 177.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -102.56 156.44 17.61 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.274 179.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -73.49 115.63 13.1 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.947 0.403 . . . . 0.0 110.134 177.138 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 103.34 2.25 47.65 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 121.012 -0.613 . . . . 0.0 111.675 -177.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -75.33 146.77 40.66 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -113.97 113.7 44.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.514 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 41.3 mm -89.5 104.68 15.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.821 -176.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.484 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 36.4 mt-10 -102.25 107.73 18.87 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.835 -179.097 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.455 ' HB ' HG23 ' A' ' 14' ' ' THR . 76.3 t -91.92 99.93 10.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 121.335 0.588 . . . . 0.0 109.888 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.493 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 55.8 mt -105.01 103.75 15.82 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 177.524 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.517 ' HB3' HG13 ' A' ' 43' ' ' VAL . 16.4 ptt180 -100.75 150.43 22.79 Favored 'General case' 0 C--N 1.312 -1.034 0 C-N-CA 120.294 -0.563 . . . . 0.0 111.072 -173.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 28.3 m -82.91 149.85 4.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.567 -177.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -77.85 110.74 13.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 177.241 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 62.1 t80 -100.95 107.64 19.18 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.287 -0.869 . . . . 0.0 110.252 -175.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -87.27 114.53 4.14 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.63 -0.795 . . . . 0.0 111.887 179.017 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.245 0.833 0 CA-C-O 118.616 -1.102 . . . . 0.0 111.75 178.611 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 24.8 mmt . . . . . 0 N--CA 1.479 0.976 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.8 t -99.66 105.85 18.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.014 0.435 . . . . 0.0 110.06 177.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 46.0 mm -101.93 125.27 56.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.045 -178.217 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 107.24 76.72 1.01 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.626 -0.797 . . . . 0.0 111.379 -177.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.564 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.0 ptt? -85.74 130.47 34.55 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.12 0.486 . . . . 0.0 110.763 -174.037 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.468 ' HD3' HD12 ' A' ' 20' ' ' ILE . 0.6 OUTLIER -109.77 120.01 41.16 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.464 179.192 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.455 ' CE1' ' HE1' ' A' ' 8' ' ' MET . 45.0 p90 -144.06 167.99 21.07 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.838 0.351 . . . . 0.0 110.761 -175.126 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.504 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 4.7 m -120.93 128.77 53.07 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.684 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 p -108.72 122.44 63.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 121.259 0.552 . . . . 0.0 109.921 175.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.551 ' HB ' ' HG3' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -106.59 118.72 54.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.366 0.603 . . . . 0.0 109.932 179.989 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.4 m -116.47 169.78 9.06 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 177.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -53.97 -38.03 64.58 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.831 0.348 . . . . 0.0 111.58 178.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -77.96 -10.5 59.62 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.821 -175.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 152.74 170.9 19.63 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.321 -0.942 . . . . 0.0 112.578 178.211 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.551 ' HG3' ' HB ' ' A' ' 13' ' ' ILE . 36.4 ttpt -107.14 125.89 51.67 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.265 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -125.69 115.59 20.33 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.139 0.495 . . . . 0.0 111.242 -176.031 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.504 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -88.76 129.89 39.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 174.215 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.1 pp -144.7 165.9 26.73 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.955 0.407 . . . . 0.0 110.566 178.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -123.21 133.15 54.24 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.447 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.1 t -101.96 131.97 48.06 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 177.45 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -55.89 -29.31 54.86 Favored Glycine 0 CA--C 1.518 0.23 0 CA-C-N 116.169 -0.468 . . . . 0.0 113.06 -177.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.476 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -135.22 151.4 75.01 Favored Pre-proline 0 C--N 1.322 -0.591 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 178.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.564 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 28.1 Cg_endo -63.86 127.63 20.01 Favored 'Trans proline' 0 N--CA 1.464 -0.228 0 C-N-CA 122.358 2.039 . . . . 0.0 111.072 174.284 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.476 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 18.3 mmm180 -128.05 170.13 13.27 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.058 0.456 . . . . 0.0 110.894 -173.089 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.6 ttt85 -95.79 159.9 14.75 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 178.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.453 ' CG2' ' HA ' ' A' ' 54' ' ' ASP . 41.6 mm -55.74 -46.77 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 N-CA-C 110.301 -0.259 . . . . 0.0 110.301 178.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.534 ' HZ3' ' HB2' ' A' ' 30' ' ' LYS . 1.8 ttmp? -53.88 -38.56 64.87 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.856 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.418 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 32.9 t70 -62.09 -58.58 7.28 Favored 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.312 -179.514 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.5 t -60.59 -39.62 81.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.729 -179.642 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.521 HD12 ' HB ' ' A' ' 38' ' ' ILE . 15.6 tp -62.81 -47.19 84.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.654 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.42 -45.15 56.07 Favored Glycine 0 N--CA 1.448 -0.541 0 CA-C-N 115.755 -0.657 . . . . 0.0 113.13 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.418 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 34.9 mm-40 -63.47 -41.13 98.61 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.727 0.298 . . . . 0.0 111.658 -177.059 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 82.3 mt -89.22 -0.11 57.2 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.716 -0.22 . . . . 0.0 111.367 -178.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 54.58 73.01 0.42 Allowed 'General case' 0 C--O 1.232 0.181 0 CA-C-O 121.562 0.696 . . . . 0.0 110.772 179.151 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.521 ' HB ' HD12 ' A' ' 33' ' ' LEU . 68.3 mt -118.98 119.68 31.97 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.969 178.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.519 ' HB2' HG23 ' A' ' 42' ' ' THR . 7.0 Cg_exo -73.33 94.5 0.83 Allowed 'Trans proline' 0 N--CA 1.461 -0.425 0 C-N-CA 122.788 2.325 . . . . 0.0 112.34 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 13.4 tt -72.09 -23.07 21.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.362 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -60.81 -34.97 75.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.418 -178.311 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.519 HG23 ' HB2' ' A' ' 39' ' ' PRO . 12.9 t -102.62 -1.52 30.08 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -171.478 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.486 HG13 HG22 ' A' ' 42' ' ' THR . 18.2 m -136.89 -179.77 3.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 O-C-N 122.029 -0.42 . . . . 0.0 110.785 178.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.0 t -115.83 125.76 73.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.05 0.452 . . . . 0.0 111.118 -176.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.6 t -105.31 131.43 54.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.821 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.523 ' HG2' HD13 ' A' ' 51' ' ' ILE . 95.5 mttt -118.85 149.28 41.8 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.135 178.415 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.0 tttm -107.5 104.31 13.84 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 169.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 68.02 -73.89 0.08 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 123.81 0.844 . . . . 0.0 110.662 -174.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -148.4 11.85 1.17 Allowed Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 121.056 -0.592 . . . . 0.0 111.988 178.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -110.86 147.55 34.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.606 0.241 . . . . 0.0 110.805 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.523 HD13 ' HG2' ' A' ' 46' ' ' LYS . 29.6 mm -83.07 116.7 27.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.4 m -126.46 165.32 24.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.075 -175.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 37.8 pt -99.83 -177.21 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.653 172.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.453 ' HA ' ' CG2' ' A' ' 29' ' ' ILE . 6.6 p-10 -83.18 6.54 18.98 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.087 0.47 . . . . 0.0 111.41 -173.31 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -95.27 0.51 53.91 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.152 -175.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -81.15 163.16 23.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.534 176.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.22 154.85 21.17 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.504 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 21.9 mt -103.49 143.15 15.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.065 -179.159 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -123.16 171.18 9.52 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.235 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -70.75 133.76 46.85 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.845 178.486 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.47 30.63 58.1 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.942 -0.647 . . . . 0.0 111.837 -178.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -98.46 162.64 13.05 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.861 0.363 . . . . 0.0 110.769 179.478 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.3 mm -127.64 125.89 66.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.92 179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 2.9 mp -115.82 124.84 72.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 177.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.519 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 35.5 tt0 -110.16 113.87 26.91 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.725 0.298 . . . . 0.0 110.224 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 89.4 t -109.07 104.93 17.86 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.323 0.582 . . . . 0.0 110.352 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.486 HD13 ' HE3' ' A' ' 46' ' ' LYS . 6.3 pt -107.01 129.88 59.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.544 178.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 13.7 ptt180 -94.4 150.02 20.68 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.104 -179.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.2 p -90.26 128.38 42.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 120.934 0.397 . . . . 0.0 110.081 178.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.407 ' C ' HD11 ' A' ' 70' ' ' ILE . 0.0 OUTLIER -84.47 119.59 33.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 177.82 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -119.74 121.71 39.8 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.051 -176.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -72.89 155.53 50.96 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.238 -178.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.245 0.803 0 CA-C-O 119.069 -0.851 . . . . 0.0 111.295 -178.979 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 23.6 ttt . . . . . 0 N--CA 1.479 0.979 0 CA-C-O 120.802 0.334 . . . . 0.0 110.78 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 46.7 t -90.88 110.8 22.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 177.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.1 tp -98.52 121.73 49.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.224 0.535 . . . . 0.0 110.05 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.55 -178.7 17.1 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 -173.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.522 ' HA ' ' HB2' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -160.44 149.17 16.87 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 117.587 0.694 . . . . 0.0 112.284 179.694 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 mtpp -118.2 131.0 56.41 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.119 173.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 24.8 p90 -147.23 157.93 43.77 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.834 0.35 . . . . 0.0 110.805 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.796 HG23 HD11 ' A' ' 63' ' ' ILE . 1.3 t -116.31 140.3 49.48 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 175.637 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.461 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 6.4 p -129.13 129.12 67.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.068 0.461 . . . . 0.0 110.754 -178.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.674 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -92.25 119.96 40.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 172.538 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.07 -157.73 0.84 Allowed 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.722 -174.059 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.902 ' HA ' ' HD2' ' A' ' 68' ' ' ARG . 15.5 t70 -58.29 -44.59 88.55 Favored 'General case' 0 N--CA 1.464 0.259 0 C-N-CA 122.894 0.478 . . . . 0.0 111.897 -171.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -91.25 -10.7 40.55 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -174.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 140.46 -162.9 26.52 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.022 -1.085 . . . . 0.0 112.269 -176.542 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.556 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 36.1 tttt -104.16 120.8 41.9 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.997 0.427 . . . . 0.0 110.836 -174.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -121.67 162.79 20.09 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.424 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -118.52 130.44 73.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.243 0.544 . . . . 0.0 109.725 -179.01 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 98.9 mt -123.44 151.75 42.35 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.72 -176.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -137.27 129.25 29.13 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.758 -0.656 . . . . 0.0 109.528 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.3 m -130.25 154.4 47.63 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.682 0.277 . . . . 0.0 110.659 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.06 -10.91 70.84 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.735 -176.343 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.408 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -124.21 140.12 34.25 Favored Pre-proline 0 C--N 1.323 -0.58 0 O-C-N 122.718 -0.283 . . . . 0.0 110.432 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 25' ' ' ALA . 14.2 Cg_exo -69.27 107.32 1.74 Allowed 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.668 2.246 . . . . 0.0 111.101 176.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 29.7 mmm180 -110.13 169.62 8.61 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.93 0.395 . . . . 0.0 110.605 -176.209 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.531 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 15.1 ttm180 -103.83 160.89 14.41 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.301 178.054 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.535 HG12 ' O ' ' A' ' 56' ' ' GLU . 40.6 mm -53.81 -48.95 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.707 0.289 . . . . 0.0 110.525 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 32.9 tttp -60.41 -24.71 65.37 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.697 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -70.67 -52.36 21.69 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.955 0.407 . . . . 0.0 110.24 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 50.3 t -71.69 -41.07 70.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.374 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.508 HD23 ' HB ' ' A' ' 40' ' ' ILE . 22.0 tp -63.52 -41.49 98.49 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.215 179.253 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.39 -32.13 68.33 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.058 178.375 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.76 -42.4 98.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.068 0.461 . . . . 0.0 110.091 -179.503 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 85.3 mt -91.0 -12.38 36.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.783 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 59.95 77.63 0.31 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.131 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.432 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 68.6 mt -123.76 128.87 25.01 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.999 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.88 115.0 3.36 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.536 2.157 . . . . 0.0 112.92 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.508 ' HB ' HD23 ' A' ' 33' ' ' LEU . 11.3 tp -79.9 -6.05 9.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.803 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -67.26 -43.38 82.01 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.693 -171.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.542 HG22 HG13 ' A' ' 43' ' ' VAL . 8.8 t -92.37 -20.55 20.95 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 113.881 1.067 . . . . 0.0 113.881 -165.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.542 HG13 HG22 ' A' ' 42' ' ' THR . 34.3 m -117.95 163.46 15.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.165 -0.614 . . . . 0.0 111.398 -177.804 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -103.29 139.45 24.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.85 -173.128 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.536 HG23 HG22 ' A' ' 66' ' ' VAL . 89.4 t -120.39 136.53 57.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.939 0.4 . . . . 0.0 110.584 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.575 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 98.1 mttt -128.4 149.62 50.47 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.538 178.483 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.768 ' HE2' ' HB3' ' A' ' 56' ' ' GLU . 52.4 mttm -95.27 100.46 12.24 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.822 -0.806 . . . . 0.0 108.822 167.565 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 66.88 -32.54 0.19 Allowed 'General case' 0 N--CA 1.471 0.609 0 O-C-N 123.953 0.783 . . . . 0.0 111.895 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.558 ' H ' ' C ' ' A' ' 47' ' ' LYS . . . 178.74 -21.5 0.04 OUTLIER Glycine 0 CA--C 1.522 0.511 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.091 -178.34 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -85.85 127.37 34.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.936 0.368 . . . . 0.0 110.419 -178.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.418 HD11 ' H ' ' A' ' 51' ' ' ILE . 3.7 mp -64.82 123.72 18.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 120.64 0.257 . . . . 0.0 110.548 -178.149 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.799 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 27.6 m -130.57 178.76 4.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.091 -177.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 29.6 pt -118.04 -174.5 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.323 177.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.451 ' O ' ' HB ' ' A' ' 29' ' ' ILE . 9.4 p-10 -75.08 -14.58 60.6 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -176.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -84.9 9.33 14.65 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -178.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.799 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 35.0 mm-40 -85.15 137.15 33.2 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.87 0.367 . . . . 0.0 110.731 176.433 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.531 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.1 mp0 -76.96 156.28 32.07 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.406 -179.11 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 58.0 mt -98.26 124.59 51.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -113.46 154.06 27.63 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.581 -178.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.522 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 19.1 t70 -69.11 124.58 24.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.825 178.363 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.46 4.59 70.5 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.845 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -94.01 156.88 16.37 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.796 HD11 HG23 ' A' ' 11' ' ' THR . 47.6 mm -121.73 123.33 69.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 120.776 0.322 . . . . 0.0 110.421 -173.329 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.461 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.2 mm -99.98 107.97 21.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.16 0.505 . . . . 0.0 110.377 -178.304 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.674 ' HA ' HG22 ' A' ' 13' ' ' ILE . 6.3 mm-40 -100.11 97.21 8.06 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.006 -177.446 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.536 HG22 HG23 ' A' ' 45' ' ' VAL . 85.7 t -95.68 106.1 17.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.447 0.641 . . . . 0.0 110.031 177.147 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.2 mt -92.29 99.77 10.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.748 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.902 ' HD2' ' HA ' ' A' ' 15' ' ' ASP . 9.2 ptm180 -75.37 123.12 24.82 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 176.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 26.8 m -85.51 139.32 17.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-O 120.875 0.369 . . . . 0.0 110.58 -178.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 8.3 tt -80.75 103.94 8.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.561 0.696 . . . . 0.0 110.188 177.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -98.85 111.29 23.73 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.864 -177.04 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -141.25 126.3 3.02 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.27 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.879 0 CA-C-O 118.913 -0.937 . . . . 0.0 111.968 178.09 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 53.8 ttm . . . . . 0 N--CA 1.481 1.089 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 58.8 t -82.63 104.67 11.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 121.2 0.524 . . . . 0.0 109.728 179.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 9.6 tp -94.77 141.41 15.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.435 178.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 79.8 -178.12 53.94 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.314 -175.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.405 ' HE2' ' CE1' ' A' ' 10' ' ' PHE . 25.4 ptt? -160.67 137.85 9.16 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 120.961 0.41 . . . . 0.0 111.094 -178.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.664 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 53.6 mtmt -112.15 110.01 20.03 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 169.13 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.405 ' CE1' ' HE2' ' A' ' 8' ' ' MET . 29.2 p90 -122.7 157.12 32.98 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.409 -175.439 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 7.8 m -113.96 117.82 32.42 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.426 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.1 p -102.51 123.45 55.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-O 121.282 0.563 . . . . 0.0 109.906 178.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.448 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -95.68 122.6 47.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -179.655 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.41 HG23 ' H ' ' A' ' 15' ' ' ASP . 0.7 OUTLIER -127.5 175.58 8.13 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.342 -0.845 . . . . 0.0 109.266 -178.609 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.41 ' H ' HG23 ' A' ' 14' ' ' THR . 13.0 p-10 -67.94 -17.7 64.53 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 111.654 0.242 . . . . 0.0 111.654 -176.7 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -91.3 -7.92 49.69 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.891 0.376 . . . . 0.0 110.891 179.115 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 141.05 -179.09 19.67 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.147 179.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.448 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 36.7 ttmt -100.73 110.41 22.51 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.172 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 8.6 mtpp -107.36 114.6 28.73 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.386 -170.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.516 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -82.9 120.58 34.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 173.324 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 95.3 mt -118.63 146.21 44.84 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.374 -177.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.664 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.2 OUTLIER -121.6 141.01 51.51 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.148 0.499 . . . . 0.0 110.842 177.667 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.1 t -135.94 147.04 47.91 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.496 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -76.14 -9.79 85.44 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.679 -179.34 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -136.81 146.06 53.55 Favored Pre-proline 0 C--N 1.326 -0.422 0 O-C-N 122.831 -0.217 . . . . 0.0 110.618 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -63.49 131.37 31.5 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.349 2.033 . . . . 0.0 111.307 176.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.506 ' HD2' ' HB3' ' A' ' 31' ' ' ASP . 15.9 tpp180 -123.39 155.51 37.24 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.004 -175.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.554 ' HG2' ' HA ' ' A' ' 57' ' ' GLU . 96.8 mtt180 -104.18 165.01 11.33 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.765 -0.198 . . . . 0.0 110.715 178.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 45.6 mm -54.8 -55.78 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.974 -175.03 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.888 ' HB3' ' HZ3' ' A' ' 30' ' ' LYS . 2.8 ttpm? -53.15 -39.95 63.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.138 0.494 . . . . 0.0 110.959 179.373 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.506 ' HB3' ' HD2' ' A' ' 27' ' ' ARG . 3.1 m-20 -64.61 -52.44 57.49 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.951 -176.334 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.0 t -62.98 -47.46 92.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.099 0.476 . . . . 0.0 110.713 178.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 14.5 tp -64.7 -38.46 91.06 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.603 -177.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.12 -42.61 66.94 Favored Glycine 0 N--CA 1.447 -0.572 0 CA-C-N 115.492 -0.776 . . . . 0.0 113.108 -179.095 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -68.04 -31.56 71.3 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.903 0.351 . . . . 0.0 111.263 -178.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 97.1 mt -83.0 -4.05 57.89 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.921 0.391 . . . . 0.0 110.292 176.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 55.14 61.81 2.76 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.931 -178.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 62.0 mt -116.98 114.44 39.15 Favored Pre-proline 0 C--N 1.323 -0.577 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.488 175.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.414 ' O ' HG22 ' A' ' 42' ' ' THR . 32.4 Cg_exo -59.57 113.15 1.49 Allowed 'Trans proline' 0 N--CA 1.464 -0.21 0 C-N-CA 122.76 2.306 . . . . 0.0 112.558 -178.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 14.6 tt -63.01 -20.23 25.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 121.383 0.611 . . . . 0.0 110.589 178.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -63.62 -29.96 71.14 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.152 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.414 HG22 ' O ' ' A' ' 39' ' ' PRO . 3.6 t -108.4 4.98 24.97 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-O 120.914 0.388 . . . . 0.0 111.665 -170.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.3 m -136.54 164.57 30.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.14 0.495 . . . . 0.0 111.466 -179.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 56.7 t -123.26 129.28 74.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.499 176.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.0 t -107.3 130.87 58.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 121.283 0.563 . . . . 0.0 111.536 -175.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.812 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 96.3 mttt -117.8 131.88 56.52 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.311 176.274 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.473 ' HB2' HG22 ' A' ' 52' ' ' VAL . 65.0 tttp -93.07 106.29 18.27 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 174.46 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.528 ' HA ' ' HB ' ' A' ' 63' ' ' ILE . 12.5 t-20 68.94 -66.06 0.26 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.064 -177.122 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -159.2 17.23 0.25 Allowed Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.809 -0.516 . . . . 0.0 111.809 179.034 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -131.19 131.27 43.88 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 -177.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.5 mt -64.02 128.86 27.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 176.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.737 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 19.6 m -132.94 178.75 5.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.933 0.397 . . . . 0.0 111.864 -173.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 32.8 pt -88.89 172.73 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.882 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.518 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 6.6 p-10 -76.4 -20.72 56.84 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.326 -176.256 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 68.5 tt0 -85.43 4.99 32.99 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.04 0.448 . . . . 0.0 110.719 -178.056 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.737 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 7.5 mm-40 -72.44 129.89 39.41 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.122 0.487 . . . . 0.0 111.226 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.554 ' HA ' ' HG2' ' A' ' 28' ' ' ARG . 4.7 pt-20 -86.87 140.69 29.4 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.423 179.3 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.459 HG21 HD12 ' A' ' 64' ' ' ILE . 12.0 mt -92.11 150.82 3.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.218 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -124.6 164.65 19.39 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.035 0.445 . . . . 0.0 110.702 -177.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -67.6 128.06 35.07 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.373 176.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.49 12.02 79.05 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.114 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -96.99 161.79 13.68 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 178.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.528 ' HB ' ' HA ' ' A' ' 48' ' ' ASN . 46.4 mm -115.38 138.96 44.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.037 -176.089 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.46 HG22 HG23 ' A' ' 66' ' ' VAL . 49.8 mm -118.29 118.6 58.62 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 176.428 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.812 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 42.7 tt0 -107.5 107.54 18.44 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.46 HG23 HG22 ' A' ' 64' ' ' ILE . 86.0 t -111.99 109.56 28.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.204 0.526 . . . . 0.0 110.51 -179.355 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -114.02 139.0 42.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.426 HH11 ' HD3' ' A' ' 68' ' ' ARG . 35.0 mtm-85 -67.73 154.91 40.48 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 174.377 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.1 p -81.95 136.28 23.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-O 121.656 0.741 . . . . 0.0 111.52 -170.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -98.45 126.32 51.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.111 -0.949 . . . . 0.0 108.803 174.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 16.1 p90 -124.17 139.94 53.44 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.795 -176.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.62 118.12 5.13 Favored Glycine 0 N--CA 1.445 -0.716 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.993 179.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.025 0 CA-C-O 118.174 -1.348 . . . . 0.0 111.104 178.922 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 24.5 ttt . . . . . 0 N--CA 1.481 1.112 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 8.8 p -89.69 131.66 36.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.099 0.476 . . . . 0.0 111.09 -178.156 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 65.4 mt -119.06 124.88 73.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 176.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 97.63 67.04 0.91 Allowed Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.452 -0.88 . . . . 0.0 111.404 -177.215 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.525 ' HE3' ' HB ' ' A' ' 58' ' ' ILE . 26.1 ptt? -87.4 149.95 24.13 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.643 -0.278 . . . . 0.0 111.089 -174.415 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.542 ' HD3' ' OD1' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -129.68 128.96 43.62 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 168.808 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -125.44 153.17 43.88 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -177.593 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.539 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.8 m -109.81 117.67 34.48 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.176 -179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.547 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 3.1 p -112.23 123.41 67.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.458 -178.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.571 HG23 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -88.06 121.02 37.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 177.769 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.92 -162.05 1.14 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.747 -174.264 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -61.96 -45.92 91.54 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 112.202 0.445 . . . . 0.0 112.202 -171.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -87.74 -0.82 57.44 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 111.999 0.37 . . . . 0.0 111.999 -175.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 137.12 -164.73 25.27 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.128 -1.034 . . . . 0.0 112.653 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.558 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.0 ttpt -92.23 116.76 29.24 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.035 0.445 . . . . 0.0 110.212 -177.524 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 41.4 tptt -115.2 113.3 23.74 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.996 -172.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.539 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -84.32 120.54 35.27 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 CA-C-O 121.69 0.757 . . . . 0.0 109.795 174.175 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 97.4 mt -116.02 136.59 52.89 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.24 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.526 ' HG3' ' HB3' ' A' ' 9' ' ' LYS . 39.3 tt0 -113.5 139.49 48.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.275 -0.42 . . . . 0.0 109.974 179.679 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.2 t -132.92 132.91 42.56 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 178.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -66.46 -15.1 63.27 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 121.157 -0.544 . . . . 0.0 113.401 -175.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -133.9 142.32 43.06 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.896 0.348 . . . . 0.0 110.805 -178.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -54.43 133.95 58.96 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.465 2.11 . . . . 0.0 110.845 173.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.444 ' HG3' ' CB ' ' A' ' 31' ' ' ASP . 0.1 OUTLIER -132.56 156.21 47.26 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.487 -168.071 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.428 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 10.2 ttt85 -92.69 158.66 15.82 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 174.192 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 40.8 mm -59.96 -36.94 70.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.126 0.489 . . . . 0.0 109.814 176.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -67.21 -19.83 65.61 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.756 -177.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.444 ' CB ' ' HG3' ' A' ' 27' ' ' ARG . 3.2 m-20 -65.64 -61.8 1.88 Allowed 'General case' 0 CA--C 1.517 -0.312 0 CA-C-O 121.186 0.517 . . . . 0.0 109.766 173.73 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.5 t -59.7 -42.19 87.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.326 179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.541 HD23 ' HB ' ' A' ' 38' ' ' ILE . 1.2 tm? -63.94 -47.6 79.82 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.759 -178.445 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.21 -47.43 36.87 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 116.049 -0.523 . . . . 0.0 113.608 -174.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.4 mm-40 -73.26 -37.16 66.4 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -173.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 79.9 mt -87.64 -13.73 41.9 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.979 -0.288 . . . . 0.0 111.029 -179.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 58.97 77.77 0.29 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.598 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.541 ' HB ' HD23 ' A' ' 33' ' ' LEU . 65.1 mt -118.75 133.21 23.63 Favored Pre-proline 0 C--N 1.319 -0.731 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.51 -179.572 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_exo -62.83 100.49 0.24 Allowed 'Trans proline' 0 CA--C 1.529 0.252 0 C-N-CA 122.562 2.174 . . . . 0.0 112.401 178.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.541 ' HB ' HD21 ' A' ' 33' ' ' LEU . 8.2 tp -85.74 -25.13 6.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.549 -177.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 18.3 tp10 -76.06 -20.55 57.64 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.964 -173.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.49 HG21 HG13 ' A' ' 43' ' ' VAL . 12.9 t -109.1 -10.82 14.99 Favored 'General case' 0 CA--C 1.534 0.365 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 -170.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.49 HG13 HG21 ' A' ' 42' ' ' THR . 25.9 m -122.35 158.54 26.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.049 -179.424 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.0 t -94.98 113.12 28.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.037 -175.65 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 90.4 t -102.83 131.17 51.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.057 0.455 . . . . 0.0 110.439 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.724 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 97.9 mttt -117.28 126.39 52.65 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.948 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.483 ' HB3' HG12 ' A' ' 52' ' ' VAL . 71.1 tttt -96.82 106.06 18.3 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.362 175.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 71.08 -53.24 0.68 Allowed 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 123.947 0.899 . . . . 0.0 110.861 -177.331 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.49 21.49 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.077 178.292 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . 0.593 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 18.6 mm-40 -125.18 143.62 50.85 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.409 HD11 ' N ' ' A' ' 51' ' ' ILE . 3.2 mp -74.61 113.76 13.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 176.388 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.717 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 35.6 m -124.9 178.47 3.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-O 121.14 0.495 . . . . 0.0 111.834 -173.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 23.8 pt -123.22 -171.31 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.597 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -70.08 -12.74 61.82 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.087 -0.506 . . . . 0.0 112.056 -176.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -81.91 -8.51 59.68 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.522 -174.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.717 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 22.0 mm-40 -81.49 163.2 22.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.002 0.43 . . . . 0.0 111.97 -176.445 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.428 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 0.0 OUTLIER -103.15 159.24 15.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.169 177.468 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.525 ' HB ' ' HE3' ' A' ' 8' ' ' MET . 17.9 mt -103.85 154.48 5.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.025 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -128.49 168.41 15.7 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.924 0.392 . . . . 0.0 110.857 -177.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.542 ' OD1' ' HD3' ' A' ' 9' ' ' LYS . 30.8 t70 -81.12 129.42 34.56 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.854 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.04 26.58 72.12 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 121.076 -0.583 . . . . 0.0 111.935 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -97.33 160.97 14.02 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.962 0.411 . . . . 0.0 110.823 -178.055 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 31.3 mm -111.01 113.4 44.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.418 -175.304 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.547 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.1 mm -102.3 109.4 26.25 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.724 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 38.8 tt0 -99.65 99.99 10.92 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.223 -178.735 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 92.3 t -100.37 103.1 14.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.46 0.647 . . . . 0.0 110.522 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 24.2 mt -91.89 99.24 9.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.481 179.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.457 ' HD2' ' O ' ' A' ' 68' ' ' ARG . 0.1 OUTLIER -63.44 151.38 41.26 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.624 175.582 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -82.56 113.34 21.67 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-O 121.522 0.677 . . . . 0.0 111.878 -170.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -90.65 101.72 12.66 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.725 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 169.483 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 22.3 t80 -90.97 110.6 21.86 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.452 -173.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -118.52 115.58 3.16 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.838 -0.696 . . . . 0.0 111.931 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.173 0 CA-C-O 118.544 -1.142 . . . . 0.0 111.591 178.464 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 48.7 ttm . . . . . 0 N--CA 1.483 1.203 0 CA-C-O 120.707 0.289 . . . . 0.0 110.839 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.6 t -108.24 106.01 19.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.525 175.546 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 pt -107.27 122.43 61.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 121.194 0.521 . . . . 0.0 109.747 175.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 113.16 93.94 2.09 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -170.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.406 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.5 ptt? -106.1 144.72 32.41 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.38 0.609 . . . . 0.0 112.293 -165.76 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.507 ' HG2' ' OD1' ' A' ' 60' ' ' ASP . 23.8 pttm -107.06 141.45 38.28 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.289 -0.869 . . . . 0.0 108.911 168.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 31.1 p90 -156.72 147.96 22.2 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.853 0.359 . . . . 0.0 110.163 178.285 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 9.5 t -112.41 138.01 49.76 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.15 0.5 . . . . 0.0 110.225 178.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.751 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.7 p -126.9 134.54 65.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.966 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.607 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 8.1 tt -88.19 124.85 41.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.944 174.454 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -116.68 174.18 6.22 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.138 -0.937 . . . . 0.0 108.542 177.176 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -58.4 -34.17 70.44 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.25 0.548 . . . . 0.0 110.719 178.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -77.07 -10.79 59.61 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.698 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 136.39 176.76 14.54 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.414 -0.898 . . . . 0.0 112.783 178.579 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.607 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 45.4 tttt -96.43 116.64 29.38 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 6.6 mtpm? -129.65 147.87 51.49 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.845 -175.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.591 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -111.15 131.23 62.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -177.388 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.444 ' N ' HD11 ' A' ' 20' ' ' ILE . 2.0 pt? -134.8 165.1 26.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.751 0.31 . . . . 0.0 111.084 -175.742 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -112.44 150.6 30.94 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.337 -179.299 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.4 t -136.03 134.62 38.69 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 175.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.06 -44.94 95.1 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 121.26 -0.495 . . . . 0.0 113.153 -176.141 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -110.88 146.56 34.68 Favored Pre-proline 0 C--N 1.321 -0.637 0 O-C-N 122.625 -0.338 . . . . 0.0 110.741 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.406 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 25.0 Cg_exo -63.72 119.82 7.01 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.682 2.255 . . . . 0.0 111.2 175.282 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 17.2 mmm180 -115.0 177.18 4.74 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.729 -174.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 54.8 ttm-85 -108.38 159.97 16.24 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.466 HD13 ' HE2' ' A' ' 47' ' ' LYS . 38.0 mm -56.87 -48.76 80.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.913 0.387 . . . . 0.0 110.392 176.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.5 tptm -59.6 -28.04 66.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.186 178.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -65.15 -62.09 1.75 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.849 0.356 . . . . 0.0 110.475 178.637 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.3 t -59.89 -42.94 90.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.704 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.512 HD21 ' HB ' ' A' ' 40' ' ' ILE . 24.0 tp -64.65 -43.45 93.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.811 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.22 -40.21 71.06 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.917 -0.583 . . . . 0.0 112.753 -177.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.5 mm-40 -62.5 -38.71 90.97 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.914 0.388 . . . . 0.0 110.964 178.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.1 mt -83.87 -10.96 57.63 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.505 179.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 54.08 61.54 3.01 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.669 -177.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.434 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 69.2 mt -106.6 115.33 60.81 Favored Pre-proline 0 C--N 1.32 -0.704 0 CA-C-N 115.868 -0.605 . . . . 0.0 109.68 176.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -56.81 113.3 1.41 Allowed 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.695 2.263 . . . . 0.0 112.406 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.512 ' HB ' HD21 ' A' ' 33' ' ' LEU . 15.0 tt -72.7 -6.54 8.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.485 0.659 . . . . 0.0 110.819 -178.514 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -67.83 -29.28 68.4 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.998 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.5 HG21 HG11 ' A' ' 43' ' ' VAL . 9.3 t -106.44 0.05 24.49 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.734 -173.754 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.542 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 34.3 m -132.29 156.26 42.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.021 0.439 . . . . 0.0 111.46 -177.322 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.572 HG23 ' HB ' ' A' ' 69' ' ' VAL . 59.0 t -113.8 139.67 38.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.383 176.16 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.432 HG13 HG22 ' A' ' 29' ' ' ILE . 37.1 t -102.98 127.42 56.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.032 0.444 . . . . 0.0 110.218 -179.258 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.587 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 41.1 mttm -124.75 145.02 49.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.401 -178.081 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.587 ' HG2' HG21 ' A' ' 52' ' ' VAL . 28.8 mmtp -112.15 102.41 10.6 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 169.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.9 m120 56.05 24.55 7.93 Favored 'General case' 0 N--CA 1.465 0.323 0 O-C-N 123.451 0.469 . . . . 0.0 111.598 -178.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 115.95 -21.04 12.59 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.921 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . 0.467 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 17.0 mm-40 -85.3 132.28 34.28 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.772 0.32 . . . . 0.0 110.833 -176.187 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.407 HD13 ' N ' ' A' ' 51' ' ' ILE . 3.3 mp -73.99 116.76 16.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.957 0.408 . . . . 0.0 110.294 -179.39 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.883 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 29.3 m -123.63 173.94 8.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.673 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 28.1 pt -101.52 175.3 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.572 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.507 ' HB3' HD13 ' A' ' 40' ' ' ILE . 9.5 p-10 -74.53 -15.52 60.86 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.552 -177.437 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.1 tt0 -81.62 -5.08 57.71 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.823 0.344 . . . . 0.0 110.9 -178.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.883 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 17.2 mm-40 -69.16 142.3 54.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.824 0.345 . . . . 0.0 110.944 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 51.1 mp0 -79.9 166.52 21.57 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.562 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.513 HG23 HD13 ' A' ' 64' ' ' ILE . 55.2 mt -112.45 139.25 38.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 175.355 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 80.3 m-85 -124.18 162.24 24.04 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.778 0.323 . . . . 0.0 110.695 -176.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.507 ' OD1' ' HG2' ' A' ' 9' ' ' LYS . 21.6 t70 -71.77 117.33 13.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.329 177.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.53 -9.56 60.71 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 -179.106 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -78.09 143.83 37.04 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.493 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.504 HG23 HG21 ' A' ' 11' ' ' THR . 45.1 mt -115.35 118.5 58.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-O 121.23 0.538 . . . . 0.0 111.126 -173.42 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.751 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 4.0 mp -101.7 130.91 50.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.623 -178.47 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.587 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 53.0 mt-10 -120.64 118.53 30.38 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 178.647 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 62.0 t -114.06 102.79 14.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.129 0.49 . . . . 0.0 110.235 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.08 137.95 51.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 -179.01 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.542 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 76.0 mtp180 -65.43 138.96 58.46 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.976 0.417 . . . . 0.0 110.717 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.572 ' HB ' HG23 ' A' ' 44' ' ' VAL . 14.9 p -84.0 148.29 5.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.01 -174.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 5.3 tp -78.47 102.04 4.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.777 0.798 . . . . 0.0 110.085 176.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 28.3 p90 -73.23 153.98 40.41 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.687 179.546 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -84.92 53.85 4.86 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.928 -0.653 . . . . 0.0 111.932 178.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.594 -1.114 . . . . 0.0 111.759 -178.635 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 0.979 0 CA-C-O 120.752 0.311 . . . . 0.0 110.189 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.6 p -83.61 119.78 33.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.335 0.588 . . . . 0.0 110.48 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 60.0 mt -96.48 122.25 47.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.013 -179.208 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.99 -179.54 16.53 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.446 -178.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.481 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 25.5 ptt? -156.07 137.91 14.36 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.032 0.444 . . . . 0.0 110.887 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -123.72 114.58 20.12 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 174.462 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -127.98 167.99 15.9 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.283 -173.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.455 ' HB ' HD12 ' A' ' 20' ' ' ILE . 12.9 t -115.42 138.51 50.93 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.922 0.391 . . . . 0.0 110.318 178.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.469 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.4 p -128.41 136.79 59.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.099 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.569 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -107.98 124.85 64.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.3 0.571 . . . . 0.0 109.815 177.785 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.7 p -129.15 -163.03 1.25 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.238 -179.038 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -67.57 -24.36 65.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.024 0.44 . . . . 0.0 110.664 178.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -82.69 -11.5 58.29 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.393 0.616 . . . . 0.0 110.48 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 115.93 -167.65 12.49 Favored Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.419 -176.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.569 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 33.1 ttpt -98.99 127.87 45.0 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -177.599 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.456 ' HE3' ' HB2' ' A' ' 19' ' ' LYS . 29.9 ttmt -137.57 164.26 29.19 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.482 -174.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.455 HD12 ' HB ' ' A' ' 11' ' ' THR . 34.3 mm -98.38 126.44 51.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.7 0.286 . . . . 0.0 111.015 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.45 HD13 HG11 ' A' ' 12' ' ' VAL . 6.9 mp -111.51 144.44 40.73 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.192 176.443 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -127.25 134.88 50.02 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.146 -177.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.0 t -134.19 143.79 48.08 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 177.017 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.6 -18.38 75.58 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 121.234 -0.508 . . . . 0.0 113.246 -176.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -139.07 151.14 67.26 Favored Pre-proline 0 C--N 1.324 -0.539 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.481 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 25.0 Cg_exo -63.96 119.53 6.61 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.394 2.063 . . . . 0.0 111.234 174.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.41 ' HB3' ' CB ' ' A' ' 31' ' ' ASP . 50.9 mmm-85 -116.6 157.66 24.96 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.191 -175.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.596 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 23.4 mtt180 -82.08 167.35 18.88 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 172.044 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.533 ' HB ' ' HA ' ' A' ' 54' ' ' ASP . 48.9 mm -61.14 -35.16 63.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 168.363 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 40.7 tptt -61.37 -33.92 74.45 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 114.662 -1.154 . . . . 0.0 110.822 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.41 ' CB ' ' HB3' ' A' ' 27' ' ' ARG . 4.5 m-20 -65.87 -58.48 5.49 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.317 177.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 58.6 t -59.43 -53.04 53.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.329 -176.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.551 ' HG ' ' HB ' ' A' ' 38' ' ' ILE . 10.7 mp -71.82 -35.88 70.06 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.367 -176.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.83 -43.6 58.36 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.662 179.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -73.09 -33.04 65.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.023 0.439 . . . . 0.0 111.154 -175.101 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.0 mt -97.35 -5.99 35.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.449 -0.342 . . . . 0.0 111.511 -178.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 62.23 75.18 0.41 Allowed 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.684 0.754 . . . . 0.0 110.717 -176.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.551 ' HB ' ' HG ' ' A' ' 33' ' ' LEU . 67.4 mt -123.66 116.27 27.93 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.756 178.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 17.1 Cg_exo -67.04 109.64 1.77 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.658 2.238 . . . . 0.0 112.906 -178.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.446 ' HB ' HD21 ' A' ' 33' ' ' LEU . 9.9 tt -81.59 -5.74 9.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 122.009 0.909 . . . . 0.0 109.203 176.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -69.84 -31.64 69.6 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.855 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.53 HG21 HG11 ' A' ' 43' ' ' VAL . 4.6 t -96.14 -36.95 10.79 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.71 0.633 . . . . 0.0 112.71 -172.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.53 HG11 HG21 ' A' ' 42' ' ' THR . 21.3 m -116.56 162.61 14.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 C-N-CA 120.888 -0.325 . . . . 0.0 111.069 -175.745 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.9 t -102.93 131.93 50.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 120.855 0.36 . . . . 0.0 111.671 -173.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.0 t -103.65 130.5 54.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.938 176.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.607 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 92.5 mttt -118.81 143.61 46.83 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.842 0.353 . . . . 0.0 111.442 179.451 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.754 ' HG2' HG23 ' A' ' 52' ' ' VAL . 10.0 mmtp -100.57 102.2 13.3 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 170.273 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 65.49 -1.01 1.06 Allowed 'General case' 0 CA--C 1.541 0.619 0 O-C-N 123.426 0.454 . . . . 0.0 111.512 178.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 132.2 -10.64 5.34 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 121.107 -0.568 . . . . 0.0 111.907 -176.513 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . 0.44 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 14.6 mm100 -87.07 128.1 35.11 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 122.045 0.138 . . . . 0.0 110.664 178.735 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.401 HD11 ' N ' ' A' ' 51' ' ' ILE . 3.8 mp -71.32 114.85 10.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.037 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.754 HG23 ' HG2' ' A' ' 47' ' ' LYS . 28.1 m -125.77 178.79 3.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.117 0.484 . . . . 0.0 111.52 -174.591 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 24.7 pt -115.09 -170.92 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.348 177.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.533 ' HA ' ' HB ' ' A' ' 29' ' ' ILE . 35.1 p-10 -77.49 -7.19 55.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.656 -175.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -72.79 -22.16 60.88 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.918 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.535 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 8.0 mm-40 -69.11 135.71 51.14 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.497 0.554 . . . . 0.0 112.497 -174.379 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.596 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 58.1 mp0 -82.38 144.2 30.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.914 173.315 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 30.9 mt -91.21 142.34 13.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 176.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -119.4 162.2 19.22 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.856 0.36 . . . . 0.0 110.75 -177.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -69.06 131.14 44.55 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.599 173.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.59 23.51 75.07 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.924 -177.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 31.2 t0 -97.4 154.04 17.72 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 178.046 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.443 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.0 mp -110.21 116.78 53.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-O 121.03 0.443 . . . . 0.0 110.525 -177.618 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.469 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 41.5 mm -103.55 108.84 25.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.899 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.607 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 44.5 mt-10 -102.22 107.16 18.13 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 178.205 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 93.4 t -97.05 102.45 13.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.38 0.609 . . . . 0.0 109.681 178.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 64.0 mt -96.36 105.88 17.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.406 -177.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.472 ' HA ' HG12 ' A' ' 43' ' ' VAL . 0.6 OUTLIER -75.92 131.48 39.65 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.521 174.641 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 34.9 m -83.31 149.66 4.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.715 -177.31 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 9.4 tt -77.33 112.23 15.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.527 0.679 . . . . 0.0 109.892 178.236 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 48.8 t80 -89.33 -25.62 21.52 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.824 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 122.85 -177.03 16.59 Favored Glycine 0 N--CA 1.444 -0.805 0 CA-C-N 115.441 -0.8 . . . . 0.0 111.876 178.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.86 0 CA-C-O 119.022 -0.877 . . . . 0.0 111.073 178.928 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 13.7 tpt . . . . . 0 N--CA 1.477 0.898 0 CA-C-O 120.647 0.26 . . . . 0.0 110.32 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.7 t -108.32 122.3 62.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.067 178.178 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.402 HD13 ' N ' ' A' ' 6' ' ' ILE . 3.2 mp -97.15 121.92 48.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 178.264 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.33 179.96 45.16 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.14 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.532 ' HA ' ' OD1' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -159.91 158.07 30.15 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.762 0.315 . . . . 0.0 110.221 178.701 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.547 ' HB2' HD12 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -133.79 145.78 50.08 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 173.32 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.49 ' CD2' HD13 ' A' ' 64' ' ' ILE . 38.4 p90 -144.41 141.06 29.39 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.388 -178.507 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.618 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 18.0 m -95.39 118.35 31.98 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.079 0.466 . . . . 0.0 110.06 177.114 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.2 p -107.33 134.17 49.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.955 -179.666 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.49 HG23 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -103.76 127.48 57.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 121.528 0.68 . . . . 0.0 109.6 177.647 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 16.7 m -141.81 166.86 23.58 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.5 m-20 -63.73 -17.77 63.35 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.868 0.366 . . . . 0.0 111.076 177.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -77.73 -10.98 59.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.335 0.588 . . . . 0.0 110.132 175.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 129.44 157.87 9.32 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 112.124 179.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.9 ttmt -86.1 109.96 19.21 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 173.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -129.14 131.86 47.26 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.271 -173.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.618 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -81.84 124.3 38.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.397 0.618 . . . . 0.0 110.042 176.042 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.487 HD11 ' N ' ' A' ' 22' ' ' GLU . 1.1 tm? -106.81 135.28 48.62 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -178.367 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.487 ' N ' HD11 ' A' ' 21' ' ' LEU . 4.9 tm-20 -115.36 131.53 56.9 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -177.018 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.2 m -135.4 126.64 28.24 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.83 0.348 . . . . 0.0 110.787 -179.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -72.0 -17.57 77.16 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.079 178.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -118.77 121.72 30.43 Favored Pre-proline 0 C--N 1.321 -0.665 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 176.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_exo -48.61 139.13 24.21 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.138 2.559 . . . . 0.0 111.729 177.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.536 ' HG3' ' HB2' ' A' ' 31' ' ' ASP . 1.9 tpp85 -133.51 147.48 51.62 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.761 0.315 . . . . 0.0 111.122 -170.576 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.504 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 40.0 ttm105 -91.57 161.1 15.08 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 176.108 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 33.8 mm -58.95 -51.12 76.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 110.376 -0.231 . . . . 0.0 110.376 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.4 tttp -54.83 -36.03 64.59 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.891 176.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.536 ' HB2' ' HG3' ' A' ' 27' ' ' ARG . 22.7 m-20 -61.38 -58.45 8.18 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.145 179.177 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.7 t -60.56 -43.17 93.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.086 0.469 . . . . 0.0 110.672 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.548 HD22 ' HB ' ' A' ' 40' ' ' ILE . 9.3 tp -61.55 -48.18 82.16 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.731 -179.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.88 -38.77 60.24 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.531 -0.759 . . . . 0.0 113.036 -178.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -68.15 -41.74 81.13 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 122.526 0.33 . . . . 0.0 111.48 -176.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.1 mt -89.82 0.34 57.09 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.707 0.289 . . . . 0.0 110.9 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 53.75 65.79 1.41 Allowed 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.753 -178.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.533 ' HB ' HD11 ' A' ' 33' ' ' LEU . 63.2 mt -102.63 121.81 48.34 Favored Pre-proline 0 C--N 1.318 -0.798 0 CA-C-N 115.256 -0.883 . . . . 0.0 109.32 177.671 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 13.8 Cg_exo -68.74 102.53 0.88 Allowed 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.612 2.208 . . . . 0.0 112.492 -178.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.548 ' HB ' HD22 ' A' ' 33' ' ' LEU . 13.2 tt -71.24 -6.51 7.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.736 0.779 . . . . 0.0 109.835 177.034 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 -59.74 -31.77 69.95 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.248 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 12.0 t -130.35 12.01 5.45 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.001 0.429 . . . . 0.0 111.805 -171.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.522 HG11 ' HG2' ' A' ' 68' ' ' ARG . 29.9 m -128.51 144.35 38.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 O-C-N 121.707 -0.621 . . . . 0.0 111.524 -179.298 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.0 t -109.57 131.14 61.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.09 177.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.1 t -103.1 128.49 56.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.032 0.444 . . . . 0.0 110.501 -177.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.551 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 53.3 mttp -123.18 133.39 54.24 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.257 179.372 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.637 ' HG2' HG23 ' A' ' 52' ' ' VAL . 21.5 mmtp -95.02 105.97 17.93 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 171.365 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 18.0 m120 59.52 21.09 9.57 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.361 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 110.51 -17.67 28.16 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.731 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -87.6 131.61 34.36 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 122.636 -0.332 . . . . 0.0 110.827 -177.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.476 HD11 ' H ' ' A' ' 51' ' ' ILE . 4.2 mp -67.25 122.08 17.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.994 179.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 1.136 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 20.5 m -123.65 178.99 2.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.952 -173.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 41.4 pt -113.52 174.66 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.377 0.608 . . . . 0.0 112.626 -171.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -53.33 -39.5 64.14 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.31 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -82.68 0.31 43.85 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -172.332 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 1.136 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 15.6 mm-40 -61.33 133.18 55.57 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.825 0.345 . . . . 0.0 111.023 178.426 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.504 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 31.2 mt-10 -101.92 150.15 23.49 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.374 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 48.7 mt -100.59 126.89 54.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.259 -177.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -108.58 171.52 7.37 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.439 -178.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.532 ' OD1' ' HA ' ' A' ' 8' ' ' MET . 25.8 t70 -69.66 112.81 6.39 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.888 0.375 . . . . 0.0 110.366 -178.436 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.83 36.8 5.94 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.785 -0.722 . . . . 0.0 111.477 -177.268 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.404 ' OD1' ' HD2' ' A' ' 47' ' ' LYS . 2.7 t0 -96.04 161.31 14.03 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 42.2 mm -128.65 112.65 26.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.847 0.356 . . . . 0.0 110.223 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.49 HD13 ' CD2' ' A' ' 10' ' ' PHE . 2.9 mp -110.62 118.62 57.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.148 0.499 . . . . 0.0 110.527 -177.528 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.551 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 41.6 mt-10 -105.42 114.08 28.04 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.227 176.589 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 86.9 t -100.65 108.55 23.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.155 0.502 . . . . 0.0 109.849 177.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 47.7 mt -112.04 117.25 54.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.74 -0.663 . . . . 0.0 110.127 -176.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.522 ' HG2' HG11 ' A' ' 43' ' ' VAL . 49.4 mtm180 -75.01 133.66 41.6 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.587 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -101.31 122.61 53.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.213 0.53 . . . . 0.0 110.46 179.313 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 48.0 mm -87.08 103.42 13.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.165 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 56.0 t80 -118.14 127.33 53.66 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.17 -179.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -87.18 -56.13 2.23 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.512 -177.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.514 -1.159 . . . . 0.0 111.651 -178.282 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 86.9 mtp . . . . . 0 N--CA 1.48 1.037 0 CA-C-O 120.72 0.295 . . . . 0.0 110.51 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.1 t -105.01 108.37 24.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 116.312 -0.403 . . . . 0.0 109.936 175.04 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 69.4 mt -96.42 122.13 47.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 177.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 105.5 -176.99 22.71 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 -175.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.42 158.57 29.7 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 117.077 0.439 . . . . 0.0 111.525 -179.008 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 25.8 mtpp -120.28 137.91 53.98 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.22 176.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.551 ' CD2' HD12 ' A' ' 64' ' ' ILE . 44.4 p90 -150.13 162.89 39.56 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.002 0.43 . . . . 0.0 110.837 178.216 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 t -109.28 138.85 45.01 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.794 177.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.553 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 5.3 p -129.25 122.13 55.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.25 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.561 HG21 ' HA ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -88.0 125.0 41.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.814 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.456 ' N ' HD12 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -132.62 -171.19 2.6 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.449 -175.732 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -56.81 -46.01 81.87 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -175.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -90.42 7.68 37.52 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 111.722 0.267 . . . . 0.0 111.722 -173.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 131.02 -169.77 21.53 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.328 178.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.55 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.7 ttmt -100.8 123.01 44.38 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.883 0.373 . . . . 0.0 110.085 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 51.0 mttm -103.15 146.36 28.53 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.005 -176.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -120.65 121.15 64.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 170.552 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.3 pp -138.49 171.76 13.9 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.885 0.374 . . . . 0.0 111.4 -173.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -131.61 142.53 49.9 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.249 -174.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -121.56 143.44 49.29 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 176.26 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -73.79 -13.81 80.35 Favored Glycine 0 C--N 1.33 0.226 0 C-N-CA 121.165 -0.54 . . . . 0.0 112.759 -174.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.416 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -138.85 144.32 41.05 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 177.795 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -57.5 120.59 8.61 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 122.321 2.014 . . . . 0.0 111.096 176.387 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.416 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 17.8 mmt180 -113.22 155.97 24.1 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.269 0.557 . . . . 0.0 111.221 -174.096 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.568 ' HD3' ' HA ' ' A' ' 55' ' ' GLU . 28.0 ttm180 -95.48 162.44 13.65 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 173.351 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.519 HD12 HD13 ' A' ' 58' ' ' ILE . 29.2 mm -54.56 -39.53 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.927 0.394 . . . . 0.0 110.733 179.248 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.493 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 17.1 tptm -64.25 -25.93 68.28 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.103 179.331 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.4 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 67.3 m-20 -73.54 -46.59 46.68 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-O 120.689 0.281 . . . . 0.0 110.638 178.707 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.1 t -61.47 -50.16 81.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.642 -178.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -68.36 -29.12 67.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.368 177.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.33 -42.68 64.92 Favored Glycine 0 CA--C 1.522 0.497 0 CA-C-N 115.985 -0.552 . . . . 0.0 112.736 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.4 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 7.2 mm-40 -68.95 -35.72 77.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.849 0.357 . . . . 0.0 111.115 -179.303 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.0 mt -85.64 -14.52 45.33 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.434 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 63.43 20.35 12.2 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.772 179.032 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.436 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 69.6 mt -79.86 131.54 63.41 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.983 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 22.2 Cg_exo -63.54 105.15 0.49 Allowed 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.491 2.127 . . . . 0.0 112.162 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 13.0 tt -67.8 -17.32 22.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.516 0.674 . . . . 0.0 110.377 178.312 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.3 tp10 -64.65 -37.93 89.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.503 -0.772 . . . . 0.0 111.885 -176.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.543 HG22 HG12 ' A' ' 43' ' ' VAL . 10.5 t -85.82 -9.88 56.33 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -170.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.543 HG12 HG22 ' A' ' 42' ' ' THR . 30.8 m -131.06 169.29 21.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 O-C-N 121.974 -0.454 . . . . 0.0 111.118 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.581 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 46.9 t -107.26 134.63 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.778 0.323 . . . . 0.0 111.079 -176.621 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.1 t -108.67 133.21 54.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.975 0.417 . . . . 0.0 110.72 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.61 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 73.6 mttt -118.53 146.54 44.47 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.144 177.732 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.811 ' HG2' HG23 ' A' ' 52' ' ' VAL . 4.0 mmtp -117.69 103.04 9.63 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.125 172.565 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.8 t-20 67.99 7.78 6.04 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.954 176.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 127.95 -25.04 5.02 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.86 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 71.9 mt-30 -87.74 142.42 27.84 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.71 0.255 . . . . 0.0 111.148 -178.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.409 HD11 ' N ' ' A' ' 51' ' ' ILE . 3.5 mp -77.99 119.58 27.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 177.017 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.811 HG23 ' HG2' ' A' ' 47' ' ' LYS . 27.5 m -124.97 178.67 3.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.062 0.458 . . . . 0.0 112.081 -170.723 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 32.2 pt -106.59 -174.01 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.618 178.233 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.493 ' HB2' ' HD3' ' A' ' 30' ' ' LYS . 15.6 p-10 -77.6 -15.2 59.37 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.446 -176.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.568 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 65.3 mm-40 -84.53 5.28 28.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.757 0.313 . . . . 0.0 111.653 -178.56 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.698 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 26.3 mm-40 -80.93 127.77 32.94 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.905 0.384 . . . . 0.0 110.63 176.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.562 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 33.8 mt-10 -88.9 148.01 24.05 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.494 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.519 HD13 HD12 ' A' ' 29' ' ' ILE . 25.3 mt -101.54 120.1 50.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.269 -177.457 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.463 ' O ' ' HB2' ' A' ' 62' ' ' ASP . 90.9 m-85 -99.31 170.58 8.55 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.585 -178.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -70.26 114.76 8.71 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.84 0.353 . . . . 0.0 110.605 178.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.26 11.71 38.31 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.705 -177.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.463 ' HB2' ' O ' ' A' ' 59' ' ' PHE . 2.7 t0 -74.49 161.03 30.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 110.277 -177.835 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.8 mm -128.21 111.8 25.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.553 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 2.7 mp -108.95 119.17 58.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.189 0.518 . . . . 0.0 110.649 -178.264 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.61 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 39.7 mt-10 -105.91 112.59 25.71 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.477 176.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 73.1 t -97.33 106.88 19.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.485 0.66 . . . . 0.0 110.424 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.581 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 58.8 mt -93.54 93.22 3.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.11 -179.534 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.404 ' HA ' HG13 ' A' ' 43' ' ' VAL . 0.0 OUTLIER -71.03 140.65 50.83 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 173.256 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.692 HG22 ' HA3' ' A' ' 72' ' ' GLY . 28.8 m -82.95 137.98 20.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.366 0.603 . . . . 0.0 111.806 -171.127 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.568 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -78.23 137.06 22.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.532 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.568 ' HB3' ' O ' ' A' ' 70' ' ' ILE . 69.7 t80 78.63 -5.73 2.0 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.536 0.684 . . . . 0.0 109.981 -174.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.692 ' HA3' HG22 ' A' ' 69' ' ' VAL . . . -94.6 99.45 2.45 Favored Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 111.503 -0.639 . . . . 0.0 111.503 176.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.2 0 CA-C-O 118.255 -1.303 . . . . 0.0 111.202 -178.851 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.571 ' SD ' HD13 ' A' ' 6' ' ' ILE . 48.5 ttm . . . . . 0 N--CA 1.476 0.856 0 N-CA-C 110.137 -0.319 . . . . 0.0 110.137 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 47.7 t -85.6 105.06 13.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.027 0.441 . . . . 0.0 110.269 179.19 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.571 HD13 ' SD ' ' A' ' 4' ' ' MET . 50.0 mm -108.03 131.26 58.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.762 178.293 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.05 -156.99 19.18 Favored Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 -176.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.566 ' HE2' ' HB ' ' A' ' 58' ' ' ILE . 0.0 OUTLIER -160.69 151.82 18.97 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.919 0.39 . . . . 0.0 111.49 -179.465 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 37.2 ttpt -117.19 119.79 36.3 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 173.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -139.03 167.92 20.98 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.903 0.382 . . . . 0.0 110.835 -173.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.555 ' HB ' HD13 ' A' ' 20' ' ' ILE . 11.4 t -115.04 138.97 50.26 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-O 121.195 0.522 . . . . 0.0 110.738 178.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.478 HG22 ' HB ' ' A' ' 64' ' ' ILE . 10.0 p -127.09 138.28 55.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.253 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.484 HG23 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -116.93 121.24 67.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.345 0.593 . . . . 0.0 109.964 179.955 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 72.8 p -130.88 -163.73 1.35 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.083 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.825 ' HB3' ' HD3' ' A' ' 68' ' ' ARG . 8.7 p-10 -69.97 -21.92 63.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.88 0.371 . . . . 0.0 110.832 178.44 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -82.15 -10.81 59.04 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.478 0.656 . . . . 0.0 110.059 178.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 121.56 -167.91 14.38 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.046 178.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.8 ttmt -104.09 115.23 30.05 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -112.48 154.96 25.07 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.981 0.419 . . . . 0.0 112.009 -174.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.555 HD13 ' HB ' ' A' ' 11' ' ' THR . 24.3 mm -109.06 121.6 62.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 170.459 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -128.53 161.29 29.91 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.064 0.459 . . . . 0.0 110.99 -178.617 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -126.4 141.17 51.99 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.137 -173.441 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.2 t -130.15 140.57 50.76 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 175.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -80.87 -16.12 75.86 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.344 -177.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -138.42 148.61 59.9 Favored Pre-proline 0 C--N 1.321 -0.651 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.159 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -57.74 142.49 96.03 Favored 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.604 2.203 . . . . 0.0 111.782 177.182 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.524 ' HG3' ' HB2' ' A' ' 31' ' ' ASP . 10.4 tpt180 -137.92 158.37 44.48 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.489 -0.559 . . . . 0.0 109.489 -172.253 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.572 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 76.3 mtm180 -102.34 173.62 6.28 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.834 0.349 . . . . 0.0 110.804 173.534 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.577 ' HB ' ' HA ' ' A' ' 54' ' ' ASP . 18.3 mt -68.14 -42.79 85.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.794 175.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.425 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 82.9 tttt -60.69 -32.3 71.53 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.193 176.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.524 ' HB2' ' HG3' ' A' ' 27' ' ' ARG . 81.0 m-20 -67.91 -41.54 82.51 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.701 178.762 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 68.0 t -75.61 -52.75 17.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.862 0.363 . . . . 0.0 110.921 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 10.9 mp -61.78 -35.35 77.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.938 178.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.39 -33.68 68.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.151 177.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -60.52 -45.46 93.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.883 0.373 . . . . 0.0 110.73 -178.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.4 mt -102.0 6.73 41.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.814 -176.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 53.59 69.56 0.69 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.552 0.692 . . . . 0.0 111.064 -176.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 62.8 mt -111.5 117.37 49.23 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.065 179.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.519 ' HB2' HG22 ' A' ' 42' ' ' THR . 17.0 Cg_exo -67.05 113.64 2.9 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.889 2.393 . . . . 0.0 112.016 178.383 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 10.8 tt -79.6 -13.04 13.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.501 0.667 . . . . 0.0 110.59 -178.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -75.63 -17.24 60.06 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.58 -177.027 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.548 HG21 HG13 ' A' ' 43' ' ' VAL . 9.8 t -108.71 -8.33 15.42 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -174.13 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.548 HG13 HG21 ' A' ' 42' ' ' THR . 17.8 m -133.24 167.09 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 O-C-N 122.099 -0.376 . . . . 0.0 110.872 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.44 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 51.9 t -105.26 121.95 57.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.91 -178.222 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.8 t -103.71 127.07 58.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.031 177.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.615 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 98.8 mttt -122.82 144.61 49.07 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.991 0.424 . . . . 0.0 111.82 -178.812 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.556 ' HG2' HG23 ' A' ' 52' ' ' VAL . 17.9 mmtp -100.92 101.9 12.81 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.229 167.753 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.8 t-20 63.28 2.33 1.11 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.996 0.518 . . . . 0.0 111.805 178.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 136.14 -17.27 3.85 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 121.083 -0.579 . . . . 0.0 112.353 -178.533 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . 0.49 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 17.6 mm-40 -87.16 129.53 34.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.407 0.146 . . . . 0.0 110.939 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.6 mp -69.36 120.78 17.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 176.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.556 HG23 ' HG2' ' A' ' 47' ' ' LYS . 17.4 m -124.95 177.48 4.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.149 -176.785 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.459 ' O ' HD13 ' A' ' 29' ' ' ILE . 26.9 pt -113.0 179.63 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.282 174.578 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.577 ' HA ' ' HB ' ' A' ' 29' ' ' ILE . 8.4 p-10 -73.22 -6.09 43.62 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.851 -175.338 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -81.43 -2.12 48.3 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.389 -176.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 58.9 mm-40 -89.69 150.39 22.36 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 122.171 -0.33 . . . . 0.0 111.518 -177.34 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.572 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 21.0 mp0 -88.05 157.07 18.99 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.112 177.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.566 ' HB ' ' HE2' ' A' ' 8' ' ' MET . 2.6 mm -96.47 134.48 33.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 173.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -116.63 167.48 11.03 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.027 0.442 . . . . 0.0 111.275 -175.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -73.97 129.51 38.02 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.111 175.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.75 18.72 79.52 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.433 -176.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -91.51 157.06 17.24 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 179.631 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.448 HG12 HG22 ' A' ' 11' ' ' THR . 10.5 mt -128.3 114.27 33.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.228 0.537 . . . . 0.0 110.897 -175.331 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.478 ' HB ' HG22 ' A' ' 12' ' ' VAL . 22.0 mm -96.67 106.89 19.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.278 -178.373 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.615 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 35.4 tt0 -97.19 101.99 13.66 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 176.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.431 HG23 HG23 ' A' ' 64' ' ' ILE . 80.3 t -100.24 105.94 18.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.209 0.528 . . . . 0.0 110.116 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.44 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 26.2 mt -91.96 95.88 5.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.086 178.415 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.825 ' HD3' ' HB3' ' A' ' 15' ' ' ASP . 1.2 ptm180 -74.97 156.65 36.07 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.639 178.094 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -83.2 124.24 39.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-O 121.436 0.636 . . . . 0.0 110.586 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 4.7 tp -87.01 102.08 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.749 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 167.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 29.9 t80 -65.23 104.32 0.91 Allowed 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.421 0.629 . . . . 0.0 111.321 -170.473 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -168.37 -109.58 0.22 Allowed Glycine 0 N--CA 1.442 -0.962 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.294 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.097 0 CA-C-O 117.98 -1.455 . . . . 0.0 111.329 -179.854 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 25.3 mmt . . . . . 0 N--CA 1.48 1.05 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 41.9 t -98.19 127.58 50.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 178.343 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 62.4 mt -82.88 122.1 36.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.385 179.002 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 112.27 120.3 3.81 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.979 -0.629 . . . . 0.0 111.73 -177.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.47 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.1 ptt? -113.77 134.38 54.81 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.331 0.586 . . . . 0.0 111.379 -175.354 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.821 ' HD3' ' HB3' ' A' ' 22' ' ' GLU . 6.1 tppt? -106.79 126.64 52.55 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.025 176.37 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.428 ' CE1' ' HE2' ' A' ' 8' ' ' MET . 49.7 p90 -152.81 147.63 26.26 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.141 0.496 . . . . 0.0 111.342 179.135 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.542 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.1 t -98.56 142.59 29.96 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.015 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.6 p -118.73 119.49 61.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.505 0.669 . . . . 0.0 110.002 176.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.507 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -106.75 117.03 51.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-O 121.864 0.84 . . . . 0.0 108.928 176.998 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.406 HG23 ' H ' ' A' ' 15' ' ' ASP . 1.4 m -114.75 175.33 5.54 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.221 -177.472 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.406 ' H ' HG23 ' A' ' 14' ' ' THR . 28.1 t70 -56.34 -23.29 36.35 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-O 120.95 0.405 . . . . 0.0 111.475 178.501 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -87.09 -12.27 47.67 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.559 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 133.43 -174.81 20.52 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.382 -0.913 . . . . 0.0 112.184 -177.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.507 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.7 ttmt -109.94 139.49 44.99 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.66 0.267 . . . . 0.0 110.997 -175.303 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -150.23 136.48 18.77 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 173.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.542 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -98.74 136.18 30.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.748 0.309 . . . . 0.0 110.341 -177.642 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.3 pp -138.58 170.54 15.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.087 177.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.821 ' HB3' ' HD3' ' A' ' 9' ' ' LYS . 13.3 pt-20 -138.84 150.33 45.9 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.925 0.393 . . . . 0.0 111.396 -178.325 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 40.8 m -135.61 133.69 38.52 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.115 177.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -74.31 4.08 35.77 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 121.326 -0.464 . . . . 0.0 113.252 -177.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.442 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -135.35 127.97 18.08 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.648 0.224 . . . . 0.0 110.504 178.527 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.47 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 21.9 Cg_exo -65.15 128.77 21.28 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.781 2.321 . . . . 0.0 110.982 176.159 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.567 ' HA ' ' NE ' ' A' ' 27' ' ' ARG . 0.0 OUTLIER -134.21 171.43 14.25 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.406 -170.838 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.4 ttp-105 -104.03 160.72 14.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.704 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 38.2 mm -56.49 -47.49 81.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.34 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.499 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 29.7 tptp -55.57 -37.99 68.77 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.335 -179.631 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -69.52 -57.43 5.22 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.006 -178.682 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 69.1 t -61.3 -47.93 91.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.855 -177.072 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 19.6 tp -68.02 -35.72 78.75 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.22 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.11 -44.28 61.22 Favored Glycine 0 N--CA 1.447 -0.633 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.62 -179.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -68.97 -21.86 64.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.735 0.302 . . . . 0.0 111.427 179.679 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.5 mt -89.25 -2.87 58.65 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.004 0.43 . . . . 0.0 110.224 174.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 57.48 45.69 19.21 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.125 176.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.425 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 69.0 mt -106.68 117.29 57.23 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.573 176.125 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 16.5 Cg_exo -67.54 112.41 2.61 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.773 2.315 . . . . 0.0 112.766 -176.493 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.537 ' HA ' HG22 ' A' ' 43' ' ' VAL . 11.2 tt -69.23 -14.68 18.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.587 0.708 . . . . 0.0 109.885 177.466 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -60.48 -28.96 68.75 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.61 -179.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 12.9 t -122.53 7.86 9.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.031 0.443 . . . . 0.0 111.589 -172.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 3.6 m -131.65 149.32 32.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 C-N-CA 120.386 -0.525 . . . . 0.0 110.768 -179.162 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.6 t -99.57 129.75 49.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.132 0.491 . . . . 0.0 110.288 179.134 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.8 t -103.3 127.48 57.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.555 -178.651 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.59 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 65.8 mttt -119.29 139.87 51.21 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.696 178.576 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.912 ' HB3' ' HZ3' ' A' ' 47' ' ' LYS . 9.1 mtpm? -127.07 115.88 19.84 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.928 175.152 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 62.36 22.56 13.3 Favored 'General case' 0 C--N 1.326 -0.419 0 O-C-N 123.597 0.56 . . . . 0.0 110.377 178.075 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.85 -14.41 57.43 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.548 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . 0.457 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 68.3 mt-30 -88.07 140.56 29.37 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 122.102 0.161 . . . . 0.0 111.046 -175.625 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.416 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.4 mp -80.07 113.16 19.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 174.124 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.866 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 35.8 m -125.55 178.92 3.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.071 0.462 . . . . 0.0 111.863 -169.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 31.2 pt -112.62 -170.86 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.645 178.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.499 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 7.9 p-10 -81.15 -7.87 59.65 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.794 -174.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -91.08 12.36 20.14 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-O 121.544 0.688 . . . . 0.0 110.216 -177.772 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.866 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 8.3 mm-40 -88.3 128.24 35.48 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.147 179.069 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.559 ' O ' ' HE3' ' A' ' 47' ' ' LYS . 10.7 mm-40 -76.6 142.61 40.65 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.797 177.06 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 39.4 mt -92.23 137.59 21.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 177.119 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -117.06 149.0 41.01 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.055 0.455 . . . . 0.0 111.228 -174.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -66.71 117.2 8.51 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.788 176.168 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.21 11.8 53.46 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 121.152 -0.547 . . . . 0.0 112.223 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 36.6 t0 -97.68 161.94 13.52 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 179.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.436 HD12 HG22 ' A' ' 11' ' ' THR . 50.5 mm -112.24 126.18 69.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.822 0.344 . . . . 0.0 110.531 -177.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 47.3 mm -107.08 130.2 59.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.435 -179.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.59 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 33.7 mt-10 -122.11 129.2 52.15 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 177.651 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 54.3 t -122.33 110.29 26.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.311 0.577 . . . . 0.0 110.634 177.173 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.5 mt -118.28 101.7 12.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.407 -178.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.561 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 14.3 ptt180 -77.87 144.07 37.26 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.085 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -83.25 117.3 28.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.613 0.721 . . . . 0.0 110.62 -175.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 6.8 tp -95.7 128.09 47.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.377 -0.829 . . . . 0.0 109.956 179.774 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 7.3 p90 -81.91 87.57 6.4 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.634 0.731 . . . . 0.0 109.939 177.007 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -85.69 98.01 2.24 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.471 -0.786 . . . . 0.0 112.012 -177.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.965 0 CA-C-O 118.734 -1.037 . . . . 0.0 111.701 178.653 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 27.8 ttt . . . . . 0 N--CA 1.479 0.98 0 N-CA-C 110.078 -0.341 . . . . 0.0 110.078 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.1 t -90.02 104.92 15.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-O 121.078 0.466 . . . . 0.0 109.9 177.254 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.1 tp -117.31 122.11 69.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.743 177.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.91 151.75 28.2 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.612 -175.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.469 ' HE2' ' HB2' ' A' ' 27' ' ' ARG . 17.1 mtm -128.98 139.91 51.89 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.876 0.369 . . . . 0.0 110.622 -176.051 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -103.89 111.11 23.51 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 173.385 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 23.5 p90 -138.96 161.48 37.25 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.106 0.479 . . . . 0.0 110.923 -178.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.407 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.5 t -118.7 144.3 46.31 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.2 p -117.16 126.3 74.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.122 0.486 . . . . 0.0 109.721 176.278 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.523 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -112.86 127.73 69.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.247 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.408 HG23 ' O ' ' A' ' 66' ' ' VAL . 6.8 m -144.2 -177.04 5.26 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 -177.092 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.405 ' H ' HG21 ' A' ' 14' ' ' THR . 0.8 OUTLIER -49.46 -32.94 13.02 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.184 0.516 . . . . 0.0 110.892 173.714 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -80.5 4.25 18.91 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.153 -177.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 107.49 -177.37 21.35 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.067 177.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.523 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 40.0 ttmt -104.71 117.29 33.72 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 176.464 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -130.62 139.49 50.39 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.077 0.465 . . . . 0.0 110.61 -176.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.449 HD11 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -91.72 137.79 21.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.155 -176.236 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.449 ' N ' HD11 ' A' ' 20' ' ' ILE . 2.2 pt? -137.65 147.69 45.14 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 178.036 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -123.82 126.73 46.96 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.866 0.365 . . . . 0.0 110.412 -177.041 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.0 m -118.91 124.8 47.98 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.896 178.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -77.55 21.22 3.1 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 121.127 -0.559 . . . . 0.0 113.175 -178.538 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.407 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -139.23 138.95 21.58 Favored Pre-proline 0 C--N 1.322 -0.59 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 178.004 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -62.79 127.65 21.12 Favored 'Trans proline' 0 CA--C 1.531 0.337 0 C-N-CA 122.72 2.28 . . . . 0.0 111.484 175.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.469 ' HB2' ' HE2' ' A' ' 8' ' ' MET . 13.9 mmt180 -126.01 160.59 29.63 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.145 0.497 . . . . 0.0 111.298 -172.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.577 ' HG2' ' HA ' ' A' ' 57' ' ' GLU . 65.3 mtm-85 -113.65 168.56 9.67 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 164.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.733 HD12 HG12 ' A' ' 45' ' ' VAL . 24.9 mt -60.76 -45.41 97.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 120.646 0.26 . . . . 0.0 110.566 -178.265 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -61.28 -32.45 72.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.026 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.448 ' OD2' ' HD2' ' A' ' 27' ' ' ARG . 25.6 t70 -73.57 -42.36 61.72 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.484 -179.427 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.4 t -71.3 -51.79 31.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.006 0.431 . . . . 0.0 110.548 177.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 26.2 tp -61.4 -37.85 84.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.427 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.46 -33.31 72.3 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.476 177.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -71.84 -34.11 69.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.167 0.508 . . . . 0.0 109.995 177.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.2 mt -76.92 -10.56 59.45 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.258 174.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 63.3 45.89 4.75 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.689 176.178 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 62.2 mt -115.8 123.08 31.65 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.141 178.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_exo -62.69 132.27 36.94 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.754 2.303 . . . . 0.0 112.339 179.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 10.0 tp -70.38 -15.36 19.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.291 0.567 . . . . 0.0 110.61 -179.038 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -63.87 -32.91 74.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.752 178.568 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.484 HG22 HG11 ' A' ' 43' ' ' VAL . 12.0 t -104.02 -1.66 27.14 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 112.095 0.405 . . . . 0.0 112.095 -172.18 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.559 HG12 ' HG3' ' A' ' 68' ' ' ARG . 33.5 m -128.99 146.46 34.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 120.923 0.392 . . . . 0.0 111.202 -178.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.508 HG11 ' HB ' ' A' ' 67' ' ' ILE . 0.6 OUTLIER -110.02 136.94 44.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 175.555 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.733 HG12 HD12 ' A' ' 29' ' ' ILE . 32.6 t -116.21 133.59 62.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.094 0.473 . . . . 0.0 110.932 -177.777 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.743 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 98.6 mttt -117.84 130.92 56.56 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.255 177.126 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 22.5 ttmm -93.42 105.46 17.53 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 172.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 71.65 -61.3 0.49 Allowed 'General case' 0 C--N 1.33 -0.274 0 O-C-N 124.136 0.897 . . . . 0.0 110.557 -177.099 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -166.6 22.01 0.11 Allowed Glycine 0 N--CA 1.447 -0.585 0 N-CA-C 111.326 -0.709 . . . . 0.0 111.326 177.292 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 35.9 mt-30 -126.5 131.92 51.51 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.194 -0.299 . . . . 0.0 110.194 -176.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.501 HD13 ' HG2' ' A' ' 46' ' ' LYS . 38.9 mm -63.33 122.51 14.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.869 0.366 . . . . 0.0 110.628 177.615 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.683 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 17.3 m -125.74 178.4 4.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.751 -178.688 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.416 ' O ' HD13 ' A' ' 29' ' ' ILE . 26.9 pt -100.17 -177.96 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.659 176.577 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 20.7 p-10 -77.16 -30.12 54.85 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.431 -176.532 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -80.67 14.67 2.01 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 122.094 -0.379 . . . . 0.0 111.897 -173.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.683 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 76.5 mm-40 -86.05 152.07 23.19 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.82 0.343 . . . . 0.0 111.07 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.577 ' HA ' ' HG2' ' A' ' 28' ' ' ARG . 42.2 mp0 -85.52 162.15 19.04 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.925 -177.796 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 39.9 mm -103.81 144.78 13.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 174.199 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.735 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 81.0 m-85 -114.15 161.01 18.33 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.735 0.302 . . . . 0.0 110.189 179.179 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -77.63 120.87 23.18 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 175.015 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.51 9.93 68.53 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.904 -0.665 . . . . 0.0 111.789 -176.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.735 ' HB2' ' HB2' ' A' ' 59' ' ' PHE . 22.0 t0 -87.95 147.0 25.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.96 0.409 . . . . 0.0 110.181 -178.357 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 45.5 mm -105.6 122.95 59.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.23 -176.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.405 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 50.0 mm -109.78 115.19 49.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 120.886 0.374 . . . . 0.0 110.718 -177.579 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.743 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 28.3 tt0 -104.3 114.6 28.94 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.878 177.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.408 ' O ' HG23 ' A' ' 14' ' ' THR . 60.1 t -113.08 113.38 43.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.14 -179.049 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.508 ' HB ' HG11 ' A' ' 44' ' ' VAL . 3.8 mt -116.2 118.75 59.81 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.147 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.559 ' HG3' HG12 ' A' ' 43' ' ' VAL . 0.8 OUTLIER -68.28 130.09 41.86 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 176.093 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 16.9 m -86.32 116.06 28.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.331 0.586 . . . . 0.0 111.023 -177.016 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 8.4 tt -78.58 110.53 14.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.059 176.521 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 84.5 t80 -57.42 131.57 50.5 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.154 -178.628 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -81.14 72.33 2.76 Favored Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 111.606 -0.598 . . . . 0.0 111.606 178.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.255 -1.303 . . . . 0.0 111.063 -177.789 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' MET . . . . . 0.414 ' HE1' HD13 ' A' ' 6' ' ' ILE . 26.1 ttt . . . . . 0 N--CA 1.479 1.022 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 45.5 t -86.23 109.99 19.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.672 -177.501 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.418 HG23 ' O ' ' A' ' 24' ' ' GLY . 51.4 mm -94.99 120.91 45.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 109.219 -0.659 . . . . 0.0 109.219 176.551 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 133.65 163.64 10.47 Favored Glycine 0 N--CA 1.446 -0.667 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 -174.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.576 ' SD ' ' HB ' ' A' ' 58' ' ' ILE . 25.0 ptt? -160.0 137.15 9.43 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 117.173 0.487 . . . . 0.0 111.282 -176.424 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.861 ' HD3' ' HB3' ' A' ' 22' ' ' GLU . 3.8 tppt? -108.19 120.26 41.83 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 175.41 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -140.56 167.96 20.93 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.744 0.306 . . . . 0.0 110.919 -176.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.501 HG21 HD12 ' A' ' 63' ' ' ILE . 1.2 t -133.72 146.71 51.04 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 177.396 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -117.33 119.11 60.83 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.595 177.147 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -103.28 124.56 57.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.523 0.677 . . . . 0.0 109.511 178.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 4.1 m -146.02 173.17 12.41 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -178.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -64.46 -22.39 66.95 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.317 0.58 . . . . 0.0 109.954 174.338 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -72.23 -11.8 60.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.631 175.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 127.19 176.89 14.63 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.904 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -108.17 104.04 13.37 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 177.311 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -104.28 134.12 48.04 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.617 -176.163 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.436 HD12 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -103.33 129.58 54.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 177.269 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.436 ' N ' HD12 ' A' ' 20' ' ' ILE . 94.8 mt -136.26 137.21 40.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.621 -177.379 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.861 ' HB3' ' HD3' ' A' ' 9' ' ' LYS . 17.0 pt-20 -117.62 129.18 55.59 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.364 0.602 . . . . 0.0 110.012 173.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.7 m -109.7 145.46 36.51 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.268 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.418 ' O ' HG23 ' A' ' 6' ' ' ILE . . . -78.29 -10.75 85.97 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.407 -178.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.454 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.54 141.4 31.03 Favored Pre-proline 0 C--N 1.325 -0.496 0 N-CA-C 110.57 -0.159 . . . . 0.0 110.57 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.48 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 11.5 Cg_exo -71.32 123.8 9.87 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.835 2.357 . . . . 0.0 111.742 177.047 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.461 ' HB3' ' CB ' ' A' ' 31' ' ' ASP . 16.2 mmm180 -126.66 175.68 7.78 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -178.205 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.634 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 83.4 mtm180 -94.31 175.2 6.78 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.694 0.283 . . . . 0.0 110.579 175.174 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.728 HD13 HG11 ' A' ' 45' ' ' VAL . 18.2 mt -68.26 -39.73 81.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 177.45 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.529 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 28.2 tptp -59.46 -36.06 75.25 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.695 174.228 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.461 ' CB ' ' HB3' ' A' ' 27' ' ' ARG . 5.9 m-20 -66.07 -62.14 1.65 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.953 177.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.43 HG22 HG13 ' A' ' 58' ' ' ILE . 97.4 t -59.64 -60.6 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.664 -175.686 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 11.1 mp -63.24 -34.36 77.5 Favored 'General case' 0 C--N 1.333 -0.145 0 C-N-CA 120.932 -0.307 . . . . 0.0 111.135 -176.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.3 -47.24 82.07 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.871 -0.681 . . . . 0.0 112.572 -179.309 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -71.08 -22.38 62.11 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.847 0.356 . . . . 0.0 111.09 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 86.6 mt -86.77 1.69 51.37 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.683 176.425 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.9 tt0 65.17 17.17 10.93 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.23 176.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 71.8 mt -83.33 118.24 70.98 Favored Pre-proline 0 C--N 1.324 -0.54 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.129 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -59.93 92.03 0.08 OUTLIER 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 123.128 2.552 . . . . 0.0 112.567 -177.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.533 ' HA ' HG23 ' A' ' 43' ' ' VAL . 14.4 tt -76.24 -17.44 15.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.366 -177.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -67.82 -20.81 65.21 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.685 -177.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.5 t -120.23 10.8 11.42 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -175.106 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.533 HG23 ' HA ' ' A' ' 40' ' ' ILE . 31.5 m -123.0 147.39 27.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 O-C-N 121.769 -0.582 . . . . 0.0 111.372 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 58.8 t -92.48 120.68 42.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.641 178.427 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.728 HG11 HD13 ' A' ' 29' ' ' ILE . 38.5 t -103.4 130.8 53.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.04 0.448 . . . . 0.0 110.854 -176.513 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.726 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 96.9 mttt -118.61 145.78 45.14 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.3 177.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.643 ' HD2' HG12 ' A' ' 52' ' ' VAL . 60.4 mttm -109.34 102.04 10.98 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.179 168.731 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.0 m120 58.54 19.7 6.87 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.628 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 117.97 -18.21 11.54 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.741 178.601 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 70.6 mm-40 -87.57 130.04 34.88 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.881 0.341 . . . . 0.0 110.535 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.433 HD13 ' N ' ' A' ' 51' ' ' ILE . 3.7 mp -73.86 121.28 24.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.055 -179.511 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.801 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 21.2 m -123.99 178.34 3.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.191 -176.033 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.403 ' O ' HD11 ' A' ' 29' ' ' ILE . 32.0 pt -115.1 173.71 3.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 179.764 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.529 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 3.9 p30 -63.03 -23.82 67.63 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -176.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -71.56 -18.09 62.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.12 -176.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.801 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 20.0 mm-40 -67.16 141.46 57.36 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.106 0.479 . . . . 0.0 111.318 -177.701 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.634 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 21.1 mt-10 -89.21 152.02 21.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.578 -179.599 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.576 ' HB ' ' SD ' ' A' ' 8' ' ' MET . 8.1 mm -88.55 146.23 6.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 176.69 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -132.75 163.99 27.79 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.942 0.401 . . . . 0.0 110.569 -178.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -67.64 121.56 16.16 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.987 -0.552 . . . . 0.0 109.615 172.145 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.97 20.2 47.6 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.767 -177.216 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -96.15 131.49 42.54 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.412 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.501 HD12 HG21 ' A' ' 11' ' ' THR . 50.5 mm -111.57 109.99 30.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.696 0.284 . . . . 0.0 110.48 -177.234 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.463 ' HA ' ' O ' ' A' ' 46' ' ' LYS . 40.0 mm -94.97 119.25 42.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.27 -177.024 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.726 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 38.2 tt0 -103.37 120.93 41.74 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 171.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 70.8 t -107.36 108.49 25.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.155 0.502 . . . . 0.0 110.509 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 22.9 mt -103.86 109.15 26.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.756 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 19.1 mtt180 -68.12 144.06 55.18 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 176.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 34.5 m -83.49 136.21 23.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 173.318 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 8.3 tp -78.65 122.29 33.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.484 0.659 . . . . 0.0 110.403 -177.388 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -79.42 87.0 5.07 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.031 179.742 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -151.87 172.86 31.2 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.533 -178.325 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.045 -1.419 . . . . 0.0 110.737 -179.34 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 23.2 ttt . . . . . 0 N--CA 1.479 0.999 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 7.2 p -92.93 120.66 42.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.249 0.547 . . . . 0.0 110.17 179.449 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.3 pt -100.41 122.98 53.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.781 176.152 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.12 -178.09 20.56 Favored Glycine 0 N--CA 1.443 -0.898 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.148 -176.699 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.52 153.94 22.08 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.75 0.31 . . . . 0.0 111.193 -177.685 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.462 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 50.2 mtmt -105.85 128.82 53.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.002 -0.544 . . . . 0.0 109.689 174.171 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 19.3 p90 -139.28 150.26 45.24 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 120.778 0.323 . . . . 0.0 110.76 -178.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.51 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 25.3 m -111.23 120.9 43.82 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.81 0.338 . . . . 0.0 110.435 179.735 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.61 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 21.5 t -112.46 130.32 66.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.898 179.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.605 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 4.0 tt -87.53 129.56 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.807 173.869 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 30.6 p -123.52 -175.22 3.15 Favored 'General case' 0 N--CA 1.442 -0.872 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.822 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -67.63 -28.43 67.72 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.804 -175.274 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.464 ' OD1' ' HE3' ' A' ' 19' ' ' LYS . 3.1 p30 -95.79 -5.94 40.75 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 121.125 -0.23 . . . . 0.0 111.523 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 147.11 -177.36 25.45 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.554 179.08 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.605 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 62.5 tttt -99.25 108.87 21.53 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.083 0.468 . . . . 0.0 109.796 -177.763 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.464 ' HE3' ' OD1' ' A' ' 16' ' ' ASP . 78.3 mttt -103.51 124.72 49.3 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.717 -171.636 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.51 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -90.37 125.14 43.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 170.115 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.412 ' N ' HD22 ' A' ' 21' ' ' LEU . 1.9 pt? -140.52 164.89 28.95 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.462 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.3 OUTLIER -139.58 163.59 32.16 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.9 0.381 . . . . 0.0 111.54 -176.66 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.3 t -134.83 158.24 44.72 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.416 176.591 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -84.76 -4.91 86.99 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.334 -178.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -138.49 141.33 30.9 Favored Pre-proline 0 C--N 1.324 -0.504 0 N-CA-C 110.624 -0.139 . . . . 0.0 110.624 178.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -61.84 131.97 37.68 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.739 2.293 . . . . 0.0 111.498 175.301 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 37.9 mmt180 -132.96 169.49 16.72 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.032 0.444 . . . . 0.0 111.216 -174.044 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -103.14 166.18 10.59 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.467 -0.788 . . . . 0.0 108.887 167.401 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 48.9 mm -55.87 -41.37 66.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.967 0.413 . . . . 0.0 110.394 178.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 46.2 tptt -51.24 -43.29 61.45 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.166 -0.924 . . . . 0.0 111.919 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -66.19 -50.88 62.37 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.842 -174.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.15 -49.29 56.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.018 -178.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.522 HD21 ' HB ' ' A' ' 40' ' ' ILE . 28.1 tp -62.07 -40.6 96.37 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.728 -177.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.73 -44.48 94.78 Favored Glycine 0 N--CA 1.448 -0.523 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.467 -177.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 68.3 mt-10 -72.2 -29.93 64.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.638 0.256 . . . . 0.0 111.615 -179.214 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 72.6 mt -78.18 -8.34 58.19 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 121.068 -0.253 . . . . 0.0 111.006 178.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.9 tt0 64.25 26.13 13.68 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.05 175.209 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.419 ' HB ' HD11 ' A' ' 33' ' ' LEU . 64.7 mt -82.95 124.87 76.31 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.141 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -71.82 108.86 2.52 Favored 'Trans proline' 0 CA--C 1.533 0.44 0 C-N-CA 122.587 2.191 . . . . 0.0 113.02 -179.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.522 ' HB ' HD21 ' A' ' 33' ' ' LEU . 10.0 tt -73.16 -9.75 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-O 121.732 0.777 . . . . 0.0 110.286 178.392 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -69.2 -42.89 75.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.742 -176.108 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.523 HG22 HG11 ' A' ' 43' ' ' VAL . 3.3 t -86.53 -47.68 9.03 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -170.15 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.525 ' CG1' ' HA ' ' A' ' 68' ' ' ARG . 21.7 m -102.01 179.06 0.67 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.213 0 CA-C-O 120.85 0.357 . . . . 0.0 111.8 -173.161 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 30.0 t -103.98 139.55 24.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.565 -172.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 59.6 t -116.17 126.04 73.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 CA-C-O 121.029 0.442 . . . . 0.0 110.249 176.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.506 ' HG2' HD11 ' A' ' 51' ' ' ILE . 95.2 mttt -129.63 151.95 49.68 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.624 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.805 ' HG2' HG21 ' A' ' 52' ' ' VAL . 18.3 mmtp -106.04 100.8 10.33 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 169.46 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 47.6 t30 54.98 24.73 6.17 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.153 177.545 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 124.25 -27.42 5.57 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 120.957 -0.639 . . . . 0.0 113.367 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -89.46 133.96 34.32 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.903 0.351 . . . . 0.0 111.644 -174.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.506 HD11 ' HG2' ' A' ' 46' ' ' LYS . 39.2 mm -65.55 124.19 20.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.674 -0.239 . . . . 0.0 110.389 176.184 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.805 HG21 ' HG2' ' A' ' 47' ' ' LYS . 20.7 m -133.29 178.0 6.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.987 0.422 . . . . 0.0 111.223 -177.563 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.0 pt -109.48 -173.02 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.32 177.265 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 30.1 p-10 -82.19 -19.53 39.64 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 120.905 0.383 . . . . 0.0 110.961 -179.283 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -82.14 26.87 0.51 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.919 0.39 . . . . 0.0 111.856 177.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -96.54 149.95 21.18 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.052 179.132 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -78.33 170.6 16.37 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.999 -177.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 52.2 mt -128.8 120.71 52.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 172.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -112.27 162.2 15.77 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.724 -178.244 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -71.24 126.03 28.53 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.462 177.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.18 6.49 71.35 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.956 -0.64 . . . . 0.0 111.784 -179.255 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 25.8 t0 -88.58 155.79 19.43 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -179.501 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.7 mm -120.79 117.16 52.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 120.932 0.396 . . . . 0.0 110.523 -175.015 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.61 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 3.7 mp -101.71 128.22 54.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 177.873 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.549 ' HA ' HG21 ' A' ' 13' ' ' ILE . 38.2 mt-10 -115.22 107.27 15.07 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 120.771 -0.372 . . . . 0.0 110.996 -178.631 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 78.2 t -99.93 100.53 10.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 121.653 0.74 . . . . 0.0 109.05 174.326 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 51.1 mt -93.07 109.65 22.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.986 -176.131 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.525 ' HA ' ' CG1' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -64.33 140.78 58.9 Favored 'General case' 0 N--CA 1.447 -0.624 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 174.203 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.437 HG12 ' HA ' ' A' ' 43' ' ' VAL . 21.8 m -82.65 136.1 23.55 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-O 121.002 0.429 . . . . 0.0 110.573 -177.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 7.9 tp -83.64 128.59 38.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 176.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 36.9 m-85 -78.41 95.74 5.18 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.511 -175.114 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -89.17 44.3 3.09 Favored Glycine 0 N--CA 1.449 -0.492 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.759 177.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.018 0 CA-C-O 118.193 -1.337 . . . . 0.0 111.126 -179.126 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 1.016 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.4 t -97.05 118.61 43.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 175.078 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.1 pt -82.22 132.05 32.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 121.291 0.567 . . . . 0.0 110.578 -179.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.31 -178.71 17.17 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -176.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.471 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 23.5 ptt? -161.0 130.88 4.95 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.99 0.424 . . . . 0.0 110.712 179.005 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.65 ' HB3' ' HG3' ' A' ' 22' ' ' GLU . 16.4 ptmt -118.6 119.63 35.07 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 121.294 0.569 . . . . 0.0 109.574 171.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -123.79 151.61 43.12 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.089 -174.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.539 ' CG2' HG13 ' A' ' 63' ' ' ILE . 8.8 t -109.51 134.98 51.24 Favored 'General case' 0 C--N 1.316 -0.857 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.231 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.4 p -110.91 135.96 48.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.039 -179.22 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -114.46 126.54 72.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.385 0.612 . . . . 0.0 110.19 179.695 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.408 HG21 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -146.66 -163.48 1.76 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.369 178.248 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.408 ' H ' HG21 ' A' ' 14' ' ' THR . 14.2 m-20 -65.14 -21.96 66.86 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 121.108 0.48 . . . . 0.0 110.996 178.062 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -86.11 8.25 21.59 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.682 0.753 . . . . 0.0 110.274 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.79 -162.12 18.57 Favored Glycine 0 N--CA 1.448 -0.517 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.712 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -118.15 108.69 15.48 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 177.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -116.0 150.99 36.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.465 -176.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.505 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.2 OUTLIER -106.94 131.09 57.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.091 0.472 . . . . 0.0 109.886 -176.173 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.488 ' N ' HD13 ' A' ' 20' ' ' ILE . 92.2 mt -116.81 135.49 53.7 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.963 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.65 ' HG3' ' HB3' ' A' ' 9' ' ' LYS . 32.4 tt0 -108.96 126.55 53.21 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.948 0.404 . . . . 0.0 110.392 -177.456 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.5 m -118.06 145.39 44.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.958 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -83.17 -9.12 84.5 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 121.047 -0.597 . . . . 0.0 112.605 -176.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.421 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.42 141.89 32.98 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 122.849 -0.207 . . . . 0.0 111.003 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.471 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 7.3 Cg_exo -73.59 121.25 6.94 Favored 'Trans proline' 0 C--O 1.233 0.254 0 C-N-CA 122.817 2.345 . . . . 0.0 110.773 174.045 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 19.2 mmm180 -132.25 177.28 7.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.102 0.477 . . . . 0.0 110.899 -174.087 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.548 ' HG2' ' H ' ' A' ' 30' ' ' LYS . 44.7 ttm180 -94.82 160.85 14.41 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.053 -176.84 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.443 HD11 HG12 ' A' ' 58' ' ' ILE . 37.4 mm -50.97 -41.01 21.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-O 120.815 0.34 . . . . 0.0 110.155 176.315 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.548 ' H ' ' HG2' ' A' ' 28' ' ' ARG . 35.8 tptt -51.03 -37.18 43.7 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.786 -179.329 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -64.93 -62.65 1.43 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.764 0.316 . . . . 0.0 110.845 -177.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.5 t -63.39 -44.21 98.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.762 -177.616 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.774 HD13 ' HB ' ' A' ' 40' ' ' ILE . 3.0 tm? -61.72 -46.43 89.68 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.163 -179.267 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.97 -47.41 46.74 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.141 -175.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -66.53 -34.57 78.22 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 111.954 0.354 . . . . 0.0 111.954 -175.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 82.1 mt -82.6 -4.64 57.98 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.684 0.278 . . . . 0.0 110.9 179.079 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.5 tt0 57.3 34.9 25.41 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.958 177.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.555 ' HB ' HD23 ' A' ' 33' ' ' LEU . 66.0 mt -79.49 125.64 82.46 Favored Pre-proline 0 C--N 1.323 -0.587 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 177.64 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.499 ' HB2' ' HB ' ' A' ' 42' ' ' THR . 34.7 Cg_exo -60.72 101.29 0.17 Allowed 'Trans proline' 0 C--O 1.233 0.226 0 C-N-CA 122.642 2.228 . . . . 0.0 112.874 -176.851 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.774 ' HB ' HD13 ' A' ' 33' ' ' LEU . 9.9 tp -71.29 -19.11 20.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.68 0.752 . . . . 0.0 109.831 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -77.01 -32.11 56.93 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.355 176.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' A' ' 39' ' ' PRO . 22.2 m -92.39 -39.41 11.46 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.193 -171.525 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 10.9 m -112.8 163.17 10.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.458 -175.645 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.401 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 47.3 t -109.89 140.27 29.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.846 -177.827 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.8 t -113.0 130.63 66.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 121.137 0.494 . . . . 0.0 111.467 -178.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.508 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 97.3 mttt -123.08 150.88 42.6 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.743 172.505 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.929 ' HE2' HG11 ' A' ' 52' ' ' VAL . 60.1 pttt -126.76 108.08 10.73 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.638 0.732 . . . . 0.0 110.676 171.619 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.489 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 3.2 t-20 64.26 23.78 13.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.483 -1.235 . . . . 0.0 111.771 174.399 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 112.79 -6.33 25.89 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.8 177.561 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 8.3 mm-40 -111.35 114.54 27.78 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.707 0.289 . . . . 0.0 111.501 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.477 HD11 ' N ' ' A' ' 52' ' ' VAL . 0.1 OUTLIER -62.98 127.15 22.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 175.574 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.929 HG11 ' HE2' ' A' ' 47' ' ' LYS . 23.4 m -138.63 155.89 28.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.084 0.469 . . . . 0.0 111.574 -174.356 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 30.4 pt -96.93 -175.55 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.908 177.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -69.57 -8.91 51.37 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.837 -0.62 . . . . 0.0 112.082 -175.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 29.4 tp10 -81.94 -11.13 59.03 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.03 0.443 . . . . 0.0 111.098 -177.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.724 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 70.1 mm-40 -86.11 146.08 26.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -174.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.5 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.6 mp0 -80.83 160.89 24.68 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.59 173.841 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.443 HG12 HD11 ' A' ' 29' ' ' ILE . 39.9 mt -105.69 147.38 11.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 175.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.489 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 98.9 m-85 -111.38 151.84 28.01 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.274 0.559 . . . . 0.0 111.341 -178.138 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.465 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 29.7 t70 -69.61 120.85 16.01 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.958 172.736 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.13 19.31 55.89 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.797 -0.716 . . . . 0.0 111.992 -177.197 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.489 ' OD1' ' HB2' ' A' ' 48' ' ' ASN . 24.0 t0 -94.88 159.9 14.83 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 120.928 0.394 . . . . 0.0 110.448 -179.477 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.539 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.3 mp -117.05 108.55 25.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.03 0.443 . . . . 0.0 110.211 -175.785 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.467 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 1.9 mp -92.77 119.13 39.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-O 121.173 0.511 . . . . 0.0 110.175 -178.59 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.508 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 44.8 tt0 -105.22 115.8 30.87 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.646 178.512 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 79.3 t -100.81 102.62 13.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.352 0.596 . . . . 0.0 110.115 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.401 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 49.1 mt -93.27 93.13 3.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.165 -179.009 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.616 ' HD2' ' O ' ' A' ' 68' ' ' ARG . 0.2 OUTLIER -69.86 152.97 43.92 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 170.67 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 26.9 m -80.79 146.68 7.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 C-N-CA 120.497 -0.481 . . . . 0.0 110.0 -176.282 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.522 HG22 ' O ' ' A' ' 70' ' ' ILE . 0.0 OUTLIER -77.98 101.68 3.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 122.862 1.315 . . . . 0.0 109.814 -175.493 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -151.05 -70.22 0.17 Allowed 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 106.439 -1.689 . . . . 0.0 106.439 174.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 51.1 -102.78 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.57 0 CA-C-N 114.335 -1.302 . . . . 0.0 114.249 164.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.536 -1.147 . . . . 0.0 111.128 -177.914 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 68.3 mtt . . . . . 0 N--CA 1.484 1.232 0 CA-C-O 120.629 0.252 . . . . 0.0 110.421 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 58.7 t -104.89 105.48 18.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 120.915 0.388 . . . . 0.0 110.186 179.622 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 47.4 mm -112.31 130.14 66.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.444 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.452 ' HA2' ' O ' ' A' ' 23' ' ' SER . . . 85.24 100.64 0.68 Allowed Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.351 -176.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.459 ' HE2' ' HB3' ' A' ' 23' ' ' SER . 0.0 OUTLIER -126.1 149.67 48.76 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 -176.704 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.628 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 96.0 mttt -109.75 140.61 43.44 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.297 176.793 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -145.83 152.82 40.12 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.966 0.412 . . . . 0.0 110.268 174.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.505 HG21 ' HG2' ' A' ' 18' ' ' LYS . 4.7 m -110.61 118.06 35.18 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.774 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.639 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.7 p -111.49 132.05 61.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.795 -177.381 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.543 HG23 ' HA ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -87.63 124.56 40.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.293 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.5 p -134.49 -171.06 2.67 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.298 -177.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -74.85 -27.4 60.25 Favored 'General case' 0 N--CA 1.464 0.246 0 O-C-N 122.393 -0.192 . . . . 0.0 111.499 -173.394 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -83.73 -6.23 59.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.112 0.482 . . . . 0.0 110.331 178.306 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 131.4 -173.52 20.4 Favored Glycine 0 N--CA 1.443 -0.839 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 -179.007 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.542 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 66.5 tttt -90.47 106.52 18.55 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.153 0.502 . . . . 0.0 109.788 178.007 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.7 tptm -103.61 121.34 42.72 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.199 -170.056 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.505 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -92.1 126.2 44.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 173.061 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.404 ' N ' HD11 ' A' ' 20' ' ' ILE . 4.0 pp -144.52 162.8 35.65 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.047 177.648 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.628 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -111.91 162.87 14.85 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.138 0.494 . . . . 0.0 110.961 -179.893 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.459 ' HB3' ' HE2' ' A' ' 8' ' ' MET . 40.6 t -130.41 140.59 50.57 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.657 -0.702 . . . . 0.0 109.224 176.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -53.81 -38.62 59.94 Favored Glycine 0 C--N 1.331 0.265 0 O-C-N 123.558 0.537 . . . . 0.0 112.523 -179.168 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.44 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -137.99 152.07 71.35 Favored Pre-proline 0 C--N 1.321 -0.638 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 176.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -59.08 128.38 27.54 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.375 2.05 . . . . 0.0 111.2 174.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.44 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 20.4 mmm180 -129.38 170.7 13.33 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.921 0.391 . . . . 0.0 110.455 -175.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.618 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 45.4 ttm180 -77.34 155.75 31.74 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.099 177.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.56 HG21 HG13 ' A' ' 45' ' ' VAL . 38.1 mm -53.17 -46.59 55.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 CA-C-O 121.712 0.768 . . . . 0.0 109.732 175.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.489 ' HB3' ' HE2' ' A' ' 30' ' ' LYS . 28.7 ttpt -72.39 -20.65 61.41 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.785 -1.098 . . . . 0.0 111.428 -178.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -66.57 -53.48 34.08 Favored 'General case' 0 CA--C 1.514 -0.43 0 CA-C-O 121.094 0.473 . . . . 0.0 109.779 176.389 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.8 t -68.21 -50.02 61.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.928 -177.665 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.507 HD23 ' HB ' ' A' ' 40' ' ' ILE . 15.0 tp -70.48 -28.68 65.17 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.488 -177.117 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.5 -39.47 95.64 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.165 174.7 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -62.59 -39.0 92.33 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.925 0.393 . . . . 0.0 110.658 177.04 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 91.7 mt -75.75 -15.08 60.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.028 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 59.21 75.66 0.39 Allowed 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.523 0.678 . . . . 0.0 110.929 -177.484 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 80.8 mt -134.15 130.45 20.31 Favored Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.195 176.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.463 ' HB2' HG21 ' A' ' 42' ' ' THR . 19.5 Cg_endo -58.61 90.46 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.779 2.32 . . . . 0.0 112.916 -179.608 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.507 ' HB ' HD23 ' A' ' 33' ' ' LEU . 18.9 tt -75.87 -9.81 12.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.672 -178.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -75.5 -43.15 50.68 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.761 -177.08 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.463 HG21 ' HB2' ' A' ' 39' ' ' PRO . 10.0 t -95.27 -5.27 44.04 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -170.182 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.583 ' HB ' ' HA ' ' A' ' 68' ' ' ARG . 17.9 m -115.42 167.94 7.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.906 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.1 t -97.32 123.44 49.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.023 0.44 . . . . 0.0 111.457 -173.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . 0.56 HG13 HG21 ' A' ' 29' ' ' ILE . 61.4 t -103.67 126.57 58.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.94 176.409 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.675 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 25.2 mttm -119.41 114.32 22.15 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.568 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.403 ' HB3' HG13 ' A' ' 52' ' ' VAL . 86.6 tttt -93.64 110.14 21.76 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.828 177.88 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 64.76 16.98 10.75 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.606 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 114.14 -29.16 7.86 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.104 -0.57 . . . . 0.0 112.554 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 15.2 mm100 -88.39 140.88 29.02 Favored 'General case' 0 C--N 1.327 -0.413 0 O-C-N 122.846 -0.208 . . . . 0.0 110.779 -176.62 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 3.4 mp -69.89 118.77 14.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 177.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.403 HG13 ' HB3' ' A' ' 47' ' ' LYS . 34.5 m -122.43 169.93 13.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.087 0.47 . . . . 0.0 110.998 -178.257 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.7 pp -87.76 165.97 2.0 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.906 175.652 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -70.81 -10.59 59.85 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.901 -0.591 . . . . 0.0 112.087 -175.029 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.589 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 2.1 tp10 -83.61 -9.59 58.8 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.449 -175.716 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.417 ' O ' HG12 ' A' ' 29' ' ' ILE . 14.8 mm-40 -66.8 149.67 50.22 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.989 0.423 . . . . 0.0 112.068 -178.311 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.618 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 43.7 mt-10 -103.83 152.64 21.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.576 -179.547 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.491 HG12 HD13 ' A' ' 29' ' ' ILE . 23.6 mt -97.38 143.09 13.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.532 -178.578 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -125.97 171.77 10.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.261 -179.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.42 ' HA ' ' HB2' ' A' ' 8' ' ' MET . 27.0 t70 -71.02 122.58 20.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.813 0.34 . . . . 0.0 111.555 -175.441 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.78 14.13 57.04 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.444 176.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -91.51 161.49 14.94 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.937 0.399 . . . . 0.0 110.368 -178.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.1 mm -120.03 127.36 75.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.927 -176.527 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.639 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.4 mm -116.66 116.39 52.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 120.975 0.417 . . . . 0.0 110.918 -176.707 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.675 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 38.8 mm-40 -104.19 113.79 27.58 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.216 178.813 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 55.9 t -105.18 110.26 30.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.429 0.633 . . . . 0.0 110.289 174.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 62.5 mt -113.16 109.52 28.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.808 -179.12 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.583 ' HA ' ' HB ' ' A' ' 43' ' ' VAL . 13.3 ptt180 -65.29 154.44 38.22 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.996 177.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.7 p -82.77 147.59 5.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 178.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 13.3 tt -80.24 108.42 13.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.576 0.703 . . . . 0.0 110.176 178.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 81.9 t80 -132.1 111.55 11.57 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.635 -0.712 . . . . 0.0 109.505 177.319 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 160.59 72.75 0.02 OUTLIER Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.395 -0.907 . . . . 0.0 112.292 -179.302 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.962 0 CA-C-O 118.997 -0.89 . . . . 0.0 111.311 178.03 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 86.4 mtp . . . . . 0 N--CA 1.478 0.939 0 CA-C-O 120.844 0.354 . . . . 0.0 110.245 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.0 t -89.49 121.4 39.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 178.714 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.4 tp -104.12 122.4 56.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.332 0.587 . . . . 0.0 110.135 179.379 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 106.49 -172.4 18.47 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 -177.147 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.558 ' HA ' ' HB2' ' A' ' 60' ' ' ASP . 26.2 ptt? -160.67 129.09 4.61 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.106 0.479 . . . . 0.0 111.069 179.301 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -111.38 112.39 24.11 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 174.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.459 ' CE1' ' HE3' ' A' ' 8' ' ' MET . 49.2 p90 -136.72 168.13 20.11 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.556 -173.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.483 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.5 t -119.04 146.5 45.0 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.321 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 p -126.02 122.83 62.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.917 176.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.492 HG23 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -101.94 124.86 56.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.565 0.698 . . . . 0.0 110.083 -179.398 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.4 HG23 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -146.08 -160.43 1.15 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.163 177.904 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.4 ' H ' HG23 ' A' ' 14' ' ' THR . 4.7 m-20 -60.71 -29.66 69.49 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.185 0.517 . . . . 0.0 110.594 176.538 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -72.29 -3.19 22.32 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.556 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.04 -167.21 20.47 Favored Glycine 0 N--CA 1.444 -0.823 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -176.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.0 ttmt -93.14 102.97 15.29 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 175.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 84.1 tttt -106.83 120.44 42.02 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.771 -172.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.502 HD12 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -98.62 136.5 29.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.094 -178.871 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.502 ' N ' HD12 ' A' ' 20' ' ' ILE . 4.3 pp -140.33 162.65 34.8 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.684 0.278 . . . . 0.0 110.731 179.221 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -114.97 144.24 43.91 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -178.13 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 47.0 t -131.33 131.55 43.83 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.654 0.264 . . . . 0.0 110.453 -177.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.88 -16.84 74.85 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.221 -0.514 . . . . 0.0 112.778 -179.124 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.457 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.21 144.24 42.41 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 122.785 -0.244 . . . . 0.0 110.967 179.492 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 25' ' ' ALA . 3.0 Cg_exo -75.15 130.14 12.86 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.741 2.294 . . . . 0.0 110.99 174.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 9.5 mtp180 -136.85 164.95 27.09 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.897 0.38 . . . . 0.0 110.71 -175.34 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.599 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 16.3 ttp85 -92.47 164.47 13.45 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.99 -176.823 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.479 HG12 ' O ' ' A' ' 56' ' ' GLU . 45.5 mm -51.84 -46.52 40.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 122.183 0.193 . . . . 0.0 111.288 -179.406 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.468 ' HB2' ' OD2' ' A' ' 54' ' ' ASP . 6.1 tptm -65.19 -26.97 68.38 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.836 0.31 . . . . 0.0 111.836 -177.151 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.403 ' O ' ' HG3' ' A' ' 35' ' ' GLU . 19.8 m-20 -62.72 -57.98 9.08 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 176.367 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 46.1 t -64.51 -41.28 91.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.626 -179.345 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.463 HD22 ' HB ' ' A' ' 38' ' ' ILE . 3.1 tm? -61.57 -46.56 89.39 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.117 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.62 -38.42 93.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 121.133 -0.556 . . . . 0.0 112.583 -178.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.403 ' HG3' ' O ' ' A' ' 31' ' ' ASP . 48.7 mt-10 -65.8 -46.96 76.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.597 0.237 . . . . 0.0 111.518 179.27 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 91.7 mt -76.33 -16.25 59.8 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.755 0.312 . . . . 0.0 110.764 -178.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 60.65 37.24 19.33 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.511 177.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.463 ' HB ' HD22 ' A' ' 33' ' ' LEU . 66.7 mt -79.47 132.48 62.01 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.54 177.752 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -60.59 98.57 0.13 Allowed 'Trans proline' 0 CA--C 1.529 0.255 0 C-N-CA 122.546 2.164 . . . . 0.0 112.437 179.636 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.5 ' HA ' HG21 ' A' ' 43' ' ' VAL . 10.7 tp -69.87 -13.6 17.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.445 0.64 . . . . 0.0 110.149 -179.501 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -64.58 -21.74 66.78 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.245 -0.889 . . . . 0.0 111.076 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.8 t -127.3 10.39 6.8 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 112.282 0.475 . . . . 0.0 112.282 -173.347 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.513 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 35.3 m -131.9 142.26 43.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.121 0.486 . . . . 0.0 111.166 -179.262 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -118.12 138.92 47.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.79 178.378 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.6 t -103.73 136.09 38.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 121.248 0.547 . . . . 0.0 111.071 -176.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.609 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 56.5 mttm -118.1 147.77 42.96 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.008 175.688 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.501 ' HG2' HG23 ' A' ' 52' ' ' VAL . 19.1 mmtp -108.63 101.61 10.74 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.516 172.444 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.463 HD21 ' HA ' ' A' ' 48' ' ' ASN . 0.8 OUTLIER 57.5 27.33 13.86 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.738 177.296 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 116.5 -28.82 7.28 Favored Glycine 0 CA--C 1.522 0.478 0 C-N-CA 121.227 -0.511 . . . . 0.0 113.266 -179.245 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 70.4 mm-40 -88.14 139.81 30.12 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 117.054 0.427 . . . . 0.0 111.38 -172.477 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 26.2 mm -74.63 126.31 35.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.85 0.357 . . . . 0.0 111.052 179.117 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.501 HG23 ' HG2' ' A' ' 47' ' ' LYS . 25.2 m -128.76 178.48 4.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.206 178.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 47.0 pt -118.99 -173.46 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.394 0.616 . . . . 0.0 111.785 -178.401 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.468 ' OD2' ' HB2' ' A' ' 30' ' ' LYS . 16.6 t70 -64.78 -19.98 66.12 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.131 -175.74 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.403 ' HA ' ' HD2' ' A' ' 28' ' ' ARG . 6.0 mm-40 -90.41 3.96 52.3 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.129 -0.487 . . . . 0.0 112.274 -173.468 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.479 ' O ' HG12 ' A' ' 29' ' ' ILE . 0.5 OUTLIER -85.5 135.71 33.72 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.074 0.464 . . . . 0.0 111.366 -179.843 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.599 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 7.1 mp0 -82.11 153.49 26.04 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.257 175.5 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.487 HG21 HD11 ' A' ' 64' ' ' ILE . 22.4 mt -95.84 143.37 12.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 175.309 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.566 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 80.3 m-85 -119.51 153.41 35.39 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.212 0.53 . . . . 0.0 111.369 -174.5 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.558 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 29.1 t70 -62.58 121.14 12.6 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.231 172.555 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.13 8.71 74.8 Favored Glycine 0 C--O 1.229 -0.218 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.138 -179.331 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.566 ' HB2' ' HB2' ' A' ' 59' ' ' PHE . 31.4 t70 -93.8 146.96 23.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 -179.653 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 37.9 mm -107.79 128.15 63.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.764 0.316 . . . . 0.0 110.905 -174.219 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.487 HD11 HG21 ' A' ' 58' ' ' ILE . 39.2 mm -108.5 118.48 56.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.946 -177.156 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.609 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 19.0 mp0 -106.09 121.47 44.21 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 172.378 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 97.2 t -105.53 104.04 16.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.198 0.523 . . . . 0.0 110.386 178.02 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.49 HD11 ' HD2' ' A' ' 46' ' ' LYS . 3.1 mp -106.02 114.06 44.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.625 -179.566 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.846 HH11 ' HB2' ' A' ' 68' ' ' ARG . 1.7 mtm105 -63.84 141.42 58.77 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 175.708 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -90.08 120.29 38.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 174.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.56 111.35 15.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 121.841 0.829 . . . . 0.0 109.586 -179.407 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -89.16 142.76 27.37 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.136 -0.938 . . . . 0.0 109.784 -177.033 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -77.26 64.67 3.14 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.29 179.097 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.14 0 CA-C-O 118.081 -1.4 . . . . 0.0 111.109 -178.911 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 50.1 ttm . . . . . 0 N--CA 1.479 1.008 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.2 p -83.03 108.38 15.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.571 0.7 . . . . 0.0 110.424 178.251 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 54.2 mt -108.87 122.72 63.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.954 179.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.61 166.41 13.31 Favored Glycine 0 N--CA 1.441 -0.97 0 C-N-CA 120.542 -0.837 . . . . 0.0 111.903 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.63 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 0.7 OUTLIER -136.88 139.34 41.57 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 -176.83 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.607 ' HA ' ' HB3' ' A' ' 22' ' ' GLU . 18.0 ttmm -101.03 116.56 33.13 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 172.053 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -136.75 165.48 25.82 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 120.925 0.393 . . . . 0.0 110.442 -179.137 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.872 ' HB ' HD13 ' A' ' 20' ' ' ILE . 12.1 t -121.13 137.2 54.77 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-O 121.288 0.566 . . . . 0.0 110.591 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.1 p -115.15 135.13 56.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.362 176.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.536 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -109.64 122.4 64.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.447 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.82 -165.01 1.54 Allowed 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.067 178.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -71.13 -13.49 61.97 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.09 0.472 . . . . 0.0 110.244 177.485 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -84.49 -9.79 58.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.503 0.668 . . . . 0.0 109.967 175.426 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 112.2 -178.67 19.2 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.986 -179.022 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.536 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.4 ttmt -92.8 114.76 27.4 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 176.011 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.411 ' HB2' ' HE3' ' A' ' 19' ' ' LYS . 30.9 ttmt -127.07 149.1 50.08 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.931 -171.186 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.872 HD13 ' HB ' ' A' ' 11' ' ' THR . 37.5 mm -94.77 126.3 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.829 -178.521 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 3.9 pp -144.64 144.95 31.52 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 172.676 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.607 ' HB3' ' HA ' ' A' ' 9' ' ' LYS . 12.6 pt-20 -139.42 163.4 32.62 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.804 0.335 . . . . 0.0 111.129 -176.144 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.7 t -129.03 165.53 20.99 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.102 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -101.67 14.05 57.78 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 177.314 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -139.3 142.85 33.94 Favored Pre-proline 0 C--N 1.324 -0.509 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 175.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.63 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 34.6 Cg_exo -61.19 136.39 64.37 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.611 2.207 . . . . 0.0 111.15 175.778 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.873 ' HG3' ' HB3' ' A' ' 31' ' ' ASP . 0.0 OUTLIER -140.37 157.87 44.89 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.346 0.593 . . . . 0.0 112.105 -173.06 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.542 ' HD3' ' HA ' ' A' ' 55' ' ' GLU . 43.5 ttm180 -107.06 163.41 13.01 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.08 -0.963 . . . . 0.0 109.134 176.414 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.568 HG13 ' O ' ' A' ' 56' ' ' GLU . 10.1 mt -60.08 -48.32 88.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.375 0 CA-C-O 121.359 0.6 . . . . 0.0 109.615 176.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.9 tptp -51.4 -35.95 41.39 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.678 173.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.873 ' HB3' ' HG3' ' A' ' 27' ' ' ARG . 0.2 OUTLIER -72.45 -55.58 6.78 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.676 179.079 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.408 HG21 ' O ' ' A' ' 28' ' ' ARG . 58.7 t -59.67 -61.07 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.287 -177.687 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.789 ' HG ' HD13 ' A' ' 40' ' ' ILE . 4.1 mm? -69.16 -28.37 66.36 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 121.118 -0.233 . . . . 0.0 111.224 -177.222 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.29 -43.33 63.28 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.454 179.158 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -71.98 -34.52 69.0 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.764 0.316 . . . . 0.0 110.64 178.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.404 ' HG ' ' O ' ' A' ' 32' ' ' VAL . 94.8 mt -73.22 -17.9 61.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.793 0.33 . . . . 0.0 110.147 175.382 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 61.86 36.77 15.79 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.892 174.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.403 HG22 ' HD2' ' A' ' 39' ' ' PRO . 72.4 mt -92.07 139.0 24.29 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.038 179.599 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.403 ' HD2' HG22 ' A' ' 38' ' ' ILE . 35.9 Cg_endo -65.87 65.39 0.42 Allowed 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 122.975 2.45 . . . . 0.0 113.133 177.495 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.789 HD13 ' HG ' ' A' ' 33' ' ' LEU . 7.6 tt -65.62 -22.35 30.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.843 177.593 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -66.29 -19.92 65.96 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.219 -0.9 . . . . 0.0 112.548 -173.111 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.6 t -109.16 11.86 25.33 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.36 -0.536 . . . . 0.0 111.913 -173.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 32.7 m -133.63 173.58 14.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.505 0.193 . . . . 0.0 110.784 178.23 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.834 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 46.5 t -88.26 129.86 38.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.729 0.3 . . . . 0.0 111.242 -175.39 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 19.2 t -108.33 126.04 65.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.826 -179.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.593 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 82.3 mttt -123.25 118.44 27.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.872 175.689 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -97.25 108.42 21.15 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 172.576 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 64.93 14.58 9.38 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.636 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 108.67 -13.08 35.54 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 121.14 -0.552 . . . . 0.0 112.096 -178.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 31.9 mm-40 -89.93 129.39 36.29 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 60.4 mt -72.49 105.78 2.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.263 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.6 m -116.83 171.31 5.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.484 -171.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 35.0 pt -89.45 166.92 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 166.799 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.413 ' O ' ' HB ' ' A' ' 29' ' ' ILE . 14.0 p-10 -77.71 -1.33 30.61 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 120.758 0.313 . . . . 0.0 111.74 -174.485 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.542 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 3.9 tp10 -82.88 12.34 4.98 Favored 'General case' 0 CA--C 1.539 0.547 0 CA-C-O 121.08 0.467 . . . . 0.0 111.066 -177.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.568 ' O ' HG13 ' A' ' 29' ' ' ILE . 26.6 mm-40 -91.23 143.33 26.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.528 178.786 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.529 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 12.3 mp0 -76.0 161.96 28.47 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.849 0.357 . . . . 0.0 110.305 173.4 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.528 ' HB ' ' HE3' ' A' ' 8' ' ' MET . 8.6 mm -104.31 141.34 20.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 174.019 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -118.13 169.8 9.39 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.73 176.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -78.02 122.07 25.07 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.735 -174.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.72 11.53 56.71 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.252 -177.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -83.55 160.81 21.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.979 0.419 . . . . 0.0 110.717 -178.427 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.533 HG12 HG21 ' A' ' 11' ' ' THR . 20.2 mt -129.0 111.28 22.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.452 -179.835 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.405 HD11 ' N ' ' A' ' 64' ' ' ILE . 3.2 mp -95.11 115.67 34.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.277 0.561 . . . . 0.0 109.925 -179.736 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.593 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 37.5 mt-10 -102.29 104.96 15.52 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.086 179.352 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 55.4 t -97.46 107.41 20.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.552 0.691 . . . . 0.0 109.8 178.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.834 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 54.6 mt -92.61 95.07 5.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.251 -176.642 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.63 125.37 26.64 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 173.506 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 14.9 p -83.55 148.21 5.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.655 -174.635 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 7.1 tt -78.17 119.29 26.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 172.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 4.2 t80 -84.83 107.92 17.23 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.41 -171.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -88.09 -82.34 1.24 Allowed Glycine 0 N--CA 1.447 -0.62 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.132 178.075 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.004 0 CA-C-O 119.05 -0.861 . . . . 0.0 111.592 -179.335 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 24.6 ttt . . . . . 0 N--CA 1.48 1.041 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 39.0 t -82.81 104.6 11.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 175.286 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 7.5 tp -111.22 124.93 68.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.811 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 121.9 -177.47 16.44 Favored Glycine 0 N--CA 1.443 -0.876 0 C-N-CA 120.728 -0.749 . . . . 0.0 111.689 -178.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.591 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 25.1 ptt? -156.78 130.99 8.51 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.161 0.505 . . . . 0.0 111.158 -179.328 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.4 ' HE2' ' HB2' ' A' ' 9' ' ' LYS . 7.4 tppt? -101.05 120.03 39.61 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.063 174.136 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 10.0 p90 -141.33 151.75 43.83 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.247 0.546 . . . . 0.0 110.777 -179.727 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.457 HG21 ' HG2' ' A' ' 18' ' ' LYS . 5.8 m -118.13 128.73 55.01 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.881 178.699 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.766 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.6 p -104.66 122.93 58.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.242 0.544 . . . . 0.0 110.443 178.076 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.436 HG23 ' HG2' ' A' ' 65' ' ' GLU . 7.3 tp -87.53 123.73 40.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 121.213 0.53 . . . . 0.0 109.666 176.026 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.437 ' HB ' ' OD1' ' A' ' 16' ' ' ASP . 0.2 OUTLIER -135.67 -177.19 4.56 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.416 -0.811 . . . . 0.0 108.905 -179.788 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.435 ' H ' HG22 ' A' ' 14' ' ' THR . 4.2 p-10 -71.46 -17.95 62.34 Favored 'General case' 0 C--N 1.327 -0.396 0 O-C-N 122.254 -0.279 . . . . 0.0 111.286 -177.159 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.437 ' OD1' ' HB ' ' A' ' 14' ' ' THR . 9.2 p-10 -90.29 4.23 51.31 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.866 0.365 . . . . 0.0 110.757 179.751 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 122.1 -166.32 14.78 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.778 175.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.457 ' HG2' HG21 ' A' ' 11' ' ' THR . 37.4 tttm -90.34 106.64 18.63 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.402 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.473 ' HB3' HG13 ' A' ' 12' ' ' VAL . 22.7 tttp -103.32 99.02 8.85 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.83 -167.844 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.553 HD12 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -86.12 133.41 29.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.779 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.553 ' N ' HD12 ' A' ' 20' ' ' ILE . 2.1 pt? -144.13 168.23 20.51 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 177.351 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -134.7 148.67 50.36 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.829 0.347 . . . . 0.0 110.445 -177.208 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 22.1 m -129.2 131.97 47.19 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.781 174.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.21 -16.14 59.71 Favored Glycine 0 C--N 1.33 0.246 0 CA-C-N 116.059 -0.519 . . . . 0.0 113.314 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -139.39 144.79 41.43 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 176.075 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.591 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 23.3 Cg_exo -65.69 146.34 83.8 Favored 'Trans proline' 0 C--O 1.234 0.324 0 C-N-CA 122.896 2.397 . . . . 0.0 111.595 176.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.549 ' HD3' ' OD2' ' A' ' 31' ' ' ASP . 96.4 mtt180 -140.16 168.22 20.31 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.309 0.576 . . . . 0.0 111.487 -175.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.592 ' HD3' ' HA ' ' A' ' 55' ' ' GLU . 37.0 ttm105 -94.17 152.52 18.67 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.077 -0.965 . . . . 0.0 108.555 171.022 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.523 HG12 ' O ' ' A' ' 56' ' ' GLU . 46.8 mm -51.13 -44.05 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 122.349 0.26 . . . . 0.0 111.601 -177.532 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.1 tptm -58.43 -27.2 64.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.138 -176.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.549 ' OD2' ' HD3' ' A' ' 27' ' ' ARG . 20.2 t70 -72.47 -53.3 12.49 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.684 -178.101 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 47.5 t -64.97 -44.13 96.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 CA-C-O 121.223 0.535 . . . . 0.0 110.202 178.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.487 HD21 ' HB ' ' A' ' 40' ' ' ILE . 20.7 tp -62.6 -35.66 80.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.977 178.27 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.75 -33.54 66.56 Favored Glycine 0 N--CA 1.449 -0.457 0 CA-C-N 115.446 -0.797 . . . . 0.0 113.099 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -66.37 -46.89 75.14 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 120.851 0.357 . . . . 0.0 111.211 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 92.9 mt -83.58 -16.15 46.42 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.732 -177.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.9 tp10 54.85 80.98 0.11 Allowed 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.824 0.821 . . . . 0.0 110.615 -176.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.452 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 67.8 mt -120.83 127.81 26.07 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.412 178.792 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.47 ' HB2' HG22 ' A' ' 42' ' ' THR . 16.0 Cg_exo -67.16 104.02 0.82 Allowed 'Trans proline' 0 N--CA 1.46 -0.446 0 C-N-CA 122.584 2.189 . . . . 0.0 112.486 -179.248 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.487 ' HB ' HD21 ' A' ' 33' ' ' LEU . 10.7 tt -66.79 -6.07 4.11 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 121.834 0.826 . . . . 0.0 110.237 177.117 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 21.4 tp10 -72.89 -36.2 67.29 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.095 -0.957 . . . . 0.0 110.853 177.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.513 HG21 HG12 ' A' ' 43' ' ' VAL . 15.3 t -101.21 -24.68 14.21 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 120.911 -0.316 . . . . 0.0 111.531 -175.392 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.55 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 34.2 m -116.93 141.56 34.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 110.062 -0.348 . . . . 0.0 110.062 177.074 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.443 HG12 HD11 ' A' ' 51' ' ' ILE . 38.4 t -105.0 140.36 23.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 120.922 0.392 . . . . 0.0 110.653 -177.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 6.9 p -103.39 131.16 52.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.805 -178.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.627 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 87.6 mttt -118.75 146.32 44.86 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.253 177.647 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.731 ' HG2' HG23 ' A' ' 52' ' ' VAL . 13.8 mmtp -109.37 101.25 10.25 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 167.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.5 t-20 50.17 61.11 3.36 Favored 'General case' 0 CA--C 1.537 0.479 0 O-C-N 123.697 0.623 . . . . 0.0 111.122 -179.45 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 87.54 -23.38 12.8 Favored Glycine 0 CA--C 1.52 0.35 0 CA-C-N 116.031 -0.531 . . . . 0.0 113.585 176.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 14.5 mm100 -96.56 127.56 42.67 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 117.06 0.43 . . . . 0.0 111.942 -172.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.532 HD13 ' HG2' ' A' ' 46' ' ' LYS . 33.7 mm -65.2 127.88 26.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.248 177.097 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.731 HG23 ' HG2' ' A' ' 47' ' ' LYS . 29.5 m -131.65 178.8 5.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.075 0.464 . . . . 0.0 111.368 -177.293 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.4 pt -107.81 177.24 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.558 178.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -74.35 -12.9 60.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.033 0.444 . . . . 0.0 110.84 -177.126 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.592 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 14.2 mm-40 -79.99 -5.3 55.47 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.866 179.574 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.523 ' O ' HG12 ' A' ' 29' ' ' ILE . 3.7 mm-40 -68.98 140.04 55.03 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.742 0.306 . . . . 0.0 110.93 178.019 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLU . . . . . 0.558 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 39.3 mt-10 -96.16 147.57 23.61 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 175.197 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.477 ' HB ' ' SD ' ' A' ' 8' ' ' MET . 19.2 mt -89.19 135.22 26.46 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -118.53 146.4 44.59 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.557 -0.292 . . . . 0.0 110.874 -177.089 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.561 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 18.7 t70 -58.66 116.87 3.99 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.598 173.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.14 -17.72 47.44 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 121.039 -0.601 . . . . 0.0 112.145 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 33.2 t0 -77.87 150.77 34.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.888 0.375 . . . . 0.0 110.05 -179.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.1 mm -105.94 115.45 47.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.162 0.506 . . . . 0.0 110.411 -175.203 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.766 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 9.0 tp -95.71 133.26 37.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.38 -179.057 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.627 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 28.6 mt-10 -131.7 130.38 41.93 Favored 'General case' 0 C--N 1.317 -0.814 0 O-C-N 122.166 -0.334 . . . . 0.0 110.795 -175.024 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 86.9 t -115.56 103.97 16.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.173 0.511 . . . . 0.0 109.87 178.149 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 25.6 mt -123.58 109.67 23.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.588 -176.662 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.55 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -66.7 124.28 22.46 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 173.114 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.47 127.55 39.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-O 121.185 0.517 . . . . 0.0 110.74 -175.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 6.4 tp -79.26 100.69 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 CA-C-O 122.144 0.973 . . . . 0.0 109.386 176.613 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 84.1 t80 -121.07 -42.12 2.5 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.242 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -163.25 179.69 38.26 Favored Glycine 0 N--CA 1.441 -0.994 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.003 176.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.083 0 CA-C-O 118.315 -1.269 . . . . 0.0 111.175 -179.817 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.234 0.256 0 CA-C-O 121.068 0.461 . . . . 0.0 110.864 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.29 105.96 0.21 Allowed Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -177.653 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' MET . . . . . 0.584 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.1 ptt? -110.48 130.54 55.53 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.858 0.361 . . . . 0.0 111.044 -174.768 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.44 ' HB2' ' HB3' ' A' ' 22' ' ' GLU . 3.5 ttpm? -115.03 126.6 54.92 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 174.731 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 28.8 p90 -138.79 167.89 21.0 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.313 -175.482 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.492 ' HB ' HD13 ' A' ' 20' ' ' ILE . 13.1 t -125.38 132.02 52.86 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.201 0.524 . . . . 0.0 110.911 178.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.539 HG22 ' HB ' ' A' ' 64' ' ' ILE . 63.0 t -109.28 119.3 58.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 115.458 -0.792 . . . . 0.0 108.946 174.111 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.539 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -100.34 128.98 51.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.269 0.557 . . . . 0.0 109.949 -177.948 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.415 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -141.34 -162.81 1.44 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.508 -0.769 . . . . 0.0 108.949 178.507 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.415 ' H ' HG22 ' A' ' 14' ' ' THR . 3.7 m-20 -60.97 -27.44 68.27 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.329 0.585 . . . . 0.0 110.537 176.632 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -74.46 -9.42 58.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.507 178.45 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.31 -163.75 19.05 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 111.416 -0.674 . . . . 0.0 111.416 -177.827 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -76.8 118.76 19.74 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.053 0.454 . . . . 0.0 110.361 175.666 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 19.8 mtpp -102.48 121.83 43.12 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.18 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.492 HD13 ' HB ' ' A' ' 11' ' ' THR . 21.7 mm -100.32 120.84 50.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.027 0.442 . . . . 0.0 110.913 -177.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.436 HD23 ' N ' ' A' ' 21' ' ' LEU . 2.1 pt? -144.32 141.32 29.68 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.047 176.771 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.44 ' HB3' ' HB2' ' A' ' 9' ' ' LYS . 6.7 pt-20 -121.54 139.01 54.06 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.274 0.559 . . . . 0.0 110.763 178.652 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.9 t -119.9 130.88 55.04 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.518 -0.764 . . . . 0.0 109.446 -176.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -63.43 -31.99 82.63 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 121.23 -0.51 . . . . 0.0 112.868 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.436 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -106.82 123.81 37.41 Favored Pre-proline 0 C--N 1.322 -0.596 0 O-C-N 122.822 -0.222 . . . . 0.0 110.621 178.713 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.584 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 26.1 Cg_exo -63.71 110.89 1.37 Allowed 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.868 2.379 . . . . 0.0 111.544 175.815 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.436 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 14.4 mmm180 -118.57 177.11 4.95 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.232 0.539 . . . . 0.0 111.808 -171.295 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.684 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 15.6 ttp180 -89.88 157.61 17.81 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.946 -179.389 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.57 HD13 HG12 ' A' ' 58' ' ' ILE . 27.1 mm -50.22 -47.41 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 CA-C-O 120.833 0.349 . . . . 0.0 110.308 177.684 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.51 ' HB2' ' O ' ' A' ' 54' ' ' ASP . 46.3 tttp -59.63 -29.56 68.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.275 -176.537 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -64.89 -61.84 1.92 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.057 0.456 . . . . 0.0 110.372 -178.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.1 t -64.84 -38.96 84.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.556 -179.187 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.458 ' CD1' ' HB ' ' A' ' 38' ' ' ILE . 20.7 tp -63.21 -41.16 99.11 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.363 178.863 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.23 -35.19 63.97 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 116.009 -0.541 . . . . 0.0 113.376 179.457 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.442 ' HA ' ' OE1' ' A' ' 35' ' ' GLU . 5.5 mm-40 -65.13 -42.12 94.18 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 117.058 0.429 . . . . 0.0 111.295 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.6 mt -86.11 -8.4 57.9 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 175.005 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 40.27 70.12 0.27 Allowed 'General case' 0 C--O 1.234 0.269 0 CA-C-N 114.54 -1.209 . . . . 0.0 111.662 -173.511 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.458 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 63.8 mt -92.6 112.58 56.23 Favored Pre-proline 0 C--N 1.321 -0.667 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 174.701 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.539 ' HB2' HG22 ' A' ' 42' ' ' THR . 34.1 Cg_exo -60.29 103.43 0.21 Allowed 'Trans proline' 0 N--CA 1.46 -0.485 0 C-N-CA 122.693 2.262 . . . . 0.0 112.789 -173.664 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 8.1 tt -65.28 -11.34 11.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 CA-C-O 121.903 0.858 . . . . 0.0 109.493 175.345 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -66.36 -26.69 67.39 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 114.543 -1.208 . . . . 0.0 111.468 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.539 HG22 ' HB2' ' A' ' 39' ' ' PRO . 5.1 t -125.69 -7.84 6.78 Favored 'General case' 0 C--O 1.234 0.259 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -175.123 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.697 HG12 ' HB3' ' A' ' 68' ' ' ARG . 2.4 m -121.25 149.55 24.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.668 -177.124 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.4 t -98.85 130.83 47.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.55 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.9 t -103.03 126.73 57.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.137 0.494 . . . . 0.0 110.793 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.609 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 25.5 mttm -125.91 140.56 52.54 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.969 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.552 ' HD2' HG11 ' A' ' 52' ' ' VAL . 31.8 mttm -106.54 102.12 11.53 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.544 171.251 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 60.3 14.85 4.93 Favored 'General case' 0 CA--C 1.536 0.43 0 O-C-N 123.665 0.603 . . . . 0.0 111.164 178.577 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 126.9 -30.25 4.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.788 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 81.9 mm-40 -86.55 134.21 33.67 Favored 'General case' 0 C--N 1.327 -0.389 0 O-C-N 122.416 -0.461 . . . . 0.0 110.631 -176.024 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.434 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.7 mp -75.21 118.99 22.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -177.478 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.552 HG11 ' HD2' ' A' ' 47' ' ' LYS . 28.0 m -122.27 166.79 16.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 121.074 0.464 . . . . 0.0 110.745 -177.594 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 22.6 pt -97.81 175.41 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.859 174.616 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.51 ' O ' ' HB2' ' A' ' 30' ' ' LYS . 13.9 p-10 -81.89 12.84 3.68 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.289 -175.08 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -93.41 -15.84 25.23 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.707 -178.078 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.423 ' O ' ' HG3' ' A' ' 28' ' ' ARG . 60.6 mm-40 -77.33 160.74 28.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.196 -177.886 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.684 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.1 mp0 -94.17 163.17 13.57 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.989 0.423 . . . . 0.0 111.234 -178.779 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.57 HG12 HD13 ' A' ' 29' ' ' ILE . 45.8 mt -102.18 144.39 13.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 176.471 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -129.44 155.62 45.4 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.977 0.418 . . . . 0.0 110.693 -176.776 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.528 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 25.5 t70 -66.55 111.14 3.46 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.356 176.774 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.58 9.99 42.25 Favored Glycine 0 N--CA 1.445 -0.767 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.242 -177.081 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 26.2 t70 -88.44 146.3 25.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.859 0.362 . . . . 0.0 110.458 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.426 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.0 mp -113.99 115.91 51.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.278 -178.147 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.539 ' HB ' HG22 ' A' ' 12' ' ' VAL . 4.1 mp -102.04 110.3 28.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.606 179.297 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.609 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 44.1 mt-10 -96.98 98.12 9.81 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.564 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.442 HG23 HG22 ' A' ' 64' ' ' ILE . 87.3 t -92.22 101.54 12.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.418 0.628 . . . . 0.0 109.842 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 63.4 mt -109.26 99.97 9.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.501 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.697 ' HB3' HG12 ' A' ' 43' ' ' VAL . 24.3 ptt180 . . . . . 0 C--N 1.321 -0.654 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 173.575 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.2 pt . . . . . 0 N--CA 1.451 -0.406 0 CA-C-O 121.05 0.452 . . . . 0.0 110.15 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.87 178.6 16.39 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.59 -178.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' MET . . . . . 0.434 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 1.2 mpp? -140.02 140.53 36.23 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.758 0.313 . . . . 0.0 110.67 -176.721 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -111.61 111.43 22.42 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 168.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -134.12 167.75 20.09 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 120.906 0.384 . . . . 0.0 110.679 -172.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.544 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 25.8 m -126.38 123.35 37.75 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 177.045 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.517 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.6 p -105.33 123.87 59.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.294 0.568 . . . . 0.0 110.227 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.447 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -107.26 130.54 59.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 121.157 0.503 . . . . 0.0 109.888 179.28 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.461 HG23 ' HB ' ' A' ' 66' ' ' VAL . 0.2 OUTLIER -146.2 -160.42 1.15 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 177.6 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.415 ' H ' HG22 ' A' ' 14' ' ' THR . 1.3 m-20 -58.81 -25.94 63.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.906 0.384 . . . . 0.0 111.413 179.087 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -89.1 10.2 22.64 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.522 -177.231 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.55 -156.65 18.9 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.459 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 54.4 mttm -105.59 103.51 13.04 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -178.648 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.8 tptm -106.75 115.06 29.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.87 0.367 . . . . 0.0 111.098 -175.714 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.544 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -78.59 128.61 38.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 176.798 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 96.7 mt -131.51 139.0 49.18 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.778 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -128.61 146.0 50.98 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.023 0.439 . . . . 0.0 110.602 179.596 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.5 m -135.24 136.23 41.56 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.886 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -86.8 17.97 37.61 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.509 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.446 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.51 131.51 16.18 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 178.876 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 25' ' ' ALA . 27.9 Cg_exo -62.45 112.68 1.66 Allowed 'Trans proline' 0 C--O 1.234 0.321 0 C-N-CA 122.693 2.262 . . . . 0.0 111.482 177.302 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -133.0 153.13 51.78 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.075 0.464 . . . . 0.0 111.01 -176.107 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.575 ' HG3' ' O ' ' A' ' 56' ' ' GLU . 23.6 ttm180 -83.49 164.73 19.68 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.387 -178.552 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.503 HD13 HG12 ' A' ' 58' ' ' ILE . 31.9 mm -51.56 -49.54 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 CA-C-O 120.714 0.292 . . . . 0.0 110.324 176.808 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 33.4 tttp -60.36 -29.58 69.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.843 -178.619 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.484 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 1.1 t70 -67.68 -50.4 57.92 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -177.649 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 60.9 t -73.26 -39.74 56.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.461 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.547 HD21 ' HB ' ' A' ' 40' ' ' ILE . 36.2 tp -62.65 -39.45 93.93 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.376 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.04 -37.91 95.26 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.783 -0.644 . . . . 0.0 112.156 177.062 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.484 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 6.9 mm-40 -64.23 -41.54 96.95 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.151 0.501 . . . . 0.0 110.323 176.061 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 95.0 mt -76.76 -16.23 59.53 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.935 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 62.93 26.56 15.59 Favored 'General case' 0 CA--C 1.537 0.448 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.055 174.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.409 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 75.1 mt -86.74 122.61 71.5 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.561 -178.74 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 18.5 Cg_exo -66.42 110.13 1.75 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.713 2.275 . . . . 0.0 112.268 178.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.547 ' HB ' HD21 ' A' ' 33' ' ' LEU . 13.3 tt -68.02 -17.54 22.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.574 178.796 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -56.98 -40.16 76.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.932 -178.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.411 HG23 HG13 ' A' ' 43' ' ' VAL . 14.8 t -98.01 2.12 48.55 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.817 0.341 . . . . 0.0 111.783 -172.32 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.544 HG12 ' HB3' ' A' ' 68' ' ' ARG . 12.0 m -129.07 171.5 16.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 O-C-N 122.032 -0.417 . . . . 0.0 111.389 -176.294 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.5 ' HB ' ' O ' ' A' ' 67' ' ' ILE . 61.0 t -126.55 136.44 60.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 173.369 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.5 t -106.27 127.81 61.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.964 0.412 . . . . 0.0 111.341 -175.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.517 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 85.7 mttt -118.01 120.78 38.84 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.561 174.718 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.471 ' HE3' ' O ' ' A' ' 57' ' ' GLU . 10.0 mtpm? -97.32 104.29 16.29 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 174.159 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 62.43 18.17 10.12 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.719 -176.085 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 109.66 -13.92 32.46 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.685 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -87.63 123.92 32.98 Favored 'General case' 0 C--N 1.326 -0.418 0 O-C-N 122.759 -0.259 . . . . 0.0 110.682 -178.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 65.6 mt -75.06 121.65 27.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.076 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.835 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 28.2 m -135.72 177.42 6.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.28 -175.572 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.433 HG13 ' H ' ' A' ' 55' ' ' GLU . 42.7 pt -102.74 -175.09 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.353 174.783 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -80.08 -7.68 59.0 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.73 -175.293 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.433 ' H ' HG13 ' A' ' 53' ' ' ILE . 6.8 tp10 -89.95 10.99 21.8 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-O 121.232 0.539 . . . . 0.0 110.793 -178.668 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.835 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 59.3 mm-40 -89.24 148.77 23.42 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.016 0.436 . . . . 0.0 111.536 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.471 ' O ' ' HE3' ' A' ' 47' ' ' LYS . 1.4 tp10 -85.51 142.74 28.96 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.129 -177.71 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.503 HG12 HD13 ' A' ' 29' ' ' ILE . 45.4 mt -88.98 130.77 37.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 177.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -102.56 156.44 17.61 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.274 179.058 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -73.49 115.63 13.1 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.947 0.403 . . . . 0.0 110.134 177.138 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 103.34 2.25 47.65 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 121.012 -0.613 . . . . 0.0 111.675 -177.445 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -75.33 146.77 40.66 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -113.97 113.7 44.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.517 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 41.3 mm -89.5 104.68 15.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.821 -176.839 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.517 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 36.4 mt-10 -102.25 107.73 18.87 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.835 -179.097 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.461 ' HB ' HG23 ' A' ' 14' ' ' THR . 76.3 t -91.92 99.93 10.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 121.335 0.588 . . . . 0.0 109.888 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.5 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 55.8 mt -105.01 103.75 15.82 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 177.524 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.544 ' HB3' HG12 ' A' ' 43' ' ' VAL . 16.4 ptt180 . . . . . 0 C--N 1.312 -1.034 0 C-N-CA 120.294 -0.563 . . . . 0.0 111.072 -173.787 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 46.0 mm . . . . . 0 N--CA 1.452 -0.331 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 107.24 76.72 1.01 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.626 -0.797 . . . . 0.0 111.379 -177.755 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' MET . . . . . 0.573 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.0 ptt? -85.74 130.47 34.55 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.12 0.486 . . . . 0.0 110.763 -174.037 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.484 ' HD3' HD11 ' A' ' 20' ' ' ILE . 0.6 OUTLIER -109.77 120.01 41.16 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.464 179.192 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 45.0 p90 -144.06 167.99 21.07 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.838 0.351 . . . . 0.0 110.761 -175.126 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.515 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 4.7 m -120.93 128.77 53.07 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.684 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 p -108.72 122.44 63.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 121.259 0.552 . . . . 0.0 109.921 175.792 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.565 ' HB ' ' HG3' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -106.59 118.72 54.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.366 0.603 . . . . 0.0 109.932 179.989 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.424 HG22 ' H ' ' A' ' 15' ' ' ASP . 2.4 m -116.47 169.78 9.06 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 177.066 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.424 ' H ' HG22 ' A' ' 14' ' ' THR . 29.1 t70 -53.97 -38.03 64.58 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.831 0.348 . . . . 0.0 111.58 178.293 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -77.96 -10.5 59.62 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.821 -175.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 152.74 170.9 19.63 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.321 -0.942 . . . . 0.0 112.578 178.211 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.565 ' HG3' ' HB ' ' A' ' 13' ' ' ILE . 36.4 ttpt -107.14 125.89 51.67 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.265 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -125.69 115.59 20.33 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.139 0.495 . . . . 0.0 111.242 -176.031 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.515 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -88.76 129.89 39.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 174.215 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.4 ' N ' HD13 ' A' ' 20' ' ' ILE . 4.1 pp -144.7 165.9 26.73 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.955 0.407 . . . . 0.0 110.566 178.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -123.21 133.15 54.24 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.447 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.1 t -101.96 131.97 48.06 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 177.45 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -55.89 -29.31 54.86 Favored Glycine 0 CA--C 1.518 0.23 0 CA-C-N 116.169 -0.468 . . . . 0.0 113.06 -177.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.489 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -135.22 151.4 75.01 Favored Pre-proline 0 C--N 1.322 -0.591 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 178.834 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.573 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 28.1 Cg_endo -63.86 127.63 20.01 Favored 'Trans proline' 0 N--CA 1.464 -0.228 0 C-N-CA 122.358 2.039 . . . . 0.0 111.072 174.284 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 18.3 mmm180 -128.05 170.13 13.27 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.058 0.456 . . . . 0.0 110.894 -173.089 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.6 ttt85 -95.79 159.9 14.75 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 178.484 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.462 ' CG2' ' HA ' ' A' ' 54' ' ' ASP . 41.6 mm -55.74 -46.77 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 N-CA-C 110.301 -0.259 . . . . 0.0 110.301 178.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.8 ttmp? -53.88 -38.56 64.87 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.856 178.245 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.431 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 32.9 t70 -62.09 -58.58 7.28 Favored 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.312 -179.514 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.5 t -60.59 -39.62 81.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.729 -179.642 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.568 HD12 ' HB ' ' A' ' 38' ' ' ILE . 15.6 tp -62.81 -47.19 84.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.654 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.42 -45.15 56.07 Favored Glycine 0 N--CA 1.448 -0.541 0 CA-C-N 115.755 -0.657 . . . . 0.0 113.13 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.431 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 34.9 mm-40 -63.47 -41.13 98.61 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.727 0.298 . . . . 0.0 111.658 -177.059 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 82.3 mt -89.22 -0.11 57.2 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.716 -0.22 . . . . 0.0 111.367 -178.038 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 54.58 73.01 0.42 Allowed 'General case' 0 C--O 1.232 0.181 0 CA-C-O 121.562 0.696 . . . . 0.0 110.772 179.151 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.568 ' HB ' HD12 ' A' ' 33' ' ' LEU . 68.3 mt -118.98 119.68 31.97 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.969 178.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.568 ' HB2' HG22 ' A' ' 42' ' ' THR . 7.0 Cg_exo -73.33 94.5 0.83 Allowed 'Trans proline' 0 N--CA 1.461 -0.425 0 C-N-CA 122.788 2.325 . . . . 0.0 112.34 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 13.4 tt -72.09 -23.07 21.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.362 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -60.81 -34.97 75.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.418 -178.311 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.568 HG22 ' HB2' ' A' ' 39' ' ' PRO . 12.9 t -102.62 -1.52 30.08 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -171.478 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.542 HG13 HG23 ' A' ' 42' ' ' THR . 18.2 m -136.89 -179.77 3.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 O-C-N 122.029 -0.42 . . . . 0.0 110.785 178.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.0 t -115.83 125.76 73.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.05 0.452 . . . . 0.0 111.118 -176.607 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.6 t -105.31 131.43 54.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.821 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.61 ' HG2' HD13 ' A' ' 51' ' ' ILE . 95.5 mttt -118.85 149.28 41.8 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.135 178.415 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.0 tttm -107.5 104.31 13.84 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 169.712 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 68.02 -73.89 0.08 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 123.81 0.844 . . . . 0.0 110.662 -174.8 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -148.4 11.85 1.17 Allowed Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 121.056 -0.592 . . . . 0.0 111.988 178.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -110.86 147.55 34.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.606 0.241 . . . . 0.0 110.805 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.61 HD13 ' HG2' ' A' ' 46' ' ' LYS . 29.6 mm -83.07 116.7 27.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.4 m -126.46 165.32 24.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.075 -175.612 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.456 HG13 ' H ' ' A' ' 55' ' ' GLU . 37.8 pt -99.83 -177.21 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.653 172.36 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.462 ' HA ' ' CG2' ' A' ' 29' ' ' ILE . 6.6 p-10 -83.18 6.54 18.98 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.087 0.47 . . . . 0.0 111.41 -173.31 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.456 ' H ' HG13 ' A' ' 53' ' ' ILE . 4.7 tp10 -95.27 0.51 53.91 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.152 -175.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -81.15 163.16 23.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.534 176.525 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.22 154.85 21.17 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.504 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 21.9 mt -103.49 143.15 15.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.065 -179.159 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -123.16 171.18 9.52 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.235 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -70.75 133.76 46.85 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.845 178.486 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.47 30.63 58.1 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.942 -0.647 . . . . 0.0 111.837 -178.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -98.46 162.64 13.05 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.861 0.363 . . . . 0.0 110.769 179.478 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.3 mm -127.64 125.89 66.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.92 179.688 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 2.9 mp -115.82 124.84 72.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 177.656 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.536 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 35.5 tt0 -110.16 113.87 26.91 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.725 0.298 . . . . 0.0 110.224 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 89.4 t -109.07 104.93 17.86 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.323 0.582 . . . . 0.0 110.352 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.525 HD11 ' HE3' ' A' ' 46' ' ' LYS . 6.3 pt -107.01 129.88 59.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.544 178.802 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.411 HH11 ' HD2' ' A' ' 68' ' ' ARG . 13.7 ptt180 . . . . . 0 C--N 1.32 -0.689 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.104 -179.132 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.1 tp . . . . . 0 N--CA 1.45 -0.452 0 CA-C-O 121.224 0.535 . . . . 0.0 110.05 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.55 -178.7 17.1 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 -173.409 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' MET . . . . . 0.518 ' HA ' ' HB2' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -160.44 149.17 16.87 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 117.587 0.694 . . . . 0.0 112.284 179.694 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 mtpp -118.2 131.0 56.41 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.119 173.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 24.8 p90 -147.23 157.93 43.77 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.834 0.35 . . . . 0.0 110.805 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.734 HG22 HD12 ' A' ' 63' ' ' ILE . 1.3 t -116.31 140.3 49.48 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 175.637 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.469 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 6.4 p -129.13 129.12 67.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.068 0.461 . . . . 0.0 110.754 -178.4 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.732 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -92.25 119.96 40.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 172.538 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.07 -157.73 0.84 Allowed 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.722 -174.059 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.923 ' HA ' ' HD2' ' A' ' 68' ' ' ARG . 15.5 t70 -58.29 -44.59 88.55 Favored 'General case' 0 N--CA 1.464 0.259 0 C-N-CA 122.894 0.478 . . . . 0.0 111.897 -171.832 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -91.25 -10.7 40.55 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -174.784 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 140.46 -162.9 26.52 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.022 -1.085 . . . . 0.0 112.269 -176.542 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.556 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 36.1 tttt -104.16 120.8 41.9 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.997 0.427 . . . . 0.0 110.836 -174.489 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -121.67 162.79 20.09 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.424 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.413 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -118.52 130.44 73.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.243 0.544 . . . . 0.0 109.725 -179.01 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 98.9 mt -123.44 151.75 42.35 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.72 -176.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -137.27 129.25 29.13 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.758 -0.656 . . . . 0.0 109.528 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.3 m -130.25 154.4 47.63 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.682 0.277 . . . . 0.0 110.659 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.06 -10.91 70.84 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.735 -176.343 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.421 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -124.21 140.12 34.25 Favored Pre-proline 0 C--N 1.323 -0.58 0 O-C-N 122.718 -0.283 . . . . 0.0 110.432 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 25' ' ' ALA . 14.2 Cg_exo -69.27 107.32 1.74 Allowed 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.668 2.246 . . . . 0.0 111.101 176.146 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 29.7 mmm180 -110.13 169.62 8.61 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.93 0.395 . . . . 0.0 110.605 -176.209 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.565 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 15.1 ttm180 -103.83 160.89 14.41 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.301 178.054 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.551 HG12 ' O ' ' A' ' 56' ' ' GLU . 40.6 mm -53.81 -48.95 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.707 0.289 . . . . 0.0 110.525 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 32.9 tttp -60.41 -24.71 65.37 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.697 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -70.67 -52.36 21.69 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.955 0.407 . . . . 0.0 110.24 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 50.3 t -71.69 -41.07 70.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.374 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.53 HD21 ' HB ' ' A' ' 40' ' ' ILE . 22.0 tp -63.52 -41.49 98.49 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.215 179.253 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.39 -32.13 68.33 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.058 178.375 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.76 -42.4 98.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.068 0.461 . . . . 0.0 110.091 -179.503 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 85.3 mt -91.0 -12.38 36.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.783 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 59.95 77.63 0.31 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.131 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.441 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 68.6 mt -123.76 128.87 25.01 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.999 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.88 115.0 3.36 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.536 2.157 . . . . 0.0 112.92 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.53 ' HB ' HD21 ' A' ' 33' ' ' LEU . 11.3 tp -79.9 -6.05 9.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.803 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -67.26 -43.38 82.01 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.693 -171.242 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.578 HG23 HG13 ' A' ' 43' ' ' VAL . 8.8 t -92.37 -20.55 20.95 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 113.881 1.067 . . . . 0.0 113.881 -165.542 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.578 HG13 HG23 ' A' ' 42' ' ' THR . 34.3 m -117.95 163.46 15.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.165 -0.614 . . . . 0.0 111.398 -177.804 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -103.29 139.45 24.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.85 -173.128 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.55 HG22 HG22 ' A' ' 66' ' ' VAL . 89.4 t -120.39 136.53 57.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.939 0.4 . . . . 0.0 110.584 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.603 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 98.1 mttt -128.4 149.62 50.47 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.538 178.483 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.8 ' HE2' ' HB3' ' A' ' 56' ' ' GLU . 52.4 mttm -95.27 100.46 12.24 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.822 -0.806 . . . . 0.0 108.822 167.565 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 66.88 -32.54 0.19 Allowed 'General case' 0 N--CA 1.471 0.609 0 O-C-N 123.953 0.783 . . . . 0.0 111.895 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.517 ' H ' ' C ' ' A' ' 47' ' ' LYS . . . 178.74 -21.5 0.04 OUTLIER Glycine 0 CA--C 1.522 0.511 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.091 -178.34 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -85.85 127.37 34.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.936 0.368 . . . . 0.0 110.419 -178.344 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.488 ' H ' HD12 ' A' ' 51' ' ' ILE . 3.7 mp -64.82 123.72 18.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 120.64 0.257 . . . . 0.0 110.548 -178.149 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.827 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 27.6 m -130.57 178.76 4.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.091 -177.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 29.6 pt -118.04 -174.5 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.323 177.444 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.457 ' O ' ' HB ' ' A' ' 29' ' ' ILE . 9.4 p-10 -75.08 -14.58 60.6 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -176.558 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -84.9 9.33 14.65 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -178.868 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.827 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 35.0 mm-40 -85.15 137.15 33.2 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.87 0.367 . . . . 0.0 110.731 176.433 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.565 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.1 mp0 -76.96 156.28 32.07 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.406 -179.11 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 58.0 mt -98.26 124.59 51.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -113.46 154.06 27.63 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.581 -178.004 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.518 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 19.1 t70 -69.11 124.58 24.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.825 178.363 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.46 4.59 70.5 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.845 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -94.01 156.88 16.37 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.734 HD12 HG22 ' A' ' 11' ' ' THR . 47.6 mm -121.73 123.33 69.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 120.776 0.322 . . . . 0.0 110.421 -173.329 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.469 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.2 mm -99.98 107.97 21.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.16 0.505 . . . . 0.0 110.377 -178.304 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.732 ' HA ' HG22 ' A' ' 13' ' ' ILE . 6.3 mm-40 -100.11 97.21 8.06 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.006 -177.446 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.55 HG22 HG22 ' A' ' 45' ' ' VAL . 85.7 t -95.68 106.1 17.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.447 0.641 . . . . 0.0 110.031 177.147 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.2 mt -92.29 99.77 10.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.748 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.923 ' HD2' ' HA ' ' A' ' 15' ' ' ASP . 9.2 ptm180 . . . . . 0 C--N 1.323 -0.58 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 176.884 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 9.6 tp . . . . . 0 N--CA 1.449 -0.489 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 79.8 -178.12 53.94 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.314 -175.887 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 25.4 ptt? -160.67 137.85 9.16 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 120.961 0.41 . . . . 0.0 111.094 -178.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.678 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 53.6 mtmt -112.15 110.01 20.03 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 169.13 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 29.2 p90 -122.7 157.12 32.98 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.409 -175.439 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.526 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 7.8 m -113.96 117.82 32.42 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.426 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.1 p -102.51 123.45 55.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-O 121.282 0.563 . . . . 0.0 109.906 178.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.473 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -95.68 122.6 47.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -179.655 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.48 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.7 OUTLIER -127.5 175.58 8.13 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.342 -0.845 . . . . 0.0 109.266 -178.609 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.48 ' H ' HG22 ' A' ' 14' ' ' THR . 13.0 p-10 -67.94 -17.7 64.53 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 111.654 0.242 . . . . 0.0 111.654 -176.7 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -91.3 -7.92 49.69 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.891 0.376 . . . . 0.0 110.891 179.115 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 141.05 -179.09 19.67 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.147 179.394 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 36.7 ttmt -100.73 110.41 22.51 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.172 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 8.6 mtpp -107.36 114.6 28.73 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.386 -170.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.526 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -82.9 120.58 34.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 173.324 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 95.3 mt -118.63 146.21 44.84 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.374 -177.257 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.678 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.2 OUTLIER -121.6 141.01 51.51 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.148 0.499 . . . . 0.0 110.842 177.667 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.1 t -135.94 147.04 47.91 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.496 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -76.14 -9.79 85.44 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.679 -179.34 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -136.81 146.06 53.55 Favored Pre-proline 0 C--N 1.326 -0.422 0 O-C-N 122.831 -0.217 . . . . 0.0 110.618 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -63.49 131.37 31.5 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.349 2.033 . . . . 0.0 111.307 176.107 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.528 ' HD2' ' HB3' ' A' ' 31' ' ' ASP . 15.9 tpp180 -123.39 155.51 37.24 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.004 -175.884 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.569 ' HG2' ' HA ' ' A' ' 57' ' ' GLU . 96.8 mtt180 -104.18 165.01 11.33 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.765 -0.198 . . . . 0.0 110.715 178.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 45.6 mm -54.8 -55.78 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.974 -175.03 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.531 ' HB3' ' NZ ' ' A' ' 30' ' ' LYS . 2.8 ttpm? -53.15 -39.95 63.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.138 0.494 . . . . 0.0 110.959 179.373 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.528 ' HB3' ' HD2' ' A' ' 27' ' ' ARG . 3.1 m-20 -64.61 -52.44 57.49 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.951 -176.334 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.0 t -62.98 -47.46 92.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.099 0.476 . . . . 0.0 110.713 178.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 14.5 tp -64.7 -38.46 91.06 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.603 -177.483 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.12 -42.61 66.94 Favored Glycine 0 N--CA 1.447 -0.572 0 CA-C-N 115.492 -0.776 . . . . 0.0 113.108 -179.095 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -68.04 -31.56 71.3 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.903 0.351 . . . . 0.0 111.263 -178.734 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 97.1 mt -83.0 -4.05 57.89 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.921 0.391 . . . . 0.0 110.292 176.232 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 55.14 61.81 2.76 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.931 -178.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 62.0 mt -116.98 114.44 39.15 Favored Pre-proline 0 C--N 1.323 -0.577 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.488 175.192 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.425 ' O ' HG22 ' A' ' 42' ' ' THR . 32.4 Cg_exo -59.57 113.15 1.49 Allowed 'Trans proline' 0 N--CA 1.464 -0.21 0 C-N-CA 122.76 2.306 . . . . 0.0 112.558 -178.916 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 14.6 tt -63.01 -20.23 25.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 121.383 0.611 . . . . 0.0 110.589 178.608 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -63.62 -29.96 71.14 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.152 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.425 HG22 ' O ' ' A' ' 39' ' ' PRO . 3.6 t -108.4 4.98 24.97 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-O 120.914 0.388 . . . . 0.0 111.665 -170.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.3 m -136.54 164.57 30.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.14 0.495 . . . . 0.0 111.466 -179.378 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 56.7 t -123.26 129.28 74.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.499 176.235 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.0 t -107.3 130.87 58.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 121.283 0.563 . . . . 0.0 111.536 -175.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.831 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 96.3 mttt -117.8 131.88 56.52 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.311 176.274 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.489 ' HB2' HG21 ' A' ' 52' ' ' VAL . 65.0 tttp -93.07 106.29 18.27 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 174.46 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.546 ' HA ' ' HB ' ' A' ' 63' ' ' ILE . 12.5 t-20 68.94 -66.06 0.26 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.064 -177.122 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -159.2 17.23 0.25 Allowed Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.809 -0.516 . . . . 0.0 111.809 179.034 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -131.19 131.27 43.88 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 -177.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.5 mt -64.02 128.86 27.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 176.068 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.767 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 19.6 m -132.94 178.75 5.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.933 0.397 . . . . 0.0 111.864 -173.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 32.8 pt -88.89 172.73 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.882 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.509 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 6.6 p-10 -76.4 -20.72 56.84 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.326 -176.256 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 68.5 tt0 -85.43 4.99 32.99 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.04 0.448 . . . . 0.0 110.719 -178.056 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.767 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 7.5 mm-40 -72.44 129.89 39.41 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.122 0.487 . . . . 0.0 111.226 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.569 ' HA ' ' HG2' ' A' ' 28' ' ' ARG . 4.7 pt-20 -86.87 140.69 29.4 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.423 179.3 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.456 HG23 HD11 ' A' ' 64' ' ' ILE . 12.0 mt -92.11 150.82 3.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.218 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -124.6 164.65 19.39 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.035 0.445 . . . . 0.0 110.702 -177.355 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -67.6 128.06 35.07 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.373 176.301 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.49 12.02 79.05 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.114 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -96.99 161.79 13.68 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 178.836 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.546 ' HB ' ' HA ' ' A' ' 48' ' ' ASN . 46.4 mm -115.38 138.96 44.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.037 -176.089 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.475 HG22 HG23 ' A' ' 66' ' ' VAL . 49.8 mm -118.29 118.6 58.62 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 176.428 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.831 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 42.7 tt0 -107.5 107.54 18.44 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.475 HG23 HG22 ' A' ' 64' ' ' ILE . 86.0 t -111.99 109.56 28.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.204 0.526 . . . . 0.0 110.51 -179.355 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -114.02 139.0 42.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.445 HH11 ' HD3' ' A' ' 68' ' ' ARG . 35.0 mtm-85 . . . . . 0 C--N 1.323 -0.563 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 174.377 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 65.4 mt . . . . . 0 N--CA 1.454 -0.247 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 97.63 67.04 0.91 Allowed Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.452 -0.88 . . . . 0.0 111.404 -177.215 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' MET . . . . . 0.41 ' HB2' ' HA ' ' A' ' 60' ' ' ASP . 26.1 ptt? -87.4 149.95 24.13 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.643 -0.278 . . . . 0.0 111.089 -174.415 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.55 ' HD3' ' OD1' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -129.68 128.96 43.62 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 168.808 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -125.44 153.17 43.88 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -177.593 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.56 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.8 m -109.81 117.67 34.48 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.176 -179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.552 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 3.1 p -112.23 123.41 67.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.458 -178.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.608 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -88.06 121.02 37.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 177.769 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.92 -162.05 1.14 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.747 -174.264 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -61.96 -45.92 91.54 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 112.202 0.445 . . . . 0.0 112.202 -171.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -87.74 -0.82 57.44 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 111.999 0.37 . . . . 0.0 111.999 -175.526 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 137.12 -164.73 25.27 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.128 -1.034 . . . . 0.0 112.653 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.589 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.0 ttpt -92.23 116.76 29.24 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.035 0.445 . . . . 0.0 110.212 -177.524 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 41.4 tptt -115.2 113.3 23.74 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.996 -172.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.56 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -84.32 120.54 35.27 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 CA-C-O 121.69 0.757 . . . . 0.0 109.795 174.175 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 97.4 mt -116.02 136.59 52.89 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.24 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.528 ' HG3' ' HB3' ' A' ' 9' ' ' LYS . 39.3 tt0 -113.5 139.49 48.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.275 -0.42 . . . . 0.0 109.974 179.679 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.2 t -132.92 132.91 42.56 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 178.575 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -66.46 -15.1 63.27 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 121.157 -0.544 . . . . 0.0 113.401 -175.428 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -133.9 142.32 43.06 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.896 0.348 . . . . 0.0 110.805 -178.605 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -54.43 133.95 58.96 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.465 2.11 . . . . 0.0 110.845 173.665 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.465 ' HG3' ' CB ' ' A' ' 31' ' ' ASP . 0.1 OUTLIER -132.56 156.21 47.26 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.487 -168.071 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.448 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 10.2 ttt85 -92.69 158.66 15.82 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 174.192 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 40.8 mm -59.96 -36.94 70.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.126 0.489 . . . . 0.0 109.814 176.061 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -67.21 -19.83 65.61 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.756 -177.041 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.465 ' CB ' ' HG3' ' A' ' 27' ' ' ARG . 3.2 m-20 -65.64 -61.8 1.88 Allowed 'General case' 0 CA--C 1.517 -0.312 0 CA-C-O 121.186 0.517 . . . . 0.0 109.766 173.73 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.5 t -59.7 -42.19 87.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.326 179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.589 HD21 ' HB ' ' A' ' 40' ' ' ILE . 1.2 tm? -63.94 -47.6 79.82 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.759 -178.445 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.21 -47.43 36.87 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 116.049 -0.523 . . . . 0.0 113.608 -174.595 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.4 mm-40 -73.26 -37.16 66.4 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -173.417 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 79.9 mt -87.64 -13.73 41.9 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.979 -0.288 . . . . 0.0 111.029 -179.094 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 58.97 77.77 0.29 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.598 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.576 ' HB ' HD22 ' A' ' 33' ' ' LEU . 65.1 mt -118.75 133.21 23.63 Favored Pre-proline 0 C--N 1.319 -0.731 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.51 -179.572 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 29.6 Cg_exo -62.83 100.49 0.24 Allowed 'Trans proline' 0 CA--C 1.529 0.252 0 C-N-CA 122.562 2.174 . . . . 0.0 112.401 178.525 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.589 ' HB ' HD21 ' A' ' 33' ' ' LEU . 8.2 tp -85.74 -25.13 6.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.549 -177.753 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 18.3 tp10 -76.06 -20.55 57.64 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.964 -173.084 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.531 HG23 HG13 ' A' ' 43' ' ' VAL . 12.9 t -109.1 -10.82 14.99 Favored 'General case' 0 CA--C 1.534 0.365 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 -170.704 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.531 HG13 HG23 ' A' ' 42' ' ' THR . 25.9 m -122.35 158.54 26.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.049 -179.424 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.0 t -94.98 113.12 28.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.037 -175.65 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 90.4 t -102.83 131.17 51.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.057 0.455 . . . . 0.0 110.439 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.737 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 97.9 mttt -117.28 126.39 52.65 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.948 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.504 ' HB3' HG11 ' A' ' 52' ' ' VAL . 71.1 tttt -96.82 106.06 18.3 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.362 175.655 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 71.08 -53.24 0.68 Allowed 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 123.947 0.899 . . . . 0.0 110.861 -177.331 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.49 21.49 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.077 178.292 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLN . . . . . 0.592 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 18.6 mm-40 -125.18 143.62 50.85 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.421 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.2 mp -74.61 113.76 13.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 176.388 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.745 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 35.6 m -124.9 178.47 3.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-O 121.14 0.495 . . . . 0.0 111.834 -173.312 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.447 HG13 ' H ' ' A' ' 55' ' ' GLU . 23.8 pt -123.22 -171.31 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.597 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -70.08 -12.74 61.82 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.087 -0.506 . . . . 0.0 112.056 -176.367 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.447 ' H ' HG13 ' A' ' 53' ' ' ILE . 7.5 tp10 -81.91 -8.51 59.68 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.522 -174.169 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.745 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 22.0 mm-40 -81.49 163.2 22.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.002 0.43 . . . . 0.0 111.97 -176.445 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.448 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 0.0 OUTLIER -103.15 159.24 15.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.169 177.468 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 17.9 mt -103.85 154.48 5.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.025 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -128.49 168.41 15.7 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.924 0.392 . . . . 0.0 110.857 -177.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.55 ' OD1' ' HD3' ' A' ' 9' ' ' LYS . 30.8 t70 -81.12 129.42 34.56 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.854 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.04 26.58 72.12 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 121.076 -0.583 . . . . 0.0 111.935 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -97.33 160.97 14.02 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.962 0.411 . . . . 0.0 110.823 -178.055 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 31.3 mm -111.01 113.4 44.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.418 -175.304 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.552 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.1 mm -102.3 109.4 26.25 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.737 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 38.8 tt0 -99.65 99.99 10.92 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.223 -178.735 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 92.3 t -100.37 103.1 14.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.46 0.647 . . . . 0.0 110.522 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 24.2 mt -91.89 99.24 9.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.481 179.342 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.459 ' O ' ' HD2' ' A' ' 68' ' ' ARG . 0.1 OUTLIER . . . . . 0 C--N 1.323 -0.567 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.624 175.582 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 pt . . . . . 0 N--CA 1.452 -0.359 0 CA-C-O 121.194 0.521 . . . . 0.0 109.747 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 113.16 93.94 2.09 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -170.396 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' MET . . . . . 0.417 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.5 ptt? -106.1 144.72 32.41 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.38 0.609 . . . . 0.0 112.293 -165.76 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.521 ' HG2' ' OD1' ' A' ' 60' ' ' ASP . 23.8 pttm -107.06 141.45 38.28 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.289 -0.869 . . . . 0.0 108.911 168.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 31.1 p90 -156.72 147.96 22.2 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.853 0.359 . . . . 0.0 110.163 178.285 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.623 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 9.5 t -112.41 138.01 49.76 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.15 0.5 . . . . 0.0 110.225 178.308 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.762 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.7 p -126.9 134.54 65.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.966 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.669 HG22 ' HA ' ' A' ' 65' ' ' GLU . 8.1 tt -88.19 124.85 41.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.944 174.454 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.411 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.7 OUTLIER -116.68 174.18 6.22 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.138 -0.937 . . . . 0.0 108.542 177.176 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.411 ' H ' HG22 ' A' ' 14' ' ' THR . 25.6 t70 -58.4 -34.17 70.44 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.25 0.548 . . . . 0.0 110.719 178.839 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -77.07 -10.79 59.61 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.698 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 136.39 176.76 14.54 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.414 -0.898 . . . . 0.0 112.783 178.579 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.641 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 45.4 tttt -96.43 116.64 29.38 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 6.6 mtpm? -129.65 147.87 51.49 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.845 -175.389 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.623 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -111.15 131.23 62.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -177.388 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.456 ' N ' HD13 ' A' ' 20' ' ' ILE . 2.0 pt? -134.8 165.1 26.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.751 0.31 . . . . 0.0 111.084 -175.742 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -112.44 150.6 30.94 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.337 -179.299 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.4 t -136.03 134.62 38.69 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 175.002 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.06 -44.94 95.1 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 121.26 -0.495 . . . . 0.0 113.153 -176.141 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -110.88 146.56 34.68 Favored Pre-proline 0 C--N 1.321 -0.637 0 O-C-N 122.625 -0.338 . . . . 0.0 110.741 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.417 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 25.0 Cg_exo -63.72 119.82 7.01 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.682 2.255 . . . . 0.0 111.2 175.282 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.414 ' HE ' ' CG ' ' A' ' 31' ' ' ASP . 17.2 mmm180 -115.0 177.18 4.74 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.729 -174.333 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 54.8 ttm-85 -108.38 159.97 16.24 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.4 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.505 HD11 ' HE2' ' A' ' 47' ' ' LYS . 38.0 mm -56.87 -48.76 80.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.913 0.387 . . . . 0.0 110.392 176.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.5 tptm -59.6 -28.04 66.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.186 178.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.414 ' CG ' ' HE ' ' A' ' 27' ' ' ARG . 30.0 t70 -65.15 -62.09 1.75 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.849 0.356 . . . . 0.0 110.475 178.637 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.3 t -59.89 -42.94 90.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.704 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.513 HD21 ' HB ' ' A' ' 40' ' ' ILE . 24.0 tp -64.65 -43.45 93.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.811 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.22 -40.21 71.06 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.917 -0.583 . . . . 0.0 112.753 -177.888 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.5 mm-40 -62.5 -38.71 90.97 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.914 0.388 . . . . 0.0 110.964 178.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.1 mt -83.87 -10.96 57.63 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.505 179.333 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 54.08 61.54 3.01 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.669 -177.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.449 ' HB ' HD12 ' A' ' 33' ' ' LEU . 69.2 mt -106.6 115.33 60.81 Favored Pre-proline 0 C--N 1.32 -0.704 0 CA-C-N 115.868 -0.605 . . . . 0.0 109.68 176.381 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -56.81 113.3 1.41 Allowed 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.695 2.263 . . . . 0.0 112.406 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.521 HD12 ' HB3' ' A' ' 54' ' ' ASP . 15.0 tt -72.7 -6.54 8.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.485 0.659 . . . . 0.0 110.819 -178.514 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -67.83 -29.28 68.4 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.998 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.534 HG23 HG13 ' A' ' 43' ' ' VAL . 9.3 t -106.44 0.05 24.49 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.734 -173.754 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.557 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 34.3 m -132.29 156.26 42.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.021 0.439 . . . . 0.0 111.46 -177.322 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 59.0 t -113.8 139.67 38.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.383 176.16 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.43 HG11 HG21 ' A' ' 29' ' ' ILE . 37.1 t -102.98 127.42 56.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.032 0.444 . . . . 0.0 110.218 -179.258 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.618 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 41.1 mttm -124.75 145.02 49.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.401 -178.081 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.582 ' HG2' HG21 ' A' ' 52' ' ' VAL . 28.8 mmtp -112.15 102.41 10.6 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 169.863 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.9 m120 56.05 24.55 7.93 Favored 'General case' 0 N--CA 1.465 0.323 0 O-C-N 123.451 0.469 . . . . 0.0 111.598 -178.054 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 115.95 -21.04 12.59 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.921 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 17.0 mm-40 -85.3 132.28 34.28 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.772 0.32 . . . . 0.0 110.833 -176.187 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.3 mp -73.99 116.76 16.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.957 0.408 . . . . 0.0 110.294 -179.39 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.906 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 29.3 m -123.63 173.94 8.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.673 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 28.1 pt -101.52 175.3 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.572 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.521 ' HB3' HD12 ' A' ' 40' ' ' ILE . 9.5 p-10 -74.53 -15.52 60.86 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.552 -177.437 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.1 tt0 -81.62 -5.08 57.71 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.823 0.344 . . . . 0.0 110.9 -178.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.906 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 17.2 mm-40 -69.16 142.3 54.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.824 0.345 . . . . 0.0 110.944 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 51.1 mp0 -79.9 166.52 21.57 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.562 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.517 HG23 HD11 ' A' ' 64' ' ' ILE . 55.2 mt -112.45 139.25 38.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 175.355 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 80.3 m-85 -124.18 162.24 24.04 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.778 0.323 . . . . 0.0 110.695 -176.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.521 ' OD1' ' HG2' ' A' ' 9' ' ' LYS . 21.6 t70 -71.77 117.33 13.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.329 177.556 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.53 -9.56 60.71 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 -179.106 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -78.09 143.83 37.04 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.493 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.563 HG23 HG23 ' A' ' 11' ' ' THR . 45.1 mt -115.35 118.5 58.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-O 121.23 0.538 . . . . 0.0 111.126 -173.42 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.762 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 4.0 mp -101.7 130.91 50.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.623 -178.47 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.669 ' HA ' HG22 ' A' ' 13' ' ' ILE . 53.0 mt-10 -120.64 118.53 30.38 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 178.647 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 62.0 t -114.06 102.79 14.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.129 0.49 . . . . 0.0 110.235 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.08 137.95 51.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 -179.01 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.557 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 76.0 mtp180 . . . . . 0 C--N 1.326 -0.446 0 CA-C-O 120.976 0.417 . . . . 0.0 110.717 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 60.0 mt . . . . . 0 N--CA 1.454 -0.248 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.99 -179.54 16.53 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.446 -178.831 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' MET . . . . . 0.496 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 25.5 ptt? -156.07 137.91 14.36 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.032 0.444 . . . . 0.0 110.887 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.402 ' HE3' ' HB2' ' A' ' 22' ' ' GLU . 30.4 tttt -123.72 114.58 20.12 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 174.462 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -127.98 167.99 15.9 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.283 -173.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.458 ' HB ' HD13 ' A' ' 20' ' ' ILE . 12.9 t -115.42 138.51 50.93 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.922 0.391 . . . . 0.0 110.318 178.86 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.4 p -128.41 136.79 59.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.099 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.585 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -107.98 124.85 64.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.3 0.571 . . . . 0.0 109.815 177.785 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.7 p -129.15 -163.03 1.25 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.238 -179.038 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -67.57 -24.36 65.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.024 0.44 . . . . 0.0 110.664 178.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -82.69 -11.5 58.29 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.393 0.616 . . . . 0.0 110.48 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 115.93 -167.65 12.49 Favored Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.419 -176.659 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.585 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 33.1 ttpt -98.99 127.87 45.0 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -177.599 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.457 ' HE3' ' HB2' ' A' ' 19' ' ' LYS . 29.9 ttmt -137.57 164.26 29.19 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.482 -174.417 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.458 HD13 ' HB ' ' A' ' 11' ' ' THR . 34.3 mm -98.38 126.44 51.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.7 0.286 . . . . 0.0 111.015 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.446 HD13 HG12 ' A' ' 12' ' ' VAL . 6.9 mp -111.51 144.44 40.73 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.192 176.443 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.402 ' HB2' ' HE3' ' A' ' 9' ' ' LYS . 40.6 tt0 -127.25 134.88 50.02 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.146 -177.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.0 t -134.19 143.79 48.08 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 177.017 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.6 -18.38 75.58 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 121.234 -0.508 . . . . 0.0 113.246 -176.429 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -139.07 151.14 67.26 Favored Pre-proline 0 C--N 1.324 -0.539 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.496 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 25.0 Cg_exo -63.96 119.53 6.61 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.394 2.063 . . . . 0.0 111.234 174.417 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.421 ' HB3' ' CB ' ' A' ' 31' ' ' ASP . 50.9 mmm-85 -116.6 157.66 24.96 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.191 -175.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.625 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 23.4 mtt180 -82.08 167.35 18.88 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 172.044 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.547 ' HB ' ' HA ' ' A' ' 54' ' ' ASP . 48.9 mm -61.14 -35.16 63.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 168.363 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 40.7 tptt -61.37 -33.92 74.45 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 114.662 -1.154 . . . . 0.0 110.822 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.421 ' CB ' ' HB3' ' A' ' 27' ' ' ARG . 4.5 m-20 -65.87 -58.48 5.49 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.317 177.659 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 58.6 t -59.43 -53.04 53.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.329 -176.332 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.573 ' HG ' ' HB ' ' A' ' 38' ' ' ILE . 10.7 mp -71.82 -35.88 70.06 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.367 -176.755 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.83 -43.6 58.36 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.662 179.63 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -73.09 -33.04 65.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.023 0.439 . . . . 0.0 111.154 -175.101 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.0 mt -97.35 -5.99 35.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.449 -0.342 . . . . 0.0 111.511 -178.539 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 62.23 75.18 0.41 Allowed 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.684 0.754 . . . . 0.0 110.717 -176.681 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.573 ' HB ' ' HG ' ' A' ' 33' ' ' LEU . 67.4 mt -123.66 116.27 27.93 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.756 178.914 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 17.1 Cg_exo -67.04 109.64 1.77 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.658 2.238 . . . . 0.0 112.906 -178.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.444 ' HB ' HD23 ' A' ' 33' ' ' LEU . 9.9 tt -81.59 -5.74 9.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 122.009 0.909 . . . . 0.0 109.203 176.275 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -69.84 -31.64 69.6 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.855 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.58 HG23 HG13 ' A' ' 43' ' ' VAL . 4.6 t -96.14 -36.95 10.79 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.71 0.633 . . . . 0.0 112.71 -172.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.58 HG13 HG23 ' A' ' 42' ' ' THR . 21.3 m -116.56 162.61 14.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 C-N-CA 120.888 -0.325 . . . . 0.0 111.069 -175.745 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.9 t -102.93 131.93 50.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 120.855 0.36 . . . . 0.0 111.671 -173.119 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.0 t -103.65 130.5 54.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.938 176.739 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.639 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 92.5 mttt -118.81 143.61 46.83 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.842 0.353 . . . . 0.0 111.442 179.451 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.774 ' HG2' HG21 ' A' ' 52' ' ' VAL . 10.0 mmtp -100.57 102.2 13.3 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 170.273 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 65.49 -1.01 1.06 Allowed 'General case' 0 CA--C 1.541 0.619 0 O-C-N 123.426 0.454 . . . . 0.0 111.512 178.678 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 132.2 -10.64 5.34 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 121.107 -0.568 . . . . 0.0 111.907 -176.513 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLN . . . . . 0.428 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 14.6 mm100 -87.07 128.1 35.11 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 122.045 0.138 . . . . 0.0 110.664 178.735 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.404 ' H ' HD12 ' A' ' 51' ' ' ILE . 3.8 mp -71.32 114.85 10.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.037 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.774 HG21 ' HG2' ' A' ' 47' ' ' LYS . 28.1 m -125.77 178.79 3.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.117 0.484 . . . . 0.0 111.52 -174.591 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.44 HG13 ' H ' ' A' ' 55' ' ' GLU . 24.7 pt -115.09 -170.92 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.348 177.263 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.547 ' HA ' ' HB ' ' A' ' 29' ' ' ILE . 35.1 p-10 -77.49 -7.19 55.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.656 -175.774 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.44 ' H ' HG13 ' A' ' 53' ' ' ILE . 7.5 tp10 -72.79 -22.16 60.88 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.918 -179.429 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.565 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 8.0 mm-40 -69.11 135.71 51.14 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.497 0.554 . . . . 0.0 112.497 -174.379 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.625 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 58.1 mp0 -82.38 144.2 30.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.914 173.315 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 30.9 mt -91.21 142.34 13.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 176.604 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -119.4 162.2 19.22 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.856 0.36 . . . . 0.0 110.75 -177.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -69.06 131.14 44.55 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.599 173.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.59 23.51 75.07 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.924 -177.515 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 31.2 t0 -97.4 154.04 17.72 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 178.046 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.447 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.0 mp -110.21 116.78 53.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-O 121.03 0.443 . . . . 0.0 110.525 -177.618 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 41.5 mm -103.55 108.84 25.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.899 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.639 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 44.5 mt-10 -102.22 107.16 18.13 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 178.205 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 93.4 t -97.05 102.45 13.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.38 0.609 . . . . 0.0 109.681 178.348 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 64.0 mt -96.36 105.88 17.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.406 -177.302 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.488 ' HA ' ' CG1' ' A' ' 43' ' ' VAL . 0.6 OUTLIER . . . . . 0 C--N 1.32 -0.711 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.521 174.641 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.437 ' N ' HD12 ' A' ' 6' ' ' ILE . 3.2 mp . . . . . 0 N--CA 1.455 -0.224 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.33 179.96 45.16 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.14 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' MET . . . . . 0.543 ' HA ' ' OD1' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -159.91 158.07 30.15 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.762 0.315 . . . . 0.0 110.221 178.701 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.601 ' HB2' HD11 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -133.79 145.78 50.08 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 173.32 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.5 ' CD2' HD13 ' A' ' 64' ' ' ILE . 38.4 p90 -144.41 141.06 29.39 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.388 -178.507 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.643 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 18.0 m -95.39 118.35 31.98 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.079 0.466 . . . . 0.0 110.06 177.114 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.2 p -107.33 134.17 49.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.955 -179.666 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.496 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -103.76 127.48 57.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 121.528 0.68 . . . . 0.0 109.6 177.647 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 16.7 m -141.81 166.86 23.58 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.12 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.5 m-20 -63.73 -17.77 63.35 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.868 0.366 . . . . 0.0 111.076 177.223 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -77.73 -10.98 59.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.335 0.588 . . . . 0.0 110.132 175.083 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 129.44 157.87 9.32 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 112.124 179.225 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.441 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.9 ttmt -86.1 109.96 19.21 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 173.61 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -129.14 131.86 47.26 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.271 -173.053 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.643 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -81.84 124.3 38.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.397 0.618 . . . . 0.0 110.042 176.042 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.47 HD13 ' N ' ' A' ' 22' ' ' GLU . 1.1 tm? -106.81 135.28 48.62 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -178.367 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.47 ' N ' HD13 ' A' ' 21' ' ' LEU . 4.9 tm-20 -115.36 131.53 56.9 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -177.018 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.2 m -135.4 126.64 28.24 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.83 0.348 . . . . 0.0 110.787 -179.288 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -72.0 -17.57 77.16 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.079 178.271 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -118.77 121.72 30.43 Favored Pre-proline 0 C--N 1.321 -0.665 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 176.757 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_exo -48.61 139.13 24.21 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.138 2.559 . . . . 0.0 111.729 177.65 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.571 ' HG3' ' HB2' ' A' ' 31' ' ' ASP . 1.9 tpp85 -133.51 147.48 51.62 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.761 0.315 . . . . 0.0 111.122 -170.576 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.555 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 40.0 ttm105 -91.57 161.1 15.08 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 176.108 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 33.8 mm -58.95 -51.12 76.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 110.376 -0.231 . . . . 0.0 110.376 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.4 tttp -54.83 -36.03 64.59 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.891 176.706 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.571 ' HB2' ' HG3' ' A' ' 27' ' ' ARG . 22.7 m-20 -61.38 -58.45 8.18 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.145 179.177 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.7 t -60.56 -43.17 93.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.086 0.469 . . . . 0.0 110.672 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.642 HD21 ' HB ' ' A' ' 40' ' ' ILE . 9.3 tp -61.55 -48.18 82.16 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.731 -179.496 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.88 -38.77 60.24 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.531 -0.759 . . . . 0.0 113.036 -178.589 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -68.15 -41.74 81.13 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 122.526 0.33 . . . . 0.0 111.48 -176.295 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.1 mt -89.82 0.34 57.09 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.707 0.289 . . . . 0.0 110.9 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 53.75 65.79 1.41 Allowed 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.753 -178.171 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.586 ' HB ' HD12 ' A' ' 33' ' ' LEU . 63.2 mt -102.63 121.81 48.34 Favored Pre-proline 0 C--N 1.318 -0.798 0 CA-C-N 115.256 -0.883 . . . . 0.0 109.32 177.671 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 13.8 Cg_exo -68.74 102.53 0.88 Allowed 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.612 2.208 . . . . 0.0 112.492 -178.747 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.642 ' HB ' HD21 ' A' ' 33' ' ' LEU . 13.2 tt -71.24 -6.51 7.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.736 0.779 . . . . 0.0 109.835 177.034 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 -59.74 -31.77 69.95 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.248 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 12.0 t -130.35 12.01 5.45 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.001 0.429 . . . . 0.0 111.805 -171.542 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.561 HG12 ' HG2' ' A' ' 68' ' ' ARG . 29.9 m -128.51 144.35 38.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 O-C-N 121.707 -0.621 . . . . 0.0 111.524 -179.298 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.0 t -109.57 131.14 61.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.09 177.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.1 t -103.1 128.49 56.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.032 0.444 . . . . 0.0 110.501 -177.803 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.58 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 53.3 mttp -123.18 133.39 54.24 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.257 179.372 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.635 ' HG2' HG21 ' A' ' 52' ' ' VAL . 21.5 mmtp -95.02 105.97 17.93 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 171.365 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 18.0 m120 59.52 21.09 9.57 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.361 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 110.51 -17.67 28.16 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.731 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -87.6 131.61 34.36 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 122.636 -0.332 . . . . 0.0 110.827 -177.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.51 ' H ' HD12 ' A' ' 51' ' ' ILE . 4.2 mp -67.25 122.08 17.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.994 179.684 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 1.148 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 20.5 m -123.65 178.99 2.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.952 -173.865 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 41.4 pt -113.52 174.66 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.377 0.608 . . . . 0.0 112.626 -171.597 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -53.33 -39.5 64.14 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.31 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.4 ' HG2' ' O ' ' A' ' 55' ' ' GLU . 38.4 tt0 -82.68 0.31 43.85 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -172.332 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 1.148 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 15.6 mm-40 -61.33 133.18 55.57 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.825 0.345 . . . . 0.0 111.023 178.426 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.555 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 31.2 mt-10 -101.92 150.15 23.49 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.374 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 48.7 mt -100.59 126.89 54.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.259 -177.759 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -108.58 171.52 7.37 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.439 -178.113 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.543 ' OD1' ' HA ' ' A' ' 8' ' ' MET . 25.8 t70 -69.66 112.81 6.39 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.888 0.375 . . . . 0.0 110.366 -178.436 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.83 36.8 5.94 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.785 -0.722 . . . . 0.0 111.477 -177.268 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.408 ' OD1' ' HD2' ' A' ' 47' ' ' LYS . 2.7 t0 -96.04 161.31 14.03 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 42.2 mm -128.65 112.65 26.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.847 0.356 . . . . 0.0 110.223 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.5 HD13 ' CD2' ' A' ' 10' ' ' PHE . 2.9 mp -110.62 118.62 57.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.148 0.499 . . . . 0.0 110.527 -177.528 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.58 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 41.6 mt-10 -105.42 114.08 28.04 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.227 176.589 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 86.9 t -100.65 108.55 23.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.155 0.502 . . . . 0.0 109.849 177.651 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 47.7 mt -112.04 117.25 54.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.74 -0.663 . . . . 0.0 110.127 -176.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.561 ' HG2' HG12 ' A' ' 43' ' ' VAL . 49.4 mtm180 . . . . . 0 C--N 1.322 -0.614 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.587 -179.657 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 69.4 mt . . . . . 0 N--CA 1.451 -0.416 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 105.5 -176.99 22.71 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 -175.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.42 158.57 29.7 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 117.077 0.439 . . . . 0.0 111.525 -179.008 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 25.8 mtpp -120.28 137.91 53.98 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.22 176.575 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.561 ' CD2' HD13 ' A' ' 64' ' ' ILE . 44.4 p90 -150.13 162.89 39.56 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.002 0.43 . . . . 0.0 110.837 178.216 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 t -109.28 138.85 45.01 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.794 177.676 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.558 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 5.3 p -129.25 122.13 55.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.25 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.642 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -88.0 125.0 41.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.814 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.448 ' N ' HD13 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -132.62 -171.19 2.6 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.449 -175.732 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -56.81 -46.01 81.87 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -175.192 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -90.42 7.68 37.52 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 111.722 0.267 . . . . 0.0 111.722 -173.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 131.02 -169.77 21.53 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.328 178.272 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.562 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.7 ttmt -100.8 123.01 44.38 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.883 0.373 . . . . 0.0 110.085 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 51.0 mttm -103.15 146.36 28.53 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.005 -176.663 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -120.65 121.15 64.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 170.552 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.415 HD11 ' CZ ' ' A' ' 10' ' ' PHE . 4.3 pp -138.49 171.76 13.9 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.885 0.374 . . . . 0.0 111.4 -173.809 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -131.61 142.53 49.9 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.249 -174.588 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -121.56 143.44 49.29 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 176.26 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -73.79 -13.81 80.35 Favored Glycine 0 C--N 1.33 0.226 0 C-N-CA 121.165 -0.54 . . . . 0.0 112.759 -174.243 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.421 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -138.85 144.32 41.05 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 177.795 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -57.5 120.59 8.61 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 122.321 2.014 . . . . 0.0 111.096 176.387 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.421 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 17.8 mmt180 -113.22 155.97 24.1 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.269 0.557 . . . . 0.0 111.221 -174.096 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.603 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 28.0 ttm180 -95.48 162.44 13.65 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 173.351 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.538 HD13 HD11 ' A' ' 58' ' ' ILE . 29.2 mm -54.56 -39.53 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.927 0.394 . . . . 0.0 110.733 179.248 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.507 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 17.1 tptm -64.25 -25.93 68.28 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.103 179.331 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.411 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 67.3 m-20 -73.54 -46.59 46.68 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-O 120.689 0.281 . . . . 0.0 110.638 178.707 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.1 t -61.47 -50.16 81.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.642 -178.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.43 HD13 ' HA ' ' A' ' 33' ' ' LEU . 4.1 mm? -68.36 -29.12 67.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.368 177.067 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.33 -42.68 64.92 Favored Glycine 0 CA--C 1.522 0.497 0 CA-C-N 115.985 -0.552 . . . . 0.0 112.736 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.411 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 7.2 mm-40 -68.95 -35.72 77.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.849 0.357 . . . . 0.0 111.115 -179.303 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.0 mt -85.64 -14.52 45.33 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.434 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 63.43 20.35 12.2 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.772 179.032 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.451 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 69.6 mt -79.86 131.54 63.41 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.983 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 22.2 Cg_exo -63.54 105.15 0.49 Allowed 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.491 2.127 . . . . 0.0 112.162 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.417 ' HB ' ' HG ' ' A' ' 33' ' ' LEU . 13.0 tt -67.8 -17.32 22.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.516 0.674 . . . . 0.0 110.377 178.312 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.3 tp10 -64.65 -37.93 89.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.503 -0.772 . . . . 0.0 111.885 -176.712 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.58 HG23 HG13 ' A' ' 43' ' ' VAL . 10.5 t -85.82 -9.88 56.33 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -170.658 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.58 HG13 HG23 ' A' ' 42' ' ' THR . 30.8 m -131.06 169.29 21.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 O-C-N 121.974 -0.454 . . . . 0.0 111.118 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.599 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 46.9 t -107.26 134.63 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.778 0.323 . . . . 0.0 111.079 -176.621 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.1 t -108.67 133.21 54.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.975 0.417 . . . . 0.0 110.72 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.649 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 73.6 mttt -118.53 146.54 44.47 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.144 177.732 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.846 ' HG2' HG21 ' A' ' 52' ' ' VAL . 4.0 mmtp -117.69 103.04 9.63 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.125 172.565 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.8 t-20 67.99 7.78 6.04 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.954 176.704 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 127.95 -25.04 5.02 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.86 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 71.9 mt-30 -87.74 142.42 27.84 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.71 0.255 . . . . 0.0 111.148 -178.211 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.409 HD12 ' N ' ' A' ' 51' ' ' ILE . 3.5 mp -77.99 119.58 27.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 177.017 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.846 HG21 ' HG2' ' A' ' 47' ' ' LYS . 27.5 m -124.97 178.67 3.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.062 0.458 . . . . 0.0 112.081 -170.723 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 32.2 pt -106.59 -174.01 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.618 178.233 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.507 ' HB2' ' HD3' ' A' ' 30' ' ' LYS . 15.6 p-10 -77.6 -15.2 59.37 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.446 -176.022 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.597 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 65.3 mm-40 -84.53 5.28 28.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.757 0.313 . . . . 0.0 111.653 -178.56 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.731 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 26.3 mm-40 -80.93 127.77 32.94 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.905 0.384 . . . . 0.0 110.63 176.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.603 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 33.8 mt-10 -88.9 148.01 24.05 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.494 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.538 HD11 HD13 ' A' ' 29' ' ' ILE . 25.3 mt -101.54 120.1 50.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.269 -177.457 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.482 ' O ' ' HB2' ' A' ' 62' ' ' ASP . 90.9 m-85 -99.31 170.58 8.55 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.585 -178.508 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -70.26 114.76 8.71 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.84 0.353 . . . . 0.0 110.605 178.847 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.26 11.71 38.31 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.705 -177.374 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.482 ' HB2' ' O ' ' A' ' 59' ' ' PHE . 2.7 t0 -74.49 161.03 30.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 110.277 -177.835 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.8 mm -128.21 111.8 25.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.561 HD13 ' CD2' ' A' ' 10' ' ' PHE . 2.7 mp -108.95 119.17 58.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.189 0.518 . . . . 0.0 110.649 -178.264 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.649 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 39.7 mt-10 -105.91 112.59 25.71 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.477 176.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 73.1 t -97.33 106.88 19.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.485 0.66 . . . . 0.0 110.424 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.599 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 58.8 mt -93.54 93.22 3.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.11 -179.534 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.478 ' HA ' HG12 ' A' ' 43' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.319 -0.727 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 173.256 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.412 HG22 ' O ' ' A' ' 24' ' ' GLY . 50.0 mm . . . . . 0 N--CA 1.454 -0.229 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.05 -156.99 19.18 Favored Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 -176.344 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.69 151.82 18.97 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.919 0.39 . . . . 0.0 111.49 -179.465 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 37.2 ttpt -117.19 119.79 36.3 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 173.064 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -139.03 167.92 20.98 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.903 0.382 . . . . 0.0 110.835 -173.889 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.56 ' HB ' HD13 ' A' ' 20' ' ' ILE . 11.4 t -115.04 138.97 50.26 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-O 121.195 0.522 . . . . 0.0 110.738 178.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.474 HG23 ' HB ' ' A' ' 64' ' ' ILE . 10.0 p -127.09 138.28 55.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.253 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.494 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -116.93 121.24 67.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.345 0.593 . . . . 0.0 109.964 179.955 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 72.8 p -130.88 -163.73 1.35 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.083 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.837 ' HB3' ' HD3' ' A' ' 68' ' ' ARG . 8.7 p-10 -69.97 -21.92 63.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.88 0.371 . . . . 0.0 110.832 178.44 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -82.15 -10.81 59.04 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.478 0.656 . . . . 0.0 110.059 178.563 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 121.56 -167.91 14.38 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.046 178.753 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.8 ttmt -104.09 115.23 30.05 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -112.48 154.96 25.07 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.981 0.419 . . . . 0.0 112.009 -174.569 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.56 HD13 ' HB ' ' A' ' 11' ' ' THR . 24.3 mm -109.06 121.6 62.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 170.459 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.435 ' H ' HD23 ' A' ' 21' ' ' LEU . 1.9 pt? -128.53 161.29 29.91 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.064 0.459 . . . . 0.0 110.99 -178.617 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -126.4 141.17 51.99 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.137 -173.441 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.2 t -130.15 140.57 50.76 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 175.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.412 ' O ' HG22 ' A' ' 6' ' ' ILE . . . -80.87 -16.12 75.86 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.344 -177.543 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -138.42 148.61 59.9 Favored Pre-proline 0 C--N 1.321 -0.651 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.159 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -57.74 142.49 96.03 Favored 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.604 2.203 . . . . 0.0 111.782 177.182 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.564 ' HG3' ' HB2' ' A' ' 31' ' ' ASP . 10.4 tpt180 -137.92 158.37 44.48 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.489 -0.559 . . . . 0.0 109.489 -172.253 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.591 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 76.3 mtm180 -102.34 173.62 6.28 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.834 0.349 . . . . 0.0 110.804 173.534 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.607 ' HB ' ' HA ' ' A' ' 54' ' ' ASP . 18.3 mt -68.14 -42.79 85.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.794 175.875 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.414 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 82.9 tttt -60.69 -32.3 71.53 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.193 176.363 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.564 ' HB2' ' HG3' ' A' ' 27' ' ' ARG . 81.0 m-20 -67.91 -41.54 82.51 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.701 178.762 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 68.0 t -75.61 -52.75 17.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.862 0.363 . . . . 0.0 110.921 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.402 ' HG ' ' HB ' ' A' ' 38' ' ' ILE . 10.9 mp -61.78 -35.35 77.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.938 178.705 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.39 -33.68 68.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.151 177.222 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.401 ' HB2' ' O ' ' A' ' 31' ' ' ASP . 3.6 tp10 -60.52 -45.46 93.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.883 0.373 . . . . 0.0 110.73 -178.775 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.4 mt -102.0 6.73 41.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.814 -176.235 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 53.59 69.56 0.69 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.552 0.692 . . . . 0.0 111.064 -176.706 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.402 ' HB ' ' HG ' ' A' ' 33' ' ' LEU . 62.8 mt -111.5 117.37 49.23 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.065 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.515 ' HB2' HG22 ' A' ' 42' ' ' THR . 17.0 Cg_exo -67.05 113.64 2.9 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.889 2.393 . . . . 0.0 112.016 178.383 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 10.8 tt -79.6 -13.04 13.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.501 0.667 . . . . 0.0 110.59 -178.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -75.63 -17.24 60.06 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.58 -177.027 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.563 HG23 HG13 ' A' ' 43' ' ' VAL . 9.8 t -108.71 -8.33 15.42 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -174.13 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.563 HG13 HG23 ' A' ' 42' ' ' THR . 17.8 m -133.24 167.09 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 O-C-N 122.099 -0.376 . . . . 0.0 110.872 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.462 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 51.9 t -105.26 121.95 57.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.91 -178.222 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.8 t -103.71 127.07 58.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.031 177.515 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.632 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 98.8 mttt -122.82 144.61 49.07 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.991 0.424 . . . . 0.0 111.82 -178.812 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.561 ' HG2' HG21 ' A' ' 52' ' ' VAL . 17.9 mmtp -100.92 101.9 12.81 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.229 167.753 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.8 t-20 63.28 2.33 1.11 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.996 0.518 . . . . 0.0 111.805 178.674 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 136.14 -17.27 3.85 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 121.083 -0.579 . . . . 0.0 112.353 -178.533 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLN . . . . . 0.475 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 17.6 mm-40 -87.16 129.53 34.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.407 0.146 . . . . 0.0 110.939 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.6 mp -69.36 120.78 17.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 176.669 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.561 HG21 ' HG2' ' A' ' 47' ' ' LYS . 17.4 m -124.95 177.48 4.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.149 -176.785 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.471 ' O ' HD12 ' A' ' 29' ' ' ILE . 26.9 pt -113.0 179.63 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.282 174.578 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.607 ' HA ' ' HB ' ' A' ' 29' ' ' ILE . 8.4 p-10 -73.22 -6.09 43.62 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.851 -175.338 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -81.43 -2.12 48.3 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.389 -176.498 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 58.9 mm-40 -89.69 150.39 22.36 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 122.171 -0.33 . . . . 0.0 111.518 -177.34 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.591 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 21.0 mp0 -88.05 157.07 18.99 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.112 177.835 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.463 HG12 ' O ' ' A' ' 27' ' ' ARG . 2.6 mm -96.47 134.48 33.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 173.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -116.63 167.48 11.03 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.027 0.442 . . . . 0.0 111.275 -175.343 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -73.97 129.51 38.02 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.111 175.872 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.75 18.72 79.52 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.433 -176.642 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -91.51 157.06 17.24 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 179.631 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.457 HG12 HG22 ' A' ' 11' ' ' THR . 10.5 mt -128.3 114.27 33.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.228 0.537 . . . . 0.0 110.897 -175.331 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.474 ' HB ' HG23 ' A' ' 12' ' ' VAL . 22.0 mm -96.67 106.89 19.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.278 -178.373 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.632 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 35.4 tt0 -97.19 101.99 13.66 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 176.596 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.46 HG23 HG22 ' A' ' 64' ' ' ILE . 80.3 t -100.24 105.94 18.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.209 0.528 . . . . 0.0 110.116 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.462 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 26.2 mt -91.96 95.88 5.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.086 178.415 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.837 ' HD3' ' HB3' ' A' ' 15' ' ' ASP . 1.2 ptm180 . . . . . 0 C--N 1.32 -0.679 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.639 178.094 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 62.4 mt . . . . . 0 N--CA 1.453 -0.323 0 CA-C-O 120.965 0.412 . . . . 0.0 110.385 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 112.27 120.3 3.81 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.979 -0.629 . . . . 0.0 111.73 -177.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' MET . . . . . 0.495 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.1 ptt? -113.77 134.38 54.81 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.331 0.586 . . . . 0.0 111.379 -175.354 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.853 ' HD3' ' HB3' ' A' ' 22' ' ' GLU . 6.1 tppt? -106.79 126.64 52.55 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.025 176.37 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -152.81 147.63 26.26 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.141 0.496 . . . . 0.0 111.342 179.135 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.563 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.1 t -98.56 142.59 29.96 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.015 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.6 p -118.73 119.49 61.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.505 0.669 . . . . 0.0 110.002 176.328 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.51 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -106.75 117.03 51.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-O 121.864 0.84 . . . . 0.0 108.928 176.998 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.485 HG22 ' H ' ' A' ' 15' ' ' ASP . 1.4 m -114.75 175.33 5.54 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.221 -177.472 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.485 ' H ' HG22 ' A' ' 14' ' ' THR . 28.1 t70 -56.34 -23.29 36.35 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-O 120.95 0.405 . . . . 0.0 111.475 178.501 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -87.09 -12.27 47.67 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.559 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 133.43 -174.81 20.52 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.382 -0.913 . . . . 0.0 112.184 -177.276 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.51 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.7 ttmt -109.94 139.49 44.99 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.66 0.267 . . . . 0.0 110.997 -175.303 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -150.23 136.48 18.77 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 173.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.563 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -98.74 136.18 30.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.748 0.309 . . . . 0.0 110.341 -177.642 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.3 pp -138.58 170.54 15.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.087 177.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.853 ' HB3' ' HD3' ' A' ' 9' ' ' LYS . 13.3 pt-20 -138.84 150.33 45.9 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.925 0.393 . . . . 0.0 111.396 -178.325 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 40.8 m -135.61 133.69 38.52 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.115 177.739 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -74.31 4.08 35.77 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 121.326 -0.464 . . . . 0.0 113.252 -177.421 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.465 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -135.35 127.97 18.08 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.648 0.224 . . . . 0.0 110.504 178.527 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.495 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 21.9 Cg_exo -65.15 128.77 21.28 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.781 2.321 . . . . 0.0 110.982 176.159 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.56 ' NE ' ' HA ' ' A' ' 27' ' ' ARG . 0.0 OUTLIER -134.21 171.43 14.25 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.406 -170.838 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.4 ttp-105 -104.03 160.72 14.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.704 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 38.2 mm -56.49 -47.49 81.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.34 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.483 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 29.7 tptp -55.57 -37.99 68.77 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.335 -179.631 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -69.52 -57.43 5.22 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.006 -178.682 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 69.1 t -61.3 -47.93 91.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.855 -177.072 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 19.6 tp -68.02 -35.72 78.75 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.22 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.11 -44.28 61.22 Favored Glycine 0 N--CA 1.447 -0.633 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.62 -179.458 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -68.97 -21.86 64.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.735 0.302 . . . . 0.0 111.427 179.679 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.5 mt -89.25 -2.87 58.65 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.004 0.43 . . . . 0.0 110.224 174.527 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 57.48 45.69 19.21 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.125 176.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.429 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 69.0 mt -106.68 117.29 57.23 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.573 176.125 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 16.5 Cg_exo -67.54 112.41 2.61 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.773 2.315 . . . . 0.0 112.766 -176.493 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.563 ' HA ' HG22 ' A' ' 43' ' ' VAL . 11.2 tt -69.23 -14.68 18.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.587 0.708 . . . . 0.0 109.885 177.466 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -60.48 -28.96 68.75 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.61 -179.376 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 12.9 t -122.53 7.86 9.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.031 0.443 . . . . 0.0 111.589 -172.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.589 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 3.6 m -131.65 149.32 32.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 C-N-CA 120.386 -0.525 . . . . 0.0 110.768 -179.162 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.6 t -99.57 129.75 49.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.132 0.491 . . . . 0.0 110.288 179.134 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.8 t -103.3 127.48 57.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.555 -178.651 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.638 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 65.8 mttt -119.29 139.87 51.21 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.696 178.576 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.569 ' HE3' ' O ' ' A' ' 57' ' ' GLU . 9.1 mtpm? -127.07 115.88 19.84 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.928 175.152 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 62.36 22.56 13.3 Favored 'General case' 0 C--N 1.326 -0.419 0 O-C-N 123.597 0.56 . . . . 0.0 110.377 178.075 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.85 -14.41 57.43 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.548 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLN . . . . . 0.465 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 68.3 mt-30 -88.07 140.56 29.37 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 122.102 0.161 . . . . 0.0 111.046 -175.625 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.411 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.4 mp -80.07 113.16 19.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 174.124 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.886 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 35.8 m -125.55 178.92 3.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.071 0.462 . . . . 0.0 111.863 -169.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.428 HG13 ' H ' ' A' ' 55' ' ' GLU . 31.2 pt -112.62 -170.86 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.645 178.863 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.483 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 7.9 p-10 -81.15 -7.87 59.65 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.794 -174.869 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.428 ' H ' HG13 ' A' ' 53' ' ' ILE . 0.7 OUTLIER -91.08 12.36 20.14 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-O 121.544 0.688 . . . . 0.0 110.216 -177.772 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.886 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 8.3 mm-40 -88.3 128.24 35.48 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.147 179.069 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.569 ' O ' ' HE3' ' A' ' 47' ' ' LYS . 10.7 mm-40 -76.6 142.61 40.65 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.797 177.06 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 39.4 mt -92.23 137.59 21.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 177.119 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -117.06 149.0 41.01 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.055 0.455 . . . . 0.0 111.228 -174.807 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -66.71 117.2 8.51 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.788 176.168 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.21 11.8 53.46 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 121.152 -0.547 . . . . 0.0 112.223 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 36.6 t0 -97.68 161.94 13.52 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 179.718 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.436 HD12 HG22 ' A' ' 11' ' ' THR . 50.5 mm -112.24 126.18 69.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.822 0.344 . . . . 0.0 110.531 -177.717 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 47.3 mm -107.08 130.2 59.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.435 -179.69 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.638 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 33.7 mt-10 -122.11 129.2 52.15 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 177.651 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 54.3 t -122.33 110.29 26.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.311 0.577 . . . . 0.0 110.634 177.173 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.5 mt -118.28 101.7 12.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.407 -178.919 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.589 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 14.3 ptt180 . . . . . 0 C--N 1.319 -0.722 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.085 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.1 tp . . . . . 0 N--CA 1.452 -0.353 0 CA-C-O 121.098 0.475 . . . . 0.0 109.743 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.91 151.75 28.2 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.612 -175.876 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' MET . . . . . 0.502 ' HE1' ' HB2' ' A' ' 27' ' ' ARG . 17.1 mtm -128.98 139.91 51.89 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.876 0.369 . . . . 0.0 110.622 -176.051 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -103.89 111.11 23.51 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 173.385 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 23.5 p90 -138.96 161.48 37.25 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.106 0.479 . . . . 0.0 110.923 -178.679 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.432 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.5 t -118.7 144.3 46.31 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.408 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.2 p -117.16 126.3 74.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.122 0.486 . . . . 0.0 109.721 176.278 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.556 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -112.86 127.73 69.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.247 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.628 HG22 ' H ' ' A' ' 15' ' ' ASP . 6.8 m -144.2 -177.04 5.26 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 -177.092 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.628 ' H ' HG22 ' A' ' 14' ' ' THR . 0.8 OUTLIER -49.46 -32.94 13.02 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.184 0.516 . . . . 0.0 110.892 173.714 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -80.5 4.25 18.91 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.153 -177.083 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 107.49 -177.37 21.35 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.067 177.625 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.556 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 40.0 ttmt -104.71 117.29 33.72 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 176.464 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -130.62 139.49 50.39 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.077 0.465 . . . . 0.0 110.61 -176.883 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.453 HD13 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -91.72 137.79 21.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.155 -176.236 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.453 ' N ' HD13 ' A' ' 20' ' ' ILE . 2.2 pt? -137.65 147.69 45.14 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 178.036 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -123.82 126.73 46.96 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.866 0.365 . . . . 0.0 110.412 -177.041 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.0 m -118.91 124.8 47.98 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.896 178.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -77.55 21.22 3.1 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 121.127 -0.559 . . . . 0.0 113.175 -178.538 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.419 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -139.23 138.95 21.58 Favored Pre-proline 0 C--N 1.322 -0.59 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 178.004 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -62.79 127.65 21.12 Favored 'Trans proline' 0 CA--C 1.531 0.337 0 C-N-CA 122.72 2.28 . . . . 0.0 111.484 175.643 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.502 ' HB2' ' HE1' ' A' ' 8' ' ' MET . 13.9 mmt180 -126.01 160.59 29.63 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.145 0.497 . . . . 0.0 111.298 -172.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.599 ' HG2' ' HA ' ' A' ' 57' ' ' GLU . 65.3 mtm-85 -113.65 168.56 9.67 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 164.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.744 HD13 HG11 ' A' ' 45' ' ' VAL . 24.9 mt -60.76 -45.41 97.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 120.646 0.26 . . . . 0.0 110.566 -178.265 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -61.28 -32.45 72.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.026 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.47 ' OD2' ' HD2' ' A' ' 27' ' ' ARG . 25.6 t70 -73.57 -42.36 61.72 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.484 -179.427 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.4 t -71.3 -51.79 31.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.006 0.431 . . . . 0.0 110.548 177.81 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 26.2 tp -61.4 -37.85 84.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.427 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.46 -33.31 72.3 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.476 177.846 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -71.84 -34.11 69.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.167 0.508 . . . . 0.0 109.995 177.336 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.2 mt -76.92 -10.56 59.45 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.258 174.701 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 63.3 45.89 4.75 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.689 176.178 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 62.2 mt -115.8 123.08 31.65 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.141 178.77 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_exo -62.69 132.27 36.94 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.754 2.303 . . . . 0.0 112.339 179.29 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 10.0 tp -70.38 -15.36 19.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.291 0.567 . . . . 0.0 110.61 -179.038 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -63.87 -32.91 74.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.752 178.568 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.509 HG23 HG13 ' A' ' 43' ' ' VAL . 12.0 t -104.02 -1.66 27.14 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 112.095 0.405 . . . . 0.0 112.095 -172.18 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.591 HG12 ' HG3' ' A' ' 68' ' ' ARG . 33.5 m -128.99 146.46 34.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 120.923 0.392 . . . . 0.0 111.202 -178.301 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.518 HG12 ' HB ' ' A' ' 67' ' ' ILE . 0.6 OUTLIER -110.02 136.94 44.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 175.555 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.744 HG11 HD13 ' A' ' 29' ' ' ILE . 32.6 t -116.21 133.59 62.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.094 0.473 . . . . 0.0 110.932 -177.777 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.758 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 98.6 mttt -117.84 130.92 56.56 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.255 177.126 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 22.5 ttmm -93.42 105.46 17.53 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 172.792 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 71.65 -61.3 0.49 Allowed 'General case' 0 C--N 1.33 -0.274 0 O-C-N 124.136 0.897 . . . . 0.0 110.557 -177.099 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -166.6 22.01 0.11 Allowed Glycine 0 N--CA 1.447 -0.585 0 N-CA-C 111.326 -0.709 . . . . 0.0 111.326 177.292 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 35.9 mt-30 -126.5 131.92 51.51 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.194 -0.299 . . . . 0.0 110.194 -176.24 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.542 HD13 ' HG2' ' A' ' 46' ' ' LYS . 38.9 mm -63.33 122.51 14.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.869 0.366 . . . . 0.0 110.628 177.615 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.7 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 17.3 m -125.74 178.4 4.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.751 -178.688 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.423 ' O ' HD12 ' A' ' 29' ' ' ILE . 26.9 pt -100.17 -177.96 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.659 176.577 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 20.7 p-10 -77.16 -30.12 54.85 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.431 -176.532 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -80.67 14.67 2.01 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 122.094 -0.379 . . . . 0.0 111.897 -173.636 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.7 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 76.5 mm-40 -86.05 152.07 23.19 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.82 0.343 . . . . 0.0 111.07 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.599 ' HA ' ' HG2' ' A' ' 28' ' ' ARG . 42.2 mp0 -85.52 162.15 19.04 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.925 -177.796 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 39.9 mm -103.81 144.78 13.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 174.199 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.751 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 81.0 m-85 -114.15 161.01 18.33 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.735 0.302 . . . . 0.0 110.189 179.179 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -77.63 120.87 23.18 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 175.015 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.51 9.93 68.53 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.904 -0.665 . . . . 0.0 111.789 -176.105 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.751 ' HB2' ' HB2' ' A' ' 59' ' ' PHE . 22.0 t0 -87.95 147.0 25.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.96 0.409 . . . . 0.0 110.181 -178.357 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 45.5 mm -105.6 122.95 59.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.23 -176.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.408 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 50.0 mm -109.78 115.19 49.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 120.886 0.374 . . . . 0.0 110.718 -177.579 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.758 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 28.3 tt0 -104.3 114.6 28.94 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.878 177.841 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.424 ' O ' HG23 ' A' ' 14' ' ' THR . 60.1 t -113.08 113.38 43.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.14 -179.049 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.518 ' HB ' HG12 ' A' ' 44' ' ' VAL . 3.8 mt -116.2 118.75 59.81 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.147 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.591 ' HG3' HG12 ' A' ' 43' ' ' VAL . 0.8 OUTLIER . . . . . 0 C--N 1.323 -0.557 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 176.093 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ILE . . . . . 0.425 HG22 ' O ' ' A' ' 24' ' ' GLY . 51.4 mm . . . . . 0 N--CA 1.447 -0.583 0 N-CA-C 109.219 -0.659 . . . . 0.0 109.219 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 133.65 163.64 10.47 Favored Glycine 0 N--CA 1.446 -0.667 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 -174.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' MET . . . . . 0.57 ' SD ' ' HB ' ' A' ' 58' ' ' ILE . 25.0 ptt? -160.0 137.15 9.43 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 117.173 0.487 . . . . 0.0 111.282 -176.424 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.876 ' HD3' ' HB3' ' A' ' 22' ' ' GLU . 3.8 tppt? -108.19 120.26 41.83 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 175.41 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -140.56 167.96 20.93 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.744 0.306 . . . . 0.0 110.919 -176.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.497 HG22 HD12 ' A' ' 63' ' ' ILE . 1.2 t -133.72 146.71 51.04 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 177.396 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -117.33 119.11 60.83 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.595 177.147 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -103.28 124.56 57.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.523 0.677 . . . . 0.0 109.511 178.456 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.424 HG22 ' H ' ' A' ' 15' ' ' ASP . 4.1 m -146.02 173.17 12.41 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -178.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.424 ' H ' HG22 ' A' ' 14' ' ' THR . 8.8 p-10 -64.46 -22.39 66.95 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.317 0.58 . . . . 0.0 109.954 174.338 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -72.23 -11.8 60.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.631 175.706 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 127.19 176.89 14.63 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.904 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -108.17 104.04 13.37 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 177.311 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -104.28 134.12 48.04 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.617 -176.163 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.447 HD13 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -103.33 129.58 54.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 177.269 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.447 ' N ' HD13 ' A' ' 20' ' ' ILE . 94.8 mt -136.26 137.21 40.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.621 -177.379 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.876 ' HB3' ' HD3' ' A' ' 9' ' ' LYS . 17.0 pt-20 -117.62 129.18 55.59 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.364 0.602 . . . . 0.0 110.012 173.742 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.7 m -109.7 145.46 36.51 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.268 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.425 ' O ' HG22 ' A' ' 6' ' ' ILE . . . -78.29 -10.75 85.97 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.407 -178.591 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.466 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.54 141.4 31.03 Favored Pre-proline 0 C--N 1.325 -0.496 0 N-CA-C 110.57 -0.159 . . . . 0.0 110.57 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.487 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 11.5 Cg_exo -71.32 123.8 9.87 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.835 2.357 . . . . 0.0 111.742 177.047 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.476 ' HB3' ' CB ' ' A' ' 31' ' ' ASP . 16.2 mmm180 -126.66 175.68 7.78 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -178.205 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.672 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 83.4 mtm180 -94.31 175.2 6.78 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.694 0.283 . . . . 0.0 110.579 175.174 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.732 HD13 HG11 ' A' ' 45' ' ' VAL . 18.2 mt -68.26 -39.73 81.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 177.45 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.535 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 28.2 tptp -59.46 -36.06 75.25 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.695 174.228 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.476 ' CB ' ' HB3' ' A' ' 27' ' ' ARG . 5.9 m-20 -66.07 -62.14 1.65 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.953 177.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.466 HG21 HG13 ' A' ' 58' ' ' ILE . 97.4 t -59.64 -60.6 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.664 -175.686 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 11.1 mp -63.24 -34.36 77.5 Favored 'General case' 0 C--N 1.333 -0.145 0 C-N-CA 120.932 -0.307 . . . . 0.0 111.135 -176.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.3 -47.24 82.07 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.871 -0.681 . . . . 0.0 112.572 -179.309 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -71.08 -22.38 62.11 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.847 0.356 . . . . 0.0 111.09 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 86.6 mt -86.77 1.69 51.37 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.683 176.425 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.9 tt0 65.17 17.17 10.93 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.23 176.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.402 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 71.8 mt -83.33 118.24 70.98 Favored Pre-proline 0 C--N 1.324 -0.54 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.129 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 36.3 Cg_exo -59.93 92.03 0.08 OUTLIER 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 123.128 2.552 . . . . 0.0 112.567 -177.929 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.548 ' HA ' HG22 ' A' ' 43' ' ' VAL . 14.4 tt -76.24 -17.44 15.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.366 -177.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -67.82 -20.81 65.21 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.685 -177.72 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.5 t -120.23 10.8 11.42 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -175.106 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.548 HG22 ' HA ' ' A' ' 40' ' ' ILE . 31.5 m -123.0 147.39 27.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 O-C-N 121.769 -0.582 . . . . 0.0 111.372 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.414 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 58.8 t -92.48 120.68 42.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.641 178.427 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.732 HG11 HD13 ' A' ' 29' ' ' ILE . 38.5 t -103.4 130.8 53.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.04 0.448 . . . . 0.0 110.854 -176.513 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.745 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 96.9 mttt -118.61 145.78 45.14 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.3 177.821 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.648 ' HD2' HG11 ' A' ' 52' ' ' VAL . 60.4 mttm -109.34 102.04 10.98 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.179 168.731 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.0 m120 58.54 19.7 6.87 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.628 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 117.97 -18.21 11.54 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.741 178.601 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 70.6 mm-40 -87.57 130.04 34.88 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.881 0.341 . . . . 0.0 110.535 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.425 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.7 mp -73.86 121.28 24.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.055 -179.511 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.828 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 21.2 m -123.99 178.34 3.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.191 -176.033 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.406 ' O ' HD12 ' A' ' 29' ' ' ILE . 32.0 pt -115.1 173.71 3.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 179.764 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.535 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 3.9 p30 -63.03 -23.82 67.63 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -176.893 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -71.56 -18.09 62.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.12 -176.585 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.828 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 20.0 mm-40 -67.16 141.46 57.36 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.106 0.479 . . . . 0.0 111.318 -177.701 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.672 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 21.1 mt-10 -89.21 152.02 21.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.578 -179.599 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.57 ' HB ' ' SD ' ' A' ' 8' ' ' MET . 8.1 mm -88.55 146.23 6.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 176.69 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -132.75 163.99 27.79 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.942 0.401 . . . . 0.0 110.569 -178.399 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -67.64 121.56 16.16 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.987 -0.552 . . . . 0.0 109.615 172.145 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.97 20.2 47.6 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.767 -177.216 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -96.15 131.49 42.54 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.412 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.497 HD12 HG22 ' A' ' 11' ' ' THR . 50.5 mm -111.57 109.99 30.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.696 0.284 . . . . 0.0 110.48 -177.234 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.472 ' HA ' ' O ' ' A' ' 46' ' ' LYS . 40.0 mm -94.97 119.25 42.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.27 -177.024 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.745 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 38.2 tt0 -103.37 120.93 41.74 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 171.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 70.8 t -107.36 108.49 25.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.155 0.502 . . . . 0.0 110.509 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.414 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 22.9 mt -103.86 109.15 26.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.756 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 19.1 mtt180 . . . . . 0 C--N 1.325 -0.498 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 176.903 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.3 pt . . . . . 0 N--CA 1.45 -0.437 0 CA-C-O 121.078 0.466 . . . . 0.0 109.781 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.12 -178.09 20.56 Favored Glycine 0 N--CA 1.443 -0.898 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.148 -176.699 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.52 153.94 22.08 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.75 0.31 . . . . 0.0 111.193 -177.685 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.483 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 50.2 mtmt -105.85 128.82 53.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.002 -0.544 . . . . 0.0 109.689 174.171 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 19.3 p90 -139.28 150.26 45.24 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 120.778 0.323 . . . . 0.0 110.76 -178.914 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.522 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 25.3 m -111.23 120.9 43.82 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.81 0.338 . . . . 0.0 110.435 179.735 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.617 HG22 ' HB ' ' A' ' 64' ' ' ILE . 21.5 t -112.46 130.32 66.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.898 179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.636 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 4.0 tt -87.53 129.56 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.807 173.869 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 30.6 p -123.52 -175.22 3.15 Favored 'General case' 0 N--CA 1.442 -0.872 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.822 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -67.63 -28.43 67.72 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.804 -175.274 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.468 ' OD1' ' HE3' ' A' ' 19' ' ' LYS . 3.1 p30 -95.79 -5.94 40.75 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 121.125 -0.23 . . . . 0.0 111.523 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 147.11 -177.36 25.45 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.554 179.08 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.636 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 62.5 tttt -99.25 108.87 21.53 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.083 0.468 . . . . 0.0 109.796 -177.763 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.468 ' HE3' ' OD1' ' A' ' 16' ' ' ASP . 78.3 mttt -103.51 124.72 49.3 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.717 -171.636 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.522 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -90.37 125.14 43.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 170.115 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.423 HD23 ' N ' ' A' ' 21' ' ' LEU . 1.9 pt? -140.52 164.89 28.95 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.483 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.3 OUTLIER -139.58 163.59 32.16 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.9 0.381 . . . . 0.0 111.54 -176.66 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.3 t -134.83 158.24 44.72 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.416 176.591 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -84.76 -4.91 86.99 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.334 -178.866 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -138.49 141.33 30.9 Favored Pre-proline 0 C--N 1.324 -0.504 0 N-CA-C 110.624 -0.139 . . . . 0.0 110.624 178.833 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -61.84 131.97 37.68 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.739 2.293 . . . . 0.0 111.498 175.301 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 37.9 mmt180 -132.96 169.49 16.72 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.032 0.444 . . . . 0.0 111.216 -174.044 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -103.14 166.18 10.59 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.467 -0.788 . . . . 0.0 108.887 167.401 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 48.9 mm -55.87 -41.37 66.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.967 0.413 . . . . 0.0 110.394 178.754 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 46.2 tptt -51.24 -43.29 61.45 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.166 -0.924 . . . . 0.0 111.919 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -66.19 -50.88 62.37 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.842 -174.613 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.15 -49.29 56.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.018 -178.843 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.556 HD21 ' HB ' ' A' ' 40' ' ' ILE . 28.1 tp -62.07 -40.6 96.37 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.728 -177.74 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.73 -44.48 94.78 Favored Glycine 0 N--CA 1.448 -0.523 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.467 -177.817 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 68.3 mt-10 -72.2 -29.93 64.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.638 0.256 . . . . 0.0 111.615 -179.214 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 72.6 mt -78.18 -8.34 58.19 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 121.068 -0.253 . . . . 0.0 111.006 178.739 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.9 tt0 64.25 26.13 13.68 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.05 175.209 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.438 ' HB ' HD12 ' A' ' 33' ' ' LEU . 64.7 mt -82.95 124.87 76.31 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.141 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -71.82 108.86 2.52 Favored 'Trans proline' 0 CA--C 1.533 0.44 0 C-N-CA 122.587 2.191 . . . . 0.0 113.02 -179.376 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.556 ' HB ' HD21 ' A' ' 33' ' ' LEU . 10.0 tt -73.16 -9.75 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-O 121.732 0.777 . . . . 0.0 110.286 178.392 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -69.2 -42.89 75.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.742 -176.108 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.569 HG23 HG13 ' A' ' 43' ' ' VAL . 3.3 t -86.53 -47.68 9.03 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -170.15 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.569 HG13 HG23 ' A' ' 42' ' ' THR . 21.7 m -102.01 179.06 0.67 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.213 0 CA-C-O 120.85 0.357 . . . . 0.0 111.8 -173.161 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 30.0 t -103.98 139.55 24.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.565 -172.95 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 59.6 t -116.17 126.04 73.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 CA-C-O 121.029 0.442 . . . . 0.0 110.249 176.846 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.538 ' HG2' HD13 ' A' ' 51' ' ' ILE . 95.2 mttt -129.63 151.95 49.68 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.624 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.796 ' HG2' HG21 ' A' ' 52' ' ' VAL . 18.3 mmtp -106.04 100.8 10.33 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 169.46 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 47.6 t30 54.98 24.73 6.17 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.153 177.545 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 124.25 -27.42 5.57 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 120.957 -0.639 . . . . 0.0 113.367 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -89.46 133.96 34.32 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.903 0.351 . . . . 0.0 111.644 -174.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.538 HD13 ' HG2' ' A' ' 46' ' ' LYS . 39.2 mm -65.55 124.19 20.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.674 -0.239 . . . . 0.0 110.389 176.184 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.796 HG21 ' HG2' ' A' ' 47' ' ' LYS . 20.7 m -133.29 178.0 6.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.987 0.422 . . . . 0.0 111.223 -177.563 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.0 pt -109.48 -173.02 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.32 177.265 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 30.1 p-10 -82.19 -19.53 39.64 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 120.905 0.383 . . . . 0.0 110.961 -179.283 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -82.14 26.87 0.51 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.919 0.39 . . . . 0.0 111.856 177.648 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -96.54 149.95 21.18 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.052 179.132 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -78.33 170.6 16.37 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.999 -177.562 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 52.2 mt -128.8 120.71 52.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 172.377 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -112.27 162.2 15.77 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.724 -178.244 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -71.24 126.03 28.53 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.462 177.429 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.18 6.49 71.35 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.956 -0.64 . . . . 0.0 111.784 -179.255 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 25.8 t0 -88.58 155.79 19.43 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -179.501 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.7 mm -120.79 117.16 52.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 120.932 0.396 . . . . 0.0 110.523 -175.015 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.617 ' HB ' HG22 ' A' ' 12' ' ' VAL . 3.7 mp -101.71 128.22 54.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 177.873 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.618 ' HA ' HG22 ' A' ' 13' ' ' ILE . 38.2 mt-10 -115.22 107.27 15.07 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 120.771 -0.372 . . . . 0.0 110.996 -178.631 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 78.2 t -99.93 100.53 10.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 121.653 0.74 . . . . 0.0 109.05 174.326 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 51.1 mt -93.07 109.65 22.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.986 -176.131 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.545 ' HA ' ' CG1' ' A' ' 43' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.447 -0.624 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 174.203 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.1 pt . . . . . 0 N--CA 1.452 -0.326 0 CA-C-O 121.291 0.567 . . . . 0.0 110.578 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.31 -178.71 17.17 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -176.878 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' MET . . . . . 0.495 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 23.5 ptt? -161.0 130.88 4.95 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.99 0.424 . . . . 0.0 110.712 179.005 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.659 ' HB3' ' HG3' ' A' ' 22' ' ' GLU . 16.4 ptmt -118.6 119.63 35.07 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 121.294 0.569 . . . . 0.0 109.574 171.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -123.79 151.61 43.12 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.089 -174.731 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.548 ' CG2' HG13 ' A' ' 63' ' ' ILE . 8.8 t -109.51 134.98 51.24 Favored 'General case' 0 C--N 1.316 -0.857 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.231 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.4 p -110.91 135.96 48.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.039 -179.22 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -114.46 126.54 72.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.385 0.612 . . . . 0.0 110.19 179.695 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.411 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -146.66 -163.48 1.76 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.369 178.248 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.411 ' H ' HG22 ' A' ' 14' ' ' THR . 14.2 m-20 -65.14 -21.96 66.86 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 121.108 0.48 . . . . 0.0 110.996 178.062 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -86.11 8.25 21.59 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.682 0.753 . . . . 0.0 110.274 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.79 -162.12 18.57 Favored Glycine 0 N--CA 1.448 -0.517 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.712 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -118.15 108.69 15.48 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 177.633 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -116.0 150.99 36.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.465 -176.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.532 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.2 OUTLIER -106.94 131.09 57.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.091 0.472 . . . . 0.0 109.886 -176.173 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.502 ' N ' HD13 ' A' ' 20' ' ' ILE . 92.2 mt -116.81 135.49 53.7 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.963 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.659 ' HG3' ' HB3' ' A' ' 9' ' ' LYS . 32.4 tt0 -108.96 126.55 53.21 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.948 0.404 . . . . 0.0 110.392 -177.456 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.5 m -118.06 145.39 44.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.958 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -83.17 -9.12 84.5 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 121.047 -0.597 . . . . 0.0 112.605 -176.857 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.443 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.42 141.89 32.98 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 122.849 -0.207 . . . . 0.0 111.003 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.495 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 7.3 Cg_exo -73.59 121.25 6.94 Favored 'Trans proline' 0 C--O 1.233 0.254 0 C-N-CA 122.817 2.345 . . . . 0.0 110.773 174.045 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 19.2 mmm180 -132.25 177.28 7.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.102 0.477 . . . . 0.0 110.899 -174.087 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.588 ' HG2' ' H ' ' A' ' 30' ' ' LYS . 44.7 ttm180 -94.82 160.85 14.41 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.053 -176.84 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 56' ' ' GLU . 37.4 mm -50.97 -41.01 21.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-O 120.815 0.34 . . . . 0.0 110.155 176.315 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.588 ' H ' ' HG2' ' A' ' 28' ' ' ARG . 35.8 tptt -51.03 -37.18 43.7 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.786 -179.329 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -64.93 -62.65 1.43 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.764 0.316 . . . . 0.0 110.845 -177.912 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.5 t -63.39 -44.21 98.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.762 -177.616 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.782 HD11 ' HB ' ' A' ' 40' ' ' ILE . 3.0 tm? -61.72 -46.43 89.68 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.163 -179.267 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.97 -47.41 46.74 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.141 -175.719 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -66.53 -34.57 78.22 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 111.954 0.354 . . . . 0.0 111.954 -175.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 82.1 mt -82.6 -4.64 57.98 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.684 0.278 . . . . 0.0 110.9 179.079 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.5 tt0 57.3 34.9 25.41 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.958 177.603 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.617 ' HB ' HD22 ' A' ' 33' ' ' LEU . 66.0 mt -79.49 125.64 82.46 Favored Pre-proline 0 C--N 1.323 -0.587 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 177.64 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.514 ' HB2' ' HB ' ' A' ' 42' ' ' THR . 34.7 Cg_exo -60.72 101.29 0.17 Allowed 'Trans proline' 0 C--O 1.233 0.226 0 C-N-CA 122.642 2.228 . . . . 0.0 112.874 -176.851 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.782 ' HB ' HD11 ' A' ' 33' ' ' LEU . 9.9 tp -71.29 -19.11 20.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.68 0.752 . . . . 0.0 109.831 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -77.01 -32.11 56.93 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.355 176.81 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.514 ' HB ' ' HB2' ' A' ' 39' ' ' PRO . 22.2 m -92.39 -39.41 11.46 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.193 -171.525 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 10.9 m -112.8 163.17 10.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.458 -175.645 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.421 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 47.3 t -109.89 140.27 29.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.846 -177.827 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.8 t -113.0 130.63 66.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 121.137 0.494 . . . . 0.0 111.467 -178.669 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.524 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 97.3 mttt -123.08 150.88 42.6 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.743 172.505 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.949 ' HE2' HG11 ' A' ' 52' ' ' VAL . 60.1 pttt -126.76 108.08 10.73 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.638 0.732 . . . . 0.0 110.676 171.619 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.49 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 3.2 t-20 64.26 23.78 13.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.483 -1.235 . . . . 0.0 111.771 174.399 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 112.79 -6.33 25.89 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.8 177.561 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 8.3 mm-40 -111.35 114.54 27.78 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.707 0.289 . . . . 0.0 111.501 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.482 ' HA ' ' HG2' ' A' ' 46' ' ' LYS . 0.1 OUTLIER -62.98 127.15 22.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 175.574 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.949 HG11 ' HE2' ' A' ' 47' ' ' LYS . 23.4 m -138.63 155.89 28.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.084 0.469 . . . . 0.0 111.574 -174.356 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.459 HG13 ' H ' ' A' ' 55' ' ' GLU . 30.4 pt -96.93 -175.55 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.908 177.505 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -69.57 -8.91 51.37 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.837 -0.62 . . . . 0.0 112.082 -175.853 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.459 ' H ' HG13 ' A' ' 53' ' ' ILE . 29.4 tp10 -81.94 -11.13 59.03 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.03 0.443 . . . . 0.0 111.098 -177.699 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.74 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 70.1 mm-40 -86.11 146.08 26.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -174.859 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.521 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.6 mp0 -80.83 160.89 24.68 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.59 173.841 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.414 HG23 HD11 ' A' ' 64' ' ' ILE . 39.9 mt -105.69 147.38 11.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 175.833 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.506 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 98.9 m-85 -111.38 151.84 28.01 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.274 0.559 . . . . 0.0 111.341 -178.138 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.463 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 29.7 t70 -69.61 120.85 16.01 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.958 172.736 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.13 19.31 55.89 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.797 -0.716 . . . . 0.0 111.992 -177.197 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.506 ' HB2' ' HB2' ' A' ' 59' ' ' PHE . 24.0 t0 -94.88 159.9 14.83 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 120.928 0.394 . . . . 0.0 110.448 -179.477 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.548 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.3 mp -117.05 108.55 25.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.03 0.443 . . . . 0.0 110.211 -175.785 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 1.9 mp -92.77 119.13 39.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-O 121.173 0.511 . . . . 0.0 110.175 -178.59 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.524 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 44.8 tt0 -105.22 115.8 30.87 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.646 178.512 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 79.3 t -100.81 102.62 13.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.352 0.596 . . . . 0.0 110.115 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.421 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 49.1 mt -93.27 93.13 3.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.165 -179.009 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.625 ' O ' ' HD2' ' A' ' 68' ' ' ARG . 0.2 OUTLIER . . . . . 0 C--N 1.317 -0.823 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 170.67 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 47.4 mm . . . . . 0 N--CA 1.453 -0.287 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 23' ' ' SER . . . 85.24 100.64 0.68 Allowed Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.351 -176.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' MET . . . . . 0.443 ' HB2' ' HA ' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -126.1 149.67 48.76 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 -176.704 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.665 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 96.0 mttt -109.75 140.61 43.44 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.297 176.793 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -145.83 152.82 40.12 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.966 0.412 . . . . 0.0 110.268 174.748 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.593 HG22 ' HG2' ' A' ' 18' ' ' LYS . 4.7 m -110.61 118.06 35.18 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.774 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.647 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.7 p -111.49 132.05 61.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.795 -177.381 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.587 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -87.63 124.56 40.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.293 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.4 ' N ' HD13 ' A' ' 13' ' ' ILE . 2.5 p -134.49 -171.06 2.67 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.298 -177.629 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -74.85 -27.4 60.25 Favored 'General case' 0 N--CA 1.464 0.246 0 O-C-N 122.393 -0.192 . . . . 0.0 111.499 -173.394 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -83.73 -6.23 59.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.112 0.482 . . . . 0.0 110.331 178.306 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 131.4 -173.52 20.4 Favored Glycine 0 N--CA 1.443 -0.839 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 -179.007 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.593 ' HG2' HG22 ' A' ' 11' ' ' THR . 66.5 tttt -90.47 106.52 18.55 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.153 0.502 . . . . 0.0 109.788 178.007 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.7 tptm -103.61 121.34 42.72 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.199 -170.056 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.527 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -92.1 126.2 44.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 173.061 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.412 ' N ' HD13 ' A' ' 20' ' ' ILE . 4.0 pp -144.52 162.8 35.65 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.047 177.648 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.665 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -111.91 162.87 14.85 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.138 0.494 . . . . 0.0 110.961 -179.893 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.455 ' O ' ' HA2' ' A' ' 7' ' ' GLY . 40.6 t -130.41 140.59 50.57 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.657 -0.702 . . . . 0.0 109.224 176.789 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -53.81 -38.62 59.94 Favored Glycine 0 C--N 1.331 0.265 0 O-C-N 123.558 0.537 . . . . 0.0 112.523 -179.168 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.447 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -137.99 152.07 71.35 Favored Pre-proline 0 C--N 1.321 -0.638 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 176.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -59.08 128.38 27.54 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.375 2.05 . . . . 0.0 111.2 174.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.447 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 20.4 mmm180 -129.38 170.7 13.33 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.921 0.391 . . . . 0.0 110.455 -175.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.638 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 45.4 ttm180 -77.34 155.75 31.74 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.099 177.789 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.581 HG21 HG11 ' A' ' 45' ' ' VAL . 38.1 mm -53.17 -46.59 55.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 CA-C-O 121.712 0.768 . . . . 0.0 109.732 175.882 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.499 ' HB3' ' HE2' ' A' ' 30' ' ' LYS . 28.7 ttpt -72.39 -20.65 61.41 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.785 -1.098 . . . . 0.0 111.428 -178.893 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -66.57 -53.48 34.08 Favored 'General case' 0 CA--C 1.514 -0.43 0 CA-C-O 121.094 0.473 . . . . 0.0 109.779 176.389 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.8 t -68.21 -50.02 61.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.928 -177.665 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.561 HD23 ' HB ' ' A' ' 40' ' ' ILE . 15.0 tp -70.48 -28.68 65.17 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.488 -177.117 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.5 -39.47 95.64 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.165 174.7 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -62.59 -39.0 92.33 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.925 0.393 . . . . 0.0 110.658 177.04 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 91.7 mt -75.75 -15.08 60.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.028 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 59.21 75.66 0.39 Allowed 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.523 0.678 . . . . 0.0 110.929 -177.484 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 80.8 mt -134.15 130.45 20.31 Favored Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.195 176.68 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.471 ' HB2' HG22 ' A' ' 42' ' ' THR . 19.5 Cg_endo -58.61 90.46 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.779 2.32 . . . . 0.0 112.916 -179.608 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.561 ' HB ' HD23 ' A' ' 33' ' ' LEU . 18.9 tt -75.87 -9.81 12.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.672 -178.902 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -75.5 -43.15 50.68 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.761 -177.08 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.471 HG22 ' HB2' ' A' ' 39' ' ' PRO . 10.0 t -95.27 -5.27 44.04 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -170.182 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.583 ' HB ' ' HA ' ' A' ' 68' ' ' ARG . 17.9 m -115.42 167.94 7.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.906 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.1 t -97.32 123.44 49.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.023 0.44 . . . . 0.0 111.457 -173.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.581 HG11 HG21 ' A' ' 29' ' ' ILE . 61.4 t -103.67 126.57 58.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.94 176.409 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.724 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 25.2 mttm -119.41 114.32 22.15 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.568 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.42 ' HB3' HG11 ' A' ' 52' ' ' VAL . 86.6 tttt -93.64 110.14 21.76 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.828 177.88 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 64.76 16.98 10.75 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.606 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 114.14 -29.16 7.86 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.104 -0.57 . . . . 0.0 112.554 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 15.2 mm100 -88.39 140.88 29.02 Favored 'General case' 0 C--N 1.327 -0.413 0 O-C-N 122.846 -0.208 . . . . 0.0 110.779 -176.62 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 3.4 mp -69.89 118.77 14.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 177.637 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.42 HG11 ' HB3' ' A' ' 47' ' ' LYS . 34.5 m -122.43 169.93 13.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.087 0.47 . . . . 0.0 110.998 -178.257 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.7 pp -87.76 165.97 2.0 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.906 175.652 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -70.81 -10.59 59.85 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.901 -0.591 . . . . 0.0 112.087 -175.029 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.604 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 2.1 tp10 -83.61 -9.59 58.8 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.449 -175.716 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.435 ' O ' HG12 ' A' ' 29' ' ' ILE . 14.8 mm-40 -66.8 149.67 50.22 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.989 0.423 . . . . 0.0 112.068 -178.311 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.638 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 43.7 mt-10 -103.83 152.64 21.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.576 -179.547 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.481 HG12 HD13 ' A' ' 29' ' ' ILE . 23.6 mt -97.38 143.09 13.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.532 -178.578 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -125.97 171.77 10.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.261 -179.789 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.443 ' HA ' ' HB2' ' A' ' 8' ' ' MET . 27.0 t70 -71.02 122.58 20.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.813 0.34 . . . . 0.0 111.555 -175.441 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.78 14.13 57.04 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.444 176.469 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -91.51 161.49 14.94 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.937 0.399 . . . . 0.0 110.368 -178.866 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.1 mm -120.03 127.36 75.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.927 -176.527 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.647 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.4 mm -116.66 116.39 52.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 120.975 0.417 . . . . 0.0 110.918 -176.707 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.724 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 38.8 mm-40 -104.19 113.79 27.58 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.216 178.813 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 55.9 t -105.18 110.26 30.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.429 0.633 . . . . 0.0 110.289 174.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 62.5 mt -113.16 109.52 28.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.808 -179.12 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.583 ' HA ' ' HB ' ' A' ' 43' ' ' VAL . 13.3 ptt180 . . . . . 0 C--N 1.325 -0.496 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.996 177.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.4 tp . . . . . 0 N--CA 1.452 -0.348 0 CA-C-O 121.332 0.587 . . . . 0.0 110.135 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 106.49 -172.4 18.47 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 -177.147 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' MET . . . . . 0.555 ' HA ' ' HB2' ' A' ' 60' ' ' ASP . 26.2 ptt? -160.67 129.09 4.61 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.106 0.479 . . . . 0.0 111.069 179.301 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -111.38 112.39 24.11 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 174.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.44 ' CZ ' HD11 ' A' ' 21' ' ' LEU . 49.2 p90 -136.72 168.13 20.11 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.556 -173.898 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.5 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.5 t -119.04 146.5 45.0 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.321 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 p -126.02 122.83 62.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.917 176.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.524 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -101.94 124.86 56.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.565 0.698 . . . . 0.0 110.083 -179.398 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.4 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -146.08 -160.43 1.15 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.163 177.904 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.4 ' H ' HG22 ' A' ' 14' ' ' THR . 4.7 m-20 -60.71 -29.66 69.49 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.185 0.517 . . . . 0.0 110.594 176.538 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -72.29 -3.19 22.32 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.556 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.04 -167.21 20.47 Favored Glycine 0 N--CA 1.444 -0.823 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -176.454 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.0 ttmt -93.14 102.97 15.29 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 175.704 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 84.1 tttt -106.83 120.44 42.02 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.771 -172.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.517 HD13 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -98.62 136.5 29.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.094 -178.871 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.517 ' N ' HD13 ' A' ' 20' ' ' ILE . 4.3 pp -140.33 162.65 34.8 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.684 0.278 . . . . 0.0 110.731 179.221 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -114.97 144.24 43.91 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -178.13 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 47.0 t -131.33 131.55 43.83 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.654 0.264 . . . . 0.0 110.453 -177.489 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.88 -16.84 74.85 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.221 -0.514 . . . . 0.0 112.778 -179.124 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.47 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.21 144.24 42.41 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 122.785 -0.244 . . . . 0.0 110.967 179.492 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.471 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 3.0 Cg_exo -75.15 130.14 12.86 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.741 2.294 . . . . 0.0 110.99 174.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 9.5 mtp180 -136.85 164.95 27.09 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.897 0.38 . . . . 0.0 110.71 -175.34 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.629 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 16.3 ttp85 -92.47 164.47 13.45 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.99 -176.823 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.497 HG12 ' O ' ' A' ' 56' ' ' GLU . 45.5 mm -51.84 -46.52 40.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 122.183 0.193 . . . . 0.0 111.288 -179.406 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.474 ' HB2' ' OD2' ' A' ' 54' ' ' ASP . 6.1 tptm -65.19 -26.97 68.38 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.836 0.31 . . . . 0.0 111.836 -177.151 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -62.72 -57.98 9.08 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 176.367 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 46.1 t -64.51 -41.28 91.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.626 -179.345 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.461 HD22 ' HB ' ' A' ' 38' ' ' ILE . 3.1 tm? -61.57 -46.56 89.39 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.117 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.62 -38.42 93.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 121.133 -0.556 . . . . 0.0 112.583 -178.761 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -65.8 -46.96 76.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.597 0.237 . . . . 0.0 111.518 179.27 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 91.7 mt -76.33 -16.25 59.8 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.755 0.312 . . . . 0.0 110.764 -178.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 60.65 37.24 19.33 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.511 177.872 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.461 ' HB ' HD22 ' A' ' 33' ' ' LEU . 66.7 mt -79.47 132.48 62.01 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.54 177.752 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -60.59 98.57 0.13 Allowed 'Trans proline' 0 CA--C 1.529 0.255 0 C-N-CA 122.546 2.164 . . . . 0.0 112.437 179.636 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.51 ' HA ' HG22 ' A' ' 43' ' ' VAL . 10.7 tp -69.87 -13.6 17.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.445 0.64 . . . . 0.0 110.149 -179.501 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -64.58 -21.74 66.78 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.245 -0.889 . . . . 0.0 111.076 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.8 t -127.3 10.39 6.8 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 112.282 0.475 . . . . 0.0 112.282 -173.347 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 35.3 m -131.9 142.26 43.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.121 0.486 . . . . 0.0 111.166 -179.262 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -118.12 138.92 47.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.79 178.378 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.6 t -103.73 136.09 38.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 121.248 0.547 . . . . 0.0 111.071 -176.634 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.646 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 56.5 mttm -118.1 147.77 42.96 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.008 175.688 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.587 ' HG2' HG21 ' A' ' 52' ' ' VAL . 19.1 mmtp -108.63 101.61 10.74 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.516 172.444 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 25.4 t30 57.5 27.33 13.86 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.738 177.296 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 116.5 -28.82 7.28 Favored Glycine 0 CA--C 1.522 0.478 0 C-N-CA 121.227 -0.511 . . . . 0.0 113.266 -179.245 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 70.4 mm-40 -88.14 139.81 30.12 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 117.054 0.427 . . . . 0.0 111.38 -172.477 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 26.2 mm -74.63 126.31 35.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.85 0.357 . . . . 0.0 111.052 179.117 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.587 HG21 ' HG2' ' A' ' 47' ' ' LYS . 25.2 m -128.76 178.48 4.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.206 178.882 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.442 HG13 ' H ' ' A' ' 55' ' ' GLU . 47.0 pt -118.99 -173.46 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.394 0.616 . . . . 0.0 111.785 -178.401 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.474 ' OD2' ' HB2' ' A' ' 30' ' ' LYS . 16.6 t70 -64.78 -19.98 66.12 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.131 -175.74 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.451 ' HA ' ' HD2' ' A' ' 28' ' ' ARG . 6.0 mm-40 -90.41 3.96 52.3 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.129 -0.487 . . . . 0.0 112.274 -173.468 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.497 ' O ' HG12 ' A' ' 29' ' ' ILE . 0.5 OUTLIER -85.5 135.71 33.72 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.074 0.464 . . . . 0.0 111.366 -179.843 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.629 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 7.1 mp0 -82.11 153.49 26.04 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.257 175.5 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.503 HG23 HD11 ' A' ' 64' ' ' ILE . 22.4 mt -95.84 143.37 12.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 175.309 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.593 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 80.3 m-85 -119.51 153.41 35.39 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.212 0.53 . . . . 0.0 111.369 -174.5 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.555 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 29.1 t70 -62.58 121.14 12.6 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.231 172.555 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.13 8.71 74.8 Favored Glycine 0 C--O 1.229 -0.218 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.138 -179.331 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.593 ' HB2' ' HB2' ' A' ' 59' ' ' PHE . 31.4 t70 -93.8 146.96 23.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 -179.653 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 37.9 mm -107.79 128.15 63.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.764 0.316 . . . . 0.0 110.905 -174.219 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.503 HD11 HG23 ' A' ' 58' ' ' ILE . 39.2 mm -108.5 118.48 56.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.946 -177.156 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.646 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 19.0 mp0 -106.09 121.47 44.21 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 172.378 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 97.2 t -105.53 104.04 16.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.198 0.523 . . . . 0.0 110.386 178.02 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.513 HD13 ' HD2' ' A' ' 46' ' ' LYS . 3.1 mp -106.02 114.06 44.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.625 -179.566 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.871 ' HB2' HH11 ' A' ' 68' ' ' ARG . 1.7 mtm105 . . . . . 0 C--N 1.322 -0.62 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 175.708 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 54.2 mt . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.61 166.41 13.31 Favored Glycine 0 N--CA 1.441 -0.97 0 C-N-CA 120.542 -0.837 . . . . 0.0 111.903 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' MET . . . . . 0.645 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 0.7 OUTLIER -136.88 139.34 41.57 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 -176.83 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.647 ' HA ' ' HB3' ' A' ' 22' ' ' GLU . 18.0 ttmm -101.03 116.56 33.13 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 172.053 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -136.75 165.48 25.82 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 120.925 0.393 . . . . 0.0 110.442 -179.137 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.867 ' HB ' HD13 ' A' ' 20' ' ' ILE . 12.1 t -121.13 137.2 54.77 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-O 121.288 0.566 . . . . 0.0 110.591 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.402 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.1 p -115.15 135.13 56.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.362 176.802 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.548 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -109.64 122.4 64.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.447 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.82 -165.01 1.54 Allowed 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.067 178.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -71.13 -13.49 61.97 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.09 0.472 . . . . 0.0 110.244 177.485 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -84.49 -9.79 58.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.503 0.668 . . . . 0.0 109.967 175.426 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 112.2 -178.67 19.2 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.986 -179.022 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.4 ttmt -92.8 114.76 27.4 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 176.011 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.403 ' HB2' ' HE3' ' A' ' 19' ' ' LYS . 30.9 ttmt -127.07 149.1 50.08 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.931 -171.186 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.867 HD13 ' HB ' ' A' ' 11' ' ' THR . 37.5 mm -94.77 126.3 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.829 -178.521 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 3.9 pp -144.64 144.95 31.52 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 172.676 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.647 ' HB3' ' HA ' ' A' ' 9' ' ' LYS . 12.6 pt-20 -139.42 163.4 32.62 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.804 0.335 . . . . 0.0 111.129 -176.144 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.7 t -129.03 165.53 20.99 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.102 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -101.67 14.05 57.78 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 177.314 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -139.3 142.85 33.94 Favored Pre-proline 0 C--N 1.324 -0.509 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 175.769 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.645 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 34.6 Cg_exo -61.19 136.39 64.37 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.611 2.207 . . . . 0.0 111.15 175.778 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.902 ' HG3' ' HB3' ' A' ' 31' ' ' ASP . 0.0 OUTLIER -140.37 157.87 44.89 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.346 0.593 . . . . 0.0 112.105 -173.06 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.572 ' HD3' ' HA ' ' A' ' 55' ' ' GLU . 43.5 ttm180 -107.06 163.41 13.01 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.08 -0.963 . . . . 0.0 109.134 176.414 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.579 HG13 ' O ' ' A' ' 56' ' ' GLU . 10.1 mt -60.08 -48.32 88.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.375 0 CA-C-O 121.359 0.6 . . . . 0.0 109.615 176.882 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.9 tptp -51.4 -35.95 41.39 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.678 173.436 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.902 ' HB3' ' HG3' ' A' ' 27' ' ' ARG . 0.2 OUTLIER -72.45 -55.58 6.78 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.676 179.079 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 28' ' ' ARG . 58.7 t -59.67 -61.07 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.287 -177.687 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.817 ' HG ' HD12 ' A' ' 40' ' ' ILE . 4.1 mm? -69.16 -28.37 66.36 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 121.118 -0.233 . . . . 0.0 111.224 -177.222 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.29 -43.33 63.28 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.454 179.158 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -71.98 -34.52 69.0 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.764 0.316 . . . . 0.0 110.64 178.355 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.415 ' HG ' ' O ' ' A' ' 32' ' ' VAL . 94.8 mt -73.22 -17.9 61.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.793 0.33 . . . . 0.0 110.147 175.382 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 61.86 36.77 15.79 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.892 174.879 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.404 HG23 ' HD2' ' A' ' 39' ' ' PRO . 72.4 mt -92.07 139.0 24.29 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.038 179.599 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.404 ' HD2' HG23 ' A' ' 38' ' ' ILE . 35.9 Cg_endo -65.87 65.39 0.42 Allowed 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 122.975 2.45 . . . . 0.0 113.133 177.495 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.817 HD12 ' HG ' ' A' ' 33' ' ' LEU . 7.6 tt -65.62 -22.35 30.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.843 177.593 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -66.29 -19.92 65.96 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.219 -0.9 . . . . 0.0 112.548 -173.111 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.6 t -109.16 11.86 25.33 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.36 -0.536 . . . . 0.0 111.913 -173.468 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 32.7 m -133.63 173.58 14.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.505 0.193 . . . . 0.0 110.784 178.23 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.852 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 46.5 t -88.26 129.86 38.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.729 0.3 . . . . 0.0 111.242 -175.39 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 19.2 t -108.33 126.04 65.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.826 -179.642 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.626 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 82.3 mttt -123.25 118.44 27.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.872 175.689 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -97.25 108.42 21.15 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 172.576 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 64.93 14.58 9.38 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.636 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 108.67 -13.08 35.54 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 121.14 -0.552 . . . . 0.0 112.096 -178.774 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 31.9 mm-40 -89.93 129.39 36.29 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.465 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 60.4 mt -72.49 105.78 2.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.263 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.6 m -116.83 171.31 5.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.484 -171.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 35.0 pt -89.45 166.92 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 166.799 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.427 ' O ' ' HB ' ' A' ' 29' ' ' ILE . 14.0 p-10 -77.71 -1.33 30.61 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 120.758 0.313 . . . . 0.0 111.74 -174.485 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.572 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 3.9 tp10 -82.88 12.34 4.98 Favored 'General case' 0 CA--C 1.539 0.547 0 CA-C-O 121.08 0.467 . . . . 0.0 111.066 -177.921 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.579 ' O ' HG13 ' A' ' 29' ' ' ILE . 26.6 mm-40 -91.23 143.33 26.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.528 178.786 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.538 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 12.3 mp0 -76.0 161.96 28.47 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.849 0.357 . . . . 0.0 110.305 173.4 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 8.6 mm -104.31 141.34 20.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 174.019 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -118.13 169.8 9.39 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.73 176.597 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -78.02 122.07 25.07 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.735 -174.573 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.72 11.53 56.71 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.252 -177.719 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -83.55 160.81 21.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.979 0.419 . . . . 0.0 110.717 -178.427 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.542 HG12 HG22 ' A' ' 11' ' ' THR . 20.2 mt -129.0 111.28 22.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.452 -179.835 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.414 HD12 ' N ' ' A' ' 64' ' ' ILE . 3.2 mp -95.11 115.67 34.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.277 0.561 . . . . 0.0 109.925 -179.736 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.626 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 37.5 mt-10 -102.29 104.96 15.52 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.086 179.352 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 55.4 t -97.46 107.41 20.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.552 0.691 . . . . 0.0 109.8 178.434 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.852 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 54.6 mt -92.61 95.07 5.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.251 -176.642 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.323 -0.558 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 173.506 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 7.5 tp . . . . . 0 N--CA 1.448 -0.561 0 CA-C-O 121.055 0.455 . . . . 0.0 109.811 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 121.9 -177.47 16.44 Favored Glycine 0 N--CA 1.443 -0.876 0 C-N-CA 120.728 -0.749 . . . . 0.0 111.689 -178.87 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' MET . . . . . 0.61 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 25.1 ptt? -156.78 130.99 8.51 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.161 0.505 . . . . 0.0 111.158 -179.328 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.405 ' HE2' ' HB2' ' A' ' 9' ' ' LYS . 7.4 tppt? -101.05 120.03 39.61 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.063 174.136 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 10.0 p90 -141.33 151.75 43.83 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.247 0.546 . . . . 0.0 110.777 -179.727 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.468 HG21 ' HG2' ' A' ' 18' ' ' LYS . 5.8 m -118.13 128.73 55.01 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.881 178.699 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.774 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.6 p -104.66 122.93 58.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.242 0.544 . . . . 0.0 110.443 178.076 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.451 HG22 ' HG2' ' A' ' 65' ' ' GLU . 7.3 tp -87.53 123.73 40.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 121.213 0.53 . . . . 0.0 109.666 176.026 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.471 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -135.67 -177.19 4.56 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.416 -0.811 . . . . 0.0 108.905 -179.788 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.471 ' H ' HG22 ' A' ' 14' ' ' THR . 4.2 p-10 -71.46 -17.95 62.34 Favored 'General case' 0 C--N 1.327 -0.396 0 O-C-N 122.254 -0.279 . . . . 0.0 111.286 -177.159 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.437 ' OD1' ' HB ' ' A' ' 14' ' ' THR . 9.2 p-10 -90.29 4.23 51.31 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.866 0.365 . . . . 0.0 110.757 179.751 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 122.1 -166.32 14.78 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.778 175.581 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.468 ' HG2' HG21 ' A' ' 11' ' ' THR . 37.4 tttm -90.34 106.64 18.63 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.402 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.527 ' HB3' HG13 ' A' ' 12' ' ' VAL . 22.7 tttp -103.32 99.02 8.85 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.83 -167.844 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.559 HD13 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -86.12 133.41 29.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.779 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.559 ' N ' HD13 ' A' ' 20' ' ' ILE . 2.1 pt? -144.13 168.23 20.51 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 177.351 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -134.7 148.67 50.36 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.829 0.347 . . . . 0.0 110.445 -177.208 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 22.1 m -129.2 131.97 47.19 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.781 174.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.21 -16.14 59.71 Favored Glycine 0 C--N 1.33 0.246 0 CA-C-N 116.059 -0.519 . . . . 0.0 113.314 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.417 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -139.39 144.79 41.43 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 176.075 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.61 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 23.3 Cg_exo -65.69 146.34 83.8 Favored 'Trans proline' 0 C--O 1.234 0.324 0 C-N-CA 122.896 2.397 . . . . 0.0 111.595 176.832 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.557 ' HD3' ' OD2' ' A' ' 31' ' ' ASP . 96.4 mtt180 -140.16 168.22 20.31 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.309 0.576 . . . . 0.0 111.487 -175.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.601 ' HD3' ' HA ' ' A' ' 55' ' ' GLU . 37.0 ttm105 -94.17 152.52 18.67 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.077 -0.965 . . . . 0.0 108.555 171.022 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.533 HG12 ' O ' ' A' ' 56' ' ' GLU . 46.8 mm -51.13 -44.05 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 122.349 0.26 . . . . 0.0 111.601 -177.532 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.1 tptm -58.43 -27.2 64.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.138 -176.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.557 ' OD2' ' HD3' ' A' ' 27' ' ' ARG . 20.2 t70 -72.47 -53.3 12.49 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.684 -178.101 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 47.5 t -64.97 -44.13 96.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 CA-C-O 121.223 0.535 . . . . 0.0 110.202 178.735 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.506 HD21 ' HB ' ' A' ' 40' ' ' ILE . 20.7 tp -62.6 -35.66 80.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.977 178.27 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.75 -33.54 66.56 Favored Glycine 0 N--CA 1.449 -0.457 0 CA-C-N 115.446 -0.797 . . . . 0.0 113.099 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -66.37 -46.89 75.14 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 120.851 0.357 . . . . 0.0 111.211 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 92.9 mt -83.58 -16.15 46.42 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.732 -177.876 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.9 tp10 54.85 80.98 0.11 Allowed 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.824 0.821 . . . . 0.0 110.615 -176.645 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.461 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 67.8 mt -120.83 127.81 26.07 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.412 178.792 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.476 ' HB2' HG22 ' A' ' 42' ' ' THR . 16.0 Cg_exo -67.16 104.02 0.82 Allowed 'Trans proline' 0 N--CA 1.46 -0.446 0 C-N-CA 122.584 2.189 . . . . 0.0 112.486 -179.248 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.506 ' HB ' HD21 ' A' ' 33' ' ' LEU . 10.7 tt -66.79 -6.07 4.11 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 121.834 0.826 . . . . 0.0 110.237 177.117 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 21.4 tp10 -72.89 -36.2 67.29 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.095 -0.957 . . . . 0.0 110.853 177.016 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.529 HG23 HG13 ' A' ' 43' ' ' VAL . 15.3 t -101.21 -24.68 14.21 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 120.911 -0.316 . . . . 0.0 111.531 -175.392 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.581 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 34.2 m -116.93 141.56 34.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 110.062 -0.348 . . . . 0.0 110.062 177.074 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.458 HG11 HD12 ' A' ' 51' ' ' ILE . 38.4 t -105.0 140.36 23.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 120.922 0.392 . . . . 0.0 110.653 -177.47 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 6.9 p -103.39 131.16 52.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.805 -178.843 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.65 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 87.6 mttt -118.75 146.32 44.86 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.253 177.647 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.755 ' HG2' HG21 ' A' ' 52' ' ' VAL . 13.8 mmtp -109.37 101.25 10.25 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 167.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.5 t-20 50.17 61.11 3.36 Favored 'General case' 0 CA--C 1.537 0.479 0 O-C-N 123.697 0.623 . . . . 0.0 111.122 -179.45 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 87.54 -23.38 12.8 Favored Glycine 0 CA--C 1.52 0.35 0 CA-C-N 116.031 -0.531 . . . . 0.0 113.585 176.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 14.5 mm100 -96.56 127.56 42.67 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 117.06 0.43 . . . . 0.0 111.942 -172.388 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.591 HD13 ' HG2' ' A' ' 46' ' ' LYS . 33.7 mm -65.2 127.88 26.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.248 177.097 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.755 HG21 ' HG2' ' A' ' 47' ' ' LYS . 29.5 m -131.65 178.8 5.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.075 0.464 . . . . 0.0 111.368 -177.293 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.4 pt -107.81 177.24 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.558 178.871 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -74.35 -12.9 60.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.033 0.444 . . . . 0.0 110.84 -177.126 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.601 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 14.2 mm-40 -79.99 -5.3 55.47 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.866 179.574 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.533 ' O ' HG12 ' A' ' 29' ' ' ILE . 3.7 mm-40 -68.98 140.04 55.03 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.742 0.306 . . . . 0.0 110.93 178.019 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLU . . . . . 0.584 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 39.3 mt-10 -96.16 147.57 23.61 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 175.197 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.481 ' HB ' ' SD ' ' A' ' 8' ' ' MET . 19.2 mt -89.19 135.22 26.46 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -118.53 146.4 44.59 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.557 -0.292 . . . . 0.0 110.874 -177.089 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.567 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 18.7 t70 -58.66 116.87 3.99 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.598 173.874 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.14 -17.72 47.44 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 121.039 -0.601 . . . . 0.0 112.145 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 33.2 t0 -77.87 150.77 34.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.888 0.375 . . . . 0.0 110.05 -179.539 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.1 mm -105.94 115.45 47.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.162 0.506 . . . . 0.0 110.411 -175.203 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.774 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 9.0 tp -95.71 133.26 37.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.38 -179.057 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.65 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 28.6 mt-10 -131.7 130.38 41.93 Favored 'General case' 0 C--N 1.317 -0.814 0 O-C-N 122.166 -0.334 . . . . 0.0 110.795 -175.024 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 86.9 t -115.56 103.97 16.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.173 0.511 . . . . 0.0 109.87 178.149 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 25.6 mt -123.58 109.67 23.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.588 -176.662 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.581 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.533 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 173.114 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.712 ' SD ' HG23 ' A' ' 5' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.482 1.134 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.712 HG23 ' SD ' ' A' ' 4' ' ' MET . 83.1 t -109.26 121.31 62.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 171.495 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.501 HD13 ' H ' ' A' ' 6' ' ' ILE . 0.1 OUTLIER -87.81 132.7 32.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 121.068 0.461 . . . . 0.0 110.864 -179.222 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.29 105.96 0.21 Allowed Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -177.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.584 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.1 ptt? -110.48 130.54 55.53 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.858 0.361 . . . . 0.0 111.044 -174.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.44 ' HB2' ' HB3' ' A' ' 22' ' ' GLU . 3.5 ttpm? -115.03 126.6 54.92 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 174.731 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 28.8 p90 -138.79 167.89 21.0 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.313 -175.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.492 ' HB ' HD13 ' A' ' 20' ' ' ILE . 13.1 t -125.38 132.02 52.86 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.201 0.524 . . . . 0.0 110.911 178.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.539 HG22 ' HB ' ' A' ' 64' ' ' ILE . 63.0 t -109.28 119.3 58.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 115.458 -0.792 . . . . 0.0 108.946 174.111 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.539 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -100.34 128.98 51.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.269 0.557 . . . . 0.0 109.949 -177.948 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.415 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -141.34 -162.81 1.44 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.508 -0.769 . . . . 0.0 108.949 178.507 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.415 ' H ' HG22 ' A' ' 14' ' ' THR . 3.7 m-20 -60.97 -27.44 68.27 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.329 0.585 . . . . 0.0 110.537 176.632 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -74.46 -9.42 58.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.507 178.45 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.31 -163.75 19.05 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 111.416 -0.674 . . . . 0.0 111.416 -177.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -76.8 118.76 19.74 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.053 0.454 . . . . 0.0 110.361 175.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 19.8 mtpp -102.48 121.83 43.12 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.18 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.492 HD13 ' HB ' ' A' ' 11' ' ' THR . 21.7 mm -100.32 120.84 50.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.027 0.442 . . . . 0.0 110.913 -177.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.436 HD23 ' N ' ' A' ' 21' ' ' LEU . 2.1 pt? -144.32 141.32 29.68 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.047 176.771 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.44 ' HB3' ' HB2' ' A' ' 9' ' ' LYS . 6.7 pt-20 -121.54 139.01 54.06 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.274 0.559 . . . . 0.0 110.763 178.652 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.9 t -119.9 130.88 55.04 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.518 -0.764 . . . . 0.0 109.446 -176.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -63.43 -31.99 82.63 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 121.23 -0.51 . . . . 0.0 112.868 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.436 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -106.82 123.81 37.41 Favored Pre-proline 0 C--N 1.322 -0.596 0 O-C-N 122.822 -0.222 . . . . 0.0 110.621 178.713 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.584 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 26.1 Cg_exo -63.71 110.89 1.37 Allowed 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.868 2.379 . . . . 0.0 111.544 175.815 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.436 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 14.4 mmm180 -118.57 177.11 4.95 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.232 0.539 . . . . 0.0 111.808 -171.295 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.684 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 15.6 ttp180 -89.88 157.61 17.81 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.946 -179.389 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.57 HD13 HG12 ' A' ' 58' ' ' ILE . 27.1 mm -50.22 -47.41 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 CA-C-O 120.833 0.349 . . . . 0.0 110.308 177.684 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.51 ' HB2' ' O ' ' A' ' 54' ' ' ASP . 46.3 tttp -59.63 -29.56 68.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.275 -176.537 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -64.89 -61.84 1.92 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.057 0.456 . . . . 0.0 110.372 -178.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.1 t -64.84 -38.96 84.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.556 -179.187 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.458 ' CD1' ' HB ' ' A' ' 38' ' ' ILE . 20.7 tp -63.21 -41.16 99.11 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.363 178.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.23 -35.19 63.97 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 116.009 -0.541 . . . . 0.0 113.376 179.457 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.442 ' HA ' ' OE1' ' A' ' 35' ' ' GLU . 5.5 mm-40 -65.13 -42.12 94.18 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 117.058 0.429 . . . . 0.0 111.295 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.6 mt -86.11 -8.4 57.9 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 175.005 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 40.27 70.12 0.27 Allowed 'General case' 0 C--O 1.234 0.269 0 CA-C-N 114.54 -1.209 . . . . 0.0 111.662 -173.511 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.458 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 63.8 mt -92.6 112.58 56.23 Favored Pre-proline 0 C--N 1.321 -0.667 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 174.701 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.539 ' HB2' HG22 ' A' ' 42' ' ' THR . 34.1 Cg_exo -60.29 103.43 0.21 Allowed 'Trans proline' 0 N--CA 1.46 -0.485 0 C-N-CA 122.693 2.262 . . . . 0.0 112.789 -173.664 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 8.1 tt -65.28 -11.34 11.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 CA-C-O 121.903 0.858 . . . . 0.0 109.493 175.345 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -66.36 -26.69 67.39 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 114.543 -1.208 . . . . 0.0 111.468 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.539 HG22 ' HB2' ' A' ' 39' ' ' PRO . 5.1 t -125.69 -7.84 6.78 Favored 'General case' 0 C--O 1.234 0.259 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -175.123 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.697 HG12 ' HB3' ' A' ' 68' ' ' ARG . 2.4 m -121.25 149.55 24.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.668 -177.124 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.4 t -98.85 130.83 47.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.55 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.9 t -103.03 126.73 57.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.137 0.494 . . . . 0.0 110.793 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.609 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 25.5 mttm -125.91 140.56 52.54 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.969 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.552 ' HD2' HG11 ' A' ' 52' ' ' VAL . 31.8 mttm -106.54 102.12 11.53 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.544 171.251 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 60.3 14.85 4.93 Favored 'General case' 0 CA--C 1.536 0.43 0 O-C-N 123.665 0.603 . . . . 0.0 111.164 178.577 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 126.9 -30.25 4.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.788 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 81.9 mm-40 -86.55 134.21 33.67 Favored 'General case' 0 C--N 1.327 -0.389 0 O-C-N 122.416 -0.461 . . . . 0.0 110.631 -176.024 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.434 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.7 mp -75.21 118.99 22.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -177.478 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.552 HG11 ' HD2' ' A' ' 47' ' ' LYS . 28.0 m -122.27 166.79 16.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 121.074 0.464 . . . . 0.0 110.745 -177.594 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 22.6 pt -97.81 175.41 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.859 174.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.51 ' O ' ' HB2' ' A' ' 30' ' ' LYS . 13.9 p-10 -81.89 12.84 3.68 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.289 -175.08 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -93.41 -15.84 25.23 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.707 -178.078 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.423 ' O ' ' HG3' ' A' ' 28' ' ' ARG . 60.6 mm-40 -77.33 160.74 28.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.196 -177.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.684 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.1 mp0 -94.17 163.17 13.57 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.989 0.423 . . . . 0.0 111.234 -178.779 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.57 HG12 HD13 ' A' ' 29' ' ' ILE . 45.8 mt -102.18 144.39 13.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 176.471 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -129.44 155.62 45.4 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.977 0.418 . . . . 0.0 110.693 -176.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.528 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 25.5 t70 -66.55 111.14 3.46 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.356 176.774 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.58 9.99 42.25 Favored Glycine 0 N--CA 1.445 -0.767 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.242 -177.081 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 26.2 t70 -88.44 146.3 25.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.859 0.362 . . . . 0.0 110.458 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.426 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.0 mp -113.99 115.91 51.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.278 -178.147 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.539 ' HB ' HG22 ' A' ' 12' ' ' VAL . 4.1 mp -102.04 110.3 28.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.606 179.297 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.609 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 44.1 mt-10 -96.98 98.12 9.81 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.564 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.442 HG23 HG22 ' A' ' 64' ' ' ILE . 87.3 t -92.22 101.54 12.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.418 0.628 . . . . 0.0 109.842 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 63.4 mt -109.26 99.97 9.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.501 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.697 ' HB3' HG12 ' A' ' 43' ' ' VAL . 24.3 ptt180 -77.09 135.34 38.59 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 173.575 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.645 HG13 ' HA3' ' A' ' 72' ' ' GLY . 7.7 p -83.09 140.48 16.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.174 0.512 . . . . 0.0 111.615 -169.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 9.9 tt -77.31 138.08 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.577 178.098 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 35.7 t80 63.79 29.71 14.71 Favored 'General case' 0 CA--C 1.534 0.341 0 CA-C-O 121.821 0.819 . . . . 0.0 109.543 -175.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.645 ' HA3' HG13 ' A' ' 69' ' ' VAL . . . -97.72 72.9 0.65 Allowed Glycine 0 N--CA 1.446 -0.662 0 CA-C-N 115.496 -0.774 . . . . 0.0 111.77 179.31 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.865 0 CA-C-O 118.872 -0.96 . . . . 0.0 111.59 -179.499 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 27.6 ttt . . . . . 0 N--CA 1.478 0.966 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 47.6 t -83.54 118.02 30.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.763 -176.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.2 pt -113.32 127.57 70.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.15 176.19 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.87 178.6 16.39 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.59 -178.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.434 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 1.2 mpp? -140.02 140.53 36.23 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.758 0.313 . . . . 0.0 110.67 -176.721 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -111.61 111.43 22.42 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 168.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -134.12 167.75 20.09 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 120.906 0.384 . . . . 0.0 110.679 -172.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.544 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 25.8 m -126.38 123.35 37.75 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 177.045 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.517 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.6 p -105.33 123.87 59.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.294 0.568 . . . . 0.0 110.227 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.447 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -107.26 130.54 59.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 121.157 0.503 . . . . 0.0 109.888 179.28 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.461 HG23 ' HB ' ' A' ' 66' ' ' VAL . 0.2 OUTLIER -146.2 -160.42 1.15 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 177.6 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.415 ' H ' HG22 ' A' ' 14' ' ' THR . 1.3 m-20 -58.81 -25.94 63.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.906 0.384 . . . . 0.0 111.413 179.087 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -89.1 10.2 22.64 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.522 -177.231 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.55 -156.65 18.9 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.459 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 54.4 mttm -105.59 103.51 13.04 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -178.648 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.8 tptm -106.75 115.06 29.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.87 0.367 . . . . 0.0 111.098 -175.714 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.544 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -78.59 128.61 38.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 176.798 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 96.7 mt -131.51 139.0 49.18 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.778 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -128.61 146.0 50.98 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.023 0.439 . . . . 0.0 110.602 179.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.5 m -135.24 136.23 41.56 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.886 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -86.8 17.97 37.61 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.509 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.446 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.51 131.51 16.18 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 178.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 25' ' ' ALA . 27.9 Cg_exo -62.45 112.68 1.66 Allowed 'Trans proline' 0 C--O 1.234 0.321 0 C-N-CA 122.693 2.262 . . . . 0.0 111.482 177.302 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -133.0 153.13 51.78 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.075 0.464 . . . . 0.0 111.01 -176.107 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.575 ' HG3' ' O ' ' A' ' 56' ' ' GLU . 23.6 ttm180 -83.49 164.73 19.68 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.387 -178.552 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.503 HD13 HG12 ' A' ' 58' ' ' ILE . 31.9 mm -51.56 -49.54 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 CA-C-O 120.714 0.292 . . . . 0.0 110.324 176.808 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 33.4 tttp -60.36 -29.58 69.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.843 -178.619 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.484 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 1.1 t70 -67.68 -50.4 57.92 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -177.649 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 60.9 t -73.26 -39.74 56.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.461 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.547 HD21 ' HB ' ' A' ' 40' ' ' ILE . 36.2 tp -62.65 -39.45 93.93 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.376 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.04 -37.91 95.26 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.783 -0.644 . . . . 0.0 112.156 177.062 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.484 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 6.9 mm-40 -64.23 -41.54 96.95 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.151 0.501 . . . . 0.0 110.323 176.061 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 95.0 mt -76.76 -16.23 59.53 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.935 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 62.93 26.56 15.59 Favored 'General case' 0 CA--C 1.537 0.448 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.055 174.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.409 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 75.1 mt -86.74 122.61 71.5 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.561 -178.74 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 18.5 Cg_exo -66.42 110.13 1.75 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.713 2.275 . . . . 0.0 112.268 178.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.547 ' HB ' HD21 ' A' ' 33' ' ' LEU . 13.3 tt -68.02 -17.54 22.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.574 178.796 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -56.98 -40.16 76.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.932 -178.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.411 HG23 HG13 ' A' ' 43' ' ' VAL . 14.8 t -98.01 2.12 48.55 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.817 0.341 . . . . 0.0 111.783 -172.32 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.544 HG12 ' HB3' ' A' ' 68' ' ' ARG . 12.0 m -129.07 171.5 16.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 O-C-N 122.032 -0.417 . . . . 0.0 111.389 -176.294 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.5 ' HB ' ' O ' ' A' ' 67' ' ' ILE . 61.0 t -126.55 136.44 60.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 173.369 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.5 t -106.27 127.81 61.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.964 0.412 . . . . 0.0 111.341 -175.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.517 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 85.7 mttt -118.01 120.78 38.84 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.561 174.718 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.471 ' HE3' ' O ' ' A' ' 57' ' ' GLU . 10.0 mtpm? -97.32 104.29 16.29 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 174.159 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 62.43 18.17 10.12 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.719 -176.085 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 109.66 -13.92 32.46 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.685 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -87.63 123.92 32.98 Favored 'General case' 0 C--N 1.326 -0.418 0 O-C-N 122.759 -0.259 . . . . 0.0 110.682 -178.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 65.6 mt -75.06 121.65 27.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.076 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.835 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 28.2 m -135.72 177.42 6.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.28 -175.572 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.433 HG13 ' H ' ' A' ' 55' ' ' GLU . 42.7 pt -102.74 -175.09 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.353 174.783 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -80.08 -7.68 59.0 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.73 -175.293 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.433 ' H ' HG13 ' A' ' 53' ' ' ILE . 6.8 tp10 -89.95 10.99 21.8 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-O 121.232 0.539 . . . . 0.0 110.793 -178.668 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.835 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 59.3 mm-40 -89.24 148.77 23.42 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.016 0.436 . . . . 0.0 111.536 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.471 ' O ' ' HE3' ' A' ' 47' ' ' LYS . 1.4 tp10 -85.51 142.74 28.96 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.129 -177.71 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.503 HG12 HD13 ' A' ' 29' ' ' ILE . 45.4 mt -88.98 130.77 37.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 177.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -102.56 156.44 17.61 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.274 179.058 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -73.49 115.63 13.1 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.947 0.403 . . . . 0.0 110.134 177.138 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 103.34 2.25 47.65 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 121.012 -0.613 . . . . 0.0 111.675 -177.445 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -75.33 146.77 40.66 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -113.97 113.7 44.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.517 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 41.3 mm -89.5 104.68 15.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.821 -176.839 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.517 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 36.4 mt-10 -102.25 107.73 18.87 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.835 -179.097 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.461 ' HB ' HG23 ' A' ' 14' ' ' THR . 76.3 t -91.92 99.93 10.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 121.335 0.588 . . . . 0.0 109.888 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.5 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 55.8 mt -105.01 103.75 15.82 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 177.524 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.544 ' HB3' HG12 ' A' ' 43' ' ' VAL . 16.4 ptt180 -100.75 150.43 22.79 Favored 'General case' 0 C--N 1.312 -1.034 0 C-N-CA 120.294 -0.563 . . . . 0.0 111.072 -173.787 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 28.3 m -82.91 149.85 4.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.567 -177.63 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.408 HD13 ' C ' ' A' ' 70' ' ' ILE . 0.0 OUTLIER -77.85 110.74 13.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 177.241 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 62.1 t80 -100.95 107.64 19.18 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.287 -0.869 . . . . 0.0 110.252 -175.442 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -87.27 114.53 4.14 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.63 -0.795 . . . . 0.0 111.887 179.017 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.245 0.833 0 CA-C-O 118.616 -1.102 . . . . 0.0 111.75 178.611 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 24.8 mmt . . . . . 0 N--CA 1.479 0.976 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.8 t -99.66 105.85 18.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.014 0.435 . . . . 0.0 110.06 177.332 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 46.0 mm -101.93 125.27 56.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.045 -178.217 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 107.24 76.72 1.01 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.626 -0.797 . . . . 0.0 111.379 -177.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.573 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.0 ptt? -85.74 130.47 34.55 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.12 0.486 . . . . 0.0 110.763 -174.037 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.484 ' HD3' HD11 ' A' ' 20' ' ' ILE . 0.6 OUTLIER -109.77 120.01 41.16 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.464 179.192 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 45.0 p90 -144.06 167.99 21.07 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.838 0.351 . . . . 0.0 110.761 -175.126 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.515 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 4.7 m -120.93 128.77 53.07 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.684 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 p -108.72 122.44 63.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 121.259 0.552 . . . . 0.0 109.921 175.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.565 ' HB ' ' HG3' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -106.59 118.72 54.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.366 0.603 . . . . 0.0 109.932 179.989 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.424 HG22 ' H ' ' A' ' 15' ' ' ASP . 2.4 m -116.47 169.78 9.06 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 177.066 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.424 ' H ' HG22 ' A' ' 14' ' ' THR . 29.1 t70 -53.97 -38.03 64.58 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.831 0.348 . . . . 0.0 111.58 178.293 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -77.96 -10.5 59.62 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.821 -175.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 152.74 170.9 19.63 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.321 -0.942 . . . . 0.0 112.578 178.211 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.565 ' HG3' ' HB ' ' A' ' 13' ' ' ILE . 36.4 ttpt -107.14 125.89 51.67 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.265 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -125.69 115.59 20.33 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.139 0.495 . . . . 0.0 111.242 -176.031 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.515 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -88.76 129.89 39.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 174.215 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.4 ' N ' HD13 ' A' ' 20' ' ' ILE . 4.1 pp -144.7 165.9 26.73 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.955 0.407 . . . . 0.0 110.566 178.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -123.21 133.15 54.24 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.447 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.1 t -101.96 131.97 48.06 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 177.45 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -55.89 -29.31 54.86 Favored Glycine 0 CA--C 1.518 0.23 0 CA-C-N 116.169 -0.468 . . . . 0.0 113.06 -177.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.489 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -135.22 151.4 75.01 Favored Pre-proline 0 C--N 1.322 -0.591 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 178.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.573 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 28.1 Cg_endo -63.86 127.63 20.01 Favored 'Trans proline' 0 N--CA 1.464 -0.228 0 C-N-CA 122.358 2.039 . . . . 0.0 111.072 174.284 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 18.3 mmm180 -128.05 170.13 13.27 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.058 0.456 . . . . 0.0 110.894 -173.089 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.6 ttt85 -95.79 159.9 14.75 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 178.484 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.462 ' CG2' ' HA ' ' A' ' 54' ' ' ASP . 41.6 mm -55.74 -46.77 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 N-CA-C 110.301 -0.259 . . . . 0.0 110.301 178.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.8 ttmp? -53.88 -38.56 64.87 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.856 178.245 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.431 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 32.9 t70 -62.09 -58.58 7.28 Favored 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.312 -179.514 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.5 t -60.59 -39.62 81.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.729 -179.642 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.568 HD12 ' HB ' ' A' ' 38' ' ' ILE . 15.6 tp -62.81 -47.19 84.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.654 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.42 -45.15 56.07 Favored Glycine 0 N--CA 1.448 -0.541 0 CA-C-N 115.755 -0.657 . . . . 0.0 113.13 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.431 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 34.9 mm-40 -63.47 -41.13 98.61 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.727 0.298 . . . . 0.0 111.658 -177.059 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 82.3 mt -89.22 -0.11 57.2 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.716 -0.22 . . . . 0.0 111.367 -178.038 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 54.58 73.01 0.42 Allowed 'General case' 0 C--O 1.232 0.181 0 CA-C-O 121.562 0.696 . . . . 0.0 110.772 179.151 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.568 ' HB ' HD12 ' A' ' 33' ' ' LEU . 68.3 mt -118.98 119.68 31.97 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.969 178.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.568 ' HB2' HG22 ' A' ' 42' ' ' THR . 7.0 Cg_exo -73.33 94.5 0.83 Allowed 'Trans proline' 0 N--CA 1.461 -0.425 0 C-N-CA 122.788 2.325 . . . . 0.0 112.34 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 13.4 tt -72.09 -23.07 21.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.362 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -60.81 -34.97 75.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.418 -178.311 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.568 HG22 ' HB2' ' A' ' 39' ' ' PRO . 12.9 t -102.62 -1.52 30.08 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -171.478 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.542 HG13 HG23 ' A' ' 42' ' ' THR . 18.2 m -136.89 -179.77 3.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 O-C-N 122.029 -0.42 . . . . 0.0 110.785 178.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.0 t -115.83 125.76 73.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.05 0.452 . . . . 0.0 111.118 -176.607 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.6 t -105.31 131.43 54.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.821 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.61 ' HG2' HD13 ' A' ' 51' ' ' ILE . 95.5 mttt -118.85 149.28 41.8 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.135 178.415 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.0 tttm -107.5 104.31 13.84 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 169.712 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 68.02 -73.89 0.08 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 123.81 0.844 . . . . 0.0 110.662 -174.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -148.4 11.85 1.17 Allowed Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 121.056 -0.592 . . . . 0.0 111.988 178.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -110.86 147.55 34.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.606 0.241 . . . . 0.0 110.805 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.61 HD13 ' HG2' ' A' ' 46' ' ' LYS . 29.6 mm -83.07 116.7 27.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.4 m -126.46 165.32 24.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.075 -175.612 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.456 HG13 ' H ' ' A' ' 55' ' ' GLU . 37.8 pt -99.83 -177.21 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.653 172.36 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.462 ' HA ' ' CG2' ' A' ' 29' ' ' ILE . 6.6 p-10 -83.18 6.54 18.98 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.087 0.47 . . . . 0.0 111.41 -173.31 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.456 ' H ' HG13 ' A' ' 53' ' ' ILE . 4.7 tp10 -95.27 0.51 53.91 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.152 -175.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -81.15 163.16 23.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.534 176.525 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.22 154.85 21.17 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.504 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 21.9 mt -103.49 143.15 15.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.065 -179.159 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -123.16 171.18 9.52 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.235 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -70.75 133.76 46.85 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.845 178.486 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.47 30.63 58.1 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.942 -0.647 . . . . 0.0 111.837 -178.83 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -98.46 162.64 13.05 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.861 0.363 . . . . 0.0 110.769 179.478 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.3 mm -127.64 125.89 66.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.92 179.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 2.9 mp -115.82 124.84 72.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 177.656 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.536 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 35.5 tt0 -110.16 113.87 26.91 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.725 0.298 . . . . 0.0 110.224 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 89.4 t -109.07 104.93 17.86 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.323 0.582 . . . . 0.0 110.352 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.525 HD11 ' HE3' ' A' ' 46' ' ' LYS . 6.3 pt -107.01 129.88 59.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.544 178.802 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.411 HH11 ' HD2' ' A' ' 68' ' ' ARG . 13.7 ptt180 -94.4 150.02 20.68 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.104 -179.132 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.2 p -90.26 128.38 42.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 120.934 0.397 . . . . 0.0 110.081 178.582 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -84.47 119.59 33.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 177.82 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -119.74 121.71 39.8 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.051 -176.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -72.89 155.53 50.96 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.238 -178.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.245 0.803 0 CA-C-O 119.069 -0.851 . . . . 0.0 111.295 -178.979 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 23.6 ttt . . . . . 0 N--CA 1.479 0.979 0 CA-C-O 120.802 0.334 . . . . 0.0 110.78 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 46.7 t -90.88 110.8 22.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 177.203 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.1 tp -98.52 121.73 49.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.224 0.535 . . . . 0.0 110.05 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.55 -178.7 17.1 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 -173.409 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.518 ' HA ' ' HB2' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -160.44 149.17 16.87 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 117.587 0.694 . . . . 0.0 112.284 179.694 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 mtpp -118.2 131.0 56.41 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.119 173.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 24.8 p90 -147.23 157.93 43.77 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.834 0.35 . . . . 0.0 110.805 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.734 HG22 HD12 ' A' ' 63' ' ' ILE . 1.3 t -116.31 140.3 49.48 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 175.637 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.469 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 6.4 p -129.13 129.12 67.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.068 0.461 . . . . 0.0 110.754 -178.4 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.732 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -92.25 119.96 40.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 172.538 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.07 -157.73 0.84 Allowed 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.722 -174.059 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.923 ' HA ' ' HD2' ' A' ' 68' ' ' ARG . 15.5 t70 -58.29 -44.59 88.55 Favored 'General case' 0 N--CA 1.464 0.259 0 C-N-CA 122.894 0.478 . . . . 0.0 111.897 -171.832 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -91.25 -10.7 40.55 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -174.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 140.46 -162.9 26.52 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.022 -1.085 . . . . 0.0 112.269 -176.542 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.556 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 36.1 tttt -104.16 120.8 41.9 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.997 0.427 . . . . 0.0 110.836 -174.489 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -121.67 162.79 20.09 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.424 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.413 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -118.52 130.44 73.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.243 0.544 . . . . 0.0 109.725 -179.01 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 98.9 mt -123.44 151.75 42.35 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.72 -176.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -137.27 129.25 29.13 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.758 -0.656 . . . . 0.0 109.528 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.3 m -130.25 154.4 47.63 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.682 0.277 . . . . 0.0 110.659 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.06 -10.91 70.84 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.735 -176.343 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.421 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -124.21 140.12 34.25 Favored Pre-proline 0 C--N 1.323 -0.58 0 O-C-N 122.718 -0.283 . . . . 0.0 110.432 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 25' ' ' ALA . 14.2 Cg_exo -69.27 107.32 1.74 Allowed 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.668 2.246 . . . . 0.0 111.101 176.146 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 29.7 mmm180 -110.13 169.62 8.61 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.93 0.395 . . . . 0.0 110.605 -176.209 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.565 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 15.1 ttm180 -103.83 160.89 14.41 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.301 178.054 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.551 HG12 ' O ' ' A' ' 56' ' ' GLU . 40.6 mm -53.81 -48.95 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.707 0.289 . . . . 0.0 110.525 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 32.9 tttp -60.41 -24.71 65.37 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.697 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -70.67 -52.36 21.69 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.955 0.407 . . . . 0.0 110.24 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 50.3 t -71.69 -41.07 70.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.374 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.53 HD21 ' HB ' ' A' ' 40' ' ' ILE . 22.0 tp -63.52 -41.49 98.49 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.215 179.253 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.39 -32.13 68.33 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.058 178.375 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.76 -42.4 98.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.068 0.461 . . . . 0.0 110.091 -179.503 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 85.3 mt -91.0 -12.38 36.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.783 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 59.95 77.63 0.31 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.131 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.441 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 68.6 mt -123.76 128.87 25.01 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.999 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.88 115.0 3.36 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.536 2.157 . . . . 0.0 112.92 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.53 ' HB ' HD21 ' A' ' 33' ' ' LEU . 11.3 tp -79.9 -6.05 9.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.803 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -67.26 -43.38 82.01 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.693 -171.242 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.578 HG23 HG13 ' A' ' 43' ' ' VAL . 8.8 t -92.37 -20.55 20.95 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 113.881 1.067 . . . . 0.0 113.881 -165.542 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.578 HG13 HG23 ' A' ' 42' ' ' THR . 34.3 m -117.95 163.46 15.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.165 -0.614 . . . . 0.0 111.398 -177.804 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -103.29 139.45 24.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.85 -173.128 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.55 HG22 HG22 ' A' ' 66' ' ' VAL . 89.4 t -120.39 136.53 57.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.939 0.4 . . . . 0.0 110.584 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.603 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 98.1 mttt -128.4 149.62 50.47 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.538 178.483 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.8 ' HE2' ' HB3' ' A' ' 56' ' ' GLU . 52.4 mttm -95.27 100.46 12.24 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.822 -0.806 . . . . 0.0 108.822 167.565 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 66.88 -32.54 0.19 Allowed 'General case' 0 N--CA 1.471 0.609 0 O-C-N 123.953 0.783 . . . . 0.0 111.895 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.517 ' H ' ' C ' ' A' ' 47' ' ' LYS . . . 178.74 -21.5 0.04 OUTLIER Glycine 0 CA--C 1.522 0.511 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.091 -178.34 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -85.85 127.37 34.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.936 0.368 . . . . 0.0 110.419 -178.344 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.488 ' H ' HD12 ' A' ' 51' ' ' ILE . 3.7 mp -64.82 123.72 18.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 120.64 0.257 . . . . 0.0 110.548 -178.149 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.827 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 27.6 m -130.57 178.76 4.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.091 -177.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 29.6 pt -118.04 -174.5 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.323 177.444 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.457 ' O ' ' HB ' ' A' ' 29' ' ' ILE . 9.4 p-10 -75.08 -14.58 60.6 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -176.558 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -84.9 9.33 14.65 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -178.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.827 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 35.0 mm-40 -85.15 137.15 33.2 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.87 0.367 . . . . 0.0 110.731 176.433 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.565 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.1 mp0 -76.96 156.28 32.07 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.406 -179.11 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 58.0 mt -98.26 124.59 51.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -113.46 154.06 27.63 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.581 -178.004 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.518 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 19.1 t70 -69.11 124.58 24.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.825 178.363 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.46 4.59 70.5 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.845 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -94.01 156.88 16.37 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.734 HD12 HG22 ' A' ' 11' ' ' THR . 47.6 mm -121.73 123.33 69.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 120.776 0.322 . . . . 0.0 110.421 -173.329 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.469 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.2 mm -99.98 107.97 21.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.16 0.505 . . . . 0.0 110.377 -178.304 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.732 ' HA ' HG22 ' A' ' 13' ' ' ILE . 6.3 mm-40 -100.11 97.21 8.06 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.006 -177.446 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.55 HG22 HG22 ' A' ' 45' ' ' VAL . 85.7 t -95.68 106.1 17.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.447 0.641 . . . . 0.0 110.031 177.147 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.2 mt -92.29 99.77 10.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.748 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.923 ' HD2' ' HA ' ' A' ' 15' ' ' ASP . 9.2 ptm180 -75.37 123.12 24.82 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 176.884 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 26.8 m -85.51 139.32 17.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-O 120.875 0.369 . . . . 0.0 110.58 -178.227 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 8.3 tt -80.75 103.94 8.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.561 0.696 . . . . 0.0 110.188 177.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -98.85 111.29 23.73 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.864 -177.04 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -141.25 126.3 3.02 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.27 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.879 0 CA-C-O 118.913 -0.937 . . . . 0.0 111.968 178.09 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 53.8 ttm . . . . . 0 N--CA 1.481 1.089 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 58.8 t -82.63 104.67 11.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 121.2 0.524 . . . . 0.0 109.728 179.369 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 9.6 tp -94.77 141.41 15.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.435 178.571 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 79.8 -178.12 53.94 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.314 -175.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 25.4 ptt? -160.67 137.85 9.16 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 120.961 0.41 . . . . 0.0 111.094 -178.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.678 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 53.6 mtmt -112.15 110.01 20.03 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 169.13 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 29.2 p90 -122.7 157.12 32.98 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.409 -175.439 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.526 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 7.8 m -113.96 117.82 32.42 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.426 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.1 p -102.51 123.45 55.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-O 121.282 0.563 . . . . 0.0 109.906 178.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.473 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -95.68 122.6 47.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -179.655 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.48 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.7 OUTLIER -127.5 175.58 8.13 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.342 -0.845 . . . . 0.0 109.266 -178.609 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.48 ' H ' HG22 ' A' ' 14' ' ' THR . 13.0 p-10 -67.94 -17.7 64.53 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 111.654 0.242 . . . . 0.0 111.654 -176.7 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -91.3 -7.92 49.69 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.891 0.376 . . . . 0.0 110.891 179.115 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 141.05 -179.09 19.67 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.147 179.394 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 36.7 ttmt -100.73 110.41 22.51 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.172 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 8.6 mtpp -107.36 114.6 28.73 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.386 -170.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.526 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -82.9 120.58 34.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 173.324 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 95.3 mt -118.63 146.21 44.84 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.374 -177.257 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.678 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.2 OUTLIER -121.6 141.01 51.51 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.148 0.499 . . . . 0.0 110.842 177.667 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.1 t -135.94 147.04 47.91 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.496 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -76.14 -9.79 85.44 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.679 -179.34 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -136.81 146.06 53.55 Favored Pre-proline 0 C--N 1.326 -0.422 0 O-C-N 122.831 -0.217 . . . . 0.0 110.618 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -63.49 131.37 31.5 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.349 2.033 . . . . 0.0 111.307 176.107 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.528 ' HD2' ' HB3' ' A' ' 31' ' ' ASP . 15.9 tpp180 -123.39 155.51 37.24 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.004 -175.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.569 ' HG2' ' HA ' ' A' ' 57' ' ' GLU . 96.8 mtt180 -104.18 165.01 11.33 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.765 -0.198 . . . . 0.0 110.715 178.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 45.6 mm -54.8 -55.78 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.974 -175.03 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.531 ' HB3' ' NZ ' ' A' ' 30' ' ' LYS . 2.8 ttpm? -53.15 -39.95 63.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.138 0.494 . . . . 0.0 110.959 179.373 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.528 ' HB3' ' HD2' ' A' ' 27' ' ' ARG . 3.1 m-20 -64.61 -52.44 57.49 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.951 -176.334 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.0 t -62.98 -47.46 92.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.099 0.476 . . . . 0.0 110.713 178.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 14.5 tp -64.7 -38.46 91.06 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.603 -177.483 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.12 -42.61 66.94 Favored Glycine 0 N--CA 1.447 -0.572 0 CA-C-N 115.492 -0.776 . . . . 0.0 113.108 -179.095 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -68.04 -31.56 71.3 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.903 0.351 . . . . 0.0 111.263 -178.734 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 97.1 mt -83.0 -4.05 57.89 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.921 0.391 . . . . 0.0 110.292 176.232 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 55.14 61.81 2.76 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.931 -178.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 62.0 mt -116.98 114.44 39.15 Favored Pre-proline 0 C--N 1.323 -0.577 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.488 175.192 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.425 ' O ' HG22 ' A' ' 42' ' ' THR . 32.4 Cg_exo -59.57 113.15 1.49 Allowed 'Trans proline' 0 N--CA 1.464 -0.21 0 C-N-CA 122.76 2.306 . . . . 0.0 112.558 -178.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 14.6 tt -63.01 -20.23 25.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 121.383 0.611 . . . . 0.0 110.589 178.608 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -63.62 -29.96 71.14 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.152 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.425 HG22 ' O ' ' A' ' 39' ' ' PRO . 3.6 t -108.4 4.98 24.97 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-O 120.914 0.388 . . . . 0.0 111.665 -170.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.3 m -136.54 164.57 30.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.14 0.495 . . . . 0.0 111.466 -179.378 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 56.7 t -123.26 129.28 74.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.499 176.235 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.0 t -107.3 130.87 58.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 121.283 0.563 . . . . 0.0 111.536 -175.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.831 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 96.3 mttt -117.8 131.88 56.52 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.311 176.274 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.489 ' HB2' HG21 ' A' ' 52' ' ' VAL . 65.0 tttp -93.07 106.29 18.27 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 174.46 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.546 ' HA ' ' HB ' ' A' ' 63' ' ' ILE . 12.5 t-20 68.94 -66.06 0.26 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.064 -177.122 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -159.2 17.23 0.25 Allowed Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.809 -0.516 . . . . 0.0 111.809 179.034 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -131.19 131.27 43.88 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 -177.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.5 mt -64.02 128.86 27.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 176.068 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.767 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 19.6 m -132.94 178.75 5.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.933 0.397 . . . . 0.0 111.864 -173.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 32.8 pt -88.89 172.73 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.882 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.509 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 6.6 p-10 -76.4 -20.72 56.84 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.326 -176.256 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 68.5 tt0 -85.43 4.99 32.99 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.04 0.448 . . . . 0.0 110.719 -178.056 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.767 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 7.5 mm-40 -72.44 129.89 39.41 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.122 0.487 . . . . 0.0 111.226 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.569 ' HA ' ' HG2' ' A' ' 28' ' ' ARG . 4.7 pt-20 -86.87 140.69 29.4 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.423 179.3 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.456 HG23 HD11 ' A' ' 64' ' ' ILE . 12.0 mt -92.11 150.82 3.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.218 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -124.6 164.65 19.39 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.035 0.445 . . . . 0.0 110.702 -177.355 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -67.6 128.06 35.07 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.373 176.301 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.49 12.02 79.05 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.114 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -96.99 161.79 13.68 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 178.836 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.546 ' HB ' ' HA ' ' A' ' 48' ' ' ASN . 46.4 mm -115.38 138.96 44.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.037 -176.089 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.475 HG22 HG23 ' A' ' 66' ' ' VAL . 49.8 mm -118.29 118.6 58.62 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 176.428 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.831 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 42.7 tt0 -107.5 107.54 18.44 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.475 HG23 HG22 ' A' ' 64' ' ' ILE . 86.0 t -111.99 109.56 28.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.204 0.526 . . . . 0.0 110.51 -179.355 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -114.02 139.0 42.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.445 HH11 ' HD3' ' A' ' 68' ' ' ARG . 35.0 mtm-85 -67.73 154.91 40.48 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 174.377 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.1 p -81.95 136.28 23.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-O 121.656 0.741 . . . . 0.0 111.52 -170.786 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -98.45 126.32 51.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.111 -0.949 . . . . 0.0 108.803 174.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 16.1 p90 -124.17 139.94 53.44 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.795 -176.557 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.62 118.12 5.13 Favored Glycine 0 N--CA 1.445 -0.716 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.993 179.267 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.025 0 CA-C-O 118.174 -1.348 . . . . 0.0 111.104 178.922 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 24.5 ttt . . . . . 0 N--CA 1.481 1.112 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 8.8 p -89.69 131.66 36.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.099 0.476 . . . . 0.0 111.09 -178.156 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 65.4 mt -119.06 124.88 73.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 176.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 97.63 67.04 0.91 Allowed Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.452 -0.88 . . . . 0.0 111.404 -177.215 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.41 ' HB2' ' HA ' ' A' ' 60' ' ' ASP . 26.1 ptt? -87.4 149.95 24.13 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.643 -0.278 . . . . 0.0 111.089 -174.415 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.55 ' HD3' ' OD1' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -129.68 128.96 43.62 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 168.808 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -125.44 153.17 43.88 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -177.593 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.56 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.8 m -109.81 117.67 34.48 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.176 -179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.552 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 3.1 p -112.23 123.41 67.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.458 -178.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.608 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -88.06 121.02 37.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 177.769 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.92 -162.05 1.14 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.747 -174.264 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -61.96 -45.92 91.54 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 112.202 0.445 . . . . 0.0 112.202 -171.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -87.74 -0.82 57.44 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 111.999 0.37 . . . . 0.0 111.999 -175.526 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 137.12 -164.73 25.27 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.128 -1.034 . . . . 0.0 112.653 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.589 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.0 ttpt -92.23 116.76 29.24 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.035 0.445 . . . . 0.0 110.212 -177.524 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 41.4 tptt -115.2 113.3 23.74 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.996 -172.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.56 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -84.32 120.54 35.27 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 CA-C-O 121.69 0.757 . . . . 0.0 109.795 174.175 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 97.4 mt -116.02 136.59 52.89 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.24 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.528 ' HG3' ' HB3' ' A' ' 9' ' ' LYS . 39.3 tt0 -113.5 139.49 48.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.275 -0.42 . . . . 0.0 109.974 179.679 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.2 t -132.92 132.91 42.56 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 178.575 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -66.46 -15.1 63.27 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 121.157 -0.544 . . . . 0.0 113.401 -175.428 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -133.9 142.32 43.06 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.896 0.348 . . . . 0.0 110.805 -178.605 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -54.43 133.95 58.96 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.465 2.11 . . . . 0.0 110.845 173.665 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.465 ' HG3' ' CB ' ' A' ' 31' ' ' ASP . 0.1 OUTLIER -132.56 156.21 47.26 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.487 -168.071 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.448 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 10.2 ttt85 -92.69 158.66 15.82 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 174.192 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 40.8 mm -59.96 -36.94 70.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.126 0.489 . . . . 0.0 109.814 176.061 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -67.21 -19.83 65.61 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.756 -177.041 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.465 ' CB ' ' HG3' ' A' ' 27' ' ' ARG . 3.2 m-20 -65.64 -61.8 1.88 Allowed 'General case' 0 CA--C 1.517 -0.312 0 CA-C-O 121.186 0.517 . . . . 0.0 109.766 173.73 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.5 t -59.7 -42.19 87.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.326 179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.589 HD21 ' HB ' ' A' ' 40' ' ' ILE . 1.2 tm? -63.94 -47.6 79.82 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.759 -178.445 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.21 -47.43 36.87 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 116.049 -0.523 . . . . 0.0 113.608 -174.595 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.4 mm-40 -73.26 -37.16 66.4 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -173.417 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 79.9 mt -87.64 -13.73 41.9 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.979 -0.288 . . . . 0.0 111.029 -179.094 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 58.97 77.77 0.29 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.598 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.576 ' HB ' HD22 ' A' ' 33' ' ' LEU . 65.1 mt -118.75 133.21 23.63 Favored Pre-proline 0 C--N 1.319 -0.731 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.51 -179.572 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 29.6 Cg_exo -62.83 100.49 0.24 Allowed 'Trans proline' 0 CA--C 1.529 0.252 0 C-N-CA 122.562 2.174 . . . . 0.0 112.401 178.525 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.589 ' HB ' HD21 ' A' ' 33' ' ' LEU . 8.2 tp -85.74 -25.13 6.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.549 -177.753 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 18.3 tp10 -76.06 -20.55 57.64 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.964 -173.084 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.531 HG23 HG13 ' A' ' 43' ' ' VAL . 12.9 t -109.1 -10.82 14.99 Favored 'General case' 0 CA--C 1.534 0.365 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 -170.704 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.531 HG13 HG23 ' A' ' 42' ' ' THR . 25.9 m -122.35 158.54 26.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.049 -179.424 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.0 t -94.98 113.12 28.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.037 -175.65 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 90.4 t -102.83 131.17 51.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.057 0.455 . . . . 0.0 110.439 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.737 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 97.9 mttt -117.28 126.39 52.65 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.948 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.504 ' HB3' HG11 ' A' ' 52' ' ' VAL . 71.1 tttt -96.82 106.06 18.3 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.362 175.655 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 71.08 -53.24 0.68 Allowed 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 123.947 0.899 . . . . 0.0 110.861 -177.331 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.49 21.49 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.077 178.292 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLN . . . . . 0.592 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 18.6 mm-40 -125.18 143.62 50.85 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.421 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.2 mp -74.61 113.76 13.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 176.388 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.745 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 35.6 m -124.9 178.47 3.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-O 121.14 0.495 . . . . 0.0 111.834 -173.312 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.447 HG13 ' H ' ' A' ' 55' ' ' GLU . 23.8 pt -123.22 -171.31 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.597 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -70.08 -12.74 61.82 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.087 -0.506 . . . . 0.0 112.056 -176.367 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.447 ' H ' HG13 ' A' ' 53' ' ' ILE . 7.5 tp10 -81.91 -8.51 59.68 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.522 -174.169 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.745 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 22.0 mm-40 -81.49 163.2 22.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.002 0.43 . . . . 0.0 111.97 -176.445 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.448 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 0.0 OUTLIER -103.15 159.24 15.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.169 177.468 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 17.9 mt -103.85 154.48 5.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.025 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -128.49 168.41 15.7 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.924 0.392 . . . . 0.0 110.857 -177.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.55 ' OD1' ' HD3' ' A' ' 9' ' ' LYS . 30.8 t70 -81.12 129.42 34.56 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.854 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.04 26.58 72.12 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 121.076 -0.583 . . . . 0.0 111.935 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -97.33 160.97 14.02 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.962 0.411 . . . . 0.0 110.823 -178.055 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 31.3 mm -111.01 113.4 44.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.418 -175.304 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.552 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.1 mm -102.3 109.4 26.25 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.737 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 38.8 tt0 -99.65 99.99 10.92 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.223 -178.735 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 92.3 t -100.37 103.1 14.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.46 0.647 . . . . 0.0 110.522 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 24.2 mt -91.89 99.24 9.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.481 179.342 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.459 ' O ' ' HD2' ' A' ' 68' ' ' ARG . 0.1 OUTLIER -63.44 151.38 41.26 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.624 175.582 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -82.56 113.34 21.67 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-O 121.522 0.677 . . . . 0.0 111.878 -170.16 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -90.65 101.72 12.66 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.725 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 169.483 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 22.3 t80 -90.97 110.6 21.86 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.452 -173.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -118.52 115.58 3.16 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.838 -0.696 . . . . 0.0 111.931 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.173 0 CA-C-O 118.544 -1.142 . . . . 0.0 111.591 178.464 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 48.7 ttm . . . . . 0 N--CA 1.483 1.203 0 CA-C-O 120.707 0.289 . . . . 0.0 110.839 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.6 t -108.24 106.01 19.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.525 175.546 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 pt -107.27 122.43 61.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 121.194 0.521 . . . . 0.0 109.747 175.175 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 113.16 93.94 2.09 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -170.396 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.417 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.5 ptt? -106.1 144.72 32.41 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.38 0.609 . . . . 0.0 112.293 -165.76 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.521 ' HG2' ' OD1' ' A' ' 60' ' ' ASP . 23.8 pttm -107.06 141.45 38.28 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.289 -0.869 . . . . 0.0 108.911 168.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 31.1 p90 -156.72 147.96 22.2 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.853 0.359 . . . . 0.0 110.163 178.285 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.623 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 9.5 t -112.41 138.01 49.76 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.15 0.5 . . . . 0.0 110.225 178.308 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.762 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.7 p -126.9 134.54 65.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.966 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.669 HG22 ' HA ' ' A' ' 65' ' ' GLU . 8.1 tt -88.19 124.85 41.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.944 174.454 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.411 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.7 OUTLIER -116.68 174.18 6.22 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.138 -0.937 . . . . 0.0 108.542 177.176 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.411 ' H ' HG22 ' A' ' 14' ' ' THR . 25.6 t70 -58.4 -34.17 70.44 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.25 0.548 . . . . 0.0 110.719 178.839 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -77.07 -10.79 59.61 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.698 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 136.39 176.76 14.54 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.414 -0.898 . . . . 0.0 112.783 178.579 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.641 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 45.4 tttt -96.43 116.64 29.38 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 6.6 mtpm? -129.65 147.87 51.49 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.845 -175.389 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.623 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -111.15 131.23 62.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -177.388 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.456 ' N ' HD13 ' A' ' 20' ' ' ILE . 2.0 pt? -134.8 165.1 26.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.751 0.31 . . . . 0.0 111.084 -175.742 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -112.44 150.6 30.94 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.337 -179.299 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.4 t -136.03 134.62 38.69 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 175.002 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.06 -44.94 95.1 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 121.26 -0.495 . . . . 0.0 113.153 -176.141 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -110.88 146.56 34.68 Favored Pre-proline 0 C--N 1.321 -0.637 0 O-C-N 122.625 -0.338 . . . . 0.0 110.741 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.417 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 25.0 Cg_exo -63.72 119.82 7.01 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.682 2.255 . . . . 0.0 111.2 175.282 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.414 ' HE ' ' CG ' ' A' ' 31' ' ' ASP . 17.2 mmm180 -115.0 177.18 4.74 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.729 -174.333 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 54.8 ttm-85 -108.38 159.97 16.24 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.4 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.505 HD11 ' HE2' ' A' ' 47' ' ' LYS . 38.0 mm -56.87 -48.76 80.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.913 0.387 . . . . 0.0 110.392 176.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.5 tptm -59.6 -28.04 66.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.186 178.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.414 ' CG ' ' HE ' ' A' ' 27' ' ' ARG . 30.0 t70 -65.15 -62.09 1.75 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.849 0.356 . . . . 0.0 110.475 178.637 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.3 t -59.89 -42.94 90.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.704 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.513 HD21 ' HB ' ' A' ' 40' ' ' ILE . 24.0 tp -64.65 -43.45 93.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.811 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.22 -40.21 71.06 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.917 -0.583 . . . . 0.0 112.753 -177.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.5 mm-40 -62.5 -38.71 90.97 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.914 0.388 . . . . 0.0 110.964 178.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.1 mt -83.87 -10.96 57.63 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.505 179.333 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 54.08 61.54 3.01 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.669 -177.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.449 ' HB ' HD12 ' A' ' 33' ' ' LEU . 69.2 mt -106.6 115.33 60.81 Favored Pre-proline 0 C--N 1.32 -0.704 0 CA-C-N 115.868 -0.605 . . . . 0.0 109.68 176.381 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -56.81 113.3 1.41 Allowed 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.695 2.263 . . . . 0.0 112.406 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.521 HD12 ' HB3' ' A' ' 54' ' ' ASP . 15.0 tt -72.7 -6.54 8.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.485 0.659 . . . . 0.0 110.819 -178.514 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -67.83 -29.28 68.4 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.998 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.534 HG23 HG13 ' A' ' 43' ' ' VAL . 9.3 t -106.44 0.05 24.49 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.734 -173.754 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.557 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 34.3 m -132.29 156.26 42.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.021 0.439 . . . . 0.0 111.46 -177.322 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.586 HG23 ' HB ' ' A' ' 69' ' ' VAL . 59.0 t -113.8 139.67 38.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.383 176.16 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.43 HG11 HG21 ' A' ' 29' ' ' ILE . 37.1 t -102.98 127.42 56.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.032 0.444 . . . . 0.0 110.218 -179.258 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.618 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 41.1 mttm -124.75 145.02 49.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.401 -178.081 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.582 ' HG2' HG21 ' A' ' 52' ' ' VAL . 28.8 mmtp -112.15 102.41 10.6 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 169.863 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.9 m120 56.05 24.55 7.93 Favored 'General case' 0 N--CA 1.465 0.323 0 O-C-N 123.451 0.469 . . . . 0.0 111.598 -178.054 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 115.95 -21.04 12.59 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.921 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 17.0 mm-40 -85.3 132.28 34.28 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.772 0.32 . . . . 0.0 110.833 -176.187 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.3 mp -73.99 116.76 16.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.957 0.408 . . . . 0.0 110.294 -179.39 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.906 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 29.3 m -123.63 173.94 8.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.673 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 28.1 pt -101.52 175.3 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.572 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.521 ' HB3' HD12 ' A' ' 40' ' ' ILE . 9.5 p-10 -74.53 -15.52 60.86 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.552 -177.437 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.1 tt0 -81.62 -5.08 57.71 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.823 0.344 . . . . 0.0 110.9 -178.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.906 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 17.2 mm-40 -69.16 142.3 54.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.824 0.345 . . . . 0.0 110.944 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 51.1 mp0 -79.9 166.52 21.57 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.562 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.517 HG23 HD11 ' A' ' 64' ' ' ILE . 55.2 mt -112.45 139.25 38.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 175.355 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 80.3 m-85 -124.18 162.24 24.04 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.778 0.323 . . . . 0.0 110.695 -176.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.521 ' OD1' ' HG2' ' A' ' 9' ' ' LYS . 21.6 t70 -71.77 117.33 13.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.329 177.556 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.53 -9.56 60.71 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 -179.106 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -78.09 143.83 37.04 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.493 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.563 HG23 HG23 ' A' ' 11' ' ' THR . 45.1 mt -115.35 118.5 58.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-O 121.23 0.538 . . . . 0.0 111.126 -173.42 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.762 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 4.0 mp -101.7 130.91 50.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.623 -178.47 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.669 ' HA ' HG22 ' A' ' 13' ' ' ILE . 53.0 mt-10 -120.64 118.53 30.38 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 178.647 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 62.0 t -114.06 102.79 14.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.129 0.49 . . . . 0.0 110.235 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.08 137.95 51.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 -179.01 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.557 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 76.0 mtp180 -65.43 138.96 58.46 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.976 0.417 . . . . 0.0 110.717 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.586 ' HB ' HG23 ' A' ' 44' ' ' VAL . 14.9 p -84.0 148.29 5.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.01 -174.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 5.3 tp -78.47 102.04 4.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.777 0.798 . . . . 0.0 110.085 176.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 28.3 p90 -73.23 153.98 40.41 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.687 179.546 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -84.92 53.85 4.86 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.928 -0.653 . . . . 0.0 111.932 178.77 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.594 -1.114 . . . . 0.0 111.759 -178.635 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 0.979 0 CA-C-O 120.752 0.311 . . . . 0.0 110.189 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.6 p -83.61 119.78 33.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.335 0.588 . . . . 0.0 110.48 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 60.0 mt -96.48 122.25 47.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.013 -179.208 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.99 -179.54 16.53 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.446 -178.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.496 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 25.5 ptt? -156.07 137.91 14.36 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.032 0.444 . . . . 0.0 110.887 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.402 ' HE3' ' HB2' ' A' ' 22' ' ' GLU . 30.4 tttt -123.72 114.58 20.12 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 174.462 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -127.98 167.99 15.9 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.283 -173.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.458 ' HB ' HD13 ' A' ' 20' ' ' ILE . 12.9 t -115.42 138.51 50.93 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.922 0.391 . . . . 0.0 110.318 178.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.4 p -128.41 136.79 59.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.099 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.585 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -107.98 124.85 64.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.3 0.571 . . . . 0.0 109.815 177.785 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.7 p -129.15 -163.03 1.25 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.238 -179.038 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -67.57 -24.36 65.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.024 0.44 . . . . 0.0 110.664 178.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -82.69 -11.5 58.29 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.393 0.616 . . . . 0.0 110.48 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 115.93 -167.65 12.49 Favored Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.419 -176.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.585 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 33.1 ttpt -98.99 127.87 45.0 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -177.599 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.457 ' HE3' ' HB2' ' A' ' 19' ' ' LYS . 29.9 ttmt -137.57 164.26 29.19 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.482 -174.417 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.458 HD13 ' HB ' ' A' ' 11' ' ' THR . 34.3 mm -98.38 126.44 51.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.7 0.286 . . . . 0.0 111.015 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.446 HD13 HG12 ' A' ' 12' ' ' VAL . 6.9 mp -111.51 144.44 40.73 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.192 176.443 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.402 ' HB2' ' HE3' ' A' ' 9' ' ' LYS . 40.6 tt0 -127.25 134.88 50.02 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.146 -177.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.0 t -134.19 143.79 48.08 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 177.017 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.6 -18.38 75.58 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 121.234 -0.508 . . . . 0.0 113.246 -176.429 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -139.07 151.14 67.26 Favored Pre-proline 0 C--N 1.324 -0.539 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.496 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 25.0 Cg_exo -63.96 119.53 6.61 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.394 2.063 . . . . 0.0 111.234 174.417 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.421 ' HB3' ' CB ' ' A' ' 31' ' ' ASP . 50.9 mmm-85 -116.6 157.66 24.96 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.191 -175.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.625 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 23.4 mtt180 -82.08 167.35 18.88 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 172.044 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.547 ' HB ' ' HA ' ' A' ' 54' ' ' ASP . 48.9 mm -61.14 -35.16 63.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 168.363 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 40.7 tptt -61.37 -33.92 74.45 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 114.662 -1.154 . . . . 0.0 110.822 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.421 ' CB ' ' HB3' ' A' ' 27' ' ' ARG . 4.5 m-20 -65.87 -58.48 5.49 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.317 177.659 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 58.6 t -59.43 -53.04 53.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.329 -176.332 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.573 ' HG ' ' HB ' ' A' ' 38' ' ' ILE . 10.7 mp -71.82 -35.88 70.06 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.367 -176.755 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.83 -43.6 58.36 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.662 179.63 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -73.09 -33.04 65.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.023 0.439 . . . . 0.0 111.154 -175.101 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.0 mt -97.35 -5.99 35.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.449 -0.342 . . . . 0.0 111.511 -178.539 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 62.23 75.18 0.41 Allowed 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.684 0.754 . . . . 0.0 110.717 -176.681 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.573 ' HB ' ' HG ' ' A' ' 33' ' ' LEU . 67.4 mt -123.66 116.27 27.93 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.756 178.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 17.1 Cg_exo -67.04 109.64 1.77 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.658 2.238 . . . . 0.0 112.906 -178.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.444 ' HB ' HD23 ' A' ' 33' ' ' LEU . 9.9 tt -81.59 -5.74 9.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 122.009 0.909 . . . . 0.0 109.203 176.275 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -69.84 -31.64 69.6 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.855 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.58 HG23 HG13 ' A' ' 43' ' ' VAL . 4.6 t -96.14 -36.95 10.79 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.71 0.633 . . . . 0.0 112.71 -172.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.58 HG13 HG23 ' A' ' 42' ' ' THR . 21.3 m -116.56 162.61 14.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 C-N-CA 120.888 -0.325 . . . . 0.0 111.069 -175.745 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.9 t -102.93 131.93 50.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 120.855 0.36 . . . . 0.0 111.671 -173.119 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.0 t -103.65 130.5 54.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.938 176.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.639 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 92.5 mttt -118.81 143.61 46.83 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.842 0.353 . . . . 0.0 111.442 179.451 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.774 ' HG2' HG21 ' A' ' 52' ' ' VAL . 10.0 mmtp -100.57 102.2 13.3 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 170.273 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 65.49 -1.01 1.06 Allowed 'General case' 0 CA--C 1.541 0.619 0 O-C-N 123.426 0.454 . . . . 0.0 111.512 178.678 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 132.2 -10.64 5.34 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 121.107 -0.568 . . . . 0.0 111.907 -176.513 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLN . . . . . 0.428 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 14.6 mm100 -87.07 128.1 35.11 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 122.045 0.138 . . . . 0.0 110.664 178.735 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.404 ' H ' HD12 ' A' ' 51' ' ' ILE . 3.8 mp -71.32 114.85 10.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.037 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.774 HG21 ' HG2' ' A' ' 47' ' ' LYS . 28.1 m -125.77 178.79 3.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.117 0.484 . . . . 0.0 111.52 -174.591 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.44 HG13 ' H ' ' A' ' 55' ' ' GLU . 24.7 pt -115.09 -170.92 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.348 177.263 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.547 ' HA ' ' HB ' ' A' ' 29' ' ' ILE . 35.1 p-10 -77.49 -7.19 55.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.656 -175.774 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.44 ' H ' HG13 ' A' ' 53' ' ' ILE . 7.5 tp10 -72.79 -22.16 60.88 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.918 -179.429 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.565 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 8.0 mm-40 -69.11 135.71 51.14 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.497 0.554 . . . . 0.0 112.497 -174.379 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.625 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 58.1 mp0 -82.38 144.2 30.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.914 173.315 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 30.9 mt -91.21 142.34 13.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 176.604 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -119.4 162.2 19.22 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.856 0.36 . . . . 0.0 110.75 -177.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -69.06 131.14 44.55 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.599 173.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.59 23.51 75.07 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.924 -177.515 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 31.2 t0 -97.4 154.04 17.72 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 178.046 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.447 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.0 mp -110.21 116.78 53.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-O 121.03 0.443 . . . . 0.0 110.525 -177.618 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 41.5 mm -103.55 108.84 25.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.899 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.639 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 44.5 mt-10 -102.22 107.16 18.13 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 178.205 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 93.4 t -97.05 102.45 13.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.38 0.609 . . . . 0.0 109.681 178.348 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 64.0 mt -96.36 105.88 17.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.406 -177.302 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.488 ' HA ' ' CG1' ' A' ' 43' ' ' VAL . 0.6 OUTLIER -75.92 131.48 39.65 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.521 174.641 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 34.9 m -83.31 149.66 4.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.715 -177.31 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 9.4 tt -77.33 112.23 15.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.527 0.679 . . . . 0.0 109.892 178.236 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 48.8 t80 -89.33 -25.62 21.52 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.824 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 122.85 -177.03 16.59 Favored Glycine 0 N--CA 1.444 -0.805 0 CA-C-N 115.441 -0.8 . . . . 0.0 111.876 178.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.86 0 CA-C-O 119.022 -0.877 . . . . 0.0 111.073 178.928 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 13.7 tpt . . . . . 0 N--CA 1.477 0.898 0 CA-C-O 120.647 0.26 . . . . 0.0 110.32 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.7 t -108.32 122.3 62.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.067 178.178 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.437 ' N ' HD12 ' A' ' 6' ' ' ILE . 3.2 mp -97.15 121.92 48.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 178.264 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.33 179.96 45.16 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.14 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.543 ' HA ' ' OD1' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -159.91 158.07 30.15 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.762 0.315 . . . . 0.0 110.221 178.701 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.601 ' HB2' HD11 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -133.79 145.78 50.08 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 173.32 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.5 ' CD2' HD13 ' A' ' 64' ' ' ILE . 38.4 p90 -144.41 141.06 29.39 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.388 -178.507 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.643 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 18.0 m -95.39 118.35 31.98 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.079 0.466 . . . . 0.0 110.06 177.114 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.2 p -107.33 134.17 49.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.955 -179.666 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.496 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -103.76 127.48 57.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 121.528 0.68 . . . . 0.0 109.6 177.647 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 16.7 m -141.81 166.86 23.58 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.12 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.5 m-20 -63.73 -17.77 63.35 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.868 0.366 . . . . 0.0 111.076 177.223 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -77.73 -10.98 59.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.335 0.588 . . . . 0.0 110.132 175.083 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 129.44 157.87 9.32 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 112.124 179.225 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.441 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.9 ttmt -86.1 109.96 19.21 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 173.61 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -129.14 131.86 47.26 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.271 -173.053 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.643 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -81.84 124.3 38.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.397 0.618 . . . . 0.0 110.042 176.042 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.47 HD13 ' N ' ' A' ' 22' ' ' GLU . 1.1 tm? -106.81 135.28 48.62 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -178.367 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.47 ' N ' HD13 ' A' ' 21' ' ' LEU . 4.9 tm-20 -115.36 131.53 56.9 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -177.018 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.2 m -135.4 126.64 28.24 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.83 0.348 . . . . 0.0 110.787 -179.288 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -72.0 -17.57 77.16 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.079 178.271 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -118.77 121.72 30.43 Favored Pre-proline 0 C--N 1.321 -0.665 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 176.757 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_exo -48.61 139.13 24.21 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.138 2.559 . . . . 0.0 111.729 177.65 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.571 ' HG3' ' HB2' ' A' ' 31' ' ' ASP . 1.9 tpp85 -133.51 147.48 51.62 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.761 0.315 . . . . 0.0 111.122 -170.576 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.555 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 40.0 ttm105 -91.57 161.1 15.08 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 176.108 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 33.8 mm -58.95 -51.12 76.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 110.376 -0.231 . . . . 0.0 110.376 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.4 tttp -54.83 -36.03 64.59 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.891 176.706 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.571 ' HB2' ' HG3' ' A' ' 27' ' ' ARG . 22.7 m-20 -61.38 -58.45 8.18 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.145 179.177 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.7 t -60.56 -43.17 93.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.086 0.469 . . . . 0.0 110.672 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.642 HD21 ' HB ' ' A' ' 40' ' ' ILE . 9.3 tp -61.55 -48.18 82.16 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.731 -179.496 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.88 -38.77 60.24 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.531 -0.759 . . . . 0.0 113.036 -178.589 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -68.15 -41.74 81.13 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 122.526 0.33 . . . . 0.0 111.48 -176.295 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.1 mt -89.82 0.34 57.09 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.707 0.289 . . . . 0.0 110.9 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 53.75 65.79 1.41 Allowed 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.753 -178.171 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.586 ' HB ' HD12 ' A' ' 33' ' ' LEU . 63.2 mt -102.63 121.81 48.34 Favored Pre-proline 0 C--N 1.318 -0.798 0 CA-C-N 115.256 -0.883 . . . . 0.0 109.32 177.671 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 13.8 Cg_exo -68.74 102.53 0.88 Allowed 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.612 2.208 . . . . 0.0 112.492 -178.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.642 ' HB ' HD21 ' A' ' 33' ' ' LEU . 13.2 tt -71.24 -6.51 7.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.736 0.779 . . . . 0.0 109.835 177.034 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 -59.74 -31.77 69.95 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.248 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 12.0 t -130.35 12.01 5.45 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.001 0.429 . . . . 0.0 111.805 -171.542 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.561 HG12 ' HG2' ' A' ' 68' ' ' ARG . 29.9 m -128.51 144.35 38.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 O-C-N 121.707 -0.621 . . . . 0.0 111.524 -179.298 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.0 t -109.57 131.14 61.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.09 177.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.1 t -103.1 128.49 56.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.032 0.444 . . . . 0.0 110.501 -177.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.58 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 53.3 mttp -123.18 133.39 54.24 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.257 179.372 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.635 ' HG2' HG21 ' A' ' 52' ' ' VAL . 21.5 mmtp -95.02 105.97 17.93 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 171.365 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 18.0 m120 59.52 21.09 9.57 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.361 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 110.51 -17.67 28.16 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.731 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -87.6 131.61 34.36 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 122.636 -0.332 . . . . 0.0 110.827 -177.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.51 ' H ' HD12 ' A' ' 51' ' ' ILE . 4.2 mp -67.25 122.08 17.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.994 179.684 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 1.148 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 20.5 m -123.65 178.99 2.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.952 -173.865 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 41.4 pt -113.52 174.66 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.377 0.608 . . . . 0.0 112.626 -171.597 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -53.33 -39.5 64.14 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.31 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.4 ' HG2' ' O ' ' A' ' 55' ' ' GLU . 38.4 tt0 -82.68 0.31 43.85 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -172.332 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 1.148 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 15.6 mm-40 -61.33 133.18 55.57 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.825 0.345 . . . . 0.0 111.023 178.426 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.555 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 31.2 mt-10 -101.92 150.15 23.49 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.374 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 48.7 mt -100.59 126.89 54.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.259 -177.759 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -108.58 171.52 7.37 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.439 -178.113 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.543 ' OD1' ' HA ' ' A' ' 8' ' ' MET . 25.8 t70 -69.66 112.81 6.39 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.888 0.375 . . . . 0.0 110.366 -178.436 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.83 36.8 5.94 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.785 -0.722 . . . . 0.0 111.477 -177.268 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.408 ' OD1' ' HD2' ' A' ' 47' ' ' LYS . 2.7 t0 -96.04 161.31 14.03 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 42.2 mm -128.65 112.65 26.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.847 0.356 . . . . 0.0 110.223 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.5 HD13 ' CD2' ' A' ' 10' ' ' PHE . 2.9 mp -110.62 118.62 57.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.148 0.499 . . . . 0.0 110.527 -177.528 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.58 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 41.6 mt-10 -105.42 114.08 28.04 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.227 176.589 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 86.9 t -100.65 108.55 23.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.155 0.502 . . . . 0.0 109.849 177.651 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 47.7 mt -112.04 117.25 54.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.74 -0.663 . . . . 0.0 110.127 -176.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.561 ' HG2' HG12 ' A' ' 43' ' ' VAL . 49.4 mtm180 -75.01 133.66 41.6 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.587 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -101.31 122.61 53.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.213 0.53 . . . . 0.0 110.46 179.313 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 48.0 mm -87.08 103.42 13.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.165 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 56.0 t80 -118.14 127.33 53.66 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.17 -179.344 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -87.18 -56.13 2.23 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.512 -177.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.514 -1.159 . . . . 0.0 111.651 -178.282 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 86.9 mtp . . . . . 0 N--CA 1.48 1.037 0 CA-C-O 120.72 0.295 . . . . 0.0 110.51 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.1 t -105.01 108.37 24.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 116.312 -0.403 . . . . 0.0 109.936 175.04 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 69.4 mt -96.42 122.13 47.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 177.379 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 105.5 -176.99 22.71 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 -175.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.42 158.57 29.7 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 117.077 0.439 . . . . 0.0 111.525 -179.008 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 25.8 mtpp -120.28 137.91 53.98 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.22 176.575 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.561 ' CD2' HD13 ' A' ' 64' ' ' ILE . 44.4 p90 -150.13 162.89 39.56 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.002 0.43 . . . . 0.0 110.837 178.216 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 t -109.28 138.85 45.01 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.794 177.676 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.558 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 5.3 p -129.25 122.13 55.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.25 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.642 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -88.0 125.0 41.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.814 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.448 ' N ' HD13 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -132.62 -171.19 2.6 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.449 -175.732 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -56.81 -46.01 81.87 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -175.192 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -90.42 7.68 37.52 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 111.722 0.267 . . . . 0.0 111.722 -173.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 131.02 -169.77 21.53 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.328 178.272 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.562 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.7 ttmt -100.8 123.01 44.38 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.883 0.373 . . . . 0.0 110.085 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 51.0 mttm -103.15 146.36 28.53 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.005 -176.663 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -120.65 121.15 64.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 170.552 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.415 HD11 ' CZ ' ' A' ' 10' ' ' PHE . 4.3 pp -138.49 171.76 13.9 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.885 0.374 . . . . 0.0 111.4 -173.809 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -131.61 142.53 49.9 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.249 -174.588 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -121.56 143.44 49.29 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 176.26 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -73.79 -13.81 80.35 Favored Glycine 0 C--N 1.33 0.226 0 C-N-CA 121.165 -0.54 . . . . 0.0 112.759 -174.243 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.421 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -138.85 144.32 41.05 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 177.795 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -57.5 120.59 8.61 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 122.321 2.014 . . . . 0.0 111.096 176.387 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.421 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 17.8 mmt180 -113.22 155.97 24.1 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.269 0.557 . . . . 0.0 111.221 -174.096 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.603 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 28.0 ttm180 -95.48 162.44 13.65 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 173.351 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.538 HD13 HD11 ' A' ' 58' ' ' ILE . 29.2 mm -54.56 -39.53 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.927 0.394 . . . . 0.0 110.733 179.248 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.507 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 17.1 tptm -64.25 -25.93 68.28 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.103 179.331 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.411 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 67.3 m-20 -73.54 -46.59 46.68 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-O 120.689 0.281 . . . . 0.0 110.638 178.707 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.1 t -61.47 -50.16 81.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.642 -178.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.43 HD13 ' HA ' ' A' ' 33' ' ' LEU . 4.1 mm? -68.36 -29.12 67.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.368 177.067 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.33 -42.68 64.92 Favored Glycine 0 CA--C 1.522 0.497 0 CA-C-N 115.985 -0.552 . . . . 0.0 112.736 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.411 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 7.2 mm-40 -68.95 -35.72 77.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.849 0.357 . . . . 0.0 111.115 -179.303 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.0 mt -85.64 -14.52 45.33 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.434 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 63.43 20.35 12.2 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.772 179.032 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.451 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 69.6 mt -79.86 131.54 63.41 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.983 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 22.2 Cg_exo -63.54 105.15 0.49 Allowed 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.491 2.127 . . . . 0.0 112.162 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.417 ' HB ' ' HG ' ' A' ' 33' ' ' LEU . 13.0 tt -67.8 -17.32 22.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.516 0.674 . . . . 0.0 110.377 178.312 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.3 tp10 -64.65 -37.93 89.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.503 -0.772 . . . . 0.0 111.885 -176.712 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.58 HG23 HG13 ' A' ' 43' ' ' VAL . 10.5 t -85.82 -9.88 56.33 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -170.658 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.58 HG13 HG23 ' A' ' 42' ' ' THR . 30.8 m -131.06 169.29 21.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 O-C-N 121.974 -0.454 . . . . 0.0 111.118 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.599 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 46.9 t -107.26 134.63 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.778 0.323 . . . . 0.0 111.079 -176.621 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.1 t -108.67 133.21 54.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.975 0.417 . . . . 0.0 110.72 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.649 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 73.6 mttt -118.53 146.54 44.47 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.144 177.732 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.846 ' HG2' HG21 ' A' ' 52' ' ' VAL . 4.0 mmtp -117.69 103.04 9.63 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.125 172.565 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.8 t-20 67.99 7.78 6.04 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.954 176.704 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 127.95 -25.04 5.02 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.86 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 71.9 mt-30 -87.74 142.42 27.84 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.71 0.255 . . . . 0.0 111.148 -178.211 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.409 HD12 ' N ' ' A' ' 51' ' ' ILE . 3.5 mp -77.99 119.58 27.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 177.017 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.846 HG21 ' HG2' ' A' ' 47' ' ' LYS . 27.5 m -124.97 178.67 3.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.062 0.458 . . . . 0.0 112.081 -170.723 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 32.2 pt -106.59 -174.01 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.618 178.233 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.507 ' HB2' ' HD3' ' A' ' 30' ' ' LYS . 15.6 p-10 -77.6 -15.2 59.37 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.446 -176.022 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.597 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 65.3 mm-40 -84.53 5.28 28.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.757 0.313 . . . . 0.0 111.653 -178.56 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.731 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 26.3 mm-40 -80.93 127.77 32.94 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.905 0.384 . . . . 0.0 110.63 176.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.603 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 33.8 mt-10 -88.9 148.01 24.05 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.494 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.538 HD11 HD13 ' A' ' 29' ' ' ILE . 25.3 mt -101.54 120.1 50.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.269 -177.457 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.482 ' O ' ' HB2' ' A' ' 62' ' ' ASP . 90.9 m-85 -99.31 170.58 8.55 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.585 -178.508 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -70.26 114.76 8.71 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.84 0.353 . . . . 0.0 110.605 178.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.26 11.71 38.31 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.705 -177.374 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.482 ' HB2' ' O ' ' A' ' 59' ' ' PHE . 2.7 t0 -74.49 161.03 30.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 110.277 -177.835 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.8 mm -128.21 111.8 25.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.561 HD13 ' CD2' ' A' ' 10' ' ' PHE . 2.7 mp -108.95 119.17 58.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.189 0.518 . . . . 0.0 110.649 -178.264 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.649 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 39.7 mt-10 -105.91 112.59 25.71 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.477 176.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 73.1 t -97.33 106.88 19.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.485 0.66 . . . . 0.0 110.424 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.599 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 58.8 mt -93.54 93.22 3.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.11 -179.534 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.478 ' HA ' HG12 ' A' ' 43' ' ' VAL . 0.0 OUTLIER -71.03 140.65 50.83 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 173.256 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.698 HG23 ' HA3' ' A' ' 72' ' ' GLY . 28.8 m -82.95 137.98 20.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.366 0.603 . . . . 0.0 111.806 -171.127 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.578 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -78.23 137.06 22.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.532 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.578 ' HB3' ' O ' ' A' ' 70' ' ' ILE . 69.7 t80 78.63 -5.73 2.0 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.536 0.684 . . . . 0.0 109.981 -174.862 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.698 ' HA3' HG23 ' A' ' 69' ' ' VAL . . . -94.6 99.45 2.45 Favored Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 111.503 -0.639 . . . . 0.0 111.503 176.818 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.2 0 CA-C-O 118.255 -1.303 . . . . 0.0 111.202 -178.851 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 4' ' ' MET . . . . . 0.576 ' SD ' HD11 ' A' ' 6' ' ' ILE . 48.5 ttm . . . . . 0 N--CA 1.476 0.856 0 N-CA-C 110.137 -0.319 . . . . 0.0 110.137 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 47.7 t -85.6 105.06 13.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.027 0.441 . . . . 0.0 110.269 179.19 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.576 HD11 ' SD ' ' A' ' 4' ' ' MET . 50.0 mm -108.03 131.26 58.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.762 178.293 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.05 -156.99 19.18 Favored Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 -176.344 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.69 151.82 18.97 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.919 0.39 . . . . 0.0 111.49 -179.465 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 37.2 ttpt -117.19 119.79 36.3 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 173.064 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -139.03 167.92 20.98 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.903 0.382 . . . . 0.0 110.835 -173.889 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.56 ' HB ' HD13 ' A' ' 20' ' ' ILE . 11.4 t -115.04 138.97 50.26 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-O 121.195 0.522 . . . . 0.0 110.738 178.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.474 HG23 ' HB ' ' A' ' 64' ' ' ILE . 10.0 p -127.09 138.28 55.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.253 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.494 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -116.93 121.24 67.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.345 0.593 . . . . 0.0 109.964 179.955 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 72.8 p -130.88 -163.73 1.35 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.083 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.837 ' HB3' ' HD3' ' A' ' 68' ' ' ARG . 8.7 p-10 -69.97 -21.92 63.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.88 0.371 . . . . 0.0 110.832 178.44 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -82.15 -10.81 59.04 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.478 0.656 . . . . 0.0 110.059 178.563 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 121.56 -167.91 14.38 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.046 178.753 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.8 ttmt -104.09 115.23 30.05 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -112.48 154.96 25.07 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.981 0.419 . . . . 0.0 112.009 -174.569 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.56 HD13 ' HB ' ' A' ' 11' ' ' THR . 24.3 mm -109.06 121.6 62.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 170.459 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.435 ' H ' HD23 ' A' ' 21' ' ' LEU . 1.9 pt? -128.53 161.29 29.91 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.064 0.459 . . . . 0.0 110.99 -178.617 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -126.4 141.17 51.99 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.137 -173.441 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.2 t -130.15 140.57 50.76 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 175.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.412 ' O ' HG22 ' A' ' 6' ' ' ILE . . . -80.87 -16.12 75.86 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.344 -177.543 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -138.42 148.61 59.9 Favored Pre-proline 0 C--N 1.321 -0.651 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.159 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -57.74 142.49 96.03 Favored 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.604 2.203 . . . . 0.0 111.782 177.182 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.564 ' HG3' ' HB2' ' A' ' 31' ' ' ASP . 10.4 tpt180 -137.92 158.37 44.48 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.489 -0.559 . . . . 0.0 109.489 -172.253 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.591 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 76.3 mtm180 -102.34 173.62 6.28 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.834 0.349 . . . . 0.0 110.804 173.534 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.607 ' HB ' ' HA ' ' A' ' 54' ' ' ASP . 18.3 mt -68.14 -42.79 85.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.794 175.875 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.414 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 82.9 tttt -60.69 -32.3 71.53 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.193 176.363 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.564 ' HB2' ' HG3' ' A' ' 27' ' ' ARG . 81.0 m-20 -67.91 -41.54 82.51 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.701 178.762 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 68.0 t -75.61 -52.75 17.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.862 0.363 . . . . 0.0 110.921 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.402 ' HG ' ' HB ' ' A' ' 38' ' ' ILE . 10.9 mp -61.78 -35.35 77.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.938 178.705 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.39 -33.68 68.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.151 177.222 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.401 ' HB2' ' O ' ' A' ' 31' ' ' ASP . 3.6 tp10 -60.52 -45.46 93.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.883 0.373 . . . . 0.0 110.73 -178.775 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.4 mt -102.0 6.73 41.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.814 -176.235 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 53.59 69.56 0.69 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.552 0.692 . . . . 0.0 111.064 -176.706 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.402 ' HB ' ' HG ' ' A' ' 33' ' ' LEU . 62.8 mt -111.5 117.37 49.23 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.065 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.515 ' HB2' HG22 ' A' ' 42' ' ' THR . 17.0 Cg_exo -67.05 113.64 2.9 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.889 2.393 . . . . 0.0 112.016 178.383 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 10.8 tt -79.6 -13.04 13.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.501 0.667 . . . . 0.0 110.59 -178.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -75.63 -17.24 60.06 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.58 -177.027 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.563 HG23 HG13 ' A' ' 43' ' ' VAL . 9.8 t -108.71 -8.33 15.42 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -174.13 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.563 HG13 HG23 ' A' ' 42' ' ' THR . 17.8 m -133.24 167.09 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 O-C-N 122.099 -0.376 . . . . 0.0 110.872 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.462 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 51.9 t -105.26 121.95 57.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.91 -178.222 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.8 t -103.71 127.07 58.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.031 177.515 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.632 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 98.8 mttt -122.82 144.61 49.07 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.991 0.424 . . . . 0.0 111.82 -178.812 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.561 ' HG2' HG21 ' A' ' 52' ' ' VAL . 17.9 mmtp -100.92 101.9 12.81 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.229 167.753 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.8 t-20 63.28 2.33 1.11 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.996 0.518 . . . . 0.0 111.805 178.674 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 136.14 -17.27 3.85 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 121.083 -0.579 . . . . 0.0 112.353 -178.533 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLN . . . . . 0.475 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 17.6 mm-40 -87.16 129.53 34.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.407 0.146 . . . . 0.0 110.939 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.6 mp -69.36 120.78 17.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 176.669 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.561 HG21 ' HG2' ' A' ' 47' ' ' LYS . 17.4 m -124.95 177.48 4.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.149 -176.785 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.471 ' O ' HD12 ' A' ' 29' ' ' ILE . 26.9 pt -113.0 179.63 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.282 174.578 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.607 ' HA ' ' HB ' ' A' ' 29' ' ' ILE . 8.4 p-10 -73.22 -6.09 43.62 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.851 -175.338 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -81.43 -2.12 48.3 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.389 -176.498 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 58.9 mm-40 -89.69 150.39 22.36 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 122.171 -0.33 . . . . 0.0 111.518 -177.34 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.591 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 21.0 mp0 -88.05 157.07 18.99 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.112 177.835 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.463 HG12 ' O ' ' A' ' 27' ' ' ARG . 2.6 mm -96.47 134.48 33.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 173.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -116.63 167.48 11.03 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.027 0.442 . . . . 0.0 111.275 -175.343 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -73.97 129.51 38.02 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.111 175.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.75 18.72 79.52 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.433 -176.642 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -91.51 157.06 17.24 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 179.631 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.457 HG12 HG22 ' A' ' 11' ' ' THR . 10.5 mt -128.3 114.27 33.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.228 0.537 . . . . 0.0 110.897 -175.331 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.474 ' HB ' HG23 ' A' ' 12' ' ' VAL . 22.0 mm -96.67 106.89 19.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.278 -178.373 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.632 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 35.4 tt0 -97.19 101.99 13.66 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 176.596 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.46 HG23 HG22 ' A' ' 64' ' ' ILE . 80.3 t -100.24 105.94 18.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.209 0.528 . . . . 0.0 110.116 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.462 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 26.2 mt -91.96 95.88 5.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.086 178.415 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.837 ' HD3' ' HB3' ' A' ' 15' ' ' ASP . 1.2 ptm180 -74.97 156.65 36.07 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.639 178.094 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -83.2 124.24 39.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-O 121.436 0.636 . . . . 0.0 110.586 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 4.7 tp -87.01 102.08 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.749 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 167.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 29.9 t80 -65.23 104.32 0.91 Allowed 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.421 0.629 . . . . 0.0 111.321 -170.473 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -168.37 -109.58 0.22 Allowed Glycine 0 N--CA 1.442 -0.962 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.294 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.097 0 CA-C-O 117.98 -1.455 . . . . 0.0 111.329 -179.854 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 25.3 mmt . . . . . 0 N--CA 1.48 1.05 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 41.9 t -98.19 127.58 50.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 178.343 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 62.4 mt -82.88 122.1 36.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.385 179.002 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 112.27 120.3 3.81 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.979 -0.629 . . . . 0.0 111.73 -177.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.495 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.1 ptt? -113.77 134.38 54.81 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.331 0.586 . . . . 0.0 111.379 -175.354 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.853 ' HD3' ' HB3' ' A' ' 22' ' ' GLU . 6.1 tppt? -106.79 126.64 52.55 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.025 176.37 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -152.81 147.63 26.26 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.141 0.496 . . . . 0.0 111.342 179.135 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.563 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.1 t -98.56 142.59 29.96 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.015 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.6 p -118.73 119.49 61.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.505 0.669 . . . . 0.0 110.002 176.328 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.51 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -106.75 117.03 51.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-O 121.864 0.84 . . . . 0.0 108.928 176.998 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.485 HG22 ' H ' ' A' ' 15' ' ' ASP . 1.4 m -114.75 175.33 5.54 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.221 -177.472 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.485 ' H ' HG22 ' A' ' 14' ' ' THR . 28.1 t70 -56.34 -23.29 36.35 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-O 120.95 0.405 . . . . 0.0 111.475 178.501 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -87.09 -12.27 47.67 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.559 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 133.43 -174.81 20.52 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.382 -0.913 . . . . 0.0 112.184 -177.276 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.51 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.7 ttmt -109.94 139.49 44.99 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.66 0.267 . . . . 0.0 110.997 -175.303 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -150.23 136.48 18.77 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 173.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.563 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -98.74 136.18 30.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.748 0.309 . . . . 0.0 110.341 -177.642 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.3 pp -138.58 170.54 15.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.087 177.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.853 ' HB3' ' HD3' ' A' ' 9' ' ' LYS . 13.3 pt-20 -138.84 150.33 45.9 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.925 0.393 . . . . 0.0 111.396 -178.325 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 40.8 m -135.61 133.69 38.52 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.115 177.739 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -74.31 4.08 35.77 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 121.326 -0.464 . . . . 0.0 113.252 -177.421 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.465 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -135.35 127.97 18.08 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.648 0.224 . . . . 0.0 110.504 178.527 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.495 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 21.9 Cg_exo -65.15 128.77 21.28 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.781 2.321 . . . . 0.0 110.982 176.159 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.56 ' NE ' ' HA ' ' A' ' 27' ' ' ARG . 0.0 OUTLIER -134.21 171.43 14.25 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.406 -170.838 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.4 ttp-105 -104.03 160.72 14.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.704 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 38.2 mm -56.49 -47.49 81.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.34 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.483 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 29.7 tptp -55.57 -37.99 68.77 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.335 -179.631 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -69.52 -57.43 5.22 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.006 -178.682 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 69.1 t -61.3 -47.93 91.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.855 -177.072 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 19.6 tp -68.02 -35.72 78.75 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.22 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.11 -44.28 61.22 Favored Glycine 0 N--CA 1.447 -0.633 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.62 -179.458 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -68.97 -21.86 64.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.735 0.302 . . . . 0.0 111.427 179.679 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.5 mt -89.25 -2.87 58.65 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.004 0.43 . . . . 0.0 110.224 174.527 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 57.48 45.69 19.21 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.125 176.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.429 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 69.0 mt -106.68 117.29 57.23 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.573 176.125 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 16.5 Cg_exo -67.54 112.41 2.61 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.773 2.315 . . . . 0.0 112.766 -176.493 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.563 ' HA ' HG22 ' A' ' 43' ' ' VAL . 11.2 tt -69.23 -14.68 18.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.587 0.708 . . . . 0.0 109.885 177.466 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -60.48 -28.96 68.75 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.61 -179.376 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 12.9 t -122.53 7.86 9.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.031 0.443 . . . . 0.0 111.589 -172.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.589 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 3.6 m -131.65 149.32 32.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 C-N-CA 120.386 -0.525 . . . . 0.0 110.768 -179.162 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.6 t -99.57 129.75 49.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.132 0.491 . . . . 0.0 110.288 179.134 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.8 t -103.3 127.48 57.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.555 -178.651 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.638 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 65.8 mttt -119.29 139.87 51.21 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.696 178.576 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.569 ' HE3' ' O ' ' A' ' 57' ' ' GLU . 9.1 mtpm? -127.07 115.88 19.84 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.928 175.152 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 62.36 22.56 13.3 Favored 'General case' 0 C--N 1.326 -0.419 0 O-C-N 123.597 0.56 . . . . 0.0 110.377 178.075 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.85 -14.41 57.43 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.548 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLN . . . . . 0.465 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 68.3 mt-30 -88.07 140.56 29.37 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 122.102 0.161 . . . . 0.0 111.046 -175.625 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.411 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.4 mp -80.07 113.16 19.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 174.124 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.886 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 35.8 m -125.55 178.92 3.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.071 0.462 . . . . 0.0 111.863 -169.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.428 HG13 ' H ' ' A' ' 55' ' ' GLU . 31.2 pt -112.62 -170.86 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.645 178.863 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.483 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 7.9 p-10 -81.15 -7.87 59.65 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.794 -174.869 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.428 ' H ' HG13 ' A' ' 53' ' ' ILE . 0.7 OUTLIER -91.08 12.36 20.14 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-O 121.544 0.688 . . . . 0.0 110.216 -177.772 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.886 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 8.3 mm-40 -88.3 128.24 35.48 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.147 179.069 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.569 ' O ' ' HE3' ' A' ' 47' ' ' LYS . 10.7 mm-40 -76.6 142.61 40.65 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.797 177.06 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 39.4 mt -92.23 137.59 21.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 177.119 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -117.06 149.0 41.01 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.055 0.455 . . . . 0.0 111.228 -174.807 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -66.71 117.2 8.51 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.788 176.168 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.21 11.8 53.46 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 121.152 -0.547 . . . . 0.0 112.223 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 36.6 t0 -97.68 161.94 13.52 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 179.718 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.436 HD12 HG22 ' A' ' 11' ' ' THR . 50.5 mm -112.24 126.18 69.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.822 0.344 . . . . 0.0 110.531 -177.717 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 47.3 mm -107.08 130.2 59.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.435 -179.69 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.638 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 33.7 mt-10 -122.11 129.2 52.15 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 177.651 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 54.3 t -122.33 110.29 26.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.311 0.577 . . . . 0.0 110.634 177.173 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.5 mt -118.28 101.7 12.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.407 -178.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.589 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 14.3 ptt180 -77.87 144.07 37.26 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.085 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -83.25 117.3 28.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.613 0.721 . . . . 0.0 110.62 -175.612 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 6.8 tp -95.7 128.09 47.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.377 -0.829 . . . . 0.0 109.956 179.774 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 7.3 p90 -81.91 87.57 6.4 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.634 0.731 . . . . 0.0 109.939 177.007 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -85.69 98.01 2.24 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.471 -0.786 . . . . 0.0 112.012 -177.757 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.965 0 CA-C-O 118.734 -1.037 . . . . 0.0 111.701 178.653 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 27.8 ttt . . . . . 0 N--CA 1.479 0.98 0 N-CA-C 110.078 -0.341 . . . . 0.0 110.078 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.1 t -90.02 104.92 15.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-O 121.078 0.466 . . . . 0.0 109.9 177.254 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.1 tp -117.31 122.11 69.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.743 177.158 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.91 151.75 28.2 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.612 -175.876 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.502 ' HE1' ' HB2' ' A' ' 27' ' ' ARG . 17.1 mtm -128.98 139.91 51.89 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.876 0.369 . . . . 0.0 110.622 -176.051 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -103.89 111.11 23.51 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 173.385 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 23.5 p90 -138.96 161.48 37.25 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.106 0.479 . . . . 0.0 110.923 -178.679 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.432 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.5 t -118.7 144.3 46.31 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.408 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.2 p -117.16 126.3 74.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.122 0.486 . . . . 0.0 109.721 176.278 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.556 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -112.86 127.73 69.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.247 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.628 HG22 ' H ' ' A' ' 15' ' ' ASP . 6.8 m -144.2 -177.04 5.26 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 -177.092 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.628 ' H ' HG22 ' A' ' 14' ' ' THR . 0.8 OUTLIER -49.46 -32.94 13.02 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.184 0.516 . . . . 0.0 110.892 173.714 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -80.5 4.25 18.91 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.153 -177.083 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 107.49 -177.37 21.35 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.067 177.625 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.556 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 40.0 ttmt -104.71 117.29 33.72 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 176.464 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -130.62 139.49 50.39 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.077 0.465 . . . . 0.0 110.61 -176.883 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.453 HD13 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -91.72 137.79 21.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.155 -176.236 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.453 ' N ' HD13 ' A' ' 20' ' ' ILE . 2.2 pt? -137.65 147.69 45.14 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 178.036 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -123.82 126.73 46.96 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.866 0.365 . . . . 0.0 110.412 -177.041 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.0 m -118.91 124.8 47.98 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.896 178.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -77.55 21.22 3.1 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 121.127 -0.559 . . . . 0.0 113.175 -178.538 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.419 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -139.23 138.95 21.58 Favored Pre-proline 0 C--N 1.322 -0.59 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 178.004 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -62.79 127.65 21.12 Favored 'Trans proline' 0 CA--C 1.531 0.337 0 C-N-CA 122.72 2.28 . . . . 0.0 111.484 175.643 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.502 ' HB2' ' HE1' ' A' ' 8' ' ' MET . 13.9 mmt180 -126.01 160.59 29.63 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.145 0.497 . . . . 0.0 111.298 -172.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.599 ' HG2' ' HA ' ' A' ' 57' ' ' GLU . 65.3 mtm-85 -113.65 168.56 9.67 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 164.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.744 HD13 HG11 ' A' ' 45' ' ' VAL . 24.9 mt -60.76 -45.41 97.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 120.646 0.26 . . . . 0.0 110.566 -178.265 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -61.28 -32.45 72.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.026 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.47 ' OD2' ' HD2' ' A' ' 27' ' ' ARG . 25.6 t70 -73.57 -42.36 61.72 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.484 -179.427 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.4 t -71.3 -51.79 31.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.006 0.431 . . . . 0.0 110.548 177.81 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 26.2 tp -61.4 -37.85 84.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.427 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.46 -33.31 72.3 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.476 177.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -71.84 -34.11 69.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.167 0.508 . . . . 0.0 109.995 177.336 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.2 mt -76.92 -10.56 59.45 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.258 174.701 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 63.3 45.89 4.75 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.689 176.178 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 62.2 mt -115.8 123.08 31.65 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.141 178.77 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_exo -62.69 132.27 36.94 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.754 2.303 . . . . 0.0 112.339 179.29 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 10.0 tp -70.38 -15.36 19.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.291 0.567 . . . . 0.0 110.61 -179.038 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -63.87 -32.91 74.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.752 178.568 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.509 HG23 HG13 ' A' ' 43' ' ' VAL . 12.0 t -104.02 -1.66 27.14 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 112.095 0.405 . . . . 0.0 112.095 -172.18 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.591 HG12 ' HG3' ' A' ' 68' ' ' ARG . 33.5 m -128.99 146.46 34.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 120.923 0.392 . . . . 0.0 111.202 -178.301 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.518 HG12 ' HB ' ' A' ' 67' ' ' ILE . 0.6 OUTLIER -110.02 136.94 44.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 175.555 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.744 HG11 HD13 ' A' ' 29' ' ' ILE . 32.6 t -116.21 133.59 62.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.094 0.473 . . . . 0.0 110.932 -177.777 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.758 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 98.6 mttt -117.84 130.92 56.56 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.255 177.126 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 22.5 ttmm -93.42 105.46 17.53 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 172.792 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 71.65 -61.3 0.49 Allowed 'General case' 0 C--N 1.33 -0.274 0 O-C-N 124.136 0.897 . . . . 0.0 110.557 -177.099 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -166.6 22.01 0.11 Allowed Glycine 0 N--CA 1.447 -0.585 0 N-CA-C 111.326 -0.709 . . . . 0.0 111.326 177.292 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 35.9 mt-30 -126.5 131.92 51.51 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.194 -0.299 . . . . 0.0 110.194 -176.24 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.542 HD13 ' HG2' ' A' ' 46' ' ' LYS . 38.9 mm -63.33 122.51 14.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.869 0.366 . . . . 0.0 110.628 177.615 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.7 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 17.3 m -125.74 178.4 4.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.751 -178.688 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.423 ' O ' HD12 ' A' ' 29' ' ' ILE . 26.9 pt -100.17 -177.96 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.659 176.577 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 20.7 p-10 -77.16 -30.12 54.85 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.431 -176.532 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -80.67 14.67 2.01 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 122.094 -0.379 . . . . 0.0 111.897 -173.636 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.7 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 76.5 mm-40 -86.05 152.07 23.19 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.82 0.343 . . . . 0.0 111.07 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.599 ' HA ' ' HG2' ' A' ' 28' ' ' ARG . 42.2 mp0 -85.52 162.15 19.04 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.925 -177.796 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 39.9 mm -103.81 144.78 13.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 174.199 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.751 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 81.0 m-85 -114.15 161.01 18.33 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.735 0.302 . . . . 0.0 110.189 179.179 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -77.63 120.87 23.18 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 175.015 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.51 9.93 68.53 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.904 -0.665 . . . . 0.0 111.789 -176.105 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.751 ' HB2' ' HB2' ' A' ' 59' ' ' PHE . 22.0 t0 -87.95 147.0 25.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.96 0.409 . . . . 0.0 110.181 -178.357 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 45.5 mm -105.6 122.95 59.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.23 -176.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.408 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 50.0 mm -109.78 115.19 49.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 120.886 0.374 . . . . 0.0 110.718 -177.579 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.758 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 28.3 tt0 -104.3 114.6 28.94 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.878 177.841 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.424 ' O ' HG23 ' A' ' 14' ' ' THR . 60.1 t -113.08 113.38 43.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.14 -179.049 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.518 ' HB ' HG12 ' A' ' 44' ' ' VAL . 3.8 mt -116.2 118.75 59.81 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.147 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.591 ' HG3' HG12 ' A' ' 43' ' ' VAL . 0.8 OUTLIER -68.28 130.09 41.86 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 176.093 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 16.9 m -86.32 116.06 28.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.331 0.586 . . . . 0.0 111.023 -177.016 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 8.4 tt -78.58 110.53 14.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.059 176.521 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 84.5 t80 -57.42 131.57 50.5 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.154 -178.628 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -81.14 72.33 2.76 Favored Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 111.606 -0.598 . . . . 0.0 111.606 178.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.255 -1.303 . . . . 0.0 111.063 -177.789 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 26.1 ttt . . . . . 0 N--CA 1.479 1.022 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 45.5 t -86.23 109.99 19.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.672 -177.501 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.425 HG22 ' O ' ' A' ' 24' ' ' GLY . 51.4 mm -94.99 120.91 45.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 109.219 -0.659 . . . . 0.0 109.219 176.551 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 133.65 163.64 10.47 Favored Glycine 0 N--CA 1.446 -0.667 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 -174.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.57 ' SD ' ' HB ' ' A' ' 58' ' ' ILE . 25.0 ptt? -160.0 137.15 9.43 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 117.173 0.487 . . . . 0.0 111.282 -176.424 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.876 ' HD3' ' HB3' ' A' ' 22' ' ' GLU . 3.8 tppt? -108.19 120.26 41.83 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 175.41 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -140.56 167.96 20.93 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.744 0.306 . . . . 0.0 110.919 -176.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.497 HG22 HD12 ' A' ' 63' ' ' ILE . 1.2 t -133.72 146.71 51.04 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 177.396 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -117.33 119.11 60.83 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.595 177.147 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -103.28 124.56 57.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.523 0.677 . . . . 0.0 109.511 178.456 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.424 HG22 ' H ' ' A' ' 15' ' ' ASP . 4.1 m -146.02 173.17 12.41 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -178.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.424 ' H ' HG22 ' A' ' 14' ' ' THR . 8.8 p-10 -64.46 -22.39 66.95 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.317 0.58 . . . . 0.0 109.954 174.338 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -72.23 -11.8 60.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.631 175.706 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 127.19 176.89 14.63 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.904 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -108.17 104.04 13.37 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 177.311 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -104.28 134.12 48.04 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.617 -176.163 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.447 HD13 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -103.33 129.58 54.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 177.269 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.447 ' N ' HD13 ' A' ' 20' ' ' ILE . 94.8 mt -136.26 137.21 40.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.621 -177.379 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.876 ' HB3' ' HD3' ' A' ' 9' ' ' LYS . 17.0 pt-20 -117.62 129.18 55.59 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.364 0.602 . . . . 0.0 110.012 173.742 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.7 m -109.7 145.46 36.51 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.268 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.425 ' O ' HG22 ' A' ' 6' ' ' ILE . . . -78.29 -10.75 85.97 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.407 -178.591 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.466 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.54 141.4 31.03 Favored Pre-proline 0 C--N 1.325 -0.496 0 N-CA-C 110.57 -0.159 . . . . 0.0 110.57 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.487 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 11.5 Cg_exo -71.32 123.8 9.87 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.835 2.357 . . . . 0.0 111.742 177.047 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.476 ' HB3' ' CB ' ' A' ' 31' ' ' ASP . 16.2 mmm180 -126.66 175.68 7.78 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -178.205 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.672 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 83.4 mtm180 -94.31 175.2 6.78 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.694 0.283 . . . . 0.0 110.579 175.174 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.732 HD13 HG11 ' A' ' 45' ' ' VAL . 18.2 mt -68.26 -39.73 81.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 177.45 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.535 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 28.2 tptp -59.46 -36.06 75.25 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.695 174.228 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.476 ' CB ' ' HB3' ' A' ' 27' ' ' ARG . 5.9 m-20 -66.07 -62.14 1.65 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.953 177.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.466 HG21 HG13 ' A' ' 58' ' ' ILE . 97.4 t -59.64 -60.6 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.664 -175.686 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 11.1 mp -63.24 -34.36 77.5 Favored 'General case' 0 C--N 1.333 -0.145 0 C-N-CA 120.932 -0.307 . . . . 0.0 111.135 -176.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.3 -47.24 82.07 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.871 -0.681 . . . . 0.0 112.572 -179.309 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -71.08 -22.38 62.11 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.847 0.356 . . . . 0.0 111.09 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 86.6 mt -86.77 1.69 51.37 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.683 176.425 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.9 tt0 65.17 17.17 10.93 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.23 176.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.402 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 71.8 mt -83.33 118.24 70.98 Favored Pre-proline 0 C--N 1.324 -0.54 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.129 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 36.3 Cg_exo -59.93 92.03 0.08 OUTLIER 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 123.128 2.552 . . . . 0.0 112.567 -177.929 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.548 ' HA ' HG22 ' A' ' 43' ' ' VAL . 14.4 tt -76.24 -17.44 15.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.366 -177.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -67.82 -20.81 65.21 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.685 -177.72 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.5 t -120.23 10.8 11.42 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -175.106 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.548 HG22 ' HA ' ' A' ' 40' ' ' ILE . 31.5 m -123.0 147.39 27.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 O-C-N 121.769 -0.582 . . . . 0.0 111.372 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.414 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 58.8 t -92.48 120.68 42.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.641 178.427 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.732 HG11 HD13 ' A' ' 29' ' ' ILE . 38.5 t -103.4 130.8 53.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.04 0.448 . . . . 0.0 110.854 -176.513 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.745 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 96.9 mttt -118.61 145.78 45.14 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.3 177.821 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.648 ' HD2' HG11 ' A' ' 52' ' ' VAL . 60.4 mttm -109.34 102.04 10.98 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.179 168.731 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.0 m120 58.54 19.7 6.87 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.628 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 117.97 -18.21 11.54 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.741 178.601 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 70.6 mm-40 -87.57 130.04 34.88 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.881 0.341 . . . . 0.0 110.535 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.425 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.7 mp -73.86 121.28 24.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.055 -179.511 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.828 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 21.2 m -123.99 178.34 3.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.191 -176.033 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.406 ' O ' HD12 ' A' ' 29' ' ' ILE . 32.0 pt -115.1 173.71 3.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 179.764 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.535 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 3.9 p30 -63.03 -23.82 67.63 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -176.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -71.56 -18.09 62.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.12 -176.585 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.828 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 20.0 mm-40 -67.16 141.46 57.36 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.106 0.479 . . . . 0.0 111.318 -177.701 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.672 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 21.1 mt-10 -89.21 152.02 21.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.578 -179.599 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.57 ' HB ' ' SD ' ' A' ' 8' ' ' MET . 8.1 mm -88.55 146.23 6.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 176.69 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -132.75 163.99 27.79 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.942 0.401 . . . . 0.0 110.569 -178.399 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -67.64 121.56 16.16 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.987 -0.552 . . . . 0.0 109.615 172.145 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.97 20.2 47.6 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.767 -177.216 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -96.15 131.49 42.54 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.412 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.497 HD12 HG22 ' A' ' 11' ' ' THR . 50.5 mm -111.57 109.99 30.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.696 0.284 . . . . 0.0 110.48 -177.234 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.472 ' HA ' ' O ' ' A' ' 46' ' ' LYS . 40.0 mm -94.97 119.25 42.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.27 -177.024 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.745 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 38.2 tt0 -103.37 120.93 41.74 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 171.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 70.8 t -107.36 108.49 25.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.155 0.502 . . . . 0.0 110.509 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.414 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 22.9 mt -103.86 109.15 26.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.756 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 19.1 mtt180 -68.12 144.06 55.18 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 176.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 34.5 m -83.49 136.21 23.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 173.318 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 8.3 tp -78.65 122.29 33.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.484 0.659 . . . . 0.0 110.403 -177.388 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -79.42 87.0 5.07 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.031 179.742 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -151.87 172.86 31.2 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.533 -178.325 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.045 -1.419 . . . . 0.0 110.737 -179.34 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 23.2 ttt . . . . . 0 N--CA 1.479 0.999 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 7.2 p -92.93 120.66 42.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.249 0.547 . . . . 0.0 110.17 179.449 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.3 pt -100.41 122.98 53.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.781 176.152 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.12 -178.09 20.56 Favored Glycine 0 N--CA 1.443 -0.898 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.148 -176.699 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.52 153.94 22.08 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.75 0.31 . . . . 0.0 111.193 -177.685 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.483 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 50.2 mtmt -105.85 128.82 53.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.002 -0.544 . . . . 0.0 109.689 174.171 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 19.3 p90 -139.28 150.26 45.24 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 120.778 0.323 . . . . 0.0 110.76 -178.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.522 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 25.3 m -111.23 120.9 43.82 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.81 0.338 . . . . 0.0 110.435 179.735 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.617 HG22 ' HB ' ' A' ' 64' ' ' ILE . 21.5 t -112.46 130.32 66.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.898 179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.636 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 4.0 tt -87.53 129.56 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.807 173.869 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 30.6 p -123.52 -175.22 3.15 Favored 'General case' 0 N--CA 1.442 -0.872 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.822 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -67.63 -28.43 67.72 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.804 -175.274 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.468 ' OD1' ' HE3' ' A' ' 19' ' ' LYS . 3.1 p30 -95.79 -5.94 40.75 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 121.125 -0.23 . . . . 0.0 111.523 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 147.11 -177.36 25.45 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.554 179.08 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.636 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 62.5 tttt -99.25 108.87 21.53 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.083 0.468 . . . . 0.0 109.796 -177.763 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.468 ' HE3' ' OD1' ' A' ' 16' ' ' ASP . 78.3 mttt -103.51 124.72 49.3 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.717 -171.636 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.522 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -90.37 125.14 43.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 170.115 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.423 HD23 ' N ' ' A' ' 21' ' ' LEU . 1.9 pt? -140.52 164.89 28.95 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.483 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.3 OUTLIER -139.58 163.59 32.16 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.9 0.381 . . . . 0.0 111.54 -176.66 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.3 t -134.83 158.24 44.72 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.416 176.591 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -84.76 -4.91 86.99 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.334 -178.866 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -138.49 141.33 30.9 Favored Pre-proline 0 C--N 1.324 -0.504 0 N-CA-C 110.624 -0.139 . . . . 0.0 110.624 178.833 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -61.84 131.97 37.68 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.739 2.293 . . . . 0.0 111.498 175.301 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 37.9 mmt180 -132.96 169.49 16.72 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.032 0.444 . . . . 0.0 111.216 -174.044 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -103.14 166.18 10.59 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.467 -0.788 . . . . 0.0 108.887 167.401 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 48.9 mm -55.87 -41.37 66.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.967 0.413 . . . . 0.0 110.394 178.754 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 46.2 tptt -51.24 -43.29 61.45 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.166 -0.924 . . . . 0.0 111.919 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -66.19 -50.88 62.37 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.842 -174.613 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.15 -49.29 56.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.018 -178.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.556 HD21 ' HB ' ' A' ' 40' ' ' ILE . 28.1 tp -62.07 -40.6 96.37 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.728 -177.74 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.73 -44.48 94.78 Favored Glycine 0 N--CA 1.448 -0.523 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.467 -177.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 68.3 mt-10 -72.2 -29.93 64.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.638 0.256 . . . . 0.0 111.615 -179.214 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 72.6 mt -78.18 -8.34 58.19 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 121.068 -0.253 . . . . 0.0 111.006 178.739 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.9 tt0 64.25 26.13 13.68 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.05 175.209 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.438 ' HB ' HD12 ' A' ' 33' ' ' LEU . 64.7 mt -82.95 124.87 76.31 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.141 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -71.82 108.86 2.52 Favored 'Trans proline' 0 CA--C 1.533 0.44 0 C-N-CA 122.587 2.191 . . . . 0.0 113.02 -179.376 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.556 ' HB ' HD21 ' A' ' 33' ' ' LEU . 10.0 tt -73.16 -9.75 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-O 121.732 0.777 . . . . 0.0 110.286 178.392 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -69.2 -42.89 75.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.742 -176.108 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.569 HG23 HG13 ' A' ' 43' ' ' VAL . 3.3 t -86.53 -47.68 9.03 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -170.15 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.569 HG13 HG23 ' A' ' 42' ' ' THR . 21.7 m -102.01 179.06 0.67 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.213 0 CA-C-O 120.85 0.357 . . . . 0.0 111.8 -173.161 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 30.0 t -103.98 139.55 24.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.565 -172.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 59.6 t -116.17 126.04 73.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 CA-C-O 121.029 0.442 . . . . 0.0 110.249 176.846 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.538 ' HG2' HD13 ' A' ' 51' ' ' ILE . 95.2 mttt -129.63 151.95 49.68 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.624 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.796 ' HG2' HG21 ' A' ' 52' ' ' VAL . 18.3 mmtp -106.04 100.8 10.33 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 169.46 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 47.6 t30 54.98 24.73 6.17 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.153 177.545 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 124.25 -27.42 5.57 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 120.957 -0.639 . . . . 0.0 113.367 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -89.46 133.96 34.32 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.903 0.351 . . . . 0.0 111.644 -174.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.538 HD13 ' HG2' ' A' ' 46' ' ' LYS . 39.2 mm -65.55 124.19 20.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.674 -0.239 . . . . 0.0 110.389 176.184 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.796 HG21 ' HG2' ' A' ' 47' ' ' LYS . 20.7 m -133.29 178.0 6.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.987 0.422 . . . . 0.0 111.223 -177.563 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.0 pt -109.48 -173.02 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.32 177.265 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 30.1 p-10 -82.19 -19.53 39.64 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 120.905 0.383 . . . . 0.0 110.961 -179.283 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -82.14 26.87 0.51 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.919 0.39 . . . . 0.0 111.856 177.648 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -96.54 149.95 21.18 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.052 179.132 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -78.33 170.6 16.37 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.999 -177.562 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 52.2 mt -128.8 120.71 52.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 172.377 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -112.27 162.2 15.77 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.724 -178.244 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -71.24 126.03 28.53 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.462 177.429 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.18 6.49 71.35 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.956 -0.64 . . . . 0.0 111.784 -179.255 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 25.8 t0 -88.58 155.79 19.43 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -179.501 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.7 mm -120.79 117.16 52.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 120.932 0.396 . . . . 0.0 110.523 -175.015 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.617 ' HB ' HG22 ' A' ' 12' ' ' VAL . 3.7 mp -101.71 128.22 54.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 177.873 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.618 ' HA ' HG22 ' A' ' 13' ' ' ILE . 38.2 mt-10 -115.22 107.27 15.07 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 120.771 -0.372 . . . . 0.0 110.996 -178.631 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 78.2 t -99.93 100.53 10.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 121.653 0.74 . . . . 0.0 109.05 174.326 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 51.1 mt -93.07 109.65 22.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.986 -176.131 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.545 ' HA ' ' CG1' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -64.33 140.78 58.9 Favored 'General case' 0 N--CA 1.447 -0.624 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 174.203 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.463 HG13 ' HA ' ' A' ' 43' ' ' VAL . 21.8 m -82.65 136.1 23.55 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-O 121.002 0.429 . . . . 0.0 110.573 -177.862 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 7.9 tp -83.64 128.59 38.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 176.643 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 36.9 m-85 -78.41 95.74 5.18 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.511 -175.114 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -89.17 44.3 3.09 Favored Glycine 0 N--CA 1.449 -0.492 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.759 177.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.018 0 CA-C-O 118.193 -1.337 . . . . 0.0 111.126 -179.126 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 1.016 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.4 t -97.05 118.61 43.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 175.078 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.1 pt -82.22 132.05 32.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 121.291 0.567 . . . . 0.0 110.578 -179.62 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.31 -178.71 17.17 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -176.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.495 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 23.5 ptt? -161.0 130.88 4.95 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.99 0.424 . . . . 0.0 110.712 179.005 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.659 ' HB3' ' HG3' ' A' ' 22' ' ' GLU . 16.4 ptmt -118.6 119.63 35.07 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 121.294 0.569 . . . . 0.0 109.574 171.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -123.79 151.61 43.12 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.089 -174.731 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.548 ' CG2' HG13 ' A' ' 63' ' ' ILE . 8.8 t -109.51 134.98 51.24 Favored 'General case' 0 C--N 1.316 -0.857 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.231 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.4 p -110.91 135.96 48.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.039 -179.22 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -114.46 126.54 72.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.385 0.612 . . . . 0.0 110.19 179.695 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.411 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -146.66 -163.48 1.76 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.369 178.248 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.411 ' H ' HG22 ' A' ' 14' ' ' THR . 14.2 m-20 -65.14 -21.96 66.86 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 121.108 0.48 . . . . 0.0 110.996 178.062 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -86.11 8.25 21.59 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.682 0.753 . . . . 0.0 110.274 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.79 -162.12 18.57 Favored Glycine 0 N--CA 1.448 -0.517 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.712 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -118.15 108.69 15.48 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 177.633 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -116.0 150.99 36.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.465 -176.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.532 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.2 OUTLIER -106.94 131.09 57.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.091 0.472 . . . . 0.0 109.886 -176.173 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.502 ' N ' HD13 ' A' ' 20' ' ' ILE . 92.2 mt -116.81 135.49 53.7 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.963 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.659 ' HG3' ' HB3' ' A' ' 9' ' ' LYS . 32.4 tt0 -108.96 126.55 53.21 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.948 0.404 . . . . 0.0 110.392 -177.456 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.5 m -118.06 145.39 44.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.958 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -83.17 -9.12 84.5 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 121.047 -0.597 . . . . 0.0 112.605 -176.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.443 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.42 141.89 32.98 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 122.849 -0.207 . . . . 0.0 111.003 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.495 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 7.3 Cg_exo -73.59 121.25 6.94 Favored 'Trans proline' 0 C--O 1.233 0.254 0 C-N-CA 122.817 2.345 . . . . 0.0 110.773 174.045 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 19.2 mmm180 -132.25 177.28 7.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.102 0.477 . . . . 0.0 110.899 -174.087 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.588 ' HG2' ' H ' ' A' ' 30' ' ' LYS . 44.7 ttm180 -94.82 160.85 14.41 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.053 -176.84 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 56' ' ' GLU . 37.4 mm -50.97 -41.01 21.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-O 120.815 0.34 . . . . 0.0 110.155 176.315 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.588 ' H ' ' HG2' ' A' ' 28' ' ' ARG . 35.8 tptt -51.03 -37.18 43.7 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.786 -179.329 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -64.93 -62.65 1.43 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.764 0.316 . . . . 0.0 110.845 -177.912 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.5 t -63.39 -44.21 98.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.762 -177.616 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.782 HD11 ' HB ' ' A' ' 40' ' ' ILE . 3.0 tm? -61.72 -46.43 89.68 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.163 -179.267 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.97 -47.41 46.74 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.141 -175.719 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -66.53 -34.57 78.22 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 111.954 0.354 . . . . 0.0 111.954 -175.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 82.1 mt -82.6 -4.64 57.98 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.684 0.278 . . . . 0.0 110.9 179.079 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.5 tt0 57.3 34.9 25.41 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.958 177.603 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.617 ' HB ' HD22 ' A' ' 33' ' ' LEU . 66.0 mt -79.49 125.64 82.46 Favored Pre-proline 0 C--N 1.323 -0.587 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 177.64 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.514 ' HB2' ' HB ' ' A' ' 42' ' ' THR . 34.7 Cg_exo -60.72 101.29 0.17 Allowed 'Trans proline' 0 C--O 1.233 0.226 0 C-N-CA 122.642 2.228 . . . . 0.0 112.874 -176.851 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.782 ' HB ' HD11 ' A' ' 33' ' ' LEU . 9.9 tp -71.29 -19.11 20.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.68 0.752 . . . . 0.0 109.831 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -77.01 -32.11 56.93 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.355 176.81 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.514 ' HB ' ' HB2' ' A' ' 39' ' ' PRO . 22.2 m -92.39 -39.41 11.46 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.193 -171.525 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 10.9 m -112.8 163.17 10.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.458 -175.645 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.421 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 47.3 t -109.89 140.27 29.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.846 -177.827 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.8 t -113.0 130.63 66.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 121.137 0.494 . . . . 0.0 111.467 -178.669 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.524 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 97.3 mttt -123.08 150.88 42.6 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.743 172.505 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.949 ' HE2' HG11 ' A' ' 52' ' ' VAL . 60.1 pttt -126.76 108.08 10.73 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.638 0.732 . . . . 0.0 110.676 171.619 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.49 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 3.2 t-20 64.26 23.78 13.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.483 -1.235 . . . . 0.0 111.771 174.399 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 112.79 -6.33 25.89 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.8 177.561 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 8.3 mm-40 -111.35 114.54 27.78 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.707 0.289 . . . . 0.0 111.501 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.482 ' HA ' ' HG2' ' A' ' 46' ' ' LYS . 0.1 OUTLIER -62.98 127.15 22.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 175.574 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.949 HG11 ' HE2' ' A' ' 47' ' ' LYS . 23.4 m -138.63 155.89 28.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.084 0.469 . . . . 0.0 111.574 -174.356 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.459 HG13 ' H ' ' A' ' 55' ' ' GLU . 30.4 pt -96.93 -175.55 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.908 177.505 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -69.57 -8.91 51.37 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.837 -0.62 . . . . 0.0 112.082 -175.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.459 ' H ' HG13 ' A' ' 53' ' ' ILE . 29.4 tp10 -81.94 -11.13 59.03 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.03 0.443 . . . . 0.0 111.098 -177.699 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.74 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 70.1 mm-40 -86.11 146.08 26.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -174.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.521 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.6 mp0 -80.83 160.89 24.68 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.59 173.841 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.414 HG23 HD11 ' A' ' 64' ' ' ILE . 39.9 mt -105.69 147.38 11.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 175.833 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.506 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 98.9 m-85 -111.38 151.84 28.01 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.274 0.559 . . . . 0.0 111.341 -178.138 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.463 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 29.7 t70 -69.61 120.85 16.01 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.958 172.736 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.13 19.31 55.89 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.797 -0.716 . . . . 0.0 111.992 -177.197 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.506 ' HB2' ' HB2' ' A' ' 59' ' ' PHE . 24.0 t0 -94.88 159.9 14.83 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 120.928 0.394 . . . . 0.0 110.448 -179.477 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.548 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.3 mp -117.05 108.55 25.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.03 0.443 . . . . 0.0 110.211 -175.785 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 1.9 mp -92.77 119.13 39.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-O 121.173 0.511 . . . . 0.0 110.175 -178.59 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.524 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 44.8 tt0 -105.22 115.8 30.87 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.646 178.512 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 79.3 t -100.81 102.62 13.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.352 0.596 . . . . 0.0 110.115 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.421 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 49.1 mt -93.27 93.13 3.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.165 -179.009 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.625 ' O ' ' HD2' ' A' ' 68' ' ' ARG . 0.2 OUTLIER -69.86 152.97 43.92 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 170.67 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 26.9 m -80.79 146.68 7.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 C-N-CA 120.497 -0.481 . . . . 0.0 110.0 -176.282 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.482 HG23 ' O ' ' A' ' 70' ' ' ILE . 0.0 OUTLIER -77.98 101.68 3.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 122.862 1.315 . . . . 0.0 109.814 -175.493 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -151.05 -70.22 0.17 Allowed 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 106.439 -1.689 . . . . 0.0 106.439 174.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 51.1 -102.78 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.57 0 CA-C-N 114.335 -1.302 . . . . 0.0 114.249 164.329 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.536 -1.147 . . . . 0.0 111.128 -177.914 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 68.3 mtt . . . . . 0 N--CA 1.484 1.232 0 CA-C-O 120.629 0.252 . . . . 0.0 110.421 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 58.7 t -104.89 105.48 18.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 120.915 0.388 . . . . 0.0 110.186 179.622 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 47.4 mm -112.31 130.14 66.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.444 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 23' ' ' SER . . . 85.24 100.64 0.68 Allowed Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.351 -176.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.443 ' HB2' ' HA ' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -126.1 149.67 48.76 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 -176.704 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.665 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 96.0 mttt -109.75 140.61 43.44 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.297 176.793 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -145.83 152.82 40.12 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.966 0.412 . . . . 0.0 110.268 174.748 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.593 HG22 ' HG2' ' A' ' 18' ' ' LYS . 4.7 m -110.61 118.06 35.18 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.774 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.647 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.7 p -111.49 132.05 61.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.795 -177.381 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.587 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -87.63 124.56 40.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.293 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.4 ' N ' HD13 ' A' ' 13' ' ' ILE . 2.5 p -134.49 -171.06 2.67 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.298 -177.629 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -74.85 -27.4 60.25 Favored 'General case' 0 N--CA 1.464 0.246 0 O-C-N 122.393 -0.192 . . . . 0.0 111.499 -173.394 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -83.73 -6.23 59.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.112 0.482 . . . . 0.0 110.331 178.306 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 131.4 -173.52 20.4 Favored Glycine 0 N--CA 1.443 -0.839 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 -179.007 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.593 ' HG2' HG22 ' A' ' 11' ' ' THR . 66.5 tttt -90.47 106.52 18.55 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.153 0.502 . . . . 0.0 109.788 178.007 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.7 tptm -103.61 121.34 42.72 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.199 -170.056 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.527 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -92.1 126.2 44.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 173.061 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.412 ' N ' HD13 ' A' ' 20' ' ' ILE . 4.0 pp -144.52 162.8 35.65 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.047 177.648 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.665 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -111.91 162.87 14.85 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.138 0.494 . . . . 0.0 110.961 -179.893 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.455 ' O ' ' HA2' ' A' ' 7' ' ' GLY . 40.6 t -130.41 140.59 50.57 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.657 -0.702 . . . . 0.0 109.224 176.789 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -53.81 -38.62 59.94 Favored Glycine 0 C--N 1.331 0.265 0 O-C-N 123.558 0.537 . . . . 0.0 112.523 -179.168 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.447 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -137.99 152.07 71.35 Favored Pre-proline 0 C--N 1.321 -0.638 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 176.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -59.08 128.38 27.54 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.375 2.05 . . . . 0.0 111.2 174.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.447 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 20.4 mmm180 -129.38 170.7 13.33 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.921 0.391 . . . . 0.0 110.455 -175.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.638 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 45.4 ttm180 -77.34 155.75 31.74 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.099 177.789 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.581 HG21 HG11 ' A' ' 45' ' ' VAL . 38.1 mm -53.17 -46.59 55.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 CA-C-O 121.712 0.768 . . . . 0.0 109.732 175.882 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.499 ' HB3' ' HE2' ' A' ' 30' ' ' LYS . 28.7 ttpt -72.39 -20.65 61.41 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.785 -1.098 . . . . 0.0 111.428 -178.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -66.57 -53.48 34.08 Favored 'General case' 0 CA--C 1.514 -0.43 0 CA-C-O 121.094 0.473 . . . . 0.0 109.779 176.389 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.8 t -68.21 -50.02 61.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.928 -177.665 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.561 HD23 ' HB ' ' A' ' 40' ' ' ILE . 15.0 tp -70.48 -28.68 65.17 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.488 -177.117 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.5 -39.47 95.64 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.165 174.7 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -62.59 -39.0 92.33 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.925 0.393 . . . . 0.0 110.658 177.04 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 91.7 mt -75.75 -15.08 60.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.028 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 59.21 75.66 0.39 Allowed 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.523 0.678 . . . . 0.0 110.929 -177.484 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 80.8 mt -134.15 130.45 20.31 Favored Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.195 176.68 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.471 ' HB2' HG22 ' A' ' 42' ' ' THR . 19.5 Cg_endo -58.61 90.46 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.779 2.32 . . . . 0.0 112.916 -179.608 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.561 ' HB ' HD23 ' A' ' 33' ' ' LEU . 18.9 tt -75.87 -9.81 12.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.672 -178.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -75.5 -43.15 50.68 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.761 -177.08 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.471 HG22 ' HB2' ' A' ' 39' ' ' PRO . 10.0 t -95.27 -5.27 44.04 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -170.182 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.583 ' HB ' ' HA ' ' A' ' 68' ' ' ARG . 17.9 m -115.42 167.94 7.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.906 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.1 t -97.32 123.44 49.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.023 0.44 . . . . 0.0 111.457 -173.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.581 HG11 HG21 ' A' ' 29' ' ' ILE . 61.4 t -103.67 126.57 58.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.94 176.409 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.724 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 25.2 mttm -119.41 114.32 22.15 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.568 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.42 ' HB3' HG11 ' A' ' 52' ' ' VAL . 86.6 tttt -93.64 110.14 21.76 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.828 177.88 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 64.76 16.98 10.75 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.606 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 114.14 -29.16 7.86 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.104 -0.57 . . . . 0.0 112.554 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 15.2 mm100 -88.39 140.88 29.02 Favored 'General case' 0 C--N 1.327 -0.413 0 O-C-N 122.846 -0.208 . . . . 0.0 110.779 -176.62 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 3.4 mp -69.89 118.77 14.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 177.637 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.42 HG11 ' HB3' ' A' ' 47' ' ' LYS . 34.5 m -122.43 169.93 13.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.087 0.47 . . . . 0.0 110.998 -178.257 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.7 pp -87.76 165.97 2.0 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.906 175.652 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -70.81 -10.59 59.85 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.901 -0.591 . . . . 0.0 112.087 -175.029 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.604 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 2.1 tp10 -83.61 -9.59 58.8 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.449 -175.716 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.435 ' O ' HG12 ' A' ' 29' ' ' ILE . 14.8 mm-40 -66.8 149.67 50.22 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.989 0.423 . . . . 0.0 112.068 -178.311 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.638 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 43.7 mt-10 -103.83 152.64 21.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.576 -179.547 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.481 HG12 HD13 ' A' ' 29' ' ' ILE . 23.6 mt -97.38 143.09 13.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.532 -178.578 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -125.97 171.77 10.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.261 -179.789 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.443 ' HA ' ' HB2' ' A' ' 8' ' ' MET . 27.0 t70 -71.02 122.58 20.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.813 0.34 . . . . 0.0 111.555 -175.441 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.78 14.13 57.04 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.444 176.469 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -91.51 161.49 14.94 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.937 0.399 . . . . 0.0 110.368 -178.866 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.1 mm -120.03 127.36 75.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.927 -176.527 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.647 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.4 mm -116.66 116.39 52.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 120.975 0.417 . . . . 0.0 110.918 -176.707 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.724 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 38.8 mm-40 -104.19 113.79 27.58 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.216 178.813 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 55.9 t -105.18 110.26 30.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.429 0.633 . . . . 0.0 110.289 174.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 62.5 mt -113.16 109.52 28.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.808 -179.12 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.583 ' HA ' ' HB ' ' A' ' 43' ' ' VAL . 13.3 ptt180 -65.29 154.44 38.22 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.996 177.93 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.7 p -82.77 147.59 5.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 178.864 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 13.3 tt -80.24 108.42 13.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.576 0.703 . . . . 0.0 110.176 178.678 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 81.9 t80 -132.1 111.55 11.57 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.635 -0.712 . . . . 0.0 109.505 177.319 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 160.59 72.75 0.02 OUTLIER Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.395 -0.907 . . . . 0.0 112.292 -179.302 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.962 0 CA-C-O 118.997 -0.89 . . . . 0.0 111.311 178.03 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 86.4 mtp . . . . . 0 N--CA 1.478 0.939 0 CA-C-O 120.844 0.354 . . . . 0.0 110.245 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.0 t -89.49 121.4 39.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 178.714 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.4 tp -104.12 122.4 56.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.332 0.587 . . . . 0.0 110.135 179.379 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 106.49 -172.4 18.47 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 -177.147 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.555 ' HA ' ' HB2' ' A' ' 60' ' ' ASP . 26.2 ptt? -160.67 129.09 4.61 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.106 0.479 . . . . 0.0 111.069 179.301 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -111.38 112.39 24.11 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 174.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.44 ' CZ ' HD11 ' A' ' 21' ' ' LEU . 49.2 p90 -136.72 168.13 20.11 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.556 -173.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.5 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.5 t -119.04 146.5 45.0 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.321 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 p -126.02 122.83 62.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.917 176.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.524 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -101.94 124.86 56.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.565 0.698 . . . . 0.0 110.083 -179.398 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.4 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -146.08 -160.43 1.15 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.163 177.904 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.4 ' H ' HG22 ' A' ' 14' ' ' THR . 4.7 m-20 -60.71 -29.66 69.49 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.185 0.517 . . . . 0.0 110.594 176.538 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -72.29 -3.19 22.32 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.556 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.04 -167.21 20.47 Favored Glycine 0 N--CA 1.444 -0.823 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -176.454 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.0 ttmt -93.14 102.97 15.29 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 175.704 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 84.1 tttt -106.83 120.44 42.02 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.771 -172.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.517 HD13 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -98.62 136.5 29.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.094 -178.871 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.517 ' N ' HD13 ' A' ' 20' ' ' ILE . 4.3 pp -140.33 162.65 34.8 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.684 0.278 . . . . 0.0 110.731 179.221 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -114.97 144.24 43.91 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -178.13 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 47.0 t -131.33 131.55 43.83 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.654 0.264 . . . . 0.0 110.453 -177.489 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.88 -16.84 74.85 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.221 -0.514 . . . . 0.0 112.778 -179.124 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.47 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.21 144.24 42.41 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 122.785 -0.244 . . . . 0.0 110.967 179.492 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.471 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 3.0 Cg_exo -75.15 130.14 12.86 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.741 2.294 . . . . 0.0 110.99 174.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 9.5 mtp180 -136.85 164.95 27.09 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.897 0.38 . . . . 0.0 110.71 -175.34 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.629 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 16.3 ttp85 -92.47 164.47 13.45 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.99 -176.823 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.497 HG12 ' O ' ' A' ' 56' ' ' GLU . 45.5 mm -51.84 -46.52 40.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 122.183 0.193 . . . . 0.0 111.288 -179.406 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.474 ' HB2' ' OD2' ' A' ' 54' ' ' ASP . 6.1 tptm -65.19 -26.97 68.38 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.836 0.31 . . . . 0.0 111.836 -177.151 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -62.72 -57.98 9.08 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 176.367 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 46.1 t -64.51 -41.28 91.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.626 -179.345 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.461 HD22 ' HB ' ' A' ' 38' ' ' ILE . 3.1 tm? -61.57 -46.56 89.39 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.117 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.62 -38.42 93.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 121.133 -0.556 . . . . 0.0 112.583 -178.761 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -65.8 -46.96 76.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.597 0.237 . . . . 0.0 111.518 179.27 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 91.7 mt -76.33 -16.25 59.8 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.755 0.312 . . . . 0.0 110.764 -178.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 60.65 37.24 19.33 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.511 177.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.461 ' HB ' HD22 ' A' ' 33' ' ' LEU . 66.7 mt -79.47 132.48 62.01 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.54 177.752 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -60.59 98.57 0.13 Allowed 'Trans proline' 0 CA--C 1.529 0.255 0 C-N-CA 122.546 2.164 . . . . 0.0 112.437 179.636 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.51 ' HA ' HG22 ' A' ' 43' ' ' VAL . 10.7 tp -69.87 -13.6 17.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.445 0.64 . . . . 0.0 110.149 -179.501 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -64.58 -21.74 66.78 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.245 -0.889 . . . . 0.0 111.076 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.8 t -127.3 10.39 6.8 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 112.282 0.475 . . . . 0.0 112.282 -173.347 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 35.3 m -131.9 142.26 43.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.121 0.486 . . . . 0.0 111.166 -179.262 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -118.12 138.92 47.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.79 178.378 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.6 t -103.73 136.09 38.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 121.248 0.547 . . . . 0.0 111.071 -176.634 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.646 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 56.5 mttm -118.1 147.77 42.96 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.008 175.688 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.587 ' HG2' HG21 ' A' ' 52' ' ' VAL . 19.1 mmtp -108.63 101.61 10.74 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.516 172.444 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 25.4 t30 57.5 27.33 13.86 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.738 177.296 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 116.5 -28.82 7.28 Favored Glycine 0 CA--C 1.522 0.478 0 C-N-CA 121.227 -0.511 . . . . 0.0 113.266 -179.245 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 70.4 mm-40 -88.14 139.81 30.12 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 117.054 0.427 . . . . 0.0 111.38 -172.477 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 26.2 mm -74.63 126.31 35.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.85 0.357 . . . . 0.0 111.052 179.117 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.587 HG21 ' HG2' ' A' ' 47' ' ' LYS . 25.2 m -128.76 178.48 4.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.206 178.882 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.442 HG13 ' H ' ' A' ' 55' ' ' GLU . 47.0 pt -118.99 -173.46 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.394 0.616 . . . . 0.0 111.785 -178.401 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.474 ' OD2' ' HB2' ' A' ' 30' ' ' LYS . 16.6 t70 -64.78 -19.98 66.12 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.131 -175.74 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.451 ' HA ' ' HD2' ' A' ' 28' ' ' ARG . 6.0 mm-40 -90.41 3.96 52.3 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.129 -0.487 . . . . 0.0 112.274 -173.468 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.497 ' O ' HG12 ' A' ' 29' ' ' ILE . 0.5 OUTLIER -85.5 135.71 33.72 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.074 0.464 . . . . 0.0 111.366 -179.843 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.629 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 7.1 mp0 -82.11 153.49 26.04 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.257 175.5 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.503 HG23 HD11 ' A' ' 64' ' ' ILE . 22.4 mt -95.84 143.37 12.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 175.309 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.593 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 80.3 m-85 -119.51 153.41 35.39 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.212 0.53 . . . . 0.0 111.369 -174.5 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.555 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 29.1 t70 -62.58 121.14 12.6 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.231 172.555 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.13 8.71 74.8 Favored Glycine 0 C--O 1.229 -0.218 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.138 -179.331 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.593 ' HB2' ' HB2' ' A' ' 59' ' ' PHE . 31.4 t70 -93.8 146.96 23.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 -179.653 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 37.9 mm -107.79 128.15 63.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.764 0.316 . . . . 0.0 110.905 -174.219 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.503 HD11 HG23 ' A' ' 58' ' ' ILE . 39.2 mm -108.5 118.48 56.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.946 -177.156 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.646 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 19.0 mp0 -106.09 121.47 44.21 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 172.378 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 97.2 t -105.53 104.04 16.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.198 0.523 . . . . 0.0 110.386 178.02 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.513 HD13 ' HD2' ' A' ' 46' ' ' LYS . 3.1 mp -106.02 114.06 44.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.625 -179.566 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.871 ' HB2' HH11 ' A' ' 68' ' ' ARG . 1.7 mtm105 -63.84 141.42 58.77 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 175.708 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -90.08 120.29 38.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 174.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.56 111.35 15.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 121.841 0.829 . . . . 0.0 109.586 -179.407 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -89.16 142.76 27.37 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.136 -0.938 . . . . 0.0 109.784 -177.033 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -77.26 64.67 3.14 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.29 179.097 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.14 0 CA-C-O 118.081 -1.4 . . . . 0.0 111.109 -178.911 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 50.1 ttm . . . . . 0 N--CA 1.479 1.008 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.2 p -83.03 108.38 15.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.571 0.7 . . . . 0.0 110.424 178.251 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 54.2 mt -108.87 122.72 63.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.954 179.817 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.61 166.41 13.31 Favored Glycine 0 N--CA 1.441 -0.97 0 C-N-CA 120.542 -0.837 . . . . 0.0 111.903 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.645 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 0.7 OUTLIER -136.88 139.34 41.57 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 -176.83 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.647 ' HA ' ' HB3' ' A' ' 22' ' ' GLU . 18.0 ttmm -101.03 116.56 33.13 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 172.053 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -136.75 165.48 25.82 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 120.925 0.393 . . . . 0.0 110.442 -179.137 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.867 ' HB ' HD13 ' A' ' 20' ' ' ILE . 12.1 t -121.13 137.2 54.77 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-O 121.288 0.566 . . . . 0.0 110.591 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.402 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.1 p -115.15 135.13 56.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.362 176.802 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.548 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -109.64 122.4 64.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.447 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.82 -165.01 1.54 Allowed 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.067 178.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -71.13 -13.49 61.97 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.09 0.472 . . . . 0.0 110.244 177.485 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -84.49 -9.79 58.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.503 0.668 . . . . 0.0 109.967 175.426 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 112.2 -178.67 19.2 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.986 -179.022 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.4 ttmt -92.8 114.76 27.4 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 176.011 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.403 ' HB2' ' HE3' ' A' ' 19' ' ' LYS . 30.9 ttmt -127.07 149.1 50.08 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.931 -171.186 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.867 HD13 ' HB ' ' A' ' 11' ' ' THR . 37.5 mm -94.77 126.3 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.829 -178.521 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 3.9 pp -144.64 144.95 31.52 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 172.676 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.647 ' HB3' ' HA ' ' A' ' 9' ' ' LYS . 12.6 pt-20 -139.42 163.4 32.62 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.804 0.335 . . . . 0.0 111.129 -176.144 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.7 t -129.03 165.53 20.99 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.102 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -101.67 14.05 57.78 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 177.314 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -139.3 142.85 33.94 Favored Pre-proline 0 C--N 1.324 -0.509 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 175.769 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.645 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 34.6 Cg_exo -61.19 136.39 64.37 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.611 2.207 . . . . 0.0 111.15 175.778 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.902 ' HG3' ' HB3' ' A' ' 31' ' ' ASP . 0.0 OUTLIER -140.37 157.87 44.89 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.346 0.593 . . . . 0.0 112.105 -173.06 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.572 ' HD3' ' HA ' ' A' ' 55' ' ' GLU . 43.5 ttm180 -107.06 163.41 13.01 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.08 -0.963 . . . . 0.0 109.134 176.414 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.579 HG13 ' O ' ' A' ' 56' ' ' GLU . 10.1 mt -60.08 -48.32 88.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.375 0 CA-C-O 121.359 0.6 . . . . 0.0 109.615 176.882 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.9 tptp -51.4 -35.95 41.39 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.678 173.436 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.902 ' HB3' ' HG3' ' A' ' 27' ' ' ARG . 0.2 OUTLIER -72.45 -55.58 6.78 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.676 179.079 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 28' ' ' ARG . 58.7 t -59.67 -61.07 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.287 -177.687 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.817 ' HG ' HD12 ' A' ' 40' ' ' ILE . 4.1 mm? -69.16 -28.37 66.36 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 121.118 -0.233 . . . . 0.0 111.224 -177.222 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.29 -43.33 63.28 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.454 179.158 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -71.98 -34.52 69.0 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.764 0.316 . . . . 0.0 110.64 178.355 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.415 ' HG ' ' O ' ' A' ' 32' ' ' VAL . 94.8 mt -73.22 -17.9 61.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.793 0.33 . . . . 0.0 110.147 175.382 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 61.86 36.77 15.79 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.892 174.879 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.404 HG23 ' HD2' ' A' ' 39' ' ' PRO . 72.4 mt -92.07 139.0 24.29 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.038 179.599 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.404 ' HD2' HG23 ' A' ' 38' ' ' ILE . 35.9 Cg_endo -65.87 65.39 0.42 Allowed 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 122.975 2.45 . . . . 0.0 113.133 177.495 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.817 HD12 ' HG ' ' A' ' 33' ' ' LEU . 7.6 tt -65.62 -22.35 30.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.843 177.593 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -66.29 -19.92 65.96 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.219 -0.9 . . . . 0.0 112.548 -173.111 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.6 t -109.16 11.86 25.33 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.36 -0.536 . . . . 0.0 111.913 -173.468 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 32.7 m -133.63 173.58 14.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.505 0.193 . . . . 0.0 110.784 178.23 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.852 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 46.5 t -88.26 129.86 38.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.729 0.3 . . . . 0.0 111.242 -175.39 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 19.2 t -108.33 126.04 65.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.826 -179.642 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.626 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 82.3 mttt -123.25 118.44 27.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.872 175.689 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -97.25 108.42 21.15 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 172.576 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 64.93 14.58 9.38 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.636 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 108.67 -13.08 35.54 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 121.14 -0.552 . . . . 0.0 112.096 -178.774 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 31.9 mm-40 -89.93 129.39 36.29 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.465 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 60.4 mt -72.49 105.78 2.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.263 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.6 m -116.83 171.31 5.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.484 -171.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 35.0 pt -89.45 166.92 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 166.799 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.427 ' O ' ' HB ' ' A' ' 29' ' ' ILE . 14.0 p-10 -77.71 -1.33 30.61 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 120.758 0.313 . . . . 0.0 111.74 -174.485 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.572 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 3.9 tp10 -82.88 12.34 4.98 Favored 'General case' 0 CA--C 1.539 0.547 0 CA-C-O 121.08 0.467 . . . . 0.0 111.066 -177.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.579 ' O ' HG13 ' A' ' 29' ' ' ILE . 26.6 mm-40 -91.23 143.33 26.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.528 178.786 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.538 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 12.3 mp0 -76.0 161.96 28.47 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.849 0.357 . . . . 0.0 110.305 173.4 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 8.6 mm -104.31 141.34 20.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 174.019 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -118.13 169.8 9.39 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.73 176.597 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -78.02 122.07 25.07 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.735 -174.573 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.72 11.53 56.71 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.252 -177.719 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -83.55 160.81 21.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.979 0.419 . . . . 0.0 110.717 -178.427 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.542 HG12 HG22 ' A' ' 11' ' ' THR . 20.2 mt -129.0 111.28 22.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.452 -179.835 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.414 HD12 ' N ' ' A' ' 64' ' ' ILE . 3.2 mp -95.11 115.67 34.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.277 0.561 . . . . 0.0 109.925 -179.736 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.626 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 37.5 mt-10 -102.29 104.96 15.52 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.086 179.352 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 55.4 t -97.46 107.41 20.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.552 0.691 . . . . 0.0 109.8 178.434 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.852 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 54.6 mt -92.61 95.07 5.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.251 -176.642 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.63 125.37 26.64 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 173.506 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 14.9 p -83.55 148.21 5.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.655 -174.635 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 7.1 tt -78.17 119.29 26.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 172.66 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 4.2 t80 -84.83 107.92 17.23 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.41 -171.608 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -88.09 -82.34 1.24 Allowed Glycine 0 N--CA 1.447 -0.62 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.132 178.075 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.004 0 CA-C-O 119.05 -0.861 . . . . 0.0 111.592 -179.335 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 24.6 ttt . . . . . 0 N--CA 1.48 1.041 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 39.0 t -82.81 104.6 11.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 175.286 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 7.5 tp -111.22 124.93 68.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.811 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 121.9 -177.47 16.44 Favored Glycine 0 N--CA 1.443 -0.876 0 C-N-CA 120.728 -0.749 . . . . 0.0 111.689 -178.87 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.61 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 25.1 ptt? -156.78 130.99 8.51 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.161 0.505 . . . . 0.0 111.158 -179.328 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.405 ' HE2' ' HB2' ' A' ' 9' ' ' LYS . 7.4 tppt? -101.05 120.03 39.61 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.063 174.136 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 10.0 p90 -141.33 151.75 43.83 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.247 0.546 . . . . 0.0 110.777 -179.727 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.468 HG21 ' HG2' ' A' ' 18' ' ' LYS . 5.8 m -118.13 128.73 55.01 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.881 178.699 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.774 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.6 p -104.66 122.93 58.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.242 0.544 . . . . 0.0 110.443 178.076 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.451 HG22 ' HG2' ' A' ' 65' ' ' GLU . 7.3 tp -87.53 123.73 40.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 121.213 0.53 . . . . 0.0 109.666 176.026 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.471 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -135.67 -177.19 4.56 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.416 -0.811 . . . . 0.0 108.905 -179.788 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.471 ' H ' HG22 ' A' ' 14' ' ' THR . 4.2 p-10 -71.46 -17.95 62.34 Favored 'General case' 0 C--N 1.327 -0.396 0 O-C-N 122.254 -0.279 . . . . 0.0 111.286 -177.159 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.437 ' OD1' ' HB ' ' A' ' 14' ' ' THR . 9.2 p-10 -90.29 4.23 51.31 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.866 0.365 . . . . 0.0 110.757 179.751 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 122.1 -166.32 14.78 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.778 175.581 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.468 ' HG2' HG21 ' A' ' 11' ' ' THR . 37.4 tttm -90.34 106.64 18.63 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.402 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.527 ' HB3' HG13 ' A' ' 12' ' ' VAL . 22.7 tttp -103.32 99.02 8.85 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.83 -167.844 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.559 HD13 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -86.12 133.41 29.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.779 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.559 ' N ' HD13 ' A' ' 20' ' ' ILE . 2.1 pt? -144.13 168.23 20.51 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 177.351 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -134.7 148.67 50.36 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.829 0.347 . . . . 0.0 110.445 -177.208 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 22.1 m -129.2 131.97 47.19 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.781 174.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.21 -16.14 59.71 Favored Glycine 0 C--N 1.33 0.246 0 CA-C-N 116.059 -0.519 . . . . 0.0 113.314 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.417 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -139.39 144.79 41.43 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 176.075 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.61 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 23.3 Cg_exo -65.69 146.34 83.8 Favored 'Trans proline' 0 C--O 1.234 0.324 0 C-N-CA 122.896 2.397 . . . . 0.0 111.595 176.832 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.557 ' HD3' ' OD2' ' A' ' 31' ' ' ASP . 96.4 mtt180 -140.16 168.22 20.31 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.309 0.576 . . . . 0.0 111.487 -175.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.601 ' HD3' ' HA ' ' A' ' 55' ' ' GLU . 37.0 ttm105 -94.17 152.52 18.67 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.077 -0.965 . . . . 0.0 108.555 171.022 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.533 HG12 ' O ' ' A' ' 56' ' ' GLU . 46.8 mm -51.13 -44.05 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 122.349 0.26 . . . . 0.0 111.601 -177.532 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.1 tptm -58.43 -27.2 64.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.138 -176.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.557 ' OD2' ' HD3' ' A' ' 27' ' ' ARG . 20.2 t70 -72.47 -53.3 12.49 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.684 -178.101 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 47.5 t -64.97 -44.13 96.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 CA-C-O 121.223 0.535 . . . . 0.0 110.202 178.735 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.506 HD21 ' HB ' ' A' ' 40' ' ' ILE . 20.7 tp -62.6 -35.66 80.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.977 178.27 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.75 -33.54 66.56 Favored Glycine 0 N--CA 1.449 -0.457 0 CA-C-N 115.446 -0.797 . . . . 0.0 113.099 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -66.37 -46.89 75.14 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 120.851 0.357 . . . . 0.0 111.211 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 92.9 mt -83.58 -16.15 46.42 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.732 -177.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.9 tp10 54.85 80.98 0.11 Allowed 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.824 0.821 . . . . 0.0 110.615 -176.645 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.461 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 67.8 mt -120.83 127.81 26.07 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.412 178.792 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.476 ' HB2' HG22 ' A' ' 42' ' ' THR . 16.0 Cg_exo -67.16 104.02 0.82 Allowed 'Trans proline' 0 N--CA 1.46 -0.446 0 C-N-CA 122.584 2.189 . . . . 0.0 112.486 -179.248 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.506 ' HB ' HD21 ' A' ' 33' ' ' LEU . 10.7 tt -66.79 -6.07 4.11 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 121.834 0.826 . . . . 0.0 110.237 177.117 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 21.4 tp10 -72.89 -36.2 67.29 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.095 -0.957 . . . . 0.0 110.853 177.016 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.529 HG23 HG13 ' A' ' 43' ' ' VAL . 15.3 t -101.21 -24.68 14.21 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 120.911 -0.316 . . . . 0.0 111.531 -175.392 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.581 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 34.2 m -116.93 141.56 34.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 110.062 -0.348 . . . . 0.0 110.062 177.074 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.458 HG11 HD12 ' A' ' 51' ' ' ILE . 38.4 t -105.0 140.36 23.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 120.922 0.392 . . . . 0.0 110.653 -177.47 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 6.9 p -103.39 131.16 52.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.805 -178.843 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.65 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 87.6 mttt -118.75 146.32 44.86 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.253 177.647 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.755 ' HG2' HG21 ' A' ' 52' ' ' VAL . 13.8 mmtp -109.37 101.25 10.25 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 167.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.5 t-20 50.17 61.11 3.36 Favored 'General case' 0 CA--C 1.537 0.479 0 O-C-N 123.697 0.623 . . . . 0.0 111.122 -179.45 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 87.54 -23.38 12.8 Favored Glycine 0 CA--C 1.52 0.35 0 CA-C-N 116.031 -0.531 . . . . 0.0 113.585 176.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 14.5 mm100 -96.56 127.56 42.67 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 117.06 0.43 . . . . 0.0 111.942 -172.388 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.591 HD13 ' HG2' ' A' ' 46' ' ' LYS . 33.7 mm -65.2 127.88 26.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.248 177.097 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.755 HG21 ' HG2' ' A' ' 47' ' ' LYS . 29.5 m -131.65 178.8 5.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.075 0.464 . . . . 0.0 111.368 -177.293 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.4 pt -107.81 177.24 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.558 178.871 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -74.35 -12.9 60.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.033 0.444 . . . . 0.0 110.84 -177.126 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.601 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 14.2 mm-40 -79.99 -5.3 55.47 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.866 179.574 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.533 ' O ' HG12 ' A' ' 29' ' ' ILE . 3.7 mm-40 -68.98 140.04 55.03 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.742 0.306 . . . . 0.0 110.93 178.019 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLU . . . . . 0.584 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 39.3 mt-10 -96.16 147.57 23.61 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 175.197 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.481 ' HB ' ' SD ' ' A' ' 8' ' ' MET . 19.2 mt -89.19 135.22 26.46 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -118.53 146.4 44.59 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.557 -0.292 . . . . 0.0 110.874 -177.089 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.567 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 18.7 t70 -58.66 116.87 3.99 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.598 173.874 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.14 -17.72 47.44 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 121.039 -0.601 . . . . 0.0 112.145 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 33.2 t0 -77.87 150.77 34.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.888 0.375 . . . . 0.0 110.05 -179.539 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.1 mm -105.94 115.45 47.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.162 0.506 . . . . 0.0 110.411 -175.203 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.774 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 9.0 tp -95.71 133.26 37.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.38 -179.057 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.65 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 28.6 mt-10 -131.7 130.38 41.93 Favored 'General case' 0 C--N 1.317 -0.814 0 O-C-N 122.166 -0.334 . . . . 0.0 110.795 -175.024 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 86.9 t -115.56 103.97 16.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.173 0.511 . . . . 0.0 109.87 178.149 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 25.6 mt -123.58 109.67 23.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.588 -176.662 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.581 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -66.7 124.28 22.46 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 173.114 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.47 127.55 39.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-O 121.185 0.517 . . . . 0.0 110.74 -175.517 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 6.4 tp -79.26 100.69 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 CA-C-O 122.144 0.973 . . . . 0.0 109.386 176.613 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 84.1 t80 -121.07 -42.12 2.5 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.242 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -163.25 179.69 38.26 Favored Glycine 0 N--CA 1.441 -0.994 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.003 176.629 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.083 0 CA-C-O 118.315 -1.269 . . . . 0.0 111.175 -179.817 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.234 0.256 0 CA-C-O 121.068 0.461 . . . . 0.0 110.864 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.29 105.96 0.21 Allowed Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -177.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . 0.584 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.1 ptt? -110.48 130.54 55.53 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.858 0.361 . . . . 0.0 111.044 -174.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.44 ' HB2' ' HB3' ' A' ' 22' ' ' GLU . 3.5 ttpm? -115.03 126.6 54.92 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 174.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 28.8 p90 -138.79 167.89 21.0 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.313 -175.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.492 ' HB ' HD13 ' A' ' 20' ' ' ILE . 13.1 t -125.38 132.02 52.86 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.201 0.524 . . . . 0.0 110.911 178.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.539 HG22 ' HB ' ' A' ' 64' ' ' ILE . 63.0 t -109.28 119.3 58.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 115.458 -0.792 . . . . 0.0 108.946 174.111 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.539 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -100.34 128.98 51.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.269 0.557 . . . . 0.0 109.949 -177.948 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.415 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -141.34 -162.81 1.44 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.508 -0.769 . . . . 0.0 108.949 178.507 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.415 ' H ' HG22 ' A' ' 14' ' ' THR . 3.7 m-20 -60.97 -27.44 68.27 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.329 0.585 . . . . 0.0 110.537 176.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -74.46 -9.42 58.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.507 178.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.31 -163.75 19.05 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 111.416 -0.674 . . . . 0.0 111.416 -177.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -76.8 118.76 19.74 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.053 0.454 . . . . 0.0 110.361 175.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 19.8 mtpp -102.48 121.83 43.12 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.18 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.492 HD13 ' HB ' ' A' ' 11' ' ' THR . 21.7 mm -100.32 120.84 50.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.027 0.442 . . . . 0.0 110.913 -177.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.436 HD23 ' N ' ' A' ' 21' ' ' LEU . 2.1 pt? -144.32 141.32 29.68 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.047 176.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.44 ' HB3' ' HB2' ' A' ' 9' ' ' LYS . 6.7 pt-20 -121.54 139.01 54.06 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.274 0.559 . . . . 0.0 110.763 178.652 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.9 t -119.9 130.88 55.04 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.518 -0.764 . . . . 0.0 109.446 -176.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -63.43 -31.99 82.63 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 121.23 -0.51 . . . . 0.0 112.868 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.436 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -106.82 123.81 37.41 Favored Pre-proline 0 C--N 1.322 -0.596 0 O-C-N 122.822 -0.222 . . . . 0.0 110.621 178.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.584 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 26.1 Cg_exo -63.71 110.89 1.37 Allowed 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.868 2.379 . . . . 0.0 111.544 175.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.436 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 14.4 mmm180 -118.57 177.11 4.95 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.232 0.539 . . . . 0.0 111.808 -171.295 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.684 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 15.6 ttp180 -89.88 157.61 17.81 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.946 -179.389 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.57 HD13 HG12 ' A' ' 58' ' ' ILE . 27.1 mm -50.22 -47.41 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 CA-C-O 120.833 0.349 . . . . 0.0 110.308 177.684 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.51 ' HB2' ' O ' ' A' ' 54' ' ' ASP . 46.3 tttp -59.63 -29.56 68.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.275 -176.537 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -64.89 -61.84 1.92 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.057 0.456 . . . . 0.0 110.372 -178.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.1 t -64.84 -38.96 84.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.556 -179.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.458 ' CD1' ' HB ' ' A' ' 38' ' ' ILE . 20.7 tp -63.21 -41.16 99.11 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.363 178.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.23 -35.19 63.97 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 116.009 -0.541 . . . . 0.0 113.376 179.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.442 ' HA ' ' OE1' ' A' ' 35' ' ' GLU . 5.5 mm-40 -65.13 -42.12 94.18 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 117.058 0.429 . . . . 0.0 111.295 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.6 mt -86.11 -8.4 57.9 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 175.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 40.27 70.12 0.27 Allowed 'General case' 0 C--O 1.234 0.269 0 CA-C-N 114.54 -1.209 . . . . 0.0 111.662 -173.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.458 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 63.8 mt -92.6 112.58 56.23 Favored Pre-proline 0 C--N 1.321 -0.667 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 174.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.539 ' HB2' HG22 ' A' ' 42' ' ' THR . 34.1 Cg_exo -60.29 103.43 0.21 Allowed 'Trans proline' 0 N--CA 1.46 -0.485 0 C-N-CA 122.693 2.262 . . . . 0.0 112.789 -173.664 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 8.1 tt -65.28 -11.34 11.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 CA-C-O 121.903 0.858 . . . . 0.0 109.493 175.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -66.36 -26.69 67.39 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 114.543 -1.208 . . . . 0.0 111.468 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.539 HG22 ' HB2' ' A' ' 39' ' ' PRO . 5.1 t -125.69 -7.84 6.78 Favored 'General case' 0 C--O 1.234 0.259 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -175.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.697 HG12 ' HB3' ' A' ' 68' ' ' ARG . 2.4 m -121.25 149.55 24.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.668 -177.124 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.4 t -98.85 130.83 47.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.55 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.9 t -103.03 126.73 57.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.137 0.494 . . . . 0.0 110.793 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.609 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 25.5 mttm -125.91 140.56 52.54 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.969 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.552 ' HD2' HG11 ' A' ' 52' ' ' VAL . 31.8 mttm -106.54 102.12 11.53 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.544 171.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 60.3 14.85 4.93 Favored 'General case' 0 CA--C 1.536 0.43 0 O-C-N 123.665 0.603 . . . . 0.0 111.164 178.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 126.9 -30.25 4.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.788 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 81.9 mm-40 -86.55 134.21 33.67 Favored 'General case' 0 C--N 1.327 -0.389 0 O-C-N 122.416 -0.461 . . . . 0.0 110.631 -176.024 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.434 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.7 mp -75.21 118.99 22.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -177.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.552 HG11 ' HD2' ' A' ' 47' ' ' LYS . 28.0 m -122.27 166.79 16.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 121.074 0.464 . . . . 0.0 110.745 -177.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 22.6 pt -97.81 175.41 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.859 174.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.51 ' O ' ' HB2' ' A' ' 30' ' ' LYS . 13.9 p-10 -81.89 12.84 3.68 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.289 -175.08 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -93.41 -15.84 25.23 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.707 -178.078 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.423 ' O ' ' HG3' ' A' ' 28' ' ' ARG . 60.6 mm-40 -77.33 160.74 28.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.196 -177.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.684 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.1 mp0 -94.17 163.17 13.57 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.989 0.423 . . . . 0.0 111.234 -178.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.57 HG12 HD13 ' A' ' 29' ' ' ILE . 45.8 mt -102.18 144.39 13.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 176.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -129.44 155.62 45.4 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.977 0.418 . . . . 0.0 110.693 -176.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.528 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 25.5 t70 -66.55 111.14 3.46 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.356 176.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.58 9.99 42.25 Favored Glycine 0 N--CA 1.445 -0.767 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.242 -177.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 26.2 t70 -88.44 146.3 25.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.859 0.362 . . . . 0.0 110.458 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.426 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.0 mp -113.99 115.91 51.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.278 -178.147 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.539 ' HB ' HG22 ' A' ' 12' ' ' VAL . 4.1 mp -102.04 110.3 28.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.606 179.297 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.609 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 44.1 mt-10 -96.98 98.12 9.81 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.442 HG23 HG22 ' A' ' 64' ' ' ILE . 87.3 t -92.22 101.54 12.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.418 0.628 . . . . 0.0 109.842 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 63.4 mt -109.26 99.97 9.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.501 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.697 ' HB3' HG12 ' A' ' 43' ' ' VAL . 24.3 ptt180 . . . . . 0 C--N 1.321 -0.654 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 173.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.2 pt . . . . . 0 N--CA 1.451 -0.406 0 CA-C-O 121.05 0.452 . . . . 0.0 110.15 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.87 178.6 16.39 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.59 -178.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . 0.434 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 1.2 mpp? -140.02 140.53 36.23 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.758 0.313 . . . . 0.0 110.67 -176.721 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -111.61 111.43 22.42 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 168.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -134.12 167.75 20.09 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 120.906 0.384 . . . . 0.0 110.679 -172.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.544 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 25.8 m -126.38 123.35 37.75 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 177.045 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.517 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.6 p -105.33 123.87 59.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.294 0.568 . . . . 0.0 110.227 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.447 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -107.26 130.54 59.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 121.157 0.503 . . . . 0.0 109.888 179.28 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.461 HG23 ' HB ' ' A' ' 66' ' ' VAL . 0.2 OUTLIER -146.2 -160.42 1.15 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 177.6 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.415 ' H ' HG22 ' A' ' 14' ' ' THR . 1.3 m-20 -58.81 -25.94 63.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.906 0.384 . . . . 0.0 111.413 179.087 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -89.1 10.2 22.64 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.522 -177.231 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.55 -156.65 18.9 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.459 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 54.4 mttm -105.59 103.51 13.04 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -178.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.8 tptm -106.75 115.06 29.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.87 0.367 . . . . 0.0 111.098 -175.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.544 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -78.59 128.61 38.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 176.798 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 96.7 mt -131.51 139.0 49.18 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.778 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -128.61 146.0 50.98 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.023 0.439 . . . . 0.0 110.602 179.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.5 m -135.24 136.23 41.56 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.886 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -86.8 17.97 37.61 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.509 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.446 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.51 131.51 16.18 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 178.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 25' ' ' ALA . 27.9 Cg_exo -62.45 112.68 1.66 Allowed 'Trans proline' 0 C--O 1.234 0.321 0 C-N-CA 122.693 2.262 . . . . 0.0 111.482 177.302 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -133.0 153.13 51.78 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.075 0.464 . . . . 0.0 111.01 -176.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.575 ' HG3' ' O ' ' A' ' 56' ' ' GLU . 23.6 ttm180 -83.49 164.73 19.68 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.387 -178.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.503 HD13 HG12 ' A' ' 58' ' ' ILE . 31.9 mm -51.56 -49.54 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 CA-C-O 120.714 0.292 . . . . 0.0 110.324 176.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 33.4 tttp -60.36 -29.58 69.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.843 -178.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.484 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 1.1 t70 -67.68 -50.4 57.92 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -177.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 60.9 t -73.26 -39.74 56.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.461 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.547 HD21 ' HB ' ' A' ' 40' ' ' ILE . 36.2 tp -62.65 -39.45 93.93 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.376 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.04 -37.91 95.26 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.783 -0.644 . . . . 0.0 112.156 177.062 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.484 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 6.9 mm-40 -64.23 -41.54 96.95 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.151 0.501 . . . . 0.0 110.323 176.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 95.0 mt -76.76 -16.23 59.53 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.935 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 62.93 26.56 15.59 Favored 'General case' 0 CA--C 1.537 0.448 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.055 174.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.409 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 75.1 mt -86.74 122.61 71.5 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.561 -178.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 18.5 Cg_exo -66.42 110.13 1.75 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.713 2.275 . . . . 0.0 112.268 178.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.547 ' HB ' HD21 ' A' ' 33' ' ' LEU . 13.3 tt -68.02 -17.54 22.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.574 178.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -56.98 -40.16 76.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.932 -178.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.411 HG23 HG13 ' A' ' 43' ' ' VAL . 14.8 t -98.01 2.12 48.55 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.817 0.341 . . . . 0.0 111.783 -172.32 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.544 HG12 ' HB3' ' A' ' 68' ' ' ARG . 12.0 m -129.07 171.5 16.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 O-C-N 122.032 -0.417 . . . . 0.0 111.389 -176.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.5 ' HB ' ' O ' ' A' ' 67' ' ' ILE . 61.0 t -126.55 136.44 60.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 173.369 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.5 t -106.27 127.81 61.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.964 0.412 . . . . 0.0 111.341 -175.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.517 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 85.7 mttt -118.01 120.78 38.84 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.561 174.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.471 ' HE3' ' O ' ' A' ' 57' ' ' GLU . 10.0 mtpm? -97.32 104.29 16.29 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 174.159 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 12.0 m120 62.43 18.17 10.12 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.719 -176.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 109.66 -13.92 32.46 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.685 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -87.63 123.92 32.98 Favored 'General case' 0 C--N 1.326 -0.418 0 O-C-N 122.759 -0.259 . . . . 0.0 110.682 -178.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 65.6 mt -75.06 121.65 27.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.835 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 28.2 m -135.72 177.42 6.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.28 -175.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.433 HG13 ' H ' ' A' ' 55' ' ' GLU . 42.7 pt -102.74 -175.09 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.353 174.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -80.08 -7.68 59.0 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.73 -175.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.433 ' H ' HG13 ' A' ' 53' ' ' ILE . 6.8 tp10 -89.95 10.99 21.8 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-O 121.232 0.539 . . . . 0.0 110.793 -178.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.835 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 59.3 mm-40 -89.24 148.77 23.42 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.016 0.436 . . . . 0.0 111.536 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.471 ' O ' ' HE3' ' A' ' 47' ' ' LYS . 1.4 tp10 -85.51 142.74 28.96 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.129 -177.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.503 HG12 HD13 ' A' ' 29' ' ' ILE . 45.4 mt -88.98 130.77 37.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 177.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -102.56 156.44 17.61 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.274 179.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -73.49 115.63 13.1 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.947 0.403 . . . . 0.0 110.134 177.138 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 103.34 2.25 47.65 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 121.012 -0.613 . . . . 0.0 111.675 -177.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -75.33 146.77 40.66 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -113.97 113.7 44.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.517 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 41.3 mm -89.5 104.68 15.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.821 -176.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.517 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 36.4 mt-10 -102.25 107.73 18.87 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.835 -179.097 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.461 ' HB ' HG23 ' A' ' 14' ' ' THR . 76.3 t -91.92 99.93 10.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 121.335 0.588 . . . . 0.0 109.888 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.5 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 55.8 mt -105.01 103.75 15.82 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 177.524 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.544 ' HB3' HG12 ' A' ' 43' ' ' VAL . 16.4 ptt180 . . . . . 0 C--N 1.312 -1.034 0 C-N-CA 120.294 -0.563 . . . . 0.0 111.072 -173.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 46.0 mm . . . . . 0 N--CA 1.452 -0.331 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 107.24 76.72 1.01 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.626 -0.797 . . . . 0.0 111.379 -177.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . 0.573 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.0 ptt? -85.74 130.47 34.55 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.12 0.486 . . . . 0.0 110.763 -174.037 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.484 ' HD3' HD11 ' A' ' 20' ' ' ILE . 0.6 OUTLIER -109.77 120.01 41.16 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.464 179.192 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 45.0 p90 -144.06 167.99 21.07 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.838 0.351 . . . . 0.0 110.761 -175.126 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.515 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 4.7 m -120.93 128.77 53.07 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.684 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 p -108.72 122.44 63.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 121.259 0.552 . . . . 0.0 109.921 175.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.565 ' HB ' ' HG3' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -106.59 118.72 54.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.366 0.603 . . . . 0.0 109.932 179.989 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.424 HG22 ' H ' ' A' ' 15' ' ' ASP . 2.4 m -116.47 169.78 9.06 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 177.066 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.424 ' H ' HG22 ' A' ' 14' ' ' THR . 29.1 t70 -53.97 -38.03 64.58 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.831 0.348 . . . . 0.0 111.58 178.293 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -77.96 -10.5 59.62 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.821 -175.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 152.74 170.9 19.63 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.321 -0.942 . . . . 0.0 112.578 178.211 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.565 ' HG3' ' HB ' ' A' ' 13' ' ' ILE . 36.4 ttpt -107.14 125.89 51.67 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.265 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -125.69 115.59 20.33 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.139 0.495 . . . . 0.0 111.242 -176.031 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.515 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -88.76 129.89 39.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 174.215 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.4 ' N ' HD13 ' A' ' 20' ' ' ILE . 4.1 pp -144.7 165.9 26.73 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.955 0.407 . . . . 0.0 110.566 178.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -123.21 133.15 54.24 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.447 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.1 t -101.96 131.97 48.06 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 177.45 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -55.89 -29.31 54.86 Favored Glycine 0 CA--C 1.518 0.23 0 CA-C-N 116.169 -0.468 . . . . 0.0 113.06 -177.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.489 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -135.22 151.4 75.01 Favored Pre-proline 0 C--N 1.322 -0.591 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 178.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.573 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 28.1 Cg_endo -63.86 127.63 20.01 Favored 'Trans proline' 0 N--CA 1.464 -0.228 0 C-N-CA 122.358 2.039 . . . . 0.0 111.072 174.284 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 18.3 mmm180 -128.05 170.13 13.27 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.058 0.456 . . . . 0.0 110.894 -173.089 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.6 ttt85 -95.79 159.9 14.75 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 178.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.462 ' CG2' ' HA ' ' A' ' 54' ' ' ASP . 41.6 mm -55.74 -46.77 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 N-CA-C 110.301 -0.259 . . . . 0.0 110.301 178.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.8 ttmp? -53.88 -38.56 64.87 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.856 178.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.431 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 32.9 t70 -62.09 -58.58 7.28 Favored 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.312 -179.514 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.5 t -60.59 -39.62 81.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.729 -179.642 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.568 HD12 ' HB ' ' A' ' 38' ' ' ILE . 15.6 tp -62.81 -47.19 84.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.654 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.42 -45.15 56.07 Favored Glycine 0 N--CA 1.448 -0.541 0 CA-C-N 115.755 -0.657 . . . . 0.0 113.13 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.431 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 34.9 mm-40 -63.47 -41.13 98.61 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.727 0.298 . . . . 0.0 111.658 -177.059 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 82.3 mt -89.22 -0.11 57.2 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.716 -0.22 . . . . 0.0 111.367 -178.038 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 54.58 73.01 0.42 Allowed 'General case' 0 C--O 1.232 0.181 0 CA-C-O 121.562 0.696 . . . . 0.0 110.772 179.151 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.568 ' HB ' HD12 ' A' ' 33' ' ' LEU . 68.3 mt -118.98 119.68 31.97 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.969 178.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.568 ' HB2' HG22 ' A' ' 42' ' ' THR . 7.0 Cg_exo -73.33 94.5 0.83 Allowed 'Trans proline' 0 N--CA 1.461 -0.425 0 C-N-CA 122.788 2.325 . . . . 0.0 112.34 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 13.4 tt -72.09 -23.07 21.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.362 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -60.81 -34.97 75.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.418 -178.311 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.568 HG22 ' HB2' ' A' ' 39' ' ' PRO . 12.9 t -102.62 -1.52 30.08 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -171.478 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.542 HG13 HG23 ' A' ' 42' ' ' THR . 18.2 m -136.89 -179.77 3.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 O-C-N 122.029 -0.42 . . . . 0.0 110.785 178.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.0 t -115.83 125.76 73.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.05 0.452 . . . . 0.0 111.118 -176.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.6 t -105.31 131.43 54.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.821 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.61 ' HG2' HD13 ' A' ' 51' ' ' ILE . 95.5 mttt -118.85 149.28 41.8 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.135 178.415 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.0 tttm -107.5 104.31 13.84 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 169.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 68.02 -73.89 0.08 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 123.81 0.844 . . . . 0.0 110.662 -174.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -148.4 11.85 1.17 Allowed Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 121.056 -0.592 . . . . 0.0 111.988 178.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -110.86 147.55 34.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.606 0.241 . . . . 0.0 110.805 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.61 HD13 ' HG2' ' A' ' 46' ' ' LYS . 29.6 mm -83.07 116.7 27.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.4 m -126.46 165.32 24.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.075 -175.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.456 HG13 ' H ' ' A' ' 55' ' ' GLU . 37.8 pt -99.83 -177.21 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.653 172.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.462 ' HA ' ' CG2' ' A' ' 29' ' ' ILE . 6.6 p-10 -83.18 6.54 18.98 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.087 0.47 . . . . 0.0 111.41 -173.31 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.456 ' H ' HG13 ' A' ' 53' ' ' ILE . 4.7 tp10 -95.27 0.51 53.91 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.152 -175.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -81.15 163.16 23.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.534 176.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.22 154.85 21.17 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.504 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 21.9 mt -103.49 143.15 15.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.065 -179.159 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -123.16 171.18 9.52 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.235 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -70.75 133.76 46.85 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.845 178.486 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.47 30.63 58.1 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.942 -0.647 . . . . 0.0 111.837 -178.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -98.46 162.64 13.05 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.861 0.363 . . . . 0.0 110.769 179.478 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.3 mm -127.64 125.89 66.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.92 179.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 2.9 mp -115.82 124.84 72.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 177.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.536 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 35.5 tt0 -110.16 113.87 26.91 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.725 0.298 . . . . 0.0 110.224 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 89.4 t -109.07 104.93 17.86 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.323 0.582 . . . . 0.0 110.352 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.525 HD11 ' HE3' ' A' ' 46' ' ' LYS . 6.3 pt -107.01 129.88 59.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.544 178.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.411 HH11 ' HD2' ' A' ' 68' ' ' ARG . 13.7 ptt180 . . . . . 0 C--N 1.32 -0.689 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.104 -179.132 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.1 tp . . . . . 0 N--CA 1.45 -0.452 0 CA-C-O 121.224 0.535 . . . . 0.0 110.05 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.55 -178.7 17.1 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 -173.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . 0.518 ' HA ' ' HB2' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -160.44 149.17 16.87 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 117.587 0.694 . . . . 0.0 112.284 179.694 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 mtpp -118.2 131.0 56.41 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.119 173.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 24.8 p90 -147.23 157.93 43.77 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.834 0.35 . . . . 0.0 110.805 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.734 HG22 HD12 ' A' ' 63' ' ' ILE . 1.3 t -116.31 140.3 49.48 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 175.637 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.469 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 6.4 p -129.13 129.12 67.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.068 0.461 . . . . 0.0 110.754 -178.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.732 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -92.25 119.96 40.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 172.538 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.07 -157.73 0.84 Allowed 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.722 -174.059 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.923 ' HA ' ' HD2' ' A' ' 68' ' ' ARG . 15.5 t70 -58.29 -44.59 88.55 Favored 'General case' 0 N--CA 1.464 0.259 0 C-N-CA 122.894 0.478 . . . . 0.0 111.897 -171.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -91.25 -10.7 40.55 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -174.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 140.46 -162.9 26.52 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.022 -1.085 . . . . 0.0 112.269 -176.542 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.556 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 36.1 tttt -104.16 120.8 41.9 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.997 0.427 . . . . 0.0 110.836 -174.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -121.67 162.79 20.09 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.424 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.413 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -118.52 130.44 73.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.243 0.544 . . . . 0.0 109.725 -179.01 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 98.9 mt -123.44 151.75 42.35 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.72 -176.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -137.27 129.25 29.13 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.758 -0.656 . . . . 0.0 109.528 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.3 m -130.25 154.4 47.63 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.682 0.277 . . . . 0.0 110.659 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.06 -10.91 70.84 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.735 -176.343 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.421 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -124.21 140.12 34.25 Favored Pre-proline 0 C--N 1.323 -0.58 0 O-C-N 122.718 -0.283 . . . . 0.0 110.432 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 25' ' ' ALA . 14.2 Cg_exo -69.27 107.32 1.74 Allowed 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.668 2.246 . . . . 0.0 111.101 176.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 29.7 mmm180 -110.13 169.62 8.61 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.93 0.395 . . . . 0.0 110.605 -176.209 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.565 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 15.1 ttm180 -103.83 160.89 14.41 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.301 178.054 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.551 HG12 ' O ' ' A' ' 56' ' ' GLU . 40.6 mm -53.81 -48.95 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.707 0.289 . . . . 0.0 110.525 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 32.9 tttp -60.41 -24.71 65.37 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.697 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -70.67 -52.36 21.69 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.955 0.407 . . . . 0.0 110.24 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 50.3 t -71.69 -41.07 70.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.374 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.53 HD21 ' HB ' ' A' ' 40' ' ' ILE . 22.0 tp -63.52 -41.49 98.49 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.215 179.253 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.39 -32.13 68.33 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.058 178.375 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.76 -42.4 98.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.068 0.461 . . . . 0.0 110.091 -179.503 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 85.3 mt -91.0 -12.38 36.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.783 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 59.95 77.63 0.31 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.131 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.441 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 68.6 mt -123.76 128.87 25.01 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.999 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.88 115.0 3.36 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.536 2.157 . . . . 0.0 112.92 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.53 ' HB ' HD21 ' A' ' 33' ' ' LEU . 11.3 tp -79.9 -6.05 9.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.803 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -67.26 -43.38 82.01 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.693 -171.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.578 HG23 HG13 ' A' ' 43' ' ' VAL . 8.8 t -92.37 -20.55 20.95 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 113.881 1.067 . . . . 0.0 113.881 -165.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.578 HG13 HG23 ' A' ' 42' ' ' THR . 34.3 m -117.95 163.46 15.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.165 -0.614 . . . . 0.0 111.398 -177.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -103.29 139.45 24.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.85 -173.128 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.55 HG22 HG22 ' A' ' 66' ' ' VAL . 89.4 t -120.39 136.53 57.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.939 0.4 . . . . 0.0 110.584 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.603 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 98.1 mttt -128.4 149.62 50.47 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.538 178.483 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.8 ' HE2' ' HB3' ' A' ' 56' ' ' GLU . 52.4 mttm -95.27 100.46 12.24 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.822 -0.806 . . . . 0.0 108.822 167.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 66.88 -32.54 0.19 Allowed 'General case' 0 N--CA 1.471 0.609 0 O-C-N 123.953 0.783 . . . . 0.0 111.895 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.517 ' H ' ' C ' ' A' ' 47' ' ' LYS . . . 178.74 -21.5 0.04 OUTLIER Glycine 0 CA--C 1.522 0.511 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.091 -178.34 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -85.85 127.37 34.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.936 0.368 . . . . 0.0 110.419 -178.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.488 ' H ' HD12 ' A' ' 51' ' ' ILE . 3.7 mp -64.82 123.72 18.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 120.64 0.257 . . . . 0.0 110.548 -178.149 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.827 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 27.6 m -130.57 178.76 4.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.091 -177.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 29.6 pt -118.04 -174.5 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.323 177.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.457 ' O ' ' HB ' ' A' ' 29' ' ' ILE . 9.4 p-10 -75.08 -14.58 60.6 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -176.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -84.9 9.33 14.65 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -178.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.827 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 35.0 mm-40 -85.15 137.15 33.2 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.87 0.367 . . . . 0.0 110.731 176.433 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.565 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.1 mp0 -76.96 156.28 32.07 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.406 -179.11 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 58.0 mt -98.26 124.59 51.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -113.46 154.06 27.63 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.581 -178.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.518 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 19.1 t70 -69.11 124.58 24.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.825 178.363 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.46 4.59 70.5 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.845 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -94.01 156.88 16.37 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.734 HD12 HG22 ' A' ' 11' ' ' THR . 47.6 mm -121.73 123.33 69.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 120.776 0.322 . . . . 0.0 110.421 -173.329 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.469 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.2 mm -99.98 107.97 21.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.16 0.505 . . . . 0.0 110.377 -178.304 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.732 ' HA ' HG22 ' A' ' 13' ' ' ILE . 6.3 mm-40 -100.11 97.21 8.06 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.006 -177.446 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.55 HG22 HG22 ' A' ' 45' ' ' VAL . 85.7 t -95.68 106.1 17.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.447 0.641 . . . . 0.0 110.031 177.147 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.2 mt -92.29 99.77 10.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.748 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.923 ' HD2' ' HA ' ' A' ' 15' ' ' ASP . 9.2 ptm180 . . . . . 0 C--N 1.323 -0.58 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 176.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 9.6 tp . . . . . 0 N--CA 1.449 -0.489 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 79.8 -178.12 53.94 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.314 -175.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 25.4 ptt? -160.67 137.85 9.16 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 120.961 0.41 . . . . 0.0 111.094 -178.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.678 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 53.6 mtmt -112.15 110.01 20.03 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 169.13 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 29.2 p90 -122.7 157.12 32.98 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.409 -175.439 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.526 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 7.8 m -113.96 117.82 32.42 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.426 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.1 p -102.51 123.45 55.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-O 121.282 0.563 . . . . 0.0 109.906 178.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.473 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -95.68 122.6 47.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -179.655 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.48 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.7 OUTLIER -127.5 175.58 8.13 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.342 -0.845 . . . . 0.0 109.266 -178.609 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.48 ' H ' HG22 ' A' ' 14' ' ' THR . 13.0 p-10 -67.94 -17.7 64.53 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 111.654 0.242 . . . . 0.0 111.654 -176.7 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -91.3 -7.92 49.69 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.891 0.376 . . . . 0.0 110.891 179.115 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 141.05 -179.09 19.67 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.147 179.394 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 36.7 ttmt -100.73 110.41 22.51 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.172 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 8.6 mtpp -107.36 114.6 28.73 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.386 -170.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.526 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -82.9 120.58 34.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 173.324 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 95.3 mt -118.63 146.21 44.84 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.374 -177.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.678 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.2 OUTLIER -121.6 141.01 51.51 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.148 0.499 . . . . 0.0 110.842 177.667 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.1 t -135.94 147.04 47.91 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.496 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -76.14 -9.79 85.44 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.679 -179.34 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -136.81 146.06 53.55 Favored Pre-proline 0 C--N 1.326 -0.422 0 O-C-N 122.831 -0.217 . . . . 0.0 110.618 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -63.49 131.37 31.5 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.349 2.033 . . . . 0.0 111.307 176.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.528 ' HD2' ' HB3' ' A' ' 31' ' ' ASP . 15.9 tpp180 -123.39 155.51 37.24 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.004 -175.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.569 ' HG2' ' HA ' ' A' ' 57' ' ' GLU . 96.8 mtt180 -104.18 165.01 11.33 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.765 -0.198 . . . . 0.0 110.715 178.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 45.6 mm -54.8 -55.78 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.974 -175.03 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.531 ' NZ ' ' HB3' ' A' ' 30' ' ' LYS . 2.8 ttpm? -53.15 -39.95 63.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.138 0.494 . . . . 0.0 110.959 179.373 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.528 ' HB3' ' HD2' ' A' ' 27' ' ' ARG . 3.1 m-20 -64.61 -52.44 57.49 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.951 -176.334 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.0 t -62.98 -47.46 92.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.099 0.476 . . . . 0.0 110.713 178.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 14.5 tp -64.7 -38.46 91.06 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.603 -177.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.12 -42.61 66.94 Favored Glycine 0 N--CA 1.447 -0.572 0 CA-C-N 115.492 -0.776 . . . . 0.0 113.108 -179.095 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -68.04 -31.56 71.3 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.903 0.351 . . . . 0.0 111.263 -178.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 97.1 mt -83.0 -4.05 57.89 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.921 0.391 . . . . 0.0 110.292 176.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 55.14 61.81 2.76 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.931 -178.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 62.0 mt -116.98 114.44 39.15 Favored Pre-proline 0 C--N 1.323 -0.577 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.488 175.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.425 ' O ' HG22 ' A' ' 42' ' ' THR . 32.4 Cg_exo -59.57 113.15 1.49 Allowed 'Trans proline' 0 N--CA 1.464 -0.21 0 C-N-CA 122.76 2.306 . . . . 0.0 112.558 -178.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 14.6 tt -63.01 -20.23 25.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 121.383 0.611 . . . . 0.0 110.589 178.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -63.62 -29.96 71.14 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.152 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.425 HG22 ' O ' ' A' ' 39' ' ' PRO . 3.6 t -108.4 4.98 24.97 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-O 120.914 0.388 . . . . 0.0 111.665 -170.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.3 m -136.54 164.57 30.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.14 0.495 . . . . 0.0 111.466 -179.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 56.7 t -123.26 129.28 74.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.499 176.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.0 t -107.3 130.87 58.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 121.283 0.563 . . . . 0.0 111.536 -175.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.831 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 96.3 mttt -117.8 131.88 56.52 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.311 176.274 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.489 ' HB2' HG21 ' A' ' 52' ' ' VAL . 65.0 tttp -93.07 106.29 18.27 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 174.46 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.546 ' HA ' ' HB ' ' A' ' 63' ' ' ILE . 12.5 t-20 68.94 -66.06 0.26 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.064 -177.122 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -159.2 17.23 0.25 Allowed Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.809 -0.516 . . . . 0.0 111.809 179.034 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -131.19 131.27 43.88 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 -177.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.5 mt -64.02 128.86 27.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 176.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.767 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 19.6 m -132.94 178.75 5.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.933 0.397 . . . . 0.0 111.864 -173.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 32.8 pt -88.89 172.73 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.882 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.509 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 6.6 p-10 -76.4 -20.72 56.84 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.326 -176.256 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 68.5 tt0 -85.43 4.99 32.99 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.04 0.448 . . . . 0.0 110.719 -178.056 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.767 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 7.5 mm-40 -72.44 129.89 39.41 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.122 0.487 . . . . 0.0 111.226 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.569 ' HA ' ' HG2' ' A' ' 28' ' ' ARG . 4.7 pt-20 -86.87 140.69 29.4 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.423 179.3 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.456 HG23 HD11 ' A' ' 64' ' ' ILE . 12.0 mt -92.11 150.82 3.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.218 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -124.6 164.65 19.39 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.035 0.445 . . . . 0.0 110.702 -177.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -67.6 128.06 35.07 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.373 176.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.49 12.02 79.05 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.114 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -96.99 161.79 13.68 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 178.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.546 ' HB ' ' HA ' ' A' ' 48' ' ' ASN . 46.4 mm -115.38 138.96 44.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.037 -176.089 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.475 HG22 HG23 ' A' ' 66' ' ' VAL . 49.8 mm -118.29 118.6 58.62 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 176.428 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.831 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 42.7 tt0 -107.5 107.54 18.44 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.475 HG23 HG22 ' A' ' 64' ' ' ILE . 86.0 t -111.99 109.56 28.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.204 0.526 . . . . 0.0 110.51 -179.355 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -114.02 139.0 42.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.445 HH11 ' HD3' ' A' ' 68' ' ' ARG . 35.0 mtm-85 . . . . . 0 C--N 1.323 -0.563 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 174.377 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 65.4 mt . . . . . 0 N--CA 1.454 -0.247 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 97.63 67.04 0.91 Allowed Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.452 -0.88 . . . . 0.0 111.404 -177.215 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . 0.41 ' HB2' ' HA ' ' A' ' 60' ' ' ASP . 26.1 ptt? -87.4 149.95 24.13 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.643 -0.278 . . . . 0.0 111.089 -174.415 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.55 ' HD3' ' OD1' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -129.68 128.96 43.62 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 168.808 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -125.44 153.17 43.88 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -177.593 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.56 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.8 m -109.81 117.67 34.48 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.176 -179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.552 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 3.1 p -112.23 123.41 67.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.458 -178.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.608 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -88.06 121.02 37.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 177.769 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.92 -162.05 1.14 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.747 -174.264 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -61.96 -45.92 91.54 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 112.202 0.445 . . . . 0.0 112.202 -171.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -87.74 -0.82 57.44 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 111.999 0.37 . . . . 0.0 111.999 -175.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 137.12 -164.73 25.27 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.128 -1.034 . . . . 0.0 112.653 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.589 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.0 ttpt -92.23 116.76 29.24 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.035 0.445 . . . . 0.0 110.212 -177.524 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 41.4 tptt -115.2 113.3 23.74 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.996 -172.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.56 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -84.32 120.54 35.27 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 CA-C-O 121.69 0.757 . . . . 0.0 109.795 174.175 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 97.4 mt -116.02 136.59 52.89 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.24 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.528 ' HG3' ' HB3' ' A' ' 9' ' ' LYS . 39.3 tt0 -113.5 139.49 48.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.275 -0.42 . . . . 0.0 109.974 179.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.2 t -132.92 132.91 42.56 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 178.575 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -66.46 -15.1 63.27 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 121.157 -0.544 . . . . 0.0 113.401 -175.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -133.9 142.32 43.06 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.896 0.348 . . . . 0.0 110.805 -178.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -54.43 133.95 58.96 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.465 2.11 . . . . 0.0 110.845 173.665 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.465 ' HG3' ' CB ' ' A' ' 31' ' ' ASP . 0.1 OUTLIER -132.56 156.21 47.26 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.487 -168.071 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.448 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 10.2 ttt85 -92.69 158.66 15.82 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 174.192 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 40.8 mm -59.96 -36.94 70.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.126 0.489 . . . . 0.0 109.814 176.061 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -67.21 -19.83 65.61 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.756 -177.041 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.465 ' CB ' ' HG3' ' A' ' 27' ' ' ARG . 3.2 m-20 -65.64 -61.8 1.88 Allowed 'General case' 0 CA--C 1.517 -0.312 0 CA-C-O 121.186 0.517 . . . . 0.0 109.766 173.73 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.5 t -59.7 -42.19 87.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.326 179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.589 HD21 ' HB ' ' A' ' 40' ' ' ILE . 1.2 tm? -63.94 -47.6 79.82 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.759 -178.445 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.21 -47.43 36.87 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 116.049 -0.523 . . . . 0.0 113.608 -174.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.4 mm-40 -73.26 -37.16 66.4 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -173.417 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 79.9 mt -87.64 -13.73 41.9 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.979 -0.288 . . . . 0.0 111.029 -179.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 58.97 77.77 0.29 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.598 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.576 ' HB ' HD22 ' A' ' 33' ' ' LEU . 65.1 mt -118.75 133.21 23.63 Favored Pre-proline 0 C--N 1.319 -0.731 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.51 -179.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 29.6 Cg_exo -62.83 100.49 0.24 Allowed 'Trans proline' 0 CA--C 1.529 0.252 0 C-N-CA 122.562 2.174 . . . . 0.0 112.401 178.525 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.589 ' HB ' HD21 ' A' ' 33' ' ' LEU . 8.2 tp -85.74 -25.13 6.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.549 -177.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 18.3 tp10 -76.06 -20.55 57.64 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.964 -173.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.531 HG23 HG13 ' A' ' 43' ' ' VAL . 12.9 t -109.1 -10.82 14.99 Favored 'General case' 0 CA--C 1.534 0.365 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 -170.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.531 HG13 HG23 ' A' ' 42' ' ' THR . 25.9 m -122.35 158.54 26.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.049 -179.424 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.0 t -94.98 113.12 28.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.037 -175.65 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 90.4 t -102.83 131.17 51.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.057 0.455 . . . . 0.0 110.439 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.737 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 97.9 mttt -117.28 126.39 52.65 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.948 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.504 ' HB3' HG11 ' A' ' 52' ' ' VAL . 71.1 tttt -96.82 106.06 18.3 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.362 175.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 71.08 -53.24 0.68 Allowed 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 123.947 0.899 . . . . 0.0 110.861 -177.331 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.49 21.49 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.077 178.292 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . 0.592 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 18.6 mm-40 -125.18 143.62 50.85 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.421 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.2 mp -74.61 113.76 13.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 176.388 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.745 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 35.6 m -124.9 178.47 3.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-O 121.14 0.495 . . . . 0.0 111.834 -173.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.447 HG13 ' H ' ' A' ' 55' ' ' GLU . 23.8 pt -123.22 -171.31 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.597 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -70.08 -12.74 61.82 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.087 -0.506 . . . . 0.0 112.056 -176.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.447 ' H ' HG13 ' A' ' 53' ' ' ILE . 7.5 tp10 -81.91 -8.51 59.68 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.522 -174.169 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.745 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 22.0 mm-40 -81.49 163.2 22.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.002 0.43 . . . . 0.0 111.97 -176.445 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.448 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 0.0 OUTLIER -103.15 159.24 15.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.169 177.468 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 17.9 mt -103.85 154.48 5.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -128.49 168.41 15.7 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.924 0.392 . . . . 0.0 110.857 -177.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.55 ' OD1' ' HD3' ' A' ' 9' ' ' LYS . 30.8 t70 -81.12 129.42 34.56 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.854 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.04 26.58 72.12 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 121.076 -0.583 . . . . 0.0 111.935 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -97.33 160.97 14.02 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.962 0.411 . . . . 0.0 110.823 -178.055 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 31.3 mm -111.01 113.4 44.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.418 -175.304 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.552 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.1 mm -102.3 109.4 26.25 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.737 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 38.8 tt0 -99.65 99.99 10.92 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.223 -178.735 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 92.3 t -100.37 103.1 14.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.46 0.647 . . . . 0.0 110.522 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 24.2 mt -91.89 99.24 9.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.481 179.342 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.459 ' HD2' ' O ' ' A' ' 68' ' ' ARG . 0.1 OUTLIER . . . . . 0 C--N 1.323 -0.567 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.624 175.582 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 pt . . . . . 0 N--CA 1.452 -0.359 0 CA-C-O 121.194 0.521 . . . . 0.0 109.747 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 113.16 93.94 2.09 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -170.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . 0.417 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.5 ptt? -106.1 144.72 32.41 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.38 0.609 . . . . 0.0 112.293 -165.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.521 ' HG2' ' OD1' ' A' ' 60' ' ' ASP . 23.8 pttm -107.06 141.45 38.28 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.289 -0.869 . . . . 0.0 108.911 168.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 31.1 p90 -156.72 147.96 22.2 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.853 0.359 . . . . 0.0 110.163 178.285 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.623 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 9.5 t -112.41 138.01 49.76 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.15 0.5 . . . . 0.0 110.225 178.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.762 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.7 p -126.9 134.54 65.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.966 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.669 HG22 ' HA ' ' A' ' 65' ' ' GLU . 8.1 tt -88.19 124.85 41.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.944 174.454 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.411 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.7 OUTLIER -116.68 174.18 6.22 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.138 -0.937 . . . . 0.0 108.542 177.176 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.411 ' H ' HG22 ' A' ' 14' ' ' THR . 25.6 t70 -58.4 -34.17 70.44 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.25 0.548 . . . . 0.0 110.719 178.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -77.07 -10.79 59.61 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.698 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 136.39 176.76 14.54 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.414 -0.898 . . . . 0.0 112.783 178.579 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.641 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 45.4 tttt -96.43 116.64 29.38 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 6.6 mtpm? -129.65 147.87 51.49 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.845 -175.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.623 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -111.15 131.23 62.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -177.388 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.456 ' N ' HD13 ' A' ' 20' ' ' ILE . 2.0 pt? -134.8 165.1 26.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.751 0.31 . . . . 0.0 111.084 -175.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -112.44 150.6 30.94 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.337 -179.299 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.4 t -136.03 134.62 38.69 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 175.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.06 -44.94 95.1 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 121.26 -0.495 . . . . 0.0 113.153 -176.141 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -110.88 146.56 34.68 Favored Pre-proline 0 C--N 1.321 -0.637 0 O-C-N 122.625 -0.338 . . . . 0.0 110.741 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.417 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 25.0 Cg_exo -63.72 119.82 7.01 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.682 2.255 . . . . 0.0 111.2 175.282 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.414 ' HE ' ' CG ' ' A' ' 31' ' ' ASP . 17.2 mmm180 -115.0 177.18 4.74 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.729 -174.333 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 54.8 ttm-85 -108.38 159.97 16.24 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.505 HD11 ' HE2' ' A' ' 47' ' ' LYS . 38.0 mm -56.87 -48.76 80.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.913 0.387 . . . . 0.0 110.392 176.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.5 tptm -59.6 -28.04 66.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.186 178.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.414 ' CG ' ' HE ' ' A' ' 27' ' ' ARG . 30.0 t70 -65.15 -62.09 1.75 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.849 0.356 . . . . 0.0 110.475 178.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.3 t -59.89 -42.94 90.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.704 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.513 HD21 ' HB ' ' A' ' 40' ' ' ILE . 24.0 tp -64.65 -43.45 93.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.811 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.22 -40.21 71.06 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.917 -0.583 . . . . 0.0 112.753 -177.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.5 mm-40 -62.5 -38.71 90.97 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.914 0.388 . . . . 0.0 110.964 178.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.1 mt -83.87 -10.96 57.63 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.505 179.333 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 54.08 61.54 3.01 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.669 -177.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.449 ' HB ' HD12 ' A' ' 33' ' ' LEU . 69.2 mt -106.6 115.33 60.81 Favored Pre-proline 0 C--N 1.32 -0.704 0 CA-C-N 115.868 -0.605 . . . . 0.0 109.68 176.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -56.81 113.3 1.41 Allowed 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.695 2.263 . . . . 0.0 112.406 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.521 HD12 ' HB3' ' A' ' 54' ' ' ASP . 15.0 tt -72.7 -6.54 8.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.485 0.659 . . . . 0.0 110.819 -178.514 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -67.83 -29.28 68.4 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.998 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.534 HG23 HG13 ' A' ' 43' ' ' VAL . 9.3 t -106.44 0.05 24.49 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.734 -173.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.557 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 34.3 m -132.29 156.26 42.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.021 0.439 . . . . 0.0 111.46 -177.322 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 59.0 t -113.8 139.67 38.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.383 176.16 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.43 HG11 HG21 ' A' ' 29' ' ' ILE . 37.1 t -102.98 127.42 56.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.032 0.444 . . . . 0.0 110.218 -179.258 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.618 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 41.1 mttm -124.75 145.02 49.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.401 -178.081 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.582 ' HG2' HG21 ' A' ' 52' ' ' VAL . 28.8 mmtp -112.15 102.41 10.6 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 169.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.9 m120 56.05 24.55 7.93 Favored 'General case' 0 N--CA 1.465 0.323 0 O-C-N 123.451 0.469 . . . . 0.0 111.598 -178.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 115.95 -21.04 12.59 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.921 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 17.0 mm-40 -85.3 132.28 34.28 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.772 0.32 . . . . 0.0 110.833 -176.187 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.3 mp -73.99 116.76 16.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.957 0.408 . . . . 0.0 110.294 -179.39 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.906 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 29.3 m -123.63 173.94 8.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.673 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 28.1 pt -101.52 175.3 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.572 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.521 ' HB3' HD12 ' A' ' 40' ' ' ILE . 9.5 p-10 -74.53 -15.52 60.86 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.552 -177.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.1 tt0 -81.62 -5.08 57.71 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.823 0.344 . . . . 0.0 110.9 -178.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.906 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 17.2 mm-40 -69.16 142.3 54.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.824 0.345 . . . . 0.0 110.944 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 51.1 mp0 -79.9 166.52 21.57 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.562 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.517 HG23 HD11 ' A' ' 64' ' ' ILE . 55.2 mt -112.45 139.25 38.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 175.355 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 80.3 m-85 -124.18 162.24 24.04 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.778 0.323 . . . . 0.0 110.695 -176.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.521 ' OD1' ' HG2' ' A' ' 9' ' ' LYS . 21.6 t70 -71.77 117.33 13.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.329 177.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.53 -9.56 60.71 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 -179.106 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -78.09 143.83 37.04 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.493 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.563 HG23 HG23 ' A' ' 11' ' ' THR . 45.1 mt -115.35 118.5 58.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-O 121.23 0.538 . . . . 0.0 111.126 -173.42 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.762 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 4.0 mp -101.7 130.91 50.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.623 -178.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.669 ' HA ' HG22 ' A' ' 13' ' ' ILE . 53.0 mt-10 -120.64 118.53 30.38 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 178.647 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 62.0 t -114.06 102.79 14.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.129 0.49 . . . . 0.0 110.235 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.08 137.95 51.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 -179.01 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.557 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 76.0 mtp180 . . . . . 0 C--N 1.326 -0.446 0 CA-C-O 120.976 0.417 . . . . 0.0 110.717 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 60.0 mt . . . . . 0 N--CA 1.454 -0.248 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.99 -179.54 16.53 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.446 -178.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . 0.496 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 25.5 ptt? -156.07 137.91 14.36 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.032 0.444 . . . . 0.0 110.887 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.402 ' HE3' ' HB2' ' A' ' 22' ' ' GLU . 30.4 tttt -123.72 114.58 20.12 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 174.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -127.98 167.99 15.9 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.283 -173.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.458 ' HB ' HD13 ' A' ' 20' ' ' ILE . 12.9 t -115.42 138.51 50.93 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.922 0.391 . . . . 0.0 110.318 178.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.4 p -128.41 136.79 59.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.099 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.585 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -107.98 124.85 64.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.3 0.571 . . . . 0.0 109.815 177.785 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.7 p -129.15 -163.03 1.25 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.238 -179.038 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -67.57 -24.36 65.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.024 0.44 . . . . 0.0 110.664 178.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -82.69 -11.5 58.29 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.393 0.616 . . . . 0.0 110.48 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 115.93 -167.65 12.49 Favored Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.419 -176.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.585 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 33.1 ttpt -98.99 127.87 45.0 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -177.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.457 ' HE3' ' HB2' ' A' ' 19' ' ' LYS . 29.9 ttmt -137.57 164.26 29.19 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.482 -174.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.458 HD13 ' HB ' ' A' ' 11' ' ' THR . 34.3 mm -98.38 126.44 51.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.7 0.286 . . . . 0.0 111.015 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.446 HD13 HG12 ' A' ' 12' ' ' VAL . 6.9 mp -111.51 144.44 40.73 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.192 176.443 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.402 ' HB2' ' HE3' ' A' ' 9' ' ' LYS . 40.6 tt0 -127.25 134.88 50.02 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.146 -177.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.0 t -134.19 143.79 48.08 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 177.017 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.6 -18.38 75.58 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 121.234 -0.508 . . . . 0.0 113.246 -176.429 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -139.07 151.14 67.26 Favored Pre-proline 0 C--N 1.324 -0.539 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.496 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 25.0 Cg_exo -63.96 119.53 6.61 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.394 2.063 . . . . 0.0 111.234 174.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.421 ' HB3' ' CB ' ' A' ' 31' ' ' ASP . 50.9 mmm-85 -116.6 157.66 24.96 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.191 -175.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.625 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 23.4 mtt180 -82.08 167.35 18.88 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 172.044 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.547 ' HB ' ' HA ' ' A' ' 54' ' ' ASP . 48.9 mm -61.14 -35.16 63.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 168.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 40.7 tptt -61.37 -33.92 74.45 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 114.662 -1.154 . . . . 0.0 110.822 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.421 ' CB ' ' HB3' ' A' ' 27' ' ' ARG . 4.5 m-20 -65.87 -58.48 5.49 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.317 177.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 58.6 t -59.43 -53.04 53.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.329 -176.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.573 ' HG ' ' HB ' ' A' ' 38' ' ' ILE . 10.7 mp -71.82 -35.88 70.06 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.367 -176.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.83 -43.6 58.36 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.662 179.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -73.09 -33.04 65.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.023 0.439 . . . . 0.0 111.154 -175.101 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.0 mt -97.35 -5.99 35.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.449 -0.342 . . . . 0.0 111.511 -178.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 62.23 75.18 0.41 Allowed 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.684 0.754 . . . . 0.0 110.717 -176.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.573 ' HB ' ' HG ' ' A' ' 33' ' ' LEU . 67.4 mt -123.66 116.27 27.93 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.756 178.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 17.1 Cg_exo -67.04 109.64 1.77 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.658 2.238 . . . . 0.0 112.906 -178.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.444 ' HB ' HD23 ' A' ' 33' ' ' LEU . 9.9 tt -81.59 -5.74 9.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 122.009 0.909 . . . . 0.0 109.203 176.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -69.84 -31.64 69.6 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.855 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.58 HG23 HG13 ' A' ' 43' ' ' VAL . 4.6 t -96.14 -36.95 10.79 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.71 0.633 . . . . 0.0 112.71 -172.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.58 HG13 HG23 ' A' ' 42' ' ' THR . 21.3 m -116.56 162.61 14.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 C-N-CA 120.888 -0.325 . . . . 0.0 111.069 -175.745 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.9 t -102.93 131.93 50.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 120.855 0.36 . . . . 0.0 111.671 -173.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.0 t -103.65 130.5 54.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.938 176.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.639 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 92.5 mttt -118.81 143.61 46.83 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.842 0.353 . . . . 0.0 111.442 179.451 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.774 ' HG2' HG21 ' A' ' 52' ' ' VAL . 10.0 mmtp -100.57 102.2 13.3 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 170.273 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 65.49 -1.01 1.06 Allowed 'General case' 0 CA--C 1.541 0.619 0 O-C-N 123.426 0.454 . . . . 0.0 111.512 178.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 132.2 -10.64 5.34 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 121.107 -0.568 . . . . 0.0 111.907 -176.513 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . 0.428 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 14.6 mm100 -87.07 128.1 35.11 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 122.045 0.138 . . . . 0.0 110.664 178.735 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.404 ' H ' HD12 ' A' ' 51' ' ' ILE . 3.8 mp -71.32 114.85 10.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.037 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.774 HG21 ' HG2' ' A' ' 47' ' ' LYS . 28.1 m -125.77 178.79 3.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.117 0.484 . . . . 0.0 111.52 -174.591 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.44 HG13 ' H ' ' A' ' 55' ' ' GLU . 24.7 pt -115.09 -170.92 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.348 177.263 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.547 ' HA ' ' HB ' ' A' ' 29' ' ' ILE . 35.1 p-10 -77.49 -7.19 55.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.656 -175.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.44 ' H ' HG13 ' A' ' 53' ' ' ILE . 7.5 tp10 -72.79 -22.16 60.88 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.918 -179.429 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.565 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 8.0 mm-40 -69.11 135.71 51.14 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.497 0.554 . . . . 0.0 112.497 -174.379 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.625 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 58.1 mp0 -82.38 144.2 30.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.914 173.315 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 30.9 mt -91.21 142.34 13.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 176.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -119.4 162.2 19.22 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.856 0.36 . . . . 0.0 110.75 -177.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -69.06 131.14 44.55 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.599 173.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.59 23.51 75.07 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.924 -177.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 31.2 t0 -97.4 154.04 17.72 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 178.046 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.447 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.0 mp -110.21 116.78 53.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-O 121.03 0.443 . . . . 0.0 110.525 -177.618 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 41.5 mm -103.55 108.84 25.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.899 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.639 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 44.5 mt-10 -102.22 107.16 18.13 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 178.205 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 93.4 t -97.05 102.45 13.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.38 0.609 . . . . 0.0 109.681 178.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 64.0 mt -96.36 105.88 17.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.406 -177.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.488 ' HA ' ' CG1' ' A' ' 43' ' ' VAL . 0.6 OUTLIER . . . . . 0 C--N 1.32 -0.711 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.521 174.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.437 ' N ' HD12 ' A' ' 6' ' ' ILE . 3.2 mp . . . . . 0 N--CA 1.455 -0.224 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.33 179.96 45.16 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.14 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . 0.543 ' HA ' ' OD1' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -159.91 158.07 30.15 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.762 0.315 . . . . 0.0 110.221 178.701 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.601 ' HB2' HD11 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -133.79 145.78 50.08 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 173.32 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.5 ' CD2' HD13 ' A' ' 64' ' ' ILE . 38.4 p90 -144.41 141.06 29.39 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.388 -178.507 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.643 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 18.0 m -95.39 118.35 31.98 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.079 0.466 . . . . 0.0 110.06 177.114 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.2 p -107.33 134.17 49.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.955 -179.666 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.496 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -103.76 127.48 57.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 121.528 0.68 . . . . 0.0 109.6 177.647 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 16.7 m -141.81 166.86 23.58 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.5 m-20 -63.73 -17.77 63.35 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.868 0.366 . . . . 0.0 111.076 177.223 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -77.73 -10.98 59.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.335 0.588 . . . . 0.0 110.132 175.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 129.44 157.87 9.32 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 112.124 179.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.441 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.9 ttmt -86.1 109.96 19.21 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 173.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -129.14 131.86 47.26 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.271 -173.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.643 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -81.84 124.3 38.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.397 0.618 . . . . 0.0 110.042 176.042 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.47 HD13 ' N ' ' A' ' 22' ' ' GLU . 1.1 tm? -106.81 135.28 48.62 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -178.367 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.47 ' N ' HD13 ' A' ' 21' ' ' LEU . 4.9 tm-20 -115.36 131.53 56.9 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -177.018 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.2 m -135.4 126.64 28.24 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.83 0.348 . . . . 0.0 110.787 -179.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -72.0 -17.57 77.16 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.079 178.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -118.77 121.72 30.43 Favored Pre-proline 0 C--N 1.321 -0.665 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 176.757 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_exo -48.61 139.13 24.21 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.138 2.559 . . . . 0.0 111.729 177.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.571 ' HG3' ' HB2' ' A' ' 31' ' ' ASP . 1.9 tpp85 -133.51 147.48 51.62 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.761 0.315 . . . . 0.0 111.122 -170.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.555 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 40.0 ttm105 -91.57 161.1 15.08 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 176.108 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 33.8 mm -58.95 -51.12 76.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 110.376 -0.231 . . . . 0.0 110.376 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.4 tttp -54.83 -36.03 64.59 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.891 176.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.571 ' HB2' ' HG3' ' A' ' 27' ' ' ARG . 22.7 m-20 -61.38 -58.45 8.18 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.145 179.177 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.7 t -60.56 -43.17 93.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.086 0.469 . . . . 0.0 110.672 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.642 HD21 ' HB ' ' A' ' 40' ' ' ILE . 9.3 tp -61.55 -48.18 82.16 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.731 -179.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.88 -38.77 60.24 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.531 -0.759 . . . . 0.0 113.036 -178.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -68.15 -41.74 81.13 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 122.526 0.33 . . . . 0.0 111.48 -176.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.1 mt -89.82 0.34 57.09 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.707 0.289 . . . . 0.0 110.9 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 53.75 65.79 1.41 Allowed 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.753 -178.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.586 ' HB ' HD12 ' A' ' 33' ' ' LEU . 63.2 mt -102.63 121.81 48.34 Favored Pre-proline 0 C--N 1.318 -0.798 0 CA-C-N 115.256 -0.883 . . . . 0.0 109.32 177.671 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 13.8 Cg_exo -68.74 102.53 0.88 Allowed 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.612 2.208 . . . . 0.0 112.492 -178.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.642 ' HB ' HD21 ' A' ' 33' ' ' LEU . 13.2 tt -71.24 -6.51 7.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.736 0.779 . . . . 0.0 109.835 177.034 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 -59.74 -31.77 69.95 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.248 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 12.0 t -130.35 12.01 5.45 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.001 0.429 . . . . 0.0 111.805 -171.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.561 HG12 ' HG2' ' A' ' 68' ' ' ARG . 29.9 m -128.51 144.35 38.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 O-C-N 121.707 -0.621 . . . . 0.0 111.524 -179.298 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.0 t -109.57 131.14 61.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.09 177.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.1 t -103.1 128.49 56.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.032 0.444 . . . . 0.0 110.501 -177.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.58 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 53.3 mttp -123.18 133.39 54.24 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.257 179.372 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.635 ' HG2' HG21 ' A' ' 52' ' ' VAL . 21.5 mmtp -95.02 105.97 17.93 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 171.365 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 18.0 m120 59.52 21.09 9.57 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.361 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 110.51 -17.67 28.16 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.731 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -87.6 131.61 34.36 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 122.636 -0.332 . . . . 0.0 110.827 -177.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.51 ' H ' HD12 ' A' ' 51' ' ' ILE . 4.2 mp -67.25 122.08 17.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.994 179.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 1.148 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 20.5 m -123.65 178.99 2.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.952 -173.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 41.4 pt -113.52 174.66 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.377 0.608 . . . . 0.0 112.626 -171.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -53.33 -39.5 64.14 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.31 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.4 ' HG2' ' O ' ' A' ' 55' ' ' GLU . 38.4 tt0 -82.68 0.31 43.85 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -172.332 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 1.148 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 15.6 mm-40 -61.33 133.18 55.57 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.825 0.345 . . . . 0.0 111.023 178.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.555 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 31.2 mt-10 -101.92 150.15 23.49 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.374 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 48.7 mt -100.59 126.89 54.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.259 -177.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -108.58 171.52 7.37 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.439 -178.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.543 ' OD1' ' HA ' ' A' ' 8' ' ' MET . 25.8 t70 -69.66 112.81 6.39 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.888 0.375 . . . . 0.0 110.366 -178.436 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.83 36.8 5.94 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.785 -0.722 . . . . 0.0 111.477 -177.268 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.408 ' OD1' ' HD2' ' A' ' 47' ' ' LYS . 2.7 t0 -96.04 161.31 14.03 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 42.2 mm -128.65 112.65 26.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.847 0.356 . . . . 0.0 110.223 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.5 HD13 ' CD2' ' A' ' 10' ' ' PHE . 2.9 mp -110.62 118.62 57.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.148 0.499 . . . . 0.0 110.527 -177.528 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.58 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 41.6 mt-10 -105.42 114.08 28.04 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.227 176.589 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 86.9 t -100.65 108.55 23.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.155 0.502 . . . . 0.0 109.849 177.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 47.7 mt -112.04 117.25 54.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.74 -0.663 . . . . 0.0 110.127 -176.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.561 ' HG2' HG12 ' A' ' 43' ' ' VAL . 49.4 mtm180 . . . . . 0 C--N 1.322 -0.614 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.587 -179.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 69.4 mt . . . . . 0 N--CA 1.451 -0.416 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 105.5 -176.99 22.71 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 -175.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.42 158.57 29.7 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 117.077 0.439 . . . . 0.0 111.525 -179.008 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 25.8 mtpp -120.28 137.91 53.98 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.22 176.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.561 ' CD2' HD13 ' A' ' 64' ' ' ILE . 44.4 p90 -150.13 162.89 39.56 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.002 0.43 . . . . 0.0 110.837 178.216 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 t -109.28 138.85 45.01 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.794 177.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.558 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 5.3 p -129.25 122.13 55.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.25 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.642 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -88.0 125.0 41.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.814 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.448 ' N ' HD13 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -132.62 -171.19 2.6 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.449 -175.732 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -56.81 -46.01 81.87 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -175.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -90.42 7.68 37.52 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 111.722 0.267 . . . . 0.0 111.722 -173.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 131.02 -169.77 21.53 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.328 178.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.562 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.7 ttmt -100.8 123.01 44.38 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.883 0.373 . . . . 0.0 110.085 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 51.0 mttm -103.15 146.36 28.53 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.005 -176.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -120.65 121.15 64.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 170.552 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.415 HD11 ' CZ ' ' A' ' 10' ' ' PHE . 4.3 pp -138.49 171.76 13.9 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.885 0.374 . . . . 0.0 111.4 -173.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -131.61 142.53 49.9 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.249 -174.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -121.56 143.44 49.29 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 176.26 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -73.79 -13.81 80.35 Favored Glycine 0 C--N 1.33 0.226 0 C-N-CA 121.165 -0.54 . . . . 0.0 112.759 -174.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.421 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -138.85 144.32 41.05 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 177.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -57.5 120.59 8.61 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 122.321 2.014 . . . . 0.0 111.096 176.387 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.421 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 17.8 mmt180 -113.22 155.97 24.1 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.269 0.557 . . . . 0.0 111.221 -174.096 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.603 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 28.0 ttm180 -95.48 162.44 13.65 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 173.351 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.538 HD13 HD11 ' A' ' 58' ' ' ILE . 29.2 mm -54.56 -39.53 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.927 0.394 . . . . 0.0 110.733 179.248 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.507 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 17.1 tptm -64.25 -25.93 68.28 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.103 179.331 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.411 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 67.3 m-20 -73.54 -46.59 46.68 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-O 120.689 0.281 . . . . 0.0 110.638 178.707 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.1 t -61.47 -50.16 81.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.642 -178.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.43 HD13 ' HA ' ' A' ' 33' ' ' LEU . 4.1 mm? -68.36 -29.12 67.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.368 177.067 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.33 -42.68 64.92 Favored Glycine 0 CA--C 1.522 0.497 0 CA-C-N 115.985 -0.552 . . . . 0.0 112.736 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.411 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 7.2 mm-40 -68.95 -35.72 77.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.849 0.357 . . . . 0.0 111.115 -179.303 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.0 mt -85.64 -14.52 45.33 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.434 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 63.43 20.35 12.2 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.772 179.032 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.451 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 69.6 mt -79.86 131.54 63.41 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.983 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 22.2 Cg_exo -63.54 105.15 0.49 Allowed 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.491 2.127 . . . . 0.0 112.162 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.417 ' HB ' ' HG ' ' A' ' 33' ' ' LEU . 13.0 tt -67.8 -17.32 22.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.516 0.674 . . . . 0.0 110.377 178.312 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.3 tp10 -64.65 -37.93 89.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.503 -0.772 . . . . 0.0 111.885 -176.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.58 HG23 HG13 ' A' ' 43' ' ' VAL . 10.5 t -85.82 -9.88 56.33 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -170.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.58 HG13 HG23 ' A' ' 42' ' ' THR . 30.8 m -131.06 169.29 21.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 O-C-N 121.974 -0.454 . . . . 0.0 111.118 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.599 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 46.9 t -107.26 134.63 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.778 0.323 . . . . 0.0 111.079 -176.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.1 t -108.67 133.21 54.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.975 0.417 . . . . 0.0 110.72 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.649 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 73.6 mttt -118.53 146.54 44.47 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.144 177.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.846 ' HG2' HG21 ' A' ' 52' ' ' VAL . 4.0 mmtp -117.69 103.04 9.63 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.125 172.565 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.8 t-20 67.99 7.78 6.04 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.954 176.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 127.95 -25.04 5.02 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.86 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 71.9 mt-30 -87.74 142.42 27.84 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.71 0.255 . . . . 0.0 111.148 -178.211 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.409 HD12 ' N ' ' A' ' 51' ' ' ILE . 3.5 mp -77.99 119.58 27.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 177.017 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.846 HG21 ' HG2' ' A' ' 47' ' ' LYS . 27.5 m -124.97 178.67 3.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.062 0.458 . . . . 0.0 112.081 -170.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 32.2 pt -106.59 -174.01 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.618 178.233 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.507 ' HB2' ' HD3' ' A' ' 30' ' ' LYS . 15.6 p-10 -77.6 -15.2 59.37 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.446 -176.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.597 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 65.3 mm-40 -84.53 5.28 28.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.757 0.313 . . . . 0.0 111.653 -178.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.731 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 26.3 mm-40 -80.93 127.77 32.94 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.905 0.384 . . . . 0.0 110.63 176.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.603 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 33.8 mt-10 -88.9 148.01 24.05 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.494 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.538 HD11 HD13 ' A' ' 29' ' ' ILE . 25.3 mt -101.54 120.1 50.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.269 -177.457 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.482 ' O ' ' HB2' ' A' ' 62' ' ' ASP . 90.9 m-85 -99.31 170.58 8.55 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.585 -178.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -70.26 114.76 8.71 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.84 0.353 . . . . 0.0 110.605 178.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.26 11.71 38.31 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.705 -177.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.482 ' HB2' ' O ' ' A' ' 59' ' ' PHE . 2.7 t0 -74.49 161.03 30.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 110.277 -177.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.8 mm -128.21 111.8 25.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.561 HD13 ' CD2' ' A' ' 10' ' ' PHE . 2.7 mp -108.95 119.17 58.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.189 0.518 . . . . 0.0 110.649 -178.264 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.649 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 39.7 mt-10 -105.91 112.59 25.71 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.477 176.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 73.1 t -97.33 106.88 19.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.485 0.66 . . . . 0.0 110.424 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.599 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 58.8 mt -93.54 93.22 3.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.11 -179.534 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.478 ' HA ' HG12 ' A' ' 43' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.319 -0.727 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 173.256 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.412 HG22 ' O ' ' A' ' 24' ' ' GLY . 50.0 mm . . . . . 0 N--CA 1.454 -0.229 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.05 -156.99 19.18 Favored Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 -176.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.69 151.82 18.97 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.919 0.39 . . . . 0.0 111.49 -179.465 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 37.2 ttpt -117.19 119.79 36.3 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 173.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -139.03 167.92 20.98 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.903 0.382 . . . . 0.0 110.835 -173.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.56 ' HB ' HD13 ' A' ' 20' ' ' ILE . 11.4 t -115.04 138.97 50.26 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-O 121.195 0.522 . . . . 0.0 110.738 178.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.474 HG23 ' HB ' ' A' ' 64' ' ' ILE . 10.0 p -127.09 138.28 55.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.253 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.494 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -116.93 121.24 67.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.345 0.593 . . . . 0.0 109.964 179.955 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 72.8 p -130.88 -163.73 1.35 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.083 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.837 ' HB3' ' HD3' ' A' ' 68' ' ' ARG . 8.7 p-10 -69.97 -21.92 63.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.88 0.371 . . . . 0.0 110.832 178.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -82.15 -10.81 59.04 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.478 0.656 . . . . 0.0 110.059 178.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 121.56 -167.91 14.38 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.046 178.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.8 ttmt -104.09 115.23 30.05 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -112.48 154.96 25.07 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.981 0.419 . . . . 0.0 112.009 -174.569 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.56 HD13 ' HB ' ' A' ' 11' ' ' THR . 24.3 mm -109.06 121.6 62.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 170.459 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.435 HD23 ' H ' ' A' ' 21' ' ' LEU . 1.9 pt? -128.53 161.29 29.91 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.064 0.459 . . . . 0.0 110.99 -178.617 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -126.4 141.17 51.99 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.137 -173.441 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.2 t -130.15 140.57 50.76 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 175.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.412 ' O ' HG22 ' A' ' 6' ' ' ILE . . . -80.87 -16.12 75.86 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.344 -177.543 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -138.42 148.61 59.9 Favored Pre-proline 0 C--N 1.321 -0.651 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.159 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -57.74 142.49 96.03 Favored 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.604 2.203 . . . . 0.0 111.782 177.182 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.564 ' HG3' ' HB2' ' A' ' 31' ' ' ASP . 10.4 tpt180 -137.92 158.37 44.48 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.489 -0.559 . . . . 0.0 109.489 -172.253 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.591 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 76.3 mtm180 -102.34 173.62 6.28 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.834 0.349 . . . . 0.0 110.804 173.534 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.607 ' HB ' ' HA ' ' A' ' 54' ' ' ASP . 18.3 mt -68.14 -42.79 85.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.794 175.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.414 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 82.9 tttt -60.69 -32.3 71.53 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.193 176.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.564 ' HB2' ' HG3' ' A' ' 27' ' ' ARG . 81.0 m-20 -67.91 -41.54 82.51 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.701 178.762 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 68.0 t -75.61 -52.75 17.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.862 0.363 . . . . 0.0 110.921 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.402 ' HG ' ' HB ' ' A' ' 38' ' ' ILE . 10.9 mp -61.78 -35.35 77.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.938 178.705 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.39 -33.68 68.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.151 177.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.401 ' HB2' ' O ' ' A' ' 31' ' ' ASP . 3.6 tp10 -60.52 -45.46 93.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.883 0.373 . . . . 0.0 110.73 -178.775 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.4 mt -102.0 6.73 41.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.814 -176.235 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 53.59 69.56 0.69 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.552 0.692 . . . . 0.0 111.064 -176.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.402 ' HB ' ' HG ' ' A' ' 33' ' ' LEU . 62.8 mt -111.5 117.37 49.23 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.065 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.515 ' HB2' HG22 ' A' ' 42' ' ' THR . 17.0 Cg_exo -67.05 113.64 2.9 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.889 2.393 . . . . 0.0 112.016 178.383 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 10.8 tt -79.6 -13.04 13.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.501 0.667 . . . . 0.0 110.59 -178.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -75.63 -17.24 60.06 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.58 -177.027 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.563 HG23 HG13 ' A' ' 43' ' ' VAL . 9.8 t -108.71 -8.33 15.42 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -174.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.563 HG13 HG23 ' A' ' 42' ' ' THR . 17.8 m -133.24 167.09 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 O-C-N 122.099 -0.376 . . . . 0.0 110.872 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.462 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 51.9 t -105.26 121.95 57.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.91 -178.222 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.8 t -103.71 127.07 58.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.031 177.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.632 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 98.8 mttt -122.82 144.61 49.07 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.991 0.424 . . . . 0.0 111.82 -178.812 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.561 ' HG2' HG21 ' A' ' 52' ' ' VAL . 17.9 mmtp -100.92 101.9 12.81 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.229 167.753 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.8 t-20 63.28 2.33 1.11 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.996 0.518 . . . . 0.0 111.805 178.674 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 136.14 -17.27 3.85 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 121.083 -0.579 . . . . 0.0 112.353 -178.533 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . 0.475 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 17.6 mm-40 -87.16 129.53 34.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.407 0.146 . . . . 0.0 110.939 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.6 mp -69.36 120.78 17.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 176.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.561 HG21 ' HG2' ' A' ' 47' ' ' LYS . 17.4 m -124.95 177.48 4.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.149 -176.785 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.471 ' O ' HD12 ' A' ' 29' ' ' ILE . 26.9 pt -113.0 179.63 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.282 174.578 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.607 ' HA ' ' HB ' ' A' ' 29' ' ' ILE . 8.4 p-10 -73.22 -6.09 43.62 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.851 -175.338 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -81.43 -2.12 48.3 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.389 -176.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 58.9 mm-40 -89.69 150.39 22.36 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 122.171 -0.33 . . . . 0.0 111.518 -177.34 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.591 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 21.0 mp0 -88.05 157.07 18.99 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.112 177.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.463 HG12 ' O ' ' A' ' 27' ' ' ARG . 2.6 mm -96.47 134.48 33.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 173.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -116.63 167.48 11.03 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.027 0.442 . . . . 0.0 111.275 -175.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -73.97 129.51 38.02 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.111 175.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.75 18.72 79.52 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.433 -176.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -91.51 157.06 17.24 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 179.631 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.457 HG12 HG22 ' A' ' 11' ' ' THR . 10.5 mt -128.3 114.27 33.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.228 0.537 . . . . 0.0 110.897 -175.331 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.474 ' HB ' HG23 ' A' ' 12' ' ' VAL . 22.0 mm -96.67 106.89 19.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.278 -178.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.632 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 35.4 tt0 -97.19 101.99 13.66 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 176.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.46 HG23 HG22 ' A' ' 64' ' ' ILE . 80.3 t -100.24 105.94 18.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.209 0.528 . . . . 0.0 110.116 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.462 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 26.2 mt -91.96 95.88 5.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.086 178.415 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.837 ' HD3' ' HB3' ' A' ' 15' ' ' ASP . 1.2 ptm180 . . . . . 0 C--N 1.32 -0.679 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.639 178.094 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 62.4 mt . . . . . 0 N--CA 1.453 -0.323 0 CA-C-O 120.965 0.412 . . . . 0.0 110.385 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 112.27 120.3 3.81 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.979 -0.629 . . . . 0.0 111.73 -177.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . 0.495 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.1 ptt? -113.77 134.38 54.81 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.331 0.586 . . . . 0.0 111.379 -175.354 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.853 ' HD3' ' HB3' ' A' ' 22' ' ' GLU . 6.1 tppt? -106.79 126.64 52.55 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.025 176.37 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -152.81 147.63 26.26 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.141 0.496 . . . . 0.0 111.342 179.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.563 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.1 t -98.56 142.59 29.96 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.015 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.6 p -118.73 119.49 61.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.505 0.669 . . . . 0.0 110.002 176.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.51 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -106.75 117.03 51.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-O 121.864 0.84 . . . . 0.0 108.928 176.998 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.485 HG22 ' H ' ' A' ' 15' ' ' ASP . 1.4 m -114.75 175.33 5.54 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.221 -177.472 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.485 ' H ' HG22 ' A' ' 14' ' ' THR . 28.1 t70 -56.34 -23.29 36.35 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-O 120.95 0.405 . . . . 0.0 111.475 178.501 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -87.09 -12.27 47.67 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.559 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 133.43 -174.81 20.52 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.382 -0.913 . . . . 0.0 112.184 -177.276 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.51 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.7 ttmt -109.94 139.49 44.99 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.66 0.267 . . . . 0.0 110.997 -175.303 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -150.23 136.48 18.77 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 173.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.563 HD11 ' HG3' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -98.74 136.18 30.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.748 0.309 . . . . 0.0 110.341 -177.642 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.3 pp -138.58 170.54 15.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.087 177.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.853 ' HB3' ' HD3' ' A' ' 9' ' ' LYS . 13.3 pt-20 -138.84 150.33 45.9 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.925 0.393 . . . . 0.0 111.396 -178.325 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 40.8 m -135.61 133.69 38.52 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.115 177.739 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -74.31 4.08 35.77 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 121.326 -0.464 . . . . 0.0 113.252 -177.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.465 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -135.35 127.97 18.08 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.648 0.224 . . . . 0.0 110.504 178.527 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.495 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 21.9 Cg_exo -65.15 128.77 21.28 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.781 2.321 . . . . 0.0 110.982 176.159 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.56 ' HA ' ' NE ' ' A' ' 27' ' ' ARG . 0.0 OUTLIER -134.21 171.43 14.25 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.406 -170.838 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.4 ttp-105 -104.03 160.72 14.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.704 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 38.2 mm -56.49 -47.49 81.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.34 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.483 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 29.7 tptp -55.57 -37.99 68.77 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.335 -179.631 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -69.52 -57.43 5.22 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.006 -178.682 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 69.1 t -61.3 -47.93 91.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.855 -177.072 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 19.6 tp -68.02 -35.72 78.75 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.22 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.11 -44.28 61.22 Favored Glycine 0 N--CA 1.447 -0.633 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.62 -179.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -68.97 -21.86 64.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.735 0.302 . . . . 0.0 111.427 179.679 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.5 mt -89.25 -2.87 58.65 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.004 0.43 . . . . 0.0 110.224 174.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 57.48 45.69 19.21 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.125 176.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.429 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 69.0 mt -106.68 117.29 57.23 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.573 176.125 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 16.5 Cg_exo -67.54 112.41 2.61 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.773 2.315 . . . . 0.0 112.766 -176.493 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.563 ' HA ' HG22 ' A' ' 43' ' ' VAL . 11.2 tt -69.23 -14.68 18.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.587 0.708 . . . . 0.0 109.885 177.466 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -60.48 -28.96 68.75 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.61 -179.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 12.9 t -122.53 7.86 9.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.031 0.443 . . . . 0.0 111.589 -172.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.589 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 3.6 m -131.65 149.32 32.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 C-N-CA 120.386 -0.525 . . . . 0.0 110.768 -179.162 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.6 t -99.57 129.75 49.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.132 0.491 . . . . 0.0 110.288 179.134 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.8 t -103.3 127.48 57.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.555 -178.651 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.638 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 65.8 mttt -119.29 139.87 51.21 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.696 178.576 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.569 ' HE3' ' O ' ' A' ' 57' ' ' GLU . 9.1 mtpm? -127.07 115.88 19.84 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.928 175.152 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 62.36 22.56 13.3 Favored 'General case' 0 C--N 1.326 -0.419 0 O-C-N 123.597 0.56 . . . . 0.0 110.377 178.075 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.85 -14.41 57.43 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.548 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . 0.465 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 68.3 mt-30 -88.07 140.56 29.37 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 122.102 0.161 . . . . 0.0 111.046 -175.625 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.411 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.4 mp -80.07 113.16 19.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 174.124 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.886 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 35.8 m -125.55 178.92 3.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.071 0.462 . . . . 0.0 111.863 -169.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.428 HG13 ' H ' ' A' ' 55' ' ' GLU . 31.2 pt -112.62 -170.86 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.645 178.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.483 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 7.9 p-10 -81.15 -7.87 59.65 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.794 -174.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.428 ' H ' HG13 ' A' ' 53' ' ' ILE . 0.7 OUTLIER -91.08 12.36 20.14 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-O 121.544 0.688 . . . . 0.0 110.216 -177.772 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.886 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 8.3 mm-40 -88.3 128.24 35.48 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.147 179.069 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.569 ' O ' ' HE3' ' A' ' 47' ' ' LYS . 10.7 mm-40 -76.6 142.61 40.65 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.797 177.06 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 39.4 mt -92.23 137.59 21.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 177.119 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -117.06 149.0 41.01 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.055 0.455 . . . . 0.0 111.228 -174.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -66.71 117.2 8.51 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.788 176.168 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.21 11.8 53.46 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 121.152 -0.547 . . . . 0.0 112.223 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 36.6 t0 -97.68 161.94 13.52 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 179.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.436 HD12 HG22 ' A' ' 11' ' ' THR . 50.5 mm -112.24 126.18 69.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.822 0.344 . . . . 0.0 110.531 -177.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 47.3 mm -107.08 130.2 59.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.435 -179.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.638 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 33.7 mt-10 -122.11 129.2 52.15 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 177.651 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 54.3 t -122.33 110.29 26.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.311 0.577 . . . . 0.0 110.634 177.173 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.5 mt -118.28 101.7 12.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.407 -178.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.589 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 14.3 ptt180 . . . . . 0 C--N 1.319 -0.722 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.085 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.1 tp . . . . . 0 N--CA 1.452 -0.353 0 CA-C-O 121.098 0.475 . . . . 0.0 109.743 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.91 151.75 28.2 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.612 -175.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . 0.502 ' HE1' ' HB2' ' A' ' 27' ' ' ARG . 17.1 mtm -128.98 139.91 51.89 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.876 0.369 . . . . 0.0 110.622 -176.051 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -103.89 111.11 23.51 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 173.385 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 23.5 p90 -138.96 161.48 37.25 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.106 0.479 . . . . 0.0 110.923 -178.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.432 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.5 t -118.7 144.3 46.31 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.408 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.2 p -117.16 126.3 74.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.122 0.486 . . . . 0.0 109.721 176.278 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.556 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -112.86 127.73 69.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.247 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.628 HG22 ' H ' ' A' ' 15' ' ' ASP . 6.8 m -144.2 -177.04 5.26 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 -177.092 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.628 ' H ' HG22 ' A' ' 14' ' ' THR . 0.8 OUTLIER -49.46 -32.94 13.02 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.184 0.516 . . . . 0.0 110.892 173.714 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -80.5 4.25 18.91 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.153 -177.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 107.49 -177.37 21.35 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.067 177.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.556 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 40.0 ttmt -104.71 117.29 33.72 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 176.464 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -130.62 139.49 50.39 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.077 0.465 . . . . 0.0 110.61 -176.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.453 HD13 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -91.72 137.79 21.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.155 -176.236 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.453 ' N ' HD13 ' A' ' 20' ' ' ILE . 2.2 pt? -137.65 147.69 45.14 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 178.036 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -123.82 126.73 46.96 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.866 0.365 . . . . 0.0 110.412 -177.041 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.0 m -118.91 124.8 47.98 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.896 178.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -77.55 21.22 3.1 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 121.127 -0.559 . . . . 0.0 113.175 -178.538 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.419 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -139.23 138.95 21.58 Favored Pre-proline 0 C--N 1.322 -0.59 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 178.004 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -62.79 127.65 21.12 Favored 'Trans proline' 0 CA--C 1.531 0.337 0 C-N-CA 122.72 2.28 . . . . 0.0 111.484 175.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.502 ' HB2' ' HE1' ' A' ' 8' ' ' MET . 13.9 mmt180 -126.01 160.59 29.63 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.145 0.497 . . . . 0.0 111.298 -172.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.599 ' HG2' ' HA ' ' A' ' 57' ' ' GLU . 65.3 mtm-85 -113.65 168.56 9.67 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 164.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.744 HD13 HG11 ' A' ' 45' ' ' VAL . 24.9 mt -60.76 -45.41 97.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 120.646 0.26 . . . . 0.0 110.566 -178.265 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -61.28 -32.45 72.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.026 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.47 ' OD2' ' HD2' ' A' ' 27' ' ' ARG . 25.6 t70 -73.57 -42.36 61.72 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.484 -179.427 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.4 t -71.3 -51.79 31.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.006 0.431 . . . . 0.0 110.548 177.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 26.2 tp -61.4 -37.85 84.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.427 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.46 -33.31 72.3 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.476 177.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -71.84 -34.11 69.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.167 0.508 . . . . 0.0 109.995 177.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.2 mt -76.92 -10.56 59.45 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.258 174.701 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 63.3 45.89 4.75 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.689 176.178 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 62.2 mt -115.8 123.08 31.65 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.141 178.77 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_exo -62.69 132.27 36.94 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.754 2.303 . . . . 0.0 112.339 179.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 10.0 tp -70.38 -15.36 19.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.291 0.567 . . . . 0.0 110.61 -179.038 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -63.87 -32.91 74.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.752 178.568 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.509 HG23 HG13 ' A' ' 43' ' ' VAL . 12.0 t -104.02 -1.66 27.14 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 112.095 0.405 . . . . 0.0 112.095 -172.18 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.591 HG12 ' HG3' ' A' ' 68' ' ' ARG . 33.5 m -128.99 146.46 34.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 120.923 0.392 . . . . 0.0 111.202 -178.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.518 HG12 ' HB ' ' A' ' 67' ' ' ILE . 0.6 OUTLIER -110.02 136.94 44.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 175.555 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.744 HG11 HD13 ' A' ' 29' ' ' ILE . 32.6 t -116.21 133.59 62.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.094 0.473 . . . . 0.0 110.932 -177.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.758 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 98.6 mttt -117.84 130.92 56.56 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.255 177.126 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 22.5 ttmm -93.42 105.46 17.53 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 172.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 71.65 -61.3 0.49 Allowed 'General case' 0 C--N 1.33 -0.274 0 O-C-N 124.136 0.897 . . . . 0.0 110.557 -177.099 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -166.6 22.01 0.11 Allowed Glycine 0 N--CA 1.447 -0.585 0 N-CA-C 111.326 -0.709 . . . . 0.0 111.326 177.292 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 35.9 mt-30 -126.5 131.92 51.51 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.194 -0.299 . . . . 0.0 110.194 -176.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.542 HD13 ' HG2' ' A' ' 46' ' ' LYS . 38.9 mm -63.33 122.51 14.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.869 0.366 . . . . 0.0 110.628 177.615 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.7 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 17.3 m -125.74 178.4 4.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.751 -178.688 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.423 ' O ' HD12 ' A' ' 29' ' ' ILE . 26.9 pt -100.17 -177.96 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.659 176.577 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 20.7 p-10 -77.16 -30.12 54.85 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.431 -176.532 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -80.67 14.67 2.01 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 122.094 -0.379 . . . . 0.0 111.897 -173.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.7 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 76.5 mm-40 -86.05 152.07 23.19 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.82 0.343 . . . . 0.0 111.07 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.599 ' HA ' ' HG2' ' A' ' 28' ' ' ARG . 42.2 mp0 -85.52 162.15 19.04 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.925 -177.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 39.9 mm -103.81 144.78 13.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 174.199 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.751 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 81.0 m-85 -114.15 161.01 18.33 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.735 0.302 . . . . 0.0 110.189 179.179 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -77.63 120.87 23.18 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 175.015 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.51 9.93 68.53 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.904 -0.665 . . . . 0.0 111.789 -176.105 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.751 ' HB2' ' HB2' ' A' ' 59' ' ' PHE . 22.0 t0 -87.95 147.0 25.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.96 0.409 . . . . 0.0 110.181 -178.357 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 45.5 mm -105.6 122.95 59.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.23 -176.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.408 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 50.0 mm -109.78 115.19 49.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 120.886 0.374 . . . . 0.0 110.718 -177.579 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.758 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 28.3 tt0 -104.3 114.6 28.94 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.878 177.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.424 ' O ' HG23 ' A' ' 14' ' ' THR . 60.1 t -113.08 113.38 43.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.14 -179.049 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.518 ' HB ' HG12 ' A' ' 44' ' ' VAL . 3.8 mt -116.2 118.75 59.81 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.147 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.591 ' HG3' HG12 ' A' ' 43' ' ' VAL . 0.8 OUTLIER . . . . . 0 C--N 1.323 -0.557 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 176.093 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . 0.425 HG22 ' O ' ' A' ' 24' ' ' GLY . 51.4 mm . . . . . 0 N--CA 1.447 -0.583 0 N-CA-C 109.219 -0.659 . . . . 0.0 109.219 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 133.65 163.64 10.47 Favored Glycine 0 N--CA 1.446 -0.667 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 -174.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . 0.57 ' SD ' ' HB ' ' A' ' 58' ' ' ILE . 25.0 ptt? -160.0 137.15 9.43 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 117.173 0.487 . . . . 0.0 111.282 -176.424 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.876 ' HD3' ' HB3' ' A' ' 22' ' ' GLU . 3.8 tppt? -108.19 120.26 41.83 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 175.41 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -140.56 167.96 20.93 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.744 0.306 . . . . 0.0 110.919 -176.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.497 HG22 HD12 ' A' ' 63' ' ' ILE . 1.2 t -133.72 146.71 51.04 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 177.396 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -117.33 119.11 60.83 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.595 177.147 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -103.28 124.56 57.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.523 0.677 . . . . 0.0 109.511 178.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.424 HG22 ' H ' ' A' ' 15' ' ' ASP . 4.1 m -146.02 173.17 12.41 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -178.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.424 ' H ' HG22 ' A' ' 14' ' ' THR . 8.8 p-10 -64.46 -22.39 66.95 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.317 0.58 . . . . 0.0 109.954 174.338 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -72.23 -11.8 60.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.631 175.706 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 127.19 176.89 14.63 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.904 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -108.17 104.04 13.37 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 177.311 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -104.28 134.12 48.04 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.617 -176.163 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.447 HD13 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -103.33 129.58 54.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 177.269 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.447 ' N ' HD13 ' A' ' 20' ' ' ILE . 94.8 mt -136.26 137.21 40.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.621 -177.379 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.876 ' HB3' ' HD3' ' A' ' 9' ' ' LYS . 17.0 pt-20 -117.62 129.18 55.59 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.364 0.602 . . . . 0.0 110.012 173.742 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.7 m -109.7 145.46 36.51 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.268 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.425 ' O ' HG22 ' A' ' 6' ' ' ILE . . . -78.29 -10.75 85.97 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.407 -178.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.466 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.54 141.4 31.03 Favored Pre-proline 0 C--N 1.325 -0.496 0 N-CA-C 110.57 -0.159 . . . . 0.0 110.57 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.487 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 11.5 Cg_exo -71.32 123.8 9.87 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.835 2.357 . . . . 0.0 111.742 177.047 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.476 ' HB3' ' CB ' ' A' ' 31' ' ' ASP . 16.2 mmm180 -126.66 175.68 7.78 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -178.205 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.672 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 83.4 mtm180 -94.31 175.2 6.78 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.694 0.283 . . . . 0.0 110.579 175.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.732 HD13 HG11 ' A' ' 45' ' ' VAL . 18.2 mt -68.26 -39.73 81.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 177.45 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.535 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 28.2 tptp -59.46 -36.06 75.25 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.695 174.228 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.476 ' CB ' ' HB3' ' A' ' 27' ' ' ARG . 5.9 m-20 -66.07 -62.14 1.65 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.953 177.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.466 HG21 HG13 ' A' ' 58' ' ' ILE . 97.4 t -59.64 -60.6 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.664 -175.686 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 11.1 mp -63.24 -34.36 77.5 Favored 'General case' 0 C--N 1.333 -0.145 0 C-N-CA 120.932 -0.307 . . . . 0.0 111.135 -176.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.3 -47.24 82.07 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.871 -0.681 . . . . 0.0 112.572 -179.309 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -71.08 -22.38 62.11 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.847 0.356 . . . . 0.0 111.09 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 86.6 mt -86.77 1.69 51.37 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.683 176.425 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.9 tt0 65.17 17.17 10.93 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.23 176.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.402 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 71.8 mt -83.33 118.24 70.98 Favored Pre-proline 0 C--N 1.324 -0.54 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.129 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 36.3 Cg_exo -59.93 92.03 0.08 OUTLIER 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 123.128 2.552 . . . . 0.0 112.567 -177.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.548 ' HA ' HG22 ' A' ' 43' ' ' VAL . 14.4 tt -76.24 -17.44 15.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.366 -177.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -67.82 -20.81 65.21 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.685 -177.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.5 t -120.23 10.8 11.42 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -175.106 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.548 HG22 ' HA ' ' A' ' 40' ' ' ILE . 31.5 m -123.0 147.39 27.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 O-C-N 121.769 -0.582 . . . . 0.0 111.372 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.414 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 58.8 t -92.48 120.68 42.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.641 178.427 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.732 HG11 HD13 ' A' ' 29' ' ' ILE . 38.5 t -103.4 130.8 53.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.04 0.448 . . . . 0.0 110.854 -176.513 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.745 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 96.9 mttt -118.61 145.78 45.14 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.3 177.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.648 ' HD2' HG11 ' A' ' 52' ' ' VAL . 60.4 mttm -109.34 102.04 10.98 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.179 168.731 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.0 m120 58.54 19.7 6.87 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.628 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 117.97 -18.21 11.54 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.741 178.601 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 70.6 mm-40 -87.57 130.04 34.88 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.881 0.341 . . . . 0.0 110.535 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.425 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.7 mp -73.86 121.28 24.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.055 -179.511 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.828 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 21.2 m -123.99 178.34 3.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.191 -176.033 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.406 ' O ' HD12 ' A' ' 29' ' ' ILE . 32.0 pt -115.1 173.71 3.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 179.764 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.535 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 3.9 p30 -63.03 -23.82 67.63 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -176.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -71.56 -18.09 62.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.12 -176.585 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.828 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 20.0 mm-40 -67.16 141.46 57.36 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.106 0.479 . . . . 0.0 111.318 -177.701 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.672 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 21.1 mt-10 -89.21 152.02 21.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.578 -179.599 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.57 ' HB ' ' SD ' ' A' ' 8' ' ' MET . 8.1 mm -88.55 146.23 6.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 176.69 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -132.75 163.99 27.79 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.942 0.401 . . . . 0.0 110.569 -178.399 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -67.64 121.56 16.16 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.987 -0.552 . . . . 0.0 109.615 172.145 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.97 20.2 47.6 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.767 -177.216 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -96.15 131.49 42.54 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.412 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.497 HD12 HG22 ' A' ' 11' ' ' THR . 50.5 mm -111.57 109.99 30.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.696 0.284 . . . . 0.0 110.48 -177.234 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.472 ' HA ' ' O ' ' A' ' 46' ' ' LYS . 40.0 mm -94.97 119.25 42.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.27 -177.024 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.745 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 38.2 tt0 -103.37 120.93 41.74 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 171.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 70.8 t -107.36 108.49 25.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.155 0.502 . . . . 0.0 110.509 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.414 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 22.9 mt -103.86 109.15 26.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.756 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 19.1 mtt180 . . . . . 0 C--N 1.325 -0.498 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 176.903 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.3 pt . . . . . 0 N--CA 1.45 -0.437 0 CA-C-O 121.078 0.466 . . . . 0.0 109.781 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.12 -178.09 20.56 Favored Glycine 0 N--CA 1.443 -0.898 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.148 -176.699 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.52 153.94 22.08 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.75 0.31 . . . . 0.0 111.193 -177.685 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.483 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 50.2 mtmt -105.85 128.82 53.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.002 -0.544 . . . . 0.0 109.689 174.171 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 19.3 p90 -139.28 150.26 45.24 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 120.778 0.323 . . . . 0.0 110.76 -178.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.522 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 25.3 m -111.23 120.9 43.82 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.81 0.338 . . . . 0.0 110.435 179.735 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.617 HG22 ' HB ' ' A' ' 64' ' ' ILE . 21.5 t -112.46 130.32 66.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.898 179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.636 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 4.0 tt -87.53 129.56 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.807 173.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 30.6 p -123.52 -175.22 3.15 Favored 'General case' 0 N--CA 1.442 -0.872 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.822 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -67.63 -28.43 67.72 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.804 -175.274 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.468 ' OD1' ' HE3' ' A' ' 19' ' ' LYS . 3.1 p30 -95.79 -5.94 40.75 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 121.125 -0.23 . . . . 0.0 111.523 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 147.11 -177.36 25.45 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.554 179.08 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.636 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 62.5 tttt -99.25 108.87 21.53 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.083 0.468 . . . . 0.0 109.796 -177.763 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.468 ' HE3' ' OD1' ' A' ' 16' ' ' ASP . 78.3 mttt -103.51 124.72 49.3 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.717 -171.636 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.522 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -90.37 125.14 43.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 170.115 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.423 HD23 ' N ' ' A' ' 21' ' ' LEU . 1.9 pt? -140.52 164.89 28.95 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.483 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.3 OUTLIER -139.58 163.59 32.16 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.9 0.381 . . . . 0.0 111.54 -176.66 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.3 t -134.83 158.24 44.72 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.416 176.591 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -84.76 -4.91 86.99 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.334 -178.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -138.49 141.33 30.9 Favored Pre-proline 0 C--N 1.324 -0.504 0 N-CA-C 110.624 -0.139 . . . . 0.0 110.624 178.833 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -61.84 131.97 37.68 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.739 2.293 . . . . 0.0 111.498 175.301 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 37.9 mmt180 -132.96 169.49 16.72 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.032 0.444 . . . . 0.0 111.216 -174.044 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -103.14 166.18 10.59 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.467 -0.788 . . . . 0.0 108.887 167.401 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 48.9 mm -55.87 -41.37 66.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.967 0.413 . . . . 0.0 110.394 178.754 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 46.2 tptt -51.24 -43.29 61.45 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.166 -0.924 . . . . 0.0 111.919 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -66.19 -50.88 62.37 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.842 -174.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.15 -49.29 56.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.018 -178.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.556 HD21 ' HB ' ' A' ' 40' ' ' ILE . 28.1 tp -62.07 -40.6 96.37 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.728 -177.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.73 -44.48 94.78 Favored Glycine 0 N--CA 1.448 -0.523 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.467 -177.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 68.3 mt-10 -72.2 -29.93 64.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.638 0.256 . . . . 0.0 111.615 -179.214 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 72.6 mt -78.18 -8.34 58.19 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 121.068 -0.253 . . . . 0.0 111.006 178.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.9 tt0 64.25 26.13 13.68 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.05 175.209 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.438 ' HB ' HD12 ' A' ' 33' ' ' LEU . 64.7 mt -82.95 124.87 76.31 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.141 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -71.82 108.86 2.52 Favored 'Trans proline' 0 CA--C 1.533 0.44 0 C-N-CA 122.587 2.191 . . . . 0.0 113.02 -179.376 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.556 ' HB ' HD21 ' A' ' 33' ' ' LEU . 10.0 tt -73.16 -9.75 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-O 121.732 0.777 . . . . 0.0 110.286 178.392 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -69.2 -42.89 75.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.742 -176.108 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.569 HG23 HG13 ' A' ' 43' ' ' VAL . 3.3 t -86.53 -47.68 9.03 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -170.15 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.569 HG13 HG23 ' A' ' 42' ' ' THR . 21.7 m -102.01 179.06 0.67 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.213 0 CA-C-O 120.85 0.357 . . . . 0.0 111.8 -173.161 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 30.0 t -103.98 139.55 24.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.565 -172.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 59.6 t -116.17 126.04 73.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 CA-C-O 121.029 0.442 . . . . 0.0 110.249 176.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.538 ' HG2' HD13 ' A' ' 51' ' ' ILE . 95.2 mttt -129.63 151.95 49.68 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.624 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.796 ' HG2' HG21 ' A' ' 52' ' ' VAL . 18.3 mmtp -106.04 100.8 10.33 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 169.46 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 47.6 t30 54.98 24.73 6.17 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.153 177.545 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 124.25 -27.42 5.57 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 120.957 -0.639 . . . . 0.0 113.367 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -89.46 133.96 34.32 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.903 0.351 . . . . 0.0 111.644 -174.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.538 HD13 ' HG2' ' A' ' 46' ' ' LYS . 39.2 mm -65.55 124.19 20.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.674 -0.239 . . . . 0.0 110.389 176.184 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.796 HG21 ' HG2' ' A' ' 47' ' ' LYS . 20.7 m -133.29 178.0 6.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.987 0.422 . . . . 0.0 111.223 -177.563 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.0 pt -109.48 -173.02 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.32 177.265 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 30.1 p-10 -82.19 -19.53 39.64 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 120.905 0.383 . . . . 0.0 110.961 -179.283 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -82.14 26.87 0.51 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.919 0.39 . . . . 0.0 111.856 177.648 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -96.54 149.95 21.18 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.052 179.132 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -78.33 170.6 16.37 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.999 -177.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 52.2 mt -128.8 120.71 52.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 172.377 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -112.27 162.2 15.77 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.724 -178.244 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -71.24 126.03 28.53 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.462 177.429 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.18 6.49 71.35 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.956 -0.64 . . . . 0.0 111.784 -179.255 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 25.8 t0 -88.58 155.79 19.43 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -179.501 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.7 mm -120.79 117.16 52.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 120.932 0.396 . . . . 0.0 110.523 -175.015 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.617 ' HB ' HG22 ' A' ' 12' ' ' VAL . 3.7 mp -101.71 128.22 54.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 177.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.618 ' HA ' HG22 ' A' ' 13' ' ' ILE . 38.2 mt-10 -115.22 107.27 15.07 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 120.771 -0.372 . . . . 0.0 110.996 -178.631 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 78.2 t -99.93 100.53 10.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 121.653 0.74 . . . . 0.0 109.05 174.326 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 51.1 mt -93.07 109.65 22.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.986 -176.131 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.545 ' HA ' ' CG1' ' A' ' 43' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.447 -0.624 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 174.203 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.1 pt . . . . . 0 N--CA 1.452 -0.326 0 CA-C-O 121.291 0.567 . . . . 0.0 110.578 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.31 -178.71 17.17 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -176.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . 0.495 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 23.5 ptt? -161.0 130.88 4.95 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.99 0.424 . . . . 0.0 110.712 179.005 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.659 ' HB3' ' HG3' ' A' ' 22' ' ' GLU . 16.4 ptmt -118.6 119.63 35.07 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 121.294 0.569 . . . . 0.0 109.574 171.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -123.79 151.61 43.12 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.089 -174.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.548 ' CG2' HG13 ' A' ' 63' ' ' ILE . 8.8 t -109.51 134.98 51.24 Favored 'General case' 0 C--N 1.316 -0.857 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.231 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.4 p -110.91 135.96 48.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.039 -179.22 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -114.46 126.54 72.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.385 0.612 . . . . 0.0 110.19 179.695 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.411 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -146.66 -163.48 1.76 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.369 178.248 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.411 ' H ' HG22 ' A' ' 14' ' ' THR . 14.2 m-20 -65.14 -21.96 66.86 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 121.108 0.48 . . . . 0.0 110.996 178.062 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -86.11 8.25 21.59 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.682 0.753 . . . . 0.0 110.274 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.79 -162.12 18.57 Favored Glycine 0 N--CA 1.448 -0.517 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.712 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -118.15 108.69 15.48 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 177.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -116.0 150.99 36.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.465 -176.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.532 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.2 OUTLIER -106.94 131.09 57.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.091 0.472 . . . . 0.0 109.886 -176.173 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.502 ' N ' HD13 ' A' ' 20' ' ' ILE . 92.2 mt -116.81 135.49 53.7 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.963 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.659 ' HG3' ' HB3' ' A' ' 9' ' ' LYS . 32.4 tt0 -108.96 126.55 53.21 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.948 0.404 . . . . 0.0 110.392 -177.456 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.5 m -118.06 145.39 44.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.958 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -83.17 -9.12 84.5 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 121.047 -0.597 . . . . 0.0 112.605 -176.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.443 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.42 141.89 32.98 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 122.849 -0.207 . . . . 0.0 111.003 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.495 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 7.3 Cg_exo -73.59 121.25 6.94 Favored 'Trans proline' 0 C--O 1.233 0.254 0 C-N-CA 122.817 2.345 . . . . 0.0 110.773 174.045 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 19.2 mmm180 -132.25 177.28 7.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.102 0.477 . . . . 0.0 110.899 -174.087 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.588 ' HG2' ' H ' ' A' ' 30' ' ' LYS . 44.7 ttm180 -94.82 160.85 14.41 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.053 -176.84 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 56' ' ' GLU . 37.4 mm -50.97 -41.01 21.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-O 120.815 0.34 . . . . 0.0 110.155 176.315 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.588 ' H ' ' HG2' ' A' ' 28' ' ' ARG . 35.8 tptt -51.03 -37.18 43.7 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.786 -179.329 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -64.93 -62.65 1.43 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.764 0.316 . . . . 0.0 110.845 -177.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.5 t -63.39 -44.21 98.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.762 -177.616 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.782 HD11 ' HB ' ' A' ' 40' ' ' ILE . 3.0 tm? -61.72 -46.43 89.68 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.163 -179.267 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.97 -47.41 46.74 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.141 -175.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -66.53 -34.57 78.22 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 111.954 0.354 . . . . 0.0 111.954 -175.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 82.1 mt -82.6 -4.64 57.98 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.684 0.278 . . . . 0.0 110.9 179.079 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.5 tt0 57.3 34.9 25.41 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.958 177.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.617 ' HB ' HD22 ' A' ' 33' ' ' LEU . 66.0 mt -79.49 125.64 82.46 Favored Pre-proline 0 C--N 1.323 -0.587 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 177.64 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.514 ' HB2' ' HB ' ' A' ' 42' ' ' THR . 34.7 Cg_exo -60.72 101.29 0.17 Allowed 'Trans proline' 0 C--O 1.233 0.226 0 C-N-CA 122.642 2.228 . . . . 0.0 112.874 -176.851 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.782 ' HB ' HD11 ' A' ' 33' ' ' LEU . 9.9 tp -71.29 -19.11 20.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.68 0.752 . . . . 0.0 109.831 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -77.01 -32.11 56.93 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.355 176.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.514 ' HB ' ' HB2' ' A' ' 39' ' ' PRO . 22.2 m -92.39 -39.41 11.46 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.193 -171.525 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 10.9 m -112.8 163.17 10.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.458 -175.645 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.421 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 47.3 t -109.89 140.27 29.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.846 -177.827 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.8 t -113.0 130.63 66.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 121.137 0.494 . . . . 0.0 111.467 -178.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.524 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 97.3 mttt -123.08 150.88 42.6 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.743 172.505 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.949 ' HE2' HG11 ' A' ' 52' ' ' VAL . 60.1 pttt -126.76 108.08 10.73 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.638 0.732 . . . . 0.0 110.676 171.619 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.49 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 3.2 t-20 64.26 23.78 13.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.483 -1.235 . . . . 0.0 111.771 174.399 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 112.79 -6.33 25.89 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.8 177.561 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 8.3 mm-40 -111.35 114.54 27.78 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.707 0.289 . . . . 0.0 111.501 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.482 ' HA ' ' HG2' ' A' ' 46' ' ' LYS . 0.1 OUTLIER -62.98 127.15 22.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 175.574 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.949 HG11 ' HE2' ' A' ' 47' ' ' LYS . 23.4 m -138.63 155.89 28.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.084 0.469 . . . . 0.0 111.574 -174.356 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.459 HG13 ' H ' ' A' ' 55' ' ' GLU . 30.4 pt -96.93 -175.55 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.908 177.505 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -69.57 -8.91 51.37 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.837 -0.62 . . . . 0.0 112.082 -175.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.459 ' H ' HG13 ' A' ' 53' ' ' ILE . 29.4 tp10 -81.94 -11.13 59.03 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.03 0.443 . . . . 0.0 111.098 -177.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.74 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 70.1 mm-40 -86.11 146.08 26.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -174.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.521 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.6 mp0 -80.83 160.89 24.68 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.59 173.841 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.414 HG23 HD11 ' A' ' 64' ' ' ILE . 39.9 mt -105.69 147.38 11.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 175.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.506 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 98.9 m-85 -111.38 151.84 28.01 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.274 0.559 . . . . 0.0 111.341 -178.138 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.463 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 29.7 t70 -69.61 120.85 16.01 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.958 172.736 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.13 19.31 55.89 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.797 -0.716 . . . . 0.0 111.992 -177.197 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.506 ' HB2' ' HB2' ' A' ' 59' ' ' PHE . 24.0 t0 -94.88 159.9 14.83 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 120.928 0.394 . . . . 0.0 110.448 -179.477 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.548 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.3 mp -117.05 108.55 25.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.03 0.443 . . . . 0.0 110.211 -175.785 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 1.9 mp -92.77 119.13 39.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-O 121.173 0.511 . . . . 0.0 110.175 -178.59 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.524 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 44.8 tt0 -105.22 115.8 30.87 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.646 178.512 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 79.3 t -100.81 102.62 13.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.352 0.596 . . . . 0.0 110.115 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.421 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 49.1 mt -93.27 93.13 3.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.165 -179.009 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.625 ' HD2' ' O ' ' A' ' 68' ' ' ARG . 0.2 OUTLIER . . . . . 0 C--N 1.317 -0.823 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 170.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 47.4 mm . . . . . 0 N--CA 1.453 -0.287 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 23' ' ' SER . . . 85.24 100.64 0.68 Allowed Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.351 -176.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . 0.443 ' HB2' ' HA ' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -126.1 149.67 48.76 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 -176.704 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.665 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 96.0 mttt -109.75 140.61 43.44 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.297 176.793 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -145.83 152.82 40.12 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.966 0.412 . . . . 0.0 110.268 174.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.593 HG22 ' HG2' ' A' ' 18' ' ' LYS . 4.7 m -110.61 118.06 35.18 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.774 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.647 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.7 p -111.49 132.05 61.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.795 -177.381 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.587 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -87.63 124.56 40.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.293 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.4 ' N ' HD13 ' A' ' 13' ' ' ILE . 2.5 p -134.49 -171.06 2.67 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.298 -177.629 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -74.85 -27.4 60.25 Favored 'General case' 0 N--CA 1.464 0.246 0 O-C-N 122.393 -0.192 . . . . 0.0 111.499 -173.394 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -83.73 -6.23 59.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.112 0.482 . . . . 0.0 110.331 178.306 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 131.4 -173.52 20.4 Favored Glycine 0 N--CA 1.443 -0.839 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 -179.007 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.593 ' HG2' HG22 ' A' ' 11' ' ' THR . 66.5 tttt -90.47 106.52 18.55 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.153 0.502 . . . . 0.0 109.788 178.007 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.7 tptm -103.61 121.34 42.72 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.199 -170.056 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.527 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -92.1 126.2 44.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 173.061 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.412 ' N ' HD13 ' A' ' 20' ' ' ILE . 4.0 pp -144.52 162.8 35.65 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.047 177.648 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.665 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -111.91 162.87 14.85 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.138 0.494 . . . . 0.0 110.961 -179.893 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.455 ' O ' ' HA2' ' A' ' 7' ' ' GLY . 40.6 t -130.41 140.59 50.57 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.657 -0.702 . . . . 0.0 109.224 176.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -53.81 -38.62 59.94 Favored Glycine 0 C--N 1.331 0.265 0 O-C-N 123.558 0.537 . . . . 0.0 112.523 -179.168 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.447 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -137.99 152.07 71.35 Favored Pre-proline 0 C--N 1.321 -0.638 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 176.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -59.08 128.38 27.54 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.375 2.05 . . . . 0.0 111.2 174.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.447 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 20.4 mmm180 -129.38 170.7 13.33 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.921 0.391 . . . . 0.0 110.455 -175.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.638 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 45.4 ttm180 -77.34 155.75 31.74 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.099 177.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.581 HG21 HG11 ' A' ' 45' ' ' VAL . 38.1 mm -53.17 -46.59 55.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 CA-C-O 121.712 0.768 . . . . 0.0 109.732 175.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.499 ' HB3' ' HE2' ' A' ' 30' ' ' LYS . 28.7 ttpt -72.39 -20.65 61.41 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.785 -1.098 . . . . 0.0 111.428 -178.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -66.57 -53.48 34.08 Favored 'General case' 0 CA--C 1.514 -0.43 0 CA-C-O 121.094 0.473 . . . . 0.0 109.779 176.389 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.8 t -68.21 -50.02 61.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.928 -177.665 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.561 HD23 ' HB ' ' A' ' 40' ' ' ILE . 15.0 tp -70.48 -28.68 65.17 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.488 -177.117 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.5 -39.47 95.64 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.165 174.7 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -62.59 -39.0 92.33 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.925 0.393 . . . . 0.0 110.658 177.04 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 91.7 mt -75.75 -15.08 60.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.028 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 59.21 75.66 0.39 Allowed 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.523 0.678 . . . . 0.0 110.929 -177.484 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 80.8 mt -134.15 130.45 20.31 Favored Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.195 176.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.471 ' HB2' HG22 ' A' ' 42' ' ' THR . 19.5 Cg_endo -58.61 90.46 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.779 2.32 . . . . 0.0 112.916 -179.608 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.561 ' HB ' HD23 ' A' ' 33' ' ' LEU . 18.9 tt -75.87 -9.81 12.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.672 -178.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -75.5 -43.15 50.68 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.761 -177.08 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.471 HG22 ' HB2' ' A' ' 39' ' ' PRO . 10.0 t -95.27 -5.27 44.04 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -170.182 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.583 ' HB ' ' HA ' ' A' ' 68' ' ' ARG . 17.9 m -115.42 167.94 7.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.906 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.1 t -97.32 123.44 49.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.023 0.44 . . . . 0.0 111.457 -173.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.581 HG11 HG21 ' A' ' 29' ' ' ILE . 61.4 t -103.67 126.57 58.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.94 176.409 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.724 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 25.2 mttm -119.41 114.32 22.15 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.568 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.42 ' HB3' HG11 ' A' ' 52' ' ' VAL . 86.6 tttt -93.64 110.14 21.76 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.828 177.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 64.76 16.98 10.75 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.606 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 114.14 -29.16 7.86 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.104 -0.57 . . . . 0.0 112.554 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 15.2 mm100 -88.39 140.88 29.02 Favored 'General case' 0 C--N 1.327 -0.413 0 O-C-N 122.846 -0.208 . . . . 0.0 110.779 -176.62 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 3.4 mp -69.89 118.77 14.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 177.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.42 HG11 ' HB3' ' A' ' 47' ' ' LYS . 34.5 m -122.43 169.93 13.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.087 0.47 . . . . 0.0 110.998 -178.257 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.7 pp -87.76 165.97 2.0 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.906 175.652 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -70.81 -10.59 59.85 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.901 -0.591 . . . . 0.0 112.087 -175.029 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.604 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 2.1 tp10 -83.61 -9.59 58.8 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.449 -175.716 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.435 ' O ' HG12 ' A' ' 29' ' ' ILE . 14.8 mm-40 -66.8 149.67 50.22 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.989 0.423 . . . . 0.0 112.068 -178.311 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.638 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 43.7 mt-10 -103.83 152.64 21.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.576 -179.547 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.481 HG12 HD13 ' A' ' 29' ' ' ILE . 23.6 mt -97.38 143.09 13.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.532 -178.578 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -125.97 171.77 10.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.261 -179.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.443 ' HA ' ' HB2' ' A' ' 8' ' ' MET . 27.0 t70 -71.02 122.58 20.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.813 0.34 . . . . 0.0 111.555 -175.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.78 14.13 57.04 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.444 176.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -91.51 161.49 14.94 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.937 0.399 . . . . 0.0 110.368 -178.866 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.1 mm -120.03 127.36 75.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.927 -176.527 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.647 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.4 mm -116.66 116.39 52.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 120.975 0.417 . . . . 0.0 110.918 -176.707 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.724 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 38.8 mm-40 -104.19 113.79 27.58 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.216 178.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 55.9 t -105.18 110.26 30.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.429 0.633 . . . . 0.0 110.289 174.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 62.5 mt -113.16 109.52 28.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.808 -179.12 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.583 ' HA ' ' HB ' ' A' ' 43' ' ' VAL . 13.3 ptt180 . . . . . 0 C--N 1.325 -0.496 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.996 177.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.4 tp . . . . . 0 N--CA 1.452 -0.348 0 CA-C-O 121.332 0.587 . . . . 0.0 110.135 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 106.49 -172.4 18.47 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 -177.147 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . 0.555 ' HA ' ' HB2' ' A' ' 60' ' ' ASP . 26.2 ptt? -160.67 129.09 4.61 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.106 0.479 . . . . 0.0 111.069 179.301 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -111.38 112.39 24.11 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 174.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.44 ' CZ ' HD11 ' A' ' 21' ' ' LEU . 49.2 p90 -136.72 168.13 20.11 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.556 -173.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.5 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.5 t -119.04 146.5 45.0 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.321 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 p -126.02 122.83 62.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.917 176.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.524 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -101.94 124.86 56.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.565 0.698 . . . . 0.0 110.083 -179.398 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.4 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -146.08 -160.43 1.15 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.163 177.904 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.4 ' H ' HG22 ' A' ' 14' ' ' THR . 4.7 m-20 -60.71 -29.66 69.49 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.185 0.517 . . . . 0.0 110.594 176.538 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -72.29 -3.19 22.32 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.556 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.04 -167.21 20.47 Favored Glycine 0 N--CA 1.444 -0.823 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -176.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.0 ttmt -93.14 102.97 15.29 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 175.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 84.1 tttt -106.83 120.44 42.02 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.771 -172.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.517 HD13 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -98.62 136.5 29.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.094 -178.871 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.517 ' N ' HD13 ' A' ' 20' ' ' ILE . 4.3 pp -140.33 162.65 34.8 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.684 0.278 . . . . 0.0 110.731 179.221 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -114.97 144.24 43.91 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -178.13 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 47.0 t -131.33 131.55 43.83 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.654 0.264 . . . . 0.0 110.453 -177.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.88 -16.84 74.85 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.221 -0.514 . . . . 0.0 112.778 -179.124 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.47 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.21 144.24 42.41 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 122.785 -0.244 . . . . 0.0 110.967 179.492 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.471 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 3.0 Cg_exo -75.15 130.14 12.86 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.741 2.294 . . . . 0.0 110.99 174.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 9.5 mtp180 -136.85 164.95 27.09 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.897 0.38 . . . . 0.0 110.71 -175.34 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.629 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 16.3 ttp85 -92.47 164.47 13.45 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.99 -176.823 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.497 HG12 ' O ' ' A' ' 56' ' ' GLU . 45.5 mm -51.84 -46.52 40.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 122.183 0.193 . . . . 0.0 111.288 -179.406 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.474 ' HB2' ' OD2' ' A' ' 54' ' ' ASP . 6.1 tptm -65.19 -26.97 68.38 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.836 0.31 . . . . 0.0 111.836 -177.151 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -62.72 -57.98 9.08 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 176.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 46.1 t -64.51 -41.28 91.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.626 -179.345 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.461 HD22 ' HB ' ' A' ' 38' ' ' ILE . 3.1 tm? -61.57 -46.56 89.39 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.117 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.62 -38.42 93.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 121.133 -0.556 . . . . 0.0 112.583 -178.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -65.8 -46.96 76.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.597 0.237 . . . . 0.0 111.518 179.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 91.7 mt -76.33 -16.25 59.8 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.755 0.312 . . . . 0.0 110.764 -178.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 60.65 37.24 19.33 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.511 177.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.461 ' HB ' HD22 ' A' ' 33' ' ' LEU . 66.7 mt -79.47 132.48 62.01 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.54 177.752 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -60.59 98.57 0.13 Allowed 'Trans proline' 0 CA--C 1.529 0.255 0 C-N-CA 122.546 2.164 . . . . 0.0 112.437 179.636 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.51 ' HA ' HG22 ' A' ' 43' ' ' VAL . 10.7 tp -69.87 -13.6 17.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.445 0.64 . . . . 0.0 110.149 -179.501 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -64.58 -21.74 66.78 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.245 -0.889 . . . . 0.0 111.076 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.8 t -127.3 10.39 6.8 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 112.282 0.475 . . . . 0.0 112.282 -173.347 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 35.3 m -131.9 142.26 43.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.121 0.486 . . . . 0.0 111.166 -179.262 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -118.12 138.92 47.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.79 178.378 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.6 t -103.73 136.09 38.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 121.248 0.547 . . . . 0.0 111.071 -176.634 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.646 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 56.5 mttm -118.1 147.77 42.96 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.008 175.688 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.587 ' HG2' HG21 ' A' ' 52' ' ' VAL . 19.1 mmtp -108.63 101.61 10.74 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.516 172.444 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.458 HD22 ' HA ' ' A' ' 48' ' ' ASN . 0.8 OUTLIER 57.5 27.33 13.86 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.738 177.296 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 116.5 -28.82 7.28 Favored Glycine 0 CA--C 1.522 0.478 0 C-N-CA 121.227 -0.511 . . . . 0.0 113.266 -179.245 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 70.4 mm-40 -88.14 139.81 30.12 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 117.054 0.427 . . . . 0.0 111.38 -172.477 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 26.2 mm -74.63 126.31 35.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.85 0.357 . . . . 0.0 111.052 179.117 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.587 HG21 ' HG2' ' A' ' 47' ' ' LYS . 25.2 m -128.76 178.48 4.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.206 178.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.442 HG13 ' H ' ' A' ' 55' ' ' GLU . 47.0 pt -118.99 -173.46 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.394 0.616 . . . . 0.0 111.785 -178.401 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.474 ' OD2' ' HB2' ' A' ' 30' ' ' LYS . 16.6 t70 -64.78 -19.98 66.12 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.131 -175.74 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.451 ' HA ' ' HD2' ' A' ' 28' ' ' ARG . 6.0 mm-40 -90.41 3.96 52.3 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.129 -0.487 . . . . 0.0 112.274 -173.468 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.497 ' O ' HG12 ' A' ' 29' ' ' ILE . 0.5 OUTLIER -85.5 135.71 33.72 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.074 0.464 . . . . 0.0 111.366 -179.843 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.629 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 7.1 mp0 -82.11 153.49 26.04 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.257 175.5 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.503 HG23 HD11 ' A' ' 64' ' ' ILE . 22.4 mt -95.84 143.37 12.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 175.309 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.593 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 80.3 m-85 -119.51 153.41 35.39 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.212 0.53 . . . . 0.0 111.369 -174.5 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.555 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 29.1 t70 -62.58 121.14 12.6 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.231 172.555 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.13 8.71 74.8 Favored Glycine 0 C--O 1.229 -0.218 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.138 -179.331 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.593 ' HB2' ' HB2' ' A' ' 59' ' ' PHE . 31.4 t70 -93.8 146.96 23.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 -179.653 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 37.9 mm -107.79 128.15 63.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.764 0.316 . . . . 0.0 110.905 -174.219 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.503 HD11 HG23 ' A' ' 58' ' ' ILE . 39.2 mm -108.5 118.48 56.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.946 -177.156 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.646 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 19.0 mp0 -106.09 121.47 44.21 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 172.378 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 97.2 t -105.53 104.04 16.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.198 0.523 . . . . 0.0 110.386 178.02 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.513 HD13 ' HD2' ' A' ' 46' ' ' LYS . 3.1 mp -106.02 114.06 44.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.625 -179.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.871 HH11 ' HB2' ' A' ' 68' ' ' ARG . 1.7 mtm105 . . . . . 0 C--N 1.322 -0.62 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 175.708 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 54.2 mt . . . . . 0 N--CA 1.449 -0.509 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.61 166.41 13.31 Favored Glycine 0 N--CA 1.441 -0.97 0 C-N-CA 120.542 -0.837 . . . . 0.0 111.903 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . 0.645 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 0.7 OUTLIER -136.88 139.34 41.57 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 -176.83 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.647 ' HA ' ' HB3' ' A' ' 22' ' ' GLU . 18.0 ttmm -101.03 116.56 33.13 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 172.053 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -136.75 165.48 25.82 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 120.925 0.393 . . . . 0.0 110.442 -179.137 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.867 ' HB ' HD13 ' A' ' 20' ' ' ILE . 12.1 t -121.13 137.2 54.77 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-O 121.288 0.566 . . . . 0.0 110.591 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.402 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.1 p -115.15 135.13 56.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.362 176.802 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.548 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -109.64 122.4 64.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.447 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.82 -165.01 1.54 Allowed 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.067 178.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -71.13 -13.49 61.97 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.09 0.472 . . . . 0.0 110.244 177.485 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -84.49 -9.79 58.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.503 0.668 . . . . 0.0 109.967 175.426 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 112.2 -178.67 19.2 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.986 -179.022 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.4 ttmt -92.8 114.76 27.4 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 176.011 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.403 ' HB2' ' HE3' ' A' ' 19' ' ' LYS . 30.9 ttmt -127.07 149.1 50.08 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.931 -171.186 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.867 HD13 ' HB ' ' A' ' 11' ' ' THR . 37.5 mm -94.77 126.3 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.829 -178.521 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 3.9 pp -144.64 144.95 31.52 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 172.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.647 ' HB3' ' HA ' ' A' ' 9' ' ' LYS . 12.6 pt-20 -139.42 163.4 32.62 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.804 0.335 . . . . 0.0 111.129 -176.144 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.7 t -129.03 165.53 20.99 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.102 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -101.67 14.05 57.78 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 177.314 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -139.3 142.85 33.94 Favored Pre-proline 0 C--N 1.324 -0.509 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 175.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.645 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 34.6 Cg_exo -61.19 136.39 64.37 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.611 2.207 . . . . 0.0 111.15 175.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.902 ' HG3' ' HB3' ' A' ' 31' ' ' ASP . 0.0 OUTLIER -140.37 157.87 44.89 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.346 0.593 . . . . 0.0 112.105 -173.06 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.572 ' HD3' ' HA ' ' A' ' 55' ' ' GLU . 43.5 ttm180 -107.06 163.41 13.01 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.08 -0.963 . . . . 0.0 109.134 176.414 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.579 HG13 ' O ' ' A' ' 56' ' ' GLU . 10.1 mt -60.08 -48.32 88.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.375 0 CA-C-O 121.359 0.6 . . . . 0.0 109.615 176.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.9 tptp -51.4 -35.95 41.39 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.678 173.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.902 ' HB3' ' HG3' ' A' ' 27' ' ' ARG . 0.2 OUTLIER -72.45 -55.58 6.78 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.676 179.079 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 28' ' ' ARG . 58.7 t -59.67 -61.07 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.287 -177.687 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.817 ' HG ' HD12 ' A' ' 40' ' ' ILE . 4.1 mm? -69.16 -28.37 66.36 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 121.118 -0.233 . . . . 0.0 111.224 -177.222 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.29 -43.33 63.28 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.454 179.158 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -71.98 -34.52 69.0 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.764 0.316 . . . . 0.0 110.64 178.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.415 ' HG ' ' O ' ' A' ' 32' ' ' VAL . 94.8 mt -73.22 -17.9 61.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.793 0.33 . . . . 0.0 110.147 175.382 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 61.86 36.77 15.79 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.892 174.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.404 HG23 ' HD2' ' A' ' 39' ' ' PRO . 72.4 mt -92.07 139.0 24.29 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.038 179.599 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.404 ' HD2' HG23 ' A' ' 38' ' ' ILE . 35.9 Cg_endo -65.87 65.39 0.42 Allowed 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 122.975 2.45 . . . . 0.0 113.133 177.495 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.817 HD12 ' HG ' ' A' ' 33' ' ' LEU . 7.6 tt -65.62 -22.35 30.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.843 177.593 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -66.29 -19.92 65.96 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.219 -0.9 . . . . 0.0 112.548 -173.111 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.6 t -109.16 11.86 25.33 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.36 -0.536 . . . . 0.0 111.913 -173.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 32.7 m -133.63 173.58 14.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.505 0.193 . . . . 0.0 110.784 178.23 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.852 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 46.5 t -88.26 129.86 38.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.729 0.3 . . . . 0.0 111.242 -175.39 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 19.2 t -108.33 126.04 65.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.826 -179.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.626 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 82.3 mttt -123.25 118.44 27.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.872 175.689 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -97.25 108.42 21.15 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 172.576 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 64.93 14.58 9.38 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.636 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 108.67 -13.08 35.54 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 121.14 -0.552 . . . . 0.0 112.096 -178.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 31.9 mm-40 -89.93 129.39 36.29 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 60.4 mt -72.49 105.78 2.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.263 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.6 m -116.83 171.31 5.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.484 -171.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 35.0 pt -89.45 166.92 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 166.799 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.427 ' O ' ' HB ' ' A' ' 29' ' ' ILE . 14.0 p-10 -77.71 -1.33 30.61 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 120.758 0.313 . . . . 0.0 111.74 -174.485 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.572 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 3.9 tp10 -82.88 12.34 4.98 Favored 'General case' 0 CA--C 1.539 0.547 0 CA-C-O 121.08 0.467 . . . . 0.0 111.066 -177.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.579 ' O ' HG13 ' A' ' 29' ' ' ILE . 26.6 mm-40 -91.23 143.33 26.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.528 178.786 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.538 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 12.3 mp0 -76.0 161.96 28.47 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.849 0.357 . . . . 0.0 110.305 173.4 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 8.6 mm -104.31 141.34 20.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 174.019 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -118.13 169.8 9.39 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.73 176.597 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -78.02 122.07 25.07 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.735 -174.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.72 11.53 56.71 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.252 -177.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -83.55 160.81 21.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.979 0.419 . . . . 0.0 110.717 -178.427 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.542 HG12 HG22 ' A' ' 11' ' ' THR . 20.2 mt -129.0 111.28 22.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.452 -179.835 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 64' ' ' ILE . 3.2 mp -95.11 115.67 34.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.277 0.561 . . . . 0.0 109.925 -179.736 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.626 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 37.5 mt-10 -102.29 104.96 15.52 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.086 179.352 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 55.4 t -97.46 107.41 20.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.552 0.691 . . . . 0.0 109.8 178.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.852 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 54.6 mt -92.61 95.07 5.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.251 -176.642 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.323 -0.558 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 173.506 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 7.5 tp . . . . . 0 N--CA 1.448 -0.561 0 CA-C-O 121.055 0.455 . . . . 0.0 109.811 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 121.9 -177.47 16.44 Favored Glycine 0 N--CA 1.443 -0.876 0 C-N-CA 120.728 -0.749 . . . . 0.0 111.689 -178.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' MET . . . . . 0.61 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 25.1 ptt? -156.78 130.99 8.51 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.161 0.505 . . . . 0.0 111.158 -179.328 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.405 ' HE2' ' HB2' ' A' ' 9' ' ' LYS . 7.4 tppt? -101.05 120.03 39.61 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.063 174.136 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 10.0 p90 -141.33 151.75 43.83 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.247 0.546 . . . . 0.0 110.777 -179.727 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.468 HG21 ' HG2' ' A' ' 18' ' ' LYS . 5.8 m -118.13 128.73 55.01 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.881 178.699 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.774 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.6 p -104.66 122.93 58.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.242 0.544 . . . . 0.0 110.443 178.076 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.451 HG22 ' HG2' ' A' ' 65' ' ' GLU . 7.3 tp -87.53 123.73 40.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 121.213 0.53 . . . . 0.0 109.666 176.026 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.471 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -135.67 -177.19 4.56 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.416 -0.811 . . . . 0.0 108.905 -179.788 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.471 ' H ' HG22 ' A' ' 14' ' ' THR . 4.2 p-10 -71.46 -17.95 62.34 Favored 'General case' 0 C--N 1.327 -0.396 0 O-C-N 122.254 -0.279 . . . . 0.0 111.286 -177.159 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.437 ' OD1' ' HB ' ' A' ' 14' ' ' THR . 9.2 p-10 -90.29 4.23 51.31 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.866 0.365 . . . . 0.0 110.757 179.751 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 122.1 -166.32 14.78 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.778 175.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.468 ' HG2' HG21 ' A' ' 11' ' ' THR . 37.4 tttm -90.34 106.64 18.63 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.402 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.527 ' HB3' HG13 ' A' ' 12' ' ' VAL . 22.7 tttp -103.32 99.02 8.85 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.83 -167.844 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.559 HD13 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -86.12 133.41 29.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.779 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.559 ' N ' HD13 ' A' ' 20' ' ' ILE . 2.1 pt? -144.13 168.23 20.51 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 177.351 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -134.7 148.67 50.36 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.829 0.347 . . . . 0.0 110.445 -177.208 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 22.1 m -129.2 131.97 47.19 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.781 174.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.21 -16.14 59.71 Favored Glycine 0 C--N 1.33 0.246 0 CA-C-N 116.059 -0.519 . . . . 0.0 113.314 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.417 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -139.39 144.79 41.43 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 176.075 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.61 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 23.3 Cg_exo -65.69 146.34 83.8 Favored 'Trans proline' 0 C--O 1.234 0.324 0 C-N-CA 122.896 2.397 . . . . 0.0 111.595 176.832 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.557 ' HD3' ' OD2' ' A' ' 31' ' ' ASP . 96.4 mtt180 -140.16 168.22 20.31 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.309 0.576 . . . . 0.0 111.487 -175.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.601 ' HD3' ' HA ' ' A' ' 55' ' ' GLU . 37.0 ttm105 -94.17 152.52 18.67 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.077 -0.965 . . . . 0.0 108.555 171.022 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.533 HG12 ' O ' ' A' ' 56' ' ' GLU . 46.8 mm -51.13 -44.05 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 122.349 0.26 . . . . 0.0 111.601 -177.532 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.1 tptm -58.43 -27.2 64.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.138 -176.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.557 ' OD2' ' HD3' ' A' ' 27' ' ' ARG . 20.2 t70 -72.47 -53.3 12.49 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.684 -178.101 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 47.5 t -64.97 -44.13 96.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 CA-C-O 121.223 0.535 . . . . 0.0 110.202 178.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.506 HD21 ' HB ' ' A' ' 40' ' ' ILE . 20.7 tp -62.6 -35.66 80.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.977 178.27 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.75 -33.54 66.56 Favored Glycine 0 N--CA 1.449 -0.457 0 CA-C-N 115.446 -0.797 . . . . 0.0 113.099 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -66.37 -46.89 75.14 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 120.851 0.357 . . . . 0.0 111.211 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 92.9 mt -83.58 -16.15 46.42 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.732 -177.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.9 tp10 54.85 80.98 0.11 Allowed 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.824 0.821 . . . . 0.0 110.615 -176.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.461 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 67.8 mt -120.83 127.81 26.07 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.412 178.792 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.476 ' HB2' HG22 ' A' ' 42' ' ' THR . 16.0 Cg_exo -67.16 104.02 0.82 Allowed 'Trans proline' 0 N--CA 1.46 -0.446 0 C-N-CA 122.584 2.189 . . . . 0.0 112.486 -179.248 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.506 ' HB ' HD21 ' A' ' 33' ' ' LEU . 10.7 tt -66.79 -6.07 4.11 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 121.834 0.826 . . . . 0.0 110.237 177.117 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 21.4 tp10 -72.89 -36.2 67.29 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.095 -0.957 . . . . 0.0 110.853 177.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.529 HG23 HG13 ' A' ' 43' ' ' VAL . 15.3 t -101.21 -24.68 14.21 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 120.911 -0.316 . . . . 0.0 111.531 -175.392 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.581 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 34.2 m -116.93 141.56 34.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 110.062 -0.348 . . . . 0.0 110.062 177.074 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.458 HG11 HD12 ' A' ' 51' ' ' ILE . 38.4 t -105.0 140.36 23.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 120.922 0.392 . . . . 0.0 110.653 -177.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 6.9 p -103.39 131.16 52.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.805 -178.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.65 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 87.6 mttt -118.75 146.32 44.86 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.253 177.647 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.755 ' HG2' HG21 ' A' ' 52' ' ' VAL . 13.8 mmtp -109.37 101.25 10.25 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 167.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.5 t-20 50.17 61.11 3.36 Favored 'General case' 0 CA--C 1.537 0.479 0 O-C-N 123.697 0.623 . . . . 0.0 111.122 -179.45 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 87.54 -23.38 12.8 Favored Glycine 0 CA--C 1.52 0.35 0 CA-C-N 116.031 -0.531 . . . . 0.0 113.585 176.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 14.5 mm100 -96.56 127.56 42.67 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 117.06 0.43 . . . . 0.0 111.942 -172.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.591 HD13 ' HG2' ' A' ' 46' ' ' LYS . 33.7 mm -65.2 127.88 26.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.248 177.097 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.755 HG21 ' HG2' ' A' ' 47' ' ' LYS . 29.5 m -131.65 178.8 5.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.075 0.464 . . . . 0.0 111.368 -177.293 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.4 pt -107.81 177.24 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.558 178.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -74.35 -12.9 60.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.033 0.444 . . . . 0.0 110.84 -177.126 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.601 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 14.2 mm-40 -79.99 -5.3 55.47 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.866 179.574 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.533 ' O ' HG12 ' A' ' 29' ' ' ILE . 3.7 mm-40 -68.98 140.04 55.03 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.742 0.306 . . . . 0.0 110.93 178.019 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLU . . . . . 0.584 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 39.3 mt-10 -96.16 147.57 23.61 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 175.197 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.481 ' HB ' ' SD ' ' A' ' 8' ' ' MET . 19.2 mt -89.19 135.22 26.46 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -118.53 146.4 44.59 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.557 -0.292 . . . . 0.0 110.874 -177.089 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.567 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 18.7 t70 -58.66 116.87 3.99 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.598 173.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.14 -17.72 47.44 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 121.039 -0.601 . . . . 0.0 112.145 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 33.2 t0 -77.87 150.77 34.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.888 0.375 . . . . 0.0 110.05 -179.539 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.1 mm -105.94 115.45 47.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.162 0.506 . . . . 0.0 110.411 -175.203 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.774 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 9.0 tp -95.71 133.26 37.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.38 -179.057 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.65 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 28.6 mt-10 -131.7 130.38 41.93 Favored 'General case' 0 C--N 1.317 -0.814 0 O-C-N 122.166 -0.334 . . . . 0.0 110.795 -175.024 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 86.9 t -115.56 103.97 16.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.173 0.511 . . . . 0.0 109.87 178.149 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 25.6 mt -123.58 109.67 23.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.588 -176.662 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.581 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.533 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 173.114 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.712 ' SD ' HG23 ' A' ' 5' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.482 1.134 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.712 HG23 ' SD ' ' A' ' 4' ' ' MET . 83.1 t -109.26 121.31 62.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 171.495 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.501 HD13 ' H ' ' A' ' 6' ' ' ILE . 0.1 OUTLIER -87.81 132.7 32.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 121.068 0.461 . . . . 0.0 110.864 -179.222 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.29 105.96 0.21 Allowed Glycine 0 N--CA 1.447 -0.581 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -177.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.584 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.1 ptt? -110.48 130.54 55.53 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.858 0.361 . . . . 0.0 111.044 -174.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.44 ' HB2' ' HB3' ' A' ' 22' ' ' GLU . 3.5 ttpm? -115.03 126.6 54.92 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 174.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 28.8 p90 -138.79 167.89 21.0 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.313 -175.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.492 ' HB ' HD13 ' A' ' 20' ' ' ILE . 13.1 t -125.38 132.02 52.86 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.201 0.524 . . . . 0.0 110.911 178.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.539 HG22 ' HB ' ' A' ' 64' ' ' ILE . 63.0 t -109.28 119.3 58.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 115.458 -0.792 . . . . 0.0 108.946 174.111 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.539 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -100.34 128.98 51.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.269 0.557 . . . . 0.0 109.949 -177.948 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.415 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -141.34 -162.81 1.44 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.508 -0.769 . . . . 0.0 108.949 178.507 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.415 ' H ' HG22 ' A' ' 14' ' ' THR . 3.7 m-20 -60.97 -27.44 68.27 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.329 0.585 . . . . 0.0 110.537 176.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -74.46 -9.42 58.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.507 178.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.31 -163.75 19.05 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 111.416 -0.674 . . . . 0.0 111.416 -177.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -76.8 118.76 19.74 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.053 0.454 . . . . 0.0 110.361 175.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 19.8 mtpp -102.48 121.83 43.12 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.18 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.492 HD13 ' HB ' ' A' ' 11' ' ' THR . 21.7 mm -100.32 120.84 50.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.027 0.442 . . . . 0.0 110.913 -177.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.436 HD23 ' N ' ' A' ' 21' ' ' LEU . 2.1 pt? -144.32 141.32 29.68 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.047 176.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.44 ' HB3' ' HB2' ' A' ' 9' ' ' LYS . 6.7 pt-20 -121.54 139.01 54.06 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.274 0.559 . . . . 0.0 110.763 178.652 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.9 t -119.9 130.88 55.04 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.518 -0.764 . . . . 0.0 109.446 -176.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -63.43 -31.99 82.63 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 121.23 -0.51 . . . . 0.0 112.868 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.436 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -106.82 123.81 37.41 Favored Pre-proline 0 C--N 1.322 -0.596 0 O-C-N 122.822 -0.222 . . . . 0.0 110.621 178.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.584 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 26.1 Cg_exo -63.71 110.89 1.37 Allowed 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.868 2.379 . . . . 0.0 111.544 175.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.436 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 14.4 mmm180 -118.57 177.11 4.95 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.232 0.539 . . . . 0.0 111.808 -171.295 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.684 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 15.6 ttp180 -89.88 157.61 17.81 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.946 -179.389 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.57 HD13 HG12 ' A' ' 58' ' ' ILE . 27.1 mm -50.22 -47.41 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 CA-C-O 120.833 0.349 . . . . 0.0 110.308 177.684 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.51 ' HB2' ' O ' ' A' ' 54' ' ' ASP . 46.3 tttp -59.63 -29.56 68.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.275 -176.537 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 70.1 m-20 -64.89 -61.84 1.92 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.057 0.456 . . . . 0.0 110.372 -178.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.1 t -64.84 -38.96 84.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.556 -179.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.458 ' CD1' ' HB ' ' A' ' 38' ' ' ILE . 20.7 tp -63.21 -41.16 99.11 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.363 178.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.23 -35.19 63.97 Favored Glycine 0 CA--C 1.522 0.48 0 CA-C-N 116.009 -0.541 . . . . 0.0 113.376 179.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.442 ' HA ' ' OE1' ' A' ' 35' ' ' GLU . 5.5 mm-40 -65.13 -42.12 94.18 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 117.058 0.429 . . . . 0.0 111.295 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.6 mt -86.11 -8.4 57.9 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 175.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 40.27 70.12 0.27 Allowed 'General case' 0 C--O 1.234 0.269 0 CA-C-N 114.54 -1.209 . . . . 0.0 111.662 -173.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.458 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 63.8 mt -92.6 112.58 56.23 Favored Pre-proline 0 C--N 1.321 -0.667 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 174.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.539 ' HB2' HG22 ' A' ' 42' ' ' THR . 34.1 Cg_exo -60.29 103.43 0.21 Allowed 'Trans proline' 0 N--CA 1.46 -0.485 0 C-N-CA 122.693 2.262 . . . . 0.0 112.789 -173.664 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 8.1 tt -65.28 -11.34 11.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 CA-C-O 121.903 0.858 . . . . 0.0 109.493 175.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -66.36 -26.69 67.39 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 114.543 -1.208 . . . . 0.0 111.468 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.539 HG22 ' HB2' ' A' ' 39' ' ' PRO . 5.1 t -125.69 -7.84 6.78 Favored 'General case' 0 C--O 1.234 0.259 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -175.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.697 HG12 ' HB3' ' A' ' 68' ' ' ARG . 2.4 m -121.25 149.55 24.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.668 -177.124 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.4 t -98.85 130.83 47.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.55 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.9 t -103.03 126.73 57.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.137 0.494 . . . . 0.0 110.793 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.609 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 25.5 mttm -125.91 140.56 52.54 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.969 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.552 ' HD2' HG11 ' A' ' 52' ' ' VAL . 31.8 mttm -106.54 102.12 11.53 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.544 171.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 60.3 14.85 4.93 Favored 'General case' 0 CA--C 1.536 0.43 0 O-C-N 123.665 0.603 . . . . 0.0 111.164 178.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 126.9 -30.25 4.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.788 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 81.9 mm-40 -86.55 134.21 33.67 Favored 'General case' 0 C--N 1.327 -0.389 0 O-C-N 122.416 -0.461 . . . . 0.0 110.631 -176.024 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.434 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.7 mp -75.21 118.99 22.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -177.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.552 HG11 ' HD2' ' A' ' 47' ' ' LYS . 28.0 m -122.27 166.79 16.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 121.074 0.464 . . . . 0.0 110.745 -177.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 22.6 pt -97.81 175.41 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.859 174.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.51 ' O ' ' HB2' ' A' ' 30' ' ' LYS . 13.9 p-10 -81.89 12.84 3.68 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.289 -175.08 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -93.41 -15.84 25.23 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.707 -178.078 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.423 ' O ' ' HG3' ' A' ' 28' ' ' ARG . 60.6 mm-40 -77.33 160.74 28.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.196 -177.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.684 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.1 mp0 -94.17 163.17 13.57 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.989 0.423 . . . . 0.0 111.234 -178.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.57 HG12 HD13 ' A' ' 29' ' ' ILE . 45.8 mt -102.18 144.39 13.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 176.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -129.44 155.62 45.4 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.977 0.418 . . . . 0.0 110.693 -176.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.528 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 25.5 t70 -66.55 111.14 3.46 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.356 176.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.58 9.99 42.25 Favored Glycine 0 N--CA 1.445 -0.767 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.242 -177.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 26.2 t70 -88.44 146.3 25.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.859 0.362 . . . . 0.0 110.458 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.426 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.0 mp -113.99 115.91 51.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.278 -178.147 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.539 ' HB ' HG22 ' A' ' 12' ' ' VAL . 4.1 mp -102.04 110.3 28.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.606 179.297 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.609 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 44.1 mt-10 -96.98 98.12 9.81 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 179.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.442 HG23 HG22 ' A' ' 64' ' ' ILE . 87.3 t -92.22 101.54 12.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.418 0.628 . . . . 0.0 109.842 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 63.4 mt -109.26 99.97 9.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.501 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.697 ' HB3' HG12 ' A' ' 43' ' ' VAL . 24.3 ptt180 -77.09 135.34 38.59 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 173.575 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.645 HG13 ' HA3' ' A' ' 72' ' ' GLY . 7.7 p -83.09 140.48 16.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.174 0.512 . . . . 0.0 111.615 -169.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 9.9 tt -77.31 138.08 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.577 178.098 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 35.7 t80 63.79 29.71 14.71 Favored 'General case' 0 CA--C 1.534 0.341 0 CA-C-O 121.821 0.819 . . . . 0.0 109.543 -175.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.645 ' HA3' HG13 ' A' ' 69' ' ' VAL . . . -97.72 72.9 0.65 Allowed Glycine 0 N--CA 1.446 -0.662 0 CA-C-N 115.496 -0.774 . . . . 0.0 111.77 179.31 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.865 0 CA-C-O 118.872 -0.96 . . . . 0.0 111.59 -179.499 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 27.6 ttt . . . . . 0 N--CA 1.478 0.966 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 47.6 t -83.54 118.02 30.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.763 -176.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.2 pt -113.32 127.57 70.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.15 176.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.87 178.6 16.39 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.59 -178.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.434 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 1.2 mpp? -140.02 140.53 36.23 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.758 0.313 . . . . 0.0 110.67 -176.721 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -111.61 111.43 22.42 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 168.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 48.3 p90 -134.12 167.75 20.09 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 120.906 0.384 . . . . 0.0 110.679 -172.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.544 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 25.8 m -126.38 123.35 37.75 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 177.045 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.517 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.6 p -105.33 123.87 59.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.294 0.568 . . . . 0.0 110.227 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.447 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -107.26 130.54 59.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 121.157 0.503 . . . . 0.0 109.888 179.28 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.461 HG23 ' HB ' ' A' ' 66' ' ' VAL . 0.2 OUTLIER -146.2 -160.42 1.15 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 177.6 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.415 ' H ' HG22 ' A' ' 14' ' ' THR . 1.3 m-20 -58.81 -25.94 63.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.906 0.384 . . . . 0.0 111.413 179.087 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -89.1 10.2 22.64 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.522 -177.231 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.55 -156.65 18.9 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.459 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 54.4 mttm -105.59 103.51 13.04 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -178.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.8 tptm -106.75 115.06 29.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.87 0.367 . . . . 0.0 111.098 -175.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.544 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -78.59 128.61 38.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 176.798 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 96.7 mt -131.51 139.0 49.18 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.778 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -128.61 146.0 50.98 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.023 0.439 . . . . 0.0 110.602 179.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.5 m -135.24 136.23 41.56 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.886 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -86.8 17.97 37.61 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.914 -0.66 . . . . 0.0 112.509 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.446 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.51 131.51 16.18 Favored Pre-proline 0 C--N 1.321 -0.641 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 178.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 25' ' ' ALA . 27.9 Cg_exo -62.45 112.68 1.66 Allowed 'Trans proline' 0 C--O 1.234 0.321 0 C-N-CA 122.693 2.262 . . . . 0.0 111.482 177.302 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -133.0 153.13 51.78 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.075 0.464 . . . . 0.0 111.01 -176.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.575 ' HG3' ' O ' ' A' ' 56' ' ' GLU . 23.6 ttm180 -83.49 164.73 19.68 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.387 -178.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.503 HD13 HG12 ' A' ' 58' ' ' ILE . 31.9 mm -51.56 -49.54 33.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 CA-C-O 120.714 0.292 . . . . 0.0 110.324 176.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 33.4 tttp -60.36 -29.58 69.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.843 -178.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.484 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 1.1 t70 -67.68 -50.4 57.92 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -177.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 60.9 t -73.26 -39.74 56.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.461 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.547 HD21 ' HB ' ' A' ' 40' ' ' ILE . 36.2 tp -62.65 -39.45 93.93 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.376 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.04 -37.91 95.26 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.783 -0.644 . . . . 0.0 112.156 177.062 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.484 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 6.9 mm-40 -64.23 -41.54 96.95 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.151 0.501 . . . . 0.0 110.323 176.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 95.0 mt -76.76 -16.23 59.53 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.935 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 62.93 26.56 15.59 Favored 'General case' 0 CA--C 1.537 0.448 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.055 174.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.409 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 75.1 mt -86.74 122.61 71.5 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.561 -178.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 18.5 Cg_exo -66.42 110.13 1.75 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.713 2.275 . . . . 0.0 112.268 178.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.547 ' HB ' HD21 ' A' ' 33' ' ' LEU . 13.3 tt -68.02 -17.54 22.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.574 178.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -56.98 -40.16 76.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.932 -178.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.411 HG23 HG13 ' A' ' 43' ' ' VAL . 14.8 t -98.01 2.12 48.55 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.817 0.341 . . . . 0.0 111.783 -172.32 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.544 HG12 ' HB3' ' A' ' 68' ' ' ARG . 12.0 m -129.07 171.5 16.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 O-C-N 122.032 -0.417 . . . . 0.0 111.389 -176.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.5 ' HB ' ' O ' ' A' ' 67' ' ' ILE . 61.0 t -126.55 136.44 60.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 173.369 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.5 t -106.27 127.81 61.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 120.964 0.412 . . . . 0.0 111.341 -175.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.517 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 85.7 mttt -118.01 120.78 38.84 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.561 174.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.471 ' HE3' ' O ' ' A' ' 57' ' ' GLU . 10.0 mtpm? -97.32 104.29 16.29 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 174.159 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 12.0 m120 62.43 18.17 10.12 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.719 -176.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 109.66 -13.92 32.46 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 121.061 -0.59 . . . . 0.0 112.685 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -87.63 123.92 32.98 Favored 'General case' 0 C--N 1.326 -0.418 0 O-C-N 122.759 -0.259 . . . . 0.0 110.682 -178.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 65.6 mt -75.06 121.65 27.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 179.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.835 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 28.2 m -135.72 177.42 6.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.28 -175.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.433 HG13 ' H ' ' A' ' 55' ' ' GLU . 42.7 pt -102.74 -175.09 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.353 174.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -80.08 -7.68 59.0 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.73 -175.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.433 ' H ' HG13 ' A' ' 53' ' ' ILE . 6.8 tp10 -89.95 10.99 21.8 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-O 121.232 0.539 . . . . 0.0 110.793 -178.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.835 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 59.3 mm-40 -89.24 148.77 23.42 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.016 0.436 . . . . 0.0 111.536 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.471 ' O ' ' HE3' ' A' ' 47' ' ' LYS . 1.4 tp10 -85.51 142.74 28.96 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.129 -177.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.503 HG12 HD13 ' A' ' 29' ' ' ILE . 45.4 mt -88.98 130.77 37.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 177.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -102.56 156.44 17.61 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.274 179.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -73.49 115.63 13.1 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.947 0.403 . . . . 0.0 110.134 177.138 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 103.34 2.25 47.65 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 121.012 -0.613 . . . . 0.0 111.675 -177.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -75.33 146.77 40.66 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 49.4 mm -113.97 113.7 44.61 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.505 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.517 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 41.3 mm -89.5 104.68 15.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.821 -176.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.517 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 36.4 mt-10 -102.25 107.73 18.87 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.835 -179.097 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.461 ' HB ' HG23 ' A' ' 14' ' ' THR . 76.3 t -91.92 99.93 10.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 121.335 0.588 . . . . 0.0 109.888 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.5 ' O ' ' HB ' ' A' ' 44' ' ' VAL . 55.8 mt -105.01 103.75 15.82 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 177.524 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.544 ' HB3' HG12 ' A' ' 43' ' ' VAL . 16.4 ptt180 -100.75 150.43 22.79 Favored 'General case' 0 C--N 1.312 -1.034 0 C-N-CA 120.294 -0.563 . . . . 0.0 111.072 -173.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 28.3 m -82.91 149.85 4.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.567 -177.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.408 HD13 ' C ' ' A' ' 70' ' ' ILE . 0.0 OUTLIER -77.85 110.74 13.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 177.241 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 62.1 t80 -100.95 107.64 19.18 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.287 -0.869 . . . . 0.0 110.252 -175.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -87.27 114.53 4.14 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.63 -0.795 . . . . 0.0 111.887 179.017 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.245 0.833 0 CA-C-O 118.616 -1.102 . . . . 0.0 111.75 178.611 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 24.8 mmt . . . . . 0 N--CA 1.479 0.976 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.8 t -99.66 105.85 18.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.014 0.435 . . . . 0.0 110.06 177.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 46.0 mm -101.93 125.27 56.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.045 -178.217 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 107.24 76.72 1.01 Allowed Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.626 -0.797 . . . . 0.0 111.379 -177.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.573 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.0 ptt? -85.74 130.47 34.55 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.12 0.486 . . . . 0.0 110.763 -174.037 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.484 ' HD3' HD11 ' A' ' 20' ' ' ILE . 0.6 OUTLIER -109.77 120.01 41.16 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.464 179.192 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 45.0 p90 -144.06 167.99 21.07 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.838 0.351 . . . . 0.0 110.761 -175.126 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.515 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 4.7 m -120.93 128.77 53.07 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.684 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 p -108.72 122.44 63.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-O 121.259 0.552 . . . . 0.0 109.921 175.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.565 ' HB ' ' HG3' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -106.59 118.72 54.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.366 0.603 . . . . 0.0 109.932 179.989 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.424 HG22 ' H ' ' A' ' 15' ' ' ASP . 2.4 m -116.47 169.78 9.06 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 177.066 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.424 ' H ' HG22 ' A' ' 14' ' ' THR . 29.1 t70 -53.97 -38.03 64.58 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.831 0.348 . . . . 0.0 111.58 178.293 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -77.96 -10.5 59.62 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.821 -175.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 152.74 170.9 19.63 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.321 -0.942 . . . . 0.0 112.578 178.211 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.565 ' HG3' ' HB ' ' A' ' 13' ' ' ILE . 36.4 ttpt -107.14 125.89 51.67 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.265 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -125.69 115.59 20.33 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.139 0.495 . . . . 0.0 111.242 -176.031 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.515 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -88.76 129.89 39.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 174.215 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.4 ' N ' HD13 ' A' ' 20' ' ' ILE . 4.1 pp -144.7 165.9 26.73 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 120.955 0.407 . . . . 0.0 110.566 178.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -123.21 133.15 54.24 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.447 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.1 t -101.96 131.97 48.06 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 177.45 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -55.89 -29.31 54.86 Favored Glycine 0 CA--C 1.518 0.23 0 CA-C-N 116.169 -0.468 . . . . 0.0 113.06 -177.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.489 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -135.22 151.4 75.01 Favored Pre-proline 0 C--N 1.322 -0.591 0 N-CA-C 110.298 -0.26 . . . . 0.0 110.298 178.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.573 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 28.1 Cg_endo -63.86 127.63 20.01 Favored 'Trans proline' 0 N--CA 1.464 -0.228 0 C-N-CA 122.358 2.039 . . . . 0.0 111.072 174.284 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 18.3 mmm180 -128.05 170.13 13.27 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.058 0.456 . . . . 0.0 110.894 -173.089 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.6 ttt85 -95.79 159.9 14.75 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 178.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.462 ' CG2' ' HA ' ' A' ' 54' ' ' ASP . 41.6 mm -55.74 -46.77 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 N-CA-C 110.301 -0.259 . . . . 0.0 110.301 178.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.8 ttmp? -53.88 -38.56 64.87 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.856 178.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.431 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 32.9 t70 -62.09 -58.58 7.28 Favored 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.312 -179.514 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.5 t -60.59 -39.62 81.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.729 -179.642 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.568 HD12 ' HB ' ' A' ' 38' ' ' ILE . 15.6 tp -62.81 -47.19 84.51 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.654 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.42 -45.15 56.07 Favored Glycine 0 N--CA 1.448 -0.541 0 CA-C-N 115.755 -0.657 . . . . 0.0 113.13 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.431 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 34.9 mm-40 -63.47 -41.13 98.61 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.727 0.298 . . . . 0.0 111.658 -177.059 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 82.3 mt -89.22 -0.11 57.2 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.716 -0.22 . . . . 0.0 111.367 -178.038 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 45.3 tt0 54.58 73.01 0.42 Allowed 'General case' 0 C--O 1.232 0.181 0 CA-C-O 121.562 0.696 . . . . 0.0 110.772 179.151 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.568 ' HB ' HD12 ' A' ' 33' ' ' LEU . 68.3 mt -118.98 119.68 31.97 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.969 178.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.568 ' HB2' HG22 ' A' ' 42' ' ' THR . 7.0 Cg_exo -73.33 94.5 0.83 Allowed 'Trans proline' 0 N--CA 1.461 -0.425 0 C-N-CA 122.788 2.325 . . . . 0.0 112.34 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 13.4 tt -72.09 -23.07 21.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.362 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -60.81 -34.97 75.33 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.418 -178.311 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.568 HG22 ' HB2' ' A' ' 39' ' ' PRO . 12.9 t -102.62 -1.52 30.08 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -171.478 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.542 HG13 HG23 ' A' ' 42' ' ' THR . 18.2 m -136.89 -179.77 3.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 O-C-N 122.029 -0.42 . . . . 0.0 110.785 178.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.0 t -115.83 125.76 73.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.05 0.452 . . . . 0.0 111.118 -176.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.6 t -105.31 131.43 54.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.821 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.61 ' HG2' HD13 ' A' ' 51' ' ' ILE . 95.5 mttt -118.85 149.28 41.8 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.135 178.415 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 62.0 tttm -107.5 104.31 13.84 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 169.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 68.02 -73.89 0.08 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 123.81 0.844 . . . . 0.0 110.662 -174.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -148.4 11.85 1.17 Allowed Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 121.056 -0.592 . . . . 0.0 111.988 178.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -110.86 147.55 34.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.606 0.241 . . . . 0.0 110.805 -179.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.61 HD13 ' HG2' ' A' ' 46' ' ' LYS . 29.6 mm -83.07 116.7 27.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.4 m -126.46 165.32 24.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.075 -175.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.456 HG13 ' H ' ' A' ' 55' ' ' GLU . 37.8 pt -99.83 -177.21 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.653 172.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.462 ' HA ' ' CG2' ' A' ' 29' ' ' ILE . 6.6 p-10 -83.18 6.54 18.98 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.087 0.47 . . . . 0.0 111.41 -173.31 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.456 ' H ' HG13 ' A' ' 53' ' ' ILE . 4.7 tp10 -95.27 0.51 53.91 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.152 -175.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -81.15 163.16 23.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.534 176.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -108.22 154.85 21.17 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.504 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 21.9 mt -103.49 143.15 15.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.065 -179.159 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 -123.16 171.18 9.52 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.235 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -70.75 133.76 46.85 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.845 178.486 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.47 30.63 58.1 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.942 -0.647 . . . . 0.0 111.837 -178.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -98.46 162.64 13.05 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.861 0.363 . . . . 0.0 110.769 179.478 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.3 mm -127.64 125.89 66.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.92 179.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 2.9 mp -115.82 124.84 72.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 177.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.536 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 35.5 tt0 -110.16 113.87 26.91 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.725 0.298 . . . . 0.0 110.224 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 89.4 t -109.07 104.93 17.86 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.323 0.582 . . . . 0.0 110.352 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.525 HD11 ' HE3' ' A' ' 46' ' ' LYS . 6.3 pt -107.01 129.88 59.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.544 178.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.411 HH11 ' HD2' ' A' ' 68' ' ' ARG . 13.7 ptt180 -94.4 150.02 20.68 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.104 -179.132 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.2 p -90.26 128.38 42.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 120.934 0.397 . . . . 0.0 110.081 178.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -84.47 119.59 33.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 177.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -119.74 121.71 39.8 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.051 -176.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -72.89 155.53 50.96 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.238 -178.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.245 0.803 0 CA-C-O 119.069 -0.851 . . . . 0.0 111.295 -178.979 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 23.6 ttt . . . . . 0 N--CA 1.479 0.979 0 CA-C-O 120.802 0.334 . . . . 0.0 110.78 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 46.7 t -90.88 110.8 22.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 177.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.1 tp -98.52 121.73 49.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.224 0.535 . . . . 0.0 110.05 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.55 -178.7 17.1 Favored Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 -173.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.518 ' HA ' ' HB2' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -160.44 149.17 16.87 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 117.587 0.694 . . . . 0.0 112.284 179.694 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.9 mtpp -118.2 131.0 56.41 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.119 173.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 24.8 p90 -147.23 157.93 43.77 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.834 0.35 . . . . 0.0 110.805 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.734 HG22 HD12 ' A' ' 63' ' ' ILE . 1.3 t -116.31 140.3 49.48 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 175.637 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.469 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 6.4 p -129.13 129.12 67.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.068 0.461 . . . . 0.0 110.754 -178.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.732 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -92.25 119.96 40.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 172.538 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.07 -157.73 0.84 Allowed 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.722 -174.059 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.923 ' HA ' ' HD2' ' A' ' 68' ' ' ARG . 15.5 t70 -58.29 -44.59 88.55 Favored 'General case' 0 N--CA 1.464 0.259 0 C-N-CA 122.894 0.478 . . . . 0.0 111.897 -171.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -91.25 -10.7 40.55 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.27 0.47 . . . . 0.0 112.27 -174.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 140.46 -162.9 26.52 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.022 -1.085 . . . . 0.0 112.269 -176.542 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.556 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 36.1 tttt -104.16 120.8 41.9 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.997 0.427 . . . . 0.0 110.836 -174.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -121.67 162.79 20.09 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.424 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.413 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -118.52 130.44 73.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.243 0.544 . . . . 0.0 109.725 -179.01 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 98.9 mt -123.44 151.75 42.35 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.72 -176.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -137.27 129.25 29.13 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.758 -0.656 . . . . 0.0 109.528 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.3 m -130.25 154.4 47.63 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.682 0.277 . . . . 0.0 110.659 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.06 -10.91 70.84 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.735 -176.343 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.421 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -124.21 140.12 34.25 Favored Pre-proline 0 C--N 1.323 -0.58 0 O-C-N 122.718 -0.283 . . . . 0.0 110.432 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 25' ' ' ALA . 14.2 Cg_exo -69.27 107.32 1.74 Allowed 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.668 2.246 . . . . 0.0 111.101 176.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 29.7 mmm180 -110.13 169.62 8.61 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.93 0.395 . . . . 0.0 110.605 -176.209 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.565 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 15.1 ttm180 -103.83 160.89 14.41 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.301 178.054 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.551 HG12 ' O ' ' A' ' 56' ' ' GLU . 40.6 mm -53.81 -48.95 61.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.707 0.289 . . . . 0.0 110.525 179.094 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 32.9 tttp -60.41 -24.71 65.37 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.697 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -70.67 -52.36 21.69 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.955 0.407 . . . . 0.0 110.24 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 50.3 t -71.69 -41.07 70.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.374 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.53 HD21 ' HB ' ' A' ' 40' ' ' ILE . 22.0 tp -63.52 -41.49 98.49 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.215 179.253 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.39 -32.13 68.33 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.058 178.375 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.76 -42.4 98.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.068 0.461 . . . . 0.0 110.091 -179.503 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 85.3 mt -91.0 -12.38 36.03 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.783 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 59.95 77.63 0.31 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.131 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.441 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 68.6 mt -123.76 128.87 25.01 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.999 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.88 115.0 3.36 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.536 2.157 . . . . 0.0 112.92 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.53 ' HB ' HD21 ' A' ' 33' ' ' LEU . 11.3 tp -79.9 -6.05 9.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.803 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -67.26 -43.38 82.01 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.693 -171.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.578 HG23 HG13 ' A' ' 43' ' ' VAL . 8.8 t -92.37 -20.55 20.95 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 113.881 1.067 . . . . 0.0 113.881 -165.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.578 HG13 HG23 ' A' ' 42' ' ' THR . 34.3 m -117.95 163.46 15.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 120.165 -0.614 . . . . 0.0 111.398 -177.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -103.29 139.45 24.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.85 -173.128 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.55 HG22 HG22 ' A' ' 66' ' ' VAL . 89.4 t -120.39 136.53 57.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.939 0.4 . . . . 0.0 110.584 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.603 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 98.1 mttt -128.4 149.62 50.47 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.538 178.483 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.8 ' HE2' ' HB3' ' A' ' 56' ' ' GLU . 52.4 mttm -95.27 100.46 12.24 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.822 -0.806 . . . . 0.0 108.822 167.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 66.88 -32.54 0.19 Allowed 'General case' 0 N--CA 1.471 0.609 0 O-C-N 123.953 0.783 . . . . 0.0 111.895 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.517 ' H ' ' C ' ' A' ' 47' ' ' LYS . . . 178.74 -21.5 0.04 OUTLIER Glycine 0 CA--C 1.522 0.511 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.091 -178.34 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -85.85 127.37 34.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.936 0.368 . . . . 0.0 110.419 -178.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.488 ' H ' HD12 ' A' ' 51' ' ' ILE . 3.7 mp -64.82 123.72 18.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 120.64 0.257 . . . . 0.0 110.548 -178.149 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.827 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 27.6 m -130.57 178.76 4.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.091 -177.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 29.6 pt -118.04 -174.5 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.323 177.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.457 ' O ' ' HB ' ' A' ' 29' ' ' ILE . 9.4 p-10 -75.08 -14.58 60.6 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -176.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 20.8 mt-10 -84.9 9.33 14.65 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -178.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.827 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 35.0 mm-40 -85.15 137.15 33.2 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.87 0.367 . . . . 0.0 110.731 176.433 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.565 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.1 mp0 -76.96 156.28 32.07 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.406 -179.11 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 58.0 mt -98.26 124.59 51.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -113.46 154.06 27.63 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.581 -178.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.518 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 19.1 t70 -69.11 124.58 24.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.825 178.363 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.46 4.59 70.5 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.845 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -94.01 156.88 16.37 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.734 HD12 HG22 ' A' ' 11' ' ' THR . 47.6 mm -121.73 123.33 69.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 120.776 0.322 . . . . 0.0 110.421 -173.329 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.469 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.2 mm -99.98 107.97 21.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 121.16 0.505 . . . . 0.0 110.377 -178.304 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.732 ' HA ' HG22 ' A' ' 13' ' ' ILE . 6.3 mm-40 -100.11 97.21 8.06 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.006 -177.446 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.55 HG22 HG22 ' A' ' 45' ' ' VAL . 85.7 t -95.68 106.1 17.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.447 0.641 . . . . 0.0 110.031 177.147 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.2 mt -92.29 99.77 10.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.748 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.923 ' HD2' ' HA ' ' A' ' 15' ' ' ASP . 9.2 ptm180 -75.37 123.12 24.82 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 176.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 26.8 m -85.51 139.32 17.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-O 120.875 0.369 . . . . 0.0 110.58 -178.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 8.3 tt -80.75 103.94 8.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 121.561 0.696 . . . . 0.0 110.188 177.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -98.85 111.29 23.73 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.864 -177.04 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -141.25 126.3 3.02 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.27 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.879 0 CA-C-O 118.913 -0.937 . . . . 0.0 111.968 178.09 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 53.8 ttm . . . . . 0 N--CA 1.481 1.089 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 58.8 t -82.63 104.67 11.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 121.2 0.524 . . . . 0.0 109.728 179.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 9.6 tp -94.77 141.41 15.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.435 178.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 79.8 -178.12 53.94 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.314 -175.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 25.4 ptt? -160.67 137.85 9.16 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 120.961 0.41 . . . . 0.0 111.094 -178.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.678 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 53.6 mtmt -112.15 110.01 20.03 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 169.13 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 29.2 p90 -122.7 157.12 32.98 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.409 -175.439 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.526 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 7.8 m -113.96 117.82 32.42 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.426 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.1 p -102.51 123.45 55.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-O 121.282 0.563 . . . . 0.0 109.906 178.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.473 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -95.68 122.6 47.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -179.655 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.48 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.7 OUTLIER -127.5 175.58 8.13 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.342 -0.845 . . . . 0.0 109.266 -178.609 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.48 ' H ' HG22 ' A' ' 14' ' ' THR . 13.0 p-10 -67.94 -17.7 64.53 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 111.654 0.242 . . . . 0.0 111.654 -176.7 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -91.3 -7.92 49.69 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.891 0.376 . . . . 0.0 110.891 179.115 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 141.05 -179.09 19.67 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.147 179.394 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 36.7 ttmt -100.73 110.41 22.51 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.172 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 8.6 mtpp -107.36 114.6 28.73 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.386 -170.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.526 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -82.9 120.58 34.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 173.324 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 95.3 mt -118.63 146.21 44.84 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.374 -177.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.678 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.2 OUTLIER -121.6 141.01 51.51 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.148 0.499 . . . . 0.0 110.842 177.667 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.1 t -135.94 147.04 47.91 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.496 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -76.14 -9.79 85.44 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.679 -179.34 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -136.81 146.06 53.55 Favored Pre-proline 0 C--N 1.326 -0.422 0 O-C-N 122.831 -0.217 . . . . 0.0 110.618 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -63.49 131.37 31.5 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.349 2.033 . . . . 0.0 111.307 176.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.528 ' HD2' ' HB3' ' A' ' 31' ' ' ASP . 15.9 tpp180 -123.39 155.51 37.24 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.004 -175.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.569 ' HG2' ' HA ' ' A' ' 57' ' ' GLU . 96.8 mtt180 -104.18 165.01 11.33 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.765 -0.198 . . . . 0.0 110.715 178.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 45.6 mm -54.8 -55.78 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.974 -175.03 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.531 ' NZ ' ' HB3' ' A' ' 30' ' ' LYS . 2.8 ttpm? -53.15 -39.95 63.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.138 0.494 . . . . 0.0 110.959 179.373 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.528 ' HB3' ' HD2' ' A' ' 27' ' ' ARG . 3.1 m-20 -64.61 -52.44 57.49 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.951 -176.334 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.0 t -62.98 -47.46 92.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 121.099 0.476 . . . . 0.0 110.713 178.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 14.5 tp -64.7 -38.46 91.06 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.603 -177.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.12 -42.61 66.94 Favored Glycine 0 N--CA 1.447 -0.572 0 CA-C-N 115.492 -0.776 . . . . 0.0 113.108 -179.095 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -68.04 -31.56 71.3 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.903 0.351 . . . . 0.0 111.263 -178.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 97.1 mt -83.0 -4.05 57.89 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.921 0.391 . . . . 0.0 110.292 176.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 55.14 61.81 2.76 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.931 -178.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 62.0 mt -116.98 114.44 39.15 Favored Pre-proline 0 C--N 1.323 -0.577 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.488 175.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.425 ' O ' HG22 ' A' ' 42' ' ' THR . 32.4 Cg_exo -59.57 113.15 1.49 Allowed 'Trans proline' 0 N--CA 1.464 -0.21 0 C-N-CA 122.76 2.306 . . . . 0.0 112.558 -178.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 14.6 tt -63.01 -20.23 25.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 121.383 0.611 . . . . 0.0 110.589 178.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -63.62 -29.96 71.14 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.152 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.425 HG22 ' O ' ' A' ' 39' ' ' PRO . 3.6 t -108.4 4.98 24.97 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-O 120.914 0.388 . . . . 0.0 111.665 -170.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.3 m -136.54 164.57 30.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.14 0.495 . . . . 0.0 111.466 -179.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 56.7 t -123.26 129.28 74.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.499 176.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.0 t -107.3 130.87 58.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 121.283 0.563 . . . . 0.0 111.536 -175.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.831 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 96.3 mttt -117.8 131.88 56.52 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.311 176.274 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.489 ' HB2' HG21 ' A' ' 52' ' ' VAL . 65.0 tttp -93.07 106.29 18.27 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 174.46 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.546 ' HA ' ' HB ' ' A' ' 63' ' ' ILE . 12.5 t-20 68.94 -66.06 0.26 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.064 -177.122 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -159.2 17.23 0.25 Allowed Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.809 -0.516 . . . . 0.0 111.809 179.034 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 -131.19 131.27 43.88 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 -177.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.5 mt -64.02 128.86 27.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 176.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.767 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 19.6 m -132.94 178.75 5.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 120.933 0.397 . . . . 0.0 111.864 -173.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 32.8 pt -88.89 172.73 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.882 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.509 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 6.6 p-10 -76.4 -20.72 56.84 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.326 -176.256 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 68.5 tt0 -85.43 4.99 32.99 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.04 0.448 . . . . 0.0 110.719 -178.056 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.767 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 7.5 mm-40 -72.44 129.89 39.41 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.122 0.487 . . . . 0.0 111.226 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.569 ' HA ' ' HG2' ' A' ' 28' ' ' ARG . 4.7 pt-20 -86.87 140.69 29.4 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.423 179.3 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.456 HG23 HD11 ' A' ' 64' ' ' ILE . 12.0 mt -92.11 150.82 3.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.218 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -124.6 164.65 19.39 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.035 0.445 . . . . 0.0 110.702 -177.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -67.6 128.06 35.07 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.373 176.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 83.49 12.02 79.05 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.114 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -96.99 161.79 13.68 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 178.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.546 ' HB ' ' HA ' ' A' ' 48' ' ' ASN . 46.4 mm -115.38 138.96 44.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.037 -176.089 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.475 HG22 HG23 ' A' ' 66' ' ' VAL . 49.8 mm -118.29 118.6 58.62 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 176.428 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.831 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 42.7 tt0 -107.5 107.54 18.44 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.475 HG23 HG22 ' A' ' 64' ' ' ILE . 86.0 t -111.99 109.56 28.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.204 0.526 . . . . 0.0 110.51 -179.355 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -114.02 139.0 42.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.445 HH11 ' HD3' ' A' ' 68' ' ' ARG . 35.0 mtm-85 -67.73 154.91 40.48 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 174.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.1 p -81.95 136.28 23.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-O 121.656 0.741 . . . . 0.0 111.52 -170.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -98.45 126.32 51.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.111 -0.949 . . . . 0.0 108.803 174.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 16.1 p90 -124.17 139.94 53.44 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.795 -176.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.62 118.12 5.13 Favored Glycine 0 N--CA 1.445 -0.716 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.993 179.267 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.025 0 CA-C-O 118.174 -1.348 . . . . 0.0 111.104 178.922 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 24.5 ttt . . . . . 0 N--CA 1.481 1.112 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 8.8 p -89.69 131.66 36.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.099 0.476 . . . . 0.0 111.09 -178.156 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 65.4 mt -119.06 124.88 73.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 176.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 97.63 67.04 0.91 Allowed Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.452 -0.88 . . . . 0.0 111.404 -177.215 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.41 ' HB2' ' HA ' ' A' ' 60' ' ' ASP . 26.1 ptt? -87.4 149.95 24.13 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.643 -0.278 . . . . 0.0 111.089 -174.415 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.55 ' HD3' ' OD1' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -129.68 128.96 43.62 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 168.808 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -125.44 153.17 43.88 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -177.593 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.56 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.8 m -109.81 117.67 34.48 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.176 -179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.552 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 3.1 p -112.23 123.41 67.94 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.458 -178.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.608 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -88.06 121.02 37.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 177.769 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.92 -162.05 1.14 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.747 -174.264 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -61.96 -45.92 91.54 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 112.202 0.445 . . . . 0.0 112.202 -171.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -87.74 -0.82 57.44 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 111.999 0.37 . . . . 0.0 111.999 -175.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 137.12 -164.73 25.27 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.128 -1.034 . . . . 0.0 112.653 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.589 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.0 ttpt -92.23 116.76 29.24 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.035 0.445 . . . . 0.0 110.212 -177.524 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 41.4 tptt -115.2 113.3 23.74 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.996 -172.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.56 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -84.32 120.54 35.27 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 CA-C-O 121.69 0.757 . . . . 0.0 109.795 174.175 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 97.4 mt -116.02 136.59 52.89 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.24 -178.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.528 ' HG3' ' HB3' ' A' ' 9' ' ' LYS . 39.3 tt0 -113.5 139.49 48.91 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.275 -0.42 . . . . 0.0 109.974 179.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.2 t -132.92 132.91 42.56 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 178.575 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -66.46 -15.1 63.27 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 121.157 -0.544 . . . . 0.0 113.401 -175.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -133.9 142.32 43.06 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-N 116.896 0.348 . . . . 0.0 110.805 -178.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -54.43 133.95 58.96 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.465 2.11 . . . . 0.0 110.845 173.665 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.465 ' HG3' ' CB ' ' A' ' 31' ' ' ASP . 0.1 OUTLIER -132.56 156.21 47.26 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 120.662 -0.415 . . . . 0.0 111.487 -168.071 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.448 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 10.2 ttt85 -92.69 158.66 15.82 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 174.192 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 40.8 mm -59.96 -36.94 70.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.126 0.489 . . . . 0.0 109.814 176.061 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -67.21 -19.83 65.61 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.756 -177.041 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.465 ' CB ' ' HG3' ' A' ' 27' ' ' ARG . 3.2 m-20 -65.64 -61.8 1.88 Allowed 'General case' 0 CA--C 1.517 -0.312 0 CA-C-O 121.186 0.517 . . . . 0.0 109.766 173.73 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.5 t -59.7 -42.19 87.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.326 179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.589 HD21 ' HB ' ' A' ' 40' ' ' ILE . 1.2 tm? -63.94 -47.6 79.82 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.759 -178.445 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.21 -47.43 36.87 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 116.049 -0.523 . . . . 0.0 113.608 -174.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.4 mm-40 -73.26 -37.16 66.4 Favored 'General case' 0 C--N 1.33 -0.247 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -173.417 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 79.9 mt -87.64 -13.73 41.9 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.979 -0.288 . . . . 0.0 111.029 -179.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 58.97 77.77 0.29 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.598 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.576 ' HB ' HD22 ' A' ' 33' ' ' LEU . 65.1 mt -118.75 133.21 23.63 Favored Pre-proline 0 C--N 1.319 -0.731 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.51 -179.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 29.6 Cg_exo -62.83 100.49 0.24 Allowed 'Trans proline' 0 CA--C 1.529 0.252 0 C-N-CA 122.562 2.174 . . . . 0.0 112.401 178.525 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.589 ' HB ' HD21 ' A' ' 33' ' ' LEU . 8.2 tp -85.74 -25.13 6.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.549 -177.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 18.3 tp10 -76.06 -20.55 57.64 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.964 -173.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.531 HG23 HG13 ' A' ' 43' ' ' VAL . 12.9 t -109.1 -10.82 14.99 Favored 'General case' 0 CA--C 1.534 0.365 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 -170.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.531 HG13 HG23 ' A' ' 42' ' ' THR . 25.9 m -122.35 158.54 26.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.049 -179.424 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.0 t -94.98 113.12 28.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.037 -175.65 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 90.4 t -102.83 131.17 51.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.057 0.455 . . . . 0.0 110.439 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.737 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 97.9 mttt -117.28 126.39 52.65 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.948 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.504 ' HB3' HG11 ' A' ' 52' ' ' VAL . 71.1 tttt -96.82 106.06 18.3 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.362 175.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 71.08 -53.24 0.68 Allowed 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 123.947 0.899 . . . . 0.0 110.861 -177.331 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.49 21.49 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.077 178.292 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . 0.592 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 18.6 mm-40 -125.18 143.62 50.85 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 -177.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.421 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.2 mp -74.61 113.76 13.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 176.388 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.745 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 35.6 m -124.9 178.47 3.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-O 121.14 0.495 . . . . 0.0 111.834 -173.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.447 HG13 ' H ' ' A' ' 55' ' ' GLU . 23.8 pt -123.22 -171.31 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.597 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -70.08 -12.74 61.82 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.087 -0.506 . . . . 0.0 112.056 -176.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.447 ' H ' HG13 ' A' ' 53' ' ' ILE . 7.5 tp10 -81.91 -8.51 59.68 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.522 -174.169 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.745 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 22.0 mm-40 -81.49 163.2 22.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.002 0.43 . . . . 0.0 111.97 -176.445 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.448 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 0.0 OUTLIER -103.15 159.24 15.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.169 177.468 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 17.9 mt -103.85 154.48 5.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -128.49 168.41 15.7 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.924 0.392 . . . . 0.0 110.857 -177.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.55 ' OD1' ' HD3' ' A' ' 9' ' ' LYS . 30.8 t70 -81.12 129.42 34.56 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.854 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 72.04 26.58 72.12 Favored Glycine 0 N--CA 1.448 -0.506 0 C-N-CA 121.076 -0.583 . . . . 0.0 111.935 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -97.33 160.97 14.02 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.962 0.411 . . . . 0.0 110.823 -178.055 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 31.3 mm -111.01 113.4 44.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.418 -175.304 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.552 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.1 mm -102.3 109.4 26.25 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.737 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 38.8 tt0 -99.65 99.99 10.92 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.223 -178.735 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 92.3 t -100.37 103.1 14.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.46 0.647 . . . . 0.0 110.522 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 24.2 mt -91.89 99.24 9.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.481 179.342 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.459 ' HD2' ' O ' ' A' ' 68' ' ' ARG . 0.1 OUTLIER -63.44 151.38 41.26 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.624 175.582 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -82.56 113.34 21.67 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-O 121.522 0.677 . . . . 0.0 111.878 -170.16 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -90.65 101.72 12.66 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.725 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 169.483 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 22.3 t80 -90.97 110.6 21.86 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.452 -173.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -118.52 115.58 3.16 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.838 -0.696 . . . . 0.0 111.931 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.173 0 CA-C-O 118.544 -1.142 . . . . 0.0 111.591 178.464 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 48.7 ttm . . . . . 0 N--CA 1.483 1.203 0 CA-C-O 120.707 0.289 . . . . 0.0 110.839 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.6 t -108.24 106.01 19.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.525 175.546 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 16.0 pt -107.27 122.43 61.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 121.194 0.521 . . . . 0.0 109.747 175.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 113.16 93.94 2.09 Favored Glycine 0 N--CA 1.449 -0.48 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -170.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.417 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.5 ptt? -106.1 144.72 32.41 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.38 0.609 . . . . 0.0 112.293 -165.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.521 ' HG2' ' OD1' ' A' ' 60' ' ' ASP . 23.8 pttm -107.06 141.45 38.28 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.289 -0.869 . . . . 0.0 108.911 168.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 31.1 p90 -156.72 147.96 22.2 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.853 0.359 . . . . 0.0 110.163 178.285 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.623 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 9.5 t -112.41 138.01 49.76 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.15 0.5 . . . . 0.0 110.225 178.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.762 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.7 p -126.9 134.54 65.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.966 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.669 HG22 ' HA ' ' A' ' 65' ' ' GLU . 8.1 tt -88.19 124.85 41.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.944 174.454 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.411 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.7 OUTLIER -116.68 174.18 6.22 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.138 -0.937 . . . . 0.0 108.542 177.176 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.411 ' H ' HG22 ' A' ' 14' ' ' THR . 25.6 t70 -58.4 -34.17 70.44 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.25 0.548 . . . . 0.0 110.719 178.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -77.07 -10.79 59.61 Favored 'General case' 0 CA--C 1.535 0.395 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.698 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 136.39 176.76 14.54 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.414 -0.898 . . . . 0.0 112.783 178.579 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.641 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 45.4 tttt -96.43 116.64 29.38 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 6.6 mtpm? -129.65 147.87 51.49 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.845 -175.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.623 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -111.15 131.23 62.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -177.388 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.456 ' N ' HD13 ' A' ' 20' ' ' ILE . 2.0 pt? -134.8 165.1 26.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.751 0.31 . . . . 0.0 111.084 -175.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -112.44 150.6 30.94 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.337 -179.299 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 14.4 t -136.03 134.62 38.69 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 175.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.06 -44.94 95.1 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 121.26 -0.495 . . . . 0.0 113.153 -176.141 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -110.88 146.56 34.68 Favored Pre-proline 0 C--N 1.321 -0.637 0 O-C-N 122.625 -0.338 . . . . 0.0 110.741 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.417 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 25.0 Cg_exo -63.72 119.82 7.01 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.682 2.255 . . . . 0.0 111.2 175.282 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.414 ' HE ' ' CG ' ' A' ' 31' ' ' ASP . 17.2 mmm180 -115.0 177.18 4.74 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.729 -174.333 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 54.8 ttm-85 -108.38 159.97 16.24 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.505 HD11 ' HE2' ' A' ' 47' ' ' LYS . 38.0 mm -56.87 -48.76 80.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.913 0.387 . . . . 0.0 110.392 176.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.5 tptm -59.6 -28.04 66.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.186 178.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.414 ' CG ' ' HE ' ' A' ' 27' ' ' ARG . 30.0 t70 -65.15 -62.09 1.75 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.849 0.356 . . . . 0.0 110.475 178.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 61.3 t -59.89 -42.94 90.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.704 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.513 HD21 ' HB ' ' A' ' 40' ' ' ILE . 24.0 tp -64.65 -43.45 93.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.811 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.22 -40.21 71.06 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.917 -0.583 . . . . 0.0 112.753 -177.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.5 mm-40 -62.5 -38.71 90.97 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.914 0.388 . . . . 0.0 110.964 178.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.1 mt -83.87 -10.96 57.63 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.505 179.333 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.9 mt-10 54.08 61.54 3.01 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.669 -177.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.449 ' HB ' HD12 ' A' ' 33' ' ' LEU . 69.2 mt -106.6 115.33 60.81 Favored Pre-proline 0 C--N 1.32 -0.704 0 CA-C-N 115.868 -0.605 . . . . 0.0 109.68 176.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -56.81 113.3 1.41 Allowed 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.695 2.263 . . . . 0.0 112.406 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.521 HD12 ' HB3' ' A' ' 54' ' ' ASP . 15.0 tt -72.7 -6.54 8.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.485 0.659 . . . . 0.0 110.819 -178.514 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -67.83 -29.28 68.4 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.998 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.534 HG23 HG13 ' A' ' 43' ' ' VAL . 9.3 t -106.44 0.05 24.49 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.734 -173.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.557 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 34.3 m -132.29 156.26 42.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.021 0.439 . . . . 0.0 111.46 -177.322 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.586 HG23 ' HB ' ' A' ' 69' ' ' VAL . 59.0 t -113.8 139.67 38.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.383 176.16 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.43 HG11 HG21 ' A' ' 29' ' ' ILE . 37.1 t -102.98 127.42 56.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.032 0.444 . . . . 0.0 110.218 -179.258 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.618 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 41.1 mttm -124.75 145.02 49.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.401 -178.081 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.582 ' HG2' HG21 ' A' ' 52' ' ' VAL . 28.8 mmtp -112.15 102.41 10.6 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 169.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.9 m120 56.05 24.55 7.93 Favored 'General case' 0 N--CA 1.465 0.323 0 O-C-N 123.451 0.469 . . . . 0.0 111.598 -178.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 115.95 -21.04 12.59 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.921 179.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 17.0 mm-40 -85.3 132.28 34.28 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.772 0.32 . . . . 0.0 110.833 -176.187 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.3 mp -73.99 116.76 16.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.957 0.408 . . . . 0.0 110.294 -179.39 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.906 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 29.3 m -123.63 173.94 8.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.673 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 28.1 pt -101.52 175.3 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.572 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.521 ' HB3' HD12 ' A' ' 40' ' ' ILE . 9.5 p-10 -74.53 -15.52 60.86 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.552 -177.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 56.1 tt0 -81.62 -5.08 57.71 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.823 0.344 . . . . 0.0 110.9 -178.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.906 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 17.2 mm-40 -69.16 142.3 54.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.824 0.345 . . . . 0.0 110.944 179.046 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 51.1 mp0 -79.9 166.52 21.57 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.562 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.517 HG23 HD11 ' A' ' 64' ' ' ILE . 55.2 mt -112.45 139.25 38.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 175.355 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 80.3 m-85 -124.18 162.24 24.04 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.778 0.323 . . . . 0.0 110.695 -176.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.521 ' OD1' ' HG2' ' A' ' 9' ' ' LYS . 21.6 t70 -71.77 117.33 13.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.329 177.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 99.53 -9.56 60.71 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 -179.106 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -78.09 143.83 37.04 Favored 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.493 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.563 HG23 HG23 ' A' ' 11' ' ' THR . 45.1 mt -115.35 118.5 58.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-O 121.23 0.538 . . . . 0.0 111.126 -173.42 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.762 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 4.0 mp -101.7 130.91 50.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.623 -178.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.669 ' HA ' HG22 ' A' ' 13' ' ' ILE . 53.0 mt-10 -120.64 118.53 30.38 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 178.647 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 62.0 t -114.06 102.79 14.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.129 0.49 . . . . 0.0 110.235 -178.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.08 137.95 51.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 -179.01 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.557 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 76.0 mtp180 -65.43 138.96 58.46 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.976 0.417 . . . . 0.0 110.717 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.586 ' HB ' HG23 ' A' ' 44' ' ' VAL . 14.9 p -84.0 148.29 5.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.01 -174.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 5.3 tp -78.47 102.04 4.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.777 0.798 . . . . 0.0 110.085 176.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 28.3 p90 -73.23 153.98 40.41 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.687 179.546 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -84.92 53.85 4.86 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.928 -0.653 . . . . 0.0 111.932 178.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.594 -1.114 . . . . 0.0 111.759 -178.635 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 0.979 0 CA-C-O 120.752 0.311 . . . . 0.0 110.189 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.6 p -83.61 119.78 33.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.335 0.588 . . . . 0.0 110.48 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 60.0 mt -96.48 122.25 47.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.013 -179.208 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.99 -179.54 16.53 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.446 -178.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.496 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 25.5 ptt? -156.07 137.91 14.36 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.032 0.444 . . . . 0.0 110.887 179.245 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.402 ' HE3' ' HB2' ' A' ' 22' ' ' GLU . 30.4 tttt -123.72 114.58 20.12 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 174.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -127.98 167.99 15.9 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.283 -173.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.458 ' HB ' HD13 ' A' ' 20' ' ' ILE . 12.9 t -115.42 138.51 50.93 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.922 0.391 . . . . 0.0 110.318 178.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.4 p -128.41 136.79 59.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.099 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.585 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -107.98 124.85 64.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.3 0.571 . . . . 0.0 109.815 177.785 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.7 p -129.15 -163.03 1.25 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.238 -179.038 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -67.57 -24.36 65.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.024 0.44 . . . . 0.0 110.664 178.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -82.69 -11.5 58.29 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.393 0.616 . . . . 0.0 110.48 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 115.93 -167.65 12.49 Favored Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.419 -176.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.585 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 33.1 ttpt -98.99 127.87 45.0 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -177.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.457 ' HE3' ' HB2' ' A' ' 19' ' ' LYS . 29.9 ttmt -137.57 164.26 29.19 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.482 -174.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.458 HD13 ' HB ' ' A' ' 11' ' ' THR . 34.3 mm -98.38 126.44 51.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-O 120.7 0.286 . . . . 0.0 111.015 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.446 HD13 HG12 ' A' ' 12' ' ' VAL . 6.9 mp -111.51 144.44 40.73 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.192 176.443 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.402 ' HB2' ' HE3' ' A' ' 9' ' ' LYS . 40.6 tt0 -127.25 134.88 50.02 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.146 -177.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.0 t -134.19 143.79 48.08 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 177.017 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.6 -18.38 75.58 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 121.234 -0.508 . . . . 0.0 113.246 -176.429 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -139.07 151.14 67.26 Favored Pre-proline 0 C--N 1.324 -0.539 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.496 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 25.0 Cg_exo -63.96 119.53 6.61 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.394 2.063 . . . . 0.0 111.234 174.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.421 ' HB3' ' CB ' ' A' ' 31' ' ' ASP . 50.9 mmm-85 -116.6 157.66 24.96 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.191 -175.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.625 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 23.4 mtt180 -82.08 167.35 18.88 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 172.044 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.547 ' HB ' ' HA ' ' A' ' 54' ' ' ASP . 48.9 mm -61.14 -35.16 63.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 168.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 40.7 tptt -61.37 -33.92 74.45 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 114.662 -1.154 . . . . 0.0 110.822 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.421 ' CB ' ' HB3' ' A' ' 27' ' ' ARG . 4.5 m-20 -65.87 -58.48 5.49 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.317 177.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 58.6 t -59.43 -53.04 53.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.329 -176.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.573 ' HG ' ' HB ' ' A' ' 38' ' ' ILE . 10.7 mp -71.82 -35.88 70.06 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.367 -176.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.83 -43.6 58.36 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.662 179.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -73.09 -33.04 65.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.023 0.439 . . . . 0.0 111.154 -175.101 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.0 mt -97.35 -5.99 35.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.449 -0.342 . . . . 0.0 111.511 -178.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 62.23 75.18 0.41 Allowed 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.684 0.754 . . . . 0.0 110.717 -176.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.573 ' HB ' ' HG ' ' A' ' 33' ' ' LEU . 67.4 mt -123.66 116.27 27.93 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-N 115.392 -0.822 . . . . 0.0 109.756 178.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 17.1 Cg_exo -67.04 109.64 1.77 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.658 2.238 . . . . 0.0 112.906 -178.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.444 ' HB ' HD23 ' A' ' 33' ' ' LEU . 9.9 tt -81.59 -5.74 9.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 122.009 0.909 . . . . 0.0 109.203 176.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -69.84 -31.64 69.6 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.855 -176.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.58 HG23 HG13 ' A' ' 43' ' ' VAL . 4.6 t -96.14 -36.95 10.79 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 112.71 0.633 . . . . 0.0 112.71 -172.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.58 HG13 HG23 ' A' ' 42' ' ' THR . 21.3 m -116.56 162.61 14.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 C-N-CA 120.888 -0.325 . . . . 0.0 111.069 -175.745 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.9 t -102.93 131.93 50.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 120.855 0.36 . . . . 0.0 111.671 -173.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.0 t -103.65 130.5 54.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.938 176.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.639 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 92.5 mttt -118.81 143.61 46.83 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.842 0.353 . . . . 0.0 111.442 179.451 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.774 ' HG2' HG21 ' A' ' 52' ' ' VAL . 10.0 mmtp -100.57 102.2 13.3 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 170.273 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 65.49 -1.01 1.06 Allowed 'General case' 0 CA--C 1.541 0.619 0 O-C-N 123.426 0.454 . . . . 0.0 111.512 178.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 132.2 -10.64 5.34 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 121.107 -0.568 . . . . 0.0 111.907 -176.513 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . 0.428 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 14.6 mm100 -87.07 128.1 35.11 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 122.045 0.138 . . . . 0.0 110.664 178.735 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.404 ' H ' HD12 ' A' ' 51' ' ' ILE . 3.8 mp -71.32 114.85 10.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.037 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.774 HG21 ' HG2' ' A' ' 47' ' ' LYS . 28.1 m -125.77 178.79 3.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.117 0.484 . . . . 0.0 111.52 -174.591 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.44 HG13 ' H ' ' A' ' 55' ' ' GLU . 24.7 pt -115.09 -170.92 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.348 177.263 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.547 ' HA ' ' HB ' ' A' ' 29' ' ' ILE . 35.1 p-10 -77.49 -7.19 55.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.656 -175.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.44 ' H ' HG13 ' A' ' 53' ' ' ILE . 7.5 tp10 -72.79 -22.16 60.88 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.918 -179.429 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.565 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 8.0 mm-40 -69.11 135.71 51.14 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.497 0.554 . . . . 0.0 112.497 -174.379 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.625 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 58.1 mp0 -82.38 144.2 30.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.914 173.315 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 30.9 mt -91.21 142.34 13.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 176.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -119.4 162.2 19.22 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.856 0.36 . . . . 0.0 110.75 -177.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -69.06 131.14 44.55 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.599 173.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.59 23.51 75.07 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.924 -177.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 31.2 t0 -97.4 154.04 17.72 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 178.046 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.447 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.0 mp -110.21 116.78 53.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-O 121.03 0.443 . . . . 0.0 110.525 -177.618 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 41.5 mm -103.55 108.84 25.4 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.899 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.639 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 44.5 mt-10 -102.22 107.16 18.13 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 178.205 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 93.4 t -97.05 102.45 13.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.38 0.609 . . . . 0.0 109.681 178.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 64.0 mt -96.36 105.88 17.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.406 -177.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.488 ' HA ' ' CG1' ' A' ' 43' ' ' VAL . 0.6 OUTLIER -75.92 131.48 39.65 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.521 174.641 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 34.9 m -83.31 149.66 4.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.715 -177.31 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 9.4 tt -77.33 112.23 15.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.527 0.679 . . . . 0.0 109.892 178.236 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 48.8 t80 -89.33 -25.62 21.52 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.824 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 122.85 -177.03 16.59 Favored Glycine 0 N--CA 1.444 -0.805 0 CA-C-N 115.441 -0.8 . . . . 0.0 111.876 178.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.86 0 CA-C-O 119.022 -0.877 . . . . 0.0 111.073 178.928 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 13.7 tpt . . . . . 0 N--CA 1.477 0.898 0 CA-C-O 120.647 0.26 . . . . 0.0 110.32 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.7 t -108.32 122.3 62.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.067 178.178 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.437 ' N ' HD12 ' A' ' 6' ' ' ILE . 3.2 mp -97.15 121.92 48.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 178.264 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.33 179.96 45.16 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.14 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.543 ' HA ' ' OD1' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -159.91 158.07 30.15 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.762 0.315 . . . . 0.0 110.221 178.701 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.601 ' HB2' HD11 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -133.79 145.78 50.08 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 173.32 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.5 ' CD2' HD13 ' A' ' 64' ' ' ILE . 38.4 p90 -144.41 141.06 29.39 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.388 -178.507 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.643 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 18.0 m -95.39 118.35 31.98 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.079 0.466 . . . . 0.0 110.06 177.114 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.2 p -107.33 134.17 49.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.955 -179.666 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.496 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -103.76 127.48 57.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 121.528 0.68 . . . . 0.0 109.6 177.647 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 16.7 m -141.81 166.86 23.58 Favored 'General case' 0 C--N 1.317 -0.828 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 19.5 m-20 -63.73 -17.77 63.35 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 120.868 0.366 . . . . 0.0 111.076 177.223 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -77.73 -10.98 59.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.335 0.588 . . . . 0.0 110.132 175.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 129.44 157.87 9.32 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 112.124 179.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.441 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.9 ttmt -86.1 109.96 19.21 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 173.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -129.14 131.86 47.26 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.271 -173.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.643 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -81.84 124.3 38.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.397 0.618 . . . . 0.0 110.042 176.042 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.47 HD13 ' N ' ' A' ' 22' ' ' GLU . 1.1 tm? -106.81 135.28 48.62 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -178.367 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.47 ' N ' HD13 ' A' ' 21' ' ' LEU . 4.9 tm-20 -115.36 131.53 56.9 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -177.018 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 24.2 m -135.4 126.64 28.24 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.83 0.348 . . . . 0.0 110.787 -179.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -72.0 -17.57 77.16 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.079 178.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -118.77 121.72 30.43 Favored Pre-proline 0 C--N 1.321 -0.665 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 176.757 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_exo -48.61 139.13 24.21 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 123.138 2.559 . . . . 0.0 111.729 177.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.571 ' HG3' ' HB2' ' A' ' 31' ' ' ASP . 1.9 tpp85 -133.51 147.48 51.62 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.761 0.315 . . . . 0.0 111.122 -170.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.555 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 40.0 ttm105 -91.57 161.1 15.08 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 176.108 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 33.8 mm -58.95 -51.12 76.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 110.376 -0.231 . . . . 0.0 110.376 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.4 tttp -54.83 -36.03 64.59 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.891 176.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.571 ' HB2' ' HG3' ' A' ' 27' ' ' ARG . 22.7 m-20 -61.38 -58.45 8.18 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.145 179.177 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.7 t -60.56 -43.17 93.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 121.086 0.469 . . . . 0.0 110.672 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.642 HD21 ' HB ' ' A' ' 40' ' ' ILE . 9.3 tp -61.55 -48.18 82.16 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.731 -179.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.88 -38.77 60.24 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.531 -0.759 . . . . 0.0 113.036 -178.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.5 tt0 -68.15 -41.74 81.13 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 122.526 0.33 . . . . 0.0 111.48 -176.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.1 mt -89.82 0.34 57.09 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.707 0.289 . . . . 0.0 110.9 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 53.75 65.79 1.41 Allowed 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.753 -178.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.586 ' HB ' HD12 ' A' ' 33' ' ' LEU . 63.2 mt -102.63 121.81 48.34 Favored Pre-proline 0 C--N 1.318 -0.798 0 CA-C-N 115.256 -0.883 . . . . 0.0 109.32 177.671 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 13.8 Cg_exo -68.74 102.53 0.88 Allowed 'Trans proline' 0 N--CA 1.461 -0.409 0 C-N-CA 122.612 2.208 . . . . 0.0 112.492 -178.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.642 ' HB ' HD21 ' A' ' 33' ' ' LEU . 13.2 tt -71.24 -6.51 7.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.736 0.779 . . . . 0.0 109.835 177.034 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 -59.74 -31.77 69.95 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.248 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 12.0 t -130.35 12.01 5.45 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.001 0.429 . . . . 0.0 111.805 -171.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.561 HG12 ' HG2' ' A' ' 68' ' ' ARG . 29.9 m -128.51 144.35 38.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 O-C-N 121.707 -0.621 . . . . 0.0 111.524 -179.298 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.0 t -109.57 131.14 61.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.09 177.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.1 t -103.1 128.49 56.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.032 0.444 . . . . 0.0 110.501 -177.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.58 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 53.3 mttp -123.18 133.39 54.24 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.257 179.372 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.635 ' HG2' HG21 ' A' ' 52' ' ' VAL . 21.5 mmtp -95.02 105.97 17.93 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 171.365 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 18.0 m120 59.52 21.09 9.57 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.361 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 110.51 -17.67 28.16 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.731 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -87.6 131.61 34.36 Favored 'General case' 0 C--N 1.326 -0.445 0 O-C-N 122.636 -0.332 . . . . 0.0 110.827 -177.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.51 ' H ' HD12 ' A' ' 51' ' ' ILE . 4.2 mp -67.25 122.08 17.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.994 179.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 1.148 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 20.5 m -123.65 178.99 2.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.952 -173.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 41.4 pt -113.52 174.66 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.377 0.608 . . . . 0.0 112.626 -171.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -53.33 -39.5 64.14 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.31 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.4 ' HG2' ' O ' ' A' ' 55' ' ' GLU . 38.4 tt0 -82.68 0.31 43.85 Favored 'General case' 0 CA--C 1.535 0.392 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -172.332 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 1.148 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 15.6 mm-40 -61.33 133.18 55.57 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.825 0.345 . . . . 0.0 111.023 178.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.555 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 31.2 mt-10 -101.92 150.15 23.49 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.374 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 48.7 mt -100.59 126.89 54.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.259 -177.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -108.58 171.52 7.37 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.439 -178.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.543 ' OD1' ' HA ' ' A' ' 8' ' ' MET . 25.8 t70 -69.66 112.81 6.39 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.888 0.375 . . . . 0.0 110.366 -178.436 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 92.83 36.8 5.94 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.785 -0.722 . . . . 0.0 111.477 -177.268 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.408 ' OD1' ' HD2' ' A' ' 47' ' ' LYS . 2.7 t0 -96.04 161.31 14.03 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 -179.208 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 42.2 mm -128.65 112.65 26.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.847 0.356 . . . . 0.0 110.223 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.5 HD13 ' CD2' ' A' ' 10' ' ' PHE . 2.9 mp -110.62 118.62 57.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.148 0.499 . . . . 0.0 110.527 -177.528 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.58 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 41.6 mt-10 -105.42 114.08 28.04 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.227 176.589 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 86.9 t -100.65 108.55 23.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.155 0.502 . . . . 0.0 109.849 177.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 47.7 mt -112.04 117.25 54.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.74 -0.663 . . . . 0.0 110.127 -176.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.561 ' HG2' HG12 ' A' ' 43' ' ' VAL . 49.4 mtm180 -75.01 133.66 41.6 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.587 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.6 p -101.31 122.61 53.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.213 0.53 . . . . 0.0 110.46 179.313 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 48.0 mm -87.08 103.42 13.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.165 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 56.0 t80 -118.14 127.33 53.66 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.17 -179.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -87.18 -56.13 2.23 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.512 -177.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.514 -1.159 . . . . 0.0 111.651 -178.282 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 86.9 mtp . . . . . 0 N--CA 1.48 1.037 0 CA-C-O 120.72 0.295 . . . . 0.0 110.51 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.1 t -105.01 108.37 24.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 116.312 -0.403 . . . . 0.0 109.936 175.04 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 69.4 mt -96.42 122.13 47.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 177.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 105.5 -176.99 22.71 Favored Glycine 0 N--CA 1.442 -0.927 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 -175.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.42 158.57 29.7 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 117.077 0.439 . . . . 0.0 111.525 -179.008 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 25.8 mtpp -120.28 137.91 53.98 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.22 176.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.561 ' CD2' HD13 ' A' ' 64' ' ' ILE . 44.4 p90 -150.13 162.89 39.56 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.002 0.43 . . . . 0.0 110.837 178.216 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 t -109.28 138.85 45.01 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.794 177.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.558 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 5.3 p -129.25 122.13 55.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.25 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.642 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -88.0 125.0 41.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.814 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.448 ' N ' HD13 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -132.62 -171.19 2.6 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.449 -175.732 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -56.81 -46.01 81.87 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -175.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -90.42 7.68 37.52 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 111.722 0.267 . . . . 0.0 111.722 -173.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 131.02 -169.77 21.53 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.338 -0.934 . . . . 0.0 112.328 178.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.562 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.7 ttmt -100.8 123.01 44.38 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.883 0.373 . . . . 0.0 110.085 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 51.0 mttm -103.15 146.36 28.53 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.005 -176.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -120.65 121.15 64.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 170.552 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.415 HD11 ' CZ ' ' A' ' 10' ' ' PHE . 4.3 pp -138.49 171.76 13.9 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.885 0.374 . . . . 0.0 111.4 -173.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -131.61 142.53 49.9 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.249 -174.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -121.56 143.44 49.29 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 176.26 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -73.79 -13.81 80.35 Favored Glycine 0 C--N 1.33 0.226 0 C-N-CA 121.165 -0.54 . . . . 0.0 112.759 -174.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.421 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -138.85 144.32 41.05 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 177.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -57.5 120.59 8.61 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 122.321 2.014 . . . . 0.0 111.096 176.387 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.421 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 17.8 mmt180 -113.22 155.97 24.1 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.269 0.557 . . . . 0.0 111.221 -174.096 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.603 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 28.0 ttm180 -95.48 162.44 13.65 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 173.351 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.538 HD13 HD11 ' A' ' 58' ' ' ILE . 29.2 mm -54.56 -39.53 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 120.927 0.394 . . . . 0.0 110.733 179.248 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.507 ' HD3' ' HB2' ' A' ' 54' ' ' ASP . 17.1 tptm -64.25 -25.93 68.28 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.103 179.331 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.411 ' O ' ' HG2' ' A' ' 35' ' ' GLU . 67.3 m-20 -73.54 -46.59 46.68 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-O 120.689 0.281 . . . . 0.0 110.638 178.707 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.1 t -61.47 -50.16 81.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.642 -178.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.43 HD13 ' HA ' ' A' ' 33' ' ' LEU . 4.1 mm? -68.36 -29.12 67.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.368 177.067 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.33 -42.68 64.92 Favored Glycine 0 CA--C 1.522 0.497 0 CA-C-N 115.985 -0.552 . . . . 0.0 112.736 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.411 ' HG2' ' O ' ' A' ' 31' ' ' ASP . 7.2 mm-40 -68.95 -35.72 77.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.849 0.357 . . . . 0.0 111.115 -179.303 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 94.0 mt -85.64 -14.52 45.33 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.434 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 24.2 tt0 63.43 20.35 12.2 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.772 179.032 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.451 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 69.6 mt -79.86 131.54 63.41 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.983 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 22.2 Cg_exo -63.54 105.15 0.49 Allowed 'Trans proline' 0 N--CA 1.461 -0.417 0 C-N-CA 122.491 2.127 . . . . 0.0 112.162 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.417 ' HB ' ' HG ' ' A' ' 33' ' ' LEU . 13.0 tt -67.8 -17.32 22.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.516 0.674 . . . . 0.0 110.377 178.312 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 13.3 tp10 -64.65 -37.93 89.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.503 -0.772 . . . . 0.0 111.885 -176.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.58 HG23 HG13 ' A' ' 43' ' ' VAL . 10.5 t -85.82 -9.88 56.33 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -170.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.58 HG13 HG23 ' A' ' 42' ' ' THR . 30.8 m -131.06 169.29 21.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 O-C-N 121.974 -0.454 . . . . 0.0 111.118 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.599 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 46.9 t -107.26 134.63 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.778 0.323 . . . . 0.0 111.079 -176.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.1 t -108.67 133.21 54.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.975 0.417 . . . . 0.0 110.72 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.649 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 73.6 mttt -118.53 146.54 44.47 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.144 177.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.846 ' HG2' HG21 ' A' ' 52' ' ' VAL . 4.0 mmtp -117.69 103.04 9.63 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.125 172.565 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.8 t-20 67.99 7.78 6.04 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.954 176.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 127.95 -25.04 5.02 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.86 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 71.9 mt-30 -87.74 142.42 27.84 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.71 0.255 . . . . 0.0 111.148 -178.211 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.409 HD12 ' N ' ' A' ' 51' ' ' ILE . 3.5 mp -77.99 119.58 27.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 177.017 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.846 HG21 ' HG2' ' A' ' 47' ' ' LYS . 27.5 m -124.97 178.67 3.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.062 0.458 . . . . 0.0 112.081 -170.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 32.2 pt -106.59 -174.01 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.618 178.233 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.507 ' HB2' ' HD3' ' A' ' 30' ' ' LYS . 15.6 p-10 -77.6 -15.2 59.37 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.446 -176.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.597 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 65.3 mm-40 -84.53 5.28 28.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.757 0.313 . . . . 0.0 111.653 -178.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.731 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 26.3 mm-40 -80.93 127.77 32.94 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.905 0.384 . . . . 0.0 110.63 176.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.603 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 33.8 mt-10 -88.9 148.01 24.05 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.494 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.538 HD11 HD13 ' A' ' 29' ' ' ILE . 25.3 mt -101.54 120.1 50.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.269 -177.457 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.482 ' O ' ' HB2' ' A' ' 62' ' ' ASP . 90.9 m-85 -99.31 170.58 8.55 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.585 -178.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -70.26 114.76 8.71 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.84 0.353 . . . . 0.0 110.605 178.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.26 11.71 38.31 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.705 -177.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.482 ' HB2' ' O ' ' A' ' 59' ' ' PHE . 2.7 t0 -74.49 161.03 30.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 110.277 -177.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.8 mm -128.21 111.8 25.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -178.464 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.561 HD13 ' CD2' ' A' ' 10' ' ' PHE . 2.7 mp -108.95 119.17 58.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 121.189 0.518 . . . . 0.0 110.649 -178.264 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.649 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 39.7 mt-10 -105.91 112.59 25.71 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.477 176.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 73.1 t -97.33 106.88 19.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-O 121.485 0.66 . . . . 0.0 110.424 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.599 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 58.8 mt -93.54 93.22 3.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.11 -179.534 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.478 ' HA ' HG12 ' A' ' 43' ' ' VAL . 0.0 OUTLIER -71.03 140.65 50.83 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 173.256 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.698 HG23 ' HA3' ' A' ' 72' ' ' GLY . 28.8 m -82.95 137.98 20.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.366 0.603 . . . . 0.0 111.806 -171.127 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.578 ' O ' ' HB3' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -78.23 137.06 22.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.532 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.578 ' HB3' ' O ' ' A' ' 70' ' ' ILE . 69.7 t80 78.63 -5.73 2.0 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 121.536 0.684 . . . . 0.0 109.981 -174.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.698 ' HA3' HG23 ' A' ' 69' ' ' VAL . . . -94.6 99.45 2.45 Favored Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 111.503 -0.639 . . . . 0.0 111.503 176.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.2 0 CA-C-O 118.255 -1.303 . . . . 0.0 111.202 -178.851 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . 0.576 ' SD ' HD11 ' A' ' 6' ' ' ILE . 48.5 ttm . . . . . 0 N--CA 1.476 0.856 0 N-CA-C 110.137 -0.319 . . . . 0.0 110.137 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 47.7 t -85.6 105.06 13.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.027 0.441 . . . . 0.0 110.269 179.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.576 HD11 ' SD ' ' A' ' 4' ' ' MET . 50.0 mm -108.03 131.26 58.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.762 178.293 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 101.05 -156.99 19.18 Favored Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 -176.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.69 151.82 18.97 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.919 0.39 . . . . 0.0 111.49 -179.465 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 37.2 ttpt -117.19 119.79 36.3 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 173.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -139.03 167.92 20.98 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.903 0.382 . . . . 0.0 110.835 -173.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.56 ' HB ' HD13 ' A' ' 20' ' ' ILE . 11.4 t -115.04 138.97 50.26 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-O 121.195 0.522 . . . . 0.0 110.738 178.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.474 HG23 ' HB ' ' A' ' 64' ' ' ILE . 10.0 p -127.09 138.28 55.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.253 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.494 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -116.93 121.24 67.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.345 0.593 . . . . 0.0 109.964 179.955 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 72.8 p -130.88 -163.73 1.35 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.083 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.837 ' HB3' ' HD3' ' A' ' 68' ' ' ARG . 8.7 p-10 -69.97 -21.92 63.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.88 0.371 . . . . 0.0 110.832 178.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -82.15 -10.81 59.04 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.478 0.656 . . . . 0.0 110.059 178.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 121.56 -167.91 14.38 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.046 178.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.8 ttmt -104.09 115.23 30.05 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -112.48 154.96 25.07 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.981 0.419 . . . . 0.0 112.009 -174.569 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.56 HD13 ' HB ' ' A' ' 11' ' ' THR . 24.3 mm -109.06 121.6 62.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 170.459 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.435 HD23 ' H ' ' A' ' 21' ' ' LEU . 1.9 pt? -128.53 161.29 29.91 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.064 0.459 . . . . 0.0 110.99 -178.617 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -126.4 141.17 51.99 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.137 -173.441 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 23.2 t -130.15 140.57 50.76 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 175.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.412 ' O ' HG22 ' A' ' 6' ' ' ILE . . . -80.87 -16.12 75.86 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.344 -177.543 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -138.42 148.61 59.9 Favored Pre-proline 0 C--N 1.321 -0.651 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 178.159 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -57.74 142.49 96.03 Favored 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.604 2.203 . . . . 0.0 111.782 177.182 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.564 ' HG3' ' HB2' ' A' ' 31' ' ' ASP . 10.4 tpt180 -137.92 158.37 44.48 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.489 -0.559 . . . . 0.0 109.489 -172.253 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.591 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 76.3 mtm180 -102.34 173.62 6.28 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.834 0.349 . . . . 0.0 110.804 173.534 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.607 ' HB ' ' HA ' ' A' ' 54' ' ' ASP . 18.3 mt -68.14 -42.79 85.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.794 175.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.414 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 82.9 tttt -60.69 -32.3 71.53 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.193 176.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.564 ' HB2' ' HG3' ' A' ' 27' ' ' ARG . 81.0 m-20 -67.91 -41.54 82.51 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.701 178.762 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 68.0 t -75.61 -52.75 17.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.862 0.363 . . . . 0.0 110.921 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.402 ' HG ' ' HB ' ' A' ' 38' ' ' ILE . 10.9 mp -61.78 -35.35 77.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.938 178.705 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.39 -33.68 68.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.151 177.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.401 ' HB2' ' O ' ' A' ' 31' ' ' ASP . 3.6 tp10 -60.52 -45.46 93.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.883 0.373 . . . . 0.0 110.73 -178.775 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.4 mt -102.0 6.73 41.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.814 -176.235 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 53.59 69.56 0.69 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.552 0.692 . . . . 0.0 111.064 -176.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.402 ' HB ' ' HG ' ' A' ' 33' ' ' LEU . 62.8 mt -111.5 117.37 49.23 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.065 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.515 ' HB2' HG22 ' A' ' 42' ' ' THR . 17.0 Cg_exo -67.05 113.64 2.9 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.889 2.393 . . . . 0.0 112.016 178.383 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 10.8 tt -79.6 -13.04 13.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.501 0.667 . . . . 0.0 110.59 -178.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -75.63 -17.24 60.06 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.58 -177.027 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.563 HG23 HG13 ' A' ' 43' ' ' VAL . 9.8 t -108.71 -8.33 15.42 Favored 'General case' 0 CA--C 1.533 0.313 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -174.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.563 HG13 HG23 ' A' ' 42' ' ' THR . 17.8 m -133.24 167.09 27.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 O-C-N 122.099 -0.376 . . . . 0.0 110.872 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.462 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 51.9 t -105.26 121.95 57.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.91 -178.222 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.8 t -103.71 127.07 58.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.031 177.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.632 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 98.8 mttt -122.82 144.61 49.07 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.991 0.424 . . . . 0.0 111.82 -178.812 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.561 ' HG2' HG21 ' A' ' 52' ' ' VAL . 17.9 mmtp -100.92 101.9 12.81 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.229 167.753 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.8 t-20 63.28 2.33 1.11 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.996 0.518 . . . . 0.0 111.805 178.674 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 136.14 -17.27 3.85 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 121.083 -0.579 . . . . 0.0 112.353 -178.533 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . 0.475 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 17.6 mm-40 -87.16 129.53 34.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.407 0.146 . . . . 0.0 110.939 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.6 mp -69.36 120.78 17.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 176.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.561 HG21 ' HG2' ' A' ' 47' ' ' LYS . 17.4 m -124.95 177.48 4.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.149 -176.785 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.471 ' O ' HD12 ' A' ' 29' ' ' ILE . 26.9 pt -113.0 179.63 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.282 174.578 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.607 ' HA ' ' HB ' ' A' ' 29' ' ' ILE . 8.4 p-10 -73.22 -6.09 43.62 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.851 -175.338 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -81.43 -2.12 48.3 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.389 -176.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 58.9 mm-40 -89.69 150.39 22.36 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 122.171 -0.33 . . . . 0.0 111.518 -177.34 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.591 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 21.0 mp0 -88.05 157.07 18.99 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.112 177.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.463 HG12 ' O ' ' A' ' 27' ' ' ARG . 2.6 mm -96.47 134.48 33.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 173.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -116.63 167.48 11.03 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.027 0.442 . . . . 0.0 111.275 -175.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -73.97 129.51 38.02 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.111 175.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.75 18.72 79.52 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.433 -176.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -91.51 157.06 17.24 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 179.631 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.457 HG12 HG22 ' A' ' 11' ' ' THR . 10.5 mt -128.3 114.27 33.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.228 0.537 . . . . 0.0 110.897 -175.331 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.474 ' HB ' HG23 ' A' ' 12' ' ' VAL . 22.0 mm -96.67 106.89 19.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.278 -178.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.632 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 35.4 tt0 -97.19 101.99 13.66 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 176.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.46 HG23 HG22 ' A' ' 64' ' ' ILE . 80.3 t -100.24 105.94 18.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.209 0.528 . . . . 0.0 110.116 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.462 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 26.2 mt -91.96 95.88 5.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.086 178.415 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.837 ' HD3' ' HB3' ' A' ' 15' ' ' ASP . 1.2 ptm180 -74.97 156.65 36.07 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.639 178.094 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -83.2 124.24 39.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-O 121.436 0.636 . . . . 0.0 110.586 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 4.7 tp -87.01 102.08 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.749 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 167.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 29.9 t80 -65.23 104.32 0.91 Allowed 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.421 0.629 . . . . 0.0 111.321 -170.473 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -168.37 -109.58 0.22 Allowed Glycine 0 N--CA 1.442 -0.962 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.294 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.097 0 CA-C-O 117.98 -1.455 . . . . 0.0 111.329 -179.854 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 25.3 mmt . . . . . 0 N--CA 1.48 1.05 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 41.9 t -98.19 127.58 50.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 178.343 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 62.4 mt -82.88 122.1 36.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.385 179.002 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 112.27 120.3 3.81 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.979 -0.629 . . . . 0.0 111.73 -177.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.495 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 26.1 ptt? -113.77 134.38 54.81 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.331 0.586 . . . . 0.0 111.379 -175.354 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.853 ' HD3' ' HB3' ' A' ' 22' ' ' GLU . 6.1 tppt? -106.79 126.64 52.55 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.025 176.37 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -152.81 147.63 26.26 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.141 0.496 . . . . 0.0 111.342 179.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.563 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.1 t -98.56 142.59 29.96 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.015 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.6 p -118.73 119.49 61.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.505 0.669 . . . . 0.0 110.002 176.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.51 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -106.75 117.03 51.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-O 121.864 0.84 . . . . 0.0 108.928 176.998 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.485 HG22 ' H ' ' A' ' 15' ' ' ASP . 1.4 m -114.75 175.33 5.54 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.221 -177.472 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.485 ' H ' HG22 ' A' ' 14' ' ' THR . 28.1 t70 -56.34 -23.29 36.35 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-O 120.95 0.405 . . . . 0.0 111.475 178.501 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -87.09 -12.27 47.67 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.559 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 133.43 -174.81 20.52 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.382 -0.913 . . . . 0.0 112.184 -177.276 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.51 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.7 ttmt -109.94 139.49 44.99 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.66 0.267 . . . . 0.0 110.997 -175.303 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -150.23 136.48 18.77 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 173.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.563 HD11 ' HG3' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -98.74 136.18 30.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-O 120.748 0.309 . . . . 0.0 110.341 -177.642 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.3 pp -138.58 170.54 15.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.087 177.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.853 ' HB3' ' HD3' ' A' ' 9' ' ' LYS . 13.3 pt-20 -138.84 150.33 45.9 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.925 0.393 . . . . 0.0 111.396 -178.325 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 40.8 m -135.61 133.69 38.52 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.115 177.739 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -74.31 4.08 35.77 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 121.326 -0.464 . . . . 0.0 113.252 -177.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.465 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -135.35 127.97 18.08 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.648 0.224 . . . . 0.0 110.504 178.527 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.495 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 21.9 Cg_exo -65.15 128.77 21.28 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.781 2.321 . . . . 0.0 110.982 176.159 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.56 ' HA ' ' NE ' ' A' ' 27' ' ' ARG . 0.0 OUTLIER -134.21 171.43 14.25 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.406 -170.838 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.4 ttp-105 -104.03 160.72 14.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.704 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 38.2 mm -56.49 -47.49 81.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.34 179.354 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.483 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 29.7 tptp -55.57 -37.99 68.77 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.335 -179.631 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -69.52 -57.43 5.22 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.006 -178.682 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 69.1 t -61.3 -47.93 91.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.855 -177.072 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 19.6 tp -68.02 -35.72 78.75 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.22 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.11 -44.28 61.22 Favored Glycine 0 N--CA 1.447 -0.633 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.62 -179.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -68.97 -21.86 64.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.735 0.302 . . . . 0.0 111.427 179.679 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 88.5 mt -89.25 -2.87 58.65 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.004 0.43 . . . . 0.0 110.224 174.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 19.8 tt0 57.48 45.69 19.21 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.125 176.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.429 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 69.0 mt -106.68 117.29 57.23 Favored Pre-proline 0 C--N 1.322 -0.619 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.573 176.125 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 16.5 Cg_exo -67.54 112.41 2.61 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.773 2.315 . . . . 0.0 112.766 -176.493 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.563 ' HA ' HG22 ' A' ' 43' ' ' VAL . 11.2 tt -69.23 -14.68 18.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.587 0.708 . . . . 0.0 109.885 177.466 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -60.48 -28.96 68.75 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.61 -179.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 12.9 t -122.53 7.86 9.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.031 0.443 . . . . 0.0 111.589 -172.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.589 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 3.6 m -131.65 149.32 32.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 C-N-CA 120.386 -0.525 . . . . 0.0 110.768 -179.162 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 61.6 t -99.57 129.75 49.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.132 0.491 . . . . 0.0 110.288 179.134 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 47.8 t -103.3 127.48 57.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.555 -178.651 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.638 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 65.8 mttt -119.29 139.87 51.21 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.696 178.576 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.569 ' HE3' ' O ' ' A' ' 57' ' ' GLU . 9.1 mtpm? -127.07 115.88 19.84 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.928 175.152 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 62.36 22.56 13.3 Favored 'General case' 0 C--N 1.326 -0.419 0 O-C-N 123.597 0.56 . . . . 0.0 110.377 178.075 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.85 -14.41 57.43 Favored Glycine 0 N--CA 1.452 -0.29 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.548 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . 0.465 ' O ' ' HA ' ' A' ' 46' ' ' LYS . 68.3 mt-30 -88.07 140.56 29.37 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 122.102 0.161 . . . . 0.0 111.046 -175.625 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.411 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.4 mp -80.07 113.16 19.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 174.124 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.886 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 35.8 m -125.55 178.92 3.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.071 0.462 . . . . 0.0 111.863 -169.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.428 HG13 ' H ' ' A' ' 55' ' ' GLU . 31.2 pt -112.62 -170.86 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.645 178.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.483 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 7.9 p-10 -81.15 -7.87 59.65 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.794 -174.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.428 ' H ' HG13 ' A' ' 53' ' ' ILE . 0.7 OUTLIER -91.08 12.36 20.14 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-O 121.544 0.688 . . . . 0.0 110.216 -177.772 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.886 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 8.3 mm-40 -88.3 128.24 35.48 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.147 179.069 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.569 ' O ' ' HE3' ' A' ' 47' ' ' LYS . 10.7 mm-40 -76.6 142.61 40.65 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.758 -0.655 . . . . 0.0 109.797 177.06 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 39.4 mt -92.23 137.59 21.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 177.119 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -117.06 149.0 41.01 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.055 0.455 . . . . 0.0 111.228 -174.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -66.71 117.2 8.51 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.788 176.168 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 96.21 11.8 53.46 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 121.152 -0.547 . . . . 0.0 112.223 -178.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 36.6 t0 -97.68 161.94 13.52 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 179.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.436 HD12 HG22 ' A' ' 11' ' ' THR . 50.5 mm -112.24 126.18 69.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.822 0.344 . . . . 0.0 110.531 -177.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 47.3 mm -107.08 130.2 59.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.435 -179.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.638 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 33.7 mt-10 -122.11 129.2 52.15 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 177.651 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 54.3 t -122.33 110.29 26.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.311 0.577 . . . . 0.0 110.634 177.173 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.5 mt -118.28 101.7 12.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.407 -178.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.589 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 14.3 ptt180 -77.87 144.07 37.26 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.085 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.3 p -83.25 117.3 28.85 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.613 0.721 . . . . 0.0 110.62 -175.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 6.8 tp -95.7 128.09 47.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.377 -0.829 . . . . 0.0 109.956 179.774 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 7.3 p90 -81.91 87.57 6.4 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.634 0.731 . . . . 0.0 109.939 177.007 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -85.69 98.01 2.24 Favored Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.471 -0.786 . . . . 0.0 112.012 -177.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.965 0 CA-C-O 118.734 -1.037 . . . . 0.0 111.701 178.653 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 27.8 ttt . . . . . 0 N--CA 1.479 0.98 0 N-CA-C 110.078 -0.341 . . . . 0.0 110.078 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.1 t -90.02 104.92 15.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-O 121.078 0.466 . . . . 0.0 109.9 177.254 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.1 tp -117.31 122.11 69.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.768 -0.651 . . . . 0.0 109.743 177.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.91 151.75 28.2 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.612 -175.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.502 ' HE1' ' HB2' ' A' ' 27' ' ' ARG . 17.1 mtm -128.98 139.91 51.89 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.876 0.369 . . . . 0.0 110.622 -176.051 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -103.89 111.11 23.51 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 173.385 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 23.5 p90 -138.96 161.48 37.25 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.106 0.479 . . . . 0.0 110.923 -178.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.432 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.5 t -118.7 144.3 46.31 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.408 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.2 p -117.16 126.3 74.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-O 121.122 0.486 . . . . 0.0 109.721 176.278 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.556 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -112.86 127.73 69.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.247 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.628 HG22 ' H ' ' A' ' 15' ' ' ASP . 6.8 m -144.2 -177.04 5.26 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 -177.092 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.628 ' H ' HG22 ' A' ' 14' ' ' THR . 0.8 OUTLIER -49.46 -32.94 13.02 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.184 0.516 . . . . 0.0 110.892 173.714 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -80.5 4.25 18.91 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.153 -177.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 107.49 -177.37 21.35 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.973 -0.632 . . . . 0.0 112.067 177.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.556 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 40.0 ttmt -104.71 117.29 33.72 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 176.464 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -130.62 139.49 50.39 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.077 0.465 . . . . 0.0 110.61 -176.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.453 HD13 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -91.72 137.79 21.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.155 -176.236 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.453 ' N ' HD13 ' A' ' 20' ' ' ILE . 2.2 pt? -137.65 147.69 45.14 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 178.036 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -123.82 126.73 46.96 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.866 0.365 . . . . 0.0 110.412 -177.041 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.0 m -118.91 124.8 47.98 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.896 178.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -77.55 21.22 3.1 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 121.127 -0.559 . . . . 0.0 113.175 -178.538 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.419 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -139.23 138.95 21.58 Favored Pre-proline 0 C--N 1.322 -0.59 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 178.004 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_exo -62.79 127.65 21.12 Favored 'Trans proline' 0 CA--C 1.531 0.337 0 C-N-CA 122.72 2.28 . . . . 0.0 111.484 175.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.502 ' HB2' ' HE1' ' A' ' 8' ' ' MET . 13.9 mmt180 -126.01 160.59 29.63 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.145 0.497 . . . . 0.0 111.298 -172.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.599 ' HG2' ' HA ' ' A' ' 57' ' ' GLU . 65.3 mtm-85 -113.65 168.56 9.67 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 164.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.744 HD13 HG11 ' A' ' 45' ' ' VAL . 24.9 mt -60.76 -45.41 97.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 120.646 0.26 . . . . 0.0 110.566 -178.265 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -61.28 -32.45 72.29 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.026 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.47 ' OD2' ' HD2' ' A' ' 27' ' ' ARG . 25.6 t70 -73.57 -42.36 61.72 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.484 -179.427 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.4 t -71.3 -51.79 31.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.006 0.431 . . . . 0.0 110.548 177.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 26.2 tp -61.4 -37.85 84.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.427 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.46 -33.31 72.3 Favored Glycine 0 N--CA 1.451 -0.318 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.476 177.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -71.84 -34.11 69.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.167 0.508 . . . . 0.0 109.995 177.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 96.2 mt -76.92 -10.56 59.45 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.258 174.701 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 63.3 45.89 4.75 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.689 176.178 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 62.2 mt -115.8 123.08 31.65 Favored Pre-proline 0 C--N 1.323 -0.587 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.141 178.77 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_exo -62.69 132.27 36.94 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.754 2.303 . . . . 0.0 112.339 179.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 10.0 tp -70.38 -15.36 19.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.291 0.567 . . . . 0.0 110.61 -179.038 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -63.87 -32.91 74.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.752 178.568 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.509 HG23 HG13 ' A' ' 43' ' ' VAL . 12.0 t -104.02 -1.66 27.14 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 112.095 0.405 . . . . 0.0 112.095 -172.18 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.591 HG12 ' HG3' ' A' ' 68' ' ' ARG . 33.5 m -128.99 146.46 34.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 120.923 0.392 . . . . 0.0 111.202 -178.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.518 HG12 ' HB ' ' A' ' 67' ' ' ILE . 0.6 OUTLIER -110.02 136.94 44.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 175.555 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.744 HG11 HD13 ' A' ' 29' ' ' ILE . 32.6 t -116.21 133.59 62.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-O 121.094 0.473 . . . . 0.0 110.932 -177.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.758 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 98.6 mttt -117.84 130.92 56.56 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.255 177.126 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 22.5 ttmm -93.42 105.46 17.53 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 172.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 71.65 -61.3 0.49 Allowed 'General case' 0 C--N 1.33 -0.274 0 O-C-N 124.136 0.897 . . . . 0.0 110.557 -177.099 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -166.6 22.01 0.11 Allowed Glycine 0 N--CA 1.447 -0.585 0 N-CA-C 111.326 -0.709 . . . . 0.0 111.326 177.292 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 35.9 mt-30 -126.5 131.92 51.51 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.194 -0.299 . . . . 0.0 110.194 -176.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.542 HD13 ' HG2' ' A' ' 46' ' ' LYS . 38.9 mm -63.33 122.51 14.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.869 0.366 . . . . 0.0 110.628 177.615 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.7 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 17.3 m -125.74 178.4 4.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.751 -178.688 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.423 ' O ' HD12 ' A' ' 29' ' ' ILE . 26.9 pt -100.17 -177.96 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.659 176.577 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 20.7 p-10 -77.16 -30.12 54.85 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.431 -176.532 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -80.67 14.67 2.01 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 122.094 -0.379 . . . . 0.0 111.897 -173.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.7 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 76.5 mm-40 -86.05 152.07 23.19 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.82 0.343 . . . . 0.0 111.07 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.599 ' HA ' ' HG2' ' A' ' 28' ' ' ARG . 42.2 mp0 -85.52 162.15 19.04 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.925 -177.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 39.9 mm -103.81 144.78 13.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 174.199 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.751 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 81.0 m-85 -114.15 161.01 18.33 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.735 0.302 . . . . 0.0 110.189 179.179 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -77.63 120.87 23.18 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 175.015 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.51 9.93 68.53 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.904 -0.665 . . . . 0.0 111.789 -176.105 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.751 ' HB2' ' HB2' ' A' ' 59' ' ' PHE . 22.0 t0 -87.95 147.0 25.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.96 0.409 . . . . 0.0 110.181 -178.357 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 45.5 mm -105.6 122.95 59.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.23 -176.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.408 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 50.0 mm -109.78 115.19 49.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-O 120.886 0.374 . . . . 0.0 110.718 -177.579 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.758 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 28.3 tt0 -104.3 114.6 28.94 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.878 177.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.424 ' O ' HG23 ' A' ' 14' ' ' THR . 60.1 t -113.08 113.38 43.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.14 -179.049 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.518 ' HB ' HG12 ' A' ' 44' ' ' VAL . 3.8 mt -116.2 118.75 59.81 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.147 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.591 ' HG3' HG12 ' A' ' 43' ' ' VAL . 0.8 OUTLIER -68.28 130.09 41.86 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 176.093 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 16.9 m -86.32 116.06 28.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.331 0.586 . . . . 0.0 111.023 -177.016 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 8.4 tt -78.58 110.53 14.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.059 176.521 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 84.5 t80 -57.42 131.57 50.5 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.154 -178.628 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -81.14 72.33 2.76 Favored Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 111.606 -0.598 . . . . 0.0 111.606 178.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.255 -1.303 . . . . 0.0 111.063 -177.789 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 26.1 ttt . . . . . 0 N--CA 1.479 1.022 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 45.5 t -86.23 109.99 19.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.672 -177.501 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.425 HG22 ' O ' ' A' ' 24' ' ' GLY . 51.4 mm -94.99 120.91 45.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 109.219 -0.659 . . . . 0.0 109.219 176.551 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 133.65 163.64 10.47 Favored Glycine 0 N--CA 1.446 -0.667 0 N-CA-C 110.771 -0.931 . . . . 0.0 110.771 -174.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.57 ' SD ' ' HB ' ' A' ' 58' ' ' ILE . 25.0 ptt? -160.0 137.15 9.43 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 117.173 0.487 . . . . 0.0 111.282 -176.424 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.876 ' HD3' ' HB3' ' A' ' 22' ' ' GLU . 3.8 tppt? -108.19 120.26 41.83 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 175.41 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -140.56 167.96 20.93 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.744 0.306 . . . . 0.0 110.919 -176.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.497 HG22 HD12 ' A' ' 63' ' ' ILE . 1.2 t -133.72 146.71 51.04 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 177.396 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -117.33 119.11 60.83 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.595 177.147 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -103.28 124.56 57.53 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.523 0.677 . . . . 0.0 109.511 178.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.424 HG22 ' H ' ' A' ' 15' ' ' ASP . 4.1 m -146.02 173.17 12.41 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -178.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.424 ' H ' HG22 ' A' ' 14' ' ' THR . 8.8 p-10 -64.46 -22.39 66.95 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.317 0.58 . . . . 0.0 109.954 174.338 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -72.23 -11.8 60.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.631 175.706 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 127.19 176.89 14.63 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.904 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -108.17 104.04 13.37 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 177.311 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -104.28 134.12 48.04 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.617 -176.163 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.447 HD13 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -103.33 129.58 54.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 177.269 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.447 ' N ' HD13 ' A' ' 20' ' ' ILE . 94.8 mt -136.26 137.21 40.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.621 -177.379 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.876 ' HB3' ' HD3' ' A' ' 9' ' ' LYS . 17.0 pt-20 -117.62 129.18 55.59 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.364 0.602 . . . . 0.0 110.012 173.742 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 18.7 m -109.7 145.46 36.51 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.268 -178.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.425 ' O ' HG22 ' A' ' 6' ' ' ILE . . . -78.29 -10.75 85.97 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.407 -178.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.466 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.54 141.4 31.03 Favored Pre-proline 0 C--N 1.325 -0.496 0 N-CA-C 110.57 -0.159 . . . . 0.0 110.57 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.487 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 11.5 Cg_exo -71.32 123.8 9.87 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.835 2.357 . . . . 0.0 111.742 177.047 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.476 ' HB3' ' CB ' ' A' ' 31' ' ' ASP . 16.2 mmm180 -126.66 175.68 7.78 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -178.205 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.672 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 83.4 mtm180 -94.31 175.2 6.78 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.694 0.283 . . . . 0.0 110.579 175.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.732 HD13 HG11 ' A' ' 45' ' ' VAL . 18.2 mt -68.26 -39.73 81.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 177.45 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.535 ' HB2' ' HB2' ' A' ' 54' ' ' ASP . 28.2 tptp -59.46 -36.06 75.25 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.695 174.228 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.476 ' CB ' ' HB3' ' A' ' 27' ' ' ARG . 5.9 m-20 -66.07 -62.14 1.65 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.953 177.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.466 HG21 HG13 ' A' ' 58' ' ' ILE . 97.4 t -59.64 -60.6 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.664 -175.686 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 11.1 mp -63.24 -34.36 77.5 Favored 'General case' 0 C--N 1.333 -0.145 0 C-N-CA 120.932 -0.307 . . . . 0.0 111.135 -176.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.3 -47.24 82.07 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.871 -0.681 . . . . 0.0 112.572 -179.309 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -71.08 -22.38 62.11 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.847 0.356 . . . . 0.0 111.09 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 86.6 mt -86.77 1.69 51.37 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.683 176.425 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.9 tt0 65.17 17.17 10.93 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.23 176.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.402 ' HA ' ' HD3' ' A' ' 39' ' ' PRO . 71.8 mt -83.33 118.24 70.98 Favored Pre-proline 0 C--N 1.324 -0.54 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.129 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 38' ' ' ILE . 36.3 Cg_exo -59.93 92.03 0.08 OUTLIER 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 123.128 2.552 . . . . 0.0 112.567 -177.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.548 ' HA ' HG22 ' A' ' 43' ' ' VAL . 14.4 tt -76.24 -17.44 15.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.366 -177.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -67.82 -20.81 65.21 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.685 -177.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.5 t -120.23 10.8 11.42 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -175.106 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.548 HG22 ' HA ' ' A' ' 40' ' ' ILE . 31.5 m -123.0 147.39 27.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 O-C-N 121.769 -0.582 . . . . 0.0 111.372 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.414 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 58.8 t -92.48 120.68 42.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.641 178.427 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.732 HG11 HD13 ' A' ' 29' ' ' ILE . 38.5 t -103.4 130.8 53.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.04 0.448 . . . . 0.0 110.854 -176.513 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.745 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 96.9 mttt -118.61 145.78 45.14 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.3 177.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.648 ' HD2' HG11 ' A' ' 52' ' ' VAL . 60.4 mttm -109.34 102.04 10.98 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.179 168.731 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.0 m120 58.54 19.7 6.87 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.628 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 117.97 -18.21 11.54 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.741 178.601 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 70.6 mm-40 -87.57 130.04 34.88 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.881 0.341 . . . . 0.0 110.535 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.425 ' N ' HD12 ' A' ' 51' ' ' ILE . 3.7 mp -73.86 121.28 24.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.055 -179.511 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.828 ' HB ' ' HG3' ' A' ' 56' ' ' GLU . 21.2 m -123.99 178.34 3.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.191 -176.033 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.406 ' O ' HD12 ' A' ' 29' ' ' ILE . 32.0 pt -115.1 173.71 3.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.907 179.764 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.535 ' HB2' ' HB2' ' A' ' 30' ' ' LYS . 3.9 p30 -63.03 -23.82 67.63 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -176.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -71.56 -18.09 62.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.12 -176.585 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.828 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 20.0 mm-40 -67.16 141.46 57.36 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.106 0.479 . . . . 0.0 111.318 -177.701 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.672 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 21.1 mt-10 -89.21 152.02 21.82 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.578 -179.599 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.57 ' HB ' ' SD ' ' A' ' 8' ' ' MET . 8.1 mm -88.55 146.23 6.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 176.69 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -132.75 163.99 27.79 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.942 0.401 . . . . 0.0 110.569 -178.399 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -67.64 121.56 16.16 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.987 -0.552 . . . . 0.0 109.615 172.145 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.97 20.2 47.6 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.767 -177.216 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -96.15 131.49 42.54 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.412 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.497 HD12 HG22 ' A' ' 11' ' ' THR . 50.5 mm -111.57 109.99 30.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.696 0.284 . . . . 0.0 110.48 -177.234 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.472 ' HA ' ' O ' ' A' ' 46' ' ' LYS . 40.0 mm -94.97 119.25 42.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.27 -177.024 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.745 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 38.2 tt0 -103.37 120.93 41.74 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 171.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 70.8 t -107.36 108.49 25.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.155 0.502 . . . . 0.0 110.509 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.414 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 22.9 mt -103.86 109.15 26.33 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.756 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 19.1 mtt180 -68.12 144.06 55.18 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 176.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 34.5 m -83.49 136.21 23.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 173.318 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 8.3 tp -78.65 122.29 33.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.484 0.659 . . . . 0.0 110.403 -177.388 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -79.42 87.0 5.07 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.031 179.742 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -151.87 172.86 31.2 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.533 -178.325 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.045 -1.419 . . . . 0.0 110.737 -179.34 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 23.2 ttt . . . . . 0 N--CA 1.479 0.999 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 7.2 p -92.93 120.66 42.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.249 0.547 . . . . 0.0 110.17 179.449 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 24.3 pt -100.41 122.98 53.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.781 176.152 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 109.12 -178.09 20.56 Favored Glycine 0 N--CA 1.443 -0.898 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.148 -176.699 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -160.52 153.94 22.08 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.75 0.31 . . . . 0.0 111.193 -177.685 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.483 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 50.2 mtmt -105.85 128.82 53.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.002 -0.544 . . . . 0.0 109.689 174.171 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 19.3 p90 -139.28 150.26 45.24 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 120.778 0.323 . . . . 0.0 110.76 -178.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.522 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 25.3 m -111.23 120.9 43.82 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.81 0.338 . . . . 0.0 110.435 179.735 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.617 HG22 ' HB ' ' A' ' 64' ' ' ILE . 21.5 t -112.46 130.32 66.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.898 179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.636 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 4.0 tt -87.53 129.56 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.807 173.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 30.6 p -123.52 -175.22 3.15 Favored 'General case' 0 N--CA 1.442 -0.872 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.822 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -67.63 -28.43 67.72 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.804 -175.274 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.468 ' OD1' ' HE3' ' A' ' 19' ' ' LYS . 3.1 p30 -95.79 -5.94 40.75 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 121.125 -0.23 . . . . 0.0 111.523 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 147.11 -177.36 25.45 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.554 179.08 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.636 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 62.5 tttt -99.25 108.87 21.53 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.083 0.468 . . . . 0.0 109.796 -177.763 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.468 ' HE3' ' OD1' ' A' ' 16' ' ' ASP . 78.3 mttt -103.51 124.72 49.3 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.717 -171.636 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.522 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -90.37 125.14 43.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 170.115 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.423 HD23 ' N ' ' A' ' 21' ' ' LEU . 1.9 pt? -140.52 164.89 28.95 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.483 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.3 OUTLIER -139.58 163.59 32.16 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.9 0.381 . . . . 0.0 111.54 -176.66 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.3 t -134.83 158.24 44.72 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.416 176.591 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -84.76 -4.91 86.99 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 121.036 -0.602 . . . . 0.0 112.334 -178.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -138.49 141.33 30.9 Favored Pre-proline 0 C--N 1.324 -0.504 0 N-CA-C 110.624 -0.139 . . . . 0.0 110.624 178.833 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -61.84 131.97 37.68 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.739 2.293 . . . . 0.0 111.498 175.301 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 37.9 mmt180 -132.96 169.49 16.72 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.032 0.444 . . . . 0.0 111.216 -174.044 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 -103.14 166.18 10.59 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.467 -0.788 . . . . 0.0 108.887 167.401 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 48.9 mm -55.87 -41.37 66.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.967 0.413 . . . . 0.0 110.394 178.754 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 46.2 tptt -51.24 -43.29 61.45 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.166 -0.924 . . . . 0.0 111.919 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -66.19 -50.88 62.37 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.842 -174.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 58.7 t -70.15 -49.29 56.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.018 -178.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.556 HD21 ' HB ' ' A' ' 40' ' ' ILE . 28.1 tp -62.07 -40.6 96.37 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.728 -177.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -64.73 -44.48 94.78 Favored Glycine 0 N--CA 1.448 -0.523 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.467 -177.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 68.3 mt-10 -72.2 -29.93 64.44 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.638 0.256 . . . . 0.0 111.615 -179.214 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 72.6 mt -78.18 -8.34 58.19 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 121.068 -0.253 . . . . 0.0 111.006 178.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.9 tt0 64.25 26.13 13.68 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.05 175.209 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.438 ' HB ' HD12 ' A' ' 33' ' ' LEU . 64.7 mt -82.95 124.87 76.31 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.141 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -71.82 108.86 2.52 Favored 'Trans proline' 0 CA--C 1.533 0.44 0 C-N-CA 122.587 2.191 . . . . 0.0 113.02 -179.376 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.556 ' HB ' HD21 ' A' ' 33' ' ' LEU . 10.0 tt -73.16 -9.75 13.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-O 121.732 0.777 . . . . 0.0 110.286 178.392 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -69.2 -42.89 75.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.742 -176.108 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.569 HG23 HG13 ' A' ' 43' ' ' VAL . 3.3 t -86.53 -47.68 9.03 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -170.15 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.569 HG13 HG23 ' A' ' 42' ' ' THR . 21.7 m -102.01 179.06 0.67 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.213 0 CA-C-O 120.85 0.357 . . . . 0.0 111.8 -173.161 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 30.0 t -103.98 139.55 24.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.565 -172.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 59.6 t -116.17 126.04 73.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 CA-C-O 121.029 0.442 . . . . 0.0 110.249 176.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.538 ' HG2' HD13 ' A' ' 51' ' ' ILE . 95.2 mttt -129.63 151.95 49.68 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.624 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.796 ' HG2' HG21 ' A' ' 52' ' ' VAL . 18.3 mmtp -106.04 100.8 10.33 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 169.46 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 47.6 t30 54.98 24.73 6.17 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.153 177.545 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 124.25 -27.42 5.57 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 120.957 -0.639 . . . . 0.0 113.367 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -89.46 133.96 34.32 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.903 0.351 . . . . 0.0 111.644 -174.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.538 HD13 ' HG2' ' A' ' 46' ' ' LYS . 39.2 mm -65.55 124.19 20.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.674 -0.239 . . . . 0.0 110.389 176.184 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.796 HG21 ' HG2' ' A' ' 47' ' ' LYS . 20.7 m -133.29 178.0 6.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.987 0.422 . . . . 0.0 111.223 -177.563 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.0 pt -109.48 -173.02 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.32 177.265 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 30.1 p-10 -82.19 -19.53 39.64 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 120.905 0.383 . . . . 0.0 110.961 -179.283 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -82.14 26.87 0.51 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.919 0.39 . . . . 0.0 111.856 177.648 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -96.54 149.95 21.18 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.052 179.132 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . . . . . . . . . 27.6 mm-40 -78.33 170.6 16.37 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.999 -177.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 52.2 mt -128.8 120.71 52.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 172.377 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -112.27 162.2 15.77 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.724 -178.244 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -71.24 126.03 28.53 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.462 177.429 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 89.18 6.49 71.35 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.956 -0.64 . . . . 0.0 111.784 -179.255 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 25.8 t0 -88.58 155.79 19.43 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -179.501 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.7 mm -120.79 117.16 52.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 120.932 0.396 . . . . 0.0 110.523 -175.015 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.617 ' HB ' HG22 ' A' ' 12' ' ' VAL . 3.7 mp -101.71 128.22 54.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 177.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.618 ' HA ' HG22 ' A' ' 13' ' ' ILE . 38.2 mt-10 -115.22 107.27 15.07 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 120.771 -0.372 . . . . 0.0 110.996 -178.631 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 78.2 t -99.93 100.53 10.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-O 121.653 0.74 . . . . 0.0 109.05 174.326 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 51.1 mt -93.07 109.65 22.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.986 -176.131 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.545 ' HA ' ' CG1' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -64.33 140.78 58.9 Favored 'General case' 0 N--CA 1.447 -0.624 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 174.203 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.463 HG13 ' HA ' ' A' ' 43' ' ' VAL . 21.8 m -82.65 136.1 23.55 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-O 121.002 0.429 . . . . 0.0 110.573 -177.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 7.9 tp -83.64 128.59 38.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 176.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 36.9 m-85 -78.41 95.74 5.18 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.511 -175.114 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -89.17 44.3 3.09 Favored Glycine 0 N--CA 1.449 -0.492 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.759 177.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.018 0 CA-C-O 118.193 -1.337 . . . . 0.0 111.126 -179.126 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 1.016 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.4 t -97.05 118.61 43.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 175.078 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 25.1 pt -82.22 132.05 32.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 121.291 0.567 . . . . 0.0 110.578 -179.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 117.31 -178.71 17.17 Favored Glycine 0 N--CA 1.443 -0.896 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -176.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.495 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 23.5 ptt? -161.0 130.88 4.95 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.99 0.424 . . . . 0.0 110.712 179.005 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.659 ' HB3' ' HG3' ' A' ' 22' ' ' GLU . 16.4 ptmt -118.6 119.63 35.07 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 121.294 0.569 . . . . 0.0 109.574 171.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -123.79 151.61 43.12 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.089 -174.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.548 ' CG2' HG13 ' A' ' 63' ' ' ILE . 8.8 t -109.51 134.98 51.24 Favored 'General case' 0 C--N 1.316 -0.857 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.231 179.522 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.4 p -110.91 135.96 48.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.039 -179.22 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -114.46 126.54 72.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.385 0.612 . . . . 0.0 110.19 179.695 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.411 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -146.66 -163.48 1.76 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.369 178.248 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.411 ' H ' HG22 ' A' ' 14' ' ' THR . 14.2 m-20 -65.14 -21.96 66.86 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 121.108 0.48 . . . . 0.0 110.996 178.062 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -86.11 8.25 21.59 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.682 0.753 . . . . 0.0 110.274 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.79 -162.12 18.57 Favored Glycine 0 N--CA 1.448 -0.517 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.712 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -118.15 108.69 15.48 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 177.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -116.0 150.99 36.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.465 -176.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.532 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.2 OUTLIER -106.94 131.09 57.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 121.091 0.472 . . . . 0.0 109.886 -176.173 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.502 ' N ' HD13 ' A' ' 20' ' ' ILE . 92.2 mt -116.81 135.49 53.7 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.963 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.659 ' HG3' ' HB3' ' A' ' 9' ' ' LYS . 32.4 tt0 -108.96 126.55 53.21 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.948 0.404 . . . . 0.0 110.392 -177.456 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 13.5 m -118.06 145.39 44.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.958 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -83.17 -9.12 84.5 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 121.047 -0.597 . . . . 0.0 112.605 -176.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.443 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.42 141.89 32.98 Favored Pre-proline 0 C--N 1.325 -0.489 0 O-C-N 122.849 -0.207 . . . . 0.0 111.003 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.495 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 7.3 Cg_exo -73.59 121.25 6.94 Favored 'Trans proline' 0 C--O 1.233 0.254 0 C-N-CA 122.817 2.345 . . . . 0.0 110.773 174.045 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 19.2 mmm180 -132.25 177.28 7.7 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.102 0.477 . . . . 0.0 110.899 -174.087 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.588 ' HG2' ' H ' ' A' ' 30' ' ' LYS . 44.7 ttm180 -94.82 160.85 14.41 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.053 -176.84 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 56' ' ' GLU . 37.4 mm -50.97 -41.01 21.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-O 120.815 0.34 . . . . 0.0 110.155 176.315 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.588 ' H ' ' HG2' ' A' ' 28' ' ' ARG . 35.8 tptt -51.03 -37.18 43.7 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.786 -179.329 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -64.93 -62.65 1.43 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.764 0.316 . . . . 0.0 110.845 -177.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.5 t -63.39 -44.21 98.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.762 -177.616 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.782 HD11 ' HB ' ' A' ' 40' ' ' ILE . 3.0 tm? -61.72 -46.43 89.68 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.163 -179.267 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -69.97 -47.41 46.74 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.843 -0.617 . . . . 0.0 113.141 -175.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -66.53 -34.57 78.22 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 111.954 0.354 . . . . 0.0 111.954 -175.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 82.1 mt -82.6 -4.64 57.98 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.684 0.278 . . . . 0.0 110.9 179.079 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.5 tt0 57.3 34.9 25.41 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.958 177.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.617 ' HB ' HD22 ' A' ' 33' ' ' LEU . 66.0 mt -79.49 125.64 82.46 Favored Pre-proline 0 C--N 1.323 -0.587 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 177.64 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.514 ' HB2' ' HB ' ' A' ' 42' ' ' THR . 34.7 Cg_exo -60.72 101.29 0.17 Allowed 'Trans proline' 0 C--O 1.233 0.226 0 C-N-CA 122.642 2.228 . . . . 0.0 112.874 -176.851 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.782 ' HB ' HD11 ' A' ' 33' ' ' LEU . 9.9 tp -71.29 -19.11 20.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 121.68 0.752 . . . . 0.0 109.831 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 19.0 tt0 -77.01 -32.11 56.93 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.355 176.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.514 ' HB ' ' HB2' ' A' ' 39' ' ' PRO . 22.2 m -92.39 -39.41 11.46 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.193 -171.525 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 10.9 m -112.8 163.17 10.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.458 -175.645 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.421 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 47.3 t -109.89 140.27 29.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.846 -177.827 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.8 t -113.0 130.63 66.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 121.137 0.494 . . . . 0.0 111.467 -178.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.524 ' HB2' ' HB3' ' A' ' 65' ' ' GLU . 97.3 mttt -123.08 150.88 42.6 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.743 172.505 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.949 ' HE2' HG11 ' A' ' 52' ' ' VAL . 60.1 pttt -126.76 108.08 10.73 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.638 0.732 . . . . 0.0 110.676 171.619 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.49 ' HB2' ' OD1' ' A' ' 62' ' ' ASP . 3.2 t-20 64.26 23.78 13.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 114.483 -1.235 . . . . 0.0 111.771 174.399 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 112.79 -6.33 25.89 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.8 177.561 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 8.3 mm-40 -111.35 114.54 27.78 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.707 0.289 . . . . 0.0 111.501 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.482 ' HA ' ' HG2' ' A' ' 46' ' ' LYS . 0.1 OUTLIER -62.98 127.15 22.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 175.574 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.949 HG11 ' HE2' ' A' ' 47' ' ' LYS . 23.4 m -138.63 155.89 28.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.084 0.469 . . . . 0.0 111.574 -174.356 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.459 HG13 ' H ' ' A' ' 55' ' ' GLU . 30.4 pt -96.93 -175.55 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.908 177.505 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -69.57 -8.91 51.37 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.837 -0.62 . . . . 0.0 112.082 -175.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.459 ' H ' HG13 ' A' ' 53' ' ' ILE . 29.4 tp10 -81.94 -11.13 59.03 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.03 0.443 . . . . 0.0 111.098 -177.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.74 ' HG3' ' HB ' ' A' ' 52' ' ' VAL . 70.1 mm-40 -86.11 146.08 26.76 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -174.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.521 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 2.6 mp0 -80.83 160.89 24.68 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.59 173.841 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.414 HG23 HD11 ' A' ' 64' ' ' ILE . 39.9 mt -105.69 147.38 11.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 175.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.506 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 98.9 m-85 -111.38 151.84 28.01 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.274 0.559 . . . . 0.0 111.341 -178.138 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.463 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 29.7 t70 -69.61 120.85 16.01 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.958 172.736 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.13 19.31 55.89 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.797 -0.716 . . . . 0.0 111.992 -177.197 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.506 ' HB2' ' HB2' ' A' ' 59' ' ' PHE . 24.0 t0 -94.88 159.9 14.83 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 120.928 0.394 . . . . 0.0 110.448 -179.477 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.548 HG13 ' CG2' ' A' ' 11' ' ' THR . 2.3 mp -117.05 108.55 25.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.03 0.443 . . . . 0.0 110.211 -175.785 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 1.9 mp -92.77 119.13 39.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 CA-C-O 121.173 0.511 . . . . 0.0 110.175 -178.59 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.524 ' HB3' ' HB2' ' A' ' 46' ' ' LYS . 44.8 tt0 -105.22 115.8 30.87 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.646 178.512 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 79.3 t -100.81 102.62 13.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.352 0.596 . . . . 0.0 110.115 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.421 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 49.1 mt -93.27 93.13 3.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.165 -179.009 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.625 ' HD2' ' O ' ' A' ' 68' ' ' ARG . 0.2 OUTLIER -69.86 152.97 43.92 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 170.67 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 26.9 m -80.79 146.68 7.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 C-N-CA 120.497 -0.481 . . . . 0.0 110.0 -176.282 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.482 HG23 ' O ' ' A' ' 70' ' ' ILE . 0.0 OUTLIER -77.98 101.68 3.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 122.862 1.315 . . . . 0.0 109.814 -175.493 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -151.05 -70.22 0.17 Allowed 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 106.439 -1.689 . . . . 0.0 106.439 174.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 51.1 -102.78 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.57 0 CA-C-N 114.335 -1.302 . . . . 0.0 114.249 164.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.536 -1.147 . . . . 0.0 111.128 -177.914 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 68.3 mtt . . . . . 0 N--CA 1.484 1.232 0 CA-C-O 120.629 0.252 . . . . 0.0 110.421 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 58.7 t -104.89 105.48 18.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 120.915 0.388 . . . . 0.0 110.186 179.622 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 47.4 mm -112.31 130.14 66.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.444 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 23' ' ' SER . . . 85.24 100.64 0.68 Allowed Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.351 -176.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.443 ' HB2' ' HA ' ' A' ' 60' ' ' ASP . 0.0 OUTLIER -126.1 149.67 48.76 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 -176.704 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.665 ' HG2' ' HB3' ' A' ' 22' ' ' GLU . 96.0 mttt -109.75 140.61 43.44 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.297 176.793 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -145.83 152.82 40.12 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.966 0.412 . . . . 0.0 110.268 174.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.593 HG22 ' HG2' ' A' ' 18' ' ' LYS . 4.7 m -110.61 118.06 35.18 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.774 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.647 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.7 p -111.49 132.05 61.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.795 -177.381 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.587 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.2 OUTLIER -87.63 124.56 40.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.293 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.4 ' N ' HD13 ' A' ' 13' ' ' ILE . 2.5 p -134.49 -171.06 2.67 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.298 -177.629 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -74.85 -27.4 60.25 Favored 'General case' 0 N--CA 1.464 0.246 0 O-C-N 122.393 -0.192 . . . . 0.0 111.499 -173.394 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -83.73 -6.23 59.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.112 0.482 . . . . 0.0 110.331 178.306 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 131.4 -173.52 20.4 Favored Glycine 0 N--CA 1.443 -0.839 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 -179.007 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.593 ' HG2' HG22 ' A' ' 11' ' ' THR . 66.5 tttt -90.47 106.52 18.55 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.153 0.502 . . . . 0.0 109.788 178.007 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.7 tptm -103.61 121.34 42.72 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.199 -170.056 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.527 ' HA ' ' HA ' ' A' ' 11' ' ' THR . 0.0 OUTLIER -92.1 126.2 44.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 173.061 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.412 ' N ' HD13 ' A' ' 20' ' ' ILE . 4.0 pp -144.52 162.8 35.65 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.047 177.648 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.665 ' HB3' ' HG2' ' A' ' 9' ' ' LYS . 0.0 OUTLIER -111.91 162.87 14.85 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.138 0.494 . . . . 0.0 110.961 -179.893 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.455 ' O ' ' HA2' ' A' ' 7' ' ' GLY . 40.6 t -130.41 140.59 50.57 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.657 -0.702 . . . . 0.0 109.224 176.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -53.81 -38.62 59.94 Favored Glycine 0 C--N 1.331 0.265 0 O-C-N 123.558 0.537 . . . . 0.0 112.523 -179.168 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.447 ' O ' ' HG2' ' A' ' 27' ' ' ARG . . . -137.99 152.07 71.35 Favored Pre-proline 0 C--N 1.321 -0.638 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 176.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -59.08 128.38 27.54 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.375 2.05 . . . . 0.0 111.2 174.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.447 ' HG2' ' O ' ' A' ' 25' ' ' ALA . 20.4 mmm180 -129.38 170.7 13.33 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.921 0.391 . . . . 0.0 110.455 -175.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.638 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 45.4 ttm180 -77.34 155.75 31.74 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.099 177.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.581 HG21 HG11 ' A' ' 45' ' ' VAL . 38.1 mm -53.17 -46.59 55.96 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 CA-C-O 121.712 0.768 . . . . 0.0 109.732 175.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.499 ' HB3' ' HE2' ' A' ' 30' ' ' LYS . 28.7 ttpt -72.39 -20.65 61.41 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 114.785 -1.098 . . . . 0.0 111.428 -178.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -66.57 -53.48 34.08 Favored 'General case' 0 CA--C 1.514 -0.43 0 CA-C-O 121.094 0.473 . . . . 0.0 109.779 176.389 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 57.8 t -68.21 -50.02 61.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.928 -177.665 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.561 HD23 ' HB ' ' A' ' 40' ' ' ILE . 15.0 tp -70.48 -28.68 65.17 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.488 -177.117 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -65.5 -39.47 95.64 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.165 174.7 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -62.59 -39.0 92.33 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.925 0.393 . . . . 0.0 110.658 177.04 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 91.7 mt -75.75 -15.08 60.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.028 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 59.21 75.66 0.39 Allowed 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.523 0.678 . . . . 0.0 110.929 -177.484 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . . . . . . . . . 80.8 mt -134.15 130.45 20.31 Favored Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.195 176.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.471 ' HB2' HG22 ' A' ' 42' ' ' THR . 19.5 Cg_endo -58.61 90.46 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.779 2.32 . . . . 0.0 112.916 -179.608 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.561 ' HB ' HD23 ' A' ' 33' ' ' LEU . 18.9 tt -75.87 -9.81 12.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.672 -178.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -75.5 -43.15 50.68 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.384 -0.825 . . . . 0.0 111.761 -177.08 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.471 HG22 ' HB2' ' A' ' 39' ' ' PRO . 10.0 t -95.27 -5.27 44.04 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -170.182 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.583 ' HB ' ' HA ' ' A' ' 68' ' ' ARG . 17.9 m -115.42 167.94 7.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.906 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 49.1 t -97.32 123.44 49.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.023 0.44 . . . . 0.0 111.457 -173.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.581 HG11 HG21 ' A' ' 29' ' ' ILE . 61.4 t -103.67 126.57 58.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.94 176.409 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.724 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 25.2 mttm -119.41 114.32 22.15 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.568 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.42 ' HB3' HG11 ' A' ' 52' ' ' VAL . 86.6 tttt -93.64 110.14 21.76 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.828 177.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 64.76 16.98 10.75 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.606 -179.719 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 114.14 -29.16 7.86 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 121.104 -0.57 . . . . 0.0 112.554 179.361 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 15.2 mm100 -88.39 140.88 29.02 Favored 'General case' 0 C--N 1.327 -0.413 0 O-C-N 122.846 -0.208 . . . . 0.0 110.779 -176.62 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 3.4 mp -69.89 118.77 14.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 177.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.42 HG11 ' HB3' ' A' ' 47' ' ' LYS . 34.5 m -122.43 169.93 13.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.087 0.47 . . . . 0.0 110.998 -178.257 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.7 pp -87.76 165.97 2.0 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.906 175.652 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -70.81 -10.59 59.85 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.901 -0.591 . . . . 0.0 112.087 -175.029 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.604 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 2.1 tp10 -83.61 -9.59 58.8 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.449 -175.716 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.435 ' O ' HG12 ' A' ' 29' ' ' ILE . 14.8 mm-40 -66.8 149.67 50.22 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.989 0.423 . . . . 0.0 112.068 -178.311 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.638 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 43.7 mt-10 -103.83 152.64 21.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.576 -179.547 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.481 HG12 HD13 ' A' ' 29' ' ' ILE . 23.6 mt -97.38 143.09 13.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.532 -178.578 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -125.97 171.77 10.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.261 -179.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.443 ' HA ' ' HB2' ' A' ' 8' ' ' MET . 27.0 t70 -71.02 122.58 20.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.813 0.34 . . . . 0.0 111.555 -175.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.78 14.13 57.04 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.444 176.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -91.51 161.49 14.94 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.937 0.399 . . . . 0.0 110.368 -178.866 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 50.1 mm -120.03 127.36 75.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.927 -176.527 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.647 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 45.4 mm -116.66 116.39 52.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 120.975 0.417 . . . . 0.0 110.918 -176.707 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.724 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 38.8 mm-40 -104.19 113.79 27.58 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.216 178.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 55.9 t -105.18 110.26 30.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.429 0.633 . . . . 0.0 110.289 174.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 62.5 mt -113.16 109.52 28.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.808 -179.12 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.583 ' HA ' ' HB ' ' A' ' 43' ' ' VAL . 13.3 ptt180 -65.29 154.44 38.22 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.996 177.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.7 p -82.77 147.59 5.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 178.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 13.3 tt -80.24 108.42 13.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.576 0.703 . . . . 0.0 110.176 178.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 81.9 t80 -132.1 111.55 11.57 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.635 -0.712 . . . . 0.0 109.505 177.319 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 160.59 72.75 0.02 OUTLIER Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.395 -0.907 . . . . 0.0 112.292 -179.302 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.962 0 CA-C-O 118.997 -0.89 . . . . 0.0 111.311 178.03 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 86.4 mtp . . . . . 0 N--CA 1.478 0.939 0 CA-C-O 120.844 0.354 . . . . 0.0 110.245 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.0 t -89.49 121.4 39.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 178.714 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 6.4 tp -104.12 122.4 56.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.332 0.587 . . . . 0.0 110.135 179.379 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 106.49 -172.4 18.47 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 -177.147 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.555 ' HA ' ' HB2' ' A' ' 60' ' ' ASP . 26.2 ptt? -160.67 129.09 4.61 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.106 0.479 . . . . 0.0 111.069 179.301 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -111.38 112.39 24.11 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 174.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.44 ' CZ ' HD11 ' A' ' 21' ' ' LEU . 49.2 p90 -136.72 168.13 20.11 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.556 -173.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.5 ' HA ' ' HA ' ' A' ' 20' ' ' ILE . 1.5 t -119.04 146.5 45.0 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.321 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 p -126.02 122.83 62.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.917 176.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.524 HG22 ' HA ' ' A' ' 65' ' ' GLU . 0.0 OUTLIER -101.94 124.86 56.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.565 0.698 . . . . 0.0 110.083 -179.398 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.4 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -146.08 -160.43 1.15 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.163 177.904 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.4 ' H ' HG22 ' A' ' 14' ' ' THR . 4.7 m-20 -60.71 -29.66 69.49 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.185 0.517 . . . . 0.0 110.594 176.538 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -72.29 -3.19 22.32 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.556 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.04 -167.21 20.47 Favored Glycine 0 N--CA 1.444 -0.823 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -176.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 37.0 ttmt -93.14 102.97 15.29 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 175.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 84.1 tttt -106.83 120.44 42.02 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.771 -172.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.517 HD13 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -98.62 136.5 29.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.094 -178.871 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.517 ' N ' HD13 ' A' ' 20' ' ' ILE . 4.3 pp -140.33 162.65 34.8 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.684 0.278 . . . . 0.0 110.731 179.221 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -114.97 144.24 43.91 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 -178.13 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 47.0 t -131.33 131.55 43.83 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.654 0.264 . . . . 0.0 110.453 -177.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -70.88 -16.84 74.85 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 121.221 -0.514 . . . . 0.0 112.778 -179.124 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.47 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -138.21 144.24 42.41 Favored Pre-proline 0 C--N 1.325 -0.485 0 O-C-N 122.785 -0.244 . . . . 0.0 110.967 179.492 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.471 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 3.0 Cg_exo -75.15 130.14 12.86 Favored 'Trans proline' 0 N--CA 1.46 -0.451 0 C-N-CA 122.741 2.294 . . . . 0.0 110.99 174.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 9.5 mtp180 -136.85 164.95 27.09 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.897 0.38 . . . . 0.0 110.71 -175.34 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.629 ' HA ' ' HA ' ' A' ' 57' ' ' GLU . 16.3 ttp85 -92.47 164.47 13.45 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.99 -176.823 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.497 HG12 ' O ' ' A' ' 56' ' ' GLU . 45.5 mm -51.84 -46.52 40.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 122.183 0.193 . . . . 0.0 111.288 -179.406 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.474 ' HB2' ' OD2' ' A' ' 54' ' ' ASP . 6.1 tptm -65.19 -26.97 68.38 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.836 0.31 . . . . 0.0 111.836 -177.151 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 19.8 m-20 -62.72 -57.98 9.08 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 176.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 46.1 t -64.51 -41.28 91.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.626 -179.345 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.461 HD22 ' HB ' ' A' ' 38' ' ' ILE . 3.1 tm? -61.57 -46.56 89.39 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.117 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -66.62 -38.42 93.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 121.133 -0.556 . . . . 0.0 112.583 -178.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -65.8 -46.96 76.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.597 0.237 . . . . 0.0 111.518 179.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 91.7 mt -76.33 -16.25 59.8 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.755 0.312 . . . . 0.0 110.764 -178.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 60.65 37.24 19.33 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.511 177.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.461 ' HB ' HD22 ' A' ' 33' ' ' LEU . 66.7 mt -79.47 132.48 62.01 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.54 177.752 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -60.59 98.57 0.13 Allowed 'Trans proline' 0 CA--C 1.529 0.255 0 C-N-CA 122.546 2.164 . . . . 0.0 112.437 179.636 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.51 ' HA ' HG22 ' A' ' 43' ' ' VAL . 10.7 tp -69.87 -13.6 17.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.445 0.64 . . . . 0.0 110.149 -179.501 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -64.58 -21.74 66.78 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.245 -0.889 . . . . 0.0 111.076 -179.534 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.8 t -127.3 10.39 6.8 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 112.282 0.475 . . . . 0.0 112.282 -173.347 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 35.3 m -131.9 142.26 43.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.121 0.486 . . . . 0.0 111.166 -179.262 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.8 t -118.12 138.92 47.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.79 178.378 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.6 t -103.73 136.09 38.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 121.248 0.547 . . . . 0.0 111.071 -176.634 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.646 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 56.5 mttm -118.1 147.77 42.96 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.008 175.688 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.587 ' HG2' HG21 ' A' ' 52' ' ' VAL . 19.1 mmtp -108.63 101.61 10.74 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.516 172.444 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.458 HD22 ' HA ' ' A' ' 48' ' ' ASN . 0.8 OUTLIER 57.5 27.33 13.86 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.738 177.296 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 116.5 -28.82 7.28 Favored Glycine 0 CA--C 1.522 0.478 0 C-N-CA 121.227 -0.511 . . . . 0.0 113.266 -179.245 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 70.4 mm-40 -88.14 139.81 30.12 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 117.054 0.427 . . . . 0.0 111.38 -172.477 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 26.2 mm -74.63 126.31 35.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.85 0.357 . . . . 0.0 111.052 179.117 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.587 HG21 ' HG2' ' A' ' 47' ' ' LYS . 25.2 m -128.76 178.48 4.95 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.206 178.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.442 HG13 ' H ' ' A' ' 55' ' ' GLU . 47.0 pt -118.99 -173.46 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.394 0.616 . . . . 0.0 111.785 -178.401 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.474 ' OD2' ' HB2' ' A' ' 30' ' ' LYS . 16.6 t70 -64.78 -19.98 66.12 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.131 -175.74 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.451 ' HA ' ' HD2' ' A' ' 28' ' ' ARG . 6.0 mm-40 -90.41 3.96 52.3 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.129 -0.487 . . . . 0.0 112.274 -173.468 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.497 ' O ' HG12 ' A' ' 29' ' ' ILE . 0.5 OUTLIER -85.5 135.71 33.72 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.074 0.464 . . . . 0.0 111.366 -179.843 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.629 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 7.1 mp0 -82.11 153.49 26.04 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.257 175.5 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.503 HG23 HD11 ' A' ' 64' ' ' ILE . 22.4 mt -95.84 143.37 12.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 175.309 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.593 ' HB2' ' HB2' ' A' ' 62' ' ' ASP . 80.3 m-85 -119.51 153.41 35.39 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.212 0.53 . . . . 0.0 111.369 -174.5 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.555 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 29.1 t70 -62.58 121.14 12.6 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.231 172.555 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.13 8.71 74.8 Favored Glycine 0 C--O 1.229 -0.218 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.138 -179.331 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.593 ' HB2' ' HB2' ' A' ' 59' ' ' PHE . 31.4 t70 -93.8 146.96 23.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 -179.653 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 37.9 mm -107.79 128.15 63.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.764 0.316 . . . . 0.0 110.905 -174.219 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.503 HD11 HG23 ' A' ' 58' ' ' ILE . 39.2 mm -108.5 118.48 56.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.946 -177.156 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.646 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 19.0 mp0 -106.09 121.47 44.21 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 172.378 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 97.2 t -105.53 104.04 16.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.198 0.523 . . . . 0.0 110.386 178.02 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.513 HD13 ' HD2' ' A' ' 46' ' ' LYS . 3.1 mp -106.02 114.06 44.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.625 -179.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.871 HH11 ' HB2' ' A' ' 68' ' ' ARG . 1.7 mtm105 -63.84 141.42 58.77 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 175.708 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -90.08 120.29 38.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 174.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.56 111.35 15.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 121.841 0.829 . . . . 0.0 109.586 -179.407 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -89.16 142.76 27.37 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.136 -0.938 . . . . 0.0 109.784 -177.033 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -77.26 64.67 3.14 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.29 179.097 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.14 0 CA-C-O 118.081 -1.4 . . . . 0.0 111.109 -178.911 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 50.1 ttm . . . . . 0 N--CA 1.479 1.008 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.2 p -83.03 108.38 15.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.571 0.7 . . . . 0.0 110.424 178.251 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 54.2 mt -108.87 122.72 63.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.954 179.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.61 166.41 13.31 Favored Glycine 0 N--CA 1.441 -0.97 0 C-N-CA 120.542 -0.837 . . . . 0.0 111.903 -178.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.645 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 0.7 OUTLIER -136.88 139.34 41.57 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 -176.83 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.647 ' HA ' ' HB3' ' A' ' 22' ' ' GLU . 18.0 ttmm -101.03 116.56 33.13 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 172.053 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -136.75 165.48 25.82 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 120.925 0.393 . . . . 0.0 110.442 -179.137 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.867 ' HB ' HD13 ' A' ' 20' ' ' ILE . 12.1 t -121.13 137.2 54.77 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-O 121.288 0.566 . . . . 0.0 110.591 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.402 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.1 p -115.15 135.13 56.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.362 176.802 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.548 ' HA ' ' HA ' ' A' ' 18' ' ' LYS . 0.0 OUTLIER -109.64 122.4 64.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 177.447 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.82 -165.01 1.54 Allowed 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.067 178.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -71.13 -13.49 61.97 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.09 0.472 . . . . 0.0 110.244 177.485 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -84.49 -9.79 58.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.503 0.668 . . . . 0.0 109.967 175.426 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 112.2 -178.67 19.2 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.986 -179.022 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 13' ' ' ILE . 39.4 ttmt -92.8 114.76 27.4 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 176.011 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.403 ' HB2' ' HE3' ' A' ' 19' ' ' LYS . 30.9 ttmt -127.07 149.1 50.08 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.931 -171.186 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.867 HD13 ' HB ' ' A' ' 11' ' ' THR . 37.5 mm -94.77 126.3 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.829 -178.521 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 3.9 pp -144.64 144.95 31.52 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 172.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.647 ' HB3' ' HA ' ' A' ' 9' ' ' LYS . 12.6 pt-20 -139.42 163.4 32.62 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.804 0.335 . . . . 0.0 111.129 -176.144 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 46.7 t -129.03 165.53 20.99 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.102 179.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -101.67 14.05 57.78 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 111.623 -0.591 . . . . 0.0 111.623 177.314 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -139.3 142.85 33.94 Favored Pre-proline 0 C--N 1.324 -0.509 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 175.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.645 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 34.6 Cg_exo -61.19 136.39 64.37 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.611 2.207 . . . . 0.0 111.15 175.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.902 ' HG3' ' HB3' ' A' ' 31' ' ' ASP . 0.0 OUTLIER -140.37 157.87 44.89 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.346 0.593 . . . . 0.0 112.105 -173.06 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.572 ' HD3' ' HA ' ' A' ' 55' ' ' GLU . 43.5 ttm180 -107.06 163.41 13.01 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.08 -0.963 . . . . 0.0 109.134 176.414 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.579 HG13 ' O ' ' A' ' 56' ' ' GLU . 10.1 mt -60.08 -48.32 88.41 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.375 0 CA-C-O 121.359 0.6 . . . . 0.0 109.615 176.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.9 tptp -51.4 -35.95 41.39 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.678 173.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.902 ' HB3' ' HG3' ' A' ' 27' ' ' ARG . 0.2 OUTLIER -72.45 -55.58 6.78 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.676 179.079 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 28' ' ' ARG . 58.7 t -59.67 -61.07 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.287 -177.687 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.817 ' HG ' HD12 ' A' ' 40' ' ' ILE . 4.1 mm? -69.16 -28.37 66.36 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 121.118 -0.233 . . . . 0.0 111.224 -177.222 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.29 -43.33 63.28 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.454 179.158 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -71.98 -34.52 69.0 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.764 0.316 . . . . 0.0 110.64 178.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.415 ' HG ' ' O ' ' A' ' 32' ' ' VAL . 94.8 mt -73.22 -17.9 61.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.793 0.33 . . . . 0.0 110.147 175.382 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 61.86 36.77 15.79 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.892 174.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.404 HG23 ' HD2' ' A' ' 39' ' ' PRO . 72.4 mt -92.07 139.0 24.29 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.038 179.599 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.404 ' HD2' HG23 ' A' ' 38' ' ' ILE . 35.9 Cg_endo -65.87 65.39 0.42 Allowed 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 122.975 2.45 . . . . 0.0 113.133 177.495 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.817 HD12 ' HG ' ' A' ' 33' ' ' LEU . 7.6 tt -65.62 -22.35 30.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.843 177.593 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -66.29 -19.92 65.96 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.219 -0.9 . . . . 0.0 112.548 -173.111 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.6 t -109.16 11.86 25.33 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.36 -0.536 . . . . 0.0 111.913 -173.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 32.7 m -133.63 173.58 14.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.505 0.193 . . . . 0.0 110.784 178.23 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.852 ' HB ' ' HB ' ' A' ' 67' ' ' ILE . 46.5 t -88.26 129.86 38.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.729 0.3 . . . . 0.0 111.242 -175.39 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 19.2 t -108.33 126.04 65.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.826 -179.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.626 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 82.3 mttt -123.25 118.44 27.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.872 175.689 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 80.2 tttt -97.25 108.42 21.15 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 172.576 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 64.93 14.58 9.38 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.636 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 108.67 -13.08 35.54 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 121.14 -0.552 . . . . 0.0 112.096 -178.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 31.9 mm-40 -89.93 129.39 36.29 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 110.331 -0.248 . . . . 0.0 110.331 179.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 60.4 mt -72.49 105.78 2.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.263 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.6 m -116.83 171.31 5.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.484 -171.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 35.0 pt -89.45 166.92 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 166.799 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.427 ' O ' ' HB ' ' A' ' 29' ' ' ILE . 14.0 p-10 -77.71 -1.33 30.61 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-O 120.758 0.313 . . . . 0.0 111.74 -174.485 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.572 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 3.9 tp10 -82.88 12.34 4.98 Favored 'General case' 0 CA--C 1.539 0.547 0 CA-C-O 121.08 0.467 . . . . 0.0 111.066 -177.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.579 ' O ' HG13 ' A' ' 29' ' ' ILE . 26.6 mm-40 -91.23 143.33 26.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.528 178.786 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.538 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 12.3 mp0 -76.0 161.96 28.47 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.849 0.357 . . . . 0.0 110.305 173.4 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 8.6 mm -104.31 141.34 20.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 174.019 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -118.13 169.8 9.39 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.73 176.597 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -78.02 122.07 25.07 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.735 -174.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 94.72 11.53 56.71 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.252 -177.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -83.55 160.81 21.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.979 0.419 . . . . 0.0 110.717 -178.427 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.542 HG12 HG22 ' A' ' 11' ' ' THR . 20.2 mt -129.0 111.28 22.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.452 -179.835 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 64' ' ' ILE . 3.2 mp -95.11 115.67 34.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.277 0.561 . . . . 0.0 109.925 -179.736 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.626 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 37.5 mt-10 -102.29 104.96 15.52 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.086 179.352 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 55.4 t -97.46 107.41 20.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.552 0.691 . . . . 0.0 109.8 178.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.852 ' HB ' ' HB ' ' A' ' 44' ' ' VAL . 54.6 mt -92.61 95.07 5.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.251 -176.642 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.63 125.37 26.64 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 173.506 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 14.9 p -83.55 148.21 5.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.655 -174.635 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 7.1 tt -78.17 119.29 26.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 172.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 4.2 t80 -84.83 107.92 17.23 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.41 -171.608 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -88.09 -82.34 1.24 Allowed Glycine 0 N--CA 1.447 -0.62 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.132 178.075 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.004 0 CA-C-O 119.05 -0.861 . . . . 0.0 111.592 -179.335 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 24.6 ttt . . . . . 0 N--CA 1.48 1.041 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 39.0 t -82.81 104.6 11.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 175.286 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 7.5 tp -111.22 124.93 68.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.811 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 121.9 -177.47 16.44 Favored Glycine 0 N--CA 1.443 -0.876 0 C-N-CA 120.728 -0.749 . . . . 0.0 111.689 -178.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.61 ' SD ' ' HA ' ' A' ' 26' ' ' PRO . 25.1 ptt? -156.78 130.99 8.51 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.161 0.505 . . . . 0.0 111.158 -179.328 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.405 ' HE2' ' HB2' ' A' ' 9' ' ' LYS . 7.4 tppt? -101.05 120.03 39.61 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.063 174.136 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 10.0 p90 -141.33 151.75 43.83 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.247 0.546 . . . . 0.0 110.777 -179.727 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.468 HG21 ' HG2' ' A' ' 18' ' ' LYS . 5.8 m -118.13 128.73 55.01 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.881 178.699 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.774 ' HA ' ' O ' ' A' ' 64' ' ' ILE . 7.6 p -104.66 122.93 58.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.242 0.544 . . . . 0.0 110.443 178.076 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.451 HG22 ' HG2' ' A' ' 65' ' ' GLU . 7.3 tp -87.53 123.73 40.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 121.213 0.53 . . . . 0.0 109.666 176.026 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.471 HG22 ' H ' ' A' ' 15' ' ' ASP . 0.2 OUTLIER -135.67 -177.19 4.56 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.416 -0.811 . . . . 0.0 108.905 -179.788 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.471 ' H ' HG22 ' A' ' 14' ' ' THR . 4.2 p-10 -71.46 -17.95 62.34 Favored 'General case' 0 C--N 1.327 -0.396 0 O-C-N 122.254 -0.279 . . . . 0.0 111.286 -177.159 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.437 ' OD1' ' HB ' ' A' ' 14' ' ' THR . 9.2 p-10 -90.29 4.23 51.31 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.866 0.365 . . . . 0.0 110.757 179.751 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 122.1 -166.32 14.78 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.778 175.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.468 ' HG2' HG21 ' A' ' 11' ' ' THR . 37.4 tttm -90.34 106.64 18.63 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.402 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.527 ' HB3' HG13 ' A' ' 12' ' ' VAL . 22.7 tttp -103.32 99.02 8.85 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.83 -167.844 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.559 HD13 ' N ' ' A' ' 21' ' ' LEU . 0.0 OUTLIER -86.12 133.41 29.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.779 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.559 ' N ' HD13 ' A' ' 20' ' ' ILE . 2.1 pt? -144.13 168.23 20.51 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 177.351 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -134.7 148.67 50.36 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.829 0.347 . . . . 0.0 110.445 -177.208 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 22.1 m -129.2 131.97 47.19 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.781 174.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -64.21 -16.14 59.71 Favored Glycine 0 C--N 1.33 0.246 0 CA-C-N 116.059 -0.519 . . . . 0.0 113.314 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.417 ' HA ' ' HD3' ' A' ' 26' ' ' PRO . . . -139.39 144.79 41.43 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 176.075 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.61 ' HA ' ' SD ' ' A' ' 8' ' ' MET . 23.3 Cg_exo -65.69 146.34 83.8 Favored 'Trans proline' 0 C--O 1.234 0.324 0 C-N-CA 122.896 2.397 . . . . 0.0 111.595 176.832 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.557 ' HD3' ' OD2' ' A' ' 31' ' ' ASP . 96.4 mtt180 -140.16 168.22 20.31 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.309 0.576 . . . . 0.0 111.487 -175.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.601 ' HD3' ' HA ' ' A' ' 55' ' ' GLU . 37.0 ttm105 -94.17 152.52 18.67 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.077 -0.965 . . . . 0.0 108.555 171.022 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.533 HG12 ' O ' ' A' ' 56' ' ' GLU . 46.8 mm -51.13 -44.05 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 C-N-CA 122.349 0.26 . . . . 0.0 111.601 -177.532 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.1 tptm -58.43 -27.2 64.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.138 -176.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.557 ' OD2' ' HD3' ' A' ' 27' ' ' ARG . 20.2 t70 -72.47 -53.3 12.49 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.684 -178.101 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 47.5 t -64.97 -44.13 96.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.309 0 CA-C-O 121.223 0.535 . . . . 0.0 110.202 178.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.506 HD21 ' HB ' ' A' ' 40' ' ' ILE . 20.7 tp -62.6 -35.66 80.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.977 178.27 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -70.75 -33.54 66.56 Favored Glycine 0 N--CA 1.449 -0.457 0 CA-C-N 115.446 -0.797 . . . . 0.0 113.099 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -66.37 -46.89 75.14 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 120.851 0.357 . . . . 0.0 111.211 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 92.9 mt -83.58 -16.15 46.42 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.732 -177.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.9 tp10 54.85 80.98 0.11 Allowed 'General case' 0 C--O 1.233 0.232 0 CA-C-O 121.824 0.821 . . . . 0.0 110.615 -176.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.461 ' HB ' ' CD1' ' A' ' 33' ' ' LEU . 67.8 mt -120.83 127.81 26.07 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.412 178.792 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.476 ' HB2' HG22 ' A' ' 42' ' ' THR . 16.0 Cg_exo -67.16 104.02 0.82 Allowed 'Trans proline' 0 N--CA 1.46 -0.446 0 C-N-CA 122.584 2.189 . . . . 0.0 112.486 -179.248 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.506 ' HB ' HD21 ' A' ' 33' ' ' LEU . 10.7 tt -66.79 -6.07 4.11 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.371 0 CA-C-O 121.834 0.826 . . . . 0.0 110.237 177.117 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 21.4 tp10 -72.89 -36.2 67.29 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.095 -0.957 . . . . 0.0 110.853 177.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.529 HG23 HG13 ' A' ' 43' ' ' VAL . 15.3 t -101.21 -24.68 14.21 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 120.911 -0.316 . . . . 0.0 111.531 -175.392 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.581 ' HA ' ' HA ' ' A' ' 68' ' ' ARG . 34.2 m -116.93 141.56 34.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 110.062 -0.348 . . . . 0.0 110.062 177.074 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.458 HG11 HD12 ' A' ' 51' ' ' ILE . 38.4 t -105.0 140.36 23.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 120.922 0.392 . . . . 0.0 110.653 -177.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 6.9 p -103.39 131.16 52.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.805 -178.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.65 ' HB2' ' HB2' ' A' ' 65' ' ' GLU . 87.6 mttt -118.75 146.32 44.86 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.253 177.647 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.755 ' HG2' HG21 ' A' ' 52' ' ' VAL . 13.8 mmtp -109.37 101.25 10.25 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 167.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.5 t-20 50.17 61.11 3.36 Favored 'General case' 0 CA--C 1.537 0.479 0 O-C-N 123.697 0.623 . . . . 0.0 111.122 -179.45 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 87.54 -23.38 12.8 Favored Glycine 0 CA--C 1.52 0.35 0 CA-C-N 116.031 -0.531 . . . . 0.0 113.585 176.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLN . . . . . . . . . . . . . 14.5 mm100 -96.56 127.56 42.67 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 117.06 0.43 . . . . 0.0 111.942 -172.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.591 HD13 ' HG2' ' A' ' 46' ' ' LYS . 33.7 mm -65.2 127.88 26.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.248 177.097 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.755 HG21 ' HG2' ' A' ' 47' ' ' LYS . 29.5 m -131.65 178.8 5.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.075 0.464 . . . . 0.0 111.368 -177.293 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.4 pt -107.81 177.24 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.558 178.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -74.35 -12.9 60.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.033 0.444 . . . . 0.0 110.84 -177.126 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.601 ' HA ' ' HD3' ' A' ' 28' ' ' ARG . 14.2 mm-40 -79.99 -5.3 55.47 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.866 179.574 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.533 ' O ' HG12 ' A' ' 29' ' ' ILE . 3.7 mm-40 -68.98 140.04 55.03 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.742 0.306 . . . . 0.0 110.93 178.019 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLU . . . . . 0.584 ' HA ' ' HA ' ' A' ' 28' ' ' ARG . 39.3 mt-10 -96.16 147.57 23.61 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 175.197 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.481 ' HB ' ' SD ' ' A' ' 8' ' ' MET . 19.2 mt -89.19 135.22 26.46 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -118.53 146.4 44.59 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.557 -0.292 . . . . 0.0 110.874 -177.089 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.567 ' HB2' ' HA ' ' A' ' 8' ' ' MET . 18.7 t70 -58.66 116.87 3.99 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.598 173.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.14 -17.72 47.44 Favored Glycine 0 N--CA 1.447 -0.585 0 C-N-CA 121.039 -0.601 . . . . 0.0 112.145 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 33.2 t0 -77.87 150.77 34.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.888 0.375 . . . . 0.0 110.05 -179.539 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.1 mm -105.94 115.45 47.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-O 121.162 0.506 . . . . 0.0 110.411 -175.203 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.774 ' O ' ' HA ' ' A' ' 12' ' ' VAL . 9.0 tp -95.71 133.26 37.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.38 -179.057 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.65 ' HB2' ' HB2' ' A' ' 46' ' ' LYS . 28.6 mt-10 -131.7 130.38 41.93 Favored 'General case' 0 C--N 1.317 -0.814 0 O-C-N 122.166 -0.334 . . . . 0.0 110.795 -175.024 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 86.9 t -115.56 103.97 16.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.173 0.511 . . . . 0.0 109.87 178.149 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 25.6 mt -123.58 109.67 23.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.588 -176.662 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.581 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -66.7 124.28 22.46 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 173.114 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.47 127.55 39.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-O 121.185 0.517 . . . . 0.0 110.74 -175.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 6.4 tp -79.26 100.69 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 CA-C-O 122.144 0.973 . . . . 0.0 109.386 176.613 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 84.1 t80 -121.07 -42.12 2.5 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.242 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -163.25 179.69 38.26 Favored Glycine 0 N--CA 1.441 -0.994 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.003 176.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.083 0 CA-C-O 118.315 -1.269 . . . . 0.0 111.175 -179.817 . . . . . . . . 0 0 . 1 stop_ save_